AU2005207625A1

AU2005207625A1 - Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease

Info

Publication number: AU2005207625A1
Application number: AU2005207625A
Authority: AU
Inventors: Michal Ayalon-Soffer; Yossi Cohen; Gad S. Cojocaru; Dvir Dahary; Alexander Diber; Guy Kol; Zurit Levine; Amit Novik; Sarah Pollock; Shirley Sameah-Greenwald; Osnat Sella-Tavor; Ronen Shemesh; Amir Toporik; Shira Walach
Original assignee: Compugen Ltd
Current assignee: Compugen Ltd
Priority date: 2004-01-27
Filing date: 2005-01-27
Publication date: 2005-08-04
Also published as: CA2554585A1; WO2005069724A3; WO2005069724A2; EP1713827A2

Description

WO 2005/069724 PCT/IB2005/001306 NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS OF CARDIAC DISEASE 5 FIELD OF THE INVENTION The present invention is related to novel nucleotide and protein sequences that are diagnostic markers for cardiac disease and/or pathological conditions, including cardiac damage, and assays and methods of use thereof. 10 BACKGROUND OF THE INVENTION Cardiovascular diseases are an important cause of mortality and morbidity. Amongst all age groups considered, IHD is the most common cause of death not only in men but also in women. Coronary atherosclerosis is a chronic progressing process, associated with angina type symptoms and frequently result in Acute Myocardial Infarction (AMI). The diagnosis is 15 achieved with a combination of patient physical examination, ECG since 1950's molecular markers play the most important role in the differential diagnosis of AMI from other conditions with similar symptoms. Early diagnosis is mandatory of the establishment of early treatment (including blood diluting agents, thrombolysis, catheterization and surgery). Early molecular markers for AMI were SGOT and LDH were proved to be of very low 20 specificity and are hardly being used at present. These markers were replaced by CPK, and later on by the heart specific CPK-MB variant. Its specificity is better than for SGOT and LDH, it is still limited both in specificity and sensitivity which reach only 67% when used together with electrocardiogram. In addition, cardiac surgery, myocarditis, and electrical cardioversion often result in elevated serum levels of the CPK-MB isoenzyme. Small infarct with minor myocardial 25 cell necrosis often do not increase serum CPK-MB to a detected level. Myoglobin is another heart damage low molecular (17kD) protein but is even less specific to heart muscle compared with CPK-MB. Its advantage over CPK-MB is a rapid rise from the onset of symptoms usually between 3-6 hours. It is considered one of the earliest indicators (together with H FABP) but it lacks specificity due to significant expression in skeletal muscle - its concentration 30 is approximately two-fold lower in cardiac than skeletal muscle and the leads to seriously diminished specificity.

WO 2005/069724 PCT/IB2005/001306 2 Cardiac troponins are currently the routine serum cardiac markers used for the diagnosis of AMI. Troponin-I and Troponin-T have amino acid sequences different from those of the skeletal muscle called cTnT and cTnI (cardiac Troponin-T and I recpectively). Cardiac troponins are not found in the serum of healthy individuals and rise to up to 20 times above a 5 predefined cut-off level, therefore are very useful and sensitive in the detection of cardiac damage. They are capable of detecting very small cardiac damage - micro-infarction, it is associated with a very adverse longer term prognosis. Cardiac troponin's sensitivity is considerably higher than CPK-MB but they suffer from a few disadvantages: 1. They are not early markers - cTnI and cTnT reach peak serum value in about 12 and 48 hours respectively 10 after symptoms onset. 2. Levels of cTnI and cTnT remain elevated for up to 10 days and 14 days respectively after AMI, therefore cannot be used for the detection of re-infarction. 3. Other heart diseases such as Congestive Heart Failure and Myocarditis can increase troponins concentrations in the serum. The lack of specificity for AMI is an advantage when there are other supporting clinical evidence directing the doctor towards another diagnosis. Troponins 15 might have a diagnostic value in assessing myocardial damage after coronary artery perfusion, monitoring progression and prognosis of unstable angina, in the detection and prognosis of cardiac contusion after blunt trauma, detecting myocarditis. The heart specific variant H-FABP (Heart Fatty Acid binding protein) is a low molecular protein (15Kd) soluble non-enzyme protein. H-FABP concentration in the heart muscle is 20 greater than that in skeletal muscle, and its normal baseline concentration is several fold lower than myoglobin. In addition, it reaches peak value in the urine and blood early, within 2-3 hours from AMI. Within a period of 30-210 minutes after symptoms started, IFABP has higher sensitivity - up to 80% - when compared with other cardiac markers (CPK-MB and the troponins sensitivity were reported to be 64% in the first 6 hours after AMI). Yet, H-FABP still 25 misses every h patient in this time scale. H-FABP has other limitations as well, including 1. rising in the plasma after exercise 2. released from muscle in skeletal damage during the course of AMI (like from intramuscular injections) 3. reduced clearance in renal failure situations. The search for novel cardiac damage markers is ongoing. Other proteins are under trials for that purpose including glycogen phosphorylase BB, HIF and VEGF 21. 30 WO 2005/069724 PCT/IB2005/001306 3 SUMMARY OF THE INVENTION Markers for the cardiac disease and/or cardiac pathology, including but not limited to cardiac damage in the prior art are not sufficiently sensitive and/or accurate, alone or in combination. 5 The present invention overcomes these deficiencies of the background art by providing novel markers for cardiac disease and/or cardiac pathology, including but not limited to cardiac damage that are both sensitive and accurate. Optionally and preferably, these markers are detected in a biological sample. According b preferred embodiments of the present invention, cardiac disease and/or 10 pathology and/or condition and/or disorder may comprise one or more of Myocardial infarct, acute coronary syndrome, angina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure or any type of heart failure, the detection of reinfarction, the detection of success of thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, assessing the size of infarct in Myocardial infarct, the differential diagnosis of heart related 15 conditions from lung related conditions (as pulmonary embolism), the differential diagnosis of Dyspnea, and cardiac valves related conditions. According to preferred embodiments of the present invention, examples of suitable biological samples include but are not limited to blood, serum, plasma, blood cells, urine, sputum, saliva, stool, spinal fluid, lymph fluid, the external secretions of the skin, respiratory, 20 intestinal, and genitourinary tracts, tears, milk, neuronal tissue, and any human organ or tissue. In a preferred embodiment, the biological sample comprises cardiac tissue and/or a serum sample and/or a urine sample and/or any other tissue or liquid sample. The sample can optionally be diluted with a suitable eluant before contacting the sample to the antibody. 25 Information given in the text with regard to cellular localization was determined according to four different software programs: (i) tmhmm (from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk/services/TMHMM/TMHMM2.0b.guide.php) or (ii) tmpred (from EMBnet, maintained by the ISREC Bionformatics group and the LICR Information Technology 30 Office, Ludwig Institute for Cancer Research, Swiss Institute of Bioinformatics, http://www.ch.embnet.org/software/TMPREDform.html) for transmembrane region WO 2005/069724 PCT/IB2005/001306 4 prediction; (iii) signalp hmm or (iv) signalp nn (both from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk/services/SignalP/background/prediction.php) for signal peptide prediction. The terms "signalp hnmmi" and "signalp nn" refer to two modes of operation for the 5 program SignalP: hmm refers to Hidden Markov Model, while nn refers to neural networks. Localization was also determined through manual inspection of known protein localization and/or gene structure, and the use of heuristics by the individual inventor. In some cases for the manual inspection of cellular localization prediction inventors used the ProLoc computational platform [Einat Hazkani-Covo, Erez Levanon, Galit Rotman, Dan Graur and Amit Novik; 10 (2004) "Evolution of multicellularity in metazoa: comparative analysis of the subcellular localization of proteins in Saccharomyces, Drosophila and Caenorhabditis." Cell Biology International 2004;28(3):171-8.], which predicts protein localization based on various parameters including, protein domains (e.g., prediction of trans-membranous regions and localization thereof within the protein), pl, protein length, amino acid composition, homology to 15 pre-annotated proteins, recognition of sequence patterns which direct the protein to a certain organelle (such as, nuclear localization signal, NLS, mitochondria localization signal), signal peptide and anchor modeling and using unique domains from Pfam that are specific to a single compartment. Information is given in the text with regard to SNPs (single nucleotide polymorphisms). 20 A description of the abbreviations is as follows. "T - > C", for example, means that the SNP results in a change at the position given in the table from T to C. Similarly, "M - > Q", for example, means that the SNP has caused a change in the corresponding amino acid sequence, from methionine (M) to glutamine (Q). If, in place of a letter at the right hand side for the nucleotide sequence SNP, there is a space, it indicates that a frameshift has occurred. A 25 frameshift may also be indicated with a hyphen (-). A stop codon is indicated with an asterisk at the right hand side (*). As part of the description of an SNP, a comment may be found in parentheses after the above description of the SNP itself This comment may include an FTId, which is an identifier to a SwissProt entry that was created with the indicated SNP. An FTId is a unique and stable feature identifier, which allows construction of links directly from position 30 specific annotation in the feature table to specialized protein-related databases. The FTId is always the last component of a feature in the description field, as follows: FTId=XXX_number, WO 2005/069724 PCT/IB2005/001306 5 in which XXX is the 3-letter code for the specific feature key, separated by an underscore from a 6-digit number. In the table of the amino acid mutations of the wild type proteins of the selected splice variants of the invention, the header of the first column is "SNP position(s) on amino acid sequence", representing a position of a known mutation on amino acid sequence. 5 SNPs may optionally be used as diagnostic markers according to the present invention, alone or in combination with one or more other SNPs and/or any other diagnostic marker. Preferred embodiments of the present invention comprise such SNPs, including but not limited to novel SNPs on the known (WT or wild type) protein sequences given below, as well as novel nucleic acid and/or amino acid sequences formed through such SNPs, and/or any SNP on a 10 variant amino acid and/or nucleic acid sequence described herein. Information given in the text with regard to the Homology to the known proteins was determined by Smith-Waterman version 5.1.2 using special (non default) parameters as follows: -model=sw.model -GAPEXT=0 15 -GAPOP=100.0 -MATRIX=blosum 100 Information is given with regard to overexpression of a cluster in cancer based on microarrays. As a microarray reference, in the specific segment paragraphs, the unabbreviated tissue name was used as the reference to the type of chip for which expression was measured. 20 There are two types of microarray results: those from microarrays prepared according to a design by the present inventors, for which the microarray fabrication procedure is described in detail in Materials and Experimental Procedures section herein; and those results from microarrays using Affymetrix technology. As a microarray reference, in the specific segment paragraphs, the unabbreviated tissue name was used as the reference to the type of chip for 25 which expression was measured. For microarrays prepared according to a design by the present inventors, the probe name begins with the name of the cluster (gene), followed by an identifying number. Oligonucleotide microarray results taken from Affymetrix data were from chips available from Affymetrix Inc, Santa Clara, CA, USA (see for example data regarding the Human Genome U133 (HG-U133) Set at 30 www.affymetrix.com/products/arrays/specific/hgul33.affx; GeneChip Human Genome Ul133A 2.0 Array at www.affymetrix.com/products/arrays/specific/hgul33av2.affx; and Human WO 2005/069724 PCT/IB2005/001306 6 Genome U133 Plus 2.0 Array at www.affymetrix.com/products/arrays/specific/hgul133plus.affx). The probe names follow the Affymetrix naming convention. The data is available from NCBI Gene Expression Omnibus (see www.ncbi.nlm.nih.gov/projects/geo/ and Edgar et al, Nucleic Acids Research, 2002, Vol. 5 30, No. 1 207-210). The dataset (including results) is available from www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1133 for the Series GSE1133 database (published on March 2004); a reference to these results is as follows: Su et al (Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7. Epub 2004 Apr 09). Oligonucleotide probes for use with arrays designed by the present inventors: 10 >S67314 0 0 741 (SEQ IDNO 392) CACAGAGCCAGGATGTTCTTCTGACCTCAGTATCTACTCCAGCTCCAGCT >S67314 0 0 744 (SEQ ID NO 393) TGGCATGCTGGAACATGGACTCTAGCTAGCAAGAAGGGCTCAAGGAGGTG 15 In the heart specific clusters, a first set of abbreviations is used for the first histogram ADP = adipocyte BLD = blood BLDR = bladder 20 BRN = brain BONE = bone BM = bone marrow BRS = mammary gland CAR = cartilage 25 CNS = central nervous system COL = colon E-ADR = endocrine adrenal gland E-PAN = endocrinepancreas E-PT = endocrineparathyroid_thyroid 30 ENDO = endocrine unchar EPID = epididymis WO 2005/069724 PCT/IB2005/001306 7 GI = gastrointestinal tract GU = genitourinary HN = head and neck HRT = heart 5 KD= kidney LI = liver LUNG = lung LN = lymph node MUS = muscle 10 OV = ovary PNS = peripheral nervous system PRO = prostate SKIN= skin SPL = spleen 15 SYN = synovial membrane TCELL = immune T cells THYM thymus TST = testes UTER= cervix-uterus 20 VAS = vascular In the second histogram(s) of the heart paragraph, the oligo-probe names are abbreviated/enumerated as follows: 25 "adipocyte", "Al"; "adrenalcortex", "A2"; "adrenalgland", "A3"; "amygdala", "A4"; "appendix", "A5"; 30 "atrioventricularnode", "A6"; "bmncd105endothelial", "El"; WO 2005/069724 PCT/IB2005/001306 8 "bm cd33_myeloid", "Ml "; "bm cd34 ", "Bl"; "bmcd7 learlyerythroid", "El"; "bonemarrow", "B2"; 5 "bronchialepithelialcells", "B3"; "cardiacmyocytes", "Cl "; "caudatenucleus", "C2"; "cerebellum", "C3"; "cerebellumpeduncles", "C4"; 10 "ciliaryganglion", "CS"; "cingulatecortex", "C6"; "globuspallidus", "GI "; "heart", "HI "; "hypothalamus", "H2"; 15 "kidney", "KI"; "liver", "Lli "; "lung", "L2"; "lymphnode", "L3" "medullaoblongata", "Ml"; 20 "occipitallobe", "O1"; "olfactorybulb", "02"; "ovary", "03"; "pancreas", "PI "; "pancreaticislets", "P2"; 25 "parietallobe", "P3"; "pb_bdca4_dentriticcells", "P4"; "pb_cdl4_monocytes", "P5"; "pb_cdl9_bcells", "P6"; "pb_cd4_tcells", "P7"; 30 "pb_cd56_nkcells", "P8"; "pb_cd8_tcells", "P9"; WO 2005/069724 PCT/IB2005/001306 9 "pituitary", "Pa"; "placenta", "Pb"; "pons", "Pc"; "prefrontalcortex", "Pd"; 5 "prostate", "Pe" "salivarygland", "SIl"; "skeletalmuscle", "S2"; "skin", "S3"; "smoothmuscle", "S4"; 10 "spinalcord", "S5"; "subthalamicnucleus", "S6"; "superiorcervicalganglion", "S7"; "temporallobe", "TI"; "testis", "T2"; 15 "testisgermcell", "T3"; "testisinterstitial", "T4"; "testisleydigcell", "T5"; "testisseminiferoustubule", "S6"; "thalamus", "T7"; 20 "thymus", "T8"; "thyroid", "T9"; "tonsil", "Ta"; "trachea", "Tb"; "trigeminalganglion", "Tc" 25 "uterus", "Ul"; "uteruscorpus", "U2"; "wholeblood", "Wi"; "wholebrain", "W2"; 30 It should be noted that the terms "segment", "seg" and "node" are used interchangeably in reference to nucleic acid sequences of the present invention; they refer to portions of nucleic WO 2005/069724 PCT/IB2005/001306 10 acid sequences that were shown to have one or more properties as described below. They are also the building blocks that were used to construct complete nucleic acid sequences as described in greater detail below. Optionally and preferably, they are examples of oligonucleotides which are embodiments of the present invention, for example as amplicons, 5 hybridization units and/or from which primers and/or complementary oligonucleotides may optionally be derived, and/or for any other use. As used herein the phrase "cardiac disease" includes any type of cardiac pathology and/or disorder and/or damage, including both chronic and acute damage, as well as progression from acute to chronic damage of the heart, and also propagation of one acute event to another 10 acute event. An example of the latter may occur when an infarct is followed by another infarct in a relatively short period of time, such as within 24 hours for example. An infarct may also lead to acute heart failure immediately after the infarct, as another example. These non-limiting examples are intended to demonstrate that cardiac disease may also comprise a plurality of acute events. 15 The term "marker" in the context of the present invention refers to a nucleic acid fragment, a peptide, or a polypeptide, which is differentially present in a sample taken from patients having a cardiac disease, such as acute cardiac damage for example, as compared to a comparable sample taken from subjects who do not have cardiac disease. As used herein the phrase "differentially present" refers to differences in the quantity of 20 a marker present in a sample taken from patients having cardiac disease as compared to a comparable sample taken from patients who do not have cardiac disease. For example, a nucleic acid fragment may optionally be differentially present between the two samples if the amount of the nucleic acid fragment in one sample is significantly different from the amount of the nucleic acid fragment in the other sample, for example as measured by hybridization and/or 25 NAT-based assays. A polypeptide is differentially present between the two samples if the amount of the polypeptide in one sample is significantly different from the amount of the polypeptide in the other sample. It should be noted that if the marker is detectable in one sample and not detectable in the other, then such a marker can be considered to be differentially present. For example, in the case of acute cardiac damage, it is possible that a marker (such as a protein 30 or fragment thereof) could optionally be present in a blood sample from the patient, indicating the presence of damage; lack of presence of such a marker (and/or presence at a low level) WO 2005/069724 PCT/IB2005/001306 11 would therefore optionally and preferably indicate a lack of such damage. Alternatively, chronically damaged heart might cause a low level of the marker to be present in the blood sample, while acute damage would cause a high level to be present. One of ordinary skill in the art could easily detennrmine such relative levels of the markers; further guidance is provided in the 5 description of each individual marker below. As used herein the phrase "diagnostic" means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their sensitivity and specificity. The "sensitivity" of a diagnostic assay is the percentage of diseased individuals who test positive 10 (percent of "true positives"). Diseased individuals not detected by the assay are "false negatives." Subjects who are not diseased and who test negative in the assay are termed "true negatives." The "specificity" of a diagnostic assay is 1 minus the false positive rate, where the "false positive" rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it 15 suffices if the method provides a positive indication that aids in diagnosis. As used herein the phrase "diagnosing" refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery. The term "detecting" may also optionally encompass any of the above. 20 Diagnosis of a disease according to the present invention can be effected by determining a level of a polynucleotide or a polypeptide of the present invention in a biological sample obtained from the subject, wherein the level determined can be correlated with predisposition to, or presence or absence of the disease. It should be noted that a "biological sample obtained from the subject" may also optionally comprise a sample that has not been physically removed from 25 the subject, as described in greater detail below. As used herein, the term "level" refers to expression levels of RNA and/or protein or to DNA copy number of a marker of the present invention. Typically the level of the marker in a biological sample obtained from the subject is different (i.e., increased or decreased) from the level of the same variant in a similar sample 30 obtained from a healthy individual (examples of biological samples are described herein). Numerous well known tissue or fluid collection methods can be utilized to collect the WO 2005/069724 PCT/IB2005/001306 12 biological sample from the subject in order to determine the level of DNA, RNA and/or polypeptide of the variant of interest in the subject. Examples include, but are not limited to, fine needle biopsy, needle biopsy, core needle biopsy and surgical biopsy (e.g., brain biopsy), and lavage. Regardless of the procedure 5 employed, once a biopsy/sample is obtained the level of the variant can be determined and a diagnosis can thus be made. Determining the level of the same variant in normal tissues of the same origin is preferably effected along-side to detect an elevated expression and/or amplification and/or a decreased expression, of the variant as opposed to the normal tissues. 10 A "test amount" of a marker refers to an amount of a marker present in a sample being tested. A test amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals). A "test amount" of a marker refers to an amount of a marker in a subject's sample that is consistent with a diagnosis of cardiac disease. A test amount can be either in absolute amount 15 (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals). A "control amount" of a marker can be any amount or a range of amounts to be compared against a test amount of a marker. For example, a control amount of a marker can be the amount of a marker in a patient with cardiac disease or a person without cardiac disease. A control amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., 20 relative intensity of signals). "Detect" refers to identifying the presence, absence or amount of the object to be detected. A "label" includes any moiety or item detectable by spectroscopic, photo chemical, biochemical, immunochemical, or chemical means. For example, useful labels include 32 P, 35 S, 25 fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin-streptavadin, dioxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a target. The label often generates a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantify the amount of bound label in a sample. The label 30 can be incorporated in or attached to a primer or probe either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., incorporation of radioactive nucleotides, or biotinylated WO 2005/069724 PCT/IB2005/001306 13 nucleotides that are recognized by streptavadin. The label may be directly or indirectly detectable. Indirect detection can involve the binding of a second label to the first label, directly or indirectly. For example, the label can be the ligand of a binding partner, such as biotin, which is a binding partner for streptavadin, or a nucleotide sequence, which is the binding partner for a 5 complementary sequence, to which it can specifically hybridize. The binding partner may itself be directly detectable, for example, an antibody may be itself labeled with a fluorescent molecule. The binding partner also may be indirectly detectable, for example, a nucleic acid having a complementary nucleotide sequence can be a part of a branched DNA molecule that is in turn detectable through hybridization with other labeled nucleic acid molecules (see, e.g., P. 10 D. Fahrlander and A. Klausner, Bio/Technology 6:1165 (1988)). Quantitation of the signal is achieved by, e.g., scintillation counting, densitometry, or flow cytometry. Exemplary detectable labels, optionally and preferably for use with inunmmunoassays, include but are not limited to magnetic beads, fluorescent dyes, radiolabels, enzymes (e.g., horse radish peroxide, alkaline phosphatase and others commonly used in an ELISA), and calorimetric 15 labels such as colloidal gold or colored glass or plastic beads. Alternatively, the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated simultaneously with the mixture. 20 "Immunoassay" is an assay that uses an antibody to specifically bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen. The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide (or other epitope), 25 refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times greater than the background (non-specific signal) and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may 30 require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to seminal basic protein from specific species such as rat, mouse, or WO 2005/069724 PCT/IB2005/001306 14 human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with seminal basic protein and not with other proteins, except for polymorphic variants and alleles of seminal basic protein. This selection may be achieved by subtracting out antibodies that cross-react with seminal basic protein molecules from other species. A variety of 5 immunoassay formats may be used to select antibodies specifically innunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be 10 at least twice background signal or noise and more typically more than 10 to 100 times background. According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a transcript selected from the group consisting of SEQ ID NOs: 1, 2, 3 and4. 15 According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a segment selected from the group consisting of SEQ ID NOs: 65, 66, 67, 68, 69, 70, 71 and 72. According to preferred embodiments of the present invention, there is provided a isolated polypeptide comprising a protein variant selected from the group consisting of SEQ ID 20 NOs: 281,282, 283 and 284. According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a transcript selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, 9 and 10 According to preferred embodiments of the present invention, there is provided ai 25 isolated polynucleotide comprising a segment selected from the goup consisting of SEQ ID NOs: 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94. According to preferred embodiments of the present invention, there is provided al isolated polypeptide comprising a protein variant selected from the group consisting of SEQ ID NOs: 285, 286, 287, 288, 289, 290 and 291 30 According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP WO 2005/069724 PCT/IB2005/001306 15 CONSISTING OF SEQ ID NOs: 12, 13, 14, 15, 16 and 17 According to preferred embodiments of the present invention, there is provided am isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 5 112. According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 292, 293, 294, 295 and 296 According to preferred embodiments of the present invention, there is provided a 10 isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 18 and 19. According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 113, 114, 115, 116, 117, 118, 119, 120, 121 and 122. 15 According to preferred embodiments of the present invention, there is provided a isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 297 and 298. According to preferred embodiments of the present invention, there is provided ai isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP 20 CONSISTING OF SEQ ID NOs: 20 and 21. According to preferred embodiments of the present invention, there is provided ai isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 123, 124, 125, 126, 127, 128 and 129. According to preferred embodiments of the present invention, there is provided al 25 isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 299 and 300. According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 26,27,28,29 and 30. 30 According to preferred embodiments of the present invention, there is provided at isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING WO 2005/069724 PCT/IB2005/001306 16 OF SEQ ID NOs: 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162 and 163. According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 305; 306; 307 and 308 5 According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 31, 32, 33, 34, 35, 36 and 37. According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING 10 OF SEQ ID NOs: 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185 and 186 According to preferred embodiments of the present invention, there is provided a isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 309, 310, 311 and 312. 15 According to preferred embodiments of the present invention, there is provided al isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 38, 39,40 and 41. According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING 20 OF SEQ ID NOs: 187, 188, 189, 190, 191, 192, 193, 194, 195 and 196. According to preferred embodiments of the present invention, there is provided ai isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 313, 314, 315 and 316. According to preferred embodiments of the present invention, there is provided aM 25 isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 42, 43, 44, 45, 46, 47, 48, 49 and 50. According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207 and 208.

WO 2005/069724 PCT/IB2005/001306 17 According to preferred embodiments of the present invention, there is provided a isolated polypeptide comprising a protein variant SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 317, 318, 319, 320, 321, 322, 323, 324 and 325. According to preferred embodiments of the present invention, there is provided a 5 isolated polynucleotide comprising a transcript SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs:51, 52, 53, 54, 55, 56, 57, 58, 59 and 60. According to preferred embodiments of the present invention, there is provided a isolated polynucleotide comprising a segment SELECTED FROM THE GROUP CONSISTING OF SEQ ID NOs: 209 to 273. 10 According to preferred embodiments of the present invention, there is provided a isolated polypeptide comprising a protein variant selected from the group consisting of SEQ ID NOs: 326 to 334. According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a transcript selected from the group consisting of SEQ ID 15 NOs: 22-25, 353 or 386. According to preferred embodiments of the present invention, there is provided ai isolated polynucleotide comprising a segment selected from the group consisting of SEQ ID NOs: 130-149. According to preferred embodiments of the present invention, there is provided al 20 isolated polypeptide comprising a protein variant selected fri-om the group consisting of SEQ ID NOs: 301-304, 325, 354-356 or 387. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 326, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 1855 of SEQ ID NO.338, which 25 also corresponds to amino acids 1 - 1855 of SEQ ID NO.326, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1856 - 1904 of SEQ ID NO. 326, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 30 According to preferred embodiments of the present invention, there is provided an WO 2005/069724 PCT/IB2005/001306 18 isolated polypeptide encoding for a tail of SEQ ID NO. 326, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT in SEQ ID NO. 5 326. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 327, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 1326 of SEQ ID NO. 339, which also corresponds to amino acids 1 - 1326 of SEQ ID NO. 327, and a second amino acid 10 sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1327 - 1336 of SEQ ID NO. 327, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an 15 isolated polypeptide encoding for a tail of SEQ ID NO. 327, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRPSGEGGQA in SEQ ID NO. 327. According to preferred embodiments of the present invention, there is provided a 20 isolated chimeric polypeptide encoding for SEQ ID NO. 328, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 1508 of SEQ ID NO. 339, which also corresponds to amino acids 1 - 1508 of SEQ ID NO. 328, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence 25 corresponding to amino acids 1509 - 1534 of SEQ ID NO. 328, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided m isolated polypeptide encoding for a tail of SEQ ID NO. 328, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 30 about 90% and most preferably at least about 95% homologous to the sequence GVLGVQEARDELVGGRAMQGQGEHRL in SEQ ID NO. 328.

WO 2005/069724 PCT/IB2005/001306 19 According to preferred embodiments of the present invention, there is provided aM isolated chimeric polypeptide encoding for SEQ ID NO. 329, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 1763 of SEQ ID NO. 338, which also corresponds to amino acids 1 - 1763 of SEQ ID NO. 329, and a second 5 amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresporxlnding to amino acids 1764 - 1788 of SEQ ID NO. 329, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an 10 isolated polypeptide encoding for a tail of SEQ ID NO. 329, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSDRPPSASPKDRNKALGPGQATVL in SEQ ID NO. 329. According to preferred embodiments of the present invention, there is provided a 15 isolated chimeric polypeptide encoding for SEQ ID NO. 330, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 22 of SEQ ID NO. 330, and a second amino acid sequence being at least 90 % homologous to amino acids 528 - 1939 of SEQ ID NO. 340, which also 20 corresponds to amino acids 23 - 1434 of SEQ ID NO. 330, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a head of SEQ ID NO. 330, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 25 about 90% and most preferably at least about 95% homologous to the sequence MGLWKPGSVLSDSLFASSPCPQ of SEQ ID NO. 330. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 331, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 527 of SEQ ID NO. 339, which 30 also corresponds to amino acids 1 - 527 of SEQ ID NO. 331, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least WO 2005/069724 PCT/IB2005/001306 20 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 528 - 555 of SEQ ID NO. 331, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 5 According to preferred embodiments of the present invention, there is provided aM isolated polypeptide encoding for a tail of SEQ ID NO. 331,comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPPWPHHLCPLLCHPDKVVAESLLHPRN in SEQ ID NO. 331. 10 According to preferred embodiments of the present invention, there is provided al isolated chimeric polypeptide encoding for SEQ ID NO.332, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 470 of SEQ ID NO.338, which also corresponds to amino acids 1 - 470 of SEQ ID NO.332, a second amino acid sequence being at least 90 % homologous to amino acids 528 - 1855 of SEQ ID NO.338, 15 which also corresponds to amino acids 471 - 1798 of SEQ ID NO.332, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1799 - 1847 of SEQ ID NO.332, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a 20 sequential order. According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO.332, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more 25 preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise DP, having a structure as follows: a sequence starting from any of amino acid numbers 470-x to 470; and ending at any of amino acid numbers 471+ ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided at 30 isolated polypeptide encoding for a tail of SEQ ID NO. 332, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least WO 2005/069724 PCT/IB2005/001306 21 about 90% and most preferably at least about 95% homologous to the sequence VRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT in SEQ ID NO.332. According to preferred embodiments of the present invention, there is provided am 5 isolated chimeric plypeptide encoding for SEQ ID NO.333, comprising a first amino acid sequence being at least 90 % homologous to amino acids 165 - 1939 of SEQ ID NO. 340, which also corresponds to amino acids 1 - 1775 of SEQ ID NO.333. According to preferred embodiments of the present invention, there is provided M isolated chimeric polypeptide encoding for SEQ ID NO.334, comprising a first amino acid 10 sequence being at least 90 % homologous to corresponding to amino acids 1165 - 1939 of SEQ ID NO. 340, which also corresponds to amino acids 1 - 775 of SEQ ID NO.334. According to preferred embodiments of the present invention, there is provided aM isolated chimeric polypeptide encoding for SEQ ID NO.317, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 158 of SEQ ID NO. 341, which 15 also corresponds to amino acids 1 - 158 of SEQ ID NO.317. According to preferred embodiments of the present invention, there is provided aM isolated chimeric polypeptide encoding for SEQ ID NO.318, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 156 of SEQ ID NO. 341, which also corresponds to amino acids 1 - 156 of SEQ ID NO.318, and a second amino acid sequence 20 being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 157 - 166 of SEQ ID NO.318, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided at 25 isolated polypeptide encoding for a tail of SEQ ID NO.318, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in SEQ ID NO.318. According to preferred embodiments of the present invention, there is provided ai 30 isolated chimeric polypeptide encoding for SEQ ID NO.319, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 156 of SEQ ID NO. 341, which WO 2005/069724 PCT/IB2005/001306 22 also corresponds to amino acids 1 - 156 of SEQ ID NO.319, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 157 - 210 of SEQ ID NO.319, wherein said first amino acid sequence and second 5 amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO.319, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 10 about 90% and most preferably at least about 95% homologous to the sequence DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY in SEQ ID NO.319. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 320, comprising a first amino acid 15 sequence being at least 90 % homologous to amino acids 1 - 60 of Q96NR4, which also corresponds to amino acids 1 - 60 of SEQ ID NO. 320, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 61 - 114 of SEQ ID NO. 320, wherein said first amino acid sequence and second amino 20 acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO. 320, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 25 DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY in SEQ ID NO. 320. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 320, comprising a first amino acid sequence being at least 90 % homologous to amino acids 97 - 156 of SEQ ID NO. 341, which 30 also corresponds to amino acids 1 - 60 of SEQ ID NO. 320, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least WO 2005/069724 PCT/IB2005/001306 23 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 61 - 114 of SEQ ID NO. 320, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an 5 isolated chimeric polypeptide encoding for SEQ ID NO. 321, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 14 of SEQ ID NO. 342, which also corresponds to amino acids 1 - 14 of SEQ ID NO. 321, a second amino acid sequence bridging amino acid sequence comprising of S, and a third amino acid sequence being at least 90 % homologous to corresponding to amino acids 62 - 133 of SEQ ID NO. 342, which also 10 corresporls to amino acids 16 - 87 of SEQ ID NO. 321, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of SEQ ID NO. 321, comprising a 15 polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise VSI having a structure as follows (numbering according to SEQ ID NO. 321): a sequence starting from any of amino acid 20 numbers 14-x to 14; and ending at any of amino acid numbers 16 + ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided aa isolated chimeric polypeptide encoding for SEQ ID NO. 321, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at 25 least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 15 of SEQ ID NO. 321, and a second amino acid sequence being at least 90 % homologous to corresponding to amino acids 39 - 110 of SEQ ID NO. 343, which also corresponds to amino acids 16 - 87 of SEQ ID NO. 321, wherein said frst amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 30 According to preferred embodiments of the present invention, there is provided al isolated polypeptide encoding for a head of SEQ ID NO. 321, comprising a polypeptide being at WO 2005/069724 PCT/IB2005/001306 24 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MRGEHNSTSYDSAVS of SEQ ID NO. 321. According to preferred embodiments of the present invention, there is provided a 5 isolated chimeric polypeptide encoding for SEQ ID NO. 321, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 97 - 110 of SEQ ID NO. 341, which also corresponds to amino acids 1 - 14 of SEQ ID NO. 321, a second amino acid sequence bridging amino acid sequence comprising of S, and a third amino acid sequence being at least 90 % homologous to corresponding to amino acids 158 -229 ofSEQ ID NO. 341, 10 which also corresponds to amino acids 16 - 87 of SEQ ID NO. 321, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of SEQ ID NO. 321, comprising a 15 polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise VSI having a structure as follows (numbering according to SEQ ID NO. 321): a sequence starting from any of amino acid 20 numbers 14-x to 14; and ending at any of amino acid numbers 16 + ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided al isolated polypeptide encoding for a tail of SEQ ID NO. 320, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 25 about 90% and most preferably at least about 95% homologous to the sequence DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY in SEQ ID NO. 320. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 321, comprising a first amino acid 30 sequence being at least 90 % homologous to corresponding to amino acids 1 - 14 of SEQ ID NO. 342, which also corresponds to amino acids 1 - 14 of SEQ ID NO. 321, a second amino WO 2005/069724 PCT/IB2005/001306 25 acid sequence bridging amino acid sequence comprising of S, and a third amino acid sequence being at least 90 % homologous to corresponding to amino acids 62 - 133 of SEQ ID NO. 342, which also corresponds to amino acids 16 - 87 of SEQ ID NO. 321, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in 5 a sequential order. According to preferred embodiments of the present invention, there is provided al isolated polypeptide encoding for an edge portion of SEQ ID NO. 321, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more 10 preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise VSI having a structure as follows (numbering according to SEQ ID NO. 321: a sequence starting from any of amino acid numbers 14-x to 14; and ending at any of amino acid numbers 16 + ((n-2) - x), in which x varies from 0 to n-2. 15 According to preferred embodiments of the present invention, there is provided am isolated chimeric polypeptide encoding for SEQ ID NO. 321, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 15 of SEQ ID NO. 321, and a second amino acid sequence 20 being at least 90 % homologous to corresponding to amino acids 39 - 110 of SEQ ID NO. 343, which also corresponds to amino acids 16 - 87 of SEQ ID NO. 321, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for a head of SEQ ID NO. 321, comprising a polypeptide being at 25 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MRGEHNSTSYDSAVS of SEQ ID NO. 321. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 321, comprising a first amino acid 30 sequence being at least 90 % homologous to corresponding to amino acids 97 - 110 of SEQ ID NO. 341, which also corresponds to amino acids 1 - 14 of SEQ ID NO. 321, a second amino WO 2005/069724 PCT/IB2005/001306 26 acid sequence bridging amino acid sequence comprising of S, and a third amino acid sequence being at least 90 % homologous to corresponding to amino acids 158 - 229 of SEQ ID NO. 341, which also corresponds to amino acids 16 - 87 of SEQ ID NO. 321, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in 5 a sequential order. According to preferred embodiments of the present invention, there 'is provided aM isolated polypeptide encoding for an edge portion of SEQ ID NO. 321, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more 10 preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise VSI having a structure as follows (numbering according to SEQ ID NO. 321): a sequence starting from any of amino acid numbers 14-x to 14; and ending at any of amino acid numbers 16 + ((n-2) - x), in which x varies from 0 to n-2. 15 According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 322, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 62 of SEQ ID NO. 342, which also corresponds to amino acids 1 - 62 of SEQ ID NO. 322. According to preferred embodiments of the present invention, there is provided a 20 isolated chimeric polypeptide encoding for SEQ ID NO. 322., comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 23 of SEQ ID NO. 322., and a second amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 39 of SEQ ID NO. 343., 25 which also corresponds to amino acids 24 - 62 of SEQ ID NO. 322., wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for a head of SEQ ID NO. 322., comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at 30 least about 90% and most preferably at least about 95% homologous to the sequence MRGEHNSTSYDSAVIYRGFWAVL of SEQ ID NO. 322..

WO 2005/069724 PCT/IB2005/001306 27 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 322., comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 97 - 158 of SEQ ID NO. 341., which also corresponds to amino acids 1 - 62 of SEQ ID NO. 322.. 5 According to preferred embodiments of the present invention, there is provided aM isolated chimeric polypeptide encoding for SEQ ID NO. 324, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 60 of SEQ ID NO. 342, which also corresponds to amino acids 1 - 60 of SEQ ID NO. 324, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more 10 preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 61 - 70 of SEQ ID NO. 324, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO. 324, comprising a polypeptide being at 15 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in SEQ ID NO. 324. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 324, comprising a first amino acid 20 sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 23 of SEQ ID NO. 324, a second amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 37 of SEQ ID NO. 343, which also corresponds to amino acids 24 - 60 of SEQ ID NO. 324, and a third amino acid sequence being 25 at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence corresponding to amino acids 61 - 70 of SEQ ID NO. 324, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a 30 isolated polypeptide encoding for a head of SEQ ID NO. 324, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least WO 2005/069724 PCT/IB2005/001306 28 about 90% and most preferably at least about 95% homologous to the sequence MRGEHNSTSYDSAVIYRGFWAVL of SEQ ID NO. 324. According to preferred embodiments of the present invention, there is provided a3 isolated polypeptide encoding for a tail of SEQ ID NO. 324, comprising a polypeptide being at 5 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in SEQ ID NO. 324. According to preferred embodiments of the present invention, there is provided al isolated chimeric polypeptide encoding for SEQ ID NO. 324, comprising a first amino acid 10 sequence being at least 90 % homologous to corresponding to amino acids 97 - 156 of SEQ ID NO. 341, which also corresponds to amino acids 1 - 60 of SEQ ID NO. 324, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence corresponding to amino acids 61 - 70 of SEQ ID NO. 324, wherein said first amino 15 acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided am isolated polypeptide encoding for a tail of SEQ ID NO. 324, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 20 VSVGQECGSG in SEQ ID NO. 324. According to preferred embodiments of the present invention, there is provided am isolated chimeric polypeptide encoding for SEQ ID NO. 313, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 115 of SEQ ID NO. 344, which also corresponds to amino acids 1 - 115 of SEQ ID NO. 313, and a second 25 amino acid sequence being at least 90 % homologous to corresponding to amino acids 152 319 of SEQ ID NO. 344, which also corresponds to amino acids 116 - 283 of SEQ ID NO. 313, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided am 30 isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 313, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally WO 2005/069724 PCT/IB2005/001306 29 at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IY, having a structure as follows: a sequence starting from any of amino acid numbers 115-x to 115; and ending at any of amino 5 acid numbers 116+ ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 313, of cluster Z36249 comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 70 of SEQ ID NO. 345, which also corresponds to amino acids 1 - 70 of SEQ ID NO. 313, a 10 bridging amino acid K corresponding to amino acid 71 of SEQ ID NO. 313, a second amino acid sequence being at least 90 % homologous to corresponding to amino acids 72 - 115 of SEQ ID NO. 345, which also corresponds to amino acids 72 - 115 of SEQ ID NO. 313, and a third amino acid sequence being at least 90 % homologous to corresponding to amino acids 152 319 ofSEQ ID NO. 345, which also corresponds to amino acids 116 - 283 ofSEQ ID NO. 313, 15 wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 314, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 184 of SEQ ID 20 NO. 344, which also corresponds to amino acids 1 - 184 of SEQ ID NO. 314, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 185 - 197 of SEQ ID NO. 314, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 25 According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 314, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VNIFLCLGMSQKK in SEQ ID NO. 314. 30 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 314, comprising a first amino acid WO 2005/069724 PCT/IB2005/001306 30 sequence being at least 90 % homologous to corresponding to amino acids 1 - 70 of SEQ ID NO. 345, which also corresponds to amino acids 1 - 70 of SEQ ID NO. 314, a bridging amino acid K corresponding to amino acid 71 of SEQ ID NO. 314, a second amino acid sequence being at least 90 % homologous to corresponding to amino acids 72 - 184 of SEQ ID NO. 345, 5 which also corresponds to amino acids 72 - 184 of SEQ ID NO. 314, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence corresponding to amino acids 185 - 197 of SEQ ID NO. 314, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are 10 contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 314, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 15 VNIFLCLGMSQKK in SEQ ID NO. 314. According to preferred embodiments of the present invention, there is provided al isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 313, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more 20 preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IY, having a structure as follows: a sequence starting from any of amino acid numbers 115-x to 115; and ending at any of amino acid numbers 116+ ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided ai 25 isolated chimeric polypeptide encoding for SEQ ID NO. 315, comprising a first amino acid sequence being at least 90 % homologous to corresponding to amino acids 1 - 151 of SEQ ID NO. 344, which also corresponds to amino acids 1 - 151 of SEQ ID NO. 315, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence 30 corresponding to amino acids 152 - 177 of SEQ ID NO. 315, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

WO 2005/069724 PCT/IB2005/001306 31 According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 315, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 5 VRLMQSTAKSSSLILCFLCFTPVLLI in SEQ ID NO. 315. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 315, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 70 of SEQ ID NO. 345, which also corresponds to amino acids 1 - 70 of SEQ ID NO. 315, a bridging amino acid K corresponding 10 to amino acid 71 of SEQ ID NO. 315, a second amino acid sequence being at least 90 % homologous to amino acids 72 - 151 of SEQ ID NO. 345, which also corresponds to amino acids 72 - 151 of SEQ ID NO. 315, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 15 152 - 177 of SEQ ID NO. 315, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 315, comprising a polypeptide being at 20 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRLMQSTAKSSSLILCFLCFTPVLLI in SEQ ID NO. 315. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 316, comprising a first amino acid 25 sequence being at least 90 % homologous to amino acids 1 - 151 of SEQ ID NO. 344, which also corresponds to amino acids 1 - 151 of SEQ ID NO. 316, and a second amino acid sequence being at least 90 % homologous to amino acids 185 - 319 of SEQ ID NO. 344, which also corresponds to amino acids 152 - 286 of SEQ ID NO. 316, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 30 According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 316, comprising a WO 2005/069724 PCT/IB2005/001306 32 polypeptide having a length "n", wherein nis at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EL, having a structure as follows: a 5 sequence starting from any of amino acid numbers 151-x to 151; and ending at any of amino acid numbers 152+ ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 316, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 70 of SEQ ID NO. 345, which also 10 corresponds to amino acids 1 - 70 of SEQ ID NO. 316, a bridging amino acid K corresponding to amino acid 71 of SEQ ID NO. 316, a second amino acid sequence being at least 90 % homologous to amino acids 72 - 151 of SEQ ID NO. 345, which also corresponds to amino acids 72 - 151 of SEQ ID NO. 316, and a third amino acid sequence being at least 90 % homologous to amino acids 185 - 319 of SEQ ID NO. 345, which also corresponds to amino 15 acids 152 - 286 of SEQ ID NO. 316, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 316, of cluster 20 Z36249 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EL, having a structure as follows: a sequence starting from any of amino acid numbers 151-x to 151; and 25 ending at any of amino acid numbers 152+ ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided aM isolated chimeric polypeptide encoding for SEQ ID NO. 309, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 42 of SEQ ID NO. 346, which also corresponds to amino acids 1 - 42 of SEQ ID NO. 309, a bridging amino acid N corresponding 30 to amino acid 43 of SEQ ID NO. 309, a second amino acid sequence being at least 90 % homologous to amino acids 44 - 657 of SEQ ID NO. 346, which also corresponds to amino WO 2005/069724 PCT/IB2005/001306 33 acids 44 - 657 of SEQ ID NO. 309, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 658 - 708 of SEQ ID NO. 309, wherein said first amino acid sequence, bridging amino acid, 5 second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 309, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 10 about 90% and most preferably at least about 95% homologous to the sequence VRPHLTLKAPLGLRMHRDPLRTPSPKSWPLTQPLTPDATLTPQAILTPTLT in SEQ ID NO. 309. According to preferred embodiments of the present invention, there is provided am isolated chimeric polypeptide encoding for SEQ ID NO. 310, comprising a first amino acid 15 sequence being at least 90 % homologous to amino acids 1 - 42 of SEQ ID NO. 346, which also corresponds to amino acids 1 - 42 of SEQ ID NO. 310, a bridging amino acid N corresponding to amino acid 43 of SEQ ID NO. 310, a second amino acid sequence being at least 90 % homologous to amino acids 44 - 676 of SEQ ID NO. 346, which also corresponds to amino acids 44 - 676 of SEQ ID NO. 310, and a third amino acid sequence being at least 70%, 20 optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 677 - 685 of SEQ ID NO. 310, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 25 According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for a tail of SEQ ID NO. 310, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence EHGRGPGKT in SEQ ID NO. 310. 30 According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 311, comprising a first amino acid WO 2005/069724 PCT/IB2005/001306 34 sequence being at least 90 % homologous to amino acids 1 - 42 of SEQ ID NO. 346, which also corresponds to amino acids 1 - 42 of SEQ ID NO. 311, a bridging amino acid N corresponding to amino acid 43 of SEQ ID NO. 311, a second amino acid sequence being at least 90 % homologous to amino acids 44 - 657 of SEQ ID NO. 346, which also corresponds to amino 5 acids 44 - 657 of SEQ ID NO. 311, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 658 - 696 of SEQ ID NO. 311, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential 10 order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO. 311, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 15 GPGRHAGNAGTLTQSLDCDAGVPPPAFQPLSTSYIYFSE in SEQ ID NO. 311. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 312, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 42 of SEQ ID NO. 346, which also corresponds to amino acids 1 - 42 of SEQ ID NO. 312, a bridging amino acid N corresponding 20 to amino acid 43 of SEQ ID NO. 312, a second amino acid sequence being at least 90 % homologous to amino acids 44 - 610 of SEQ ID NO. 346, which also corresponds to amino acids 44 - 610 of SEQ ID NO. 312, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AMH corresponding 25 to amino acids 611 - 613 of SEQ ID NO. 312, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 305, comprising a first amino acid 30 sequence being at least 90 % homologous to amino acids 1 - 381 of SEQ ID NO. 347, which also corresponds to amino acids 1 - 381 of SEQ ID NO. 305, and a second amino acid sequence WO 2005/069724 PCT/IB2005/001306 35 being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 382 - 387 of SEQ ID NO. 305, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 5 According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO. 305, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TSLSLS in SEQ ID NO. 305. 10 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 306, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 338 of SEQ ID NO. 347, which also corresponds to amino acids 1 - 338 of SEQ ID NO. 306, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 15 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 339 - 346 of SEQ ID NO. 306, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided m isolated polypeptide encoding for a tail of SEQ ID NO. 306, comprising a polypeptide being at 20 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VLLCAQWP in SEQ ID NO. 306. According to preferred embodiments of the present invention, there is provided am isolated chimeric polypeptide encoding for SEQ ID NO. 307, comprising a first amino acid 25 sequence being at least 90 % homologous to amino acids 1 - 223 of SEQ ID NO. 347, which also corresponds to amino acids 1 - 223 of SEQ ID NO. 307, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence A corresponding to amino acids 224 - 224 of SEQ ID NO. 307, wherein said first amino acid 30 sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided am WO 2005/069724 PCT/IB2005/001306 36 isolated chimeric polypeptide encoding for SEQ ID NO. 308, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 294 of SEQ ID NO. 347, which also corresponds to amino acids 1 - 294 of SEQ ID NO. 308, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 5 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 295 - 304 of SEQ ID NO. 308, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 308, comprising a polypeptide being at 10 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RCYLRFLDIY in SEQ ID NO. 308. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 281, comprising a first amino acid 15 sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a amino acids 1 - 116 of FABHHUMAN, which also corresponds to amino acids 1 - 116 of SEQ ID NO. 281, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homoblogous to a polypeptide 20 sequence corresponding to amino acids 117 - 215 of SEQ ID NO. 281, wherein said firstand second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO. 281, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 25 about 90% and most preferably at least about 95% homologous to the sequence VRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTREWLWVRVVSGGNFLCSGFGL TQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL in SEQ ID NO. 281. According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 281, comprising a first amino acid 30 sequence being at least 90 % homologous to amino acids 1 - 116 of AAP35373, which also corresponds to amino acids 1 - 116 of SEQ ID NO. 281, and a second amino acid sequence WO 2005/069724 PCT/IB2005/001306 37 being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 117 - 215 of SEQ ID NO. 281, wherein said first and second amino acid sequences are contiguous and in a sequential order. 5 According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for a tail of SEQ ID NO. 281, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTREWLWVRVVSGGNFLCSGFGL 10 TQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL in SEQ ID NO. 281. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 282, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence 15 corresponding to amino acids 1 - 116 of FABHHUMAN, which also corresponds to amino acids 1 - 116 of SEQ ID NO. 282, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 117 - 178 of SEQ ID NO. 282, wherein said first and second amino acid sequences are 20 contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 282, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 25 DVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATKLLRPTLPSYNNHGWEELRVG KSIV in SEQ ID NO. 282. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 282, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 116 of AAP35373, which also 30 corresponds to amino acids 1 - 116 of SEQ ID NO. 282, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least WO 2005/069724 PCT/IB2005/001306 38 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 117 - 178 of SEQ ID NO. 282, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a 5 isolated polypeptide encoding for a tail of SEQ ID NO. 282, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATKLLRPTLPSYNNHGWEELRVG KSIV in SEQ ID NO. 282. 10 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 283, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence amino acids 1 - 116 of FABHHUMAN, which also corresponds to amino acids 1 - 116 of SEQ 15 ID NO. 283, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 117 - 126 of SEQ ID NO. 283, wherein said first and second amino acid sequences are contiguous and in a sequential order. 20 According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 283, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MEKLQLRNVK in SEQ ID NO. 283. 25 According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 283, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 116 of AAP35373, which also corresponds to amino acids SEQ ID NO. 283, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most 30 preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 117 - 126 of SEQ ID NO. 283, wherein said first and second amino acid sequences are WO 2005/069724 PCT/IB2005/001306 39 contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of SEQ ID NO. 283, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 5 about 90% and most preferably at least about 95% homologous to the sequence MEKLQLRNVK in SEQ ID NO. 283. According to preferred embodiments of he present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 284, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 24 of FABH- HUMAN, which also 10 corresponds to amino acids 1 - 24 of SEQ ID NO. 284, second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 25 - 35 of SEQ ID NO. 284, and a third amino acid sequence being at least 90 % homologous to amino acids 25 - 133 of FABHHUMAN, which also corresponds to amino 15 acids 36 - 144 of SEQ ID NO. 284, wherein said first, second, third and fourth amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for an edge portion of SEQ ID NO. 284, comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, 20 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for AHILITFPLPS, corresponding to SEQ ID NO. 284. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 284, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 24 of AAP35373, which also 25 corresponds to amino acids 1 - 24 of SEQ ID NO. 284, second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 25 - 35 of SEQ ID NO. 284, and a third amino acid sequence being at least 90 % homologous to amino acids 25 - 133 of AAP35373, which also corresponds to amino acids 36 30 144 of SEQ ID NO. 284, wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

WO 2005/069724 PCT/IB2005/001306 40 According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for an edge portion of SEQ ID NO. 284, comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 5 sequence encoding for AHILITFPLPS, corresponding to SEQ ID NO. 284. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 285, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 203 of SEQ ID NO. 349, which also corresponds to amino acids 1 - 203 of SEQ ID NO. 285, and a second amino acid sequence 10 being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 204 - 240 of SEQ ID NO. 285, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided aM 15 isolated polypeptide encoding for a tail of SEQ ID NO. 285, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LWLTPVIPTLWEADGGGLHEPWSWRPAWATWLQRNYL in SEQ ID NO. 285. According to preferred embodiments of the present invention, there is provided a 20 isolated chimeric polypeptide encoding for SEQ ID NO. 286, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 78 of SEQ ID NO. 349, which also corresponds to amino acids 1 - 78 of SEQ ID NO. 286, second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino 25 acids 79 - 125 of SEQ ID NO. 286, and a third amino acid sequence being at least 90 % homologous to amino acids 79 - 399 of SEQ ID NO. 349, which also corresponds to amino acids 126 - 446 of SEQ ID NO. 286, wherein said first, second and third amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a 30 isolated polypeptide encoding for an edge portion of SEQ ID NO. 286, comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, WO 2005/069724 PCT/IB2005/001306 41 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for HWQISQWWLHFQTPREEGKMKLLELSESADGAAWKRWGGNSNTHRIQ, corresponding to SEQ ID NO. 286. 5 According to preferred embodiments of the present invention, there is provided al isolated chimeric polypeptide encoding for SEQ ID NO. 287, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 140 of SEQ ID NO. 349, which also corresponds to amino acids 1 - 140 of SEQ ID NO. 287, and a second amino acid sequence being at least 90 % homologous to amino acids 203 - 399 of SEQ ID NO. 349, which also 10 corresponds to amino acids 141 - 337 of SEQ ID NO. 287, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 287, comprising a polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, 15 optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise DV, having a structure as follows: a sequence starting from any of amino acid numbers 140-x tol40; and ending at any of amino acid numbers 141+ ((n-2) - x), in which xvaries from 0 to n-2. 20 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 288, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 10 of SEQ ID NO. 288, second amino 25 acid sequence being at least 90 % homologous to amino acids 18 - 106 of SEQ ID NO. 349, which also corresponds to amino acids 11 - 99 of SEQ ID NO. 288, a third (bridging) amino acid sequence comprising D, and a fourth amino acid sequence being at least 90 % homologous to amino acids 179 - 399 of SEQ ID NO. 349, which also corresponds to amino acids 101 - 321 of SEQ ID NO. 288, wherein said first, second, third and fourth amino acid sequences are 30 contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided an WO 2005/069724 PCT/IB2005/001306 42 isolated polypeptide encoding for a head of SEQ ID NO. 288, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NETEAEQSYV of SEQ ID NO. 288. 5 According to preferred embodiments of the present invention, there is provided aM isolated polypeptide encoding for an edge portion of SEQ ID NO. 288, comprising a polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least 10 about 50 amino acids in length, wherein a least two amino acids comprise LDY having a structure as follows (numbering according to SEQ ID NO. 288): a sequence starting from any of amino acid numbers 99-x to 99; and ending at any of amino acid numbers 101 + ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided ai 15 isolated chimeric polypeptide encoding for SEQ ID NO. 289, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 15 of SEQ ID NO. 289, and a second amino acid sequence being at least 90 % homologous to corresponding to amino acids 203 - 399 of SEQ ID NO. 349, 20 which also corresponds to amino acids 16 - 212 of SEQ ID NO. 289, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a head of SEQ ID NO. 289, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 25 about 90% and most preferably at least about 95% homologous to the sequence MSSWLSAGSPSSLSV of SEQ ID NO. 289. According to preferred embodiments of the present invention, there is provided al isolated chimeric polypeptide encoding for SEQ ID NO. 290, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at 30 least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 13 of SEQ ID NO. 290, and a second amino acid sequence WO 2005/069724 PCT/IB2005/001306 43 being at least 90 % homologous to amino acids 280 - 399 of SEQ ID NO. 349, which also corresponds to amino acids 14 - 133 of SEQ ID NO. 290, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a 5 isolated polypeptide encoding for a head of SEQ ID NO. 290, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MCRGYSTLLNPVS of SEQ ID NO. 290. According to preferred embodiments of the present invention, there is provided a 10 isolated chimeric polypeptide encoding for SEQ ID NO. 291, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 246 of SEQ ID NO. 349, which also corresponds to amino acids 1 - 246 of SEQ ID NO. 291, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to 15 amino acids 247 - 252 of SEQ ID NO. 291, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a tail of SEQ ID NO. 291, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 20 about 90% and most preferably at least about 95% homologous to the sequence SRNWTQ in SEQ ID NO. 291. According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 292, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at 25 least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 1 - 10 of SEQ ID NO. 292, second amino acid sequence being at least 90 % homologous to amino acids 26 - 276 of Q96NF5, which also corresponds to amino acids 11 - 261 of SEQ ID NO. 292, followed by A, and a third amino acid sequence being at least 90 % homologous to amino acids 278 - 466 of Q96NF5, which also corresponds to amino 30 acids 263 - 451 of SEQ ID NO. 292, wherein said first, second, A, and third amino acid sequences are contiguous and in a sequential order.

WO 2005/069724 PCT/IB2005/001306 44 According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a head of SEQ ID NO. 292, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MEISLVKCSE 5 ofSEQ ID NO. 292 According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 293, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 276 of Q96NF5, which also corresponds to amino acids 1 - 276 of SEQ ID NO. 293, followed by A, a second amino acid 10 sequence being at least 90 % homologous to amino acids 278 - 372 of Q96NF5, which also corresponds to amino acids 278 - 372 of SEQ ID NO. 293, and a third amino acid sequence being at least 90 % homologous to amino acids 401 - 466 of Q96NF5, which also corresponds to amino acids 373 - 438 of SEQ ID NO. 293, wherein said first, A, second, and third amino acid sequences are contiguous and in a sequential order. 15 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 293, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino 20 acids in length, wherein at least two amino acids comprise EE, having a structure as follows: a sequence starting from any of amino acid numbers 372-x to 372; and ending at any of amino acid numbers 373+ ((n-2) - x), in which x varies from 0 to n-2. According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 294, comprising a first amino acid 25 sequence being at least 90 % homologous to amino acids 1 - 276 of Q96NF5, which also corresponds to amino acids 1 - 276 of SEQ ID NO. 294, followed by A, a second amino acid sequence being at least 90 % homologous to amino acids 278 - 401 of Q96NF5, which also corresponds to amino acids 278 - 401 of SEQ ID NO. 294, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 30 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 402 - 407 of SEQ ID NO. 294, wherein said first, A, second and third amino acid WO 2005/069724 PCT/IB2005/001306 45 sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided aM isolated polypeptide encoding for a tail of SEQ ID NO. 294, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 5 about 90% and most preferably at least about 95% homologous to the sequence PNRQDS in SEQ ID NO. 294. According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 295, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 276 of Q96NF5, which also 10 corresponds to amino acids 1 - 276 of SEQ ID NO. 295, followed by A, a second amino acid sequence being at least 90 % homologous to amino acids 278 - 374 of Q96NF5, which also corresponds to amino acids 278 - 374 of SEQ ID NO. 295, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to 15 amino acids 375 - 390 of SEQ ID NO. 295, wherein said first, A, second and third amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided aM isolated polypeptide encoding for a tail of SEQ ID NO. 295, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 20 about 90% and most preferably at least about 95% homologous to the sequence MSHELFSRFSLRLFGR in SEQ ID NO. 295. According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 296, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 261 of Q96NF5, which also 25 corresponds to amino acids 1 - 261 of SEQ ID NO. 296, a second amino acid sequence comprising A, and a third amino acid sequence being at least 90 % homologous to amino acids 263 - 451 of Q96NF5, which also corresponds to amino acids 263 - 451 of SEQ ID NO. 296, wherein said first, second and third amino acid sequences are contiguous and in a sequential order. 30 According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 297, comprising a first amino acid WO 2005/069724 PCT/IB2005/001306 46 sequence being at least 90 % homologous to amino acids 1 - 132 of Q9NPI5, which also corresponds to amino acids 1 - 132 of SEQ ID NO. 297, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to 5 amino acids 133 - 145 of SEQ ID NO. 297, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for a tail of SEQ ID NO. 297, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 10 about 90% and most preferably at least about 95% homologous to the sequence LPGRHEVPRGALP in SEQ ID NO. 297. According to preferred embodiments of the present invention, there is provided ai isolated chimeric polypeptide encoding for SEQ ID NO. 297, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 109 of Q9NZK3, which also 15 corresponds to amino acids 1 - 109 of SEQ ID NO. 297, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 110 - 145 of SEQ ID NO. 297, wherein said first and second amino acid sequences are contiguous and in a sequential order. 20 According to preferred embodiments of the present invention, there is provided aa isolated polypeptide encoding for a tail of SEQ ID NO. 297, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LVDLYSRRYFLTVPYEECKWRRSLPGRHEVPRGALP in SEQ ID NO. 297. 25 According to preferred embodiments of the present invention, there is provided ala isolated chimeric polypeptide encoding for SEQ ID NO. 298, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 107 of Q9NPI5, which also corresponds to amino acids 1 - 107 of SEQ ID NO. 298, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 30 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 108 - 121 of SEQ ID NO. 298, wherein said first and second amino acid sequences WO 2005/069724 PCT/IB2005/001306 47 are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided aM isolated polypeptide encoding for a tail of SEQ ID NO. 298, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 5 about 90% and most preferably at least about 95% homologous to the sequence NLPGRHEVPRGALP in SEQ ID NO. 298. According to preferred embodiments of the present invention, there is provided M isolated chimeric polypeptide encoding for SEQ ID NO. 298, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 107 of Q9NZK3, which also 10 corresponds to amino acids 1 - 107 of SEQ ID NO. 298, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 108 - 121 of SEQ ID NO. 298, wherein said first and second amino acid sequences are contiguous and in a sequential order. 15 According to preferred embodiments of the present invention, there is provided ai isolated polypeptide encoding for a tail of SEQ ID NO. 298, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NLPGRHEVPRGALP in SEQ ID NO. 298. 20 According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for SEQ ID NO. 299, comprising a first amino acid sequence being at least 90 % homologous to amino acids 51 - 151 of SEQ ID NO. 350, which also corresponds to amino acids 1 - 101 of SEQ ID NO. 299. According to preferred embodiments of the present invention, there is provided an 25 isolated chimeric polypeptide encoding for SEQ ID NO. 300, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MSSFSTTT corresponding to amino acids 1 - 8 of SEQ ID NO. 300, and a second amino acid sequence being at least 90 % homologous to amino acids 42 - 151 of SEQ ID NO. 350, which 30 also corresponds to amino acids 9 - 118 of SEQ ID NO. 300, wherein said first and second amino acid sequences are contiguous and in a sequential order.

WO 2005/069724 PCT/IB2005/001306 48 According to preferred embodiments of the present invention, there is provided a isolated polypeptide encoding for a head of SEQ ID NO. 300, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MSSFSTTT of 5 SEQ ID NO. 300. According to preferred embodiments of the present invention, there is provided aM isolated chimeric polypeptide encoding for SEQ ID NO. 301, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 124 of TRIC _HUMAN, which also corresponds to amino acids 1 - 124 of SEQ ID NO. 301, and a second amino acid sequence 10 being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 125- 137 of SEQ ID NO. 301, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided aM 15 isolated polypeptide encoding for a tail of SEQ ID NO. 301, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VGRMGSSGTFGVG in SEQ ID NO. 301. According to preferred embodiments of the present invention, there is provided al 20 isolated chimeric polypeptide encoding for SEQ ID NO. 302, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 8 of TRIC -HUMAN, which also corresponds to amino acids 1 - 8 of SEQ ID NO. 302, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino 25 acids 36 - 209 of TRICHUMAN, which also corresponding to amino acids 9 - 182 of SEQ ID NO. 302, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided am isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 302, comprising a 30 polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in WO 2005/069724 PCT/IB2005/001306 49 length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AK, having a structure as follows: a sequence starting from any of amino acid numbers 8-x to 8; and ending at any of amino acid numbers 9+ ((n-2) - x), in which x varies from 0 to n-2. 5 According to preferred embodiments of the present invention, there is provided a isolated chimeric polypeptide encoding for SEQ ID NO. 303, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 36 of TRICHUMAN, which also corresponds to amino acids 1 - 36 of SEQ ID NO. 303, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and 10 most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 37- 86 of SEQ ID NO. 303, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided M isolated polypeptide encoding for a tail of SEQ ID NO. 303, comprising a polypeptide being at 15 least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VGRGFLGAEYRRRRDPRPWEWGEEPGLRRGRGLRGGASGAEFCRGSCSDW in SEQ ID NO. 303. According to preferred embodiments of the present invention, there is provided aM 20 isolated chimeric polypeptide encoding for SEQ ID NO. 304, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 8 of TRICHUMAN, which also corresponds to amino acids 1 - 8 of SEQ ID NO. 304, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino 25 acids 9- 13 of SEQ ID NO. 304, wherein said first and second amino acid sequences are contiguous and in a sequential order. According to preferred embodiments of the present invention, there is provided al isolated polypeptide encoding for a tail of SEQ ID NO. 304, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least 30 about 90% and most preferably at least about 95% homologous to the sequence VRAAG in SEQ ID NO. 304.

WO 2005/069724 PCT/IB2005/001306 50 According to preferred embodiments of the present invention, there is provided al antibody capable of specifically binding to an epitope of an amino acid sequence in any one of cluster S67314, N56180, T10377, Z24874, HUMCDDANF, HUMTROPIA, HUMSMCK, H88495, Z36249, FLJ26352, HSACMHCP. Preferably, the amino acid sequence corresponds to 5 any insertion, including a bridge, edge portion, tail, or head as described herein. Preferably, the antibody is capable of differentiating between a splice variant having the epitope and a corresponding known protein. According to preferred embodiments of the present invention, there is provided a kit for detecting heart disorders, comprising a kit detecting overexpression of a splice variant. 10 Optionally, the kit comprises a NAT-based technology. Preferably, the kit further comprises at least one primer pair capable of selectively hybridizing to a nucleic acid sequence in any one of cluster S67314, N56180, T10377, Z24874, HUMCDDANF, HUMTROPIA, HUMSMCK, H88495, Z36249, FLJ26352, HSACMHCP. Optionally, the kit further comprises at least one oligonucleotide capable of selectively 15 hybridizing to a nucleic acid sequence in any one of cluster S67314, N56180, T10377, Z24874, HUMCDDANF, HUMTROPIA, HUMSMCK, H88495, Z36249, FLJ26352, HSACMHCP. Optionally, kit comprises an antibody as described herein. Preferably, the kit further comprises at least one reagent for performing an ELISA or a Western blot. According to preferred embodiments of the present invention, there is provided a method 20 for detecting heart disorders, comprising detecting overexpression of a splice variant of any of cluster S67314, N56180, T10377, Z24874, HUMCDDANF, HUMTROPIA, HUMSMCK, H88495, Z36249, FLJ26352, HSACMHCP. Optionally, detecting overexpression is performed with a NAT-based technology. Also optionally, detecting overexpression is performed with an immunoassay. 25 Preferably, the immunoassay comprises an antibody as described herein. According to preferred embodiments of the present invention, there is provided a biomarker capable of detecting heart disorders, comprising any of the above nucleic acid sequences or a fragment thereof, or amino acid sequences or a fragment thereof. According to preferred embodiments of the present invention, there is provided a method 30 for screening for heart disorders, comprising detecting cardiac disease cells or tissue with a biomarker or an antibody.

WO 2005/069724 PCT/IB2005/001306 51 According to preferred embodiments of the present invention, there is provided a method for diagnosing heart disorders, comprising detecting heart cells or tissue with a biomarker or an antibody. According to preferred embodiments of the present invention, there is provided a method 5 for monitoring disease progression, or treatment efficacy, or relapse of heart disorders, or any combination thereof, comprising detecting heart cells or tissue with a biomarker or an antibody or a method or assay as described herein. According to preferred embodiments of the present invention, there is provided a method of selecting a therapy for heart disorders, comprising detecting heart disorder alls with a 10 biomarker or an antibody or a method or assay as described herein and selecting a therapy according to the detection. A heart disorder and/or cardiac disease and/or cardiac pathology optionally comprises at least one of: Myocardial infarct, ungina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, the detection of reinfarction, the detection of success of 15 thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, assessing the size of infarct in Myocardial infarct. According to preferred embodiments of the present invention, preferably any of the above nucleic acid and/or amino acid sequences further comprises any sequence having at least about 70%, preferably at least about 80%, more preferably at least about 90%, most preferably 20 at least about 95% homology thereto. All nucleic acid sequences and/or amino acid sequences shown herein as embodiments of the present invention relate to their isolated form, as isolated polynucleotides (including for all transcripts), oligonucleotides (including for all segments, amplicons and primers), peptides (including for all tails, bridges, insertions or heads, optionally including other antibody epitopes 25 as described herein) and/or polypeptides (including for all proteins). It should be noted that oligonucleotide and polynucleotide, or peptide and polypeptide, may optionally be used interchangeably. Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The 30 following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed.

WO 2005/069724 PCT/IB2005/001306 52 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). All of these are hereby incorporated by reference as if fully set forth herein. As used herein, the following terms have the meanings ascribed to 5 them unless specified otherwise. BRIEF DESCRIPTION OF DRAWINGS Figure 1 shows a schematic summary of quantitative real-time PCR analysis. Figure 2 is a histogram showing expression of ESTs in each category, as "parts per 10 million". Figures 3 & 4 are histograms showing expression of oligonucleotides in various tissues, prob 205738_sat & prob 214285_at. Figure 5A is a histogram showing specific expression of variant FABH_HUMAN Fatty acid-binding protein transcripts in heart tissue samples as opposed to other tissues. 15 Figure 5B is a histogram showing specific expression of variant FABHHUMAN protein transcripts. Figure 6 is a histrogram showing expression of FABH_HUMAN known protein transcripts. Figure 7 is a histogram showing expression of the number of heart tissue-specific clones 20 in libraries/sequences. Figure 8 is a histogram showing the actual expression of oligonucleotides in various tissues, including heart tissue, prob 207317 s at. Figure 9 is a histogram showing specific expression of the above-indicated Calsequestrin, cardiac muscle isoform transcripts in sequence N56180, heart tissue samples. 25 Figure 10 is a histogram showing specific expression of the above-indicated Calsequestrin, cardiac muscle isoform transcripts in heart tissue samples as opposed to other tissues. Figure 11 is a histogram showing expression of concerning the number of heart tissue specific clones in libraries/sequences. 30 Figure 12 is a histogram showing specific expression of Q96NF5 transcripts in sequence T10377 in heart tissue samples.

WO 2005/069724 PCT/IB2005/001306 53 Figure 13 is a histogram showing specific expression of the Q96NF5 transcripts in sequence T10377 junc29-33 heart tissue samples. Figure 14 is a histogram showing specific expression of the above-indicated Q96NF5 transcripts T10377 seg2- 3 in heart tissue samples. 5 Figure 15 is a histogram concerning the expression of the number of heart-specific clones in libraries/sequences. Figure 16 is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 221051_sat, including heart. Figure 17A is a histogram concerning the expressions of ESTs in number of heart tissue 10 specific clones in libraries/sequences; Figure 17B is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 209957_s-at, including heart tissue. Figure 18 is a histogram showing expression of known protein transcript for HUMCDDANFT4. 15 Figure 19 is a histogram concerning expression of ESTs, the number of heart tissue specific clones in libraries/sequences Figure 20 is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 205742_at, including heart tissue. Figure 21A is a histogram showing specific expression of the above-indicated 20 TRIC HUMAN Troponin I, cardiac muscle HUMTROPIA transcripts in sequence HUMTROPIA segl0 in heart tissue. Figure 21A is a histogram showing specific expression of the TRICHUMAN Troponin I, cardiac muscle HUMTROPIA transcripts in sequence HUMTROPIA seg22 in heart tissue. Figure 22 is a histogram showing specific expression of the HUMTROPIA known protein 25 sequence in heart tissue. Figure 23 is a histogram showing ESTs concerning the number of heart tissue-specific clones in libraries/sequences Figure 24 is a histogram concerning the actual expression of oligonucleotides in various tissues, pob 205295_at, including heart tissue. 30 Figure 25 is a histogram showing ESTs concerning the number of heart tissue -specific clones in libraries/sequences WO 2005/069724 PCT/IB2005/001306 54 Figure 26 is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 207066_at, including heart tissue. Figure 27 is a histogram showing ESTs concerning the number of heart-specific clones in libraries/sequences. 5 Figure 28 is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 206029_at, including heart tissue. Figure 29 is a histogram concerning expression of ESTs in the number of heart tissue specific clones in libraries/sequences. Figure 30 is a histogram concerning the expression of ESTs in number of heart tissue 10 specific clones in libraries/sequences; Figure 31 is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 204737_sat, including heart tissue. Figure 32 is a histogram concerning the actual expression of oligonucleotides in various tissues, prob 216265_x_at, including heart tissue. 15 Figure 33 shows a diagram of a troponin I variant, HUMTROPIA_T7, with regard to introducing a mutation to block an additional ORF. Figure 34 shows Troponin PCR product after second amplification reaction: Lane 1: 1Kb MW marker (GibcoBRL Cat# 15615-016) and Lane 2: PCR product. Figure 35 shows Troponin PCR product sequence. 20 Figure 36: plasmid map of His Troponin T7 pRSETA. Figure 37 shows the complete sequence of the plasmid shown in Figure 36. Figure 38 shows the protein sequence of Troponin variant HUMTROPIA_PEA_2 T7, with the HIS-tag marked. Figure 39a shows Coomassie staining analysis of SDS-PAGE containing recombinant 25 HisTroponin; lane 1: Molecular weight marker (ProSieve color, Cambrex, Cat #50550); lane 2: HisTroponinT7 pRSETA TO; lane 3: pRSET A T3; lane 4: pRSET empty vector TO (negative control); lane 5: pRSET empty vector T3 (negative control). Figure 39b shows a Western blot analysis of recombinant HisTroponin: lane 1: His positive control protein; lane 2: HisTroponinT7 pRSETA TO; lane 3: HisTroponinT7 pRSETA 30 T3; lane 4: pRSET empty vector TO (negative control); lane 5: pRSET empty vector T3 (negative control) and lane 6: molecular weight marker (ProSieve color, Cambrex, Cat #50550).

WO 2005/069724 PCT/IB2005/001306 55 DESCRIPTION OF PREFERRED EMBODIMENTS The present invention is of novel markers for cardiac disease that are both sensitive and accurate. Biomolecular sequences (amino acid and/or nucleic acid sequences) uncovered using 5 the methodology of the present invention and described herein can be efficiently utilized as tissue or pathological markers and/or as drugs or drug targets for treating or preventing a disease. These markers are specifically released to the bloodstream under conditions of cardiac disease and/or cardiac pathology, including but not limited to cardiac damage, and/or are 10 otherwise expressed at a much higher level and/or specifically expressed in heart. The method of the present invention identifies clusters (genes) which are characterized in that the transcripts are differentially expressed in heart muscle tissue compared with other normal tissues, preferably in comparison to skeletal muscle tissue. In acute conditions under which heart muscle tissue experiences hypoxia (with or without necrosis), intracellular proteins that are not 15 normally secreted can leak through the cell membrane to the extracellular space. Therefore, heart muscle tissue differentially expressed proteins, as through analysis of EST expression, are potential acute heart damage markers. Leakage of intracellular content can also occur in chronic damage to the heart muscle, therefore proteins selected according to this method are potential markers for chronic heart 20 conditions. When a protein that is differentially expressed in heart muscle is secreted, it is even more likely to be useful as a chronic heart damage marker, since secretion implies that the protein has a physiological role exterior to the cell, and therefore may be used by the heart muscle to respond to the chronic damage. This rationale is empirically supported by the non limiting examples of the proteins BNP (brain natriuretic peptide) and ANF (atrial natriuretic 25 factor), which are differentially expressed heart muscle proteins that are secreted and which were shown to be markers for congestive heart failure. In addition, BNP and ANF are not only differentially expressed in heart tissue, they are also overexpressed dramatically (hundreds of times greater expression) when heart failure occurs. Other heart specific secreted proteins might present similar overexpression in chronic damage. 30 Optionally and preferably, the markers described herein are overexpressed in heart as opposed to muscle, as described in greater detail below. The measurement of these markers, WO 2005/069724 PCT/IB2005/001306 56 alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of cardiac disease and/or cardiac pathology, including but not limited to cardiac damage. The present invention therefore also relates to diagnostic assays for cardiac disease 5 and/or cardiac pathology, including but not limited to cardiac damage, and methods of use of such markers for detection of cardiac disease and/or cardiac pathology, including but not limited to cardiac damage (alone or in combination), optionally and preferably in a sample taken from a subject (patient), which is more preferably some type of blood sample. The present invention therefore also relates to diagnostic assays for cardiac disease 10 and/or cardiac pathology, including but not limited to cardiac damage, and methods of use of such markers for detection of cardiac disease and/or cardiac pathology, including but not limited to cardiac damage (alorie or in combination), optionally and preferably in a sample taken from a subject (patient), which is more preferably some type of blood sample. In another embodiment, the present invention relates to bridges, tails, heads and/or 15 insertions, and/or analogs, homologs and derivatives of such peptides. Such bridges, tails, heads and/or insertions are described in greater detail below with regard to the Examples. As used herein a "tail" refers to a peptide sequence at the end of an amino acid sequence that is unique to a splice variant according to the present invention. Therefore, a splice variant having such a tail may optionally be considered as a chimera, in that at least a first portion of the 20 splice variant is typically highly homologous (often 100% identical) to a portion of the corresponding known protein, while at least a second portion of the variant comprises the tail. As used herein a "head" refers to a peptide sequence at the beginning of an amino acid sequence that is unique to a splice variant according to the present invention. Therefore, a splice variant having such a head may optionally be considered as a chimera, in that at least a first 25 portion of the splice variant comprises the head, while at least a second portion is typically highly homologous (often 100% identical) to a portion of the corresponding known protein. As used herein "an edge portion" refers to a connection between two portions of a splice variant according to the present invention that were not joined in the wild type or known protein. An edge may optionally arise due to a join between the above "known protein" portion 30 of a variant and the tail, for example, and/or may occur if an internal portion of the wild type sequence is no longer present, such that two portions of the sequence are now contiguous in the WO 2005/069724 PCT/IB2005/001306 57 splice variant that were not contiguous in the known protein. A "bridge" may optionally be an edge portion as described above, but may also include a join between a head and a "known protein" portion of a variant, or a join between a tail and a "known protein" portion of a variant, or a join between an insertion and a "known protein" portion of a variant. 5 Optionally and preferably, a bridge between a tail or a head or a unique insertion, and a "known protein" portion of a variant, comprises at least about 10 amino acids, more preferably at least about 20 amino acids, most preferably at least about 30 amino acids, and even more preferably at least about 40 amino acids, in which at least one amino acid is from the tail/head/insertion and at least one amino acid is from the "known protein" portion of a variant. 10 Also optionally, the bridge may comprise any number of amino acids from about 10 to about 40 amino acids (for example, 10, 11, 12, 13...37, 38, 39, 40 amino acids in length, or any number in between). It should be noted that a bridge cannot be extended beyond the length of the sequence in either direction, and it should be assumed that every bridge description is to be read in such 15 manner that the bridge length does not extend beyond the sequence itself. Furthermore, bridges are described with regard,,to a sliding window in certain contexts below. For example, certain descriptions of the bridges feature the following format: a bridge between two edges (in which a portion of the known protein is not present in the variant) may optionally be described as follows: a bridge portion of CONTIG-NAMEP1 (representing the 20 name of the protein), comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise XX (2 amino acids in the center of the bridge, one from each end of the edge), having a 25 structure as follows (numbering according to the sequence of CONTIG-NAMEP1): a sequence starting from any of amino acid numbers 49-x to 49 (for example); and ending at any of amino acid numbers 50 + ((n-2) - x) (for example), in which x varies from 0 to n-2. In this example, it should also be read as including bridges in which n is any number of amino acids between 10-50 amino acids in length. Furthermore, the bridge polypeptide cannot extend beyond the sequence, 30 so it should be read such that 49-x (for example) is not less than 1, nor 50 + ((n-2) - x) (for example) greater than the total sequence length.

WO 2005/069724 PCT/IB2005/001306 58 In another embodiment, this invention provides antibodies specifically recognizing the splice variants and polypeptide fragments thereof of this invention. Preferably such antibodies differentially recognize splice variants of the present invention but do not recognize a corresponding known protein (such known proteins are discussed with regard to their splice 5 variants in the Examples below). In another embodiment, this invention provides an isolated nucleic acid molecule encoding for a splice variant according to the present invention, having a nucleotide sequence as set forth in any one of the sequences listed herein, or a sequence complementary thereto. In another embodiment, this invention provides an isolated nucleic acid molecule, having a 10 nucleotide sequence as set forth in any one of the sequences listed herein, or a sequence complementary thereto. In another embodiment, this invention provides an oligonucleotide of at least about 12 nucleotides, specifically hybridizable with the nucleic acid molecules of this invention. In another embodiment, this invention provides vectors, cells, liposomes and compositions comprising the isolated nucleic acids of this invention. 15 In another embodiment, this invention provides a method for detecting a splice variant according to the present invention in a biological sample, comprising: contacting a biological sample with an antibody specifically recognizing a splice variant according to the present invention under conditions whereby the antibody specifically interacts with the splice variant in the biological sample but do not recognize known corresponding proteins (wherein the known 20 protein is discussed with regard to its splice variant(s) in the Examples below), and detecting said interaction; wherein the presence of an interaction correlates with the presence of a splice variant in the biological sample. In another embodiment, this invention provides a method for detecting a splice variant nucleic acid sequences in a biological sample, comprising: hybridizing the isolated nucleic acid 25 molecules or oligonucleotide fragments of at least about a minimum length to a nucleic acid material of a biological sample and detecting a hybridization complex; wherein the presence of a hybridization complex correlates with the presence of a splice variant nucleic acid sequence in the biological sample. According to the present invention, the splice variants described herein are non-limiting 30 examples of markers for diagnosing cardiac disease and/or cardiac pathology, including but not WO 2005/069724 PCT/IB2005/001306 59 limited to cardiac damage. Each splice variant marker of the present invention can be used alone or in combination, for various uses, including but not limited to, prognosis, prediction, screening, early diagnosis, determination of progression, therapy selection and treatment monitoring of cardiac disease and/or cardiac pathology, including but not limited to cardiac 5 damage. According to optional but preferred embodiments of the present invention, any marker according to the present invention may optionally be used alone or combination. Such a combination may optionally comprise a plurality of markers described herein, optionally including any subcombination of markers, and/or a combination featuring at least one other 10 marker, for example a known marker. Furthermore, such a combination may optionally and preferably be used as described above with regard to determining a ratio between a quantitative or semi-quantitative measurement of any marker described herein to any other marker described herein, and/or any other known marker, and/or any other marker. With regard to such a ratio between any marker described herein (or a combination thereof) and a known marker, more 15 preferably the known marker comprises the "known protein" as described in greater detail below with regard to each cluster or gene. According to other preferred embodiments of the present invention, a splice variant protein or a fragment thereof, or a splice variant nucleic acid sequence or a fragment thereof, may be featured as a biomnarker for detecting cardiac disease and/or cardiac pathology, including 20 but not limited to cardiac damage, such that a biomarker may optionally comprise any of the above. According to still other preferred embodiments, the present invention optionally and preferably encompasses any amino acid sequence or fragment thereof encoded by a nucleic acid sequence corresponding to a splice variant protein as described herein. Any oligopeptide or peptide relating to such an amino acid sequence or fragment thereof may optionally also 25 (additionally or alternatively) be used as a biomarker, including but not limited to the unique amino acid sequences of these proteins that are depicted as tails, heads, insertions, edges or bridges. The present invention also optionally encompasses antibodies capable of recognizing, and/or being elicited by, such oligopeptides or peptides. The present invention also optionally and preferably encompasses any nucleic acid 30 sequence or fragment thereof, or amino acid sequence or fragment thereof, corresponding to a splice variant of the present invention as described above, optionally for any application.

WO 2005/069724 PCT/IB2005/001306 60 Non-limiting examples of methods or assays are described below. The present invention also relates to kits based upon such diagnostic methods or assays. Nucleic acid sequences and Oligonucleotides 5 Various embodiments of the present invention encompass nucleic acid sequences described hereinabove; fragments thereof, sequences hybridizable therewith, sequences homologous thereto, sequences encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or artificially induced, either randomly or in a 10 targeted fashion. The present invention encompasses nucleic acid sequences described herein; fragments thereof, sequences hybridizable therewith, sequences homologous thereto [e.g., at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to the nucleic acid sequences set forth below], sequences 15 encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or man induced, either randomly or in a targeted fashion. The present invention also encompasses homologous nucleic acid sequences (i.e., which form a part of a polynucleotide sequence of the present invention) which include sequence regions unique to the polynucleotides 20 of the present invention. In cases where the polynucleotide sequences of the present invention encode previously unidentified polypeptides, the present invention also encompasses novel polypeptides or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove. 25 A "nucleic acid fragment" or an "oligonucleotide" or a "polynucleotide" are used herein interchangeably to refer to a polymer of nucleic acids. A polynucleotide sequence of the present invention refers to a single or double stranded nucleic acid sequences which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a 30 combination of the above). As used herein the phrase "complementary polynucleotide sequence" refers to a WO 2005/069724 PCT/IB2005/001306 61 sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified in vivo or in vitro using a DNA dependent DNA polymerase. As used herein the phrase "genomic polynucleotide sequence" refers to a sequence 5 derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome. As used herein the phrase "composite polynucleotide sequence" refers to a sequence, which is composed of genomic and cDNA sequences. A composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some 10 intronic sequences interposing therebetween. The intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements. Preferred embodiments of the present invention encompass oligonucleotide probes. An example of an oligonucleotide probe which can be utilized by the present invention is 15 a single stranded polynucleotide which includes a sequence complementary to the unique sequence region of any variant according to the present invention, including but not limited to a nucleotide sequence coding for an amino sequence of a bridge, tail, head and/or insertion according to the present invention, and/or the equivalent portions of any nucleotide sequence given herein (including but not limited to a nucleotide sequence of a node, segment or amplicon 20 described herein). Alternatively, an oligonucleotide probe of the present invention can be designed to hybridize with a nucleic acid sequence encompassed by any of the above nucleic acid sequences, particularly the portions specified above, including but not limited to a nucleotide sequence coding for an amino sequence of a bridge, tail, head and/or insertion according to the present 25 invention, and/or the equivalent portions of any nucleotide sequence given herein (including but not limited to a nucleotide sequence of a node, segment or amplicon described herein). Oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for executing solid-phase synthesis 30 are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the WO 2005/069724 PCT/IB2005/001306 62 capabilities of one skilled in the art and can be accomplished via established methodologies as detailed in, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland 5 (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988) and "Oligonucleotide Synthesis" Gait, M. J., ed. (1984) utilizing solid phase chemistry, e.g. cyanoethyl phosphoramidite followed by deprotection, desalting and purification by for example, an automated trityl-on method or HPLC. Oligonucleotides used according to this aspect of the present invention are those having a 10 length selected from a range of about 10 to about 200 bases preferably about 15 to about 150 bases, more preferably about 20 to about 100 bases, most preferably about 20 to about 50 bases. Preferably, the oligonucleotide of the present invention features at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 or at least 40, bases specifically hybridizable with the biomarkers of the present invention. 15 The oligonucleotides of the present invention may comprise heterocylic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3' to 5' phosphodiester linkage. Preferably used oligonucleotides are those modified at one or more of the backbone, internucleoside linkages or bases, as is broadly described hereinunder. Specific examples of preferred oligonucleotides useful according to this aspect of the 20 present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S. Pat. NOs: 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466, 677; 5,476,925; 5,519,126; 5,536,821; 25 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050. Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and 30 aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked WO 2005/069724 PCT/IB2005/001306 63 analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms can also be used. Alternatively, modified oligonucleotide backbones that do not include a phosphorus atom 5 therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; fonnacetyl and thioformacetyl backbones; 10 methylene fonnacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts, as disclosed in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 15 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439. Other oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for complementation with the 20 appropriate polynucleotide target. An example for such an oligonucleotide mimetic, includes peptide nucleic acid (PNA). United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Other backbone modifications, which can be used in the present invention are disclosed in U.S. Pat. No: 6,303,374. 25 Oligonucleotides of the present invention may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases such as 5 methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 30 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and WO 2005/069724 PCT/IB2005/001306 64 cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8 substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5 substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8 5 azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further bases particularly useful for increasing the binding affinity of the oligomeric compounds of the invention include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6 10 1.2 oC and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications. Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not 15 limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety, 20 as disclosed in U.S. Pat. No: 6,303,374. It is not necessary for all positions in a given oligonucleotide molecule to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. It will be appreciated that oligonucleotides of the present invention may include further 25 modifications for more efficient use as diagnostic agents and/or to increase bioavailability, therapeutic efficacy and reduce cytotoxicity. To enable cellular expression of the polynucleotides of the present invention, a nucleic acid construct according to the present invention may be used, which includes at least a coding region of one of the above nucleic acid sequences, and further includes at least one cis acting 30 regulatory element. As used herein, the phrase "cis acting regulatory element" refers to a polynucleotide sequence, preferably a promoter, which binds a trans acting regulator and WO 2005/069724 PCT/IB2005/001306 65 regulates the transcription of a coding sequence located downstream thereto. Any suitable promoter sequence can be used by the nucleic acid construct of the present invention. Preferably, the promoter utilized by the nucleic acid construct of the present invention is 5 active in the specific cell population transformed. Examples of cell type-specific and/or tissue specific promoters include promoters such as albumin that is liver specific, lymphoid specific promoters [Calame et al., (1988) Adv. Immunol. 43:235-275]; in particular promoters of T-cell receptors [Winoto et al., (1989) EMBO J. 8:729-733] and immunoglobulins; [Banerji et al. (1983) Cell 33729-740], neuron-specific promoters such as the neurofilament promoter [Byrne 10 et al. (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477], pancreas-specific promoters [Edlunch et al. (1985) Science 230:912-916] or mammary gland-specific promoters such as the milk whey promoter (U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). The nucleic acid construct of the present invention can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function in up regulating the 15 transcription therefrom. The nucleic acid construct of the present invention preferably further includes an appropriate selectable marker and/or an origin of replication. Preferably, the nucleic acid construct utilized is a shuttle vector, which can propagate both in E. coli (wherein the construct comprises an appropriate selectable marker and origin of replication) and be compatible for 20 propagation in cells, or integration in a gene and a tissue of choice. The construct according to the present invention can be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial chromosome. Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (+/-), pGL3, PzeoSV2 (+/-), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is 25 commercially available from Invitrogen Co. (www.invitrogen.com). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif, includingRetro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the trasgene is transcribed from CMV promoter. Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5'LTR promoter. 30 Currently preferred in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno- WO 2005/069724 PCT/IB2005/001306 66 associated virus (AAV) and lipid-based systems. Useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a 5 retroviral construct includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is 10 already present in the viral construct. In addition, such a construct typically includes a signal sequence for secretion of the peptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence or the signal sequence of the polypeptide variants of the present invention. Optionally, the construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation 15 termination sequence. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers. 20 Hybridization assays Detection of a nucleic acid of interest in a biological sample may optionally be effected by hybridization-based assays using an oligonucleotide probe (non-limiting examples of probes according to the present invention were previously described). Traditional hybridization assays include PCR, RT-PCR, Real-time PCR, RNase 25 protection, in-situ hybridization, primer extension, Southern blots (DNA detection), dot or slot blots (DNA, RNA), and Northern blots (RNA detection) (NAT type assays are described in greater detail below). More recently, PNAs have been described (Nielsen et al. 1999, Current Opin. Biotechnol. 10:71-75). Other detection methods include kits containing probes on a dipstick setup and the like. 30 Hybridization based assays which allow the detection of a variant of interest (i.e., DNA or RNA) in a biological sample rely on the use of oligonucleotides which can be 10, 15, 20, or WO 2005/069724 PCT/IB2005/001306 67 30 to 100 nucleotides long preferably from 10 to 50, more preferably from 40 to 50 nucleotides long. Thus, the isolated polynucleotides (oligonucleotides) of the present invention are preferably hybridizable with any of the herein described nucleic acid sequences under moderate 5 to stringent hybridization conditions. Moderate to stringent hybridization conditions are characterized by a hybridization solution such as containing 10 % dextrane sulfate, 1 M NaC1, 1 % SDS and 5 x 106 cpm 32p labeled probe, at 65 'C, with a final wash solution of 0.2 x SSC and 0.1 % SDS and final wash at 65 0 C and whereas moderate hybridization is effected using a hybridization solution 10 containing 10 % dextrane sulfate, 1 M NaC1, 1 % SDS and 5 x 106 cpm 32 P labeled probe, at 65 oC, with a final wash solution of 1 x SSC and 0.1 % SDS and final wash at 50 oC. More generally, hybridization of short nucleic acids (below 200 bp in length, e.g. 17-40 bp in length) can be effected using the following exemplary hybridization protocols which can be modified according to the desired stringency; (i) hybridization solution of 6 x SSC and 1 % 15 SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 g.g/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 1 - 1.5 'C below the Tn, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 'C below the Tm; (ii) hybridization solution of 6 x SSC and 0.1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA 20 (pH 7.6), 0.5 % SDS, 100 gg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 2 - 2.5 oC below the Tmin, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 oC below the Tm, final wash solution of 6 x SSC, and final wash at 22 oC; (iii) hybridization solution of 6 x SSC and 1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % 25 SDS, 100 gg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature. The detection of hybrid duplexes can be carried out by a number of methods. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Such labels refer to radioactive, fluorescent, biological or enzymatic 30 tags or labels of standard use in the art. A label can be conjugated to either the oligonucleotide WO 2005/069724 PCT/IB2005/001306 68 probes or the nucleic acids derived from the biological sample. Probes can be labeled according to numerous well known methods. Non-limiting examples of radioactive labels include 3H, 14C, 32P, and 35S. Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and 5 antibodies. Other detectable markers for use with probes, which can enable an increase in sensitivity of the method of the invention, include biotin and radio-nucleotides. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the probe. For example, oligonucleotides of the present invention can be labeled subsequent to 10 synthesis, by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent. Alternatively, when fluorescently-labeled oligonucleotide probes are used, fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and 15 others [e.g., Kricka et al. (1992), Academic Press San Diego, Calif] can be attached to the oligonucleotides. Those skilled in the art will appreciate that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide 20 primers and probes. It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays. For instance, samples may be hybridized to an irrelevant probe and treated with RNAse A prior to hybridization, to assess false hybridization. Although the present invention is not specifically dependent on the use of a label for the 25 detection of a particular nucleic acid sequence, such a label might be beneficial, by increasing the sensitivity of the detection. Furthermore, it enables automation. Probes can be labeled according to numerous well known methods. As commonly known, radioactive nucleotides can be incorporated into probes of the invention by several methods. Non-limiting examples of radioactive labels include 3 H, 14C, 32 p, 30 and 3 5 S. Those skilled in the art will appreciate that wash steps may be employed to wash away WO 2005/069724 PCT/IB2005/001306 69 excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide primers and probes. It will be appreciated that a variety of controls may be usefully employed to improve 5 accuracy of hybridization assays. Probes of the invention can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and a-nucleotides and the like. Probes of the invention can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA. 10 NAT Assays Detection of a nucleic acid of interest in a biological sample may also optionally be effected by NAT-based assays, which involve nucleic acid amplification technology, such as PCR for example (or variations thereof such as real-time PCR for example). 15 As used herein, a "primer" defines an oligonucleotide which is capable of annealing to (hybridizing with) a target sequence, thereby creating a double stranded region which can serve as an initiation point for DNA synthesis under suitable conditions. Amplification of a selected, or target, nucleic acid sequence may be carried out by a number of suitable methods. See generally Kwoh et al., 1990, Am. Biotechnol. Lab. 8:14 20 Numerous amplification techniques have been described and can be readily adapted to suit particular needs of a person of ordinary skill. Non-limiting examples of amplification techniques include polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-based amplification, the q3 replicase system and NASBA (Kwoh et al., 1989, Proc. NatI. Acad. Sci. USA 86, 1173-1177; Lizardi et al., 1988, 25 BioTechnology 6:1197-1202; Malek et al., 1994, Methods Mol. Biol., 28:253-260; and Sambrook et al., 1989, sup ra). The terminology "amplification pair" (or "primer pair") refers herein to a pair of oligonucleotides (oligos) of the present invention, which are selected to be used together in amplifying a selected nucleic acid sequence by one of a number of types of amplification 30 processes, preferably a polymerase chain reaction. Other types of amplification processes include ligase chain reaction, strand displacement amplification, or nucleic acid sequence-based WO 2005/069724 PCT/IB2005/001306 70 amplification, as explained in greater detail below. As commonly known in the art, the oligos are designed to bind to a complementary sequence under selected conditions. In one particular embodiment, amplification of a nucleic acid sample from a patient is amplified under conditions which favor the amplification of the most abundant differentially 5 expressed nucleic acid. In one preferred embodiment, RT-PCR is carried out on an mRNA sample from a patient under conditions which favor the amplification of the most abundant mRNA. In another preferred embodiment, the amplification of the differentially expressed nucleic acids is carried out simultaneously. It will be realized by a person skilled in the art that such methods could be adapted for the detection of differentially expressed proteins instead of 10 differentially expressed nucleic acid sequences. The nucleic acid (i.e. DNA or RNA) for practicing the present invention may be obtained according to well known methods. Oligonucleotide primers of the present invention may be of any suitable length, depending on the particular assay format and the particular needs and targeted genomes 15 employed. Optionally, the oligonucleotide primers are at least 12 nucleotides in length, preferably between 15 and 24 molecules, and they may be adapted to be especially suited to a chosen nucleic acid amplification system. As commonly known in the art, the oligonucleotide primers can be designed by taking into consideration the melting point of hybridization thereof with its targeted sequence (Sambrook et al., 1989, Molecular Cloning -A Laboratory Manual, 20 2nd Edition, CSH Laboratories; Ausubel et al., 1989, in Current Protocols in Molecular Biology, John Wiley & Sons Inc., N.Y.). It will be appreciated that antisense oligonucleotides may be employed to quantify expression of a splice isoform of interest. Such detection is effected at the pre-mRNA level. Essentially the ability to quantitate transcription from a splice site of interest can be effected 25 based on splice site accessibility. Oligonucleotides may compete with splicing factors for the splice site sequences. Thus, low activity of the antisense oligonucleotide is indicative of splicing activity. The polymerase chain reaction and other nucleic acid amplification reactions are well known in the art (various non-limiting examples of these reactions are described in greater detail 30 below). The pair of oligonucleotides according to this aspect of the present invention are preferably selected to have compatible melting temperatures (Tm), e.g., melting temperatures WO 2005/069724 PCT/IB2005/001306 71 which differ by less than that 7 'C, preferably less than 5 'C, more preferably less than 4 oC, most preferably less than 3 oC, ideally between 3 'C and 0 oC. Polymnerase Chain Reaction (PCR): The polymerase chain reaction (PCR), as described in U.S. Pat. Nos. 4,683,195 and 4,683,202 to Mullis and Mullis et al., is a method of increasing 5 the concentration of a segment of target sequence in a mixture of genomic DNA without cloning or purification. This technology provides one approach to the problems of low target sequence concentration. PCR can be used to directly increase the concentration of the target to an easily detectable level. This process for amplifying the target sequence involves the introduction of a molar excess of two oligonucleotide primers which are complementary to their respective strands 10 of the double-stranded target sequence to the DNA mixture containing the desired target sequence. The mixture is denatured and then allowed to hybridize. Following hybridization, the primers are extended with polymerase so as to form complementary strands. The steps of denaturation, hybridization (annealing), and polymerase extension (elongation) can be repeated as often as needed, in order to obtain relatively high concentrations of a segment of the desired 15 target sequence. The length of the segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and, therefore, this length is a controllable parameter. Because the desired segments of the target sequence become the dominant sequences (in tennrms of concentration) in the mixture, they are said to be "PCR-amplified." 20 Ligase Chain Reaction (LCR or LAR): The ligase chain reaction [LCR; sometimes referred to as "Ligase Amplification Reaction" (LAR)] has developed into a well-recognized alternative method of amplifying nucleic acids. In LCR, four oligonucleotides, two adjacent oligonucleotides which uniquely hybridize to one strand of target DNA, and a complementary set of adjacent oligonucleotides, which hybridize to the opposite strand are mixed and DNA ligase is 25 added to the mixture. Provided that there is complete complementarity at the junction, ligase will covalently link each set of hybridized molecules. Importantly, in LCR, two probes are ligated together only when they base-pair with sequences in the target sample, without gaps or mismatches. Repeated cycles of denaturation, and ligation amplify a short segment of DNA. LCR has also been used in combination with PCR to achieve enhanced detection of single-base 30 changes: see for example Segev, PCT Publication No. W09001069 Al (1990). However, because the four oligonucleotides used in this assay can pair to form two short ligatable WO 2005/069724 PCT/IB2005/001306 72 fragments, there is the potential for the generation of target-independent background signal. The use of LCR for mutant screening is limited to the examination of specific nucleic acid positions. Self-Sustained Synthetic Reaction (3SR/NASBA): The self-sustained sequence replication reaction (3SR) is a transcription-based in vitro amplification system that can exponentially 5 amplify RNA sequences at a uniformnn temperature. The amplified RNA can then be utilized for mutation detection. In this method, an oligonucleotide primer is used to add a phage RNA polymerase promoter to the 5' end of the sequence of interest. In a cocktail of enzymes and substrates that includes a second primer, reverse transcriptase, RNase H, RNA polymerase and ribo-and deoxyribonucleoside triphosphates, the target sequence undergoes repeated rounds of 10 transcription, cDNA synthesis and second-strand synthesis to amplify the area of interest. The use of 3SR to detect mutations is kinetically limited to screening small segments of DNA (e.g., 200-300 base pairs). Q-Beta (Qj3) Replicase: In this method, a probe which recognizes the sequence of interest is attached to the replicatable RNA template for Q3 replicase. A previously identified 15 major problem with false positives resulting from the replication of unhybridized probes has been addressed through use of a sequence-specific ligation step. However, available thermostable DNA ligases are not effective on this RNA substrate, so the ligation must be performed by T4 DNA ligase at low temperatures (37 degrees C.). This prevents the use of high temperature as a means of achieving specificity as in the LCR, the ligation event can be used to 20 detect a mutation at the junction site, but not elsewhere. A successful diagnostic method must be very specific. A straight-forward method of controlling the specificity of nucleic acid hybridization is by controlling the temperature of the reaction. While the 3SR/NASBA, and Q3 systems are all able to generate a large quantity of signal, one or more of the enzymes involved in each cannot be used at high temperature (i.e., > 25 55 degrees C). Therefore the reaction temperatures cannot be raised to prevent non-specific hybridization of the probes. If probes are shortened in order to make them melt more easily at low temperatures, the likelihood of having more than one perfect match in a complex genome increases. For these reasons, PCR and LCR currently dominate the research field in detection technologies. 30 The basis of the amplification procedure in the PCR and LCR is the fact that the products of one cycle become usable templates in all subsequent cycles, consequently doubling the WO 2005/069724 PCT/IB2005/001306 73 population with each cycle. The final yield of any such doubling system can be expressed as: (I+X)n =y, where "X" is the mean efficiency (percent copied in each cycle), "n" is the number of cycles, and "y" is the overall efficiency, or yield of the reaction. If every copy of a target DNA is utilized as a template in every cycle of a polymerase chain reaction, then the mean efficiency is 5 100 %. If 20 cycles of PCR are performed, then the yield will be 220, or 1,048,576 copies of the starting material. If the reaction conditions reduce the mean efficiency to 85 %, then the yield in those 20 cycles will be only 1.8520, or 220,513 copies of the starting material. In other words, a PCR running at 85 % efficiency will yield only 21 % as much final product, compared to a reaction running at 100 % efficiency. A reaction that is reduced to 50 % mean efficiency will 10 yield less than 1 % of the possible product. In practice, routine polymerase chain reactions rarely achieve the theoretical maximum yield, and PCRs are usually run for more than 20 cycles to compensate for the lower yield. At 50 % mean efficiency, it would take 34 cycles to achieve the million-fold amplification theoretically possible in 20, and at lower efficiencies, the number of cycles required becomes 15 prohibitive. In addition, any background products that amplify with a better mean efficiency than the intended target will become the dominant products. Also, many variables can influence the mean efficiency of PCR, including target DNA length and secondary structure, primer length and design, primer and dNTP concentrations, and buffer composition, to name but a few. Contamination of the reaction with exogenous DNA 20 (e.g., DNA spilled onto lab surfaces) or cross-contamination is also a major consideration. Reaction conditions must be carefully optimized for each different primer pair and target sequence, and the process can take days, even for an experienced investigator. The laboriousness of this process, including numerous technical considerations and other factors, presents a significant drawback to using PCR in the clinical setting. Indeed, PCR has yet to 25 penetrate the clinical market in a significant way. The same concerns arise with LCR, as LCR must also be optimized to use different oligonucleotide sequences for each target sequence. In addition, both methods require expensive equipment, capable of precise temperature cycling. Many applications of nucleic acid detection technologies, such as in studies of allelic variation, involve not only detection of a specific sequence in a complex background, but also 30 the discrimination between sequences with few, or single, nucleotide differences. One method of the detection of allele-specific variants by PCR is based upon the fact that it is difficult for Taq WO 2005/069724 PCT/IB2005/001306 74 polymerase to synthesize a DNA strand when there is a mismatch between the template strand and the 3' end of the primer. An allele-specific variant may be detected by the use of a primer that is perfectly matched with only one of the possible alleles; the mismatch to the other allele acts to prevent the extension of the primer, thereby preventing the amplification of that sequence. 5 This method has a substantial limitation in that the base composition of the mismatch influences the ability to prevent extension across the mismatch, and certain mismatches do not prevent extension or have only a minimal effect. A similar 3'-mismatch strategy is used with greater effect to prevent ligation in the LCR. Any mismatch effectively blocks the action of the thennostable ligase, but LCR still has the 10 drawback of target-independent background ligation products initiating the amplification. Moreover, the combination of PCR with subsequent LCR to identify the nucleotides at individual positions is also a clearly cumbersome proposition for the clinical laboratory. The direct detection method according to various preferred embodiments of the present invention may be, for example a cycling probe reaction (CPR) or a branched DNA analysis. 15 When a sufficient amount of a nucleic acid to be detected is available, there are advantages to detecting that sequence directly, instead of making more copies of that target, (e.g., as in PCR and LCR). Most notably, a method that does not amplify the signal exponentially is more amenable to quantitative analysis. Even if the signal is enhanced by attaching multiple dyes to a single oligonucleotide, the correlation between the final signal 20 intensity and amount of target is direct. Such a system has an additional advantage that the products of the reaction will not themselves promote further reaction, so contamination of lab surfaces by the products is not as much of a concern. Recently devised techniques have sought to eliminate the use of radioactivity and/or improve the sensitivity in automatable formats. Two examples are the "Cycling Probe Reaction" (CPR), and "Branched DNA" (bDNA). 25 Cycling probe reaction (CPR): The cycling probe reaction (CPR), uses a long chimeric oligonucleotide in which a central portion is made of RNA while the two termini are made of DNA. Hybridization of the probe to a target DNA and exposure to a thermostable RNase H causes the RNA portion to be digested. This destabilizes the remaining DNA portions of the duplex, releasing the remainder of the probe from the target DNA and allowing another probe 30 molecule to repeat the process. The signal, in the form of cleaved probe molecules, accumulates at a linear rate. While the repeating process increases the signal, the RNA portion of the WO 2005/069724 PCT/IB2005/001306 75 oligonucleotide is vulnerable to RNases that may carried through sample preparation. Branched DNA: Branched DNA (bDNA), involves oligonucleotides with branched structures that allow each individual oligonucleotide to carry 35 to 40 labels (e.g., alkaline phosphatase enzymes). While this enhances the signal from a hybridization event, signal from 5 non-specific binding is similarly increased. The detection of at least one sequence change according to various preferred embodiments of the present invention may be accomplished by, for example restriction fragment length polymorphism (RFLP analysis), allele specific oligonucleotide (ASO) analysis, Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE), Single-Strand 10 Conformation Polymorphism (SSCP) analysis or Dideoxy fingerprinting (ddF). The demand for tests which allow the detection of specific nucleic acid sequences and sequence changes is growing rapidly in clinical diagnostics. As nucleic acid sequence data for genes from humans and pathogenic organisms accumulates, the demand for fast, cost-effective, and easy-to-use tests for as yet mutations within specific sequences is rapidly increasing. 15 A handful of methods have been devised to scan nucleic acid segments for mutations. One option is to determine the entire gene sequence of each test sample (e.g., a bacterial isolate). For sequences under approximately 600 nucleotides, this may be accomplished using amplified material (e.g., PCR reaction products). This avoids the time and expense associated with cloning the segment of interest. However, specialized equipment and highly trained personnel are 20 required, and the method is too labor-intense and expensive to be practical and effective in the clinical setting. In view of the difficulties associated with sequencing, a given segment of nucleic acid may be characterized on several other levels. At the lowest resolution, the size of the molecule can be determined by electrophoresis by comparison to a known standard run on the same gel. A 25 more detailed picture of the molecule may be achieved by cleavage with combinations of restriction enzymes prior to electrophoresis, to allow construction of an ordered map. The presence of specific sequences within the fragment can be detected by hybridization of a labeled probe, or the precise nucleotide sequence can be determined by partial chemical degradation or by primer extension in the presence of chain-terminating nucleotide analogs. 30 Restriction fragment length polymorphism (RFLP): For detection of single-base differences between like sequences, the requirements of the analysis are often at the highest level WO 2005/069724 PCT/IB2005/001306 76 of resolution. For cases in which the position of the nucleotide in question is known in advance, several methods have been developed for examining single base changes without direct sequencing. For example, if a mutation of interest happens to fall within a restriction recognition sequence, a change in the pattern of digestion can be used as a diagnostic tool (e.g., restriction 5 fragment length polymorphism [RFLP] analysis). Single point mutations have been also detected by the creation or destruction of RFLPs. Mutations are detected and localized by the presence and size of the RNA fragments generated by cleavage at the mismatches. Single nucleotide mismatches in DNA heteroduplexes are also recognized and cleaved by some chemicals, providing an alternative strategy to detect single 10 base substitutions, generically named the "Mismatch Chemical Cleavage" (MCC). However, this method requires the use of osmium tetroxide and piperidine, two highly noxious chemicals which are not suited for use in a clinical laboratory. RFLP analysis suffers from low sensitivity and requires a large amount of sample. When RFLP analysis is used for the detection of point mutations, it is, by its nature, limited to the 15 detection of only those single base changes which fall within a restriction sequence of a known restriction endonuclease. Moreover, the majority of the available enzymes have 4 to 6 base-pair recognition sequences, and cleave too frequently for many large-scale DNA manipulations. Thus, it is applicable only in a small fraction of cases, as most mutations do not fall within such sites. 20 A handful of rare-cutting restriction enzymes with 8 base-pair specificities have been isolated and these are widely used in genetic mapping, but these enzymes are few in number, are limited to the recognition of G+C-rich sequences, and cleave at sites that tend to be highly clustered. Recently, endonucleases encoded by group I introns have been discovered that might have greater than 12 base-pair specificity, but again, these are few in number. 25 Allele specific oligonucleotide (ASO): If the change is not in a recognition sequence, then allele-specific oligonucleotides (ASOs), can be designed to hybridize in proximity to the mutated nucleotide, such that a primer extension or ligation event can bused as the indicator of a match or a mis-match. Hybridization with radioactively labeled allelic specific oligonucleotides (ASO) also has been applied to the detection of specific point mutations. The method is based 30 on the differences in the melting temperature of short DNA fragments differing by a single nucleotide. Stringent hybridization and washing conditions can differentiate between mutant and WO 2005/069724 PCT/IB2005/001306 77 wild-type alleles. The ASO approach applied to PCR products also has been extensively utilized by various researchers to detect and characterize point mutations in ras genes and gsp/gip oncogenes. Because of the presence of various nucleotide changes in multiple positions, the ASO method requires the use of many oligonucleotides to cover all possible oncogenic 5 mutations. With either of the techniques described above (i.e., RFLP and ASO), the precise location of the suspected mutation must be known in advance of the test. That is to say, they are inapplicable when one needs to detect the presence of a mutation within a gene or sequence of interest. 10 Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE): Two other methods rely on detecting changes in electrophoretic mobility in response to minor sequence changes. One of these methods, termed "Denaturing Gradient Gel Electrophoresis" (DGGE) is based on the observation that slightly different sequences will display different patterns of local melting when electrophoretically resolved on a gradient gel. In this manner, variants can be 15 distinguished, as differences in melting properties of homoduplexes versus heteroduplexes differing in a single nucleotide can detect the presence of mutations in the target sequences because of the corresponding changes in their electrophoretic mobilities. The fragments to be analyzed, usually PCR products, are "clamped" at one end by a long stretch of G-C base pairs (30-80) to allow complete denaturation of the sequence of interest without complete dissociation 20 of the strands. The attachment of a GC "clamp" to the DNA fragments increases the fraction of mutations that can be recognized by DGGE. Attaching a GC clamp to one primer is critical to ensure that the amplified sequence has a low dissociation temperature. Modifications of the technique have been developed, using temperature gradients, and the method can be also applied to RNA:RNA duplexes. 25 Limitations on the utility of DGGE include the requirement that the denaturing conditions must be optimized for each type of DNA to be tested. Furthermore, the method requires specialized equipment to prepare the gels and maintain the needed high temperatures during electrophoresis. The expense associated with the synthesis of the clamping tail on one oligonucleotide for each sequence to be tested is also a major consideration. In addition, long 30 running times are required for DGGE. The long running time of DGGE was shortened in a modification of DGGE called constant denaturant gel electrophoresis (CDGE). CDGE requires WO 2005/069724 PCT/IB2005/001306 78 that gels be performed under different denaturant conditions in order to reach high efficiency for the detection of mutations. A technique analogous to DGGE, termed temperature gradient gel electrophoresis (TGGE), uses a thermal gradient rather than a chemical denaturant gradient. TGGE requires the 5 use of specialized equipment which can generate a temperature gradient perpendicularly oriented relative to the electrical field. TGGE can detect mutations in relatively small fragments of DNA therefore scanning of large gene segments requires the use of multiple PCR products prior to running the gel. Single-Strand Conformation Polymorphism (SSCP): Another conummon method, called 10 "Single-Strand Conformation Polymorphism" (SSCP) was developed by Hayashi, Sekya and colleagues and is based on the observation that single strands of nucleic acid can take on characteristic conformations in non-denaturing conditions, and these conformations influence electrophoretic mobility. The complementary strands assume sufficiently different structures that one strand may be resolved from the other. Changes in sequences within the fragment will 15 also change the conformation, consequently altering the mobility and allowing this to be used as an assay for sequence variations. The SSCP process involves denaturing a DNA segment (e.g., a PCR product) that is labeled on both strands, followed by slow electrophoretic separation on a non-denaturing polyacrylamide gel, so that intra-molecular interactions can form and not be disturbed during the 20 run. This technique is extremely sensitive to variations in gel composition and temperature. A serious limitation of this method is the relative difficulty encountered in comparing data generated in different laboratories, under apparently similar conditions. Dideoxy fingerprinting (ddF): The dideoxy fingerprinting (ddF) is another technique developed to scan genes for the presence of mutations. The ddF technique combines 25 components of Sanger dideoxy sequencing with SSCP. A dideoxy sequencing reaction is performed using one dideoxy terminator and then the reaction products are electrophoresed on nondenaturing polyacrylamide gels to detect alterations in mobility of the termination segments as in SSCP analysis. While ddF is an improvement over SSCP in terms of increased sensitivity, ddF requires the use of expensive dideoxynucleotides and this technique is still limited to the 30 analysis of fragments of the size suitable for SSCP (i.e., fragments of 200-300 bases for optimal detection of mutations).

WO 2005/069724 PCT/IB2005/001306 79 In addition to the above limitations, all of these methods are limited as to the size of the nucleic acid fragment that can be analyzed. For the direct sequencing approach, sequences of greater than 600 base pairs require cloning, with the consequent delays and expense of either deletion sub-cloning or primer walking, in order to cover the entire fragment. SSCP and DGGE 5 have even more severe size limitations. Because of reduced sensitivity to sequence changes, these methods are not considered suitable for larger fragments. Although SSCP is reportedly able to detect 90 % of single-base substitutions within a 200 base-pair fragment, the detection drops to less than 50 % for 400 base pair fragments. Similarly, the sensitivity of DGGE decreases as the length of the fragment reaches 500 base-pairs. The ddF technique, as a combination of direct 10 sequencing and SSCP, is also limited by the relatively small size of the DNA that can be screened. According to a presently preferred embodiment of the present invention the step of searching for any of the nucleic acid sequences described here, in tumor cells or in cells derived from a cancer patient is effected by any suitable technique, including, but not limited to, nucleic 15 acid sequencing, polymerase chain reaction, ligase chain reaction, self-sustained synthetic reaction, QP-Replicase, cycling probe reaction, branched DNA, restriction fragment length polymorphism analysis, mismatch chemical cleavage, heteroduplex analysis, allele-specific oligonucleotides, denaturing gradient gel electrophoresis, constant denaturant gel electrophoresis, temperature gradient gel electrophoresis and dideoxy fingerprinting. 20 Detection may also optionally be performed with a chip or other such device. The nucleic acid sample which includes the candidate region to be analyzed is preferably isolated, amplified and labeled with a reporter group. This reporter group can be a fluorescent group such as phycoerythrin. The labeled nucleic acid is then incubated with the probes immobilized on the chip using a fluidics station. describe the fabrication of fluidics devices and particularly 25 microcapillary devices, in silicon and glass substrates. Once the reaction is completed, the chip is inserted into a scanner and patterns of hybridization are detected. The hybridization data is collected, as a signal emitted from the reporter groups already incorporated into the nucleic acid, which is now bound to the probes attached to the chip. Since the sequence and position of each probe immobilized on the chip is 30 known, the identity of the nucleic acid hybridized to a given probe can be determined. It will be appreciated that when utilized along with automated equipment, the above WO 2005/069724 PCT/IB2005/001306 80 described detection methods can be used to screen multiple samples for a disease and/or pathological condition both rapidly and easily. Amino acid sequences and peptides 5 The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins. The terms 10 "polypeptide," "peptide" and "protein" include glycoproteins, as well as non-glycoproteins. Polypeptide products can be biochemically synthesized such as by employing standard solid phase techniques. Such methods include but are not limited to exclusive solid phase synthesis, partial solid -phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) 15 and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry. Solid phase polypeptide synthesis procedures are well known in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Peptide Syntheses (2nd Ed., Pierce Chemical Company, 1984). 20 Synthetic polypeptides can optionally be purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.], after which their composition can be confirmed via amino acid sequencing. In cases where large amounts of a polypeptide are desired, it can be generated using 25 recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516 544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511 514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, 30 Section VIII, pp 421-463. The present invention also encompasses polypeptides encoded by the polynucleotide WO 2005/069724 PCT/IB2005/001306 81 sequences of the present invention, as well as polypeptides according to the amino acid sequences described herein. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % 5 homologous to the amino acid sequences set forth below, as can be determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters, optionally and preferably including the following: filtering on (this option filters repetitive or low-complexity sequences from the query using the Seg (protein) program), scoring matrix is BLOSUM62 for proteins, word size is 3, E value is 10, gap costs are 11, 1 (initialization and 10 extension), and number of alignments shown is 50. Optionally and preferably, nucleic acid sequence homology (identity) is determined using BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters, which preferably include using the DUST filter program, and also preferably include having an E value of 10, filtering low complexity sequences and a word size of 11. Finally, the present invention also encompasses 15 fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or artificially induced, either randomly or in a targeted fashion. It will be appreciated that peptides identified according the present invention may be degradation products, synthetic peptides or recombinant peptides as well as peptidomimetics, 20 typically, synthetic peptides and peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C terminus modification, peptide bond modification, including, but not limited to, CH2-NH, CH2-S, CH2-S=O, O=C-NH, CH2-O, CH2-CH2, S=C-NH, CH=CH or 25 CF=CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified. Further details in this respect are provided hereinunder. Peptide bonds (CO-NH-) within the peptide may be substituted, for example, by N methylated bonds (-N(CH3)-CO-), ester bonds (-C(R)H-C-O-O-C(R)-N-), ketomethylen bonds 30 (-CO-CH2-), a-aza bonds (-NH-N(R)-CO-), wherein R is any alkyl, e.g., methyl, carba bonds ( CH2-NH-), hydroxyethylene bonds (-CH(OH)-CH2-), thioamide bonds (-CS-NH-), olefinic WO 2005/069724 PCT/IB2005/001306 82 double bonds (-CH=CH-), retro amide bonds (-NH-CO-), peptide derivatives (-N(R)-CH2-CO-), wherein R is the "normal" side chain, naturally presented on the carbon atom. These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time. 5 Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted for synthetic non natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr. In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex 10 carbohydrates etc). As used herein in the specification and in the claims section below the term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited 15 to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids. Table 1 non-conventional or modified amino acids which can be used with the present invention. 20 Table 1 Non-conventional amino Code Non-conventional amino acid Code acid ca-aminobutyric acid Abu L-N-methylalanine Nmala oa-amino- ca-methylbutyrate Mgabu L-N-methylarginine Nmarg aminocyclopropane- Cpro L-N-methylasparagine Nmasn Carboxylate L-N-methylaspartic acid Nmasp aminoisobutyric acid Aib L-N-methylcysteine Nmcys aminonorbomrnyl- Norb L-N-methylglutamine Nmgin WO 2005/069724 PCT/1B2005/001306 83 Carboxylate L-N.-rethylglutamic acid Nmglu Cyclohexylalanine Chexa L-N-methylhistidine Nmhis Cyclopentylalanine Cpen L-N-methylisolleucine Nmile D-alanine Dal L-N-methylleucine Nmleu D-arginine Darg L-N-rnethyllysine Nmlys D-aspartic acid Dasp L-N-methylmethionine Nmr-net D-cysteine Dcys L-N-rnethylnorleucine Nmnle D-glutamine Dgln L-N-methylnorvaline Nrnnva D-glutamic acid Dglu L-N-.methylomithine Nmorn D-histidine Dhis L-N-methylphenylalanine Nmphe D-isoleucine Dile L-N-methylproline Nmpro D-leucine Dleu L-N-inethylserine Nmser D-lysine Dlys L-N-rnethylthreonine Nmthr D-methionine Dmet L-N-methyltryptophan Nintrp D-ornithine Domn L-N-methyltyrosine Nmtyr D-phenylalanine Dphe L-N-methylvaline Nmval D-proline Dpro L-N-methylethylglycine Nmetg D-sefine Dser L-N-methyl-t-butylglycine Nmtbug D-threonine Dthr L-norleucine Mie D-tryptophan Dtrp L-norvaline Nva D-tyrosine Dtyr ca-methy-aminoisobutyrate Maib D-valine Dval ox-methyl-y-aminobutyrate Mgabu D-cL-methylalanine Dmala ax-methylcyclohexylalanine Mchexa D-u.-methylarginine Dmarg ca-methylcyclopentylalanine Mcpen D-cc-methylasparagine Dinasn ac-methyl- o-napthylalanine Manap D-cc-methylaspartate Dmasp u- methylpenicillamine Mpen D-a-methylcysteine Dmcys N-(4-aminobutyl)glycine Nglu D-a-methylglutamine Dmgln N-(2-aniinoethyl)glycine Naeg D-ua-methylhistidine Dnihis N-(3-aminopropyl)glycine Nomn WO 2005/069724 PCT/1B2005/001306 D- ci-methylisoleucine Dmile N- aino- cc-methylbutyrate Nmaabu D-a-methy11eucine Dmleu c-napthylalanine Anap D-ca-methy11ysine Dmlys N-benzylglycine Nphe D-cc-methylmethionine Dmmnet N-(2-carbamylethyl)glycifle Ngln D-u.-methylornithine Dmom N-(carbainylmethyl)glycifle Nasn D-ca-methylphenylalanine Dmphe N-(2-carboxyethyl)glycifle Nglu D-oa-rethylproline D5mpro N-(carboxymethyl)glycifle Nasp D-ca-methylserine Dmser N-cyclobutylglycine Ncbut D-cL-methylthreonine Dmthr N-cycloheptylglycine Nchep D-oa-methyltryptophan Dmtrp N-cyclohexylglycine Nohex D-c-iethyltyrosine Dmty N-cyclodecylglycine Nodec D-ac-methylvaline Dmval N-cyclododeclglycine Ncdod D-ca-methylalnine Dnmnala N-cyclooctylglycine Ncoct D-ao-methylarginine Dnrnarg N-cyclopropylglycine Ncpro D-c-methylasparagine Dnmasn N-cycloundlecylglycine Ncund D-cc-methylasparatate Dnmasp N-(2,2-diphenylethyl)glycine Nbbm D-ca-methylcysteine Dncys N-(3,3- Nbhe dipheniylpropyl)glycine D-N-methylleucine Dnmleu N-(3-indolylyethyl) glycine Nhtrp D-N-methyllysine Dnlys N-methyl- y-aminobutyrate Nmgabu N- Nmchexa D-N-methylmethionine Dnrnmet methylcyclohexylalanine D-N-mnethylornithine Dnmom N-methylcyclopentylalalife Nmcpen N-methylglycine Nala D-N-methylphenylalanine Dnphe N-methylaminoisobutyrate Nmaib D-N-methylproline Dnmpro N-(1-methylpropyl)glycine Nile D-N-methylserine Dnmser N-(2-methylpropyl)glycine Nile D-N-methylserine Dnser N-(2-methylpropyl)glycine Nleu D-N-methylthreonine Dnmthr D-N-methyltryptophan Dnmtrp N-(l -methylethyl)glycine Nva WO 2005/069724 PCT/1B2005/001306 85 D-N-rnethyltyrosine Dntyr N-rnethyla- napthylalanine Nmanap D-N-rnethylvaline Dnmval N-mrethylpenicillamine Nmpen ,y-aminobutyric acid Gabu N-(p-hydroxyphenylI)glycine Nhtyr L-t-butylglycine Thug N-(thiomethyl)glycine Ncys L-ethylglycine Etg Penicillamine Pen L-homophenylalanine Hphe Lac-methylalanine Mala L-c-methylarginine Marg L-c'.-methylasparagine Masn L- o.-methylaspartate Masp L-ct.-methy-t-butylglycine Mtbug L-cx-methylcysteine Mcys L- methylethyiglycine Metg L-u.-methylglutamine Mgln Lac-methylglutamate Mglu L-cu-methyllhistidine Mhis Lc-methylhomo Mhfphe phenylalanine L-ca-methylisoleucine Mie N-(2-rnethylthioethyl)glycine Nmet D-N-methylglutamine Dngln N-(3- Narg guanidinopropyl)glycine D-.N-methylglutamate Dnmglu N-(1 -hydroxyethyl)glycine Ntbr D-N-methylhistidine Dnmihis N-(hydroxyethyl)glycine Nser D-N-methylisoleucine Dnile N-(imnidazolylethyl)glycine Nhis D-N-methylleucine Dnmleu N-(3-indolylyethyl)glycine Nhtrp D-N-methyllysine Dnlys N-methyl-,y-aminobutyrate Nmgabu N- Nmchexa D-N-methylmethionine Dnmmet methylcyclohexylalanine D-N-methylornithine Dnmorn N-methylcyclopentylalanine Nmcpen N-methylglycine Nala D-N-methylphenylalanine Dnmphe N-methylamninoisobutyrate Nmaib D-N-methylproline Dnpro N-(1 -methylpropyl)glycine Nile D-N-methylserine Drnser N-(2-methylpropyl)glycine Nlen D-N-methyltbreonine Dnthr D-N-methyltryptophan Dntrp N-(1 -methylethyl)glycine Nval D-N-methyltyrosine, Dntyr N-methyla-napthylalanine Nmanap WO 2005/069724 PCT/IB2005/001306 86 D-N-mnethylvaline Dnmval N-methylpenicillamine Nmpen y-aminobutyric acid Gabu N-(p-hydroxyphenyl)glycine Nhtyr L-t-butylglycine Tbug N-(thiomethyl)glycine Ncys L-ethylglycine Etg Penicillamine Pen L-homophenylalanine Hphe L-c-methylalanine Mala L-a-methylarginine Marg L-c-methylasparagine Masn L-a-methylaspartate Masp L-a-methyl-t-butylglycine Mtbug L-a-methylcysteine Mcys L-methylethylglycine Metg L-a(-methylglutamine Mgln L-a-methylglutamate Mglu L-c-methylhistidine Mhis L-c- Mhphe methylhomophenylalanine L-ac-methylisoleucine Mile N-(2-methylthioethyl)glycine Nmet L-o-methylleucine Mleu L-a-methyllysine Mlys L-ac-methylmethionine Mmnet L-au-methylnorleucine Mnle L-c-methylnorvaline Mnva L-c-methylornithine Morn L-c-methylphenylalanine Mphe L-c-methylproline Mpro L-a-methylserine mser L-a-methylthreonine Mthr L-c-methylvaline Mtrp L-a-methyltyrosine Mtyr L-c-methylleucine Mval L-N- Nmhphe Nnbhm methylhomophenylalanine N-(N-(2,2-diphenylethyl) N-(N-(3,3-diphenylpropyl) carbamylmnethyl-glycine Nnbhm carbamylmethyl(1)glycine Nnbhe 1-carboxy-l-(2,2-diphenyl Nmbc ethylamino)cyclopropane Table 1 Cont. Since the peptides of the present invention are preferably utilized in diagnostics which require the peptides to be in soluble form, the peptides of the present invention preferably 5 include one or more non-natural or natural polar amino acids, including but not limited to serine and threonine which are capable of increasing peptide solubility due to their hydroxyl-containing WO 2005/069724 PCT/IB2005/001306 87 side chain. The peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclicization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized. 5 The peptides of present invention can be biochemically synthesized such as by using standard solid phase techniques. These methods include exclusive solid phase synthesis well known in the art, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic 10 acid sequence) and therefore involves different chemistry. Synthetic peptides can be purified by preparative high performance liquid chromatography and the composition of which can be confirmed via amino acid sequencing. In cases where large amounts of the peptides of the present invention are desired, the peptides of the present invention can be generated using recombinant techniques such as 15 described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 20 421-463 and also as described above. Antibodies "Antibody" refers to a polypeptide ligand that is preferably substantially encoded by an 25 immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically binds and recognizes an epitope (e.g., an antigen). The recognized immunoglobulin genes include the kappa and lambda light chain constant region genes, the alpha, gamma, delta, epsilon and mu heavy chain constant region genes, and the myriad-immunoglobulin variable region genes. Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments 30 produced by digestion with various peptidases. This includes, e.g., Fab' and F(ab)' 2 fragments. The term "antibody," as used herein, also includes antibody fragments either produced by the WO 2005/069724 PCT/IB2005/001306 88 modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies. It also includes polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, or single chain antibodies. "Fc" portion of an antibody refers to that portion of an immunoglobulin heavy chain that comprises one or more heavy chain 5 constant region domains, CH1, CH2 and CH3, but does not include the heavy chain variable region. The functional fragments of antibodies, such as Fab, F(ab')2, and Fv that are capable of binding to macrophages, are described as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of 10 whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without 15 subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as 20 a genetically fused single chain molecule. Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference). Antibody fragments according to the present invention can be prepared by proteolytic 25 hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2. This fragment can 30 be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' WO 2005/069724 PCT/IB2005/001306 89 monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. 5 R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody. Fv fragments comprise an association of VH and VL chains. This association may be 10 noncovalent, as described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL 15 domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 20 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety. Another form of an antibody fragment is a peptide coding for a single complementarity detennining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of 25 antibody-producing cells. See, for example, Larrick and Fry [Methods, 2:106-10 (1991)]. Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins 30 (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as WO 2005/069724 PCT/IB2005/001306 90 mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized 5 antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human 10 immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323 329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)]. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, 15 which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534 1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. 20 Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Human antibodies can also be produced using various techniques known in the art, 25 including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human 30 immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes haw been partially or completely inactivated. Upon challenge, human WO 2005/069724 PCT/IB2005/001306 91 antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10,: 779 5 783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995). Preferably, the antibody of this aspect of the present invention specifically binds at least one epitope of the polypeptide variants of the present invention. As used herein, the term 10 "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. 15 Optionally, a unique epitope may be created in a variant due to a change in one or more post-translational modifications, including but not limited to glycosylation and/or phosphorylation, as described below. Such a change may also cause a new epitope to be created, for example through removal of glycosylation at a particular site. An epitope according to the present invention may also optionally comprise part or all of 20 a unique sequence portion of a variant according to the present invention in combination with at least one other portion of the variant which is not contiguous to the unique sequence portion in the linear polypeptide itself, yet which are able to form an epitope in combination. One or more unique sequence portions may optionally combine with one or more other non-contiguous portions of the variant (including a portion which may have high homology to a portion of the 25 known protein) to form an epitope. Immunoassays In another embodiment of the present invention, an immunoassay can be used to qualitatively or quantitatively detect and analyze markers in a sample. This method comprises: 30 providing an antibody that specifically binds to a marker; contacting a sample with the antibody; and detecting the presence of a complex of the antibody bound to the marker in the sample.

WO 2005/069724 PCT/IB2005/001306 92 To prepare an antibody that specifically binds to a marker, purified protein markers can be used. Antibodies that specifically bind to a protein marker can be prepared using any suitable methods known in the art. After the antibody is provided, a marker can be detected and/or quantified using any of a 5 number of well recognized immunological binding assays. Useful assays include, for example, an enzyme immune assay (EIA) such as enzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), a Western blot assay, or a slot blot assay see, e.g., U.S. Pat. Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). Generally, a sample obtained from a subject can be contacted with the antibody that specifically binds the marker. 10 Optionally, the antibody can be fixed to a solid support to facilitate washing and subsequent isolation of the complex, prior to contacting the antibody with a sample. Examples of solid supports include but are not limited to glass or plastic in the form of, e.g., a microtiter plate, a stick, a bead, or a microbead. Antibodies can also be attached to a solid support. After incubating the sample with antibodies, the mixture is washed and the antibody 15 marker complex formed can be detected. This can be accomplished by incubating the washed mixture with a detection reagent. Alternatively, the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated 20 simultaneously with the mixture. Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, marker, volume of solution, concentrations and the like. Usually the 25 assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10 oC to 40 oC. The immunoassay can be used to determine a test amount of a marker in a sample from a subject. First, a test amount of a marker in a sample can be detected using the immunoassay methods described above. If a marker is present in the sample, it will form an antibody-marker 30 complex with an antibody that specifically binds the marker under suitable incubation conditions described above. The amount of an antibody-marker complex can optionally be WO 2005/069724 PCT/IB2005/001306 93 determined by comparing to a standard. As noted above, the test amount of marker need not be measured in absolute units, as long as the unit of measurement can be compared to a control amount and/or signal. Preferably used are antibodies which specifically interact with the polypeptides of the 5 present invention and not with wild type proteins or other isofonns thereof, for example. Such antibodies are directed, for example, to the unique sequence portions of the polypeptide variants of the present invention, including but not limited to bridges, heads, tails and insertions described in greater detail below. Preferred embodiments of antibodies according to the present invention are described in greater detail with regard to the section entitled "Antibodies". 10 Radio-immunoassay (RIA): In one version, this method involves precipitation of the desired substrate and in the methods detailed hereinbelow, with a specific antibody and radiolabelled antibody binding protein (e.g., protein A labeled with j25) immobilized on a precipitable carrier such as agarose beads. The number of counts in the precipitated pellet is proportional to the amount of substrate. 15 In an alternate version of the RIA, a labeled substrate and an unlabelled antibody binding protein are employed. A sample containing an unknown amount of substrate is added in varying amounts. The decrease in precipitated counts from the labeled substrate is proportional to the amount of substrate in the added sample. Enzyme linked immunosorbent assay (ELISA): This method involves fixation of a sample 20 (e.g., fixed cells or a proteinaceous solution) containing a protein substrate to a surface such as a well of a microtiter plate. A substrate specific antibody coupled to an enzyme is applied and allowed to bind to the substrate. Presence of the antibody is then detected and quantitated by a colorimetric reaction employing the enzyme coupled to the antibody. Enzymes commonly employed in this method include horseradish peroxidase and alkaline phosphatase. If well 25 calibrated and within the linear range of response, the amount of substrate present in the sample is proportional to the amount of color produced. A substrate standard is generally employed to improve quantitative accuracy. Western blot: This method involves separation of a substrate from other protein by means of an acrylamide gel followed by transfer of the substrate to a membrane (e.g., nylon or PVDF). 30 Presence of the substrate is then detected by antibodies specific to the substrate, which are in turn detected by antibody binding reagents. Antibody binding reagents may be, for example, protein WO 2005/069724 PCT/IB2005/001306 94 A, or other antibodies. Antibody binding reagents may be radiolabelled or enzyme linked as described hereinabove. Detection may be by autoradiography, colorimetric reaction or chemiluminescence. This method allows both quantitation of an amount of substrate and determination of its identity by a relative position on the membrane which is indicative of a 5 migration distance in the acrylamide gel during electrophoresis. Immunohistochemical analysis: This method involves detection of a substrate in situ in fixed cells by substrate specific antibodies. The substrate specific antibodies may be enzyme linked or linked to fluorophores. Detection is by microscopy and subjective evaluation. If enzyme linked antibodies are employed, a colorimetric reaction may be required. 10 Fluorescence activated cell sorting (FACS): This method involves detection of a substrate in situ in cells by substrate specific antibodies. The substrate specific antibodies are linked to fluorophores. Detection is by means of a cell sorting machine which reads the wavelength of light emitted from each cell as it passes through a light beam. This method may employ two or more antibodies simultaneously. 15 Radio-imaging Methods These methods include but are not limited to, positron emission tomography (PET) single photon emission computed tomography (SPECT). Both of these techniques are non invasive, and can be used to detect and/or measure a wide variety of tissue events and/or 20 functions, such as detecting cancerous cells for example. Unlike PET, SPECT can optionally be used with two labels simultaneously. SPECT has some other advantages as well, for example with regard to cost and the types of labels that can be used. For example, US Patent No. 6,696,686 describes the use of SPECT for detection of breast cancer, and is hereby incorporated by reference as if fully set forth herein. 25 Display Libraries According to still another aspect of the present invention there is provided a display library comprising a plurality of display vehicles (such as phages, viruses or bacteria) each displaying at least 6, at least 7, at least 8, at least 9, at least 10, 10-15, 12-17, 15-20, 15-30 or 20 30 50 consecutive amino acids derived from the polypeptide sequences of the present invention. Methods of constructing such display libraries are well known in the art. Such methods WO 2005/069724 PCT/IB2005/001306 95 are described in, for example, Young AC, et al., "The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neofonnans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes" J Mol Biol 1997 Dec 12;274(4):622-34; Giebel LB et al. "Screening of cyclic peptide phage libraries 5 identifies ligands that bind streptavidin with high affinities" Biochemistry 1995 Nov 28;34(47):15430-5; Davies EL et al., "Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes" J Immunol Methods 1995 Oct 12;186(1):125-35; Jones C RT al. "Current trends in molecular recognition and bioseparation" J Chromatogr A 1995 Jul 14;707(1):3-22; Deng SJ et al. "Basis for selection of improved 10 carbohydrate-binding single-chain antibodies from synthetic gene libraries" Proc Natl Acad Sci U S A 1995 May 23;92(11):4992-6; and Deng SJ et al. "Selection of antibody single-chain variable fragments with improved carbohydrate binding by phage display" J Biol Chem 1994 Apr 1;269(13):9533-8, which are incorporated herein by reference. 15 The following sections relate to Candidate Marker Examples (first section) and to Experimental Data for these Marker Examples (second section). It should be noted that Table numbering is restarted within each section. CANDIDATE MARKER EXAMPLES SECTION 20 This section relates to examples of sequences according to the present invention, including illustrative methods of selection thereof. Description of the methodology undertaken to uncover the biomolecular sequences of the present invention Human ESTs and cDNAs were obtained from GenBank versions 136 (June 15, 2003 25 ftp.ncbi.nih.gov/genbank/release.notes/gbl136.release.notes); NCBI genome assembly of April 2003; RefSeq sequences from June 2003; Genbank version 139 (December 2003); Human Genome from NCBI (Build 34) (from Oct 2003); and RefSeq sequences from December 2003. With regard to GenBank sequences, the human EST sequences from the EST (GBEST) section and the human mRNA sequences from the primate (GBPRI) section were used; also the human 30 nucleotide RefSeq mRNA sequences were used (see for example www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html and for a reference to the EST section, WO 2005/069724 PCT/IB2005/001306 96 see www.ncbi.nlm.nih.gov/dbEST/; a general reference to dbEST, the EST database in GenBank, may be found in Boguski et al, Nat Genet. 1993 Aug;4(4):332-3; all of which are hereby incorporated by reference as if fully set forth herein). Novel splice variants were predicted using the LEADS clustering and assembly system 5 as described in Sorek, R., Ast, G. & Graur, D. Alu-containing exons are alternatively spliced. Genome Res 12, 1060-7 (2002); US patent No: 6,625,545; and U.S. Pat. Appl. No. 10/426,002, published as US20040101876 on May 27 2004; all of which are hereby incorporated by reference as if fully set forth herein. Briefly, the software cleans the expressed sequences from repeats, vectors and immunoglobulins. It then aligns the expressed sequences to the genome 10 taking alternatively splicing into account and clusters overlapping expressed sequences into "clusters" that represent genes or partial genes. These were annotated using the GeneCarta (Compugen, Tel-Aviv, Israel) platform. The GeneCarta platform includes a rich pool of annotations, sequence information (particularly of spliced sequences), chromosomal information, alignments, and additional information such as 15 SNPs, gene ontology terms, expression profiles, functional analyses, detailed domain structures, known and predicted proteins and detailed homology reports. A brief explanation is provided with regard to the method of selecting the candidates. However, it should be noted that this explanation is provided for descriptive purposes only, and is not intended to be limiting in any way. The potential markers were identified by a 20 computational process that was designed to find genes and/or their splice variants that are specifically expressed in cardiac tissue, as opposed to other types of tissues and also particularly as opposed to muscle tissue, by using databases of expressed sequences. Various parameters related to the information in the EST libraries, determined according to classification by library annotation, were used to assist in locating genes and/or splice variants thereof that are 25 specifically and/or differentially expressed in heart tissues. The detailed description of the selection method and of these parameters is presented in Example 1 below. EXAMPLE 1 Identification of differentially expressed gene products - Algorithm 30 In order to distinguish between differentially expressed gene products and constitutively expressed genes (i.e., house keeping genes), an algorithm based on an analysis of frequencies was WO 2005/069724 PCT/IB2005/001306 97 configured. A specific algorithm for identification of transcripts specifically expressed in heart tissue is described hereinbelow. EST analysis 5 ESTs were taken from the following main sources: libraries contained in Genbank version 136 (June 15, 2003 ftp.ncbi.nih.gov/genbank/release.notes/gbl36.release.notes) and Genbank version 139 (December 2003); and from the LifeSeq library of Incyte Corporation (ESTs only; Wilmington, DE, USA). With regard to GenBank sequences, the human EST sequences from the EST (GBEST) section were used. 10 Library annotation - EST libraries were manually classified according to: 1. Tissue origin 2. Biological source - Examples of frequently used biological sources for construction of EST libraries include cancer cell-lines; normal tissues; cancer tissues; foetal tissues; and others such as normal cell lines and pools of 15 normal cell-lines, cancer cell-lines and combinations thereof. A specific description of abbreviations used below with regard to these tissues/cell lines etc is given above. 3. Protocol of library construction - various methods are known in the art for 20 library construction including normalized library construction; non normalized library construction; subtracted libraries; ORESTES and others (described in the annotation available in Genbank). It will be appreciated that at times the protocol of library construction is not indicated in the information available about that library. 25 The following rules were followed: EST libraries originating from identical biological samples were considered as a single library. EST libraries which included above-average levels of contamination, such as DNA contamination for example, were eliminated. The presence of such contamination was determined 30 as follows. For each library, the number of unspliced ESTs that are not fully contained within other spliced sequences was counted. If the percentage of such sequences (as compared to all WO 2005/069724 PCT/IB2005/001306 98 other sequences) was at least 4 standard deviations above the average for all libraries being analyzed, this library was tagged as being contaminated and was eliminated from further consideration in the below analysis (see also Sorek, R. & Safer, H.M. A novel algorithm for computational identification of contaminated EST libraries. Nucleic Acids Res 31, 1067-74 5 (2003)for further details). Clusters (genes) having at least five sequences including at least two sequences from the tissue of interest were analyzed. Splice variants were identified by using the LEADS software package as described above. 10 EXAMPLE 2 Identification of heart tissue specific genes For detection of heart tissue specific clusters, heart tissue libraries/sequences were compared to the total number of libraries/sequences in the cluster and in Genebank, and to the 15 relevant numbers for muscle tissue libraries/sequences. Statistical tools were employed to identify clusters that were heart tissue specific, both as compared to all other tissues and also in comparison to muscle tissue. The algorithm - for each tested tissue T and for each tested cluster the following were examined: 20 1. Each cluster includes at least 2 libraries from the tissue T. At least 3 clones (weighed - as described above) from tissue T in the cluster; 2. The following equation was then used to determine heart tissue-specific expression t/ n-t-m as compared to expression in all tissue types for a particular cluster: / -- in which n T N-T-M is the total number of ESTs available for a cluster, while N is the total number of ESTs available 25 in all of the libraries considered in the analysis (effectively all ESTs in Genbank, except for those that were rejected as belonging to contaminated libraries). This ratio was preferably set to be at least about 8, although optionally the ratio could be set to be at least about 5. 3. The following equation was then used to determine heart tissue-specific expression Ns. t expression in skeletal muscle tissue for a particular cluster: Y n in which t represents the Mv WO 2005/069724 PCT/IB2005/001306 99 number of heart tissue-specific ESTs for the cluster, while T is the number of all heart tissue specific ESTs in the analysis; m is the number of skeletal muscle tissue-specific ESTs for the cluster, while M is the number of all skeletal muscle tissue-specific ESTs in the analysis. This ratio was preferably set to be at least about 4, although optionally the ratio could be set to be at 5 least about 2. 4. Fisher exact test P-values were computed for weighted clone counts to check that the counts are statistically significant according to the following function: F(t,T,n,N) which is the probability of a cluster actually being overexpressed in heart tissue, as compared to its overall level of expression. The P-value was preferably set to be less than about le-5, although 10 optionally it could be set to be less than about le-3. The results obtained are explained in greater detail for each marker below. Actual Marker Examples 15 The following examples relate to specific actual marker examples. It should be noted that Table numbering is restarted within each example related to a particular Cluster, as indicated by the titles below. EXAMPLES SECTION 20 This Section relates to Examples of sequences according to the present invention, including experiments involving these sequences, and illustrative, non-limiting examples of methods, assays and uses thereof. The materials and experimental procedures are explained first, as all experiments used them as a basis for the work that was performed. The markers of the present invention were tested with regard to their expression in 25 various heart and non-heart tissue samples. Unless otherwise noted, all experimental data relates to variants of the present invention, named according to the segment being tested (as expression was tested through RT-PCR as described). A description of the samples used in the panel is provided in Table 1 below. Tests were then performed as described in the Examples below. 30 Table 1: Tissue samples in testing panel WO 2005/069724 PCT/IB2005/001306 100 Lot no. Source Tissue Pathology Sex/Age 1-Am-Colon (C71) 071PO10B Ambion Colon PM F/43 2-B-Colon (C69) A411078 Biochain Colon PM-Pool of 10 M&F 3-C1-Colon (C70) 1110101 Clontech Colon PM-Pool of 3 M&F 4-Am-Small Intestine 091P0201AAmbion Small Intestine PM M/75 5-B-Small Intestine A501158 Biochain Small Intestine PM M/63 6-B-Rectum A605138 Biochain Rectum PM M/25 7-B-Rectum A610297 Biochain Rectum PM M/24 8-B-Rectum A610298 Biochain Rectum PM M/27 9-Am-Stomach 110PO4A Ambion Stomach PM M/16 10-B-Stomach A501159 Biochain Stomach PM M/24 11-B-Esophagus A603814 Biochain Esophagus PM M/26 12-B-Esophagus A603813 Biochain Esophagus PM M/41 13-Am-Pancreas 071P25C Ambion Pancreas PM M/25 14-CG-Pancreas CG-255-2 Ichilov Pancreas PM M/75 15-B-Lung A409363 Biochain Lung PM F/26 16-Am-Lung (L93) 111lP0103A Ambion Lung PM F/61 17-B-Lung (L92) A503204 Biochain Lung PM M/28 18-Am-Ovary (047) 061P43A Ambion Ovary PM F/16 19-B-Ovary (048) A504087 Biochain Ovary PM F/51 20-B-Ovary (046) A504086 Biochain Ovary PM F/41 21-Am-Cervix 101P0101A Ambion Cervix PM F/40 22-B-Cervix A408211 Biochain Cervix PM F/36 23-B-Cervix A504089 Biochain Cervix PM-Pool of 5 M&F 24-B-Uterus A411074 Biochain Uterus PM-Pool of 10 M&F 25-B-Uterus A409248 Biochain Uterus PM F/43 26-B-Uterus A504090 Biochain Uterus PM-Pool of 5 M&F 27-B-Bladder A501157 Biochain Bladder PM M/29 28-Am-Bladder 071P02C Ambion Bladder PM M/20 29-B-Bladder A504088 Biochain Bladder PM-Pool of 5 M&F WO 2005/069724 PCT/IB2005/001306 101 30-Am-Placenta 021P33A Ambion Placenta PB F/33 31-B-Placenta A410165 Biochain Placenta PB F/26 32-B-Placenta A411073 Biochain Placenta PB-Pool of 5 M&F 33-B-Breast (B59) A607155 Biochain Breast PM F/36 34-Am-Breast (B63) 26486 Ambion Breast PM F/43 35-Am-Breast (B64) 23036 Ambion Breast PM F/57 36-Cl-Prostate (P53) 1070317 Clontech Prostate PB-Pool of 47 M&F 37-Am-Prostate (P42) 061P04A Ambion Prostate PM M/47 38-Am-Prostate (P59) 25955 Ambion Prostate PM M/62 39-Am-Testis 111P0104A Ambion Testis PM M/25 40-B-Testis A411147 Biochain Testis PM M/74 41-C1-Testis 1110320 Clontech Testis PB-Pool of 45 M&F 42-CG-Adrenal CG-184-10 Ichilov Adrenal PM F/81 43-B-Adrenal A610374 Biochain Adrenal PM F/83 44-B-Heart A411077 Biochain Heart PB-Pool of 5 M&F 45-CG-Heart CG-255-9 Ichilov Heart PM M/75 46-CG-Heart CG-227-1 Ichilov Heart PM F/36 47-Am-Liver 081P0101A Ambion Liver PM M/64 48-CG-Liver CG-93-3 Ichilov Liver PM F/19 49-CG-Liver CG-124-4 Ichilov Liver PM F/34 50-C1-BM 1110932 Clontech Bone Marrow PM-Pool of 8 M&F 51-CGEN-Blood WBC#5 CGEN Blood M 52-CGEN-Blood WBC#4 CGEN Blood M 53-CGEN-Blood WBC#3 CGEN Blood M 54-CG-Spleen CG-267 Ichilov Spleen PM F/25 55-CG-Spleen 111P0106B Ambion Spleen PM M/25 56-CG-Spleen A409246 Biochain Spleen PM F/12 56-CG-Thymus CG-98-7 Ichilov Thymus PM F/28 58-Am-Thymus 101P0101A Ambion Thymus PM M/14 WO 2005/069724 PCT/IB2005/001306 102 59-B-Thymus A409278 Biochain Thymus PM M/28 60-B-Thyroid A610287 Biochain Thyroid PM M/27 61-B-Thyroid A610286 Biochain Thyroid PM M/24 62-CG-Thyroid CG-119-2 Ichilov Thyroid PM F/66 63-Cl-Salivary Gland 1070319 Clontech Salivary Gland PM-Pool of 24 M&F 64-Am-Kidney 111P0101B Ambion Kidney PM-Pool of 14 M&F 65-Cl-Kidney 1110970 Clontech Kidney PM-Pool of 14 M&F 66-B-Kidney A411080 Biochain Kidney PM-Pool of 5 M&F 67-CG-Cerebellum CG-183-5 Ichilov Cerebellum PM M/74 68-CG-Cerebellum CG-212-5 Ichilov Cerebellum PM M/54 69-B-Brain A411322 Biochain Brain PM M/28 70-C1-Brain 1120022 Clontech Brain PM-Pool of 2 M&F 71-B-Brain A411079 Biochain Brain PM-Pool of 2 M&F 72-CG-Brain CG-151-1 Ichilov Brain PM F/86 73-Am-Skeletal Muscle 101P013A Ambion Skeletal Muscle PM F/28 74-C1-Skeletal Muscle 1061038 Clontech Skeletal Muscle PM-Pool of 2 M&F Materials and Experimental Procedures RNA preparation - RNA was obtained from Clontech (Franklin Lakes, NJ USA 07417, www.clontech.com), BioChain Inst. Inc. (Hayward, CA 94545 USA www.biochain.com), ABS 5 (Wilmington, DE 19801, USA, http://www.absbioreagents.com) or Ambion (Austin, TX 78744 USA, http://www.ambion.com). Alternatively, RNA was generated from tissue samples using TRI-Reagent (Molecular Research Center), according to Manufacturer's instructions. Tissue and RNA samples were obtained from patients or from postmortem. Total RNA samples were treated with DNaseI (Ambion) and purified using RNeasy columns (Qiagen). 10 RTPCR - Purified RNA (1 gg) was mixed with 150 ng Random Hexamer primers (Invitrogen) and 500 gM dNTP in a total volume of 15.6 jil. The mixture was incubated for 5 min at 65 'C and then quickly chilled on ice. Thereafter, 5 gl of 5X SuperscriptlI first strand buffer (Invitrogen), 2

.

4 1g 0.1M DTT and 40 units RNasin (Promega) were added, and the mixture was incubated for 10 min at 25 oC, followed by further incubation at 42 'C for 2 min.

WO 2005/069724 PCT/IB2005/001306 103 Then, 1 .l (200units) of SuperscriptlI (Invitrogen) was added and the reaction (final volume of 25Q1) was incubated for 50 min at 42 oC and then inactivated at 70 'C for 15min. The resulting cDNA was diluted 1:20 in TE buffer (10 mM Tris pH=8, 1 mM EDTA pH=8). Real-Time RT-PCR analysis- cDNA (5l), prepared as described above, was used as a 5 template in Real-Time PCR reactions using the SYBR Green I assay (PE Applied Biosystem) with specific primers and UNG Enzyme (Eurogentech or ABI or Roche). The amplification was effected as follows: 50 oC for 2 min, 95 oC for 10 min, and then 40 cycles of 95 oC for 15sec, followed by 60 oC for 1 min. Detection was performed by using the PE Applied Biosystem SDS 7000. The cycle in which the reactions achieved a threshold level (Ct) of fluorescence was 10 registered and was used to calculate the relative transcript quantity in the RT reactions. The relative quantity was calculated using the equation Q=efficiency ^ -c t. The efficiency of the PCR reaction was calculated from a standard curve, created by using serial dilutions of several reverse transcription (RT) reactions To minimize inherent differences in the RT reaction, the resulting relative quantities were normalized to the geometric mean of the relative quantities of 15 several housekeeping (HSKP) genes. Schematic summary of quantitative real-time PCR analysis is presented in Figure 1. As shown, the xaxis shows the cycle number. The CT = Threshold Cycle point, which is the cycle that the amplification curve crosses the fluorescence threshold that was set in the experiment. This point is a calculated cycle number in which PCR products signal is above the background level (passive dye ROX) and still in the 20 Geometric/Exponential phase (as shown, once the level of fluorescence crosses the measurement threshold, it has a geometrically increasing phase, during which measurements are most accurate, followed by a linear phase and a plateau phase; for quantitative measurements, the latter two phases do not provide accurate measurements). The yaxis shows the normalized reporter fluorescence. It should be noted that this type of analysis provides relative 25 quantification. The sequences of the housekeeping genes measured in all the examples on normal tissue samples panel were as follows: 30 RPL19 (GenBank Accession No. NM_000981), RPL19 Forward primer: TGGCAAGAAGAAGGTCTGGTTAG WO 2005/069724 PCT/IB2005/001306 104 RPL19 Reverse primer: TGATCAGCCCATCTTTGATGAG RPL19 -amplicon: TGGCAAGAAGAAGGTCTGGTTAGACCCCAATGAGACCAATGAAATCGCCAATGCCA ACTCCCGTCAGCAGATCCGGAAGCTCATCAAAGATGGGCTGATCA 5 TATA box (GenBank Accession No. NM_003194), TATA box Forward primer: CGGTTTGCTGCGGTAATCAT TATA box Reverse primer: TTTCTTGCTGCCAGTCTGGAC TATA box - -amplicon: CGGTTTGCTGCGGTAATCATGAGGATAAGAGAGCCACGAACCACGGCACTGATTTT 10 CAGTTCTGGGAAAATGGTGTGCACAGGAGCCAAGAGTGAAGAACAGTCCAGACTG GCAGCAAGAAA Ubiquitin (GenBank Accession No. BC000449) Ubiquitin Forward primer: ATTTGGGTCGCGGTTCTTG Ubiquitin Reverse primer: TGCCTTGACATTCTCGATGGT 15 Ubiquitin -amplicon: ATTTGGGTCGCGGTTCTTGTTTGTGGATCGCTGTGATCGTCACTTGACAATGCAGAT CTTCGTGAAGACTCTGACTGGTAAGACCATCACCCTCGAGG TTGAGCCCAGTGACACCATCGAGAATGTCAAGGCA SDHA (GenBank Accession No. NM_004168) SDHA Forward primer: 20 TGGGAACAAGAGGGCATCTG SDHA Reverse primer: CCACCACTGCATCAAATTCATG SDHA-amplicon: TGGGAACAAGAGGGCATCTGCTAAAGTTTCAGATTCCATTTCTGCTCAGTATCCAGT AGTGGATCATGAATTTGATGCAGTGGTGG 25 DESCRIPTION FOR CLUSTER S67314 Cluster S67314 features 4 transcript(s) and 8 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the 30 application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest WO 2005/069724 PCT/IB2005/001306 105 Transcript Name SEQ ID NO S67314_PEA 1 T4 1 S67314_PEA_1 T5 2 S67314 PEA 1 T6 3 S67314_PEA 1 T7 4 Table 2 - Segments of interest Segment Name SEQ ID NO S67314 PEA 1 node 0 65 S67314 PEA 1 node _11 66 S67314 PEA_1 node_13 67 S67314 PEA _1 node 15 68 S67314_PEA 1 node 17 69 S67314 PEA 1 node 4 70 S67314 PEA_1 node 10 71 S67314 PEA 1 node 3 72 Table 3 - Proteins of interest Protein Name SEQ ID NO S67314_PEA 1 P4 281 S67314_PEA 1 P5 282 S67314 PEA_1 P6 283 S67314_PEA 1 P7 284 5 These sequences are variants of the known protein Fatty acid-binding protein, heart (SwissProt accession identifier FABH_HUMAN; known also according to the synonyms H FABP; Muscle fatty acid-binding protein; M-FABP; Mammary-derived growth inhibitor; MDGI), referred to herein as the previously known protein. 10 Protein Fatty acid-binding protein, heart is known or believed to have the following WO 2005/069724 PCT/IB2005/001306 106 function(s): FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. The sequence for protein Fatty acid-binding protein, heart is given at the end of the application, as "Fatty acid-binding protein, heart amino acid sequence" (SEQ ID NO:348). Known polymorphisms for this sequence are as shown in Table 4. 5 Table 4 - Amino acid mutations for Known Protein SNP position(s) on Comment amino acid sequence 1 V-> A 104 L->K 124 C -> S 129 E-> Q 10 Protein Fatty acid-binding protein, heart localization is believed to be Cytoplasmic. The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: negative control of cell proliferation, which are annotation(s) related to Biological Process; and lipid binding, which are annotation(s) related to Molecular Function. 15 The GO assignment relies on information from one or more of the SwissProt/TremB1 Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. The heart-selective diagnostic marker prediction engine provided the following results 20 with regard to cluster S67314. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 2 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that WO 2005/069724 PCT/IB2005/001306 107 category, according to parts per million). Overall, the following results were obtained as shown with regard to the histogram in Figure 2, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figures 3 - 4, concerning the actual expression of oligonucleotides in 5 various tissues, including heart. This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 13.8; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific 10 ESTs which was found to be 2.6; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 1.10E-25. One particularly important measure of specificity of expression of a cluster in heart tissue 15 is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall 20 expression of the cluster in muscle-specific ESTs which was found to be 2.6, which clearly supports specific expression in heart tissue. As noted above, cluster S67314 features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Fatty acid binding protein, heart. A description of each variant protein according to the present invention is 25 now provided. Variant protein S67314_PEA _P4 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S67314_PEA_1_T4. An alignment is given to the known protein (Fatty acid-binding protein, heart) at the end of the application. One or more alignments to one or more previously published 30 protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as WO 2005/069724 PCT/IB2005/001306 108 follows: Comparison report between S67314_PEA_1_P4 and FABHHUMAN: 1.An isolated chimeric polypeptide encoding for S67314_PEA_1_P4, comprising a first 5 amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTF KNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLIL 10 corresponding to amino acids 1 - 116 of FABHHUMAN, which also corresponds to amino acids 1 - 116 of S67314_PEA_1_P4, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTREWLWVRVVSGGNFLCSGFGL 15 TQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL corresponding to amino acids 117 - 215 of S67314 PEA_1 P4, wherein said firstand second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of S67314_PEA _1 P4, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 20 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTREWLWVRVVSGGNFLCSGFGL TQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL in S67314_PEA 1_P4. 25 Comparison report between S67314_PEA_1 P4 and AAP35373: 1.An isolated chimeric polypeptide encoding for S67314_PEA 1 P4, comprising a first amino acid sequence being at least 90 % homologous to MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTF KNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLIL 30 corresponding to amino acids 1 - 116 of AAP35373, which also corresponds to amino acids 1 116 of S67314_PEA_1_P4, and a second amino acid sequence being at least 70%, optionally at WO 2005/069724 PCT/IB2005/001306 109 least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTREWLWVRVVSGGNFLCSGFGL TQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL corresponding to amino acids 5 117 - 215 of S67314 PEA 1 P4, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of S67314_PEA 1 P4, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 10 sequence VRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTREWLWVRVVSGGNFLCSGFGL TQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL in S67314_PEA_1 P4. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 15 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein bcalization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. 20 Variant protein S67314_PEA_1 P4 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314_PEA _P4 sequence provides support for the deduced sequence of this variant protein according to the 25 present invention). Table 5 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 53 K->R Yes WO 2005/069724 PCT/IB2005/001306 110 Variant protein S67314 PEA_1_P4 is encoded by the following transcript(s): S67314 PEA_1 T4, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S67314_PEA 1 T4 is shown in bold; this coding portion starts at position 925 and ends at position 1569. The transcript also has the following SNPs as listed in 5 Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314 PEA 1 P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 6 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP?. sequence 580 T-> C Yes 1082 A -> G Yes 1670 A-> C Yes 10 Variant protein S67314_PEA_1 P5 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S67314 PEA 1 T5. An alignment is given to the known protein (Fatty acid-binding protein, 15 heart) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between S67314 PEA 1_P5 and FABHHUMAN: 20 1.An isolated chimeric polypeptide encoding for S67314_PEA_1 P5, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTF 25 KNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLIL WO 2005/069724 PCT/IB2005/001306 111 corresponding to amino acids 1 - 116 of FABHHUMAN, which also corresponds to amino acids 1 - 116 of S67314_PEA_1 P5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence 5 DVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATKLLRPTLPSYNNHGWEELRVG KSIV corresponding to amino acids 117 - 178 of S67314 PEA_1_P5, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of S67314_PEA_1 P5, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 10 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATKLLRPTLPSYNNHGWEELRVG KSIV in S67314 _PEA_1 P5. Comparison report between S67314_PEA_1_P5 and AAP35373: 15 1.An isolated chimeric polypeptide encoding for S67314_PEA_1_P5, comprising a first amino acid sequence being at least 90 %: homologous to MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTF KNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLIL corresponding to amino acids 1 - 116 of AAP35373, which also corresponds to amino acids 1 20 116 of S67314_PEA_1 P5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATKLLRPTLPSYNNHGWEELRVG KSIV corresponding to amino acids 117 - 178 of S67314_PEA 1 P5, wherein said first and 25 second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of S67314_PEAlP5, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 30 DVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATKLLRPTLPSYNNHGWEELRVG KSIV in S67314_PEA_1 P5.

WO 2005/069724 PCT/IB2005/001306 112 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellular because neither of the 5 trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein S67314_PEA_1_P5 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the 10 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314_PEA_1 P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s), Previously known SNP? 9 sequence 53 K ->R Yes 15 Variant protein S67314_PEA_1_P5 is encoded by the following transcript(s): S67314_PEAlT5, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S67314_PEA_1_T5 is shown in bold; this coding portion starts at position 925 and ends at position 1458. The transcript also has the following SNPs as listed in 20 Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314_PEA_1_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence WO 2005/069724 PCT/IB2005/001306 113 580 T-> C Yes 1082 A->G Yes 1326 A-> G Yes Variant protein S67314_PEA 1 P6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 S67314_PEA_1_T6. An alignment is given to the known protein (Fatty acid-binding protein, heart) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between S67314_PEAlP6 and FABHHUMAN: 1.An isolated chimeric polypeptide encoding for S67314_PEA_1 P6, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having 15 the sequence MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTF KNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLIL corresponding to amino acids 1 - 116 of FABH_HUMAN, which also corresponds to amino acids 1 - 116 of S67314 PEA 1 P6, and a second amino acid sequence being at least 70%, 20 optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MEKLQLRNVK corresponding to amino acids 117 - 126 of S67314 PEA_1_P6, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of S67314_PEA_1 P6, comprising a 25 polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MEKLQLRNVK in S67314_PEA 1_P6.

WO 2005/069724 PCT/IB2005/001306 114 Comparison report between S67314 PEA_1_P6 and AAP35373: 1.An isolated chimeric polypeptide encoding for S67314_PEA 1_P6, comprising a first amino acid sequence being at least 90 % homologous to 5 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTF KNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLIL corresponding to amino acids 1 - 116 of AAP35373, which also corresponds to amino acids 1 116 of S67314 PEA 1 P6, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 10 95% homologous to a polypeptide having the sequence MEKLQLRNVK corresponding to amino acids 117 - 126 of S67314_PEAlP6, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of S67314_PEA_1 P6, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 15 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MEKLQLRNVK in S67314_PEA_1_P6. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 20 intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein S67314_PEA_1_P6 also has the following non-silent SNPs (Single 25 Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314_PEA_1 P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). 30 Table 9 - Amino acid mutations WO 2005/069724 PCT/IB2005/001306 115 SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 53 K -> R Yes Variant protein S67314_PEA 1_P6 is encoded by the following transcript(s): S67314_PEA_1_T6, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S67314_PEA_1_T6 is shown in bold; this coding portion starts at 5 position 925 and ends at position 1302. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314_PEA_1_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 10 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 580 T->C Yes 1082 A -> G Yes 1444 T->C Yes Variant protein S67314_PEA _lP7 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 15 S67314_PEA_1_T7. An alignment is given to the known protein (Fatty acid-binding protein, heart) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 20 Comparison report between S67314_PEA_1_P7 and FABHHUMAN: 1.An isolated chimeric polypeptide encoding for S67314_PEA_1 P7, comprising a first WO 2005/069724 PCT/IB2005/001306 116 amino acid sequence being at least 90 % homologous to MVDAFLGTWKLVDSKNFDDYMKSL corresponding to amino acids 1 - 24 of FABHHUMAN, which also corresponds to amino acids 1 - 24 of S67314_PEA 1_P7, second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more 5 preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AHILITFPLPS corresponding to amino acids 25 - 35 of S67314_PEA_1 P7, and a third amino acid sequence being at least 90 % homologous to GVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSI VTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA corresponding 10 to amino acids 25 - 133 of FABH HUMAN, which also corresponds to amino acids 36 - 144 of S67314 PEA_1 P7, wherein said first, second, third and fourth amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for an edge portion of S67314_PEA_1_P7, comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably 15 at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for AHILITFPLPS, corresponding to S67314_PEA 1_P7. Comparison report between S67314 PEA_ 1P7 and AAP35373: 20 1.An isolated chimeric polypeptide encoding for S67314_PEA 1 P7, comprising a first amino acid sequence being at least 90 % homologous to MVDAFLGTWKLVDSKNFDDYMKSL corresponding to amino acids 1 - 24 of AAP35373, which also corresponds to amino acids 1 - 24 of S67314_PEA_1 P7, second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at 25 least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AHILITFPLPS corresponding to amino acids 25 - 35 of S67314_PEA_1_P7, and a third amino acid sequence being at least 90 % homologous to GVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSI VTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA corresponding 30 to amino acids 25 - 133 of AAP35373, which also corresponds to amino acids 36 - 144 of S67314_PEA_1 P7, wherein said first, second and third amino acid sequences are contiguous WO 2005/069724 PCT/IB2005/001306 117 and in a sequential order. 2.An isolated polypeptide encoding for an edge portion of S67314_PEA 1_P7, comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% 5 homologous to the sequence encoding for AHILITFPLPS, corresponding to S67314_PEA_1 P7. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 10 intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein S67314_PEA _1 P7 also has the following non-silent SNPs (Single 15 Nucleotide Polymorphisms) as listed in Table 11, (given according b their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314_PEA _1_P7 sequence provides support for the deduced sequence of this variant protein according to the present invention). 20 Table 11 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 64 K ->R Yes Variant protein S67314_PEA_1_P7 is encoded by the following transcript(s): S67314 PEA 1 T7, for which the sequence(s) is/are given at the end of the application. The 25 coding portion of transcript S67314_PEA 1 T7 is shown in bold; this coding portion starts at position 925 and ends at position 1356. The tramcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative WO 2005/069724 PCT/IB2005/001306 118 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S67314 PEA 1 P7 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 12 - Nucleic acid SNPs SNP position on nucleotide

'

Alte t native nucleic acid Previously known SNP? sequence 580 T-> C Yes 1115 A-> G Yes 2772 G -> A Yes 2896 C ->A Yes 2918 G-> C Yes 3003 A-> G Yes 3074 T-> G Yes 1344 T-> C Yes 1522 -> T No 1540 -> A No 1540 ->T No 1578 G->A Yes 1652 G->A Yes 2263 G -> A Yes 2605 T -> C Yes 5 As noted above, cluster S67314 features 8 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of 10 particular interest. A description of each segment according to the present invention is now provided. Segment cluster S67314_PEA 1_node_0 according to the present invention is supported by 90 libraries. The number of libraries was determined as previously described. This segment WO 2005/069724 PCT/IB2005/001306 119 can be found in the following transcript(s): S67314 PEA_1_T4, S67314 PEA_1_T5, S67314_PEA_1 T6 and S67314_PEA_1 T7. Table 13 below describes the starting and ending position of this segment on each transcript. Table 13 - Segment location on transcripts Transcript name Segi ent starting position Segment ending position S67314 PEA 1 T4 1 997 S67314 PEA 1 T5 1 997 S67314 _PEA_1 T6 1 997 S67314 PEA_1 T7 1 997 5 Segment cluster S67314_PEA 1_node_ 1 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S67314 PEA_1_T4. Table 14 below describes the 10 starting and ending position of this segment on each transcript. Table 14 - Segment location on transcripts Transcript name Segment starting position Segment ending position S67314 PEA_1 T4 1273 2110 Segment cluster S67314_PEA_1 node_13 according to the present invention is supported 15 by 76 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S67314_PEA 1 T7. Table 15 below describes the starting and ending position of this segment on each transcript. Table 15 -Segment location on transcripts Transcript name Segment starting position Segment ending position S67314_PEA_1 T7 1306 3531 20 WO 2005/069724 PCT/IB2005/001306 120 Segment cluster S67314_PEA_1_node_15 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S67314_PEA_1_T5. Table 16 below describes the starting and ending position of this segment on each transcript. 5 Table 16 - Segment location on transcripts Transcript name Segment starting position Segment ending position S67314 PEA 1 T5 1273 1733 Segment cluster S67314_PEA 1_node_17 according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment 10 can be found in the following transcript(s): S67314_PEA 1_T6. Table 17 below describes the starting and ending position of this segment on each transcript. Table 17 - Segment location on transcripts Transcript name Segment starting position iSegmint ending position, S67314 PEA 1 T6 1273 1822 15 Segment cluster S67314_PEA_1_node_4 according to the present invention is supported by 101 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S67314_PEA_1_T4, S67314_PEA_1 T5, S67314 PEA 1 T6 and S67314 PEA 1 T7. Table 19 below describes the starting and ending position of this segment on each transcript. 20 Table 19 - Segment location on transcripts Transcript name Segment starting position Segment ending position S67314_PEA 1 T4 998 1170 S67314_PEA_1 T5 998 1170 S67314 PEA 1 T6 998 1170 S67314_PEA_1 T7 1031 1203 WO 2005/069724 PCT/IB2005/001306 121 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are 5 included in a separate description. Segment cluster S67314_PEA_1_node_10 according to the present invention is supported by 64 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S67314_PEA_1_T4, S67314_PEA 1 T5, S67314 PEA 1_T6 and S67314 PEA _1 T7. Table 20 below describes the starting and ending 10 position of this segment on each transcript. Table 20 - Segment location on transcripts Tanscript name Segment startingposition Segment exindng position S67314 PEA 1 T4 1171 1272 S67314_PEA_1 T5 1171 1272 S67314 PEA 1 T6 1171 1272 S67314_PEA 1 T7 1204 1305 Segment cluster S67314_PEA_1 node_3 according to the present invention is supported 15 by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S67314_PEA_1 T7. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts Transcript name Segment starting position Segment ending position S67314_PEA_1 T7 998 1030 20 Variant protein alignment to the previously known protein: Sequence name: /tmp/EQOnMn6tqU/R73CUVKUk5:FABH HUMAN Sequence documentation: WO 2005/069724 PCT/IB2005/001306 122 Alignment of: S67314 PEA 1 P4 x FABH HUMAN Alignment segment 1/1: 5 Quality: 1095.00 Escore: 0 Matching length: 115 Total length: 115 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 10 Gaps: 0 Alignment: 2 VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILT 51 15 111111111111111111 11111111 11111 111 11111111111 1 VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILT 50 52 LKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQ 101 1111111111111111 11111111111111 I1111111111111111111 20 51 LKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQ 100 102 ETTLVRELIDGKLIL 116 101 ETTLVRELIDGKLIL 115 25 Sequence name: /tmp/EQ0nMn6tqU/R73CUVKUk5:AAP35373 Sequence documentation: 30 Alignment of: S67314_PEA 1 P4 x AAP35373 Alignment segment 1/1: Quality: 1107.00 Escore: 0 35 Matching length: 116 Total length: 116 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 WO 2005/069724 PCT/IB2005/001306 123 Alignment: 1 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL 50 5 11111 jill11111 i1111111111111111111111[111111111111 1 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL 50 51 TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG 100 10 51 TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG 100 101 QETTLVRELIDGKLIL 116 101 QETTLVRELIDGKLIL 116 15 Sequence name: /tmp/ql4YPIBbdQ/SeofJfCmJW:FABH_HUMAN Sequence documentation: 20 Alignment of: S67314_PEA_1 P5 x FABH HUMAN Alignment segment 1/1: Quality: 1095.00 Escore: 0 25 Matching length: 115 Total length: 115 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 30 Alignment: 2 VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILT 51 11111 1111 11111 1111 1111 11111111111111111111111 1 VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILT 50 35 52 LKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQ 101 I1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 51 LKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQ 100 WO 2005/069724 PCT/IB2005/001306 124 102 ETTLVRELIDGKLIL 116 111111111 111111 101 ETTLVRELIDGKLIL 115 5 Sequence name: /tmp/q14YPIBbdQ/SeofJfCmJW:AAP35 37 3 Sequence documentation: 10 Alignment of: S67314_PEA_1_P5 x AAP35373 Alignment segment 1/1: Quality: 1107.00 Escore: 0 15 Matching length: 116 Total length: 116 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 20 Alignment: 1 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL 50 ll 1 1 1 11111111111111111111111 lii Ill l i111l11i 1 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL 50 25 51 TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG 100 Il1 1111111 II11 111111 11111111111 111111111111111111 51 TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG 100 30 101 QETTLVRELIDGKLIL 116 101 QETTLVRELIDGKLIL 116 Sequence name:/tmp/PXra2DxLlv/Q8GTrzNMVX:FABH_HUMAN 35 Sequence documentation: WO 2005/069724 PCT/IB2005/001306 125 Alignment of: S67314_PEA_1_P6 x FABH HUMAN Alignment segment 1/1: 5 Quality: 1095.00 Escore: 0 Matching length: 115 Total length: 115 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 10 Alignment: 2 VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILT 51 1111111111111111111111111111111111111111ii11111 15 1 VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILT 50 52 LKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQ 101 liii11i1ii111i111111111 II11111 iiIlli 1111111111 I 51 LKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQ 100 20 102 ETTLVRELIDGKLIL 116 1I1111111111111l 101 ETTLVRELIDGKLIL 115 25 Sequence name: /tmp/PXra2DxL1v/Q8GTrzNMVX:AAP35 373 Sequence documentation: Alignment of: S67314_PEA_1 P6 x AAP35373 30 Alignment segment 1/1: Quality: 1107.00 Escore: 0 Matching length: 116 Total length: 116 35 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 WO 2005/069724 PCT/IB2005/001306 126 Alignment: 1 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL 50 5 1 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL 50 51 TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG 100 51 TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG 100 10 101 QETTLVRELIDGKLIL 116 1111111111111111 101 QETTLVRELIDGKLIL 116 15 Sequence name: /tmp/xYzWyViDom/twDu3T69pd:FABH_HUMAN Sequence documentation: Alignment of: S67314_PEA 1 P7 x FABH HUMAN 20 Alignment segment 1/1: Quality: 1160.00 Escore: 0 Matching length: 132 Total length: 143 25 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 92.31 Total Percent Identity: 92.31 Gaps: 1 Alignment: 30 2 VDAFLGTWKLVDSKNFDDYMKSLAHILITFPLPSGVGFATRQVASMTKPT 51 I11111111111 1111111111 1111111111111111 1 VDAFLGTWKLVDSKNFDDYMKSL ........... GVGFATRQVASMTKPT 39 35 52 TIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGG 101 I40 TIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGG 89III1111111111111111111111111111111111111 40 TIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGG 89 WO 2005/069724 PCT/IB2005/001306 127 102 KLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA 144 l1l1111111lll1ll1 1111l11I111ll11lll11111l1 90 KLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA 132 5 Sequence name: /tmp/xYzWyViDom/twDu3T69pd:AAP35373 Sequence documentation: Alignment of: S67314 PEA 1 P7 x AAP35373 10 Alignment segment 1/1: Quality: 1172.00 Escore: 0 Matching length: 133 Total length: 144 15 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 92.36 Total Percent Identity: 92.36 Gaps: 1 Alignment: 20 1 MVDAFLGTWKLVDSKNFDDYMKSLAHILITFPLPSGVGFATRQVASMTKP 50 11111111 11111 l i 11111 11111111111111 1 MVDAFLGTWKLVDSKNFDDYMKSL. ...........GVGFATRQVASMTKP 39 25 51 TTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDG 100 11111111111111111111111111111111111111111111111111 40 TTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDG 89 101 GKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA 144 30 1111111lIll1 111111 11111111111111111III111 90 GKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA 133 Expression of FABHHUMAN Fatty acid-binding protein transcripts which are detectable by amrnplicon as depicted in sequence name S67314 specifically in heart tissue. 35 Expression of FABHHUMAN Fatty acid-binding protein transcripts detectable by or according to segl 1, S67314 amplicon(s) and S67314 segl1IF aind S67314 segl R primers was WO 2005/069724 PCT/IB2005/001306 128 measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM 004168; amplicon - SDHA 5 amplicon) was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44, 45, 46, Table 1, "Tissue samples in testing panel", above), to obtain a value of fold up-regulation for each sample relative to median of the heart. 10 Figure 5A is a histogram showing specific expression of the above-indicated FABH_HUMAN Fatty acid-binding protein transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 5A, the expression of FABH_HUMAN Fatty acid-binding protein transcripts detectable by the above amplicon(s) in heart tissue samples was significantly 15 higher than in most other samples (non heart tissue sample Nos. 1-11,13-21,23-26,28-43, 47-74, Table 1 above, "Tissue samples in testing panel"). Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: S67314 segl IF forward primer; and 20 S67314 seg 1IR reverse primer. The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: S67314 segl 1. S67314 segl IF (SEQ ID NO:61): TCCCCTGAGAGCTGTAGAAGCT 25 S67314 segl 1R (SEQ ID NO:62): CGGCCTGTGTGAGTCCAAA S67314 segl I1(SEQ ID NO:63): TCCCCTGAGAGCTGTAGAAGCTGGGACAAGAGAGTGGTTGTGGGTCAGGGTGGTAT CAGGTGGGAATTTTCTGTGTAGTGGCTTTGGACTCACACAGGCCG 30 Expression of FABHHUMAN Fatty acid-binding protein S67314 transcripts, which are detectable by amplicon as depicted in sequence name S67314 seg15 specifically in heart tissue WO 2005/069724 PCT/IB2005/001306 129 Expression of FABH_HUMAN Fatty acid-binding protein transcripts detectable by or according to segl5 node(s), S67314 segl5 amplicon(s) and S67314 segl5F and S67314 segl5R primers was measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank 5 Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon SDHA-amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of 10 the heart samples (Sample Nos. 44-46, Table 1, above "Tissue samples in testing panel"), to obtain a value of fold up-regulation for each sample relative to median of the heart. Figure 5B is a histogram showing specific expression of the above-indicated FABH_HUMAN Fatty acid-binding protein transcripts in heart tissue samples as opposed to other tissues. 15 As is evident from Figure 5B, the expression of FABH_HUMAN Fatty acid-binding protein transcripts detectable by the above amp licon(s) in heart tissue samples was significantly higher than in most other samples (non-heart tissue sample Nos. 1-9, 11-21, 23-26, 28-43, 47-74 Table 1 above, "Tissue samples in testing panel"). Primer pairs are also optionally and preferably encompassed within the present 20 invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: S67314 segl5F forward primer; and S67314 segl5R reverse primer. The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon 25 was obtained as a non-limiting illustrative example only of a suitable amplicon: S67314 segl5. S67314 segl5F (SEQ ID NO:64) Forward primer: TTCCTTGGCATCTCCAATGG S67314 segl5R (SEQ ID NO:274) Reverse primer: GCCAACTCTCAGCTCCTCCC S67314 seg15 (SEQ ID NO:275) Amplicon: TTCCTTGGCATCTCCAATGGAGTAGAGAGAAGGCAACAAAGCTTCTCAGACCCACA 30 TTACCGAGCTATAACAACCATGGCTGGGAGGAGCTGAGAGTTGGC Expression of FABH_HUMAN Fatty acid-binding protein S67314 transcripts which are WO 2005/069724 PCT/IB2005/001306 130 detectable by amplicon as depicted in sequence name S67314seg4 specifically in heart tissue Expression of FABHHUMAN Fatty acid-binding protein transcripts detectable by or according to seg4 node(s), S67314 seg4 amplicon(s) and primers S67314seg4F and S67314seg4R was measured by real time PCR (this transcript corresponds to the known or WT 5 protein). In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA-amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the 10 geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of tle quantities of the heart samples (Sample Nos. 44-46, Table 1, above), to obtain a value of relative expression for each sample relative to median of the heart samples. Figure 6 is a histogram showing relative expression of the above-indicated 15 FABH HUMAN Fatty acid-binding protein transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 6, the expression of FABHHUMAN Fatty acid-binding protein transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher than in the other samples (Sample Nos. 44-46 Table 1, "Tissue samples in testing 20 panel"). Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: S67314seg4F forward primer; and S67314seg4R reverse primer. 25 The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: S67314seg4. Forward primer S67314seg4F (SEQ ID NO:276): CCAAGCCTACCACAATCATCG 30 Reverse primer S67314seg4R (SEQ ID NO:277): CTCCACCCCCAACTTAAAGCT Amplicon S67314seg4 (SEQ ID NO:278): WO 2005/069724 PCT/IB2005/001306 131 CCAAGCCTACCACAATCATCGAAAAGAATGGGGACATTCTCACCCTAAAAACACAC AGCACCTTCAAGAACACAGAGATCAGCTTTAAGTTGGGGGTGGAG DESCRIPTION FOR CLUSTER N56180 5 Cluster N56180 features 7 transcript(s) and 22 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest Transcript Name SeqID No. N56180_T1 5 N56180 T3 6 N56180 T4 7 N56180_T5 8 N56180 T6 9 N56180 T7 10 N56180 T8 11 10 Table 2 - Segments of interest Segment Name :Seq ID No. N56180 node 2 73 N56180 node 20 74 N56180 node 22 75 N56180 node 28 76 N56180 node 34 77 N56180 node 36 78 N56180 node 4 79 N56180 node 6 80 N56180 node 0 81 N56180 node 10 82 WO 2005/069724 PCT/IB2005/001306 132 N56180_node 12 83 N56180 node_14 84 N56180 node 16 85 N56180 node 18 86 N56180 node 24 87 N56180 node 26 88 N56180 node 29 89 N56180 node 3 90 N56180 node 31 91 N56180 node 33 92 N56180 node 35 93 N56180 node_8 94 Table 3 - Proteins of interest Protein Name Seq ID No, N56180 P2 285 N56180 P4 286 N56180 P5 287 N56180_P6 288 N56180 P7 289 N56180_P8 290 N56180 P9 291 These sequences are variants of the known protein Calsequestrin, cardiac muscle isoform 5 precursor (SwissProt accession identifier CAQ2_HUMAN; known also according to the synonyms Calsequestrin 2), referred to herein as the previously known protein. Protein Calsequestrin, cardiac muscle isoform precursor is known or believed to have the following function(s): Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in muscle. The release of calcium bound to 10 calsequestrin through a calcium release channel triggers muscle contraction. The protein binds WO 2005/069724 PCT/IB2005/001306 133 40 to 50 moles of calcium. The sequence for protein Calsequestrin, cardiac muscle isoform precursor is given at the end of the application, as "Calsequestrin, cardiac muscle isoform precursor amino acid sequence" (SEQ ID NO:349). Known polymorphisms for this sequence are as shown in Table 4. 5 Table 4 - Amino acid mutations for Known Protein SNP position(s) on Comment amino acid sequence 307 D -> H (in VTSIP). /FTId=VAR_016075. 67 Q->P Protein Calsequestrin, cardiac muscle isoform precursor localization is believed to be in the sarcoplasmic reticulum's terminal cisternae luminal spaces of cardiac and slow skeletal muscle cells. 10 The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: striated muscle contraction; heart development; muscle development, which are annotation(s) related to Biological Process; calcium storage, which are annotation(s) related to Molecular Function; and smooth endoplasmic reticulum, which are annotation(s) related to Cellular Component. 15 The GO assignment relies on information from one or more of the SwissProt/TremB1 Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. The heart-selective diagnostic marker prediction engine provided the following results 20 with regard to cluster N56180. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 7 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million). 25 Overall, the following results were obtained as shown with regard to the histogram in Figure 7, concerning the number of heart-specific clones in libraries/sequences; as well as with WO 2005/069724 PCT/IB2005/001306 134 regard to the histogram in Figure 8, concerning the actual expression of oligonucleotides in various tissues, including heart. This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall 5 expression of the cluster in non-heart ESTs was found to be 11; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs was found to be 2.4; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 4.70E-14. One particularly important measure of specificity of expression of a cluster in heart tissue 10 is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall 15 expression of the cluster in muscle-specific ESTs was found to be 2.4, which clearly supports specific expression in heart tissue. As noted above, cluster N56180 features 7 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Calsequestrin, 20 cardiac muscle isoform precursor. A description of each variant protein according to the present invention is now provided. Variant protein N56180_P2 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) N56180_T1. An alignment is given to the known protein (Calsequestrin, cardiac muscle isoform precursor) at the 25 end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between N56180_P2 and CAQ2 HUMAN: 30 1.An isolated chimeric polypeptide encoding for N56180 P2, comprising a first amino acid sequence being at least 90 % homologous to WO 2005/069724 PCT/IB2005/001306 135 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEP VSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYIL KGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLEVQAFERIEDYIKLIGFFKSEDSEYY KAFEEAAEHFQPYIKFFATFDKGV corresponding to amino acids 1 - 203 of 5 CAQ2 HUMAN, which also corresponds to amino acids 1 - 203 of N56180_P2, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LWLTPVIPTLWEADGGGLHEPWSWRPAWATWLQRNYL corresponding to amino acids 204 - 240 of N56180 P2, wherein said first and second amino acid sequences are 10 contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of N56180_P2, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LWLTPVIPTLWEADGGGLHEPWSWRPAWATWLQRNYL in N56180_P2. 15 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted or localized in the sarcoplasmic reticulum's terminal cistemae luminal spaces of cardiac 20 and slow skeletal muscle cells like the WT protein. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans- membrane region.. Variant protein N56180_P2 also has the following non-silent SNPs (Single Nucleotide 25 Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7- Amino acid mutations WO 2005/069724 PCT/IB2005/001306 136 SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 66 T -> A Yes 76 V->M Yes Variant protein N56180_P2 is encoded by the following transcript(s): N56180_T1, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript N56180_T1 is shown in bold; this coding portion starts at position 242 and ends at position 961. 5 The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180 P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 8 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 74 T-> No 105 T->C Yes 2168 C -> G Yes 2289 G -> T No 2489 A -> C No 2545 A -> Yes 2638 A -> T Yes 206 G->A Yes 221 G->A Yes 228 A -> C Yes 437 A->G Yes 467 G->A Yes 1021 A -> No WO 2005/069724 PCT/IB2005/001306 137 1521 C ->T Yes 2018 C ->T Yes Variant protein N56180_P4 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) N56180_T3. An 5 alignment is given to the known protein (Calsequestrin, cardiac muscle isoform precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between N56180_P4 and CAQ2 HUMAN: 1.An isolated chimeric polypeptide encoding for N56180_P4, comprising a first amino acid sequence being at least 90 % homologous to MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEP VSSDKVTQKQFQLKEIVLE corresponding to amino acids 1 - 78 of CAQ2 HUMAN, which 15 also corresponds to amino acids 1 - 78 of N56180_P4, second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence HWQISQWWLHFQTPREEGKMKLLELSESADGAAWKRWGGNSNTHRIQ corresponding to amino acids 79 - 125 of N56180_P4, and a third amino acid sequence being at least 90 % 20 homologous to LVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVE FLLDLIEDPVEIISSKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATF DKGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMF ETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAY 25 WEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDD EDDDDDDNSDEEDNDDSDDDDDE corresponding to amino acids 79 - 399 of CAQ2 HUMAN, which also corresponds to amino acids 126 - 446 of N56180 P4, wherein said first, second and third amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for an edge portion of N56180 P4, comprising an WO 2005/069724 PCT/IB2005/001306 138 amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for HWQISQWWLHFQTPREEGKMKLLELSESADGAAWKRWGGNSNTHRIQ, corresponding 5 to N56180 P4. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 10 secreted or localized in the sarcoplasmic reticulum's terminal cisternae luminal spaces of cardiac and slow skeletal muscle cells like the WT protein. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans- membrane region.. 15 Variant protein N56180_P4 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). 20 Table 9 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 115 W -> R Yes 276 N -> No 66 T->A Yes 76 V->M Yes Variant protein N56180 P4 is encoded by the following transcript(s): N56180_T3, for which the sequence(s) is/are given at the end of tlhe application. The coding portion of transcript WO 2005/069724 PCT/IB2005/001306 139 N56180 T3 is shown in bold; this coding portion starts at position 242 and ends at position 1579. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein 5 N56180_P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 10 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 74 T-> No 105 T->C Yes 2064 C -> T Yes 2214 C -> G Yes 2335 G-> T No 2535 A-> C No 2591 A-> Yes 2684 A-> T Yes 206 G-> A Yes 221 G->A Yes 228 A-> C Yes 437 A-> G Yes 467 G-> A Yes 584 T-> C Yes 1067 A -> No 1567 C -> T Yes 10 Variant protein N56180_PS according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) N56180_T4. An alignment is given to the known protein (Calsequestrin, cardiac muscle isoform precursor) at the WO 2005/069724 PCT/IB2005/001306 140 end of the application. One or more aligmnents to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 5 Comparison report between N56180_P5 and CAQ2 HUMAN: 1.An isolated chimeric polypeptide encoding for N56180_P5, comprising a first amino acid sequence being at least 90 % homologous to MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEP VSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYIL 10 KGDRTIEFDGEFAADVLVEFLLD corresponding to amino acids 1 - 140 of CAQ2_HUMAN, which also corresponds to amino acids 1 - 140 of N56180_P5, and a second amino acid sequence being at least 90 % homologous to VAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETW EDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKT 15 FKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDD DDDNSDEEDNDDSDDDDDE corresponding to amino acids 203 - 399 of CAQ2 HUMAN, which also corresponds to amino acids 141 - 337 of N56180_P5, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated chimeric polypeptide encoding for an edge portion of N56180_P5, 20 comprising a polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise DV, having a structure as follows: a sequence starting from any of amino acid numbers 140-x to 140; and 25 ending at any of amino acid numbers 141+ ((n-2) - x), in which x varies from 0 to n-2. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 30 secreted or localized in the sarcoplasmic reticulum's terminal cisternae luminal spaces of cardiac and slow skeletal muscle cells like the WT protein. The protein localization is believed to be WO 2005/069724 PCT/IB2005/001306 141 secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region. Variant protein N56180_P5 also has the following non-silent SNPs (Single Nucleotide 5 Polymnorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 11 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 167 N -> No 66 T -> A Yes 76 V->M Yes 10 Variant protein N56180 P5 i encoded by the following transcript(s): N56180_T4, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript N56180_T4 is shown in bold; this coding portion starts at position 242 and ends at position 15 1252. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). 20 Table 12 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 74 T-> No 105 T -> C Yes WO 2005/069724 PCT/IB2005/001306 142 1887 C ->G Yes 2008 G->T No 2208 A->C No 2264 A -> Yes 2357 A -> T Yes 206 G->A Yes 221 G->A Yes 228 A->C Yes 437 A->G Yes 467 G->A Yes 740 A-> No 1240 C -> T Yes 1737 C -> T Yes Variant protein N56180_P6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) N56180_T5. An 5 alignment is given to the known protein (Calsequestrin, cardiac muscle isoform precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between N56180_P6 and CAQ2 HUMAN: 1.An isolated chimeric polypeptide encoding for N56180_P6, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NETEAEQSYV corresponding to amino acids 1 - 10 of N56180_P6, 15 second amino acid sequence being at least 90 % homologous to RAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEI VLELVAQVLEHKAIGFVMVDAKKEAKLAKKL corresponding to amino acids 18 - 106 of CAQ2 HUMAN, which also corresponds to amino acids 11 - 99 of N56180_P6, a third WO 2005/069724 PCT/IB2005/001306 143 (bridging) amino acid sequence comprising D, and a fourth amino acid sequence being at least 90 % homologous to YKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEEL VEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNT 5 DNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTA EELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE corresponding to amino acids 179 - 399 of CAQ2_HUMAN, which also corresponds to amino acids 101 - 321 of N56180_P6, wherein said first, second, third and fourth amino acid sequences are contiguous and in a sequential order. 10 2.An isolated polypeptide encoding for a head of N56180 P6, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NETEAEQSYV of N56180_P6. 3.An isolated polypeptide encoding for an edge portion of N56180_P6, comprising a 15 polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise LDY having a structure as follows (numbering according to N56180_P6): a sequence starting from any of 20 amino acid numbers 99-x to 99; and ending at any of amino acid numbers 101 + ((n-2) - x), in which x varies from 0 to n-2. Variant protein N56180_P6 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is 25 known or not; the presence of known SNPs in variant protein N56180_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 13 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 151 N -> No WO 2005/069724 PCT/IB2005/001306 144 59 T ->A Yes 69 V->M Yes Variant protein N56180_P6 is encoded by the following transcript(s): N56180_T5, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript 5 N56180 T5 is shown in bold; this coding portion starts at position 1 and ends at position 964. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P6 sequence provides support for the deduced sequence of this variant protein 10 according to the present invention). Table 14 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 176 A->G Yes 206 G->A Yes 452 A -> No 952 C -> T Yes 1449 C ->T Yes 1599 C ->G Yes 1720 G ->T No 1920 A ->C No 1976 A-> Yes 2069 A -> T Yes Variant protein N56180_P7 according to the present invention has an amino acid 15 sequence as given at the end of the application; it is encoded by transcript(s) N56180_T6. An alignment is given to the known protein (Calsequestrin, cardiac muscle isoform precursor) at the WO 2005/069724 PCT/IB2005/001306 145 end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 5 Comparison report between N56180_P7 and CAQ2_HUMAN: 1.An isolated chimeric polypeptide encoding for N56180_P7, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MSSWLSAGSPSSLSV corresponding to amino acids 1 - 15 of N56180 P7, and a 10 second amino acid sequence being at least 90 % homologous to VAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETW EDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKT FKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDD DDDNSDEEDNDDSDDDDDE corresponding to amino acids 203 - 399 of CAQ2 HUMAN, 15 which also corresponds to amino acids 16 - 212 of N56180_P7, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of N56180 P7, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence 20 MSSWLSAGSPSSLSV ofN56180 P7. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 25 intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein N56180_P7 also has the following non-silent SNPs (Single Nucleotide 30 Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is WO 2005/069724 PCT/IB2005/001306 146 known or not; the presence of known SNPs in variant protein N56180_P7 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 15 - Amino acid mutations SNP positions) on amino acid lterative amino acid(s) Previously known SNP? sequence 42 N-> No 5 Variant protein N56180_P7 is encoded by the following transcript(s): N56180_T6, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript N56180_T6 is shown in bold; this coding portion starts at position 71 and ends at position 706. The transcript also has the following SNPs as listed in Table 16 (given according to their 10 position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P7 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 16 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 194 A -> No 694 C ->T Yes 1191 C ->T Yes 1341 C ->G Yes 1462 G->T No 1662 A-> C No 1718 A -> Yes 1811 A-> T Yes 15 Variant protein N56180_P8 according to the present invention has an amino acid WO 2005/069724 PCT/IB2005/001306 147 sequence as given at the end of the application; it is encoded by transcript(s) N56180_T7. An alignment is given to the known protein (Calsequestrin, cardiac muscle isofornn precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the 5 variant protein according to the present invention to each such aligned protein is as follows: Comparison report between N56180_P8 and CAQ2 HUMAN: 1.An isolated chimeric polypeptide encoding for N56180 P8, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more 10 preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MCRGYSTLLNPVS corresponding to amino acids 1 - 13 of N56180 P8, and a second amino acid sequence being at least 90 % homologous to DGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTD ADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDD 15 DDDE corresponding to amino acids 280 - 399 of CAQ2 HUMAN, which also corresponds to amino acids 14 - 133 of N56180_P8, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of N56180 P8, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably 20 at least about 90% and most preferably at least about 95% homologous to the sequence MCRGYSTLLNPVS ofN56180 P8. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 25 programs. The variant protein is believed to be located as fillows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. 30 Variant protein N56180 P8 is encoded by the following transcript(s): N56180_T7, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript WO 2005/069724 PCT/IB2005/001306 148 N56180 T7 is shown in bold; this coding portion starts at position 97 and ends at position 495. The transcript also has the following SNPs as listed in Table 17 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein 5 N56180 P8 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 17 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP sequence 483 C -> T Yes 980 C -> T Yes 1130 C -> G Yes 1251 G ->T No 1451 A ->C No 1507 A-> Yes 1600 A ->T Yes 10 Variant protein N56180_P9 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) N56180_T8. An alignment is given to the known protein (Calsequestrin, cardiac muscle isoform precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the 15 variant protein according to the present invention to each such aligned protein is as follows: Comparison report between N56180_P9 and CAQ2_HUMAN: 1.An isolated chimeric polypeptide encoding for N56180_P9, comprising a first amino acid sequence being at least 90 % homologous to 20 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEP

VSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYIL

WO 2005/069724 PCT/IB2005/001306 149 KGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLEVQAFERIEDYIKLIGFFKSEDSEYY KAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVE FVKEHQR corresponding to amino acids 1 - 246 of CAQ2 HUMAN, which also corresponds to amino acids 1 - 246 of N56180 P9, and a second amino acid sequence being at least 70%, 5 optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRNWTQ corresponding to amino acids 247 - 252 of N56180_P9, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of N56180_P9, comprising a polypeptide 10 being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRNWTQ in N56180_P9. The location of the variant protein was determined according to results from a number of 15 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted or localized in the sarcoplasmic reticulum's terminal cisternae luminal spaces of cardiac and slow skeletal muscle cells like the WT protein. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal 20 peptide, and neither trans-membrane region prediction program predicts that this protein has a trans- membrane region.. Variant protein N56180_P9 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 18, (given according to their position(s) on ihe amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is 25 known or not; the presence of known SNPs in variant protein N56180 P9 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 18- Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 229 N-> No WO 2005/069724 PCT/IB2005/001306 150 66 T -> A Yes 76 V -> M Yes Variant protein N56180_P9 is encoded by the following transcript(s): N56180_T8, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript 5 N56180 T8 is shown in bold; this coding portion starts at position 242 and ends at position 997. The transcript also has the following SNPs as listed in Table 19 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein N56180_P9 sequence provides support for the deduced sequence of this variant protein 10 according to the present invention). Table 19 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 74 T-> No 105 T-> C Yes 1153 G->A Yes 1170 G-> A Yes 206 G-> A Yes 221 G->A Yes 228 A-> C Yes 437 A-> G Yes 467 G->A Yes 926 A -> No 1095 A -> No 1095 A-> T No As noted above, cluster N56180 features 22 segment(s), which were listed in Table 2 WO 2005/069724 PCT/IB2005/001306 151 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. 5 Segment cluster N56180_node 2 according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_Ti, N56180_T3, N56180_T4 and N56180_T8. Table 20 below describes the starting and ending position of this segment on each transcript. Table 20 - Segment location on transcripts Transcript name . Segment starting position Segment ending position N56180 T1 1 237 N56180 _T3 1 237 N56180 T4 1 237 N56180 T8 1 237 10 Segment cluster N56180_node_20 according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T1, N56180_T3, N56180_T4, N56180_T5, 15 N56180 T6 and N56180 T8. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180_T1 943 1073 N56180 T3 989 1119 N56180_T4 662 792 N56180 T5 374 504 N56180 T6 116 246 N56180 T8 848 978 WO 2005/069724 PCT/IB2005/001306 152 Segment cluster N56180_node_22 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_T8. Table 22 below describes the starting and ending position of this segment on each transcript. Table 22 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 T8 979 1259 10 Segment cluster N56180_node_28 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T7. Table 23 below describes the starting and ending position of this segment on each transcript. Table 23 - Segment location on transcripts Tranki ipt name Segmient starting positio Segment ending position N56180 T7 1 136 15 Segment cluster N56180_node_34 according to the present invention is supported by 37 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T1, N56180_T3, N56180_T4, N56180_T5, 20 N56180 T6 and N56180 T7. Table 24 below describes the starting and ending position of this segment on each transcript. Table 24 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 TI1 1397 1644 N56180_T3 1443 1690 WO 2005/069724 PCT/IB2005/001306 153 N56180 T4 1116 1363 N56180 T5 828 1075 N56180 T6 570 817 N56180 T7 359 606 Segment cluster N56180 node_36 according to the present invention is supported by 77 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_Ti, N56180_T3, N56180_T4, N56180 T5, N56180_T6 and N56180_T7. Table 25 below describes the starting and ending position of this segment on each transcript. Table 25 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180_T1 1655 2778 N56180 T3 1701 2824 N56180 T4 1374 2497 N56180 T5 1086 2209 N56180_T6 828 1951 N56180 T7 617 1740 10 Segment cluster N56180 node_4 according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_Tl, N56180_T3, N56180_T4, N56180_T5 and N56180_T8. Table 26 below describes the starting and ending position of this segment on each 15 transcript. Table 26 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180_T1 295 475 WO 2005/069724 PCT/IB2005/001306 154 N56180 T3 295 475 N56180 T4 295 475 N56180 T5 34 214 N56180 T8 295 475 Segment cluster N56180_node_6 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_T3. Table 27 below describes the starting and ending position of this segment on each transcript. Table 27 - Segment location on transcripts ,Transcript name: Segment starting position :Segment ending position N56180 T3 476 616 10 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description. Segment cluster N56180_node_0 according to the present invention is supported by 1 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T5. Table 28 below describes the starting and ending position of this segment on each transcript. Table 28 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 T5 1 33 20 Segment cluster N56180_node_10 according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be WO 2005/069724 PCT/IB2005/001306 155 found in the following transcript(s): N56180 T1, N56180_T3, N56180_T4 and N56180_T8. Table 29 below describes the starting and ending position of this segment on each transcript. Table 29 - Segment location on transcripts Transcript name Segment starting position, 'Segment ending position N56180 T1 561 661 N56180 T3 702 802 N56180 T4 561 661 N56180 T8 561 661 5 Segment cluster N56180_node_12 according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T1, N56180_T3 and N56180_T8. Table 30 below describes the starting and ending position of this segment on each transcript. 10 Table 30 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180_Tl 662 773 N56180 T3 803 914 N56180 T8 662 773 Segment cluster N56180_node_14 according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be 15 found in the following transcript(s): N56180_T1, N56180_T3, N56180_T5 and N56180_T8. Table 31 below describes the starting and ending position of this segment on each transcript. Table 31 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 Ti 774 847 N56180_T3 915 988 WO 2005/069724 PCT/IB2005/001306 156 N56180 T5 300 373 N56180 T8 774 847 Segment cluster N56180 node_16 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_T1. Table 32 below describes the starting and ending position of this segment on each transcript. Table 32 - Segment location on transcripts Traniscript name Segment starting position ,Segment Qnding position N56180 TI 848 942 10 Segment cluster N56180_node 18 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180 T6. Table 33 below describes the starting and ending position of this segment on each transcript. Table 33 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 T6 1 115 15 Segment cluster N56180_node_24 according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_Tl, N56180_T3, N56180_T4, N56180_T5 and 20 N56180_T6. Table 34 below describes the starting and ending position of this segment on each transcript. Table 34 - Segment location on transcripts Transcript name Segment starting position Segment ending position WO 2005/069724 PCT/IB2005/001306 157 N56180 T1 1074 1119 N56180 T3 1120 1165 N56180 T4 793 838 N56180 T5 505 550 N56180_T6 247 292 Segment cluster N56180 node_26 according to the present invention is supported by 28 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_T1, N56180_T3, N56180_T4, N56180_T5 and N56180 T6. Table 35 below describes the starting and ending position of this segment on each transcript. Table 35 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 T1 1120 1174 N56180 T3 1166 1220 N56180 T4 839 893 N56180_T5 551 605 N56180 T6 293 347 10 Segment cluster N56180_node_29 according to the present invention is supported by 32 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T1, N56180_T3, N56180_T4, N56180_T5, N56180 T6 and N56180 T7. Table 36 below describes the starting and ending position of this 15 segment on each transcript. Table 36- Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 TI 1175 1275 WO 2005/069724 PCT/IB2005/001306 158 N56180 T3 1221 1321 N56180 T4 894 994 N56180 T5 606 706 N56180_T6 348 448 N56180 T7 137 237 Segment cluster N56180_node_3 according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_Ti, N56180_T3, N56180_T4 and N56180_T8. Table 37 below describes the starting and ending position of this segment on each transcript. Table 37 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 T1 238 294 N56180 T3 238 294 N56180 T4 238 294 N56180 T8 238 294 10 Segment cluster N56180_node_31 according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): N56180_T1, N56180_T3, N56180_T4, N56180_T5, N56180_T6 and N56180 T7. Table 38 below describes the starting and ending position of this segment on each transcript. 15 Table 38 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 Tl 1276 1350 N56180_T3 1322 1396 N56180_T4 995 1069 WO 2005/069724 PCT/IB2005/001306 159 N56180 T5 707 781 N56180T6 449 523 N56180_T7 238 312 Segment cluster N56180_node_33 according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_T1, N56180 T3, N56180_T4, N56180_T5, N56180_T6 and N56180_T7. Table 39 below describes the starting and ending position of this segment on each transcript. Table 39 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 Tl 1351 1396 N56180 T3 1397 1442 N56180 T4 1070 1115 N56180_T5 782 827 N56180 T6 524 569 N56180_T7 313 358 10 Segment cluster N56180_node_35 according to the present invention can be found in the following transcript(s): N56180_T1, N56180_T3, N56180_T4, N56180_T5, N56180_T6 and N56180_T7. Table 40 below describes the starting and ending position of this segment on each transcript. 15 Table 40 - Segment location on transcripts Transcript name Segment starting position Segment ending position N56180 Tl 1645 1654 N56180 T3 1691 1700 N56180_T4 1364 1373 WO 2005/069724 PCT/IB2005/001306 160 N56180 T5 1076 1085 N56180 T6 818 827 N56180 T7 607 616 Segment cluster N56180_node_8 according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): N56180_T1, N56180_T3, N56180 T4, N56180_T5 and N56180 T8. Table 41 below describes the starting and ending position of this segment on each transcript. Table 41 - Segment location on transcripts Transcripti name Segment starting position Segment ending position N56180 Tl 476 560 N56180 T3 617 701 N56180 T4 476 560 N56180 T5 215 299 N56180_T8 476 560 10 Variant protein alignment to the previously known protein: Sequence name: /tmp/QH4bp760jk/sAp7DyaTKD:CAQ2_HUMAN 15 Sequence documentation: Alignment of: N56180 P2 x CAQ2_HUMAN Alignment segment 1/1: 20 Quality: 1955.00 Escore: 0 Matching length: 203 Total length: 203 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 WO 2005/069724 PCT/IB2005/001306 161 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 5 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 11 11111111111ll l liiF1 11111111 F 111111111 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 10 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEA 100 11111111111111111111111111111111111111111111111111 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEA 100 101 KLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIIS 150 15 II 11111111 FF11 11 11111111111111 F111111111 11111 101 KLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIIS 150 151 SKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFD 200 1111111111111111 11111111F1 1 1111111111 111111111 20 151 SKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFD 200 201 KGV 203 Ill 201 KGV 203 25 Sequence name: /tmp/VtcMdCiEuz/FlmsgLbcq4:CAQ2_HUMAN Sequence documentation: 30 Alignment of: N56180_P4 x CAQ2_HUMAN Alignment segment 1/1: Quality: 3806.00 Escore: 0 35 Matching length: 399 Total length: 446 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 89.46 Total Percent Identity: 89.46 Gaps: 1 WO 2005/069724 PCT/IB2005/001306 162 Alignment: 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 5 11111111111111111111111111111111111111111111111111 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLEHWQISQWWLHFQTPREEGKMKL 100 1i11111111111111111111111111 10 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLE ...................... 78 101 LELSESADGAAWKRWGGNSNTHRIQLVAQVLEHKAIGFVMVDAKKEAKLA 150 I1 I I I1 I1 1 1 1 1 1 1 1 1 1 1 11 1 1 1 79 .........................LVAQVLEHKAIGFVMVDAKKEAKLA 103 15 151 KKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKL 200 104 KKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKL 153 20 201 EVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGV 250 1 11 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 i l I 154 EVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGV 203 251 AKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLR 300 25 111111111 111111111 111111111111111111 I 204 AKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLR 253 301 PEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSI 350 11 11 11 11 111111111111111111111i111111liii111111il 30 254 PEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSI 303 351 LWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLP 400 304 LWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLP 353 35 401 TAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 446 354 TAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 399 WO 2005/069724 PCT/IB2005/001306 163 Sequence name: /tmp/lRixkfCRfD/JDL7BwYPJs:CAQ2_HUMAN Sequence documentation: 5 Alignment of: N56180_P5 x CAQ2_HUMAN Alignment segment 1/1: 10 Quality: 3202.00 Escore: 0 Matching length: 337 Total length: 399 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 84.46 Total Percent Identity: 84.46 Gaps: 1 15 Alignment: 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 1 20 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEA 100 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEA 100 25 101 KLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLD........... 140 101 KLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIIS 150 30 140 .................................................. 140 151 SKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFD 200 141 ..VAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLR 188 35 11111111 111111111111111111111111111111ll l l 201 KGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLR 250 189 RLRPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPD 238 WO 2005/069724 PCT/IB2005/001306 164 I11111111111 111111111111111111ii111111 111111111 251 RLRPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPD 300 239 LSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDD 288 5 1 1111111111111111111111111 1 11 111 11111111111 301 LSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDD 350 289 DLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 337 l1111 I1 II II11111111111I 11111111111111111111II 10 351 DLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 399 Sequence name: /tmp/rs5xPc26iA/XlzfpEDJF7:CAQ2 HUMAN Sequence documentation: 15 Alignment of: N56180_P6 x CAQ2_HUMAN Alignment segment 1/1: 20 Quality: 2955.00 Escore: 0 Matching length: 314 Total length: 385 Matching Percent Similarity: 99.04 Matching Percent Identity: 99.04 Total Percent Similarity: 80.78 Total Percent Identity: 80.78 Gaps: 1 25 Alignment: 8 SYVRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDK 57 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 30 15 SSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDK 64 58 VTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKKLD. ....... 100 65 VTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSL 114 35 100 .................................................. 100 115 YILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLEVQAFERIEDY 164 WO 2005/069724 PCT/IB2005/001306 165 101 .............. YKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEV 136 11111111111 111l1l1lll111111l1111111 165 IKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEV 214 5 137 DFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDD 186 F11 111111 1 1111 lllI 1111ll11l 11111111.ll11ll111l 215 DFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDD 264 10 187 LNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLL 236 265 LNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLL 314 237 VAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIED 286 15 111F11Fill 11 111111111 1111FF11111 11111111 F111111 315 VAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIED 364 287 VLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 321 20 365 VLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 399 Sequence name: /tmp/YOj6jtvAt2/UVZXGVRVOx:CAQ2_HUMAN Sequence documentation: 25 Alignment of: N56180_P7 x CAQ2_HUMAN Alignment segment 1/1: 30 Quality: 1959.00 Escore: 0 Matching length: 197 Total length: 197 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 35 Alignment: 16 VAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRL 65 WO 2005/069724 PCT/IB2005/001306 166 1111111111111111] 11111111111i111111111111111111111 203 VAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRL 252 66 RPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLS 115 5 IIII1IIIIIII1111I1111IIII 11I]11iII i1i1 253 RPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLS 302 116 ILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDL 165 II111111ii]ii[i1111111111iiiiiiii1111iii11111ii11 10 303 ILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDL 352 166 PTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 212 1 1 1 i1 1 1 i l i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 1 1 353 PTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE 399 15 Sequence name: /tmp/kmYMCJlGuB/no5BPO2sjR:CAQ2_HUMAN Sequence documentation: 20 Alignment of: N56180_P8 x CAQ2_HUMAN Alignment segment 1/1: Quality: 1187.00 Escore: 0 25 Matching length: 120 Total length: 120 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 30 Alignment: 14 DGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRP 63 11l111111111111111111111111111111111111111111111111 280 DGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRP 329 35 64 QIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDD 113 330 QIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDD 379I 330 QIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDD 379 WO 2005/069724 PCT/IB2005/001306 167 114 DDDDNSDEEDNDDSDDDDDE 133 11111I111111111111111 380 DDDDNSDEEDNDDSDDDDDE 399 5 Sequence name: /tmp/JIYFiyiYEk/c42Jok7Lfq:CAQ2_HUMAN Sequence documentation: 10 Alignment of: N56180_P9 x CAQ2_HUMAN Alignment segment 1/1: Quality: 2388.00 Escore: 0 15 Matching length: 246 Total length: 246 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 20 Alignment: 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 111111111111ii I IIIIEII ELII111111111111 II I 1 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50 25 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEA 100 111111111111 1111111 111111111111111111111111111111 51 LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEA 100 30 101 KLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIIS 150 II 111111111111111111l III 11111 1111111111111111111 101 KLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIIS 150 151 SKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFD 200 35 11111 1 111111 11111 11111 1111111111 1111111111111 151 SKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFD 200 201 KGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQR 246 WO 2005/069724 PCT/IB2005/001306 168 201 KGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQR 24 6 Expression of Calsequestrin, cardiac muscle isoform transcripts which are detectable by 5 amplicon as depicted in sequence name N56180 specifically in heart tissue Expression of Calsequestrin, cardiac muscle isoform transcripts detectable by or according to seg6, N56180 amplicon(s) and N56180 seg6F and N56180 seg6R primers was measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession 10 No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA-amnplicon) was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each 15 RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44, 45, 46, Table 1, above, "Tissue samples in testing panel"), to obtain a value of fold up regulation for each sample relative to median of the heart. Figure 9 is a histogram showing specific expression of the above-indicated Calsequestrin, cardiac muscle isoform transcripts in heart tissue samples as opposed to other 20 tissues. As is evident from Figure 9, the expression of Calsequestrin, cardiac muscle isoform transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher than in most other samples (non-heart tissue sample Nos. 1-21,23-26,28,30-43 47-74 Table 1 above, "Tissue samples in testing panel").

WO 2005/069724 PCT/IB2005/001306 169 Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: N56180 seg6F forward primer; and N56180 seg6R reverse primer. 5 The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: N56180 seg6. N56180 seg6F (SEQ ID NO:279): ATATCCCAGTGGTGGTTGCATT 10 N56180 seg6R (SEQ ID NO:280): CCCTCCCCAGCGTTTCC N56180 seg6 (SEQ ID NO:335): ATATCCCAGTGGTGGTTGCATTTCCAAACCCCAAGAGAGGAAGGCAAAATGAAGTT GCTGGAGTTGAGTGAATCTGCAGATGGAGCTGCGTGGAAACGCTGGGGAGGG 15 Expression of Calsequestrin, cardiac muscle isoform transcripts detectable by or according to seg node(s), N56180 amplicon(s) and N56180 seg F and N56180 seg R primers was measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon 20 Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44, 45, 46, Table 1, above, "Tissue samples in testing panel"), to 25 obtain a value of fold up-regulation for each sample relative to median of the heart. Figure 10 is a histogram showing specific expression of the above-indicated Calsequestrin, cardiac muscle isoform transcripts in heart tissue samples as opposed to other tissues.As is evident from Figure 10, the expression of Calsequestrin, cardiac muscle isoform transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher 30 than in most of the other samples (non-heart tissue sample Nos. 1-21, 23-26, 28-43, 47-74 Table 1, "Tissue samples in testing panel").

WO 2005/069724 PCT/IB2005/001306 170 Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: N56180 seg F forward primer; and N56180 seg R reverse primer. 5 The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: N56180 seg N56180 seg F (SEQ ID NO:336): TTGATACCACTTAGTGTAGCTCCAGC 10 N56180 seg R (SEQ ID NO:337): TCAAGTAGTTGCTACAGACGCCA N56180 seg (SEQ IDNO:361): TTGATACCACTTAGTGTAGCTCCAGCATGGATCAGCAAACTTTTTCTGTAAAGAACA AAATGGTAAATATTTCAGGTTCTGTGGGCCAGATGGCGTCTGTAGCAACTACTTGA 15 DESCRIPTION FOR CLUSTER T10377 Cluster T10377 features 6 transcript(s) and 18 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest Transcript Name Seq ID No. T10377 TO 12 T10377_T1 13 T10377 T2 14 T10377 T5 15 T10377 T6 16 T10377 T7 17 20 Table 2 - Segments of interest Segment Name .. Seq ID No.

WO 2005/069724 PCT/IB2005/001306 171 T10377 node_0 95 T10377 node 17 96 T10377_node 19 97 T10377_node 21 98 T10377 node 27 99 T10377 node 33 100 T10377 node 12 101 T10377 node_14 102 T10377 node 16 103 T10377_node_2 104 T10377 node 23 105 T10377_node 25 106 T10377_node 29 107 T10377 node_3 108 T10377_node 31 109 T10377_node_5 110 T10377 node 8 111 T10377_node_9 112 1I Table 3 - Proteins of interest Protein lName Seq ID No. T10377 P2 292 T10377 P5 293 T10377 P6 294 T10377_P7 295 T10377 P8 296 5 The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster T10377. Predictions were made for selective expression of transcripts of WO 2005/069724 PCT/IB2005/001306 172 this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 11 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million). 5 Overall, the following results were obtained as shown with regard to the histogram in Figure 11, concerning the number of heart-specific clones in libraries/sequences. This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 10.9. The expression level of 10 this gene in muscle was negligible; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 8.60E-15. One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as 15 opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the expression level of this gene in muscle was negligible, which clearly supports specific expression in heart tissue. 20 As noted above, cluster T10377 features 6 transcript(s), which were listed in Table 1 above. A description of each variant protein according to the present invention is now provided. Variant protein T10377_P2 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10377_T1 and T10377 T2. One or more alignments to one or more previously published protein sequences are 25 given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between T10377_P2 and Q96NF5 (SEQ ID NO:362): 1. An isolated chimeric polypeptide encoding for T10377_P2, comprising a first amino acid 30 sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a WO 2005/069724 PCT/IB2005/001306 173 polypeptide having the sequence MEISLVKCSE corresponding to amino acids 1 10 of T10377 P2, second amino acid sequence being at least 90 % homologous to ANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGVVR RSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMR 5 QKIRQLTQELSVSHAQQEYLENHIQTQSSALDRFNAMNSALASDSIGLQKTL VDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVES SQEANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFLK corresponding to amino acids 26 - 276 of Q96NF5, which also corresponds to amino acids 11 - 261 of T10377_P2, followed by A, and a third amino acid sequence being 10 at least 90 % homologous to IEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHETEMSG ELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIES LKKK LQQKQLLILQLLEKISFLEGENNELQSRLDYLTETQAKTEVETREIGVGCDLL PSQTGRTREIVMPSRNYTPYTRVLELTMKKTLT corresponding to amino acids 15 278 - 466 of Q96NF5, which also corresponds to amino acids 263 - 451 of T10377_P2, wherein said first, second, A, and third amino acid sequences are contiguous and in a sequential order. 2. An isolated polypeptide encoding for a head of T10377 P2, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably 20 at least about 90% and most preferably at least about 95% homologous to the sequence MEISLVKCSE of T10377 P2. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 25 intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein T10377_P2 also has the following non-silent SNPs (Single Nucleotide 30 Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is WO 2005/069724 PCT/IB2005/001306 174 known or not; the presence of known SNPs in variant protein T10377_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 5 -Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previolly known SNP? sequence 262 A ->V No 30 C ->S No 323 R-> G No 36 R->K No 439 T-> No 5 Variant protein T10377 P2 is encoded by the following transcript(s): T10377 T1 and T10377 T2, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10377_T1 is shown in bold; this coding portion starts at position 166 and ends at position 1518. The transcript also has the following SNPs as listed in 10 Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10377_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 6 -Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence . 152 A -> T Yes 253 T -> A No 272 G -> A No 624 A-> G Yes 786 G->A No 950 C -> T No WO 2005/069724 PCT/IB2005/001306 175 1077 A -> G No 1132 A -> G No 1482 A -> No The coding portion of transcript T10377_T2 is shown in bold; this coding portion starts at position 270 and ends at position 1622. The transcript also has the following SNPs as listed in 5 Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10377_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously knownSNP? sequence 13 G->T Yes 26 G->A Yes 890 G->A No 1054 C -> T No 1181 A-> G No 1236 A -> G No 1586 A-> No 88 C -> T Yes 115 G->A Yes 126 A-> G Yes 212 A-> G No 256 A -> T Yes 357 T -> A No 376 G -> A No 728 A-> G Yes 10 WO 2005/069724 PCT/IB2005/001306 176 Variant protein T1I 0377_P5 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10377_T5. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to 5 the present invention to each such aligned protein is as follows: Comparison report between T10377_P5 and Q96NF5: 1. An isolated chimeric polypeptide encoding for T10377_P5, comprising a first amino acid sequence being at least 90 % homologous to 10 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKE QLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEEMN YIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQ SSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDK LREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYEEKLQE 15 EQRKHSAEKEALLEETNSFLK corresponding to amino acids 1 - 276 of Q96NF5, which also corresponds to amino acids 1 - 276 of T10377_P5, followed by A, a second amino acid sequence being at least 90 % homologous to IEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHETEMSG ELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVE 20 corresponding to amino acids 278 - 372 of Q96NF5, which also corresponds to amino acids 278 - 372 of T10377_P5, and a third amino acid sequence being at least 90 % homologous to ENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNYTPY TRVLELTMKKTLT corresponding to amino acids 401 - 466 of Q96NF5, which 25 also corresponds to amino acids 373 - 438 of T10377 P5, wherein said first, A, second, and third amino acid sequences are contiguous and in a sequential order. 2. An isolated chimeric polypeptide encoding for an edge portion of T10377_P5, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino 30 acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EE, having a WO 2005/069724 PCT/IB2005/001306 177 structure as follows: a sequence starting from any of amino acid numbers 372-x to 372; and ending at any of amino acid numbers 373+ ((n-2) - x), in which x varies from 0 to n-2. The location of the variant protein was determnnined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 5 programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because one of the two signal peptide prediction programs (HMM:Signal peptide,NN:NO) predicts that this protein has a signal peptide.. Variant protein T10377_P5 also has the following non-silent SNPs (Single Nucleotide 10 Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10377_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously knovn SNP? sequence 25 R-> G No 277 A -> V No 338 R-> G No 426 T-> No 45 C -> S No 51 R->K No 15 Variant protein T10377_P5 is encoded by the following transcript(s): T10377_T5, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10377 T5 is shown in bold; this coding portion starts at position 140 and ends at position 20 1453. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein WO 2005/069724 PCT/IB2005/001306 178 T10377_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 9 - Nucleic acid SNPs SNP position on nucleotide Alternativenucleic acid ,i Previously known SNP? sequence 13 G ->T Yes 26 G ->A Yes 969 C ->T No 1096 A-> G No 1151 A ->G No 1417 A-> No 88 C -> T Yes 115 G -> A Yes 126 A-> G Yes 212 A-> G No 272 T->A No 291 G->A No 643 A->G Yes 805 G->A No 5 Variant protein T10377_P6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10377_T6. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to 10 the present invention to each such aligned protein is as follows: Comparison report between T10377P6 and Q96NF5: 1. An isolated chimeric polypeptide encoding for T10377 P6, comprising a first amino acid sequence being at least 90 % homologous to WO 2005/069724 PCT/IB2005/001306 179 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKE QLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEEMN YIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQ SSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDK 5 LREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYEEKLQE EQRKHSAEKEALLEETNSFLK corresponding to amino acids 1 - 276 of Q96NF5, which also corresponds to amino acids 1 - 276 of T10377_P6, followed by A, a second amino acid sequence being at least 90 % homologous to IEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHETEMSG 10 ELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIESLKKK LQQKQLLILQLLEKISFLEGE corresponding to amino acids 278 - 401 of Q96NF5, which also corresponds to amino acids 278 - 401 of T10377_P6, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a 15 polypeptide having the sequence PNRQDS corresponding to amino acids 402 - 407 of T10377_P6, wherein said first, A, second and third amino acid sequences are contiguous and in a sequential order. 2. An isolated polypeptide encoding for a tail of T1 0377_P6, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 20 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence PNRQDS in T10377 P6. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 25 programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because one of the two signal peptide prediction programs (HMM:Signal peptide,NN:NO) predicts that this protein has a signal peptide.. Variant protein T10377 P6 also has the following non-silent SNPs (Single Nucleotide 30 Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is WO 2005/069724 PCT/IB2005/001306 180 known or not; the presence of known SNPs in variant protein T10377_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 10 - Amino acid mutations SNP position(s) on amino acid 'Alternative amino acid(s) Previously known SNP? sequence 25 R-> G No 277 A ->V No 338 R-> G No 45 C -> S No 51 R->K No 5 Variant protein T10377_P6 is encoded by the following transcript(s): T10377_T6, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10377_T6 is shown in bold; this coding portion starts at position 140 and ends at position 1360. The transcript also has the following SNPs as listed in Table 11 (given according to their 10 position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10377_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 11 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 13 G -> T Yes 26 G -> A Yes 969 C -> T No 1096 A-> G No 1151 A-> G No 1400 A -> No WO 2005/069724 PCT/IB2005/001306 181 88 C ->T Yes 115 G->A Yes 126 A->G Yes 212 A->G No 272 T->A No 291 G->A No 643 A->G Yes 805 G->A No Variant protein T10377_P7 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10377 T7. 5 One or more aligmnents to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between T10377_P7 and Q96NF5: 10 1. An isolated chimeric polypeptide encoding for T10377_P7, comprising a first amino acid sequence being at least 90 % homologous to MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKE QLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEEMN YIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQ 15 SSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDK LREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYEEKLQE EQRKHSAEKEALLEETNSFLK corresponding to amino acids 1 - 276 of Q96NF5, which also corresponds to amino acids 1 - 276 of T10377_P7, followed by A, a second amino acid sequence being at least 90 % homologous to 20 IEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHETEMSG ELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEI corresponding to amino acids 278 - 374 of Q96NF5, which also corresponds to amino acids 278 - 374 of T10377 P7, and a third amino acid sequence being at least WO 2005/069724 PCT/IB2005/001306 182 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MSHELFSRFSLRLFGR corresponding to amino acids 375 - 390 of T10377_P7, wherein said first, A, second and third amino acid sequences are contiguous and in a 5 sequential order. 2. An isolated polypeptide encoding for a tail of T10377_P7, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MSHELFSRFSLRLFGR in T10377_P7. 10 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because one of the two signal 15 peptide prediction programs (HMM:Signal peptide,NN:NO) predicts that this protein has a signal peptide.. Variant protein T10377_P7 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 12, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is 20 known or not; the presence of known SNPs in variant protein T10377_P7 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 12 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 25 R->G No 277 A -> V No 338 R-> G No 45 C -> S No 51 R->K No WO 2005/069724 PCT/IB2005/001306 183 Variant protein T10377_P7 is encoded by the following transcript(s): T10377 T7, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10377 T7 is shown in bold; this coding portion starts at position 140 and ends at position 5 1309. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10377_P7 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 13 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 13 G->T Yes 26 G -> A Yes 969 C -> T No 1096 A-> G No 1151 A-> G No 88 C -> T Yes 115 G->A Yes 126 A-> G Yes 212 A-> G No 272 T->A No 291 G->A No 643 A->G Yes 805 G->A No Protein T10377_P8 has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10377_TO. One or more alignments to one or more previously 15 published protein sequences are given at the end of the application. A brief description of the WO 2005/069724 PCT/IB2005/001306 184 relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between T10377_P8 and Q96NF5: 5 An isolated chimeric polypeptide encoding for T10377_P8, comprising a first amino acid sequence being at least 90 % homologous to MEISLVKCSEANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYG VVRRSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMRQKIR QLTQELSVSHAQQEYLENHIQTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIK 10 DQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKL YSQYEEKLQEEQRKHSAEKEALLEETNSFLK corresponding to amino acids 1 - 261 of Q96NF5, which also corresponds to amino acids 1 - 261 of T10377_P8, a second amino acid sequence comprising A, and a third amino acid sequence being at least 90 % homologous to IEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDK 15 ERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKI SFLEGENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNYTPYTR VLELTMKKTLT corresponding to amino acids 263 - 451 of Q96NF5, which also corresponds to amino acids 263 - 451 of T10377_P8, wherein said first, second and third amino acid sequences are contiguous and in a sequential order. 20 The location of the protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because one of the two signal-peptide prediction 25 programs (HMM:Signal peptide,NN:NO) predicts that this protein has a signal peptide.. Protein T10377 P8 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 14, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in protein T10377_P8 sequence provides support for 30 the deduced sequence of this protein according to the present invention). Table 14 - Amino acid mutations WO 2005/069724 PCT/IB2005/001306 185 SNP position(s) on amino acid Alternative amnino acid(s) Previously known SNP? sequence 25 R->G No 277 V -> A No 338 R-> G No 45 C -> S No 454 T -> No 51 R->K No Protein T10377_P8 is encoded by the following transcript(s): T10377_TO, for which the sequence(s) is/are given at the end of the application The coding portion of transcript 5 T10377_TO is shown in bold; this coding portion starts at position 140 and ends at position 1537. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in protein T10377_P8 sequence provides support for the deduced sequence of this protein according to the present 10 invention). Table 15 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 13 G -> T Yes 26 G -> A Yes 969 C -> T No 1096 A -> G No 1151 A-> G No 1501 A -> No 88 C -> T Yes 115 G -> A Yes WO 2005/069724 PCT/IB2005/001306 186 126 A->G Yes 212 A->G No 272 T->A No 291 G->A No 643 A->G Yes 805 G->A No As noted above, cluster T10377 features 18 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) 5 are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. Segment cluster T10377_node 0 according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be 10 found in the following transcript(s): T10377_TO, T10377_T2, T10377_T5, T10377_T6 and T10377 T7. Table 16 below describes the starting and ending position of this segment on each transcript. Table 16- Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 TO 1 214 T10377 T2 1 214 T10377 T5 1 214 T10377_T6 1 214 T10377 T7 1 214 15 Segment cluster T10377_node_17 according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_Tl, T10377_T2, T10377_T5, WO 2005/069724 PCT/IB2005/001306 187 T10377 T6 and T10377 T7. Table 17 below describes the starting and ending position of this segment on each transcript. Table 17 - Segment location on transcripts Transcript name Segment starting position Segmentending position T10377_TO 685 817 T10377 TI 666 798 T10377 T2 770 902 T10377T5 685 817 T10377 T6 685 817 T10377 T7 685 817 5 Segment cluster T10377_node_19 according to the present invention is supported by 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_T1, T10377_T2, T10377_T5, T10377_T6 and T10377_T7. Table 18 below describes the starting and ending position of this 10 segment on each transcript. Table 18 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 TO 818 943 T10377 T1 799 924 T10377 T2 903 1028 T10377 T5 818 943 T10377 T6 818 943 T10377 T7 818 943 Segment cluster T10377_node 21 according to the present invention i supported by 42 15 libraries. The number of libraries was determined as previously described. This segment can be WO 2005/069724 PCT/IB2005/001306 188 found in the following transcript(s): T10377_TO, T10377_T1, T10377_T2, T10377 T5, T10377_T6 and T10377 T7. Table 19 below describes the starting and ending position of this segment on each transcript. Table 19 - Segment location on transcripts Transript name Segment startig position Segmen ending position T10377 TO 944 1072 T10377 Tl 925 1053 T10377 T2 1029 1157 T10377 T5 944 1072 T10377 T6 944 1072 T10377 T7 944 1072 5 Segment cluster T10377_node_27 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377 T7. Table 20 below describes the starting and 10 ending position of this segment on each transcript. Table 20 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 T7 1259 1418 Segment cluster T10377_node_33 according to the present invention is supported by 103 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_TI, T10377_T2, T10377_T5 and T10377 T6. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts Transcript name Segment starting position Segment ending position WO 2005/069724 PCT/IB2005/001306 189 T10377 TO 1444 2412 T10377 T1 1425 2393 T10377 T2 1529 2497 T10377 T5 1360 2328 T10377 T6 1343 2311 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are 5 included in a separate description. Segment cluster T10377_node_12 according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_Tl, T10377_T2, T10377_T5, 10 T10377_T6 and T10377_T7. Table 22 below describes the starting and ending position of this segment on each transcript. Table 22 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 TO 458 550 T10377 T1 439 531 T10377 T2 543 635 T10377 T5 458 550 T10377 T6 458 550 T10377 T7 458 550 15 Segment cluster T10377 node14 according to the present invention is supported by 28 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_Tl, T10377 T2, T10377_T5, T10377_T6 and T10377 T7. Table 23 below describes the starting and ending position of this WO 2005/069724 PCT/IB2005/001306 190 segment on each transcript. Table 23 - Segment location on transcripts Transdcipt name Segment starting position Segment ending position T10377 TO 551 664 T10377 TI 532 645 T10377 T2 636 749 T10377 T5 551 664 T10377 T6 551 664 T10377 T7 551 664 5 Segment cluster T10377_node_16 according to the present invention can be found in the following transcript(s): T10377_TO, T10377_T1, T10377 T2, T10377 T5, T10377_T6 and T10377_T7. Table 24 below describes the starting and ending position of this segment on each transcript. Table 24 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 TO 665 684 T10377 T1 646 665 T10377 T2 750 769 T10377 T5 665 684 T10377 T6 665 684 T10377 T7 665 684 10 Segment cluster T10377_node_2 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_Tl. Table 25 below describes the starting and 15 ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 191 Table 25 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 T1 1 110 Segment cluster T10377_node_23 according to the present invention is supported by 44 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_Tl, T10377 T2, T10377_T5, T10377_T6 and T10377_T7. Table 26 below describes the starting and ending position of this segment on each transcript. Table 26 - Segment location on transcripts Transcript name Segment starting p ition Segment ending position T10377 TO 1073 1152 T10377 T1 1054 1133 T10377 T2 1158 1237 T10377 T5 1073 1152 T10377 T6 1073 1152 T10377 T7 1073 1152 10 Segment cluster T10377 node_25 according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377 TO, T10377_Tl, T10377_T2, T10377 T5, 15 T10377_T6 and T10377_T7. Table 27 below describes the starting and ending position of this segment on each transcript. Table 27 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377_TO 1153 1258 T10377_T1 1134 1239 WO 2005/069724 PCT/IB2005/001306 192 T10377 T2 1238 1343 T10377 T5 1153 1258 T10377 T6 1153 1258 T10377 T7 1153 1258 Segment cluster T10377_node_29 according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be 5 found in the following transcript(s): T10377_TO, T10377_Tl, T10377_T2 and T10377_T6. Table 28 below describes the starting and ending position of this segment on each transcript. Table 28 - Segment location on transcripts Transcript name Segment starting position : Segment ending position T10377 TO 1259 1342 T10377 Tl 1240 1323 T10377 T2 1344 1427 T10377 T6 1259 1342 10 Segment cluster T10377_node_3 according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_Tl and T10377_T2. Table 29 below describes the starting and ending position of this segment on each transcript. Table 29 -Segment location on transcripts Transcript name Segment starting position Segment ending position' T10377 Tl 111 195 T10377 T2 215 299 15 Segment cluster T10377_node_31 according to the present invention is supported by 52 WO 2005/069724 PCT/IB2005/001306 193 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_T1, T10377 T2 and T10377_T5. Table 30 below describes the starting and ending position of this segment on each transcript. Table 30 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 TO 1343 1443 T10377 T1 1324 1424 T10377 T2 1428 1528 T10377 T5 1259 1359 5 Segment cluster T10377_node_5 according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_Ti, T10377_T2, T10377 T5, 10 T10377 T6 and T10377_T7. Table 31 below describes the starting and ending position of this segment on each transcript. Table 31 - Segment location on transcripts Transcript name Segment starting position Segment ending position T10377 TO 215 301 T10377 T1 196 282 T10377 T2 300 386 T10377 T5 215 301 T10377T6 215 301 T10377 T7 215 301 15 Segment cluster T10377_node_8 according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377 TO, T10377 T1, T10377_T2, T10377_T5, WO 2005/069724 PCT/IB2005/001306 194 T10377_T6 and T10377 T7. Table 32 below describes the starting and ending position of this segment on each transcript. Table 32 - Segment location on transcripts Transcript name Segnment starting position Segment ending position T10377 TO 302 407 T10377 T1 283 388 T10377 T2 387 492 T10377_T5 302 407 T10377_T6 302 407 T10377 T7 302 407 5 Segment cluster T10377_node_9 according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10377_TO, T10377_Ti, T10377_T2, T10377_T5, T10377_T6 and T10377_T7. Table 33 below describes the starting and ending position of this 10 segment on each transcript. Table 33 - Segment location on transcripts Transcriptiuame Segment starting position Segment ending position T10377 TO 408 457 T10377 Tl 389 438 T10377 T2 493 542 T10377 T5 408 457 T10377 T6 408 457 T10377 T7 408 457 Alignment of: T10377 P2 x Q96NF5 15 Alignment segment 1/1: WO 2005/069724 PCT/IB2005/001306 195 Quality: 4288.00 Escore: 0 Matching length: 441 Total length: 441 Matching Percent Similarity: 99.77 Matching Percent Identity: 99.77 5 Total Percent Similarity: 99.77 Total Percent Identity: 99.77 Gaps: 0 Alignment: 10 11 ANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGV 60 I II li I IIII Jil i I II11 I IIi 11 1 26 ANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGV 75 61 VRRSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEM 110 15 1111111 111111111 II 11111111 II 76 VRRSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEM 125 111 RQKIRQLTQELSVSHAQQEYLENHIQTQSSALDRFNAMNSALASDSIGLQ 160 11111111 111111iii1111111111111111111111 111111~ll1111111 20 126 RQKIRQLTQELSVSHAQQEYLENHIQTQSSALDRFNAMNSALASDSIGLQ 175 161 KTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKM 210 11111111111111111111111111111111111111111111111111 176 KTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKM 225 25 211 KVESSQEANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFL 260 111111111111111111111ii1111111111111111|111111111111 226 KVESSQEANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFL 275 30 261 KAIEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHET 310 I 1111111111111111111111111111111111111111I II IIl 276 KVIEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEHET 325 311 EMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIE 360 35 11111111111111111111111111111111111111111111111111 326 EMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIE 375 361 SLKKKLQQKQLLILQLLEKISFLEGENNELQSRLDYLTETQAKTEVETRE 410 WO 2005/069724 PCT/IB2005/001306 196 1111111l11111111IIll ii ll 111l11111lllil lI liiill 376 SLKKKLQQKQLLILQLLEKISFLEGENNELQSRLDYLTETQAKTEVETRE 425 411 IGVGCDLLPSQTGRTREIVMPSRNYTPYTRVLELTMKKTLT 451 5 426 IGVGCDLLPSQTGRTREIVMPSRNYTPYTRVLELTMKKTLT 466 Alignment of: T10377_P5 x Q96NF5 10 Alignment segment 1/1: Quality: 4159.00 Escore: 0 Matching length: 438 Total length: 466 Matching Percent Similarity: 99.77 Matching Percent Identity: 99.77 15 Total Percent Similarity: 93.78 Total Percent Identity: 93.78 Gaps: 1 Alignment: 20 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 ll11111111l1i1111lil11ll11l1111111111111ii111111111 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 11111111111111111l1111111l1111111111111111l1111111 30 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 35 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 WO 2005/069724 PCT/IB2005/001306 197 251 EKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIG 300 1l11l11111l1111l111111111111111 lllliii 11l11l1ll]lI 251 EKLQEEQRKHSAEKEALLEETNSFLKVIEEANKKMQAAEISLEEKDQRIG 300 5 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 10 351 ERIRHLDDMVHCQQKKVKQMVE ............................ 372 351 ERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEG 400 373 ENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNY 422 15 1111111111111111111111111ii1111111111111111111111 401 ENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNY 450 423 TPYTRVLELTMKKTLT 438 20 451 TPYTRVLELTMKKTLT 466 Alignment of: T10377_P6 x Q96NF5 Alignment segment 1/1: 25 Quality: 3896.00 Escore: 0 Matching length: 403 Total length: 403 Matching Percent Similarity: 99.50 Matching Percent Identity: 99.50 Total Percent Similarity: 99.50 Total Percent Identity: 99.50 30 Gaps: 0 Alignment: 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 35 111111111 1IllIll 11111111111111111111111 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 WO 2005/069724 PCT/IB2005/001306 198 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 5 111F 1 1 I 11111 1111111 11111 111111111 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 10 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 F III F 1111111F 1111F 1111F I111 1111F III 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 15 251 EKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIG 300 11111111111111 F1111111111 1 l Illl lllI llI I ll Ill ll 251 EKLQEEQRKHSAEKEALLEETNSFLKVIEEANKKMQAAEISLEEKDQRIG 300 20 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 1111111111111 F111111FF111111 11111|1111111F1111FF11F11 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 351 ERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEG 400 25 11111111111 1111111111 1 111 111111111111111 351 ERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEG 400 401 EPN 403 30 401 ENN 403 Alignment of: T10377_P7 x Q96NF5 Alignment segment 1/1: 35 Quality: 3642.00 Escore: 0 Matching length: 376 Total length: 376 Matching Percent Similarity: 99.47 Matching Percent Identity: 99.47 Total Percent Similarity: 99.47 Total Percent Identity: 99.47 WO 2005/069724 PCT/IB2005/001306 199 Gaps: 0 Alignment: 5 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 1111 fi111111I 1F 11I II lii I II 111 F 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 10 1111 11111111 111 1111111 1111111 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 II I 111 1111 11FF I I111 Il IF 15 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 1111111 1I ii 1111111 11111111 111111111111111111 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 20 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 1 1 1 I I 111111 1 11111111111111 111F1 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 25 251 EKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIG 300 11111FF 111111111111111 1 I1 1111F 1111F lI 111111 251 EKLQEEQRKHSAEKEALLEETNSFLKVIEEANKKMQAAEISLEEKDQRIG 300 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 30 | 1 111111111111 11111 1 F111111 1111111 111 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 351 ERIRHLDDMVHCQQKKVKQMVEEIMS 376 111111F 1111111111111 1 I I 35 351 ERIRHLDDMVHCQQKKVKQMVEEIES 376 Alignment of: T10377 P8 x Q96NF5 ..

WO 2005/069724 PCT/IB2005/001306 200 Alignment segment 1/1: Quality: 4519.00 Escore: 0 Matching length: 465 Total length: 466 5 Matching Percent Similarity: 99 Matching Percent Identity: 99 Total Percent Similarity: 99 Total Percent Identity: 99 Gaps: 0 Alignment: 10 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 I1111l1 11I1II111111 I I111 1 II I i~ 1 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIE 50 15 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 1111 1 11111 111111111 I ll llI l lll ill 51 RKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEE 100 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 20 111111 11111 111111 I 111111111II I F ill 101 MNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHI 150 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 I11 11111111 | 11111111 1 11 1 11 It F 1 1 11 111111111 25 151 QTQSSALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYE 200 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 1 11111111111111111111 F1111111 111111111 11 FFll Illl 201 ASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLYSQYE 250 30 251 EKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIG 300 11lF t11111111 1 111 111 1 lilllF lF ill l i l i lll 251 EKLQEEQRKHSAEKEALLEETNSFLKVIEEANKKMQAAEISLEEKDQRIG 300 35 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 1111111111111111111111111111111 EI1 Li lil ili l ll 35 301 ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLR 350 WO 2005/069724 PCT/IB2005/001306 201 351 ERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEG 400 ll1 lllll1 l111 ll11111111111 111111111111111111111111 351 ERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEG 400 5 401 ENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNY 450 llli111111 lt11 111111111111 lii11 1111111 I1I11111 401 ENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNY 450 451 TPYTRVLELTMKKTLT 466 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 451 TPYTRVLELTMKKTLT 466 Expression of Q96NF5 transcripts which are detectable by amplicon as depicted in sequence name T103 77 specifically in heart tissue. 15 Expression of Q96NF5 transcripts detectable by or according to junc25-31 node(s), T10377 amplicon(s) and T10377 junc25-31F and T10377 junc25-31R primers was measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM 000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon 20 Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44, 45, 46, Table 1, above "Tissue samples in testing panel"), to 25 obtain a value of fold up-regulation for each sample relative to median of the heart. Figure 12 is a histogram showing specific expression of the above-indicated Q96NF5 transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 12, the expression of Q96NF5 transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher than in most other samples 30 (non-heart tissue sample Nos. 1-26,28-43 47-74 Table 1, above "Tissue samples in testing panel"). Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non- WO 2005/069724 PCT/IB2005/001306 202 limiting illustrative example only of a suitable primer pair: T10377 junc25-31 F forward primer; and T10377 junc25-31R reverse primer. The present invention also preferably encompasses any amplicon obtained through the 5 use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: T10377 junc25 31. T10377 junc25- 31F (SEQ ID NO:363): AGCAGATGGTCGAGGAGAATAATG T10377 junc25-31R (SEQ ID NO:364): ATCTCTCTGGTTTCCACTTCGG 10 T10377 junc25-31 (SEQ ID NO:365): AGCAGATGGTCGAGGAGAATAATGAACTACAAAGCAGGTTGGACTATTTAACAGA AACCCAGGCCAAGACCGAAGTGGAAACCAGAGAGAT Expression of Q96NF5 transcripts detectable by or according to junc29-33 node(s), 15 T10377 amplicon(s) and T10377 junc29-33F and T10377 junc29-33R primers was measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA 20 amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44, 45, 46, Table 1, above "Tissue samples in testing panel"), to obtain a value of fold up-regulation for each sample relative to median of the heart. 25 Figure 13 is a histogram showing specific expression of the above-indicated Q96NF5 transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 13, the expression of Q96NF5 transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher than in most other samples (non-heart tissue sample Nos. 1-26, 28-43, 47-74 Table 1 above "Tissue samples in testing 30 panel"). Primer pairs are also optionally and preferably encompassed within the present WO 2005/069724 PCT/IB2005/001306 203 invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: T10377 junc29-33F forward primer; and T10377 junc29-33R reverse primer. 5 The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: T10377 junc29 33. T1 0377 junc29-33F (SEQ ID NO:366): CTTTCTTAGAAGGAGAGCCAAACAG 10 T10377 junc29-33R (SEQ ID NO:367): CCTAAGTCAGAGTTTTCTTCATGGTTAAC T10377 junc29-33 (SEQ ID NO:368): CTTTCTTAGAAGGAGAGCCAAACAGGCAGGACTCGTGAAATTGTGATGCCTTCTAG GAACTACACCCCATACACAAGAGTCCTGGAGTTAACCATGAAGAAAACTCTGACTT AGG 15 Expression of Q96NF5 transcripts detectable by or according to seg2-3 node(s), T10377 amplicon(s) and T10377 seg2-3F and T10377 seg2-3R primers was measured by real time PCR. In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM 000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA 20 amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA-amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 25 44, 45, 46, Table 1, above "Tissue samples in testing panel"), to obtain a value of fold up regulation for each sample relative to median of the heart. Figure 14 is a histogram showing specific expression of the above-indicated Q96NF5 transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 14, the expression of Q96NF5 transcripts detectable by the 30 above amplicon(s) in heart tissue samples was significantly higher than in the skeletal muscle (non-heart tissue sample Nos. 1-9,13-26,28-43,47-74 Table 1, "Tissue samples in testing WO 2005/069724 PCT/IB2005/001306 204 samples"). Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non 5 limiting illustrative example only of a suitable primer pair: T10377 seg2-3F forward primer; and T10377 seg2-3R reverse primer. The present invention also preferably encompasses any amnplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon 10 was obtained as a non-limiting illustrative example only of a suitable amplicon: T10377 seg2-3. T10377 seg2-3F (SEQ ID NO:369): CTTCGCATTGTGCATAACACAA T10377 seg2-3R (SEQ ID NO:370): GAAACTCGGATACACAATCTCCAGA T10377 seg2-3 (SEQ ID NO:371): CTTCGCATTGTGCATAACACAAGCCCTGAACCAGCTGCTTTGGGAACCCCTGGGAA 15 TAAAGTGCCCTACCTGCCTTTCAGGCACTGCCAAGCCTGGGGCATCTCTGGAGATTG TGTATCCGAGTTTC DESCRIPTION FOR CLUSTER Z24874 Cluster Z24874 features 2 transcript(s) and 10 segment(s) of interest, the names for which 20 are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest Transcript Name Seq ID No. Z24874 PEA 2 T10 18 Z24874_PEA_2 T11 19 Table 2 - Segments of interest Segment Name Seq ID No. Z24874 PEA_2 node 21 113 WO 2005/069724 PCT/IB2005/001306 205 Z24874 PEA_2 node 4 114 Z24874 PEA 2 node 0 115 Z24874 PEA 2_node 10 116 Z24874 PEA 2 node 12 117 Z24874 PEA 2 node 13 118 Z24874 PEA 2 node 14 119 Z24874_PEA _2 node 16 120 Z24874 PEA 2 node 3 121 Z24874 PEA _2 node 6 122 Table 3 - Proteins of interest Protein Name Seq ID No. Z24874_PEA_2_P5 297 Z24874_PEA_2 P6 298 5 The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster Z24874. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 15 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that 10 category, according to parts per million). Overall, the following results were obtained as shown with regard to the histogram in Figure 15, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figure 16, concerning the actual expression of oligonucleotides in various tissues, including heart. 15 This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 16.7; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific WO 2005/069724 PCT/IB2005/001306 206 ESTs which was found to be 2.1; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 3.20E-09. 5 One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as 10 described above, the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 2.1, which clearly supports specific expression in heart tissue. As noted above, cluster Z24874 fatures 2 transcript(s), which were listed in Table 1 15 above. A description of each variant protein according to the present invention is now provided. Variant protein Z24874_PEA 2_P5 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z24874_PEA_2_T10i. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the 20 variant protein according to the present invention to each such aligned protein is as follows: Comparison report between Z24874_PEA 2 P5 and Q9NPI5: 1.An isolated chimeric polypeptide encoding for Z24874_PEA _2 P5, comprising a first amino acid sequence being at least 90 % homologous to 25 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLE SLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLEGFLLYSYKPLVDLYSR RYFLTVPYEECKWRRS corresponding to amino acids 1 - 132 of Q9NPI5, which also corresponds to amino acids 1 - 132 of Z24874_PEA_2_P5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 30 90% and most preferably at least 95% homologous to a polypeptide having the sequence LPGRHEVPRGALP corresponding to amino acids 133 - 145 of Z24874_PEA 2 P5, wherein WO 2005/069724 PCT/IB2005/001306 207 said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z24874_PEA _2 P5, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 5 sequence LPGRHEVPRGALP in Z24874 PEA 2 P5. Comparison report between Z24874_PEA_2_P5 and Q9NZK3: 1.An isolated chimeric polypeptide encoding for Z24874 PEA 2 P5, comprising a first amino acid sequence being at least 90 % homologous to 10 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLE SLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLEGFLLYSYKP corresponding to amino acids 1 - 109 of Q9NZK3, which also corresponds to amino acids 1 109 of Z24874_PEA 2_P5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 15 95% homologous to a polypeptide having the sequence LVDLYSRRYFLTVPYEECKWRRSLPGRHEVPRGALP corresponding to amino acids 110 145 of Z24874_PEA_2_P5, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z24874 PEA 2 P5, comprising a 20 polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LVDLYSRRYFLTVPYEECKWRRSLPGRHEVPRGALP in Z24874_PEA 2 P5. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 25 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. 30 Variant protein Z24874_PEA 2 P5 is encoded by the following transcript(s): WO 2005/069724 PCT/IB2005/001306 208 Z24874_PEA_2_T10, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z24874_PEA 2 T10O is shown in bold; this coding portion starts at position 292 and ends at position 726. The transcript also has the following SNPs as listed in Table 4 (given according to their position on the nucleotide sequence, with the alternative 5 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z24874_PEA _2 P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 4 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleiec acid Previously known SNP? sequence 1 G->C No 70 G->A Yes 504 C->T No 645 C->T Yes 954 C-> T Yes 10 Variant protein Z24874_PEA _2_P6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z24874_PEA_2 T1 1. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the 15 variant protein according to the present invention to each such aligned protein is as follows: Comparison report between Z24874 _PEA_2_P6 and Q9NPI5: 1.An isolated chimeric polypeptide encoding for Z24874_PEA 2 P6, comprising a first amino acid sequence being at least 90 % homologous to 20 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLE SLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLEGFLLYSY corresponding to amino acids 1 - 107 of Q9NPI5, which also corresponds to amino acids 1 - 107 of Z24874_PEA_2 P6, and a second amino acid sequence being at least 70%, optionally at least WO 2005/069724 PCT/IB2005/001306 209 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NLPGRHEVPRGALP corresponding to amino acids 108 - 121 of Z24874 PEA_2 P6, wherein said first and second amino acid sequences are contiguous and in a sequential order. 5 2.An isolated polypeptide encoding for a tail of Z24874_PEA 2 P6, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NLPGRHEVPRGALP in Z24874 PEA_2_P6. 10 Comparison report between Z24874 _PEA _2 P6 and Q9NZK3: 1.An isolated chimeric polypeptide encoding for Z24874_PEA_2_P6, comprising a first amino acid sequence being at least 90 % homologous to MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLE SLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLEGFLLYSY corresponding 15 to amino acids 1 - 107 of Q9NZK3, which also corresponds to amino acids 1 - 107 of Z24874_PEA_2 P6, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NLPGRHEVPRGALP corresponding to amino acids 108 - 121 of Z24874_PEA 2 P6, wherein said first and second amino acid 20 sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z24874_PEA 2 P6, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NLPGRHEVPRGALP in Z24874_PEA_2_P6. 25 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. 30 In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein..

WO 2005/069724 PCT/IB2005/001306 210 Variant protein Z24874_PEA_2 P6 is encoded by the following transcript(s): Z24874_PEA 2 T1 1, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z24874_PEA_2_T11 is shown in bold; this coding portion starts at 5 position 292 and ends at position 654. The transcript also has the following SNPs as listed in Table 5 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z24874_PEA 2_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 5 - Nucleic acid SNPs SNIP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 1 G->C No 70 G->A Yes 504 C -> T No 882 C -> T Yes As noted above, cluster Z24874 features 10 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) 15 are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. Segment cluster Z24874_PEA_2_node_21 according to the present invention is supported 20 by 30 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA_2_T10 and Z24874_PEA 2 T11. Table 6 below describes the starting and ending position of this segment on each transcript. Table 6 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 211 Transcript name Segment starting position Segment ending position Z24874 PEA 2 T10 687 1027 Z24874_PEA_2 T1l 615 955 Segment cluster Z24874_PEA_2_node 4 according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): Z24874_PEA_2_T10 and Z24874_PEA_2 Tll. Table 7 below describes the starting and ending position of this segment on each transcript. Table 7 - Segment location on transcripts Transcript name Segment starting position Segment ending position Z24874 PEA 2 T10 138 317 Z24874_PEA 2 T1l 138 317 10 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description. Segment cluster Z24874_PEA 2 node_0 according to the present invention is supported 15 by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA_2 T10 and Z24874_PEA 2_Tll. Table 8 below describes the starting and ending position of this segment on each transcript. Table 8 -Segment location on transcripts Transcript name Segment starting position Segment ending position Z24874_PEA2 T10O 1 77 Z24874_PEA_2 TIl1 1 77 20 WO 2005/069724 PCT/IB2005/001306 212 Segment cluster Z24874_PEA_2_node 10 according to the present invention is supported by 25 libraries. The number of libraries was detennined as previously described. This segment can be found in the following transcript(s): Z24874_PEA 2 T10 and Z24874_PEA_2_T11. Table 9 below describes the starting and ending position of this segment on each transcript. 5 Table 9 - Segment location on transcripts Transcript iane ,,'Segment starting position Segment ending, position Z24874 _PEA_2 T10 409 457 Z24874 PEA_2_TIl1 409 457 Segment cluster Z24874_PEA_2 node_12 according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment 10 can be found in the following transcript(s): Z24874_PEA_2_T10 and Z24874_PEA_2 Tl 1. Table 10 below describes the starting and ending position of this segment on each transcript. Table 10 - Segment location on transcripts Transcript name Segment starting position Segment eding position Z24874 PEA_2_T10 458 524 Z24874_PEA 2 TIl1 458 524 15 Segment cluster Z24874_PEA_2_node13 according to the present invention is supported by 21 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA_2_T10 and Z24874_PEA_2_Tll. Table 11 below describes the starting and ending position of this segment on each transcript. Table 11 - Segment location on transcripts Transcript name Segment starting position Segment ending position Z24874_PEA 2 T10 525 561 Z24874_PEA_2 T1l 525 561 20 WO 2005/069724 PCT/IB2005/001306 213 Segment cluster Z24874_PEA 2_node_14 according to the present invention is supported by 20 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA_2_T10 and Z24874_PEA_2_T11. 5 Table 12 below describes the starting and ending position of this segment on each transcript. Table 12 - Segment location on transcripts Transcript name Segment starting position Segment ending position Z24874_PEA _2 T10O 562 614 Z24874 PEA 2 T1l 562 614 Segment cluster Z24874_PEA_2_node_16 according to the present invention is supported 10 by 17 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA _2 T10. Table 13 below describes the starting and ending position of this segment on each transcript. Table 13 - Segment location on transcripts Transcript name Segment starting position Segment ending position Z24874 PEA_2_T10 615 686 15 Segment cluster Z24874_PEA_2 node_3 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA 2 T10 and Z24874_PEA 2 Tll. Table 14 below describes the starting and ending position of this segment on each transcript. 20 Table 14 - Segment location on transcripts Transcript name Segment starting position Segment ending position Z24874_PEA _2 T10 78 137 Z24874_PEA_2 _Tl 78 137 WO 2005/069724 PCT/IB2005/001306 214 Segment cluster Z24874 PEA_2_node_6 according to the present invention is supported by 23 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z24874_PEA_2_T10O and Z24874_PEA2_T11. 5 Table 15 below describes the starting and ending position of this segment on each transcript. Table 15 - Segment location on transcripts Transcript mme !Segment starting position Segment ending position Z24874_PEA 2_T10 318 408 Z24874 PEA_2 Tll 318 408 Variant protein alignment to the previously known protein: 10 Sequence name: /tmp/Ro5LG3OhE3/oQvcWauNWJ:Q9NPI5 Sequence documentation: Alignment of: Z24874 PEA 2 P5 x Q9NPI5 15 Alignment segment 1/1: Quality: 1307.00 Escore: 0 Matching length: 132 Total length: 132 20 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 25 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 11 11111 1 111111111111 1111111|1111111111111 1111i 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 30 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 111111111111111111111111II I 11 111111111 11 I 111111 WO 2005/069724 PCT/IB2005/001306 215 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 101 GFLLYSYKPLVDLYSRRYFLTVPYEECKWRRS 132 1 1 1 1 1 lll 1 1 1 1 1 l l 1 1 1 1 1 l l 1I1 5 101 GFLLYSYKPLVDLYSRRYFLTVPYEECKWRRS 132 Sequence name: /tmp/Ro5LG3OhE3/oQvcWauNWJ:Q9NZK3 Sequence documentation: 10 Alignment of: Z24874_PEA 2 P5 x Q9NZK3 Alignment segment 1/1: 15 Quality: 1070.00 Escore: 0 Matching length: 109 Total length: 109 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 20 Alignment: 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 111111111||l111111111111111111111111111111111111 25 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 l il l l I Il l l l l l l l l l l l l l l l l l 1 1 1 1 1 1 1 1 1 1 1 1 1 1 l 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 30 101 GFLLYSYKP 109 111111111 101 GFLLYSYKP 109 35 Sequence name: /tmp/TxcCIAWX3r/LIzBcJOujT:Q9NPI5 Sequence documentation: WO 2005/069724 PCT/IB2005/001306 216 Alignment of: Z24874 PEA 2 P6 x Q9NPI5 Alignment segment 1/1: 5 Quality: 1048.00 Escore: 0 Matching length: 107 Total length: 107 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 10 Alignment: 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 11111 1III11111 111111111 II I III 1 11 IIII1 15 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 I lI l l I l l l l lI I l l l l l l l l l l l l l | 8 1 | 1 1 1 1 1 1 1 1 1 1 1 1 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 20 101 GFLLYSY 107 IlIIIll 101 GFLLYSY 107 25 Sequence name: /tmp/TxcCIAWX3r/LIzBcJOujT:Q9NZK3 Sequence documentation: Alignment of: Z24874 PEA 2 P6 x Q9NZK3 30 Alignment segment 1/1: Quality: 1048.00 Escore: 0 Matching length: 107 Total length: 107 35 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 WO 2005/069724 PCT/IB2005/001306 217 Alignment: 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 11ll Fll~ ll lFll F l I l I ll l l 1111111111 l 1111 111 5 1 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDG 50 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 F1111 ll F 1111 1111 F1111111 F 1 1111111 FI 11111 1111 51 FKQWDVLESLDMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLE 100 10 101 GFLLYSY 107 1111111 101 GFLLYSY 107 15 DESCRIPTION FOR CLUSTER HUMCDDANF Cluster HUMCDDANF features 2 transcript(s) and 7 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest Transcript Name Seq ID No. HUMCDDANF T3 20 HUMCDDANF T4 21 20 Table 2 - Segments of interest Segment Name Seq ID No. HUMCDDANF node 0 123 HUMCDDANF node 10 124 HUMCDDANF node 2 125 HUMCDDANF node_5 126 HUMCDDANF node 8 127 HUMCDDANF node 11 128 WO 2005/069724 PCT/IB2005/001306 218 HUMCDDANF _node_12 129 Table 3 - Proteins of interest Protein Name Seq II No. HUMCDDANFP2 299 HUMCDDANF P3 300 5 These sequences are variants of the known protein Atrial natriuretic factor precursor (SwissProt accession identifier ANFHUMAN; known also according to the synonyms ANF; Atrial natriuretic peptide; ANP; Prepronatriodilatin), referred to herein as the previously known protein; it contains Cardiodilatin-related peptide (CDP). Protein Atrial natriuretic factor precursor is known or believed to have the following 10 function(s): Atrial natriuretic factor (ANF) is a potent vasoactive substance synthesized in mammalian atria and is thought to play a key role in cardiovascular homeostasis; has a cGMP stimulating activity. The sequence for protein Atrial natriuretic factor precursor is given at the end of the application, as "Atrial natriuretic factor precursor amino acid sequence" (SEQ ID NO:350). Known polymorphisms for this sequence are as shown in Table 4. 15 Table 4 - Amino acid mutations for Known Protein SNP position(s) on Comment amino acid sequence 32 V -> M (in dbSNP:5063). /FTId=VAR 014579. 152 - 153 Missing (in isoform 2). /FTId=VAR 000594. 65 E -> D Protein Atrial natriuretic factor precursor localization is believed to be Secreted. 20 It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to WO 2005/069724 PCT/IB2005/001306 219 these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Aldosterone antagonist; Diuretic; Electrolyte absorption agonist. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in 5 the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Antihypertensive, diuretic; Antiasthma; Urological; Cardiostimulant, Antianaemic, Cardiovascular, Neuroprotective, Fertility enhancer, Male contraceptive, Hypolipaemic/Antiatherosclerosis, Hepatoprotective and renal failure. 10 The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: physiological processes; blood pressure regulation, which are annotation(s) related to Biological Process; hormone activity, which are annotation(s) related to Molecular Function; and extracellular, which are annotation(s) related to Cellular Component. The GO assignment relies on information from one or' more of the SwissProt/TremB1 15 Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster HUMCDDANF. Predictions were made for selective expression of 20 transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the yaxis of Figure 17A refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million). Overall, the following results were obtained as shown with regard to the histogram in 25 Figure 17A, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figure 17B, concerning the actual expression of oligonucleotides in various tissues, including heart. This cluster was found to be selectively expressed in heart for the following reasons: a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall 30 expression of the cluster in non-heart ESTs was found to be 56.3; The expression levels of this gene in muscle was negligible; and fisher exact test P-values were computed both for library and WO 2005/069724 PCT/IB2005/001306 220 weighted clone counts to check that the counts are statistically significant, and were found to be 1.20E-249. One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as 5 opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the expression levels of this gene in muscle was negligible, which clearly supports specific expression in heart tissue. 10 As noted above, cluster HUMCDDANF features 2 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Atrial natriuretic factor precursor. A description of each variant protein according to the present invention is now provided. Variant protein HUMCDDANFP2 according to the present invention has an amino acid 15 sequence as given at the end of the application; it is encoded by transcript(s) HUMCDDANF_T3. An alignment is given to the known protein (Atrial natriuretic factor precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein 20 is as follows: Comparison report between HUMCDDANFP2 and ANFHUMAN: 1.An isolated chimeric polypeptide encoding for HUMCDDANFP2, comprising a first amino acid sequence being at least 90 % homologous to 25 MPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRGPWDSSDRS ALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY corresponding to amino acids 51 - 151 of ANFHUMAN, which also corresponds to amino acids 1 - 101 of HUMCDDANF P2. 30 The location of the variant protein was determined according to results from a number of Different software programs and analyses, including analyses from SignalP and other specialized WO 2005/069724 PCT/IB2005/001306 221 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted 5 protein.. Variant protein HUMCDDANFP2 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCDDANFP2 10 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7 -Amino acid mutations SNP positiOn(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 20 A->V Yes 27 L->F Yes 74 S -> No 76 R-> Q Yes 15 Variant protein HUMCDDANF_P2 is encoded by the following transcript(s): HUMCDDANFT3, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMCDDANFT3 is shown in bold; this coding portion starts at position 381 and ends at position 683. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative 20 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCDDANF_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Nucleic acid SNPs WO 2005/069724 PCT/IB2005/001306 222 SNP position on nucleotide Alternative nucleic acid . Previously known SNP? sequence 199 C ->T Yes 374 A ->G No 771 T ->C Yes 778 T->C Yes 809 C -> T Yes 887 C -> G No 968 A->C Yes 439 C -> T Yes 458 C -> T No 459 C -> T Yes 602 C -> No 607 G->A Yes 684 T -> C Yes (short/long variant) 711 A->G No 757 G -> T Yes Variant protein HUMCDDANFP3 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HUMCDDANFT4. An alignment is given to the known protein (Atrial natriuretic factor precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HUMCDDANF P3 and ANF HUMAN: 1.An isolated chimeric polypeptide encoding for HUMCDDANFP3, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more WO 2005/069724 PCT/IB2005/001306 223 preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MSSFSTTT corresponding to amino aids 1 - 8 of HUMCDDANF P3, and a second amino acid sequence being at least 90 % homologous to NLLDHLEEKMPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGR 5 GPWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY corresponding to amino acids 42 - 151 of ANFHUMAN, which also corresponds to amino acids 9 - 118 of HUMCDDANFP3, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of HUMCDDANF P3, comprising a 10 polypeptide being at bast 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MSSFSTTT of HUMCDDANF P3 The location of the variant protein was determined according to results from a number of 15 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted 20 protein.. Variant protein HUMCDDANFP3 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCDDANFP3 25 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 9 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? sequence 37 A ->V Yes WO 2005/069724 PCT/IB2005/001306 224 44 L -> F Yes 91 S -> No 93 R-> Q Yes Variant protein HUMCDDANFP3 is encoded by the following transcript(s): HUMCDDANFT4, for which the sequence(s) is/are gven at the end of the application. The coding portion of transcript HUMCDDANFT4 is shown in bold; this coding portion starts at 5 position 104 and ends at position 457. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCDDANFP3 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 10 - Nucleic acid SNPs SNP position oqn nucleotide Alternative nucleic acid Previously known SNP? sequence 148 A -> G No 213 C -> T Yes 552 T -> C Yes 583 C ->T Yes 661 C ->G No 742 A ->C Yes 232 C ->T No 233 C ->T Yes 376 C-> No 381 G ->A Yes 458 T -> C Yes (short/long isoform) 485 A ->G No 531 G ->T Yes 545 T ->C Yes WO 2005/069724 PCT/IB2005/001306 224 44 L->F Yes 91 S -> No 93 R -> Q Yes Variant protein HUMCDDANF_P3 is encoded by the following transcript(s): HUMCDDANFT4, for which the sequence(s) is/are oven at the end of the application. The coding portion of transcript HUMCDDANFT4 is shown in bold; this coding portion starts at 5 position 104 and ends at position 457. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCDDANF_P3 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 10 - Nucleic acid SNPs SNP 1o"oiloil ce~eAtxntv~ukea I ~K PIC'tS' k~i1 11omb SNP:. 148 A->G No 213 C->T Yes 552 T->C Yes 583 C->T Yes 661 C->G No 742 A->C Yes 232 C->T No 233 C->T Yes 376 C -> No 381 G->A Yes 458 T -> C Yes (short/long isoform) 485 A -> G No 531 G -> T Yes 545 T -> C Yes WO 2005/069724 PCT/IB2005/001306 225 As noted above, cluster HUMCDDANF features 7 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are 5 of particular interest. A description of each segment according to the present invention is now provided. Segment cluster HUMCDDANF_node_0 according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment 10 can be found in the following transcript(s): HUMCDDANFT3. Table 11 below describes the starting and ending position of this segment on each transcript. Table 11 - Segment location on transcripts ST1ran1SCript) 1ni cmlt tlM PomeWoll "SCgmict C1(ii HUMCDDANFT3 1 353 15 Segment cluster HUMCDDANF_mnde_10 according to the present invention is supported by 49 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCDDANF_T3 and HUMCDDANF_T4. Table 12 below describes the starting and ending position of this segment on each transcript. Table 12 - Segment location on transcripts HUMCDDANFT3 813 940 HUMCDDANFT4 587 714 20 Segment cluster HUMCDDANF_node_2 according to the present invention is supported by 41 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCDDANF_T4. Table 13 below describes the 25 starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 226 Table 13 - Segment location on transcripts Transcript name Segment starting position Segmenti ending position HUMCDDANF T4 1 127 Segment cluster HUMCDDANF_node_5 according to the present invention is supported 5 by 62 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCDDANF_T3 and HUMCDDANF_T4. Table 14 below describes the starting and ending position of this segment on each transcript. Table 14 - Segment location on transcripts ~~~~~~_SegmI kl I !p sh ln'C 11lt'21dingw i o.,fflo HUMCDDANF T3 354 680 HUMCDDANF T4 128 454 10 Segment cluster HUMCDDANF_node_8 according to the present invention is supported by 56 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCDDANF_T3 and HUMCDDANF_T4. Table 15 below describes the starting and ending position of this segment on each transcript. 15 Table 15 - Segment location on transcripts nitame 'gesa ge~k e~neige HUMCDDANFT3 681 812 HUMCDDANF T4 455 586 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are 20 included in a separate description.

WO 2005/069724 PCT/IB2005/001306 227 Segment cluster HUMCDDANFnode_ II according to the present invention can be found in the following transcript(s): HUMCDDANF_T3 and HUMCDDANFT4. Table 16 below describes the starting and ending position of this segment on each transcript. Table 16 - Segment location on transcripts anscipt name Segment starting position Segment ending position HUMCDDANF T3 941 951 HUMCDDANF T4 715 725 5 Segment cluster HUMCDDANFnode_12 according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCDDANFT3 and HUMCDDANF_T4. Table 10 17 below describes the starting and ending position of this segment on each transcript. Table 17 - Segment location on transcripts HUMCDDANF T3 952 992 HUMCDDANF T4 726 766 Variant protein alignment to the previously known protein: Sequence name: /tmp/3GyiZQyJ8L/jYng3zFfcE:ANFHUMAN 15 Sequence documentation: Alignment of: HUMCDDANF P2 x ANF HUMAN 20 Alignment segment 1/1: Quality: 988.00 Escore: 0 Matching length: 101 Total length: 101 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 25 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 WO 2005/069724 PCT/IB2005/001306 228 Alignment: 1 MPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRG 50 5 i l l lll l l l l l l l l11 1 1 1 l1 1 i l l l l l l ll l l l lIl l ll 51 MPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRG 100 51 PWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFR 100 I ll l l l l l l l l I l l l l l l I l l l l l l l l l l l l l l l l l l l l l l l l l l 10 101 PWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFR 150 101 Y 101 I 151 Y 151 15 Sequence name: /tmp/mnb7OPVCPP/oTrSwgJLyB:ANF HUMAN Sequence documentation: 20 Alignment of: HUMCDDANFP3 x ANF HUMAN Alignment segment 1/1: Quality: 1076.00 Escore: 0 25 Matching length: 110 Total length: 110 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 30 Alignment: 9 NLLDHLEEKMPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQ 58 llllllllllllIlllllllllllllllll I1111111111111 42 NLLDHLEEKMPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQ 91 35 59 RDGGALGRGPWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQ 108 I l l l l I I l l l l l l I l l l LRll l l l Rl l1 1 l l l l I l l l l l l II I 1 92 RDGGALGRGPWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQ 141 WO 2005/069724 PCT/IB2005/001306 229 109 SGLGCNSFRY 118 11111I111 142 SGLGCNSFRY 151 5 Expression of Human cardiodilatin-atrial natriuretic factor (CDD-ANF) HUMCDDANF transcripts which are detectable by amplicon as depicted in sequence name HUMCDDANFjunc2-5F2R2 specifically in heart tissue Expression of Human cardiodilatin-atrial natriuretic factor (CDD-ANF) transcripts detectable by or according to junc2-5 node(s), HUMCDDANFjunc2-5F2R2 amplicon and 10 primers HUMCDDANFjunc2-5F2 HUMCDDANFjunc2-5R2 was measured by real time PCR (this transcript relates to the known or WT protein). In parallel the expression of four housekeeping genes - RPL 19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. 15 NM_004168; amplicon- SDHA-amplicon) was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the quantity of heart sample no. 45 (Table 1, above), to obtain a value of relative expression for each sample relative to this heart sample. 20 As is evident from Figure 18, the expression of Human cardiodilatin-atrial natriuretic factor (CDD-ANF) transcripts detectable by the above amplicon(s) in one of the heart tissue samples (Sample Nos. 45, Table 1, "Tissue samples in testing panel") was significantly higher than in the other samples, including other two heart samples. Sample 45 is from fibrotic heart, as opposed to heart samples 44 and 46 that are from normal hearts. (Note - the product in samples 25 10 and 11 was found to be a non-specific product by inspecting the dissociation curve that was created in the real-time PCR experiment). Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: HUMCDDANFjunc2-5F2 forward 30 primer; and HUMCDDANFjunc2-5R2 reverse primer. The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon WO 2005/069724 PCT/IB2005/001306 230 was obtained as a non-limiting illustrative example only of a suitable amplicon: HUMCDDANFjunc2-5F2R2. Forward primer HUMCDDANFjunc2-5F2 (SEQ ID NO:374): CTTCTCCACCACCACCAATTTG 5 Reverse primer HUMCDDANFjunc2-5R2 (SEQ ID NO:375): GAGAGCAGCCCCCGCT Amplicon HUMCDDANFjunc2-5F2R2 (SEQ ID NO:376): CTTCTCCACCACCACCAATTTGCTGGACCATTTGGAAGAAAAGATGCCTTTAGAAG ATGAGGTCGTGCCCCCACAAGTGCTCAGTGAGCCGAATGAAGAAGCGGGGGCTGCT 10 CTC DESCRIPTION FOR CLUSTER HUMTROPIA 15 Cluster HUMTROPIA features 4 transcript(s) and 20 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest HUMTROPIA PEA 2 T10 22 HUMTROPIA PEA_2_T15 23 HUMTROPIA PEA 2 T3 24 HUMTROPIA PEA 2 T7 25 20 Table 2 - Segments of interest HUMTROPIAPEA_2 node_0 130 HUMTROPIAPEA_2 node_10 131 HUMTROPIAPEA_2 node_22 132 WO 2005/069724 PCT/IB2005/001306 231 HUMTROPIA PEA 2_node_23 133 HUMTROPIA PEA 2 node_11 134 HUMTROPIA PEA 2 node_14 135 HUMTROPIA PEA 2_node_15 136 HUMTROPIA PEA 2_node_16 137 HUMTROPIA PEA_2 node 20 138 HUMTROPIA PEA 2 node 21 139 HUMTROPIA PEA_2 node_24 140 HUMTROPIA PEA 2 node 25 141 HUMTROPIA PEA 2 node_29 142 HUMTROPIA PEA 2 node_30 143 HUMTROPIA PEA_2 node_31 144 HUMTROPIAPEA 2 node 32 145 HUMTROPIA PEA 2 node_4 146 HUMTROPIA PEA 2 node_5 147 HUMTROPIA PEA 2 node 8 148 HUMTROPIA PEA 2 node_9 149 Table 3 - Proteins of interest HUMTROPIAPEA_2_P5 301 HUMTROPIA PEA 2 Pl2 302 HUMTROPIA PEA 2_P17 303 HUMTROPIAPEA 2 Pl8 304 These sequences are variants of the known protein Troponin I, cardiac muscle (SwissProt 5 accession identifier TRICHUMAN), referred to herein as the previously known protein and shown as SEQ ID NO: 351. Protein Troponin I, cardiac muscle is known or believed to have the following WO 2005/069724 PCT/IB2005/001306 232 function(s): Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. Troponin I, cardiac muscle Binds to actin and tropomyosin. Defects in Troponin I, cardiac muscle are the cause of familial hypertrophic cardiomyopathy type 7 (CMH7) [MIM:191044]; 5 also known as FHC type 7. CMH7 is an autosomal dominant disorder characterized by increased myocardial mass with myocyte and myofibrillar disarray. Defects in Troponin 1, cardiac muscle are the cause of familial restrictive cardiomyopathy (RCM) [MIM:115210]. RCM is a heart muscle disorder characterized by impaired filling of the ventricles with reduced volume in the presence of normal or near normal wall thickness and systolic function. The 10 disease may be associated with systemic disease but is most often idiopathic. The sequence for protein Troponin I, cardiac muscle is given at the end of the application, as "Troponin I, cardiac muscle amino acid sequence" (SEQ ID NO:351). Known polymorphisms for this sequence are as shown in Table 4. Table 4 - Amino acid mutations for Known Protein SNP pos il nIs) o nComn 81 P -> S (in CMH7). /FTId=VAR _016078. 143 L-> Q (in RCM). /FTId=VAR_016079. 144 R-> G (in CMH7). /FTId=VAR_007603. 144 R -> W (in RCM). /FTId=VAR 016080. 170 A -> T (in RCM). /FTId=VAR_016081. 177 K -> E (in RCM). /FTId=VAR_016082. 189 D -> H (in CMH7 and RCM). /FTId=VAR_016083. 191 R-> H (in RCM). /FTId=VAR _016084. 195 D -> N (in CMH7). /FTId=VAR_016085. 205 K -> Q (in CMH7). /FTId=VAR_007604. 15 In addition to the above known polymorphisms, the present inventors have uncovered two new additional SNPs (shown with regard to SEQ ID NO:352 for the resultant amino acid sequence, and SEQ ID NO:353 for the nucleic acid sequence). This SNP is C-> (missing WO 2005/069724 PCT/IB2005/001306 233 nucleotide "C"; will affect amino acid residues from 167 onwards). This will create a frame shift. A new protein will be formed. However, this SNP was located in a stretch of cytosine residues, which are known to be prone to errors in sequencing. 5 The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Cancer, lung, non-small cell; Cancer, breast; Cancer, sarcoma. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity 10 or activities of the previously known protein are as follows: Angiogenesis inhibitor; Epidermal growth factor antagonist; Fibroblast growth factor receptor antagonist. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: 15 Ophthalmological; Anticancer. The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: control of heart, which are annotation(s) related to Biological Process; and troponin complex, which are annotation(s) related to Cellular Component. The GO assignment relies on information from one or more of the SwissProt/TremBl 20 Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster HUMTROPIA. Predictions were made for selective expression of 25 transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the yaxis of Figure 19 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million). Overall, the following results were obtained as shown with regard to the histogram in 30 Figure 19, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figure 20, concerning the actual expression of oligonucleotides in WO 2005/069724 PCT/IB2005/001306 234 various tissues, including heart. This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 27.5. The expression level of 5 this gene in muscle was negligible; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 2.10E-88. One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as 10 opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the expression level of this gene in muscle was negligible which clearly supports specific expression in heart tissue. 15 As noted above, cluster HUMTROPIA features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Troponin I, cardiac muscle. A description of each variant protein according to the present invention is now provided. Variant protein HUMTROPIA_PEA_2_P5 according tb the present invention has an 20 amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMTROPIAPEA_2_T3. An alignment is given to the known protein (Troponin I, cardiac muscle) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein 25 is as follows: Comparison report between HUMTROPIAPEA_2_P5 and TRIC HUMAN: 1.An isolated chimeric polypeptide encoding for HUMTROPIAPEA_2 P5, comprising a first amino acid sequence being at least 90 % homologous to 30 MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQ

ELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAK

WO 2005/069724 PCT/IB2005/001306 235 VTKNITE corresponding to amino acids 1 - 124 of TRIC_HUMAN, which also corresponds to amino acids I - 124 of HUMTROPIA PEA_2 P5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence 5 VGRMGSSGTFGVG corresponding to amino acids 125- 137 of HUMTROPIA_PEA_2_P5, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HUMTROPIA_PEA_2 P5, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 10 sequence VGRMGSSGTFGVG in HUMTROPIAPEA_2_P5. The cellular location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the 15 cell: intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein HUMTROPIA_PEA_2_P5 is encoded by the following transcript(s): 20 HUMTROPIA_PEA 2_T3, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMTROPIA_PEA_2_T3 is shown in bold; this coding portion starts at position 148 and ends at position 558. Variant protein HUMTROPIA_PEA 2 P12 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 25 HUMTROPIA_PEA_2_T15. An alignment is given to the known protein (Troponin I, cardiac muscle) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 30 Comparison report between HUMTROPIA_PEA_2_P12 and TRIC_HUMAN: WO 2005/069724 PCT/IB2005/001306 236 l.An isolated chimeric polypeptide encoding for HUMTROPIA_PEA_2 Pl2, comprising a first amino acid sequence being at least 90 % homologous to MADGSSDA corresponding to amino acids I - 8 of TRIC_HUMAN, which also corresponds to amino acids 1 - 8 of HUMTROPIAPEA_2 PI2, and a second amino acid sequence being at least 70%, optionally 5 at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at bast 95% homologous to a polypeptide having the sequence KKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGL GFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRV RISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGMEG 10 RKKKFES corresponding to amino acids 36 - 209 of TRIC_HUMAN, which also corresponding to amino acids 9 - 182 of HUMTROPIA_PEA 2 P12, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated chimeric polypeptide encoding for an edge portion of HUMTROPIAPEA_2 P12, comprising a polypeptide having a length "n", wherein "n" is at 15 least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AK, having a structure as follows: a sequence starting from any of amino acid numbers 8-x to 8; and ending at any of amino acid numbers 9+ ((n-2) - x), in which x varies 20 from 0 to n-2. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 25 intracellularly. The protein localization is believed to be intracellular because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. 30 Variant protein HUMTROPIAPEA 2 P12 is encoded by the following transcript(s): HUMTROPIA_PEA_2_T15, for which the sequence(s) is/are given at the end of the WO 2005/069724 PCT/IB2005/001306 237 application. The coding portion of transcript HUMTROPIA PEA 2_TI5 is shown in bold; this coding portion starts at position 148 and ends at position 693. Variant protein HUMTROPIA PEA 2 P17 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HUMTROPIA_PEA 2_T7. An alignment is given to the known protein (Troponin I, cardiac muscle) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HUMTROPIA_PEA_2_P17 and TRIC_HUMAN: 1.An isolated chimeric polypeptide encoding for HUMTROPIAPEA_2 P17, comprising a first amino acid sequence being at least 90 % homologous to MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAK corresponding to amino acids 1 - 36 15 of TRICHUMAN, which also corresponds to amino acids 1 - 36 of HUMTROPIA_PEA_2_P17, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGRGFLGAEYRRRRDPRPWEWGEEPGLRRGRGLRGGASGAEFCRGSCSDW 20 corresponding to amino acids 37- 86 of HUMTROPIA_PEA_2 P17, wherein said first and second amino acid sequences are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HUMTROPIA_PEA 2_P17, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 25 sequence VGRGFLGAEYRRRRDPRPWEWGEEPGLRRGRGLRGGASGAEFCRGSCSDW in HUMTROPIA PEA 2 P17. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 30 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellular because neither of the WO 2005/069724 PCT/IB2005/001306 238 trans-membrane region prediction programs predicted a trans-memrnbrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.. Variant protein HUMTROPIA_PEA_2 Pl7 is encoded by the following transcript(s): 5 HUMTROPIA_PEA_2_T7, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMTROPIA_PEA_2_T7 is shown in bold; this coding portion starts at position 148 and ends at position 405. Variant protein HUMTROPIA_PEA 2 P18 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 10 HUMTROPIA_PEA_2 T10. An alignment is given to the known protein (Troponin I, cardiac muscle) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 15 Comparison report between HUMTROPIA_PEA_2_P18 and TRIC_HUMAN: 1 .An isolated chimeric polypeptide encoding for HUMTROPIA_PEA_2 P18, comprising a first amino acid sequence being at least 90 % homologous to MADGSSDA corresponding to amino acids 1 - 8 of TRIC_HUMAN, which also corresponds to amino acids 1 - 8 of 20 HUMTROPIA_PEA_2 P18, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRAAG corresponding to amino acids 9- 13 of HUMTROPIAPEA_2 P18, wherein said first and second amino acid sequences are contiguous and in a sequential order. 25 2.An isolated polypeptide encoding for a tail of HUMTROPIA_PEA_2 P18, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRAAG in HUMTROPIAPEA_2_P18. 30 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized WO 2005/069724 PCT/IB2005/001306 239 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted 5 protein.. Variant protein HUMTROPIAPEA_2 P18 is encoded by the following transcript(s): HUMTROPIA_PEA_2 TI0, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMTROPIA_PEA_2_T10 is shown in bold; this coding portion starts at position 148 and ends at position 186. 10 As noted above, cluster HUMTROPIA features 20 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. 15 Segment cluster HUMTROPIA_PEA 2 node_0 according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA_PEA_2_TI0, HUMTROPIA_PEA_2_T15, HUMTROPIA_PEA_2 T3 and HUMTROPIA_PEA_2_T7. Table 20 7 below describes the starting and ending position of this segment on each transcript. Table 7 - Segment location on transcripts HUMTROPIA PEA 2 T10 1 158 HUMTROPIAPEA 2_T15 1 158 HUMTROPIA PEA 2 T3 1 158 HUMTROPIAPEA_2_T7 1 158 Segment cluster HUMTROPIA_PEA 2 node_10 according to the present invention is 25 supported by 5 libraries. The number of libraries was determined as previously described. This WO 2005/069724 PCT/IB2005/001306 240 segment can be found in the following transcript(s): HUMTROPIA_PEA_2_T7. Table 8 below describes the starting and ending position of this segment on each transcript. Table 8 - Segment location on transcripts Transcript name Segment starting position Segment endxigpositon HUMTROPIA PEA 2 T7 256 660 5 Segment cluster HUMTROPIAPEA_2_node_22 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIAPEA 2 T3. Table 9 below describes the starting and ending position of this segment on each transcript. 10 Table 9 - Segment location on transcripts TIran1cript na"1me : j~ ISgenlct artiipitofr Seg1&ntenlding piti' HUMTROPIAPEA_2_T3 520 1053 Segment cluster HUMTROPIA_PEA 2 node_23 according to the present invention is supported by 49 libraries. The number of libraries was determined as previously described. This 15 segment can be found in the following transcript(s): HUMTROPIA_PEA_2 T10, HUMTROPIA_PEA_2_T15, HUMTROPIA_PEA_2_T3 and HUMTROPIAPEA_2_T7. Table 10 below describes the starting and ending position of this segment on each transcript. Table 10 - Segment location on transcripts iu ame en t~gOn ege HUMTROPIA PEA 2 T10 565 708 HUMTROPIA PEA_2_T15 436 579 HUMTROPIAPEA 2 T3 1054 1197 HUMTROPIA PEA 2 T7 925 1068 20 WO 2005/069724 PCT/IB2005/001306 241 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description. 5 Segment cluster HUMTROPIA_PEA 2 node_ 11 according to the present invention is supported by 28 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA_PEA_2_TI 0, HUMTROPIAPEA_2 TI5, HUMTROPIA PEA_2 T3 and HUMTROPIA PEA_2_T7. Table 11 below describes the starting and ending position of this segment on each transcript. I0 Table 11 - Segment location on transcripts Trnserigt name Segment starting position Segment ending position HUMTROPIA PEA 2 T10 301 342 HUMTROPIA PEA 2 T15 172 213 HUMTROPIA PEA 2 T3 256 297 HUMTROPIA PEA 2 T7 661 702 Segment cluster HUMTROPIA_PEA 2 node_14 according to the present invention is supported by 37 libraries. The number of libraries was determined as previously described. This 15 segment can be found in the following transcript(s): HUMTROPIA_PEA_2_T1i0, HUMTROPIA_PEA_2_T 15, HUMTROPIA_PEA_2_T3 and HUMTROPIA_PEA 2 T7. Table 12 below describes the starting and ending position of this segment on each transcript. Table 12 - Segment location on transcripts m e e, -0ee ~n e HUMTROPIA PEA 2_T10O 343 378 HUMTROPIAPEA 2 T15 214 249 HUMTROPIAPEA 2_T3 298 333 HUMTROPIAPEA 2_T7 703 738 20 WO 2005/069724 PCT/IB2005/001306 242 Segment cluster HUMTROPIA_PEA 2 node_15 according to the present invention is supported by 42 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA PEA_2 T10, HUMTROPIA PEA_2_T15, HUMTROPIA PEA_2_T3 and HUMTROPIAPEA_2_T7. Table 5 13 below describes the starting and ending position of this segment on each transcript. Table 13 - Segment location on transcripts Tisci eSegmient starting' position Segment ending position HUMTROPIAPEA_2_T10 379 422 HUMTROPIA PEA 2 T15 250 293 HUMTROPIAPEA 2 T3 334 377 HUMTROPIA PEA 2 T7 739 782 Segment cluster HUMTROPIAPEA 2 node_16 according to the present invention is 10 supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA_PEA_2_T10, HUMTROPIAPEA_2_T15, HUMTROPIAPEA 2_T3 and HUMTROPIAPEA_2_T7. Table 14 below describes the starting and ending position of this segment on each transcript. Table 14 - Segment location on transcripts HUMTROPIAPEA_2_T10 423 474 HUMTROPIA PEA 2 T15 294 345 HUMTROPIAPEA 2_T3 378 429 HUMTROPIA PEA 2_T7 783 834 15 Segment cluster HUMTROPIA_PEA 2 node_20 according to the present invention is supported by 44 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIAPEA_2_T10, 20 HUMTROPIA_PEA 2_T15, HUMTROPIA_PEA_2_T3 and HUMTROPIA_PEA_2_T7. Table WO 2005/069724 PCT/IB2005/001306 243 15 below describes the starting and ending position of this segment on each transcript. Table 15 - Segment location on transcripts Tr i cnpt nam Segment starting position Segment ending position HUMTROPIA PEA 2 T10 475 510 HUMTROPIA PEA 2 TI5 346 381 HUMTROPIA PEA 2 T3 430 465 HUMTROPIA PEA 2 T7 835 870 5 Segment cluster HUMTROPIA_PEA 2 node_21 according to the present invention is supported by 44 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA_PEA 2 T10, HUMTROPIAPEA 2 TI15, HUMTROPIAPEA 2 T3 and HUMTROPIAPEA_2_T7. Table 16 below describes the starting and ending position of this segment on each transcript. 10 Table 16- Segment location on transcripts HUMTROPIAPEA_2_T10 511 564 HUMTROPIA PEA 2 T15 382 435 HUMTROPIA PEA 2 T3 466 519 HUMTROPIA PEA 2_T7 871 924 Segment cluster HUMTROPIA_PEA_2 node_24 according to the present invention can be found in the following transcript(s): HUMTROPIAPEA 2_T10, 15 HUMTROPIA_PEA 2 T15, HUMTROPIA_PEA_2_T3 and HUMTROPIA_PEA_2_T7. Table 17 below describes the starting and ending position of this segment on each transcript. Table 17 - Segment location on transcripts HUMTROPIAPEA_2 T10 709 726 WO 2005/069724 PCT/IB2005/001306 244 HUMTROPIA PEA 2_T15 580 597 HUMTROPIAPEA 2_T3 1198 1215 HUMTROPIA PEA 2 T7 1069 1086 Segment cluster HUMTROPIA_PEA_2 node_25 according to the present invention can be found in the following transcript(s): HUMTROPIA_PEA_2 T10, 5 HUMTROPIAPEA 2 T15, HUMTROPIAPEA 2_T3 and HUMTROPIAPEA_2_T7. Table 18 below describes the starting and ending position of this segment on each transcript. Table 18 - Segment location on transcripts TIanscript me Segment starting position begment ndIng poLsiIon HUMTROPIA PEA 2 TO1 727 741 HUMTROPIA PEA 2 TI5 598 612 HUMTROPIA PEA 2 T3 1216 1230 HUMTROPIA PEA 2 T7 1087 1101 10 Segment cluster HUMTROPIA_PEA 2 node_29 according to the present invention can be found in the following transcript(s): HUMTROPIA_PEA_2_T10, HUMTROPIAPEA 2 T15, HUMTROPIA PEA_2_T3 and HUMTROPIAPEA_2 T7. Table 19 below describes the starting and ending position of this segment on each transcript. Table 19 - Segment location on transcripts T, i n en si i t _osi 4M ...... e HUMTROPIA PEA 2 T10O 742 761 HUMTROPIA PEA 2 T15 613 632 HUMTROPIA PEA 2 T3 1231 1250 HUMTROPIA PEA 2 T7 1102 1121 15 WO 2005/069724 PCT/IB2005/001306 245 Segment cluster HUMTROPIA_PEA 2 node_30 according to the present invention can be found in the following transcript(s): HUMTROPIA_PEA 2 T10, HUMTROPIA_PEA 2 TI5, HUMTROPIAPEA_2_T3 and HUMTROPIAPEA_2 T7. Table 20 below describes the starting and ending position of this segment on each transcript. 5 Table 20 - Segment location on transcripts Trancript name Segment starting position Segment ending position HUMTROPIA PEA 2_TIO 762 774 HUMTROPIA PEA 2 T15 633 645 HUMTROPIAPEA 2 T3 1251 1263 HUMTROPIA PEA 2 T7 1122 1134 Segment cluster HUMTROPIA_PEA_2_node_31 according to the present invention can be found in the following transcript(s): HUMTROPIA_PEA_2_TIO, 10 HUMTROPIAPEA 2 T15, HUMTROPIA PEA 2 T3 and HUMTROPIA PEA 2 T7. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts HUMTROPIA PEA 2 T10 775 798 HUMTROPIAPEA_2 T15 646 669 HUMTROPIA PEA 2 T3 1264 1287 HUMTROPIA PEA 2 T7 1135 1158 15 Segment cluster HUMTROPIAPEA 2 node_32 according to the present invention is supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA_PEA_2_TIO, HUMTROPIA_PEA 2_T15, HUMTROPIA_PEA_2_T3 and HUMTROPIA_PEA_2_T7. Table 22 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 246 Table 22 - Segment location on transcripts Transcript name Segment starting position Segment endmg position HUMTROPIA PEA 2 TIO0 799 892 HUMTROPIA PEA 2 T15 670 763 HUMTROPIA PEA 2 T3 1288 1381 HUMTROPIA PEA 2 T7 1159 1252 Segment cluster HUMTROPIAPEA 2 node_4 according to the present invention can be 5 found in the following transcript(s): HUMTROPIA_PEA 2 TI0, HUMTROPIA_PEA_2_T15, HUMTROPIAPEA_2 T3 and HUMTROPIA PEA_2_T7. Table 23 below describes the starting and ending position of this segment on each transcript. Table 23 - Segment location on transcripts Traninpt name Stgment starting positions Scmnt ending position HUMTROPIA PEA 2 Tl0 159 171 HUMTROPIA PEA 2 T15 159 171 HUMTROPIA PEA 2 T3 159 171 HUMTROPIA PEA 2 T7 159 171 10 Segment cluster HUMTROPIAPEA_2_node_5 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA_PEA 2_T10. Table 24 below describes the starting and ending position of this segment on each transcript. 15 Table 24 - Segment location on transcripts IU T OPIAPA_2 0 172 216 - en HUMTROPIAPEA_2_T10 172 216 WO 2005/069724 PCT/IB2005/001306 247 Segment cluster HUMTROPIAPEA_2_node_8 according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIA PEA 2 TI0, HUMTROPIA PEA 2_T3 and HUMTROPIA PEA_2_T7. Table 25 below describes the 5 starting and ending position of this segment on each transcript. Table 25 - Segment location on transcripts Trinscript name Segmgment starting position Segment ending position HUMTROPIA PEA 2 T10 217 266 HUMTROPIA PEA 2_T3 172 221 HUMTROPIA PEA_2 T7 172 221 Segment cluster HUMTROPIA_PEA_2_node_9 according to the present invention is 10 supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTROPIAPEA_2_T10, HUMTROPIAPEA 2 T3 and HUMTROPIAPEA_2 T7. Table 26 below describes the starting and ending position of this segment on each transcript. Table 26 - Segment location on transcripts HUMTROPIAPEA_2 TI0 267 300 HUMTROPIAPEA_2_T3 222 255 HUMTROPIAPEA 2_T7 222 255 15 Variant protein alignment to the previously known protein: Sequence name: /tmp/p5CHmauP3N/NVyK804uFt:TRICHUMAN 20 Sequence documentation: Alignment of: HUMTROPIA PEA 2 P5 x TRICHUMAN WO 2005/069724 PCT/IB2005/001306 248 Alignment segment 1/1: Quality: 1183.00 Escore: 0 5 Matching length: 124 Total length: 124 Matching Percent Similarity: 100.00 Matching Percent Identity: 99.19 Total Percent Similarity: 100.00 Total Percent Identity: 99.19 Gaps: 0 10 Alignment: 2 ADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKT 51 I l l i ll l lI l I l li l l 1 1 1 1 1 1 1 1 l l l i 1 1 1 l l l lI l l l l I l Il l l 1 ADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKT 50 15 52 LLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLH 101 I I l li l l l l l l l l I l l il l li l l l l l l l l i l1 1 1 1 1 1 l l I ll l l ll l 51 LLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLH 100 20 102 ARVDKVDEERYDIEAKVTKNITEV 125 I ll l l Il l l ll l l li l l li : 101 ARVDKVDEERYDIEAKVTKNITEI 124 Sequence name: /tmp/gCDnOSmn31/GzfEmz5N5Z:TRICHUMAN 25 Sequence documentation: Alignment of: HUMTROPIA PEA 2 PI2 x TRIC HUMAN 30 Alignment segment 1/1: Alignment: Quality: 873.00 Length: 209 35 Ratio: 4.823 Gaps: 1 Percent Similarity: 86.603 Percent Identity: 86.603 alignment block: WO 2005/069724 PCT/IB2005/001306 249 HUMTROPIA PEA 2 P12 x Troponin Align seg 1/1 to: Troponin from: 1 to: 209 5 2 ADGSSDA............................KKSKISASRKLQLKT 23 11111ll l ll 1 11 1 1 ADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKT 50 24 LLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLH 73 10 I Il l l l I 11 i l l l I l i lIl I Il I Il l lI I l l i l l l l l l l l ll 51 LLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLH 100 74 ARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVRISA 123 Il lI ll l l l l ll i i I l lI l l l l l[ i l l l I l l l l l Il l l l l l l ll l l 15 101 ARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVRISA 150 124 DAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGM 173 l I l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l i l l li l l l l l l l | 151 DAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGM 200 20 174 EGRKKKFES 182 Illillllil 201 EGRKKKFES 209 25 Sequence name: /tmp/O8saIrMOll/UUlNosjzB3:TRICHUMAN Sequence documentation: Alignment of: HUMTROPIA PEA 2 P17 x TRIC HUMAN 30 Alignment segment 1/1: Quality: 344.00 Escore: 0 Matching length: 35 Total length: 35 35 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 WO 2005/069724 PCT/IB2005/001306 250 Alignment: 2 ADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAK 36 Il l 1 l l il l l I IIIl l ll l l Il l I l ll 5 1 ADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAK 35 Sequence name: /tmp/shMGxspSCh/hLCzvaPT2j:TRIC HUMAN 10 Sequence documentation: Alignment of: HUMTROPIAPEA 2 P18 x TRIC HUMAN Alignment segment 1/1: 15 Quality: 71.00 Escore: 0 Matching length: 9 Total length: 9 Matching Percent Similarity: 88.89 Matching Percent Identity: 88.89 Total Percent Similarity: 88.89 Total Percent Identity: 88.89 20 Gaps: 0 Alignment: 2 ADGSSDAVR 10 2 5 1 1 1 1 1 1 1 I 1 ADGSSDAAR 9 Expression of TRIC_HUMAN Troponin I, cardiac muscle HUMTROPIA transcripts which are detectable by amplicon as depicted in sequence name HUMTROPIA segl0 specifically in heart 30 tissue Expression of TRIC_HUMAN Troponin I, cardiac muscle transcripts detectable by or according to segl0 node(s), HUMTROPIA segl0 amplicon(s) and HUMTROPIA segl0F2 and HUMTROPIA segl0R2 primers was measured by real time PCR. In parallel the expression of four housekeeping genes -Ubiquitin (GenBank Accession No. BC000449; amplicon 35 Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA- WO 2005/069724 PCT/IB2005/001306 251 amplicon), RPLI9 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM003194; TATA amplicon) was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then 5 divided by the median of the quantities of the heart samples (Sample Nos. 44-46, Table I, above"Tissue samples in testing panel"), to obtain a value of fold up-regulation for each sample relative to median of the heart. Figure 21A is a histogram showing specific expression of the above-indicated TRIC_HUMAN Troponin I, cardiac muscle transcripts in heart tissue samples as opposed to 10 other tissues. As is evident from Figure 21A, the expression of TRICHUMAN Troponin I, cardiac muscle transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher than in most other samples (non-heart tissue sample Nos. 1-9,11-26, 28-43, 47-74 Table 1 above "Tissue samples in testing panel"). 15 Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: HUMTROPIA segl0F2 forward primer; and HUMTROPIA segl0R2 reverse primer. 20 The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: HUMTROPIA segl0. HUMTROPIA segI Forward primer (SEQ ID NO:377): TTGCAGAGGGTCATGCTCG 25 HUMTROPIA segI Reverse primer (SEQ ID NO:378): TCCTTTGGATAGGCACTTCCC HUMTROPIA segI Amplicon (SEQ ID NO:379): TTGCAGAGGGTCATGCTCGGATTGGTGACAGCAGCCTGCGGGCGGAACTCCGTTGC CCTCGGACTTGCTTAGGGATAGATGGGAAGTGCCTATCCAAAGGA 30 Expression TRIC_HUMAN Troponin I, cardiac muscle HUMTROPIA transcripts,which are detectable by amplicon as depicted in sequence name HUMTROPIA seg22 specifically in heart WO 2005/069724 PCT/IB2005/001306 252 tissue Expression of TRIC_HUMAN Troponin I, cardiac muscle transcripts detectable by or according to seg22 node(s), HUMTROPIA seg22 amplicon(s) and HUMTROPIA seg22F and HUMTROPIA seg22R primers was measured by real time PCR. In parallel the expression of 5 four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA-amplicon), was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of 10 the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44-46, Table 1, above, "Tissue samples in testing panel"), to obtain a value of fold up-regulation for each sample relative to median of the heart. Figure 21B is a histogram showing specific expression of the above-indicated 15 TRIC_HUMAN Troponin 1, cardiac muscle transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 21B, the expression of TRIC_HUMAN Troponin I, cardiac muscle transcripts detectable by the above amplicon(s) in heart tissue samples was significantly higher than in the other samples (non-heart tissue sample Nos. 1-43, 47-74 Table 1 above, "Tissue samples in testing panel"). 20 Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: HUMTROPIA seg22F forward primer; and HUMTROPIA seg22R reverse primer. The present invention also preferably encompasses any amplicon obtained through the 25 use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: HUMTROPIA seg22. HUMTROPIA seg22 Forward primer (SEQ ID NO:380): GTGGGACGCATGGGCA HUMTROPIA seg22 Reverse primer (SEQ ID NO:381): TTGTCCTGGGTCTCCTGGG 30 HUMTROPIA seg22 Amplicon (SEQ ID NO:382):

GTGGGACGCATGGGCAGCTCGGGTACCTTCGGGGTAGGGTGAGATGGCTGGGACTT

WO 2005/069724 PCT/IB2005/001306 253 GGTCTCTGCCTGACCCCTTGCAGCTGCTTTTGGCTGCACATCCCAGGAGACCCAGGA CAA Expression of TRICHUMAN Troponin I, cardiac muscle HUMTROPIA transcripts which are 5 detectable by amplicon as depicted in sequence name HUMTROPIA seg23-24-25 specifically in heart tissue Expression of TRIC_HUMAN Troponin I, cardiac muscle transcripts detectable by or according to seg23-24-25 node(s), HUMTROPIA seg23-24-25 amplicon(s) and primers HUMTROPIA seg23-24-25F and HUMTROPIA seg23-24-25R was measured by real time 10 PCR. This transcript relates to the known or WT protein (SEQ ID NO:351). In parallel the expression of four housekeeping genes - RPL19 (GenBank Accession No. NM_000981; RPL19 amplicon), TATA box (GenBank Accession No. NM_003194; TATA amplicon), Ubiquitin (GenBank Accession No. BC000449; amplicon - Ubiquitin-amplicon) and SDHA (GenBank Accession No. NM_004168; amplicon - SDHA-amplicon) was measured similarly. For each 15 RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the heart samples (Sample Nos. 44-46 Table 1, above), to obtain a value of relative expression for each sample relative to median of the heart samples. 20 Figure 22 is a histogram showing relative expression of the above-indicated TRICHUMAN Troponin I, cardiac muscle transcripts in heart tissue samples as opposed to other tissues. As is evident from Figure 22, the expression of TRIC_HUMAN Troponin I, cardiac muscle transcripts detectable by the above amplicon(s) in heart tissue samples was significantly 25 higher than in the other samples (Sample Nos. 44-46 Table 1, "Tissue samples in testing panel"). Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non limiting illustrative example only of a suitable primer pair: HUMTROPIA seg23-24-25F 30 forward primer; and HUMTROPIA seg23-24-25FR reverse primer. The present invention also preferably encompasses any amplicon obtained through the WO 2005/069724 PCT/IB2005/001306 254 use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: HUMTROPIA seg23-24-25. Forward primer HUMTROPIA seg23-24-25F (SEQ ID NO:383): 5 AAGATCTTTGACCTTCGAGGCA Reverse primer HUMTROPIA seg23-24-25R (SEQ ID NO:384): CTGCTTGAGGTGGGCCC Amplicon HUMTROPIA seg23-24-25 (SEQ ID NO:385): AAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGAT 10 CTCTGCAGATGCCATGATGCAGGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCCTGG ACCTGCGGGCCCACCTCAAGCAG ADDITIONAL INFORMATION - VARIANT ORFS 15 With regard to the variants of this cluster, the following should be noted. Sequence T7 (also referred to herein as HUMTROPIA_PEA_2_T7 and troponin T7) has three open reading frames (ORFs) which are described in greater detail below. The sequence in SEQ ID NO: 354 shows CDS-1 frame 1 from 148 to 406 length 259 (bp) = 20 86 (aa)(similar to Troponin I N-ter) MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKVGRGFLGAEYRRRRDPRPWEW GEEPGLRRGRGLRGGASGAEFCRGSCSDW* The sequence in SEQ ID NO: 355 shows CDS-2 frame 1 from 628 to 1183 length 556 (bp) = 25 185 (aa) (similar to Troponin I C-terminal portion) MILPCSISPWQKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALSTRCQPLEL AGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTL RRVRISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSG MEGRKKKFES* 30 The sequence in SEQ ID NO: 356 shows CDS-3 frame 2 from 155 to 629 length 475 (bp) = 158 (aa)(Not similar to Troponin I)

MGAAMRLGNLALHQPQSDAAPPTTALMPRSRTPRWDGASWGQSTGAGGIQDPGSGG

WO 2005/069724 PCT/IB2005/001306 255 RSQGCEGGGDYAEGLQGRSFAEGHARIGDSSLRAELRCPRTCLGIDGKCLSKGRDPDW WMGMRGVASRRLRAQVG RGPKSGPAGFAGGVLRSPPPSSPNPPP* However, the presence of three ORFs could potentially complicate expression and also 5 determination of expression of the desired protein. The first ORF starts at +1 of Troponin sequence (first "ATG" is +1 to +3), and the second ORF starts at +8, encoding a 158 amino acid protein. Since the 2nd ATG is located very close to the first one, there is a possibility that it will be expressed as well. 10 In order to eliminate this possibility of expression of the long ORF, it is possible to optionally introduce two mutations (shown with regard to Figure 33): 1. "c" at position 57 to "a" 2. "g" at position 111 to "a" Both mutations are silent, so the protein sequence will not change. 15 Cloning and expression verification of a Troponin variant HUMTROPIA_PEA_2 T7 was performed as follows. 1. Full length validation 1.1. RNA preparation 20 Human adult normal heart RNA pool (lot# A411077) was obtained from BioChain Inst. Inc. (Hayward, CA 94545 USA www.biochain.com). Total RNA samples were treated with DNaseI (Ambion Cat # 1906). 1.2. RT PCR Purified RNA (1 ug) was mixed with 150 ng Random Hexamer primers (Invitrogen Cat 25 # 48190-011 ) and 500 uM dNTP (Takara, Cat # B9501-1) in a total volume of 15.6ul DEPC H20 (Beit Haemek, Cat # 01-852-1A). The mixture was incubated for 5 min at 65 0 C and then quickly chilled on ice. Thereafter, 5 ul of 5X SuperscriptlI first strand buffer (Invitrogen, Cat # Y00146), 2.4ul 0.1M DTT (Invitrogen, Cat #Y00147) and 40 units RNasin (Promega, Cat # N251A) were added, and the mixture was incubated for 2 min at 42 0 C. Then, 1 ul (200units) of 30 SuperscriptlI (Invitrogen, Cat #18064-022) was added and the reaction was incubated for 50 WO 2005/069724 PCT/IB2005/001306 256 mrin at 42 0 C and then inactivated at 70oC for 15mrin. The resulting cDNA was diluted 1:20 in TE buffer (10 mM Tris pH-1=8, 1 mM EDTA pH=8). 1.3. RT-PCR analysis cDNA (5ul), prepared as described above, was used as a template in PCR reactions. The 5 amplification was done using AccuPower PCR PreMix (Bioneer, Korea, Cat# K2016), under the following conditions: lul - of each primer (10uM) Tropfor (SEQ ID NO: 357) CCCTCACTGACCCTCCAAAC TropRev (SEQ ID NO: 358) CTTCCCATCTATCCCTAAGC plus 1361 - H20 were added into AccuPower PCR PreMix tube with a reaction program of 5 10 minutes at 94oC; 29 cycles of: [30 seconds at 94oC, 30 seconds at 52oC, 40 seconds at 72oC] and 10 minutes at 72oC. At the end of the PCR amplification, products were analyzed on agarose gels stained with ethidium bromide and visualized with UV light. PCR product was extracted from the gel using QiaQuickTM gel extraction kit (Qiagen

TM

, Cat #28706). The extracted DNA product then served as a template for secondary PCR reaction under the following conditions. 15 581 - Amplification X10 buffer (Invitrogen Cat # 11708021); 10y1l - purified DNA; 11l dNTPs (10mM each); I ul MgSO4 (50mM) 5 lA enhancer solution (Invitrogen, Cat # 11708021); I ul - of each primer (10 OuM); 261 - H 2 0 and 1.25 units of Taq polymerase [Platinum Pfx DNA polymerase (Invitrogen, Cat#11708021)] in a total reaction volume of 50ul. Amplification was performed with an initial denaturation step at 94oC for 3 minutes followed by 29 cycles of [94oC 20 for 30 seconds, 55'C for 30 seconds, 68 0 C for 40 seconds] and 10 minutes at 68oC. At the end of the PCR amplification, products were analyzed on agarose gels stained with ethidium bromide and visualized with UV light. PCR product was extracted from gel using QiaQuickTM gel extraction kit. The extracted DNA product (Figure 34) was sequenced by direct sequencing using the gene specific primers from above (Hy-Labs, Israel), resulting in the expected sequence 25 of Troponin variant (Figure 35). It was concluded that the predicted Troponin variant is indeed a naturally expressed variant in a normal human tissue as shown in Figure 34. 2. Cloning of Troponin variant into bacterial expression vector WO 2005/069724 PCT/IB2005/001306 257 The Troponin splice variant coding sequence was prepared for cloning by PCR amplification using the fragment described abowe as template and Platinum Pfx DNA polymerase (Invitrogen Cat # 11708021) under the following conditions: 51- Amplification X10 buffer (Invitrogen Cat # 11708021); 21 - PCR product from above; l10 - dNTPs (10mM 5 each); 1IV MgSO4 (50mM) 5pi enhancer solution (Invitrogen Cat # 11708021); 33. - H 2 0; 1Ipl - of each primer (10gM) and 1.25 units of Taq polymerase [Platinum Pfx DNA polymerase (Invitrogen Cat # 11708021)] in a total reaction volume of 50Pl with a reaction program of 3 minutes at 94 0 C; 29 cycles of: [30 seconds at 94oC, 30 seconds at 58oC, 40 seconds at 68 0 C] and 7 minutes at 68 oC. The Primers listed below include specific sequences of the nucleotide 10 sequence corresponding to the splice variant and NheI and HindIII restriction sites. Trop Nhelfor (SEQ ID NO: 359) - ACAGCTAGCATGGCGGATGGGAGCAGC TropHindIIIrev (SEQ ID NO: 360) - CCTAAGCTTCACCAATCCGAGCATGAC The PCR product was then double digested with NheI and HindIII (New England Biolabs (UK) LTD), and inserted into pRSET-A (Invitrogen, Cat# V351-20), previously 15 digested with the same enzymes, in-frame to an N-terminal 6His-tag, to give HisTroponin T7 pRSET (Figure 36). The coding sequence encodes for a protein having the 6His-tag at the N' end (6His residues in a row at one end of the protein), and 8 additional amino acids encoded by the pRSET vector. The sequence of the Troponin insert in the final plasmid, as well as its flanking regions, 20 were verified by sequencing and found to be identical to the desired sequences. The complete sequence of His Troponin T7 pRESTA is shown in Figure 37 (SEQ ID NO:386). Figure 38 shows the translated sequence of Troponin variant with the location of the His tag marked (SEQ ID NO:387). 25 3. Bacterial cell growth and induction of protein expression HisTroponin pRSETA DNA was transformed into competent BL21Gold cells (Stratagene Cat#230134). Ampicillin resistant transformants were screened and positive clones were further analyzed by restriction enzyme digestion and sequence verification.

WO 2005/069724 PCT/IB2005/001306 258 Cells containing the HisTroponin T7 pRSET vector or empty pRSET vector (as negative control) were grown in LB medium, supplemented with Ampicillin (50 tg/ml) and chloramphenicol (34 tg/ml). Cells were grown until O.D.

600 reaches 0.5. This value was reached in about 3 hours. ImM IPTG (Roche, Cat #724815) was added and the cells were 5 grown at 37oC for additional 3 hours. I ml of each culture was removed for gel analysis at To and T 3 . 3.1. Coomassie staining and Western blotting Results The time course of small-scale expression of Troponin in BL21Gold is demonstrated in 10 Figure 39a-b. The expression of a recombinant protein with the appropriate molecular weight (11 kDa) was detected both by Coomassie staining (Figure 39a) and by Western blot using anti His- antibodies (BD Clontech, Ref 631212) (Figure 39b). It was concluded that the protein encoded by Troponin variant T7 could be expressed in bacterial cells. 15 DESCRIPTION FOR CLUSTER HUMSMCK Cluster HUMSMCK features 5 transcript(s) and 14 segment(s) of interest, the names for which are given in Tables I and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. 20 Table 1 - Transcripts of interest 11 HUMSMCK T5 26 HUMSMCK T6 27 HUMSMCK T7 28 HUMSMCK T9 29 HUMSMCK T11 30 Table 2 - Segments of interest WO 2005/069724 PCT/IB2005/001306 259 -IUMSMCK node 0 150 HUMSMCK node 7 151 HUMSMCK node 12 152 HUMSMCK node 17 153 HUMSMCK node 22 154 HUMSMCK node 23 155 HUMSMCK node 25 156 HUMSMCK node 26 157 HUMSMCK node 28 158 HUMSMCK node 29 159 HUMSMCK node 32 160 HUMSMCK node 11 161 HUMSMCK node 14 162 HUMSMCK node 19 163 Table 3 - Proteins of interest HUMSMCKP4 305 HUMSMCKT5 HUMSMCKP5 306 HUMSMCK T6 HUMSMCK P6 307 HUMSMCK_T7; HUMSMCK T11 HUMSMCKP8 308 HUMSMCKT9 5 These sequences are variants of the known protein Creatine kinase, sarcomeric mitochondrial precursor (SwissProt accession identifier KCRS_HUMAN; known also according to the synonyms EC 2.7.3.2; S- MtCK; Mib-CK; Basic-type mitochondrial creatine kinase), referred to herein as the previously known protein. Protein Creatine kinase, sarcomeric mitochondrial precursor is known or believed to have 10 the following function(s): Reversibly catalyzes the transfer of phosphate between ATP and WO 2005/069724 PCT/IB2005/001306 260 various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymrnes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa. The sequence for protein Creatine kinase, sarcomeric mitochondrial precursor is given at the end of the application, as "Creatine kinase, sarcomeric 5 mitochondrial precursor amino acid sequence" (SEQ ID NO:388). Known polymorphisms for this sequence are as shown in Table 4. Table 4 - Amino acid mutations for Known Protein SNP positions) on Comment amno acid 'seqIence 74 S -> A 10 Protein Creatine kinase, sarcomeric mitochondrial precursor localization is believed to be Mitochondrial inner membrane; outer side. The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: energy pathways; muscle contraction, which are annotation(s) related 15 to Biological Process; creatine kinase; transferase, transferring phosphorus-containing groups, which are annotation(s) related to Molecular Function; and mitochondrion, which are annotation(s) related to Cellular Component. The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available 20 from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster HUMSMCK. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The 25 numbers on the y-axis of Figure 23 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

WO 2005/069724 PCT/IB2005/001306 261 Overall, the following results were obtained as shown with regard to the histogram in Figure 23, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figure 24, concerning the actual expression of oligonucleotides in various tissues, including heart. 5 This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 18.1; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 2.4; and fisher exact test P-values were computed both for library 10 and weighted clone counts to check that the counts are statistically significant, and were found to be 3.60E-23. One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to 15 non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 18.1, which clearly supports specific expression in heart tissue. 20 As noted above, cluster HUMSMCK features 5 transcript(s), which were listed in Table I above. These transcript(s) encode for protein(s) which are variant(s) of protein Creatine kinase, sarcomeric mitochondrial precursor. A description of each variant protein according to the present invention is now provided. Variant protein HUMSMCK_P4 according to the present invention has an amino acid 25 sequence as given at the end of the application; it is encoded by transcript(s) HUMSMCK_T5. An alignment is given to the known protein (Creatine kinase, sarcomeric mitochondrial precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein 30 is as follows: WO 2005/069724 PCT/IB2005/001306 262 Comparison report between HUMSMCKP4 and KCRS HUMANVi: I.An isolated chimeric polypeptide encoding for HUMSMCK_P4, comprising a first amino acid sequence being at least 90 % homologous to MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRK 5 HNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYE VFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQFDEHYVLSSRVRTGRSIRGLSL PPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPL LTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLK EVERLIQERGWEFMWNERLGYILTCPSNLGTGLRAGVHVR1PKLSKDPRFSKILENLRLQ 10 KRGTGGVDTAAVADVYDISNIDRIGRSEV corresponding to amino acids 1 - 381 of KCRS_HUMAN_VI, which also corresponds to amino acids 1 - 381 of HUMSMCK P4, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TSLSLS corresponding to amino acids 382 - 387 of HUMSMCK_P4, 15 wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HUMSMCKP4, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 20 sequence TSLSLS in HUMSMCK P4. It should be noted that the known protein sequence (KCRS_HUMAN; SEQ ID NO:388) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for KCRS_HUMAN_V1 (SEQ ID NO:347). These changes were 25 previously known to occur and are listed in the table below. Table 5 - Changes to KCRSHUMAN_ VI 75 conflict WO 2005/069724 PCT/IB2005/001306 263 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 5 intracellularly. The protein localization is believed to be intracellular because of manual inspection of known protein localization and/or gene structure. Variant protein HUMSMCK_P4 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether 10 the SNP is known or not; the presence of known SNPs in variant protein HUMSMCKP4 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 6 - Amino acid mutations 59 K -> No 60 H -> No 74 A-> S Yes 117 E-> * No 117 E-> No 249 R-> No 15 Variant protein HUMSMCK_P4 is encoded by the following transcript(s): HUMSMCK_T5, for which the sequence(s) i/are given at the end of the application. The coding portion of transcript HUMSMCK_T5 is shown in bold; this coding portion starts at position 1305 and ends at position 2465. The transcript also has the following SNPs as listed in 20 Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCK_P4 sequence provides support for the deduced WO 2005/069724 PCT/IB2005/001306 264 sequence of this variant protein according to the present invention). Table 7 - Nucleic acid SNPs SNX psiton on nucleotide Alternative nucleic acidic Previously known SNP? sequencee 223 A -> C Yes 545 G -> T Yes 1481 G -> No 1482 C -> No 1524 G-> T Yes 1653 G-> No 1653 G ->T No 2050 G-> No 2228 T-> C No 2231 G ->A No 2489 C ->T Yes 5 Variant protein HUMSMCKP5 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMSMCKT6. An alignment is given to the known protein (Creatine kinase, sarcomeric mitochondrial precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the 10 relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between HUMSMCK_P5 and KCRS_HUMAN_V I: 1.An isolated chimeric polypeptide encoding for HUMSMCK_P5, comprising a first 15 amino acid sequence being at least 90 % homologous to MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRK

HNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYE

WO 2005/069724 PCT/IB2005/001306 265 VFADLFDPVIKLRI-IHNGYDPRVMKHTTDLDASKITQGQFDEHYVLSSRVRTGRSIRGLSL PPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPL LTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLK EVERLIQERGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSK corresponding to 5 amino acids 1 - 338 of KCRS_HUMAN_V1, which also corresponds to amino acids 1 - 338 of HUMSMCK_P5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VLLCAQWP corresponding to amino acids 339 - 346 of HUMSMCK_P5, wherein said first amino acid sequence and second amino acid 10 sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HUMSMCK_P5, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VLLCAQWP in HUMSMCK_P5. 15 It should be noted that the known protein sequence (KCRS_HUMAN) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for KCRS_HUMAN_V I. These changes were previously known to occur and are listed in the table below. 20 Table 8 - Changes to KCRSHUMANVi 75 Conflict The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 25 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellular because of manual inspection of known protein localization and/or gene structure.

WO 2005/069724 PCT/IB2005/001306 266 Variant protein HUMSMCK_P5 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCK_P5 5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 9 - Amino acid mutations SNP position(s) on amino acid Alternative amino acid(s) Previously known SNP? 59 K -> No 60 H-> No 74 A-> S Yes 117 E -> * No 117 E-> No 249 R-> No 10 Variant protein HUMSMCK_P5 is encoded by the following transcript(s): HUMSMCK_T6, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMSMCKT6 is shown in bold; this coding portion starts at position 1305 and ends at position 2342. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative 15 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCK_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 10 - Nucleic acid SNPs 223 A ->C Yes WO 2005/069724 PCT/IB2005/001306 267 545 G ->T Yes 1481 G -> No 1482 C-> No 1524 G ->T Yes 1653 G -> No 1653 G -> T No 2050 G-> No 2228 T ->C No 2231 G ->A No Variant protein HUMSMCKP6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMSMCK_T7 5 and HUMSMCK_T1 1. An alignment is given to the known protein (Creatine kinase, sarcomeric mitochondrial precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HUMSMCKP6 and KCRSHUMAN VI: 1.An isolated chimeric polypeptide encoding for HUMSMCK_P6, comprising a first amino acid sequence being at least 90 % homologous to MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRK 15 HNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYE VFADLFDPVIKLRHINGYDPRVMKHTTDLDASKITQGQFDEHYVLSSRVRTGRSIRGLSL PPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLID corresponding to amino acids 1 - 223 of KCRS_HUMAN_VI, which also corresponds to amino acids 1 - 223 of HUMSMCKP6, and a second amino acid sequence being at least 70%, optionally at least 80%, 20 preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence A corresponding to amino acids 224 - 224 of HUMSMCK_P6, wherein said first amino acid sequence and second amino acid sequence are WO 2005/069724 PCT/IB2005/001306 268 contiguous and in a sequential order. It should be noted that the known protein sequence (KCRS_HUMAN) has one or more changes than the sequence given at the end of the application and named as being the amino 5 acid sequence for KCRS_HUMAN_VI. These changes were previously known to occur and are listed in the table below. Table 11 - Changes to KCRSHUMAN VI 'SNP positions) on Type of change Lamino acid sequence 75 Conflict 10 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellular because of manual inspection of known protein localization and/or gene structure. 15 Variant protein HUMSMCKP6 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 12, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCKP6 sequence provides support for the deduced sequence of this variant protein according t the 20 present invention). Table 12 - Amino acid mutations 59 K -> No 60 H -> No 74 A -> S Yes WO 2005/069724 PCT/IB2005/001306 269 117 E -> * No 117 E-> No Variant protein HUMSMCKP6 is encoded by the following transcript(s): HUMSMCK_T7 and HUMSMCKT11, for which the sequence(s) is/are given at the end of the 5 application. The coding portion of transcript HUMSMCKT7 is shown in bold; this coding portion starts at position 1305 and ends at position 1976. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the 10 presence of known SNPs in variant protein HUMSMCK_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 13 - Nucleic acid SNPs 223 A -> C Yes 545 G -> T Yes 1481 G-> No 1482 C -> No 1524 G -> T Yes 1653 G -> No 1653 G -> T No 2142 T -> C No 2145 G -> A No 2398 C -> A Yes 2521 G->A Yes 15 The coding portion of transcript HUMSMCK T11 is shown in bold; this coding portion WO 2005/069724 PCT/IB2005/001306 270 starts at position 1305 and ends at position 1976. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCK_P6 sequence provides support for the 5 deduced sequence of this variant protein according to the present invention). Table 14 - Nucleic acid SNPs SNP position on nucleotide Alternative Iuclcic acid Previously known SNP? 223 A -> C Yes 545 G -> T Yes 1481 G -> No 1482 C-> No 1524 G -> T Yes 1653 G -> No 1653 G -> T No Variant protein HUMSMCK_P8 according to the present invention has an amino acid 10 sequence as given at the end of the application; it is encoded by transcript(s) HUMSMCK_T9. An alignment is given to the known protein (Creatine kinase, sarcomeric mitochondrial precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein 15 is as follows: Comparison report between HUMSMCK_P8 and KCRSHUMAN_V 1: 1.An isolated chimeric polypeptide encoding for HUMSMCK_P8, comprising a first amino acid sequence being at least 90 % homologous to 20 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRK

HNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYE

WO 2005/069724 PCT/IB2005/001306 271 VFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQFDEHYVLSSRVRTGRSIRGLSL PPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPL LTCAGMARDWPDARG1WHNYDKTFL1IWINEEDHTRVISMEKGGNMKRVFERFCRGLK EV corresponding to amino acids I - 294 of KCRS_HUMAN V l, which also corresponds to 5 amino acids I - 294 of HUMSMCK P8, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RCYLRFLDIY corresponding to amino acids 295 - 304 of HUMSMCKP8, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 10 2.An isolated polypeptide encoding for a tail of HUMSMCK_P8, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RCYLRFLDIY in HUMSMCKP8. 15 It should be noted that the known protein sequence (KCRS_HUMAN) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for KCRS_HUMAN_V1. These changes were previously known to occur and are listed in the table below. Table 15 - Changes to KCRS_HUMAN_ Vi 75 Conflict 20 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 25 intracellularly. The protein localization is believed to be intracellular because of manual inspection of known protein localization and/or gene structure.

WO 2005/069724 PCT/IB2005/001306 272 Variant protein HUMSMCK_P8 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 16, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCKP8 5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 16 - Amino acid mutations SNP p o(soi mino acid Alternative amino acid(s<) PVeviously known SNP? sequence 59 K -> No 60 H-> No 74 A->S Yes 117 E ->* No 117 E -> No 249 R-> No 10 Variant protein HUMSMCKP8 is encoded by the following transcript(s): HUMSMCK_T9, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMSMCK_T9 is shown in bold; this coding portion starts at position 1305 and ends at position 2216. The transcript also has the following SNPs as listed in Table 17 (given according to their position on the nucleotide sequence, with the alternative 15 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMSMCK_P8 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 17 - Nucleic acid SNPs 223 A-> C Yes WO 2005/069724 PCT/IB2005/001306 273 545 G ->T Yes 1481 G -> No 1482 C-> No 1524 G->T Yes 1653 G-> No 1653 G -> T No 2050 G-> No As noted above, cluster HUMSMCK features 14 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) 5 are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. Segment cluster HUMSMCKnode_0 according to the present invention is supported by 10 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCKT5, HUMSMCK_T6, HUMSMCKT7, HUMSMCKT9 and HUMSMCKTll. Table 18 below describes the starting and ending position of this segment on each transcript. Table 18 - Segment location on transcripts HUMSMCK T5 1 1284 HUMSMCK T6 1 1284 HUMSMCK T7 1 1284 HUMSMCK T9 1 1284 HUMSMCK _TII 1 1284 15 WO 2005/069724 PCT/IB2005/001306 274 Segment cluster HUMSMCK_node_7 according to the present invention is supported by 47 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCK_T5, HUMSMCK_T6, HUMSMCK T7, HUMSMCK_T9 and HUMSMCK_TlI. Table 19 below describes the starting and ending 5 position of this segment on each transcript. Table 19 - Segment location on transcripts Transcript name Segment Segment sttirg poitin ending position HUMSMCK T5 1285 1456 HUMSMCK T6 1285 1456 HUMSMCK T7 1285 1456 HUMSMCK T9 1285 1456 HUMSMCK TI1 1285 1456 Segment cluster HUMSMCKnode_12 according to the present invention is supported by 10 54 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCKT5, HUMSMCK_T6, HUMSMCK_T7, HUMSMCK T9 and HUMSMCK T 1l. Table 20 below describes the starting and ending position of this segment on each transcript. Table 20 - Segment location on transcripts HUMSMCK T5 1476 1655 HUMSMCK T6 1476 1655 HUMSMCK T7 1476 1655 HUMSMCK T9 1476 1655 HUMSMCK T11 1476 1655 15 WO 2005/069724 PCT/IB2005/001306 275 Segment cluster HUMSMCKnode_I 7 according to the present invention is supported by 48 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCK_T5, HUMSMCKT6, HUMSMCK T7, 5 HUMSMCKT9 and HUMSMCK_TI 1. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts Iranscipt name Segmet kgment startgpooitIon ending position HUMSMCK T5 1752 1973 HUMSMCK T6 1752 1973 HUMSMCK T7 1752 1973 HUMSMCK T9 1752 1973 HUMSMCKTil 1752 1973 10 Segment cluster HUMSMCK_node_22 according to the present invention is supported by 60 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCKT5, HUMSMCK_T6, HUMSMCK_T7, HUMSMCKT9 and HUMSMCKT1 1. Table 22 below describes the starting and ending position of this segment on each transcript. 15 Table 22 - Segment location on transcripts HUMSMCKT5 2060 2183 HUMSMCK T6 2060 2183 HUMSMCKT7 1974 2097 HUMSMCK T9 2060 2183 HUMSMCK T11 1974 2097 WO 2005/069724 PCT/IB2005/001306 276 Segment cluster HUMSMCK_node_23 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can 5 be found in the following transcript(s): HUMSMCK T9 and HUMSMCK TI 1. Table 23 below describes the starting and ending position of this segment on each transcript. Table 23 - Segment location on transcripts Transerip itname Segment Segmen starting pston ending position HUMSMCK T9 2184 2382 HUMSMCK T1 1 2098 2296 10 Segment cluster HUMSMCK_node_25 according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCK_T5, HUMSMCK_T6 and HUMSMCK_T7. Table 24 below describes the starting and ending position of this segment on each transcript. 15 Table 24 - Segment location on transcripts HUMSMCKT5 2184 2318 HUMSMCKT6 2184 2318 HUMSMCKT7 2098 2232 Segment cluster HUMSMCKnode_26 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can 20 be found in the following transcript(s): HUMSMCK_T6. Table 25 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 277 Table 25 - Segment location on transcripts Transcript name Segment Segment S starting position ending position HUMSMCK T6 2319 2448 Segment cluster HUMSMCK_node_28 according to the present invention is supported by 5 59 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCK_T5 and HUMSMCK_T7. Table 26 below describes the starting and ending position of this segment on each transcript. Table 26 - Segment location on transcripts HUMSMCK T5 2319 2444 HUMSMCK T7 2233 2358 10 Segment cluster HUMSMCKnode_29 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCK_T5. Table 27 below describes the starting and ending position of this segment on each transcript. 15 Table 27 - Segment location on transcripts ansoNrnan enn oneI HUMSMCKT5 2445 2820 Segment cluster HUMSMCK_node_32 according to the present invention is supported by 62 libraries. The number of libraries was determined as previously described. This segment can WO 2005/069724 PCT/IB2005/001306 278 be found in the following transcript(s): I-IUMSMCK_T7. Table 28 below describes the starting and ending position of this segment on each transcript. Table 28 - Segment location on transcripts Transcript name Segment Segment starting position ending position HUMSMCK T7 2359 2632 5 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description. 10 Segment cluster HUMSMCKnode 11 according to the present invention can be found in the following transcript(s): HUMSMCK_T5, HUMSMCK_T6, HUMSMCKT7, HUMSMCK_T9 and HUMSMCK_T 1l. Table 29 below describes the starting and ending position of this segment on each transcript. Table 29 - Segment location on transcripts HUMSMCK T5 1457 1475 HUMSMCK T6 1457 1475 HUMSMCK T7 1457 1475 HUMSMCK T9 1457 1475 HUMSMCK T11 1457 1475 15 Segment cluster HUMSMCK_node_14 according to the present invention is supported by 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCK_T5, HUMSMCK_T6, HUMSMCK_T7, 20 HUMSMCK_T9 and HUMSMCK T 1. Table 30 below describes the starting and ending WO 2005/069724 PCT/IB2005/001306 279 position of this segment on each transcript. Table 30 - Segment location on transcripts Trnscript naie Segment Segment sta ingposition edgpostn HUMSMCK T5 1656 1751 HUMSMCK T6 1656 1751 HUMSMCK T7 1656 1751 HUMSMCK T9 1656 1751 HUMSMCK TIl1 1656 1751 5 Segment cluster HUMSMCKnodeI 9 according to the present invention is supported by 47 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMSMCKT5, HUMSMCKT6 and HUMSMCK_T9. Table 31 below describes the starting and ending position of this segment on each transcript. 10 Table 31 - Segment location on transcripts HUMSMCKT5 1974 2059 HUMSMCKT6 1974 2059 HUMSMCKT9 1974 2059 Variant protein alignment to the previously known protein: Sequence name: KCRSHUMAN V1 15 Sequence documentation: Alignment of: HUMSMCKP4 x KCRSHUMANVl ..

WO 2005/069724 PCT/IB2005/001306 280 Alignment segment 1/1: Quality: 3745.00 Escore: 0 5 Matching length: 381 Total length: 381 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 10 Alignment: 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 I I 1l i l 1ll l l l l l i l l l l I I l i l l l l l l I l l l I l lll l 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 15 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 I I l l I l l l l i l II I I I I l l l l I l l ll i l I II l l 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 20 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 I l l l I l l l l l ll l l l lII i l l l l l l l l I l l l I l l l l l 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 2 5 I l l l l l l l l l l l 11i l l l i l l il l l l l i l I I 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 201 GDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARG 250 Ill l l l l l l i l l l l l l l l l l l l lI l l l I I I I l l l i 30 201 GDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARG 250 251 IWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQE 300 I l I I i l l I l l ll l I I I IIII l l l l l l I l l l i l l 251 IWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQE 300 35 301 RGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLR 350 i301 RGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLR 350 301 RGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLR 350 WO 2005/069724 PCT/IB2005/001306 281 351 LQKRGTGGVDTAAVADVYDISNIDRIGRSEV 381 Illlllflllllllllllillllllirlll 351 LQKRGTGGVDTAAVADVYDISNIDRIGRSEV 381 5 Sequence name: KCRSHUMANV1 Sequence documentation: 10 Alignment of: HUMSMCKP5 x KCRSHUMAN Vl Alignment segment 1/1: Quality: 3344.00 Escore: 0 15 Matching length: 338 Total length: 338 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 20 Alignment: 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 Il l l l l l l l l l l l l l l l l l l l1 1 1 1 1 lll l l l l l l l l l l il l l l 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 25 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 illllIllllllllllllIllllllllllllillllilllllllllII 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 30 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 Il l l l l i l l l l l l l l l l I I I I l l l I I l l l l l l l ll I l ll l l l l ll 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 3 5l l l l l l l l l l I I I I I l l l l l l l l l l l l l l I l l l l l l l l l l l l 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 201 GDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARG 250 WO 2005/069724 PCT/IB2005/001306 282 illll~llillllllilllli lllllilllll~lllilllllllillI 201 GDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARG 250 251 IWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQE 300 5 I l l ll I II I ll i l li l l i 1 l l l l l I l l l l l l i l l l l l i l l l l l 251 IWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQE 300 301 RGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSK 338 l i l i ll l l l Ii l ll l l l i l l i l l l l l ll i l l l l l l l l 10 301 RGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSK 338 Sequence name: KCRS HUMAN Vl Sequence documentation: 15 Alignment of: HUMSMCKP6 x KCRS HUMAN Vl Alignment segment 1/1: 20 Quality: 2176.00 Escore: 0 Matching length: 223 Total length: 223 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 25 Alignment: 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 IllllllllllllIIlllllIllllllIlIIllllllIIIIIillllIIIl 30 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 I l i llll l l i l li l l li l l l l l l l l l l l l l l I I l l l l l l l I l l l l I 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 35 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 WO 2005/069724 PCT/IB2005/001306 283 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 Il l l I l ll l l ll l i l l l l l l l l l l l l l 1 1 1 1 1 l l l l l l l l li 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 5 201 GDLAGRYYKLSEMTEQDQQRLID 223 i1111 li l li l l l l lI l l l li 201 GDLAGRYYKLSEMTEQDQQRLID 223 10 Sequence name: KCRS_HUMAN_VI Sequence documentation: Alignment of: HUMSMCK_P8 x KCRSHUMAN_VI 15 Alignment segment 1/1: Quality: 2904.00 Escore: 0 Matching length: 294 Total length: 294 20 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 25 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 I I l l l il l l l l l l l l l l l l l lI ll l I I l I l l l l I l l ll l l l l l l l l l l I 1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPP 50 30 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 IlllllllllllllllIlllIllllIllllllIlllIIllIIllllI 51 SADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGH 100 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 3 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 l l l l l l l l l l 101 PFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKI 150 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 WO 2005/069724 PCT/IB2005/001306 284 151 TQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLK 200 201 GDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARG 250 5 Il illll lli l lll i l i1111 l llll l llll111111 I I l l 201 GDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARG 250 251 IWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEV 294 IllIlllilllllilllllllilllllilllllltlllllllI 10 251 IWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEV 294 DESCRIPTION FOR CLUSTER H88495 Cluster H88495 features 7 transcript(s) and 22 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the 15 application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest 'Trxisiw 4amec scj [1)No., H88495 PEA 3 T3 31 H88495_PEA 3 T4 32 H88495_PEA 3 T5 33 H88495 PEA 3 T6 34 H88495 PEA 3 T7 35 H88495 PEA 3 T8 36 H88495 PEA 3 T9 37 Table 2 - Segments of interest H88495 PEA 3 node 0 164 H88495 PEA 3 node 1 165 H88495 PEA 3 node 4 166 H88495 PEA 3 node 9 167 WO 2005/069724 PCT/IB2005/001306 285 H88495 PEA 3 node 13 168 H88495 PEA 3 node 19 169 H88495 PEA 3 node 21 170 1-188495 PEA 3 node 26 171 H88495_PEA 3 node 2 172 H88495 PEA 3 node 5 173 H88495 PEA 3 node 6 174 H88495 PEA 3 node 7 175 H88495_PEA_3 node 8 176 H88495_PEA 3 node 10 177 H88495 PEA 3 node 11 178 H88495_PEA 3 node 12 179 H88495 PEA 3 node 14 180 H88495_PEA 3 node 16 181 H88495 PEA 3 node 18 182 H88495_PEA 3 node_20 183 H88495_PEA 3 node_23 184 H88495 PEA 3 node 24 185 Table 3 - Proteins of interest H88495 PEA 3_Pl5 309 H88495 PEA_3_T3; H88495 PEA 3 T4; H88495 PEA 3 T7 H88495_PEA_3 Pl6 310 H88495 PEA 3_T5; H88495 PEA 3 T6 H88495_PEA_3 P17 311 H88495 PEA 3 T8 H88495_PEA 3 P18 312 H88495 PEA_3 T9 5 These sequences are variants of the known protein Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor (SwissProt accession identifier SRCH_HUMAN), referred to WO 2005/069724 PCT/IB2005/001306 286 herein as the previously known protein. Protein Sarcoplasmrnic reticulum histidine-rich calcium-binding protein precursor is known or believed to have the following function(s): May play a role in the regulation of calcium sequestration or release in the SR of skeletal and cardiac muscle. The sequence for protein 5 Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor is given at the end of the application, as "Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor amino acid sequence" (SEQ ID NO:389). Known polymorphisms for this sequence are as shown in Table 4. Table 4 - Amino acid mutations for Known Protein SNP' positions) on Comment amino acid Sequence 96 S -> A. /FTId=VAR 005623. 204 Missing. /FTId=VAR 011622. 10 Protein Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor localization is believed to be Sarcoplasmic reticulum lumen. 15 The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: muscle contraction, which are annotation(s) related to Biological Process; and calcium binding, which are annotation(s) related to Molecular Function. The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available 20 from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster H88495. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the 25 y-axis of Figure 25 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that WO 2005/069724 PCT/IB2005/001306 287 category, according to parts per million). Overall, the following results were obtained as shown with regard to the histogram in Figure 25, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figure 26, concerning the actual expression of oligonucleotides in 5 various tissues, including heart. This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 13.7; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific 10 ESTs which was found to be 2.3; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 1.90E-06. One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as 15 opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 13.7, which clearly 20 supports specific expression in heart tissue. As noted above, cluster H88495 features 7 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor. A description of each variant protein according to the present invention is now provided. 25 Variant protein H88495_PEA_3 P15 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) H88495_PEA_3 T3, H88495_PEA_3_ T4 and H88495_PEA 3_T7. An alignment is given to the known protein (Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor) at the end of the application. One or more alignments to one or more previously published protein 30 sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: WO 2005/069724 PCT/IB2005/001306 288 Comparison report between H88495_PEA_3_P l5 and SRCH_HUMANVI: 1.An isolated chimeric polypeptide encoding for H88495_PEA 3_P15, comprising a first amino acid sequence being at least 90 % homologous to 5 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNN corresponding to amino acids 1 - 42 of SRCH_HUMAN_VI, which also corresponds to amino acids 1 - 42 of H88495_PEA 3 P15, a bridging amino acid N corresponding to amino acid 43 of H88495_PEA 3 P15, a second amino acid sequence being at least 90 % homologous to TGVAGLSEEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 10 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRS HSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHR HRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAH RHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDDDVSTEYGHQAHRHQDHRKEE VEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV 15 QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHR QSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEERREERAEVG APLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQEYGN YQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQ corresponding to amino acids 44 20 657 of SRCHHUMANVI, which also corresponds to amino acids 44 - 657 of H88495_PEA_3_P15, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRPHLTLKAPLGLRMHRDPLRTPSPKSWPLTQPLTPDATLTPQAILTPTLT corresponding 25 to amino acids 658 - 708 of H88495_PEA_3 P15, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of H88495_PEA 3_P15, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 30 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRPHLTLKAPLGLRMHRDPLRTPSPKSWPLTQPLTPDATLTPQAILTPTLT in WO 2005/069724 PCT/IB2005/001306 289 H88495 PEA 3 PI5. It should be noted that the known protein sequence (SRCHHUMAN; SEQ ID NO:389) has one or more changes than the sequence given at the end of the application and named as 5 being the amino acid sequence for SRCH_HUMAN VI (SEQ ID NO:346). These changes were previously known to occur and are listed in the table below. Table 5 - Changes to SRCHHUMAN_V1 SNP positionWs on1 Type ofchange 97 Variant 10 The location of the variant protein was detennined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane 15 region prediction program predicts that this protein has a trans-membrane region. Variant protein H88495_PEA 3 P15 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA 3 P15 20 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 6 - Amino acid mutations 6 [P -> L No 6 P ->S No WO 2005/069724 PCT/IB2005/001306 290 43 N ->S Yes 96 A ->S Yes 364 Q -> No 580 D-> H Yes Variant protein H88495_PEA_3 P15 is encoded by the following transcript(s): H88495_PEA 3 T3, H88495_PEA_3_T4 and H88495_PEA_3 T7, for which the squence(s) 5 is/are given at the end of the application. The coding portion of transcript H88495_PEA_3_T3 is shown in bold; this coding portion starts at position 743 and ends at position 2866. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the 10 presence of known SNPs in variant protein H88495_PEA_3_Pl15 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7 - Nucleic acid SNPs 223 A -> G Yes 285 C -> T Yes 362 A-> C Yes 373 G-> C Yes 628 A ->T No 629 G ->T No 758 C ->T No 759 C ->T No 847 G->A Yes 870 A-> G Yes WO 2005/069724 PCT/IB2005/001306 291 958 G->A No 1028 G-> T Yes 1321 A->G Yes 1834 G -> No 1903 C -> T Yes 2480 G -> C Yes The coding portion of transcript H88495_PEA 3_T4 is shown in bold; this coding portion starts at position 743 and ends at position 2866. The transcript also has the following SNPs as 5 listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA_3_PI5 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Nucleic acid SNPs 223 A -> G Yes 285 C -> T Yes 362 A-> C Yes 373 G -> C Yes 628 A-> T No 629 G -> T No 758 C -> T No 759 C -> T No 847 G -> A Yes 870 A -> G Yes 958 G -> A No 1028 G -> T Yes 1321 A-> G Yes WO 2005/069724 PCT/IB2005/001306 292 1834 G-> No 1903 C -> T Yes 2480 G -> C Yes 3225 G ->A Yes The coding portion of transcript H88495_PEA_3_T7 is shown in bold; this coding portion starts at position 743 and ends at position 2866. The transcript also lus the following SNPs as 5 listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA_3_P15 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 9 - Nucleic acid SNPs ~SNIh positIn oajn1 eIIIotid Altfiatv 2%i ad viUsly kno% iiSNP? 223 A-> G Yes 285 C ->T Yes 362 A ->C Yes 373 G ->C Yes 628 A ->T No 629 G-> T No 758 C ->T No 759 C ->T No 847 G ->A Yes 870 A ->G Yes 958 G ->A No 1028 G ->T Yes 1321 A ->G Yes 1834 G -> No 1903 C->T Yes WO 2005/069724 PCT/IB2005/001306 293 2480 G ->C Yes 3106 T-> A Yes Variant protein H88495_PEA 3 PI6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 H88495_PEA 3_T5 and H88495_PEA_3 T6. An alignment is given to the known protein (Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between H88495_PEA_3_P16 and SRCHHUMAN_VI: 1.An isolated chimeric polypeptide encoding for H88495_PEA_3_P16, comprising a first amino acid sequence being at least 90 % homologous to MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNN corresponding to 15 amino acids 1 - 42 of SRCH_HUMAN_V1, which also corresponds to amino acids 1 - 42 of H88495_PEA_3_P16, a bridging amino acid N corresponding to amino acid 43 of H88495_PEA 3 P16, a second amino acid sequence being at least 90 % homologous to TGVAGLSEEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRS 20 HSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHR HRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAH RHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDDDVSTEYGHQAHRHQDHRKEE VEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHR 25 QSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEERREERAEVG APLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQEYGN YQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQFCYLCPLVCETVCAPG corresponding to amino acids 44 - 676 of SRCH_HUMAN_V1, which also corresponds to WO 2005/069724 PCT/IB2005/001306 294 amino acids 44 - 676 of H88495_PEA 3_P16, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence EHGRGPGKT corresponding to amino acids 677 - 685 of H88495_PEA 3_PI6, wherein said first amino acid 5 sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of H88495_PEA 3 P16, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 10 sequence EHGRGPGKT in H88495_PEA 3 PI6. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 15 programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because although it is a partial protein, because both trans-membrane region prediction programs predict that this protein has a trans- membrane region. 20 Variant protein H88495_PEA_3 P16 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA 3 P16 sequence provides support for the deduced sequence of this variant protein according to the 25 present invention). Table 11 - Amino acid mutations 6 P -> L No 6 P -> S No WO 2005/069724 PCT/IB2005/001306 295 43 N -> S Yes 96 A-> S Yes 364 Q -> No 580 D-> H Yes Variant protein H88495_PEA_3_P16 is encoded by the following transcript(s): H88495_PEA_3_T5 and H88495_PEA_3_T6, for which the sequence(s) is/are given at the end 5 of the application. The coding portion of transcript H88495_PEA 3_T5 is shown in bold; this coding portion starts at position 743 and ends at position 2797. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last columnn indicates whether the SNP is known or not; the 10 presence of known SNPs in variant protein H88495_PEA 3 P16 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 12 - Nucleic acid SNPs 223 A -> G Yes 285 C -> T Yes 362 A -> C Yes 373 G -> C Yes 628 A -> T No 629 G -> T No 758 C -> T No 759 C -> T No 847 G -> A Yes 870 A -> G Yes 958 G -> A No 1028 G -> T Yes WO 2005/069724 PCT/IB2005/001306 296 1321 A-> G Yes 1834 G -> No 1903 C -> T Yes 2480 G -> C Yes 2855 T-> A Yes The coding portion of transcript H88495_PEA_3_T6 is shown in bold; this coding portion starts at position 743 and ends at position 2797. The transcript also has the following SNPs as 5 listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA_3 P16 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 13 - Nucleic acid SNPs { ICVI " I" , 11 ,i% 223 A -> (G Yes 285 C -> T Yes 362 A ->C Yes 373 G ->C Yes 628 A ->T No 629 G ->T No 758 C -> T No 759 C ->T No 847 G ->A Yes 870 A ->G Yes 958 G-> A No 1028 G-> T Yes 1321 A-> G Yes 1834 G-> No WO 2005/069724 PCT/IB2005/001306 297 1903 C ->T Yes 2480 G -> C Yes 2855 T-> A Yes 3293 G->A Yes Variant protein H88495_PEA_3_P17 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 H88495_PEA 3_T8. An alignment is given to the known protein (Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between H88495_PEA 3_P17 and SRCH_HUMANVI: 1.An isolated chimeric polypeptide encoding for H88495_PEA_3 P17, comprising a first amino acid sequence being at least 90 % homologous to MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNN corresponding to 15 amino acids 1 - 42 of SRCH_HUMAN_V1, which also corresponds to amino acids 1 - 42 of H88495_PEA_3_P17, a bridging amino acid N corresponding to amino acid 43 of H88495_PEA 3_P17, a second amino acid sequence being at least 90 % homologous to TGVAGLSEEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRS 20 HSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHR HRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAH RHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDDDVSTEYGHQAHRHQDHRKEE VEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHR 25 QSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEERREERAEVG

APLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQEYGN

WO 2005/069724 PCT/IB2005/001306 298 YQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQ corresponding to amino acids 44 657 of SRCHHUMANVI, which also corresponds to amino acids 44 - 657 of H88495_PEA_3 P17, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% 5 homologous to a polypeptide having the sequence GPGRHAGNAGTLTQSLDCDAGVPPPAFQPLSTSYIYFSE corresponding to amino acids 658 - 696 of H88495_PEA_3_P17, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 10 2.An isolated polypeptide encoding for a tail of H88495_PEA_3 P17, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GPGRHAGNAGTLTQSLDCDAGVPPPAFQPLSTSYIYFSE in H88495 PEA 3 P17. 15 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 20 programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region. 25 Variant protein H88495_PEA_3_P17 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA_3 P17 sequence provides support for the deduced sequence of this variant protein according to the 30 present invention). Table 15 - Amino acid mutations WO 2005/069724 PCT/IB2005/001306 299 SNP position(s) oniamio acid Alternative amino acid(s) Previously known SNP? sequence' 6 P -> L No 6 P -> S No 43 N -> S Yes 96 A-> S Yes 364 Q -> No 580 D ->H Yes Variant protein H88495_PEA_3_P17 is encoded by the following transcript(s): H88495_PEA_3_T8, for which the sequence(s) is/are given at the end of the application. The 5 coding portion of transcript H88495_PEA_3 T8 is shown in bold; this coding portion starts at position 743 and ends at position 2830. The transcript also has the following SNPs as listed in Table 16 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA 3_P17 sequence provides support for the deduced 10 sequence of this variant protein according to the present invention). Table 16 - Nucleic acid SNPs 223 A -> G Yes 285 C -> T Yes 362 A-> C Yes 373 G -> C Yes 628 A ->T No 629 G ->T No 758 C ->T No 759 C ->T No WO 2005/069724 PCT/IB2005/001306 300 847 G ->A Yes 870 A ->G Yes 958 G ->A No 1028 G ->T Yes 1321 A ->G Yes 1834 G -> No 1903 C ->T Yes 2480 G->C Yes 2882 G -> A Yes Variant protein H88495_PEA_3_P18 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 H88495_PEA 3 T9. An alignment is given to the known protein (Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between H88495_PEA_3 P18 and SRCHHUMAN VI: 1.An isolated chimeric polypeptide encoding for H88495_PEA_3_P18, comprising a first amino acid sequence being at least 90 % homologous to MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNN corresponding to 15 amino acids 1 - 42 of SRCHHUMAN_V1, which also corresponds to amino acids 1 - 42 of H88495_PEA_3_P18, a bridging amino acid N corresponding to amino acid 43 of H88495_PEA_3_P18, a second amino acid sequence being at least 90 % homologous to TGVAGLSEEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRS 20 HSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHR HRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAH

RHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDDDVSTEYGHQAHRHQDHRKEE

WO 2005/069724 PCT/IB2005/001306 301 VEAVSGEHHHH-IVPDHRHQGHIRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHR QSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEERREERAEVG 5 APLSPDH S EEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDT corresponding to amino acids 44 - 610 of SRCH_HUMANVi, which also corresponds to amino acids 44 - 610 of H88495_PEA_3_P18, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AMH corresponding to amino acids 611 - 613 10 of H88495_PEA 3_PI8, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. The location of the variant protein was determined according to results from a number of 15 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region. 20 Variant protein H88495_PEA_3 P18 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 18, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA_3_P18 25 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 18 - Amino acid mutations 6 P -> L No WO 2005/069724 PCT/IB2005/001306 302 6 P->S No 43 N ->S Yes 96 A-> S Yes 364 Q -> No 580 D ->H Yes Variant protein H88495_PEA 3 P18 is encoded by the following transcript(s): H88495_PEA_3_T9, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript H88495_PEA_3 T9 is shown in bold; this coding portion starts at 5 position 743 and ends at position 2581. The transcript also has the following SNPs as listed in Table 19 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein H88495_PEA 3 P 8 sequence provides support for the deduced sequence of this variant protein according to the present invention). 10 Table 19 - Nucleic acid SNPs 223 A -> G Yes 285 C -> T Yes 362 A-> C Yes 373 G-> C Yes 628 A -> T No 629 G->T No 758 C -> T No 759 C -> T No 847 G -> A Yes 870 A -> G Yes 958 G -> A No 1028 G -> T Yes 1321 A -> G Yes WO 2005/069724 PCT/IB2005/001306 303 1834 G-> No 1903 C -> T Yes 2480 G -> C Yes As noted above, cluster H88495 features 22 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) 5 are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. Segment cluster H88495_PEA_3_node_0 according to the present invention is supported 10 by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA 3_T4, H88495_PEA_3_T5, H88495_PEA_3_T6, H88495_PEA_3_T7, H88495_PEA 3 T8 and H88495_PEA_3_T9. Table 20 below describes the starting and ending position of this segment on each transcript. 15 Table 20 - Segment location on transcripts H88495 PEA 3 T3 1 665 H88495 PEA 3 T4 1 665 H88495 PEA 3 T5 1 665 H88495 PEA _3 T6 1 665 H88495 PEA 3 T7 1 665 H88495 PEA 3 T8 1 665 H88495_PEA 3_T9 1 665 Segment cluster H88495_PEA_3 nodeI according to the present invention is supported WO 2005/069724 PCT/IB2005/001306 304 by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3_T4, H88495_PEA_3 T5 H88495_PEA 3_T6, H88495_PEA 3 T7, H88495_PEA 3 T8 and H88495_PEA 3 T9. Table 21 below describes the starting and ending position of this segment 5 on each transcript. Table 21 - Segment location on transcripts TrnTscript name S oeit Segment starting positi ending position H88495_PEA 3 T3 666 1178 H88495_PEA 3 T4 666 1178 H88495 PEA 3 T5 666 1178 H88495_PEA 3 T6 666 1178 H88495 PEA 3 T7 666 1178 H88495_PEA 3 T8 666 1178 H88495_PEA 3 _T9 666 1178 Segment cluster H88495_PEA_3_node_4 according to the present invention is supported 10 by 22 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3_T4, H88495_PEA 3 T5 H88495_PEA 3_T6, H88495_PEA_3_T7, H88495_PEA 3 T8 and H88495_PEA_3 T9. Table 22 below describes the starting and ending position of this segment on each transcript. 15 Table 22 - Segment location on transcripts H88495 PEA 3 T3 1210 1646 H88495 PEA 3 T4 1210 1646 H88495_PEA 3 T5 1210 1646 WO 2005/069724 PCT/IB2005/001306 305 1-88495_PEA 3 T6 1210 1646 H88495 PEA 3_T7 1210 1646 H88495 PEA 3 T8 1210 1646 H88495 PEA 3 T9 1210 1646 Segment cluster H88495 PEA_3_node_9 according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): H88495 PEA_3_T3, H88495_PEA 3_T4, H88495 PEA_3_T5, H88495_PEA_3 T6, H88495_PEA_3_T7, H88495_PEA 3_T8 and H88495_PEA_3_T9. Table 23 below describes the starting and ending position of this segment on each transcript. Table 23 - Segment location on transcripts Trans1crjpt~n exl Ieme I I C11 t H88495 PEA 3 T3 1819 2335 H88495 PEA 3 T4 1819 2335 H88495 PEA 3 T5 1819 2335 H88495 PEA 3 T6 1819 2335 H88495 PEA 3 T7 1819 2335 H88495_PEA 3 T8 1819 2335 H88495 PEA 3 T9 1819 2335 10 Segment cluster H88495_PEA 3 node_13 according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA 3 T3, H88495_PEA_3_T4, 15 H88495_PEA_3_T5, H88495_PEA_3_T6, H88495_PEA_3_T7, H88495_PEA_3 T8 and H88495_PEA_3_T9. Table 24 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 306 Table 24 - Segment location on transcripts Transcript name Segment Segment starting position ending position H88495 PEA 3 T3 2378 2509 H88495 PEA 3 T4 2378 2509 H88495 PEA 3 T5 2378 2509 H88495 PEA 3 T6 2378 2509 H88495 PEA 3 T7 2378 2509 H88495 PEA 3 T8 2378 2509 H88495_PEA_3_T9 2378 2509 Segment cluster H88495_PEA_3_node_19 according to the present invention is supported 5 by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3_T4 and H88495_PEA_3_T7. Table 25 below describes the starting and ending position of this segment on each transcript. Table 25 - Segment location on transcripts H88495 PEA 3 T3 2714 2964 H88495_PEA_3_T4 2714 2964 H88495 PEA 3 T7 2714 2964 10 Segment cluster H88495_PEA_3_node_21 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T5, H88495_PEA_3_T6 and 15 H88495_PEA_3_T7. Table 26 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 307 Table 26 - Segment location on transcripts Transeript name Segment Segment starting position ending position H88495_PEA_3_T5 2769 3095 H88495 PEA 3 T6 2769 3095 H88495 PEA 3 T7 3020 3346 Segment cluster H88495_PEA 3 node_26 according to the present invention is supported 5 by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3_T4, H88495_PEA_3_T5, H88495_PEA 3_T6, H88495_PEA_3 T7, H88495_PEA_3 T8 and H88495_PEA_3_T9. Table 27 below describes the starting and ending position of this segment on each transcript. 10 Table 27 - Segment location on transcripts H88495 PEA 3 T3 3057 3189 H88495 PEA 3 T4 3057 3298 H88495 PEA 3 T5 3125 3257 H88495 PEA 3 T6 3125 3366 H88495 PEA 3 T7 3376 3508 H88495 PEA 3 T8 2714 2955 H88495 PEA 3 T9 2735 2867 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are 15 included in a separate description.

WO 2005/069724 PCT/IB2005/001306 308 Segment cluster H88495_PEA 3_node_2 according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA 3 T3, H88495_PEA_3 T4, H88495 PEA 3_T5, H88495 PEA_3_T6, H88495_PEA_3_T7, H88495 PEA_3 T8 and 5 H88495_PEA_3_T9. Table 28 below describes the starting and ending position of this segment on each transcript. Table 28 - Segment location on transcripts TransCnp naie Segmenet Segment strtmg p osition ending position H88495 PEA 3 T3 1179 1209 H88495 PEA 3 T4 1179 1209 H88495 PEA 3 T5 1179 1209 H88495 PEA 3 T6 1179 1209 H88495_PEA 3 T7 1179 1209 H88495 PEA 3 T8 1179 1209 H88495 PEA 3 T9 1179 1209 10 Segment cluster H88495_PEA_3_node_5 according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3_T4, H88495_PEA_3 T5, H88495_PEA_3 T6, H88495 PEA 3 T7, H88495_PEA_3_T8 and H88495_PEA_3_T9. Table 29 below describes the starting and ending position of this segment 15 on each transcript. Table 29 - Segment location on transcripts H88495 PEA 3 T3 1647 1676 H88495 PEA 3 T4 1647 1676 WO 2005/069724 PCT/IB2005/001306 309 H88495 PEA 3 T5 1647 1676 H88495_PEA 3 T6 1647 1676 H88495 PEA 3 T7 1647 1676 H88495 PEA 3 T8 1647 1676 H88495 PEA 3 T9 1647 1676 Segment cluster H88495_PEA_3 node_6 according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA 3_T4, H88495_PEA 3 T5, H88495_PEA_3 T6, H88495_PEA 3_T7, H88495 PEA 3 T8 and H88495_PEA_3 T9. Table 30 below describes the starting and ending position of this segment on each transcript. Table 30 - Segment location on transcripts H88495_PEA_3_T3 1677 1763 H88495 PEA 3 T4 1677 1763 H88495_PEA 3 T5 1677 1763 H88495 PEA 3 T6 1677 1763 H88495 PEA_3 T7 1677 1763 H88495_PEA 3_T8 1677 1763 H88495_PEA_3 T9 1677 1763 10 Segment cluster H88495_PEA_3_node_7 according to the present invention can be found in the following transcript(s): H88495_PEA 3_T3, H88495_PEA 3 T4, H88495_PEA 3 T5, H88495_PEA_3_T6, H88495_PEA_3_T7, H88495_PEA_3_T8 and H88495_PEA_3_T9. Table 15 31 below describes the starting and ending position of this segment on each transcript. Table 31 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 310 Transcript nanime Segment Segment starting position ending position H88495 PEA 3 T3 1764 1773 H88495 PEA 3 T4 1764 1773 H88495 PEA 3 T5 1764 1773 H88495 PEA 3 T6 1764 1773 H88495 PEA 3 T7 1764 1773 H88495 PEA 3 T8 1764 1773 H88495 PEA 3 T9 1764 1773 Segment cluster H88495_PEA_3_node_8 according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3 T4, H88495_PEA_3_T5, H88495_PEA_3 T6, H88495 PEA_3_T7, H88495_PEA_3_T8 and H88495_PEA 3 T9. Table 32 below describes the starting and ending position of this segment on each transcript. Table 32 - Segment location on transcripts H88495 PEA 3 T3 1774 1818 H88495_PEA_3_T4 1774 1818 H88495 PEA 3 T5 1774 1818 H88495_PEA_3_T6 1774 1818 H88495 PEA 3 T7 1774 1818 H88495 PEA 3 T8 1774 1818 H88495 PEA 3 T9 1774 1818 10 Segment cluster H88495_PEA 3 node_10 according to the present invention can be WO 2005/069724 PCT/IB2005/001306 311 found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA 3 T4, H88495 PEA 3 T5, H88495_PEA 3_T6, H88495 PEA 3 T7, H88495_PEA_3_T8 and H88495 PEA_3_T9. Table 33 below describes the starting and ending position of this segment on each transcript. 5 Table 33 - Segment location on transcripts Transcript name Segment Segment starting position ending position H88495 PEA 3 T3 2336 2353 H88495 PEA 3 T4 2336 2353 H88495 PEA 3 T5 2336 2353 H88495 PEA 3 T6 2336 2353 H88495_PEA 3 T7 2336 2353 H88495 PEA 3 T8 2336 2353 H88495 PEA 3 T9 2336 2353 Segment cluster H88495_PEA 3 node_11 according to the present invention can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA 3_T4, 10 H88495 PEA_3_T5, H88495_PEA_3 T6, H88495_PEA_3_T7, H88495 PEA 3 T8 and H88495_PEA 3_T9. Table 34 below describes the starting and ending position of this segment on each transcript. Table 34 - Segment location on transcripts anH88495 PEA 3 T3 2354 2362 H88495_PEA 3 T4 2354 2362 H88495_PEA 3 T5 2354 2362 H88495 PEA 3 T6 2354 2362 H88495 PEA 3 T7 2354 2362 1188495_PEA 3 T7 2354 2362 WO 2005/069724 PCT/IB2005/001306 312 H88495 PEA 3 T8 2354 2362 H88495 PEA 3 T9 2354 2362 Segment cluster H88495_PEA 3 node_12 according to the present invention can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3 T4, 5 H88495_PEA 3 T5 H88495_PEA 3_T6, H88495_PEA_3 _T7, H88495_PEA 3_T8 and H88495_PEA_3_T9. Table 35 below describes the starting and ending position of this segment on each transcript. Table 35 - Segment location on transcripts Transcript name Segmet Segment startng posiion ending position H88495 PEA 3 T3 2363 2377 H88495 PEA 3 T4 2363 2377 H88495 PEA 3 T5 2363 2377 H88495 PEA 3 T6 2363 2377 H88495 PEA 3 T7 2363 2377 H88495 PEA 3 T8 2363 2377 H88495 PEA 3 T9 2363 2377 10 Segment cluster H88495 PEA 3 node_14 according to the present invention is supported by 33 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3 T3, H88495_PEA_3_T4, H88495_PEA 3 T5 H88495_PEA_3_T6, H88495_PEA 3 T7, H88495_PEA 3 T8 and 15 H88495_PEA_3_T9. Table 36 below describes the starting and ending position of this segment on each transcript. Table 36 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 313 Transcript name Segment Segment starting position ending position H88495 PEA 3 T3 2510 2573 H88495 PEA 3 T4 2510 2573 H88495 PEA 3 T5 2510 2573 H88495 PEA 3 T6 2510 2573 H88495 PEA 3 T7 2510 2573 H88495 PEA 3 T8 2510 2573 H88495 PEA 3 T9 2510 2573 Segment cluster H88495_PEA 3_node_16 according to the present invention is supported by 33 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): H88495_PEA 3 T3, H88495_PEA 3 T4, H88495_PEA 3 T5, H88495_PEA_3_T6, H88495_PEA_3_T7 and H88495_PE4_3_T8. Table 37 below describes the starting and ending position of this segment on each transcript. Table 37 - Segment location on transcripts H88495 PEA 3 T3 2574 2644 H88495 PEA 3 T4 2574 2644 H88495 PEA 3 T5 2574 2644 H88495_PEA_3 T6 2574 2644 H88495 PEA 3 T7 2574 2644 H88495 PEA_3_T8 2574 2644 10 Segment cluster H88495_PEA_3_node_18 according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3 T3, H88495_PEA_3_T4, WO 2005/069724 PCT/IB2005/001306 314 H88495_PEA 3 T5 H88495_PEA 3 T6, H88495_PEA_3_T7, H88495_PEA 3 T8 and H88495 PEA_3_T9. Table 38 below describes the starting and ending position of this segment on each transcript. Table 38 - Segment location on transcripts Transcript aitie,1 Segment Segment starting position ending position H88495 PEA 3 T3 2645 2713 H88495 PEA 3 T4 2645 2713 H88495 PEA 3 T5 2645 2713 H88495 PEA 3 T6 2645 2713 H88495 PEA 3 T7 2645 2713 H88495 PEA 3 T8 2645 2713 H88495 PEA 3 T9 2574 2642 5 Segment cluster H88495_PEA 3 node_20 according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA 3_T4, 10 H88495_PEA_3_T5, H88495_PEA_3_T6, H88495_PEA 3 T7 and H88495_PEA_3_T9. Table 39 below describes the starting and ending position of this segment on each transcript. Table 39 - Segment location on transcripts H88495_PEA_3 T3 2965 3019 H88495_PEA 3_T4 2965 3019 H88495 PEA 3 T5 2714 2768 H88495 PEA 3 T6 2714 2768 H88495 PEA 3 T7 2965 3019 H88495 PEA 3 T9 2643 2697 WO 2005/069724 PCT/IB2005/001306 315 Segment cluster H88495_PEA 3 node_23 according to the present invention can be found in the following transcript(s): H88495_PEA_3_T3, H88495_PEA_3_T4 and 5 H88495_PEA_3 T9. Table 40 below describes the starting and ending position of this segment on each transcript. Table 40 - Segment location on transcripts Transcriptri Segment starting position ending position H88495_PEA 3 T3 3020 3027 H88495 PEA 3 T4 3020 3027 H88495_PEA 3_T9 2698 2705 10 Segment cluster H88495 PEA 3 node_24 according to the present invention is supported by 23 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): H88495 PEA 3 T3, H88495 PEA 3 T4, H88495_PEA_3_T5, H88495 PEA 3 T6, H88495_PEA 3 T7 and H88495 PEA 3 T9. Table 41 below describes the starting and ending position of this segment on each transcript. 15 Table 41 - Segment location on transcripts H88495_PEA_3 T3 3028 3056 H88495 PEA 3 T4 3028 3056 H88495 PEA 3 T5 3096 3124 H88495_PEA 3_T6 3096 3124 H88495_PEA 3_T7 3347 3375 H88495_PEA_3 T9 2706 2734 WO 2005/069724 PCT/IB2005/001306 316 Variant protein alignment to the previously known protein: Sequence name: SRCHHUMAN Vl Sequence documentation: 5 Alignment of: H88495 PEA 3 P15 x SRCH HUMAN Vl Alignment segment 1/1: 10 Quality: 6726.00 Escore: 0 Matching length: 657 Total length: 657 Matching Percent Similarity: 100.00 Matching Percent Identity: 99.85 Total Percent Similarity: 100.00 Total Percent Identity: 99.85 Gaps: 0 15 Alignment: 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLS 50 l l l i l l l l l i l lll l l l l l l l l l l l lI I l l li l l l l l l : I l i l li l 20 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLS 50 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 I I I I llll ll l i l l l l li l l i l l l l l l l l l l l l i l l il l l l l I l 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 25 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 IlllllllillllllIllllill~llllllilllJllilllilllI 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 30 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 IIIllllilllllllllllllIlllll1illlllIlilllll 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 3 5 l l l l l l l i l l I l I l l i l l l i l I li i l lll l l l l I ll II I I I 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 WO 2005/069724 PCT/IB2005/001306 317 l l ll i l l l l i l l i l l l I l l I i llil l i i l i i l l l I l lI 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 5 I i IIIlilI llI ll Ii l II II IlIl iIllI Ill 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 I l l lil lll ill lI lill ll11 l ll l1 l ll1 l l1 l llll1 ll lF l 10 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 I l li l i l l l l I IlIl I I I l l l I llllFI F IIIfI I 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 15 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 I l I I I l l l I l l l I l l I I Ii i l l l l i l l l I l l I 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 20 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 I 1l1 IlI ll ill 11 1f I FII i 1111Ff F llli ll I lI 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 2 5 I I l I l l I l l l I l l l l l lF i l llII l i l l l l II I F 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 601 SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMG 650 I l l l l l liIII l l l l l lllI l l I I l Il I l l l I 30 601 SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMG 650 651 EHCDQCQ 657 IIIlll 651 EHCDQCQ 657 35 Sequence name: SRCH HUMAN V1 Sequence documentation: WO 2005/069724 PCT/IB2005/001306 318 Alignment of: H88495 PEA 3 PI6 x SRCH HUMAN VI Alignment segment 1/1: 5 Quality: 6935.00 Escore: 0 Matching length: 676 Total length: 676 Matching Percent Similarity: 100.00 Matching Percent Identity: 99.85 Total Percent Similarity: 100.00 Total Percent Identity: 99.85 10 Gaps: 0 Alignment: 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLS 50 15 I l l l l l l l l i ll lii l 1 l11 I I l :1 I l I 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLS 50 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 20 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 25 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 30 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 I I I l l I l I l l l l l l l l l l l l I II l l I l l l l l lI l l I l 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 3 5 I Il l l l l lI l l l lI I l l l l l l l l l I I I I I I I l l l l l I 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 WO 2005/069724 PCT/IB2005/001306 319 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 5 JI i ll l l l l l l l l l II I l l lll l l I 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 l i i li i i l l l 1l llli l l l l l l l l l l l lii Il 10 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 Ifll l lIl l I l i l l l I l l l l l l I l l I l l I l l[ 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 15 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 SIllil l l i l l i l l l l il l i l l l I l i lI l l l l l l l 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 20 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 I I l I l ll l l l I l l I l l l l lI I l l l l lI l li 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 601 SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMG 650 2 5 I l l l ll l l l l l l l l l l l I I I I l l l l l l I l t l l i 601 SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMG 650 651 EHCDQCQHCQFCYLCPLVCETVCAPG 676 Illlllll1lllllllIIIIIIII 30 651 EHCDQCQHCQFCYLCPLVCETVCAPG 676 Sequence name: SRCHHUMANVl Sequence documentation: 35 Alignment of: H88495 PEA 3 Pl7 x SRCH HUMAN Vl Alignment segment 1/1: WO 2005/069724 PCT/IB2005/001306 320 Quality: 6726.00 Escore: 0 Matching length: 657 Total length: 657 Matching Percent Similarity: 100.00 Matching Percent Identity: 99.85 5 Total Percent Similarity: 100.00 Total Percent Identity: 99.85 Gaps: 0 Alignment: 10 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLS 50 I il I l l l I l l I I I i l l l i l I i l l l l l l ll l l l l : i l l l I 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLS 50 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 15 II l l l I ll i l l l l l lIll l l l l l 1l l l 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 I Il l l I l l l l I l l l ll l l l ItI l l l I i l l 20 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 11111111FFII 111 FF111 11F 1111F IF 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 25 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 I Il l l l l l l l llli l l l l l l l l llII l l I l l I I 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 30 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 I l l I l l l lll l I I l I l l l l lI l l l l l l l I I II 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 3 5 l lI l lI II I I 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 WO 2005/069724 PCT/IB2005/001306 321 I l i l l i ll l l l l l l Il I l l l lll ll l l l l l i l l l l l I 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 5 11111111 F 11111 111111111111111lllil 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 I l l l i I l i l l l l l l l l i l l I l l l l l l I I l I I I I 10 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 I l l I l I l l l l l l i l l l l l llil l l l l l l l I I ll I l 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 15 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 i I l l l I [ I I l l l l l l l l I l i l I l l l l il l lIlIl l l l i 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 20 601 SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMG 650 11 1 l F FllilF llll IlllII I llll l l F1l 1 l 1 11 F 601 SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMG 650 651 EHCDQCQ 657 25 l11111 651 EHCDQCQ 657 Sequence name: SRCH HUMAN V1 30 Sequence documentation: Alignment of: H88495 PEA 3 P18 x SRCH HUMAN V1 Alignment segment 1/1: 35 Quality: 6206.00 Escore: 0 Matching length: 610 Total length: 610 Matching Percent Similarity: 100.00 Matching Percent Identity: 99.84 WO 2005/069724 PCT/IB2005/001306 322 Total Percent Similarity: 100.00 Total Percent Identity: 99.84 Gaps: 0 Alignment: 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLS 50 I l iF l 1 1 l l l ll l l l l l ll l I l l l l l i l l l :1 l l l l l 1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLS 50 10 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 I IEll ~ l l i l I l ll l l l i l l l 1l I l i l l l il l l I 51 EEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVAKEYG 100 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 1 5 I l l I l l i 1 1 l l l l l l l ll l l l l I I 101 HLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRH 150 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 I l i l l l l l l l l l i l l l llll ! llI I I I Ii l l l l I I I I 20 151 HLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEE 200 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 I l l I I I l l l l l 1lil l l l l l l l l I l l l l l l l l l l l l l l l l l I 201 EEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDD 250 25 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 l i l l l I l l l l l I l I lt l l l l l I l l l l l l l l l l l I l l 251 DDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH 300 30 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 I l I l l I I l l l l l l ll l l I I I I l il l l l l l l l l l I l 301 EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRD 350 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 3 5 I II I I III l I l l l l l l l l l I I 351 EEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHK 400 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 WO 2005/069724 PCT/IB2005/001306 323 III 1 I 1111l11ll111ll 11 l lii 1ll1l1l11 11l111 401 SDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEET 450 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 5l l l l l l i l l l l ill l l l l l l l l l l 451 GHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDE 500 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 l ll lii i 111l lI 11l1111111 1l I l I I 1 11l 1 1i lI 10 501 SSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEE 550 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 IlllllIlllillllIllilllllillllllllilllIllllIIII[I 551 RREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA 600 15 601 SSEEESGEDT 610 I 1 1 1l l l 1 l 601 SSEEESGEDT 610 20 DESCRIPTION FOR CLUSTER Z36249 Cluster Z36249 features 4 transcript(s) and 11 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest Z36249_PEA_3_T2 38 Z36249_PEA_3 T3 39 Z36249_PEA 3 T5 40 Z36249 PEA 3 T9 41 25 Table 2 - Segments of interest ......... 1....

WO 2005/069724 PCT/IB2005/001306 324 Z36249 PEA 3 node 0 186 Z36249 PEA 3 node 3 187 Z36249 PEA 3 node 5 188 Z36249 PEA 3 node 11 189 Z36249 PEA 3 node 14 190 Z36249 PEA 3 node 24 191 Z36249 PEA 3 node 10 192 Z36249 PEA 3 node 13 193 Z36249 PEA 3 node 17 194 Z36249 PEA 3 node 19 195 Z36249 PEA 3 node 21 196 Table 3 - Proteins of interest Poteiii1Namie S~Cq ID No.~ C~o e_ pondngrar1rpt1 " Z36249_PEA 3 P2 313 Z36249_PEA 3 T2 Z36249_PEA 3 P3 314 Z36249_PEA 3 T3 Z36249_PEA 3_ P4 315 Z36249_PEA_3 T5 Z36249_PEA 3 P5 316 Z36249_PEA 3 T9 5 The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster Z36249. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 27 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that 10 category, according to parts per million). Overall, the following results were obtained a shown with regard to the histogram in Figure 27, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figure 28, concerning the actual expression of oligonucleotides in various tissues, including heart.

WO 2005/069724 PCT/IB2005/001306 325 This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 33.8; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific 5 ESTs which was found to be 27.8; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 1.60E-47. One particularly important measure of specificity of expression of a cluster in heart tissue 10 is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall 15 expression of the cluster in muscle-specific ESTs which was found to be 33.8, which clearly supports specific expression in heart tissue As noted above, cluster Z36249 features 4 transcript(s), which were listed in Table 1 above. A description of each variant protein according to the present invention is now provided. 20 Variant protein Z36249_PEA_3_P2 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z36249_PEA 3_T2. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 25 Comparison report between Z36249_PEA_3_P2 and Q96LE7 (SEQ ID NO:344): 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3_P2, comprising a first amino acid sequence being at least 90 % homologous to MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE 30 QQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEII corresponding to amino acids 1 - 115 of Q96LE7, which also corresponds to amino acids 1 - 115 WO 2005/069724 PCT/IB2005/001306 326 of Z36249_PEA 3 P2, and a second amino acid sequence being at least 90 % homologous to YKRTALHRACLEG HLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLDVLKLLLNKG AKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDREGDTPLHDAVRLNRYK MIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTKAIFDSLRENSYKTSRIATF 5 corresponding to amino acids 152 - 319 of Q96LE7, which also corresponds to amino acids 116 - 283 of Z36249_PEA_3_P2, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated chimeric polypeptide encoding for an edge portion of Z36249 PEA 3 P2, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in 10 length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IY, having a structure as follows: a sequence starting from any of amino acid numbers I15-x to 115; and ending at any of amino acid numbers 116+ ((n-2) - x), in which x varies from 0 to n-2. 15 Comparison report between Z36249_PEA_3_P2 and Q15327 (SEQ ID NO:345): 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3 P2, comprising a first amino acid sequence being at least 90 % homologous to MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE 20 QQWKSEKQREAEL corresponding to amino acids 1 - 70 of Q15327, which also corresponds to amino acids 1 - 70 of Z36249_PEA_3_P2, a bridging amino acid K corresponding to amino acid 71 of Z36249_PEA_3_P2, a second amino acid sequence being at least 90 % homologous to KKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEII corresponding to amino acids 72 - 115 of Q15327, which also corresponds to amino acids 72 - 115 of 25 Z36249_PEA 3_P2, and a third amino acid sequence being at least 90 % homologous to YKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLDVLKLLLNKG AKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDREGDTPLHDAVRLNRYK MIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTKAIFDSLRENSYKTSRIATF corresponding to amino acids 152 - 319 of Q15327, which also corresponds to amino acids 116 30 - 283 of Z36249 PEA_3 P2, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential WO 2005/069724 PCT/IB2005/001306 327 order. 2.An isolated chimeric polypeptide encoding for an edge portion of Z36249_PEA 3 P2, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino 5 acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IY, having a structure as follows: a sequence starting from any of amino acid numbers 115-x to 115; and ending at any of amino acid numbers 116+ ((n-2) - x), in which x varies from 0 to n-2. 10 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. 15 In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein Z36249_PEA 3_P2 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 4, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether 20 the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA_3_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 4 -Amino acid mutations 34 E -> *Yes 25 Variant protein Z36249_PEA 3_P2 is encoded by the following transcript(s): Z36249_PEA_3_T2, for which the sequence(s) is/are given at the end of the application. The WO 2005/069724 PCT/IB2005/001306 328 coding portion of transcript Z36249 PEA 3 T2 is shown in bold; this coding portion starts at position 250 and ends at position 1098. The transcript also has the following SNPs as listed in Table 5 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of 5 known SNPs in variant protein Z36249_PEA 3_P2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 5 - Nucleic acid SNPs 105 T-> C Yes 208 T-> No 349 G ->T Yes 459 C ->A No 1160 A ->G Yes 1356 C ->T Yes 1417 C ->T Yes 1516 C ->T Yes 1601 C ->T Yes 1705 G ->A Yes 1761 G -> A Yes 1969 G ->A Yes 1974 G ->A Yes 2047 G-> A Yes 10 Variant protein Z36249_PEA_3_P3 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z36249_PEA_3_T3. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: WO 2005/069724 PCT/IB2005/001306 329 Comparison report between Z36249_PEA_3_P3 and Q96LE7: 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3_P3, comprising a first amino acid sequence being at least 90 % homologous to 5 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE QQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITE PVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDEYKRTALHRACLEGHLAIVEKLMEA GAQIEFRDM corresponding to amino acids 1 - 184 of Q96LE7, which also corresponds to amino acids 1 - 184 of Z36249_PEA_3_P3, and a second amino acid sequence being at least 10 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VNIFLCLGMSQKK corresponding to amino acids 185 - 197 of Z36249_PEA_3_P3, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z36249_PEA_3 P3, comprising a 15 polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VNIFLCLGMSQKK in Z36249_PEA_3_P3. Comparison report between Z36249_PEA_3_P3 and Q15327: 20 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3 P3, comprising a first amino acid sequence being at least 90 % homologous to MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE QQWKSEKQREAEL corresponding to amino acids 1 - 70 of Q15327, which also corresponds to amino acids 1 - 70 of Z36249_PEA 3_P3, a bridging amino acid K corresponding to amino 25 acid 71 of Z36249_PEA_3_P3, a second amino acid sequence being at least 90 % homologous to KKKLEQRSKLENLEDLEIIIQLKKRKKYRK'IKVPVVKEPEPEIITEPVDVPTFLKAALENK LPVVEKFLSDKNNPDVCDEYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDM corresponding to amino acids 72 - 184 of Q15327, which also corresponds to amino acids 72 30 184 of Z36249_PEA_3 P3, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least WO 2005/069724 PCT/IB2005/001306 330 95% homologous to a polypeptide having the sequence VNIFLCLGMSQKK corresponding to amino acids 185 - 197 of Z36249_PEA_3 P3, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 5 2.An isolated polypeptide encoding for a tail of Z36249_PEA 3 P3, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VNIFLCLGMSQKK in Z36249_PEA_3_P3. 10 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. 15 In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein Z36249_PEA_3_P3 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the 20 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA 3_P3 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 6 - Amino acid mutations 34 E -> *Yes 25 Variant protein Z36249_PEA_3_P3 is encoded by the following transcript(s): WO 2005/069724 PCT/IB2005/001306 331 Z36249_PEA_3_T3, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z36249_PEA_3 T3 is shown in bold; this coding portion starts at position 250 and ends at position 840. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative 5 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA 3_P3 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7 - Nucleic acid SNPs SNP position on nucleotide Aternative nucleic acid Previously known SNP' 105 T -> C Yes 208 T -> No 349 G -> T Yes 459 C -> A No 10 Variant protein Z36249_PEA 3 P4 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z36249_PEA _3_T5. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the 15 variant protein according to the present invention to each such aligned protein is as follows: Comparison report between Z36249_PEA_3 P4 and Q96LE7: 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3_P4, comprising a first amino acid sequence being at least 90 % homologous to 20 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE QQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITE PVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDE corresponding to amino acids 1 - 151 of Q96LE7, which also corresponds to amino acids 1 - 151 of Z36249_PEA_3 P4, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more WO 2005/069724 PCT/IB2005/001306 332 preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRLMQSTAKSSSLILCFLCFTPVLLI corresponding to amino acids 152 - 177 of Z36249_PEA_3 P4, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 5 2.An isolated polypeptide encoding for a tail of Z36249_PEA_3 P4, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRLMQSTAKSSSLILCFLCFTPVLLI in Z36249_PEA_3_P4. 10 Comparison report between Z36249_PEA_3_P4 and Q15327: 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3 P4, comprising a first amino acid sequence being at least 90 % homologous to MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE QQWKSEKQREAEL corresponding to amino acids 1 - 70 of Q15327, which also corresponds 15 to amino acids 1 - 70 of Z36249_PEA 3_P4, a bridging amino acid K corresponding to amino acid 71 of Z36249_PEA_3_P4, a second amino acid sequence being at least 90 % homologous to KKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENK LPVVEKFLSDKNNPDVCDE corresponding to amino acids 72 - 151 of Q15327, which also 20 corresponds to amino acids 72 - 151 of Z36249_PEA_3 P4, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRLMQSTAKSSSLILCFLCFTPVLLI corresponding to amino acids 152 - 177 of Z36249_PEA_3 P4, wherein said first amino acid sequence, bridging amino acid, second amino 25 acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z36249 PEA_3 P4, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRLMQSTAKSSSLILCFLCFTPVLLI in Z36249_PEA_3_P4. 30 The location of the variant protein was determined according to results from a number of WO 2005/069724 PCT/IB2005/001306 333 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because only one of the two trans-membrane region prediction programs (Tmpred: 1, Tmhmm: 0) has predicted that this 5 protein has a trans-membrane region. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein Z36249_PEA_3_P4 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the 10 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA_3_P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Amino acid mutations 34 E-> Yes 15 Variant protein Z36249_PEA_3 P4 is encoded by the following transcript(s): Z36249_PEA 3_T5, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z36249_PEA 3 T5 is shown in bold; this coding portion starts at 20 position 250 and ends at position 780. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA_3 P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). 25 Table 9 - Nucleic acid SNPs WO 2005/069724 PCT/IB2005/001306 334 SNP position on nucleotide Alternative nucleic acid Previousyown SNP? sequence 105 T -> C Yes 208 T-> No 349 G ->T Yes 459 C->A No 1265 T ->C Yes Variant protein Z36249_PEA_3 P5 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 Z36249_PEA_3_T9. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between Z36249_PEA_3_P5 and Q96LE7: 10 1.An isolated chimeric polypeptide encoding for Z36249_PEA_3_P5, comprising a first amino acid sequence being at least 90 % homologous to MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE QQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITE PVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDE corresponding to amino acids 1 - 151 of 15 Q96LE7, which also corresponds to amino acids 1 - 151 of Z36249_PEA_3 P5, and a second amino acid sequence being at least 90 % homologous to LESTAIHWASRGGNLDVLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACE ADLNAKDREGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNG TKAIFDSLRENSYKTSRIATF corresponding to amino acids 185 - 319 of Q96LE7, which also 20 corresponds to amino acids 152 - 286 of Z36249_PEA_3_P5, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated chimeric polypeptide encoding for an edge portion of Z36249_PEA_3_PS, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino WO 2005/069724 PCT/IB2005/001306 335 acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EL, having a structure as follows: a sequence starting from any of amino acid numbers 151-x to 151; and ending at any of amino acid numbers 152+ ((n-2) - x), in which x varies from 0 to n-2. 5 Comparison report between Z36249 PEA_3_P5 and Q15327: 1.An isolated chimeric polypeptide encoding for Z36249_PEA 3 P5, comprising a first amino acid sequence being at least 90 % homologous to MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGE 10 QQWKSEKQREAEL corresponding to amino acids 1 - 70 of Q15327, which also corresponds to amino acids 1 - 70 of Z36249_PEA_3_P5, a bridging amino acid K corresponding to amino acid 71 of Z36249_PEA_3_P5, a second amino acid sequence being at least 90 % homologous to KKKLEQRSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENK 15 LPVVEKFLSDKNNPDVCDE corresponding to amino acids 72 - 151 of Q15327, which also corresponds to amino acids 72 - 151 of Z36249_PEA_3 P5, and a third amino acid sequence being at least 90 % homologous to LESTAIHWASRGGNLDVLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACE ADLNAKDREGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNG 20 TKAIFDSLRENSYKTSRIATF corresponding to amino acids 185 - 319 of Q15327, which also corresponds to amino acids 152 - 286 of Z36249_PEA_3_P5, wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated chimeric polypeptide encoding for an edge portion of Z36249_PEA_3_P5, 25 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EL, having a structure as follows: a sequence starting from any of amino acid numbers 151-x to 151; and 30 ending at any of amino acid numbers 152+ ((n-2) - x), in which x varies from 0 to n-2.

WO 2005/069724 PCT/IB2005/001306 336 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the 5 trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein Z36249_PEA 3_P5 also has the following non-silent SNPs (Single 10 Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA 3_P5 sequence provides support for the deduced sequence of this variant protein according to the present invention). 15 Table 10 - Amino acid mutations 34 E>* Yes Variant protein Z36249_PEA 3_P5 is encoded by the following transcript(s): Z36249_PEA_3_T9, for which the sequence(s) is/are given at the end of the application. The 20 coding portion of transcript Z36249_PEA_3_T9 is shown in bold; this coding portion starts at position 250 and ends at position 1107. The transcript also has the following SNPs as listed in Table 11 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z36249_PEA_3_P5 sequence provides support for the deduced 25 sequence of this variant protein according to the present invention). Table 11 - Nucleic acid SNPs WO 2005/069724 PCT/IB2005/001306 337 SNP position on nucleotide Alternative nucleic acid Previously known SNP? ,sequence 105 T-> C Yes 208 T-> No 349 G ->T Yes 459 C ->A No 1169 A-> G Yes 1365 C -> T Yes 1426 C -> T Yes 1525 C -> T Yes 1610 C -> T Yes 1714 G->A Yes 1770 G-> A Yes As noted above, cluster Z36249 features 11 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) 5 are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. Segment cluster Z36249_PEA_3 node_0 according to the present invention is supported 10 by 42 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T2, Z36249_PEA_3_T3, Z36249_PEA_3 T5 and Z36249_PEA_3_T9. Table 12 below describes the starting and ending position of this segment on each transcript. Table 12 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 338 Z36249 PEA 3 T2 1 276 Z36249 PEA 3 T3 1 276 Z36249 PEA 3 T5 1 276 Z36249 PEA 3 T9 1 276 Segment cluster Z36249_PEA_3 node_3 according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): Z36249_PEA_3_T2, Z36249_PEA 3 T3, Z36249_PEA_3 T5 and Z36249_PEA 3 T9. Table 13 below describes the starting and ending position of this segment on each transcript. Table 13 - Segment location on transcripts stmglw pisition enC III p~osii 2 "" : = < .- ,4',;' ,£! ... .. ,, ',' Z36249 PEA 3 T2 277 456 Z36249 PEA 3 T3 277 456 Z36249 PEA 3 T5 277 456 Z36249 PEA 3 T9 277 456 10 Segment cluster Z36249_PEA_3 node_5 according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T2, Z36249_PEA 3 T3, Z36249_PEA_3 T5 and Z36249_PEA_3_T9. Table 14 below describes the starting and ending 15 position of this segment on each transcript. Table 14 - Segment location on transcripts Z36249_PEA_3_T2 457 594 WO 2005/069724 PCT/IB2005/001306 339 Z36249 PEA 3 T3 457 594 Z36249_PEA_3_T5 457 594 Z36249 PEA 3 T9 457 594 Segment cluster Z36249_PEA 3 node_11 according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): Z36249_PEA_3_T5. Table 15 below describes the starting and ending position of this segment on each transcript. Table 15 - Segment location on transcripts Transenpt nne Segment-,, Segment statingpsitn ending position Z36249 PEA_3_T5 703 1387 10 Segment cluster Z36249_PEA_3_node_14 according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T3. Table 16 below describes the starting and ending position of this segment on each transcript. Table 16 - Segment location on transcripts Z36249 PEA_3 T3 802 1472 15 Segment cluster Z36249_PEA_3 node_24 according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T2 and Z36249_PEA_3_T9. Table 20 17 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 340 Table 17 - Segment location on transcripts Transcript name Segment Segment : starting position ending position. Z36249 PEA 3 T2 991 2064 Z36249_PEA 3 T9 1000 1877 According to an optional embodiment of the present invention, short segments related to 5 the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description. Segment cluster Z36249_PEA_3_node_10 according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment 10 can be found in the following transcript(s): Z36249_PEA 3_T3, Z36249_PEA_3_T5 and Z36249_PEA 3_T9. Table 18 below describes the starting and ending position of this segment on each transcript. Table 18 - Segment location on transcripts Z36249 PEA 3 T3 595 702 Z36249_PEA_3 T5 595 702 Z36249 PEA 3 T9 595 702 15 Segment cluster Z36249_PEA 3_node_13 according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T2 and Z36249_PEA_3_T3. Table 19 below describes the starting and ending position of this segment on each transcript. 20 Table 19 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 341 Transcript name- Segment Segment starting position ending position Z36249 PEA 3 T2 595 693 Z36249_PEA 3 T3 703 801 Segment cluster Z36249_PEA_3_node_1 7 according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): Z36249_PEA_3_T2 and Z36249_PEA_3_T9. Table 20 below describes the starting and ending position of this segment on each transcript. Table 20 - Segment location on transcripts ~~Tra~~ scrip nam 1),- Post ~m StartIng siLion 1enlilg poItIln Z36249_PEA 3 T2 694 792 Z36249_PEA 3 T9 703 801 10 Segment cluster Z36249_PEA 3 node_19 according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T2 and Z36249_PEA_3_T9. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts Z36249 PEA 3 T2 793 891 Z36249_PEA 3 T9 802 900 15 Segment cluster Z36249_PEA 3 node_21 according to the present invention is supported WO 2005/069724 PCT/IB2005/001306 342 by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z36249_PEA_3_T2 and Z36249_PEA_3_T9. Table 22 below describes the starting and ending position of this segment on each transcript. Table 22 - Segment location on transcripts Transcript name Segment Segment starting position ending position Z36249 PEA 3 T2 892 990 Z36249 PEA 3 T9 901 999 5 Variant protein alignment to the previously known protein: Sequence name: Q96LE7 10 Sequence documentation: Alignment of: Z36249 PEA 3 P2 x Q96LE7 Alignment segment 1/1: 15 Quality: 2639.00 Escore: 0 Matching length: 283 Total length: 319 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 88.71 Total Percent Identity: 88.71 20 Gaps: 1 Alignment: 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 2 5 I I I I I lI I I I l I I I I I l l l l Il I 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 I lIlI I lI ll I lIIIlIl II I lIl L LI I III lll lII I1 0 30 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 WO 2005/069724 PCT/IB2005/001306 343 101 KTKVPVVKEPEPEII............................................ 115 lillllllllllli 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 5 116 .YKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLD 164 l l l l l l l l l l l l l l l l l I l l l l i l i l l l l l l 11 1 1 1 1 1 1 1 1 1 1 1 1 i 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLD 200 10 165 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 214 IllFllll l ll1 llllillllllilll l11 11 1 1 11111l ll li 201 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 250 215 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 264 1 5 F 1 Fl l I l l l l ll Fl l l l l lll l l l i l l ll 1 I I ll l ll F 251 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 300 265 AIFDSLRENSYKTSRIATF 283 llIllllllllIillll 20 301 AIFDSLRENSYKTSRIATF 319 Sequence name: Q15327 Sequence documentation: 25 Alignment of: Z36249 PEA 3 P2 x Q15327 Alignment segment 1/1: 30 Quality: 2626.00 Escore: 0 Matching length: 283 Total length: 319 Matching Percent Similarity: 99.65 Matching Percent Identity: 99.65 Total Percent Similarity: 88.40 Total Percent Identity: 88.40 Gaps: 1 35 Alignment: 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 WO 2005/069724 PCT/IB2005/001306 344 I l l l l l i l l i l Il l l l l l l l i l l l l l l l l l l l i lll l l l~ l l 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 5 i11111111111111111111 111111 1111 F1111111111111 51 HPVTLGEQQWKSEKQREAELPKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 101 KTKVPVVKEPEPEII.................... .. ............. 115 10 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 116 .YKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLD 164 1lllllllIlllllllllllIlllllllllllllllIllllll 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLD 200 15 165 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 214 lI l l l l l l l l l l l l l l lI l l l l l l l l l l l l l ll l l l l l l l l l l 201 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 250 20 215 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 264 1I l l l l l l I l l l l lll l li l l llFIl lll l I I I I l l l l ll 251 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 300 265 AIFDSLRENSYKTSRIATF 283 2 5 I l l Ii l I lI l l l l l 301 AIFDSLRENSYKTSRIATF 319 Sequence name: Q96LE7 30 Sequence documentation: Alignment of: Z36249_PEA 3 P3 x Q96LE7 Alignment segment 1/1: 35 Quality: 1785.00 Escore: 0 Matching length: 184 Total length: 184 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 WO 2005/069724 PCT/IB2005/001306 345 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 5 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 I l lFll l l l lFIl l l l l l l l lFll l Fll l l l l l l l l l l l l lll l l l l l 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 10 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 IllllllllllllllllllllllllllllllllllllllllllllllllI 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 1 5 I l l l l l l l l l l l l ll l l l l l l l l l I I l l l i l l l l l l l l l l l l l 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDM 184 IIllIllllllIlIllIllllIlllllII 20 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDM 184 Sequence name: Q15327 Sequence documentation: 25 Alignment of: Z36249 PEA 3 P3 x Q15327 Alignment segment 1/1: 30 Quality: 1772.00 Escore: 0 Matching length: 184 Total length: 184 Matching Percent Similarity: 99.46 Matching Percent Identity: 99.46 Total Percent Similarity: 99.46 Total Percent Identity: 99.46 Gaps: 0 35 Alignment: 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 WO 2005/069724 PCT/IB2005/001306 346 111111ll11l111111l1l1I1111111111111l111111lll lll 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 5 li l i l l l l l i l l l l l l I I l l l l l l l l l l l l l l l l l l I 51 HPVTLGEQQWKSEKQREAELPKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 IlllliLlllilllllllllllllllllIIIlllllllIllllllllll 10 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDM 184 IllillllIIlllIllIillllllllllllll 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDM 184 15 Sequence name: Q96LE7 Sequence documentation: 20 Alignment of: Z36249 PEA 3 P4 x Q96LE7 Alignment segment 1/1: Quality: 1464.00 Escore: 0 25 Matching length: 151 Total length: 151 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 30 Alignment: 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 Illllllllllllllllllllllllllllllllllllllllllilll 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 35 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 lllllIllllilllllllllllll51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100llllll 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 WO 2005/069724 PCT/IB2005/001306 347 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 111111111 ilI i II III II ii III lI 111111IIIl 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 5 151 E 151 151 E 151 10 Sequence name: Q15327 Sequence documentation: Alignment of: Z36249 PEA 3 P4 x Q15327 15 Alignment segment 1/1: Quality: 1451.00 Escore: 0 Matching length: 151 Total length: 151 20 Matching Percent Similarity: 99.34 Matching Percent Identity: 99.34 Total Percent Similarity: 99.34 Total Percent Identity: 99.34 Gaps: 0 Alignment: 25 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 I I I l I I I l I I i l l l l l II L I I I l ll l l l l l l llI I l l i i i 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 30 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 III l I I 11 1 IIII flllll lil llIlllllllllllI I l 51 HPVTLGEQQWKSEKQREAELPKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 3 5 l l l l l l l l i l l l l l l l l l I I I I Ill l l i l l l l l l l i l lI l l l l l 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 151 E 151 WO 2005/069724 PCT/IB2005/001306 348 151 E 151 Sequence name: Q96LE7 5 Sequence documentation: Alignment of: Z36249 PEA 3 P5 x Q96LE7 10 Alignment segment 1/1: Quality: 2670.00 Escore: 0 Matching length: 286 Total length: 319 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 15 Total Percent Similarity: 89.66 Total Percent Identity: 89.66 Gaps: 1 Alignment: 20 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 Ilil 1 ll l l l l l l ill l l l l l l l I I I l l l 11111111 l11111111 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 2 5 Il l l l l l l l ll l I l l l l l l l I l l l l l Il l l l l l l l l l l lll l l I I I 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 IllllllllllllllllllllllllllllIIlllllllllllllllI 30 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 151 E .................................LESTAIHWASRGGNLD 167 1 I I l ll I I I Il l l l l 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLD 200 35 168 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 217 I l 1 l l l l l lII I l l l II I I lI II I I I I l l I I I I I 2 5II 201 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 250 WO 2005/069724 PCT/IB2005/001306 349 218 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 267 Il l i l l l l ll l ll l i l l l l l l l l l l l l ll l l l l l l l l l 11 1 1 1 1 1 I 251 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 300 5 268 AIFDSLRENSYKTSRIATF 286 IIlll1lllllllll li 301 AIFDSLRENSYKTSRIATF 319 10 Sequence name: Q15327 Sequence documentation: Alignment of: Z36249 PEA 3 P5 x Q15327 15 Alignment segment 1/1: Quality: 2657.00 Escore: 0 Matching length: 286 Total length: 319 20 Matching Percent Similarity: 99.65 Matching Percent Identity: 99.65 Total Percent Similarity: 89.34 Total Percent Identity: 89.34 Gaps: 1 Alignment: 25 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 IllllIIlllllIIIllillllllllllIIIlllllIllilllllllll 1 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLA 50 30 51 HPVTLGEQQWKSEKQREAELKKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 I l l l l l l l l l l I l l l l l l ll l l l l l l l1 1 II I I I l l l Il l l l l l l l 51 HPVTLGEQQWKSEKQREAELPKKKLEQRSKLENLEDLEIIIQLKKRKKYR 100 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 3 5I l i l l I l ll l l I l l l l I l l l l l l l l l l l l l l l l l 101 KTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCD 150 151 E .................................LESTAIHWASRGGNLD 167 WO 2005/069724 PCT/IB2005/001306 350 I [ l l l l il lt l l l l l l l 151 EYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLD 200 168 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 217 5 l Ii llll ll lil l1111111111 lil 11111 l ll llll 201 VLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDR 250 218 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 267 ll i ll l i l ll l l l l ll l l l l lllt l l l l l l l l l l l lll l l l l Il ll l i 10 251 EGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTK 300 268 AIFDSLRENSYKTSRIATF 286 I l lII I l l l I l I II I 301 AIFDSLRENSYKTSRIATF 319 15 DESCRIPTION FOR CLUSTER Z25377 Cluster Z25377 features 9 transcript(s) and 12 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. 20 Table 1 - Transcripts of interest Z25377 PEA 1 T1 42 Z25377 PEA 1 T5 43 Z25377 PEA 1 T7 44 Z25377 PEA 1 T8 45 Z25377 PEA 1 T9 46 Z25377 PEA 1 T10 47 Z25377 PEA 1 T11 48 Z25377 PEA 1 T12 49 Z25377_PEA 1 TI3 50 WO 2005/069724 PCT/IB2005/001306 351 Table 2 - Segments of interest Segment Name Seq ID No. Z25377_PEA 1 node_5 197 Z25377_PEA 1 node 12 198 Z25377_PEA 1 node 15 199 Z25377 PEA 1 node 17 200 Z25377_PEA 1 node 18 201 Z25377 PEA 1 node 22 202 Z25377 PEA 1 node 24 203 Z25377_PEA 1 node_0 204 Z25377 PEA 1 node 7 205 Z25377 PEA 1 node 8 206 Z25377 PEA 1 node 10 207 Z25377_PEA_1_node_20 208 Table 3 - Proteins of interest Z25377 PEA 1 PI2 317 Z25377_PEAI_ TlI Z25377_PEA_1_Pl3 318 Z25377 PEA_1_TI2 Z25377_PEA 1 P14 319 Z25377_PEA 1_TI3 Z25377_PEA_1_P15 320 Z25377 PEA_1 T1 Z25377_PEA 1_P17 321 Z25377_PEA_1 T5 Z25377_PEAIPl8 322 Z25377 PEA_1_T7 Z25377_PEA 1 P19 323 Z25377 PEA 1 T8 Z25377_PEA 1 P20 324 Z25377_PEA_1 T9 Z25377_PEA_1 P21 325 Z25377_PEA 1 TIO 5 These sequences are variants of the known protein Hypothetical protein FLJ26352 (SwissProt accession identifier Q6ZP80; known also according to the synonyms RLNI6974), WO 2005/069724 PCT/IB2005/001306 352 referred to herein as the previously known protein. The sequence for protein Hypothetical protein FLJ26352 is given at the end of the application, as "Hypothetical protein FLJ26352 amino acid sequence" (SEQ ID NO:390). The heart-selective diagnostic marker prediction engine provided the following results 5 with regard to cluster Z25377. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 29 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million). 10 Overall, the following results were obtained as shown with regard to the histogram in Figure 29, concerning the number of heart-specific clones in libraries/sequences. This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 13.3; the ratio of expression 15 of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 4.9; and fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant, and were found to be 6.50E-07. One particularly important measure of specificity of expression of a cluster in heart tissue 20 is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall 25 expression of the cluster in muscle-specific ESTs which was found to be 13.3, which clearly supports specific expression in heart tissue. As noted above, cluster Z25377 features 9 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Hypothetical protein FLJ26352. A description of each variant protein according to the present invention is 30 now provided. Variant protein Z25377_PEA 1_P12 according to the present invention has an amino acid WO 2005/069724 PCT/IB2005/001306 353 sequence as given at the end of the application; it is encoded by transcript(s) Z25377_PEA 1 TI1. An alignment is given to the known protein (Hypothetical protein FLJ26352) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the 5 relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between Z25377_PEA 1_P12 and BAC85244 (SEQ ID NO:341): 1.An isolated chimeric polypeptide encoding for Z25377_PEA_1_P12, comprising a first 10 amino acid sequence being at least 90 % homologous to MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRC WFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWA VLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGI corresponding to amino acids 1 - 158 of BAC85244, which also corresponds to amino acids 1 - 158 of Z25377_PEA_1 P12. 15 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because although both signal 20 peptide prediction programs agree that this protein has a signal peptide, both trans-membrane region prediction programs predict that this protein has a trans-membrane region downstream of this signal peptide. Variant protein Z25377_PEA_1_P12 also has the following non-silent SNPs (Single 25 Nucleotide Polymorphisms) as listed in Table 4, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377_PEA_1 P12 sequence provides support for the deduced sequence of this variant protein according to the present invention). 30 Table 4 - Amino acid mutations WO 2005/069724 PCT/IB2005/001306 354 SNP position(s) on am ino acid Alternative amino acid(s) Previously known SNP? sequence 157 G ->E No Variant protein Z25377_PEA_1 PI2 is encoded by the following transcript(s): Z25377_PEAIT1 1, for which the sequence(s) is/are given at the end of the application. The 5 coding portion of transcript Z25377_PEA 1_TI I i shown in bold; this coding portion starts at position 188 and ends at position 661. The transcript also has the following SNPs as listed in Table 5 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377_PEA 1 P12 sequence provides support for the deduced 10 sequence of this variant protein according to the present invention). Table 5 - Nucleic acid SNPs 71 T-> C Yes 99 T -> Yes 657 G -> A No 933 T-> No 935 T-> A No Variant protein Z25377_PEA 1_P13 according to the present invention has an amino acid 15 sequence as given at the end of the application; it is encoded by transcript(s) Z25377_PEA 1 T12. An alignment is given to the known protein (Hypothetical protein FLJ26352) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein 20 is as follows: WO 2005/069724 PCT/IB2005/001306 355 Comparison report between Z25377_PEA_1 P13 and BAC85244: 1.An isolated chimeric polypeptide encoding for Z25377 PEA_1_P13, comprising a first amino acid sequence being at least 90 % homologous to 5 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRC WFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWA VLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAA corresponding to amino acids 1 156 of BAC85244, which also corresponds to amino acids I - 156 of Z25377_PEA_1 P13, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 10 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSVGQECGSG corresponding to amino acids 157 - 166 of Z25377_PEA_1_P13, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z25377_PEA 1 P13, comprising a 15 polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in Z25377_PEA_1_P13. The location of the variant protein was determined according to results from a number of 20 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because although both signal peptide prediction programs agree that this pmrotein has a signal peptide, both trans-membrane region prediction programs predict that this protein has a trans-membrane region downstream of 25 this signal peptide. Variant protein Z25377_PEA 1_P13 is encoded by the following transcript(s): Z25377_PEA _1T12, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA_1_T12 is shown in bold; this coding portion starts at 30 position 188 and ends at position 685. The transcript also has the following SNPs as listed in Table 6 (given according to their position on the nucleotide sequence, with the alternative WO 2005/069724 PCT/IB2005/001306 356 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377 PEA_1 P13 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 6 - Nucleic acid SNPs SNP position on nucleotide Alternativ nucleic acid Previously known SNP9 sequence, 71 T-> C Yes 99 T-> Yes 5 Variant protein Z25377_PEA 1_P14 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z25377_PEA_1_T13. An alignment is given to the known protein (Hypothetical protein 10 FLJ26352) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 15 Comparison report between Z25377_PEA 1 P14 and BAC85244: I.An isolated chimeric polypeptide encoding for Z25377_PEA_1 P14, comprising a first amino acid sequence being at least 90 % homologous to MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRC WFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWA 20 VLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAA corresponding to amino acids 1 156 of BAC85244, which also corresponds to amino acids 1 - 156 of Z25377_PEA_1 P14, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence 25 DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY corresponding to amino acids 157 - 210 of Z25377_PEA 1_P14, wherein said first amino acid WO 2005/069724 PCT/IB2005/001306 357 sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z25377_PEA 1 P14, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 5 sequence DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY in Z25377_PEA_1 P14. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 10 programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because although both signal peptide prediction programs agree that this protein has a signal peptide, both trans-membrane region prediction programs predict that this protein has a trans-membrane region downstream of this signal peptide. 15 Variant protein Z25377_PEA 1_P14 is encoded by the following transcript(s): Z25377_PEA 1_T13, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA_1_T13 is shown in bold; this coding portion starts at position 188 and ends at position 817. The transcript also has the following SNPs as listed in 20 Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377_PEA_1_P14 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 7 - Nucleic acid SNPs 71 T -> C Yes 99 T -> Yes 823 T-> No 825 T -> A No WO 2005/069724 PCT/IB2005/001306 358 Variant protein Z25377_PEA_1_P15 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 Z25377_PEA_1_T1. An alignment is given to the known protein (Hypothetical protein FLJ26352) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between Z25377_PEA_1_P15 and Q96NR4 (SEQ ID NO:342): 1.An isolated chimeric polypeptide encoding for Z25377_PEA_1_P15, comprising a first amino acid sequence being at least 90 % homologous to MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIA 15 A corresponding to amino acids 1 - 60 of Q96NR4, which also corresponds to amino acids 1 60 of Z25377_PEA_1 P15, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY 20 corresponding to amino acids 61 - 114 of Z25377_PEA_1 P15, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z25377_PEA 1 P15, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 25 sequence DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY in Z25377 PEA 1 P15. Comparison report between Z25377_PEA_1_P15 and BAC85244: 1.An isolated chimeric polypeptide encoding for Z25377_PEA_1_P15, comprising a first 30 amino acid sequence being at least 90 % homologous to

MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIA

WO 2005/069724 PCT/IB2005/001306 359 A corresponding to amino acids 97 - 156 of BAC85244, which also corresponds to amino acids 1 - 60 of Z25377_PEA 1_PI5, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence 5 DGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY corresponding to amino acids 61 - 114 of Z25377_PEA_1_P15, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z25377_PEA 1 P15, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 10 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DGISSLCYSSLSKSLLSQPLRETSSA1NDISLLQALMPLLGWTSHWTCITVGLY inZ25377 PEA 1 P15. The location of the variant protein was determined according to results from a number of 15 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because the Signalphmm software predicts that this protein has a signal anchor region. 20 Variant protein Z25377_PEA_1_P15 is encoded by the following transcript(s): Z25377_PEA_1_T1, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA_1_T1 is shown in bold; this coding portion starts at position 261 and ends at position 602. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative 25 nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377_PEA_1_P 15 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Nucleic acid SNPs WO 2005/069724 PCT/IB2005/001306 360 608 T-> No 610 T->A No Variant protein Z25377_PEA_1_P17 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 Z25377_PEAIT5. An alignment is given to the known protein (Hypothetical protein FLJ26352) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between Z25377_PEA_1_PI7 and Q96NR4: 1.An isolated chimeric polypeptide encoding for Z25377_PEA_1_P17, comprising a first amino acid sequence being at least 90 % homologous to MRGEHNSTSYDSAV corresponding to amino acids 1 - 14 of Q96NR4, which also corresponds to amino acids 1 - 14 of 15 Z25377_PEA_1_P17, a second amino acid sequence bridging amino acid sequence comprising of S, and a third amino acid sequence being at least 90 % homologous to ILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAG LLFLVVGRHIQIHH corresponding to amino acids 62 - 133 of Q96NR4, which also corresponds to amino acids 16 - 87 of Z25377_PEA_1 P17, wherein said first amino acid 20 sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for an edge portion of Z25377_PEAI_P17, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino 25 acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise VSI having a structure as follows (numbering according to Z25377_PEA_1_P17): a sequence starting from any of amino acid numbers 14-x to 14; and ending at any of amino acid numbers 16 + ((n-2) x), in which x varies from 0 to n-2.

WO 2005/069724 PCT/IB2005/001306 361 Comparison report between Z25377_PEA_1 _P17 and Q8WW45 (SEQ ID NO:343): l.An isolated chimeric polypeptide encoding for Z25377_PEA 1_P17, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more 5 preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MRGEHNSTSYDSAVS corresponding to amino acids 1 - 15 of Z25377_PEA_1_P17, and a second amino acid sequence being at least 90 % homologous to ILFSLVVMLYV1WVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAG LLFLVVGRHIQIHH corresponding to amino acids 39 - 110 of Q8WW45, which also 10 corresponds to amino acids 16 - 87 of Z25377_PEA_1 PI7, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of Z25377 PEA_1 P17, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 15 sequence MRGEHNSTSYDSAVS of Z25377_PEA_1_P17. Comparison report between Z25377_PEA 1_P17 and BAC85244: 1.An isolated chimeric polypeptide encoding for Z25377_PEA_1 P17, comprising a first amino acid sequence being at least 90 % homologous to MRGEITHNSTSYDS AV corresponding 20 to amino acids 97 - 110 of BAC85244, which also corresponds to amino acids 1 - 14 of Z25377_PEA_1_P17, a second amino acid sequence bridging amino acid sequence comprising of S, and a third amino acid sequence being at least 90 % homologous to ILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAG LLFLVVGRHIQIHH corresponding to amino acids 158 - 229 of BAC85244, which also 25 corresponds to amino acids 16 - 87 of Z25377_PEA_1 P17, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for an edge portion of Z25377_PEA_1_P17, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in 30 length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at WO 2005/069724 PCT/IB2005/001306 362 least about 50 amino acids in length, wherein at least two amino acids comprise VSI having a structure as follows (numbering according to Z25377_PEA 1_P17): a sequence starting from any of amino acid numbers 14-x to 14; and ending at any of amino acid numbers 16 + ((n-2) - x), in which x varies from 0 to n-2. 5 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because although it is a partial 10 protein, because both trans-membrane region prediction programs predict that this protein has a trans- membrane region. Variant protein Z25377_PEA 1 P17 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the 15 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or mrt; the presence of known SNPs in variant protein Z25377_PEA 1_P17 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 9- Amino acid mutations 81 R -> W Yes 20 Variant protein Z25377_PEA_1 P17 is encoded by the following transcript(s): Z25377_PEA__T5, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA 1 T5 is shown in bold; this coding portion starts at 25 position 261 and ends at position 521. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of WO 2005/069724 PCT/IB2005/001306 363 known SNPs in variant protein Z25377_PEA 1 P 17 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 10 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Previously known SNP? ~sequenceI 501 C -> T Yes 1415 T-> C Yes 1434 A -> G Yes 1822 C ->T Yes 1884 G ->A Yes 2392 C -> G Yes 2454 T ->C No 2618 C->T Yes 2724 T-> A Yes 5 Variant protein Z25377_PEA_1 P 8 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z25377_PEAlT7. An alignment is given to the known protein (Hypothetical protein FLJ26352) at the end of the application. One or more alignments to one or more previously 10 published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between Z25377_PEA_1 P18 and Q96NR4: 15 1.An isolated chimeric polypeptide encoding for Z25377_PEA_1_P18, comprising a first amino acid sequence being at least 90 % homologous to MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIA AGI corresponding to amino acids 1 - 62 of Q96NR4, which also corresponds to amino acids 1 62 ofZ25377 PEA 1 P18.

WO 2005/069724 PCT/IB2005/001306 364 Comparison report between Z25377_PEA 1_P18 and Q8WW45: I.An isolated chimeric polypeptide encoding for Z25377_PEA_1 P18, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more 5 preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MRGEHNSTSYDSAVIYRGFWAVL corresponding to amino acids 1 - 23 of Z25377_PEA 1 P18, and a second amino acid sequence being at least 90 % homologous to MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGI corresponding to amino acids 1 39 of Q8WW45, which also corresponds to amino acids 24 - 62 of Z25377_PEA_1 P18, 10 wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of Z25377_PEA_1 P18, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 15 sequence MRGEHNSTSYDSAVIYRGFWAVL of Z25377_PEA_1_P18. Comparison report between Z25377_PEAlP18 and BAC85244: 1.An isolated chimeric polypeptide encoding for Z25377_PEA 1_PI8, comprising a first amino acid sequence being at least 90 % homologous to 20 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIA AGI corresponding to amino acids 97 - 158 of BAC85244, which also corresponds to amino acids 1 - 62 of Z25377 PEA 1 P18. The location of the variant protein was determined according to results from a number of 25 different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because the Signalp_hmm software predicts that this protein has a signal anchor region. 30 Variant pmrotein Z25377_PEA_1_P18 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the WO 2005/069724 PCT/IB2005/001306 365 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377_PEA 1_PI8 sequence provides support for the deduced sequence of this variant protein according to the present invention). 5 Table 11 - Amino acid mutations SNP positions) Mon amino acid Alternative amino acd(s) P reiousl yJown SNP sequence 61 G->E No Variant protein Z25377_PEA_1 P18 is encoded by the following transcript(s): Z25377_PEA _1 T7, for which the sequence(s) is/are given at the end of the application. The 10 coding portion of transcript Z25377_PEA_1 T7 is shown in bold; this coding portion starts at position 261 and ends at position 446. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377_PEA_1_P18 sequence provides support for the deduced 15 sequence of this variant protein according to the present invention). Table 12 - Nucleic acid SNPs 442 G -> A No 718 T -> No 720 T -> A No Variant protein Z25377_PEA_1_P19 according to the present invention has an amino acid 20 sequence as given at the end of the application; it is encoded by transcript(s) Z25377_PEA_1_T8. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP WO 2005/069724 PCT/IB2005/001306 366 and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this 5 protein is a non-secreted protein. Variant protein Z25377_PEA_1 P19 is encoded by the following transcript(s): Z25377_PEAlT8, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA _ T8 is shown in bold; this coding portion starts at 10 position 127 and ends at position 261. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z25377 PEAI_P19 sequence provides support for the deduced sequence of this variant protein according to the present invention). 15 Table 13 - Nucleic acid SNPs SNE, .stonor nucle2otide* Alternative'nuclc aicid Prev WIosiv known SN .k;)" 354 C -> T Yes 508 A -> G Yes Variant protein Z25377_PEA_1_P20 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 20 Z25377_PEAlT9. An alignment is given to the known protein (Hypothetical protein FLJ26352) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 25 Comparison report between Z25377_PEA_1_P20 and Q96NR4: WO 2005/069724 PCT/IB2005/001306 367 l.An isolated chimeric polypeptide encoding for Z25377_PEA 1 P20, comprising a first amino acid sequence being at least 90 % homologous to MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIA A corresponding to amino acids 1 - 60 of Q96NR4, which also corresponds to amino acids I 5 60 of Z25377_PEA_1 P20, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSVGQECGSG corresponding to amino acids 61 - 70 of Z25377_PEA_1_P20, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 10 2.An isolated polypeptide encoding for a tail of Z25377_PEA_I_ P20, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in Z25377_PEA_1 P20. 15 Comparison report between Z25377_PEA_1 P20 and Q8WW45: I.An isolated chimeric polypeptide encoding for Z25377_PEA 1_P20, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MRGEHNSTSYDSAVIYRGFWAVL corresponding to amino acids 1 - 23 of 20 Z25377_PEA_1 P20, a second amino acid sequence being at least 90 % homologous to MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAA corresponding to amino acids 1 - 37 of Q8WW45, which also corresponds to amino acids 24 - 60 of Z25377 PEA_1_ P20, and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide 25 having the sequence VSVGQECGSG corresponding to amino acids 61 - 70 of Z25377_PEA lP20, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of Z25377_PEA_1 P20, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 30 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MRGEHNSTSYDSAVIYRGFWAVL of Z25377_PEA_1_P20.

WO 2005/069724 PCT/IB2005/001306 368 3.An isolated polypeptide encoding for a tail of Z25377_PEA I P20, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in Z25377_PEAlP20. 5 Comparison report between Z25377_PEA 1_P20 and BAC85244: I.An isolated chimeric polypeptide encoding for Z25377_PEA_1_P20, comprising a first amino acid sequence being at least 90 % homologous to MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIA 10 A corresponding to amino acids 97 - 156 of BAC85244, which also corresponds to amino acids 1 - 60 of Z25377_PEA_1 P20, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSVGQECGSG corresponding to amino acids 61 - 70 ofZ25377_PEAlP20, wherein said first amino acid sequence and second 15 amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of Z25377_PEA_1 P20, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSVGQECGSG in Z25377_PEA_1_P20. 20 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because the Signalp_hmm 25 software predicts that this protein has a signal anchor region. Variant protein Z25377_PEA 1_P20 is encoded by the following transcript(s): Z25377_PEA_1 T9, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA 1 T9 is shown in bold; this coding portion starts at position 261 and ends at position 470. 30 Variant protein Z25377_PEA _1_P21 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) WO 2005/069724 PCT/IB2005/001306 369 Z25377_PEA 1 TIO. The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly 5 because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein Z25377 PEA_1_P21 is encoded by the following transcript(s): 10 Z25377_PEA 1_TIO, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z25377_PEA_1 T10 is shown in bold; this coding portion starts at position 261 and ends at position 464. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of 15 known SNPs in variant protein Z25377 PEA_1_P21 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 14 - Nucleic acid SNPs 470 T -> No 472 T-> A No 20 As noted above, cluster Z25377 features 12 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. 25 Segment cluster Z25377_PEA_1 node_5 according to the present invention is supported WO 2005/069724 PCT/IB2005/001306 370 by I libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA_I_Tll, Z25377_PEA_I_T1TI2 and Z25377_PEAI _T13. Table 15 below describes the starting and ending position of this segment on each transcript. 5 Table 15 - Segment location on transcripts Transcript name Segment Segment starting ositin digpsion Z25377 PEA 1 TI1 1 319 Z25377 PEA 1 T12 1 319 Z25377 PEA 1 T13 1 319 Segment cluster Z25377_PEA 1 node_12 according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment 10 can be found in the following transcript(s): Z25377_PEA_1_T8. Table 16 below describes the starting and ending position of this segment on each transcript. Table 16 - Segment location on transcripts 40 Z25377 PEA 1 T8 304 708 15 Segment cluster Z25377_PEA_1_node_15 according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA 1_T1, Z25377 PEA_1_T7, Z25377_PEA_1_T9, Z25377_PEA_1_TIl, Z25377_PEA_1_T12 and Z25377_PEA 1_T13. Table 17 below describes the starting and ending position of this segment on each transcript. 20 Table 17 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 371 Transit t name Segment Segm .. ent - starting position ending position . Z25377_PEA 1 TI 304 441 Z25377_PEA 1 T7 304 441 Z25377 PEA 1 T9 304 441 Z25377 PEA 1 T11 519 656 Z25377 PEA 1 TI2 519 656 Z25377 PEA 1 T13 519 656 Segment cluster Z25377_PEA 1_ node_1 7 according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This segment 5 can be found in the following transcript(s): Z25377_PEAlT5. Table 18 below describes the starting and ending position of this segment on each transcript. Table 18 - Segment location on transcripts S Arm oltn n gS ~ 1 Z25377_PEA_1_T5 304 491 10 Segment cluster Z25377_PEA_1_node_1 8 according to the present invention is supported by 55 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA_1_T5. Table 19 below describes the starting and ending position of this segment on each transcript. Table 19 - Segment location on transcripts Z253771PEA 1_T5 492 3969 15 WO 2005/069724 PCT/IB2005/001306 372 Segment cluster Z25377_PEA_1 node_22 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA 1 TI, Z25377_PEA _I_T7, 5 Z25377 PEA_1 T10, Z25377_PEA 1 Tll and Z25377 PEA_1 T13. Table 20 below describes the starting and ending position of this segment on each transcript. Table 20 - Segment location on transcripts Transcipt name - __ ISegmnSegmnlt starting position C . ndin g position Z25377 PEA 1 TI 442 868 Z25377 PEA 1 T7 552 978 Z25377 PEA 1 TI0 304 730 Z25377 PEA 1 TIl1 767 1193 Z25377 PEA 1 T13 657 1083 10 Segment cluster Z25377_PEA 1_node_24 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA_1_T9 and Z25377_PEA_1_T12. Table 21 below describes the starting and ending position of this segment on each transcript. Table 21 - Segment location on transcripts Z25377_PEA 1 T9 442 783 Z25377_PEA 1 TI2 657 998 15 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.

WO 2005/069724 PCT/IB2005/001306 373 Segment cluster Z25377_PEA_ I _node_0 according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEAI_ 1 TI, Z25377_PEA_I _T5, 5 Z25377_PEA_1 T7, Z25377_PEA_I_T8, Z25377_PEAIT9 and Z25377_PEA 1 TI0. Table 22 below describes the starting and ending position of this segment on each transcript. Table 22 - Segment location on transcripts Transcript name Segment1 ,Segment startmg posItion ending position Z25377 PEA 1 TI 1 104 Z25377 PEA 1 T5 1 104 Z25377 PEA 1 T7 1 104 Z25377 PEA 1 T8 1 104 Z25377 PEA 1 T9 1 104 Z25377 PEA 1 TI0 1 104 10 Segment cluster Z25377_PEA_1 node_7 according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA_1_T1, Z25377_PEA 1 T5, Z25377_PEA 1 T7, Z25377_PEAlT8, Z25377_PEA 1_T9, Z25377_PEA_1_TIO, Z25377 PEA 1 Tll, Z25377 PEA 1 TI2 and Z25377 PEA 1 T13. Table 23 below 15 describes the starting and ending position of this segment on each transcript. Table 23 - Segment location on transcripts Z25377 PEA 1 TI 105 199 Z25377 PEA 1 T5 105 199 Z25377 PEA 1 T7 105 199 WO 2005/069724 PCT/IB2005/001306 374 Z25377 PEA 1 T8 105 199 Z25377 PEA 1 T9 105 199 Z25377 PEA 1 T10 105 199 Z25377 PEA 1 TI1 320 414 Z25377 PEA 1 TI2 320 414 Z25377 PEA 1 T13 320 414 Segment cluster Z25377_PEA 1 node_8 according to the present invention can be found in the following transcript(s): Z25377_PEA_1 TI, Z25377_PEA 1_T5, Z25377_PEA_1 T7, 5 Z25377 PEAIT8, Z25377 PEA _1T9, Z25377_PEA_1_T10, Z25377_PEAITI1l, Z25377_PEA_1_TI2 and Z25377_PEA_1_T13. Table 24 below describes the starting and ending position of this segment on each transcript. Table 24 - Segment location on transcripts 'Ir ts nItralc I I I! Z25377_PEA_1 T1 200 204 Z25377 PEA 1 T5 200 204 Z25377 PEA 1 T7 200 204 Z25377 PEA 1 T8 200 204 Z25377 PEA 1 T9 200 204 Z25377 PEA 1 T10 200 204 Z25377 PEA 1 Tll1 415 419 Z25377 PEA 1 T12 415 419 Z25377_PEA 1_T13 415 419 10 Segment cluster Z25377_PEA_1_node_10 according to the present invention is supported by 20 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA_1 T1, Z25377_PEA_1_T5, WO 2005/069724 PCT/IB2005/001306 375 Z25377 PEA 1 T7 Z25377_PEA 1 T8, Z25377 PEA 1 T9, Z25377_PEA I _T0, Z25377_PEA 1 TI1, Z25377_PEA_1 TI2 and Z25377_PEA_1 _T13. Table 25 below describes the starting and ending position of this segment on each transcript. Table 25 - Segment location on transcripts Transcript dxnae Segment Segment starting position ending position Z25377 PEA 1 TI 205 303 Z25377 PEA 1 T5 205 303 Z25377 PEA 1 T7 205 303 Z25377 PEA 1 T8 205 303 Z25377 PEA 1 T9 205 303 Z25377 PEA 1 T10 205 303 Z25377 PEA 1 TIl1 420 518 Z25377 PEA 1 T12 420 518 Z25377 PEA 1 TI3 420 518 5 Segment cluster Z25377_PEA 1 node_20 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z25377_PEA_1 _T7 and Z25377_PEA_1 TI 1. 10 Table 26 below describes the starting and ending position of this segment on each transcript. Table 26 - Segment location on transcripts Z25377 PEA1 T7 442 551 Z25377"PEA 1 TI1 657 766 Variant protein alignment to the previously known protein: WO 2005/069724 PCT/IB2005/001306 376 Sequence name: BAC85244 Sequence documentation: 5 Alignment of: Z25377 PEA 1 P12 x BAC85244 Alignment segment 1/1: Quality: 1575.00 Escore: 0 10 Matching length: 158 Total length: 158 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 15 Alignment: 1 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTF 50 IllIlllllll[lllIllIlllllillIIl11111lllllllllll 1 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTF 50 20 51 HHEGFFWRCWFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGE 100 1 1 1 1 1 1 1 1 1l l l l l l i l l l l llI l l l l l l l l l l i 1 1 1 1 1 1 l l l l l 51 HHEGFFWRCWFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGE 100 25 101 HNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGG 150 IllllllllIllllllIllllIIIllllllllllllIIIlIII I 101 HNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGG 150 151 GSYIAAGI 158 30 Il11111111 151 GSYIAAGI 158 Sequence name: BAC85244 35 Sequence documentation: Alignment of: Z25377 PEA 1 P13 x BAC85244 WO 2005/069724 PCT/IB2005/001306 377 Alignment segment 1/1: Quality: 1558.00 Escore: 0 5 Matching length: 156 Total length: 156 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 10 Alignment: 1 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTF 50 illIll11111111111111111111111111 11111111llll ll l l 1 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTF 50 15 51 HHEGFFWRCWFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGE 100 l ll l i l l 1 1 1 1 l 1 1 l l ll I l l l l lll l l l l lI l I l i l l l i ll 51 HHEGFFWRCWFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGE 100 20 101 HNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGG 150 IllllllllllllllllllllllilllllIllllllll[Illlll 101 HNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGG 150 151 GSYIAA 156 25 111111 151 GSYIAA 156 Sequence name: BAC85244 30 Sequence documentation: Alignment of: Z25377 PEA 1 P14 x BAC85244 Alignment segment 1/1: 35 Quality: 1559.00 Escore: 0 Matching length: 162 Total length: 162 Matching Percent Similarity: 98.15 Matching Percent Identity: 97.53 WO 2005/069724 PCT/IB2005/001306 378 Total Percent Similarity: 98.15 Total Percent Identity: 97.53 Gaps: 0 Alignment: 5 1 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTF 50 111l111111111 lilill111111 l I 111111 111111 1 1111 1 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTF 50 10 51 HHEGFFWRCWFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGE 100 Ililllllllilll11llllllllillllilllllillilllIllill 51 HHEGFFWRCWFNGIVEENDSNIWKFWYTNQPPSKNCTHAYLSPYPFMRGE 100 101 HNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGG 150 15 l 11111111llll 111111111l l llll1111 11111 l 111111 101 HNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGG 150 151 GSYIAADGISSL 162 111111 : II 20 151 GSYIAAGILFSL 162 Sequence name: Q96NR4 Sequence documentation: 25 Alignment of: Z25377 PEA 1 P15 x Q96NR4 Alignment segment 1/1: 30 Quality: 572.00 Escore: 0 Matching length: 66 Total length: 66 Matching Percent Similarity: 95.45 Matching Percent Identity: 93.94 Total Percent Similarity: 95.45 Total Percent Identity: 93.94 Gaps: 0 35 Alignment: 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 WO 2005/069724 PCT/IB2005/001306 379 I l l lil l l li I l l l l l l l l l l li l l il l l l l ll[l l l l lli l l 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 51 KAGGGSYIAADGISSL 66 5 1 1 1 1 1 1 1 1 1 1 : 1 1 51 KAGGGSYIAAGILFSL 66 Sequence name: BAC85244 10 Sequence documentation: Alignment of: Z25377 PEA 1 P15 x BAC85244 Alignment segment 1/1: 15 Quality: 572.00 Escore: 0 Matching length: 66 Total length: 66 Matching Percent Similarity: 95.45 Matching Percent Identity: 93.94 Total Percent Similarity: 95.45 Total Percent Identity: 93.94 20 Gaps: 0 Alignment: 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 2 5 l l l l lFFll l l lFll l l l l l I l l l l l l l l l ll l l l l l l I Il l 97 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 146 51 KAGGGSYIAADGISSL 66 il l l l l l l l l : 1 1 30 147 KAGGGSYIAAGILFSL 162 Sequence name: Q96NR4 Sequence documentation: 35 Alignment of: Z25377 PEA 1 P17 x Q96NR4 Alignment segment 1/1: WO 2005/069724 PCT/IB2005/001306 380 Quality: 744.00 Escore: 0 Matching length: 87 Total length: 133 Matching Percent Similarity: 98.85 Matching Percent Identity: 98.85 5 Total Percent Similarity: 64.66 Total Percent Identity: 64.66 Gaps: 1 Alignment: 10 1 MRGEHNSTSYDSAV....................... .. ........... 14 liliIIllll 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 15 .......... SILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVL 54 1 5 li l lI l l1 l l i l l l lll l l l l i l l l l l l l ll 1 1 1 l 51 KAGGGSYIAAGILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVL 100 55 YGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH 87 IlllIilllllllllllllIlllilllllll1 20 101 YGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH 133 Sequence name: Q8WW45 Sequence documentation: 25 Alignment of: Z25377 PEA 1 P17 x Q8WW45 Alignment segment 1/1: 30 Quality: 711.00 Escore: 0 Matching length: 75 Total length: 75 Matching Percent Similarity: 97.33 Matching Percent Identity: 97.33 Total Percent Similarity: 97.33 Total Percent Identity: 97.33 Gaps: 0 35 Alignment: 13 AVSILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLA 62 WO 2005/069724 PCT/IB2005/001306 381 I I lI l l ll l l l l l l l l l l ll l l l l l1 lll l l l l l l l l l 36 AAGILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLA 85 63 PAGIFFSLLAGLLFLVVGRHIQIHH 87 5 li l li l l li l l l l l l l I l l l 86 PAGIFFSLLAGLLFLVVGRHIQIHH 110 Sequence name: BAC85244 10 Sequence documentation: Alignment of: Z25377 PEA 1 P17 x BAC85244 Alignment segment 1/i: 15 Quality: 744.00 Escore: 0 Matching length: 87 Total length: 133 Matching Percent Similarity: 98.85 Matching Percent Identity: 98.85 Total Percent Similarity: 64.66 Total Percent Identity: 64.66 20 Gaps: 1 Alignment: 1 MRGEHNSTSYDSAV .................................... 14 2 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 97 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 146 15 .......... SILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVL 54 I l I lI l l l l l l II I I I l l l l l l l II l lI I l l 30 147 KAGGGSYIAAGILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVL 196 55 YGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH 87 IlllllillllllllilllllIllllllllll 197 YGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH 229 35 Sequence name: Q96NR4 Sequence documentation: WO 2005/069724 PCT/IB2005/001306 382 Alignment of: Z25377 PEA 1 P18 x Q96NR4 Alignment segment 1/1: 5 Quality: 588.00 Escore: 0 Matching length: 62 Total length: 62 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 10 Gaps: 0 Alignment: 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 15 I iil l l i111 li 1 I IIl11 111 11i l i i lii i l l l lli li l li 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 51 KAGGGSYIAAGI 62 lIl111111I l 20 51 KAGGGSYIAAGI 62 Sequence name: Q8WW45 Sequence documentation: 25 Alignment of: Z25377 PEA 1 P18 x Q8WW45 Alignment segment 1/1: 30 Quality: 358.00 Escore: 0 Matching length: 39 Total length: 39 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 35 Alignment: 24 MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGI 62 WO 2005/069724 PCT/IB2005/001306 383 lIIlllllllllllllllillllllllllllll[I 1 MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGI 39 Sequence name: BAC85244 5 Sequence documentation: Alignment of: Z25377 PEA 1 P18 x BAC85244 10 Alignment segment 1/1: Quality: 588.00 Escore: 0 Matching length: 62 Total length: 62 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 15 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 20 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 IllllllllilIllllllllllllIlllilllllllIll11111 97 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 146 51 KAGGGSYIAAGI 62 2 5 1 1 1 1 1 1 1 1 1 1 1 1 147 KAGGGSYIAAGI 158 Sequence name: Q96NR4 30 Sequence documentation: Alignment of: Z25377 PEA 1 P20 x Q96NR4 Alignment segment 1/1: 35 Quality: 571.00 Escore: 0 Matching length: 60 Total length: 60 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 WO 2005/069724 PCT/IB2005/001306 384 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 5 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 I Il l ll l l l l l i l l l l l l l l l I1 1 1 1 1 l i l l l l l ll l l l I i l l 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 10 51 KAGGGSYIAA 60 lIIII III 51 KAGGGSYIAA 60 Sequence name: Q8WW45 15 Sequence documentation: Alignment of: Z25377 PEA 1 P20 x Q8WW45 20 Alignment segment 1/1: Quality: 341.00 Escore: 0 Matching length: 37 Total length: 37 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 25 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 30 24 MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAA 60 lIIlI lllllilllillllllIIllIllllIll 1 MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAA 37 Sequence name: BAC85244 35 Sequence documentation: Alignment of: Z25377 PEA 1 P20 x BAC85244 .

WO 2005/069724 PCT/IB2005/001306 385 Alignment segment 1/1: Quality: 571.00 Escore: 0 5 Matching length: 60 Total length: 60 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 10 Alignment: 1 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 50 I ll l I ll lI l l li lll l l l I l l 11111 111111 l l l l l l l l l 111 97 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLY 146 15 51 KAGGGSYIAA 60 11111 ll II 147 KAGGGSYIAA 156 20 DESCRIPTION FOR CLUSTER HSACMHCP Cluster HSACMHCP features 10 transcript(s) and 65 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3. Table 1 - Transcripts of interest HSACMHCP PEA 1 T2 51 HSACMHCPPEA 1 T3 52 HSACMHCPPEAIT4 53 HSACMHCPPEA_1 T6 54 HSACMHCP PEA 1 T7 55 HSACMHCP PEA 1 T8 56 HSACMHCP PEA 1 T13 57 HSACMHCP PEA_1_T14 58 WO 2005/069724 PCT/IB2005/001306 386 SHSACMHCP PEA 1 TI7 59 HSACMHCP PEA 1 T26 60 Table 2 - Segments of interest SgmentName Seq ID No. HSACMHCP PEA 1 node 2 209 HSACMHCP PEA 1 node 20 210 HSACMHCP PEA 1 node 22 211 HSACMHCP PEA 1 node 25 212 HSACMHCP PEA 1 node 43 213 HSACMHCP PEA 1 node 45 214 HSACMHCP PEA 1 node 46 215 HSACMHCP PEA 1 node 48 216 HSACMHCP PEA 1 node 49 217 HSACMHCP PEA 1 node 57 218 HSACMHCP PEA 1 node 59 219 HSACMHCP PEA 1 node 61 220 HSACMHCP PEA 1 node 63 221 HSACMHCP PEA 1 node 65 222 HSACMHCP PEA 1 node 67 223 HSACMHCP PEA 1 node 71 224 HSACMHCP PEA_1_node_81 225 HSACMHCP PEA 1 node 87 226 HSACMHCP PEA 1 node 89 227 HSACMHCP PEA 1_node_96 228 HSACMHCP PEA 1 node 97 229 HSACMHCP PEA 1 node 100 230 HSACMHCPPEA_1 node_105 231 HSACMHCP PEA 1 node 106 232 WO 2005/069724 PCT/IB2005/001306 387 HSACMHCP PEA 1 node 107 233 HSACMHCP PEA_1 Inode 108 234 HSACMHCP PEA I node 111 235 HSACMHCP PEA 1 node 113 236 HSACMHCP PEA_1 node 0 237 HSACMHCP PEA 1 node 3 238 HSACMHCP PEA 1 node_4 239 HSACMHCP PEA 1_node 16 240 HSACMHCP PEA 1 node_18 241 HSACMHCPPEA 1 node 23 242 HSACMHCP PEA 1 node 27 243 HSACMHCP PEA 1 node 29 244 HSACMHCP PEA 1 node_31 245 HSACMHCPPEA 1 node_33 246 HSACMHCP PEA 1 node_35 247 HSACMHCP PEA _node_37 248 HSACMHCP PEA _ node_39 249 HSACMHCP PEA 1 node 40 250 HSACMHCPPEA 1 node_51 251 HSACMHCP PEA 1 node_53 252 HSACMHCP PEA 1 node 55 253 HSACMHCPPEA_1 node_69 254 HSACMHCP PEA 1 node 72 255 HSACMHCPPEA_1 node_73 256 HSACMHCPPEA_1_node 74 257 HSACMHCPPEA 1 node 77 258 HSACMHCPPEA 1 node_78 259 HSACMHCP PEA 1 node 80 260 HSACMHCP PEA 1 node 82 261 HSACMHCP PEA 1 node 83 262 WO 2005/069724 PCT/IB2005/001306 388 HSACMHCP PEA I node 84 263 HSACMHCP PEA 1 node 85 264 HSACMHCP PEA_1 node 90 265 HSACMHCP PEA 1 node 91 266 HSACMHCP PEA 1 node 92 267 HSACMHCP PEA 1 node 93 268 HSACMHCP PEA 1 node 95 269 HSACMHCP PEA _ node_98 270 HSACMHCP PEA 1 node 103 271 HSACMHCP PEA 1 node 104 272 HSACMHCP PEA_ lnode_109 273 Table 3 - Proteins of interest Pl'te Ni 'Seq 11) No. ~CdfrtesjpOndmrg -rta p~ HSACMHCPPEA 1_P2 326 HSACMHCPPEA_I_T2; HSACMHCP PEA 1 T6 HSACMHCP PEA 1_P3 327 HSACMHCP PEA 1 T3 HSACMHCP PEA 1 P4 328 HSACMHCP PEA 1 T4 HSACMHCP PEA 1 P6 329 HSACMHCPPEA 1 T7 HSACMHCPPEA 1 P12 330 HSACMHCP PEA 1 T13 HSACMHCP PEA 1_ P16 331 HSACMHCPPEA_1 T17 HSACMHCP PEA 1 P25 332 HSACMHCP PEA 1 T26 HSACMHCP PEA 1 P28 333 HSACMHCPPEA_1 T8 HSACMHCPPEA_1_P29 334 HSACMHCPPEA 1 T14 These sequences are variants of the known protein Myosin heavy chain, cardiac muscle 5 alpha isoform (SwissProt accession identifier MYH6_HUMAN; known also according to the synonyms MyHC-alpha), referred to herein as the previously known protein. Protein Myosin heavy chain, cardiac muscle alpha isoform is known or believed to have WO 2005/069724 PCT/IB2005/001306 389 the following function(s): Muscle contraction. The sequence for protein Myosin heavy chain, cardiac muscle alpha isoform is given at the end of the application, as "Myosin heavy chain, cardiac muscle alpha isoform amino acid sequence" (SEQ ID NO:391). Known polymorphisms for this sequence are as shown in Table 4. 5 Table 4 - Amino acid mutations for Known Protein SNP position(s) on Comment amino acid sequence 88 Q->E 574 Q ->P 608 A -> G 744 T -> A 790 M -> I 1014 V -> A 1021 S -> T 1101 A -> V 1290 A -> S 1373 W -> C 1533 K ->N 1540 L->M 1577- 1578 KL -> NV 1705- 1706 EQ -> DR 1733 E -> D 1734 A -> S 1737 T-> S 1763 D -> H 1788 M -> I 1871 D->N 1882 R -> G 1890 Q -> R WO 2005/069724 PCT/IB2005/001306 390 1933 Missing Protein Myosin heavy chain, cardiac muscle alpha isoform localization is believed to be Thick filaments of the myofibrils. 5 The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: muscle contraction; striated muscle contraction; muscle development, which are annotation(s) related to Biological Process; microfilament motor; actin binding; calmodulin binding; ATP binding, which are annotation(s) related to Molecular Function; and muscle myosin; muscle thick filament; myosin, which are annotation(s) related to Cellular 10 Component. The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>. 15 The heart-selective diagnostic marker prediction engine provided the following results with regard to cluster HSACMHCP. Predictions were made for selective expression of transcripts of this cluster in heart tissue, according to the previously described methods. The numbers on the y-axis of Figure 30 refer to weighted expression of ESTs in each category, as "parts per million" (ratio of the expression of ESTs for a particular cluster to the expression of 20 all ESTs in that category, according to parts per million). Overall, the following results were obtained as shown with regard to the histogram in Figure 30, concerning the number of heart-specific clones in libraries/sequences; as well as with regard to the histogram in Figures 31-32, concerning the actual expression of oligonucleotides in various tissues, including heart. 25 This cluster was found to be selectively expressed in heart for the following reasons: in a comparison of the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in non-heart ESTs, which was found to be 24; the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 92.5; and fisher exact test P-values were computed both for library and 30 weighted clone counts to check that the counts are statistically significant, and were found to be WO 2005/069724 PCT/IB2005/001306 391 3.20E-47. One particularly important measure of specificity of expression of a cluster in heart tissue is the previously described comparison of the ratio of expression of the cluster in heart as opposed to muscle. This cluster was found to be specifically expressed in heart as opposed to 5 non-heart ESTs as described above. However, many proteins have been shown to be generally expressed at a higher level in both heart and muscle, which is less desirable. For this cluster, as described above, the ratio of expression of the cluster in heart specific ESTs to the overall expression of the cluster in muscle-specific ESTs which was found to be 24, which clearly supports specific expression in heart tissue. 10 As noted above, cluster HSACMHCP features 10 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Myosin heavy chain, cardiac muscle alpha isoform. A description of each variant protein according to the present invention is now provided. 15 Variant protein HSACMHCP_PEA_1_P2 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSACMHCP_PEA 1_T2. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief 20 description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between HSACMHCP_PEA_l_P2 and MYH6_HUMANVI: 1.An isolated chimeric polypeptide encoding for HSACMHCP_PEA_1 P2, comprising a 25 first amino acid sequence being at least 90 % homologous to MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYT YSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSI LITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGN 30 AKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNK

KPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYK

WO 2005/069724 PCT/IB2005/001306 392 LTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVG NEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGF EIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEK PMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGT 5 VDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKG SSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVL EGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGH TKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMREFKKIVERRDALLVIQWNIR AFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEK 10 MVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMN AELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKL TKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLE RAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKK LKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKR 15 EAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQT ENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDC DLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAALDKKQRNFDKILAE 20 WKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQ LGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIER KLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSH ANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELR AVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 25 RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIAL KGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQ corresponding to amino acids 1 - 1855 of MYH6_HUMAN_V1, which also corresponds to amino acids 1 1855 of HSACMHCPPEA_1_P2, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most 30 preferably at least 95% homologous to a polypeptide having the sequence VRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT corresponding to WO 2005/069724 PCT/IB2005/001306 393 amino acids 1856 - 1904 of HSACMHCPPEA_ _P2, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HISACMHCP_PEA__1 P2, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 5 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT in HSACMHCP PEA_1 P2. It should be noted that the known protein sequence (MYH6_HUMAN; SEQ ID NO:391) 10 has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for MYH6_HUMAN_V1 (SEQ ID NO:338). These changes were previously known to occur and are listed in the table below. Table 5 - Changes to MYH6_HUMAN_V1 89 conflict 1735 conflict 15 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the 20 trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein HSACMHCP_PEA 1_P2 is encoded by the following transcript(s): 25 HSACMHCPPEA_1_T2, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA l T2 is shown in bold; this coding portion WO 2005/069724 PCT/IB2005/001306 3914 starts at position 78 and ends at position 5789. The transcript also has the following SNPs as listed in Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_1P2 sequence provides support 5 for the deduced sequence of this variant protein according to the present invention). Table 6 - Nucleic acid SNPs SNI position on nucleotide Alternative nucldic acid c\ .. Previouisy known SNP? sequencej:_ 339 G ->C Yes 488 A ->G Yes 504 A-> C Yes 887 G-> A Yes 1204 C ->A Yes 1205 A ->C Yes 1232 G ->T No 1696 T-> G No 2424 C -> A Yes 2910 C -> T Yes 3379 C -> T Yes 3465 G-> A No 4066 C -> No 4088 G-> A Yes 4391 T-> C Yes 4394 T-> C Yes 4991 C ->T No 5057 C -> T Yes 5279 G ->T Yes 5282 T-> C Yes 5286 A-> T Yes WO 2005/069724 PCT/IB2005/001306 395 5336 C ->T Yes 5664 G -> A Yes 6141 C ->T Yes 7365 T-> C Yes 7432 G -> T Yes 7665 A->G Yes 8268 C -> G Yes 8468 G->A No 8491 G ->A Yes 8534 C -> T Yes Variant protein HSACMHCP_PEA_ I_ P3 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HSACMHCP_PEAlT3. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HSACMHCP_PEA_1_P3 and MYH6_HUMAN_V2: 1.An isolated chimeric polypeptide encoding for HSACMHCP_PEA_1 P3, comprising a first amino acid sequence being at least 90 % homologous to MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK 15 VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYT YSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSI LITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGN AKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNK KPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYK 20 LTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVG

NEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGF

WO 2005/069724 PCT/IB2005/001306 396 EIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEK PMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGT VDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKG SSFQTVSALHRENLNKLMTNLRTTIIPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVL 5 EGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGH TKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIR AFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEK MVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMN AELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKL 10 TKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLE RAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKK LKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKR EAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQT 15 ENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGK corresponding to amino acids 1 - 1326 of MYH6_HUMAN_V2, which also corresponds to amino acids 1 - 1326 of HSACMHCP PEA 1 P3, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRPSGEGGQA corresponding to 20 amino acids 1327 - 1336 of HSACMHCP_PEA_1 P3, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HSACMHCP_PEA_1 P3, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the 25 sequence VRPSGEGGQA in HSACMHCP PEA_1_P3. It should be noted that the known protein sequence (MYH6_HUMAN) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for MYH6_HUMAN_V2 (SEQ ID NO:339). These changes were previously 30 known to occur and are listed in the table below. Table 7 - Changes to MYH6_HUMANV2 WO 2005/069724 PCT/IB2005/001306 397 SNP position(s) on Type of change, amino acid sequence 89 conflict The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 5 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. 10 Variant protein HSACMHCP_PEA_1_P3 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein 15 HSACMHCP_PEA_1 P3 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 8 - Amino acid mutations 88 E -> Q Yes 376 P -> Q Yes 540 M -> R No 783 L->M Yes 1101 A->V Yes 1130 A-> T No WO 2005/069724 PCT/IB2005/001306 398 Variant protein HSACMHCP_PEA 1 P3 is encoded by the following transcript(s): HSACMHCPPEA 1 _T3, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA_1 T3 is shown in bold; this coding portion starts at position 78 and ends at position 4085. The transcript also has the following SNPs as 5 listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA 1 P3 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 9 - Nucleic acid SNPs SNP position on nucleotide A1ternativenuleic aii d Previously known SNP? ~sequene_ 339 G ->C Yes 488 A ->G Yes 504 A ->C Yes 887 G->A Yes 1204 C ->A Yes 1205 A->C Yes 1232 G -> T No 1696 T -> G No 2424 C -> A Yes 2910 C -> T Yes 3379 C -> T Yes 3465 G-> A No 4403 C -> No 4425 G -> A Yes 4728 T -> C Yes 4731 T -> C Yes 5328 C -> T No 5394 C -> T Yes 5616 G -> T Yes WO 2005/069724 PCT/IB2005/001306 399 5619 T -> C Yes 5623 A -> T Yes 5673 C -> T Yes Variant protein HSACMHCPPEA_1_P4 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HSACMHCP_PEA_1 T4. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HSACMHCP_PEA_1_P4 and MYH6_HUMAN_V2: 1.An isolated chimeric polypeptide encoding for HSACMHCPPEA 1 P4, comprising a first amino acid sequence being at least 90 % homologous to MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK 15 VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYT YSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSI LITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGN AKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNK KPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYK 20 LTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVG NEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGF EIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEK PMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGT VDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKG 25 SSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVL EGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGH TKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIR

AFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEK

WO 2005/069724 PCT/IB2005/001306 400 MVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMN AELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKL TKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLE RAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKK 5 LKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKR EAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQT ENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDC DLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 10 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAE WKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQ corresponding to amino acids 1 - 1508 of MYH6 HUMAN_V2, which also corresponds to amino acids 1 - 1508 of HSACMHCP_PEA_1 P4, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and 15 most preferably at least 95% homologous to a polypeptide having the sequence GVLGVQEARDELVGGRAMQGQGEHRL corresponding to amino acids 1509 - 1534 of HSACMHCPPEA_1 P4, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a tail of HSACMHCP_PEA l_P4, comprising a 20 polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GVLGVQEARDELVGGRAMQGQGEHRL in HSACMHCPPEA 1 P4. 25 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. 30 In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.

WO 2005/069724 PCT/IB2005/001306 401 Variant protein HSACMHCP PEA 1 lP4 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether 5 the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_1 P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 11 - Amino acid mutations SNP positions) on amino cid Altenmtive imino cid(s) Previously known SNP sequence 88 E ->Q Yes 376 P->Q Yes 540 M -> R No 783 L->M Yes 1101 A -> V Yes 1130 A -> T No 1330 A -> No 10 Variant protein HSACMHCPPEA_1_P4 is encoded by the following transcript(s): HSACMHCP_PEA_l1T4, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA_1_T4 is shown in bold; this coding portion starts at position 78 and ends at position 4679. The transcript also has the following SNPs as 15 listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_1_P4 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 12 - Nucleic acid SNPs WO 2005/069724 PCT/IB2005/001306 402 SNP position on nucleotide Alternative nucleic acid Previously known SNP? sequence 339 G ->C Yes 488 A ->G Yes 504 A-> C Yes 887 G ->A Yes 1204 C ->A Yes 1205 A ->C Yes 1232 G ->T No 1696 T-> G No 2424 C -> A Yes 2910 C ->T Yes 3379 C -> T Yes 3465 G->A No 4066 C -> No 4088 G -> A Yes 4391 T->C Yes 4394 T->C Yes 4673 T-> C Yes 5095 C->T No 5161 C->T Yes 5383 G-> T Yes 5386 T->C Yes 5390 A->T Yes 5440 C -> T Yes Variant protein HSACMHCP_PEA_1_P6 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HSACMHCPPEAlT7. An alignment is given to the known protein (Myosin heavy chain, WO 2005/069724 PCT/IB2005/001306 403 cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 5 Comparison report between HSACMHCP_PEA 1 P6 and MYH6_HUMAN_VI: I.An isolated chimeric polypeptide encoding for HSACMHCP_PEA_1 P6, comprising a first amino acid sequence being at least 90 % homologous to MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK 10 VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYT YSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSI LITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGN AKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNK KPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYK 15 LTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVG NEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGF EIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEK PMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGT VDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKG 20 SSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVL EGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGH TKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIR AFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEK MVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMN 25 AELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKL TKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLE RAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKK LKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKR EAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF 30 KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQT

ENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDC

WO 2005/069724 PCT/IB2005/001306 404 DLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAE WKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQ LGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIER 5 KLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSH ANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELR AVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC RNAEEKAKKAITD corresponding to amino acids 1 - 1763 of MYH6_HUMAN_V1, which also corresponds to amino acids 1 - 1763 of HSACMHCPPEA 1 P6, and a second amino acid 10 sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSDRPPSASPKDRNKALGPGQATVL corresponding to amino acids 1764 - 1788 of HSACMHCP PEA_1 P6, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 15 2.An isolated polypeptide encoding for a tail of HSACMHCP_PEA_1 P6, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSDRPPSASPKDRNKALGPGQATVL in HSACMHCPPEA_1_P6. 20 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the 25 trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein HSACMHCP_PEA 1_P6 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 14, (given according to their position(s) on the 30 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein WO 2005/069724 PCT/IB2005/001306 405 HSACMHCP_PEA_1 P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 14 - Amino acid mutations SNP positions) on amino acid Alternative amiino acid(s) ) eiously known SNP? sence __ 88 E-> Q Yes 376 P -> Q Yes 540 M -> R No 783 L->M Yes 1101 A -> V Yes 1130 A -> T No 1330 A -> No 1737 T-> S Yes 5 Variant protein HSACMHCPPEA 1 P6 is encoded by the following transcript(s): HSACMHCPPEA 1_T7, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA_1 T7 is shown in bold; this coding portion starts at position 78 and ends at position 5441. The transcript also has the following SNPs as 10 listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCPPEA_1_P6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 15 - Nucleic acid SNPs 339 G -> C Yes 488 A -> G Yes 504 A -> C Yes WO 2005/069724 PCT/IB2005/001306 406 887 G->A Yes 1204 C ->A Yes 1205 A-> C Yes 1232 G->T No 1696 T-> G No 2424 C ->A Yes 2910 C -> T Yes 3379 C -> T Yes 3465 G -> A No 4066 C -> No 4088 G->A Yes 4391 T->C Yes 4394 T-> C Yes 4991 C -> T No 5057 C->T Yes 5279 G -> T Yes 5282 T-> C Yes 5286 A->T Yes 5336 C -> T Yes 5862 G->A Yes 6339 C -> T Yes 7563 T -> C Yes 7630 G-> T Yes 7863 A->G Yes 8466 C -> G Yes 8666 G->A No 8689 G->A Yes 8732 C -> T Yes WO 2005/069724 PCT/IB2005/001306 407 Variant protein HSACMHCPPEA lPl2 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSACMHCP_PEA_1_T13. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isobform) at the end of the application. One or more alignments to one or 5 more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: Comparison report between HSACMHCPPEA_1_P12 and MYH6_HUMAN_V3: 10 1.An isolated chimeric polypeptide encoding for HSACMHCP_PEA_1 P12, comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLWKPGSVLSDSLFASSPCPQ corresponding to amino acids 1 - 22 of HSACMHCPPEA 1 P12, and a second amino acid sequence being at least 90 % homologous 15 to PMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGT VDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKG SSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVL EGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGH 20 TKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIR AFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEK MVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMN AELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKL TKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLE 25 RAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKK LKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKR EAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKIEEAQRSLNDFTTQRAKLQT ENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDC 30 DLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ

DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAE

WO 2005/069724 PCT/IB2005/001306 408 WKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQ LGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQI KAEIER KLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSH ANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELR 5 AVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIAL KGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLLR LQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKL RAKSRDIGAKQKMHDEE corresponding to amino acids 528 - 1939 of MYH6_HUMAN_V3, 10 which also corresponds to amino acids 23 - 1434 of HSACMHCP_PEA_1 P12, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 2.An isolated polypeptide encoding for a head of HSACMHCPPEA_1 P12, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 15 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MGLWKPGSVLSDSLFASSPCPQ of HSACMHCPPEA 1 P12. It should be noted that the known protein sequence (MYH6_HUMAN) has one or more changes than the sequence given at the end of the application and named as being the amino 20 acid sequence for MYH6_HUMAN_V3 (SEQ ID NO:340). These changes were previously known to occur and are listed in the table below. Table 16- Changes to MYH6HUMANV3 1735 conflict 25 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: WO 2005/069724 PCT/IB2005/001306 409 intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. 5 Variant protein HSACMHCP_PEA 1 P12 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 17, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein 10 HSACMHCP_PEA_1 Pl2 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 17 - Amino acid mutations SN oIlns)o amotl Alternativc amno acid sj Prev 6b yd known SNP? 10 L->F Yes 35 M -> R No 278 L -> M Yes 596 A -> V Yes 625 A-> T No 825 A -> No 1232 T-> S Yes 15 Variant protein HSACMHCP_PEA_1_P12 is encoded by the following transcript(s): HSACMHCP_PEA_1_T13, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA_1_T13 is shown in bold; this coding portion starts at position 67 and ends at position 4368. The transcript also has the following SNPs as listed in Table 18 (given according to their position on the nucleotide sequence, with 20 the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCPPEA_1_P12 sequence provides WO 2005/069724 PCT/IB2005/001306 410 support for the deduced sequence of this variant protein according to the present invention). Table 18 - Nucleic acid SNPs SNP position on nucleotide Alternative nucleic acid Pre lousl known SNP sequence 94 C ->T Yes 170 T ->G No 898 C ->A Yes 1384 C ->T Yes 1853 C ->T Yes 1939 G -> A No 2540 C -> No 2562 G-> A Yes 2865 T-> C Yes 2868 T -> C Yes 3465 C ->T No 3531 C ->T Yes 3753 G-> T Yes 3756 T-> C Yes 3760 A-> T Yes 3810 C -> T Yes 5 Variant protein HSACMHCPPEA 1 P16 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSACMHCP_PEA _1T17. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief 10 description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: WO 2005/069724 PCT/IB2005/001306 411 Comparison report between HSACMHCP PEA_lP 16 and MYH16 HUMAN_V2: I.An isolated chimeric polypeptide encoding for HSACMHCP_PEA__1 Pl6, comprising a first amino acid sequence being at least 90 % homologous to MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK 5 VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYT YSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSI LITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGN AKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNK KPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYK 10 LTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVG NEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGF EIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEK corresponding to amino acids 1 - 527 of MYH6_HUMAN_V2, which also corresponds to amino acids 1 - 527 of HSACMHCP_PEA 1 _P16, and a second amino acid sequence being at least 15 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPPWPHHLCPLLCHPDKVVAESLLHPRN corresponding to amino acids 528 - 555 of HSACMHCP_PEA 1 P16, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order. 20 2.An isolated polypeptide encoding for a tail of HSACMHCPPEA 1 P16, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPPWPHHLCPLLCHPDKVVAESLLHPRN in HSACMHCP_PEA_1_P16. 25 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the 30 trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted WO 2005/069724 PCT/IB2005/001306 412 protein. Variant protein HSACMHCP_PEA_1_P16 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 20, (given according to their position(s) on the 5 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_I1PI6 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 20 - Amino acid mutations SNP positions) on aminaid Ahernative aiIo cid(s) Previously known SNP? sequence~ 88 E->Q Yes 376 P -> Q Yes 10 Variant protein HSACMHCPPEA_1_P16 is encoded by the following transcript(s): HSACMHCPPEA 1 T17, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA_1_T17 is shown in bold; this coding portion starts at position 78 and ends at position 1742. The transcript also has the following 15 SNPs as listed in Table 21 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_1_P16 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 21 - Nucleic acid SNPs 339 G -> C Yes 488 A -> G Yes 504 A -> C Yes 887 G -> A Yes WO 2005/069724 PCT/IB2005/001306 413 1204 C ->A Yes 1205 A-> C Yes 1232 G-> T No 2094 C -> T Yes 2095 G->A Yes 2347 A->G Yes Variant protein HSACMHCPPEA 1 P25 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HSACMHCP_PEA_1 T26. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HSACMHCPPEA_1 P25 and MYH6_HUMANVI: 1.An isolated chimeric polypeptide encoding for HSACMHCP_PEA_1 P25, comprising a first amino acid sequence being at least 90 % homologous to MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK 15 VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYT YSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSI LITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGN AKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNK KPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYK 20 LTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVG NEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGF EIFD corresponding to amino acids 1 - 470 of MYH6_HUMAN Vi, which also corresponds to amino acids 1 - 470 of HSACMHCP_PEA 1 P25, a second amino acid sequence being at least 90 % homologous to 25 PMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGT WO 2005/069724 PCT/IB2005/001306 414 VDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKG SSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVL EG1RICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGH TKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIR 5 AFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEK MVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMN AELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKL TKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLE RAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKK 10 LKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKR EAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQT ENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDC DLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 15 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAE WKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQ LGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIER KLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSH ANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELR 20 AVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIAL KGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQ corresponding to amino acids 528 - 1855 of MYH6_HUMAN_V1, which also corresponds to amino acids 471 - 1798 of HSACMHCP_PEA 1_P25, and a third amino acid sequence being at least 70%, 25 optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT corresponding to amino acids 1799 - 1847 of HSACMHCP_PEA_1_P25, wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential 30 order. 2.An isolated chimeric polypeptide encoding for an edge portion of WO 2005/069724 PCT/IB2005/001306 415 HSACMHCP_PEA_l P25, comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids 5 comprise DP, having a structure as follows: a sequence starting from any of amino acid numbers 470-x to 470; and ending at any of amino acid numbers 471+ ((n-2) - x), in which x varies from 0 to n-2. 3.An isolated polypeptide encoding for a tail of HSACMHCP_PEA 1 P25, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, 10 more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT in HSACMHCPPEA_1_P25. 15 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. 20 In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. Variant protein HSACMHCP_PEA 1 P25 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 23, (given according to their position(s) on the 25 amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA 1 P25 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 23 - Amino acid mutations WO 2005/069724 PCT/IB2005/001306 416 SNP position(s) oni amino acid Alternative amino acid(s) Previously known SNP? sequence 88 E-> Q Yes 376 P ->Q Yes 483 M ->R No 726 L->M Yes 1044 A -> V Yes 1073 A -> T No 1273 A -> No 1680 T -> S Yes 1806 G -> R Yes Variant protein HSACMHCP_PEAlP25 is encoded by the following transcript(s): HSACMHCP_PEA_1_T26, for which the sequence(s) is/are given at the end of the application. 5 The coding portion of transcript HSACMHCP_PEA 1 T26 is shown in bold; this coding portion starts at position 78 and ends at position 5618. The transcript also has the following SNPs as listed in Table 24 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_1_P25 sequence provides 10 support for the deduced sequence of this variant protein according to the present invention). Table 24 - Nucleic acid SNPs 339 G -> C Yes 488 A -> G Yes 504 A -> C Yes 887 G-> A Yes 1204 C -> A Yes WO 2005/069724 PCT/IB2005/001306 417 1205 A -> C Yes 1232 G->T No 1525 T->G No 2253 C -> A Yes 2739 C -> T Yes 3208 C -> T Yes 3294 G -> A No 3895 C -> No 3917 G-> A Yes 4220 T-> C Yes 4223 T->C Yes 4820 C -> T No 4886 C -> T Yes 5108 G->T Yes 5111 T-> C Yes 5115 A-> T Yes 5165 C -> T Yes 5493 G -> A Yes 5970 C -> T Yes Variant protein HSACMHCPPEA 1_P28 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HSACMHCP_PEA 1_T8. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HSACMHCPPEA_1_P28 and MYH6_HUMANV3: WO 2005/069724 PCT/IB2005/001306 418 L.An isolated chimeric polypeptide encoding for HSACMHCP PEA_1_P28, comprising a first amino acid sequence being at least 90 % homologous to MLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQA NPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNY 5 HIFYQILSNKKPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFT SEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKG LCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQ YFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGM DLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQE 10 AHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDS GKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLV MHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLD IDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRD ALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSE 15 ARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNE RLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEM AGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQ EKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATS 20 VQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQ KLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFT TQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHA LQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAK KKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQR 25 NFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQ EEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEF NQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDL NEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNL LQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSE 30 VEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHR

LDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQT

WO 2005/069724 PCT/IB2005/001306 419 EEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERAD IAESQVNKLRAKSRDIGAKQKMHDEE corresponding to amino acids 165 - 1939 of MYH6_HUMAN_V3, which also corresponds to amino acids 1 - 1775 of HSACMHCPPEA lP28. 5 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: 10 intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. 15 Variant protein HSACMHCPPEAlP28 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 26, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP PEAlP28 sequence provides support for the deduced sequence of this variant 20 protein according to the present invention). Table 26 - Amino acid mutations 212 P -> Q Yes 376 M -> R No 619 L->M Yes 937 A -> V Yes 966 A->T No 1166 A-> No 1573 T-> S Yes WO 2005/069724 PCT/IB2005/001306 420 Variant protein HSACMHCP_PEA 1 P28 is encoded by the following transcript(s): HSACMHCP_PEA_I_T8, for which the sequence(s) is/are given at the end of the application. 5 The coding portion of transcript HSACMHCP_PEA 1_T8 is shown in bold; this coding portion starts at position 12 and ends at position 5336. The transcript also has the following SNPs as listed in Table 27 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA_1_P28 sequence provides 10 support for the deduced sequence of this variant protein according to the present invention). Table 27 - Nucleic acid SNPs ~SNP' j Itjmi onn27n4:Atitv nceci Previou. kioiiS''" :scquence 329 G -> A Yes 646 C -> A Yes 647 A -> C Yes 674 G ->T No 1138 T ->G No 1866 C ->A Yes 2352 C -> T Yes 2821 C ->T Yes 2907 G-> A No 3508 C -> No 3530 G -> A Yes 3833 T-> C Yes 3836 T-> C Yes 4433 C ->T No 4499 C ->T Yes 4721 G ->T Yes 4724 T -> C Yes WO 2005/069724 PCT/IB2005/001306 421 4728 A ->T Yes 4778 C->T Yes Variant protein HSACMHCPPEA 1 P29 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) 5 HSACMHCP_PEA 1 T14. An alignment is given to the known protein (Myosin heavy chain, cardiac muscle alpha isoform) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows: 10 Comparison report between HSACMHCP_PEA_ I _P29 and MYH6_HUMAN_V3: 1.An isolated chimeric polypeptide encoding for HSACMHCP_PEA 1 P29, comprising a first amino acid sequence being at least 90 % homologous to MNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEK 15 EKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRA KLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSA RHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLA QRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDK ILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISD 20 LTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKA EIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNEMEI QLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAEL EELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSL1NQKKKMESDLTQLQSEVEEA VQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEA 25 EQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDK KNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAES QVNKLRAKSRDIGAKQKMHDEE corresponding to amino acids 1165 - 1939 of MYH6_HUMANV3, which also corresponds to amino acids 1 - 775 of HSACMHCP PEA 1 P29.

WO 2005/069724 PCT/IB2005/001306 422 The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized 5 programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because neither of the trans-membrane region prediction programs predicted a trans-membrane region for this protein. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein. 10 Variant protein HSACMHCP_PEA_1_P29 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 29, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein 15 HSACMHCP_PEA_1_P29 sequence provides support for the deduced sequence of this variant protein according to the present invention). Table 29 - Amino acid mutations 166 A -> No 573 T -> S Yes 20 Variant protein HSACMHCP_PEA_1_ P29 is encoded by the following transcript(s): HSACMHCPPEAlT14, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSACMHCP_PEA 1_T14 is shown in bold; this coding portion starts at position 150 and ends at position 2474. The transcript also has the following SNPs as listed in Table 30 (given according to their position on the nucleotide sequence, with 25 the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSACMHCP_PEA 1 P29 sequence provides WO 2005/069724 PCT/IB2005/001306 423 support for the deduced sequence of this variant protein according to the present invention). Table 30 - Nucleic acid SNPs SNP position on nucleotide Altemativenciu1e acid Previously known SNP? sequence 34 G-> T Yes 51 -> G No 646 C -> No 668 G -> A Yes 971 T-> C Yes 974 T-> C Yes 1571 C ->T No 1637 C ->T Yes 1859 G ->T Yes 1862 T-> C Yes 1866 A-> T Yes 1916 C -> T Yes As noted above, cluster HSACMHCP features 65 segment(s), which were listed in Table 5 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided. 10 Segment cluster HSACMHCP_PEA 1_node_2 according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA_1_T14. Table 31 below describes the starting and ending position of this segment on each transcript. Table 31 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 424 Transcript mine Segment Segment starting posit on endmg position HSACMHCP PEA_1T14 1 328 Segment cluster HSACMHCP_PEA 1 node_20 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEAlT2, HSACMHCP_PEA_1_T3, HSACMHCP_PEA_1_T4, HSACMHCPPEA_1_T6, HSACMHCPPEA_1_T7, HSACMHCPPEA 1 T17 and HSACMHCPPEA 1 T26. Table 32 below describes the starting and ending position of this segment on each transcript. Table 32 - Segment location on transcripts HSACMHCP PEA 1 T2 65 278 HSACMHCP PEA 1 T3 65 278 HSACMHCPPEA_1 T4 65 278 HSACMHCPPEA 1_T6 65 278 HSACMHCP PEA lT7 65 278 HSACMHCPPEA 1 T17 65 278 HSACMHCP PEA 1 T26 65 278 10 Segment cluster HSACMHCPPEA_1_node_22 according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA 1_T2, 15 HSACMHCP_PEA 1_T3, HSACMHCP_PEAIT4, HSACMHCP_PEAI_T6, HSACMHCP_PEA 1_T7, HSACMHCP_PEA_1 T17 and HSACMHCP_PEA_1 T26. Table 33 below describes the starting and ending position of this segment on each transcript. Table 33 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 425 Transcript name Segment Segment starting position endinghposition HSACMHCP PEA 1 T2 279 400 HSACMHCP PEA 1 T3 279 400 HSACMHCP PEA 1 T4 279 400 HSACMHCP PEA 1_T6 279 400 HSACMHCP PEA 1 T7 279 400 HSACMHCPPEA 1 TI7 279 400 HSACMHCP PEA 1 T26 279 400 Segment cluster HSACMHCP_PEA 1 node_25 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3 HSACMHCP_PEA 1_T4, HSACMHCP_PEA 1_T6, HSACMHCPPEA_1_T7, HSACMHCPPEA 1T17 and HSACMHCPPEA 1T26. Table 34 below describes the starting and ending position of this segment on each transcript. Table 34 - Segment location on transcripts HSACMHCPPEA 1 T2 423 579 HSACMHCP PEA 1 T3 423 579 HSACMHCP PEA_1 T4 423 579 HSACMHCP PEA 1 T6 423 579 HSACMHCP PEA 1 T7 423 579 HSACMHCPPEA_1 T17 423 579 HSACMHCP PEA 1 T26 423 579 10 Segment cluster HSACMHCPPEA_1_node_43 according to the present invention is WO 2005/069724 PCT/IB2005/001306 426 supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCP PEA_ 1 T3 HSACMHCPPEA_I_T4, HSACMHCPPEA 1 T6, HSACMHCPPEA 1 T7 HSACMHCPPEA IT8, HSACMHCPPEA _ T17 and 5 HSACMHCPPEA lT26. Table 35 below describes the starting and ending position of this segment on each transcript. Table 35 - Segment location on transcripts Transcript name Segmeint Segment starting position ending position HSACMHCP PEA 1 T2 1219 1487 HSACMHCP PEA 1_T3 1219 1487 HSACMHCP PEA 1 T4 1219 1487 HSACMHCP PEA 1 T6 1219 1487 HSACMHCP PEA 1 T7 1219 1487 HSACMHCP PEA 1 T8 661 929 HSACMHCP PEA 1 T17 1219 1487 HSACMHCPPEA _1 T26 1219 1487 10 Segment cluster HSACMHCP_PEA 1_node_45 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3 HSACMHCPPEA 1 T4, HSACMHCPPEA 1 T6, HSACMHCPPEA 1 T7, HSACMHCPPEA _ T8 and HSACMHCPPEA 1 T17. Table 36 15 below describes the starting and ending position of this segment on each transcript. Table 36 - Segment location on transcripts HSACMHCPPEA 1 T2 1488 1658 WO 2005/069724 PCT/IB2005/001306 427 I-ISACMI-HCP PEA I T3 1488 1658 HSACMHCPPEA _1 T4 1488 1658 HSACMHCP PEA I T6 1488 1658 HSACMHCP PEA _ T7 1488 1658 HSACMHCP PEA 1_T8 930 1100 HSACMHCP PEA 1 T17 1488 1658 Segment cluster HSACMHCP_PEA1__node_46 according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA_1_T17. Table 37 below describes the starting and ending position of this segment on each transcript. Table 37 - Segment location on transcripts HSACMHCPlPEA 1-T17 1659 2477 10 Segment cluster HSACMHCPPEA 1 node_48 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA 1_T13. Table 38 below describes the starting and ending position of this segment on each transcript. Table 38 - Segment location on transcripts HSACMHCPPEA_1_T13 1 132 15 Segment cluster HSACMHCP_PEA_1 node 49 according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This WO 2005/069724 PCT/IB2005/001306 428 segment can be found in the following transcript(s): HSACMHCP_PEA_I_T2, HSACMHCPPEA_1 _T3, HSACMHCP PEA 1 T4 HSACMHCP_PEA 1 T6, HSACMHCP PEA_I_T7, HSACMHCPPEA_1_T8, HSACMHCPPEAITI3 and HSACMHCP_PEA_1 T26. Table 39 below describes the starting and ending position of this 5 segment on each transcript. Table 39 - Segment location on transcripts Transcript name Segmeent Sm starting position endmg position HSACMHCP PEA 1 T2 1659 1968 HSACMHCP PEA 1 T3 1659 1968 HSACMHCP PEA 1 T4 1659 1968 HSACMHCP PEA 1 T6 1659 1968 HSACMHCP PEA 1 T7 1659 1968 HSACMHCP PEA 1 T8 1101 1410 HSACMHCP PEA 1 TI3 133 442 HSACMHCP PEA 1_T26 1488 1797 Segment cluster HSACMHCP_PEA 1 node_57 according to the present invention is 10 supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA_1 T2, HSACMHCP_PEA_1_T3, HSACMHCP_PEA 1_T4, HSACMHCP_PEA_1_T6, HSACMHCP_PEA_l1T7, HSACMHCP_PEA 1_T8, HSACMHCP_PEA 1 T13 and HSACMHCPPEA 1_T26. Table 40 below describes the starting and ending position of this 15 segment on each transcript. Table 40 - Segment location on transcripts HSACMHCPPEA 1_T2 2246 2369 WO 2005/069724 PCT/IB2005/001306 429 HSACMHCP PEA 1 T3 2246 2369 HSACMHCP PEA IT4 2246 2369 HSACMHCP PEA 1 T6 2246 2369 HSACMHCP PEA 1 T7 2246 2369 HSACMHCP PEA 1 T8 1688 1811 HSACMHCP PEA 1_T13 720 843 HSACMHCP PEA 1 T26 2075 2198 Segment cluster HSACMHCP_PEA 1 node_59 according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_1_T2, HSACMHCP PEA 1_T3, HSACMHCPPEA 1_T4, HSACMHCPPEA 1 T6, HSACMHCP_PEA_1_T7, HSACMHCP_PEAI_T8, HSACMHCP_PEA_1_T13 and HSACMHCPPEA_1_T26. Table 41 below describes the starting and ending position of this segment on each transcript. 10 Table 41 - Segment location on transcripts HSACMHCP PEA 1 T2 2370 2506 HSACMHCP PEA 1 T4 2370 2506 HSACMHCP PEA 1 T6 2370 2506 HSACMHCP PEA 1 T7 2370 2506 HSACMHCP PEA 1 T7 2370 2506 HSACMHCPPEA_1 T8 1812 1948 HSACMHCP PEA 1 T13 844 980 HSACMHCPPEA 1 T26 2199 2335 Segment cluster HSACMHCPPEA 1 node_61 according to the present invention is WO 2005/069724 PCT/IB2005/001306 430 supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCP PEA 1_T3, HSACMHCPPEA_1 T4, HSACMHCPPEA_I_T6, HSACMHCPPEA_1_T7, HSACMHCP PEA_I_T8, HSACMHCPPEA 1_T13 and 5 HSACMHCP PEA_1 T26. Table 42 below describes the starting and ending position of this segment on each transcript. Table 42 - Segment location on transcripts Transenpt name Segment Segment starting position ending position HSACMHCP PEA 1 T2 2507 2762 HSACMHCP PEA 1 T3 2507 2762 HSACMHCP PEA 1 T4 2507 2762 HSACMHCP PEA 1 T6 2507 2762 HSACMHCP PEA 1 T7 2507 2762 HSACMHCP PEA 1 T8 1949 2204 HSACMHCP PEA 1 TI3 981 1236 HSACMHCP PEA 1 T26 2336 2591 10 Segment cluster HSACMHCPPEA 1 node_63 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA 1 T2, HSACMHCP_PEA_1 T3, HSACMHCPPEA__1 T4, HSACMHCP_PEA_1 T6, HSACMHCP PEA 1 T7, HSACMHCP PEA_1 T8, HSACMHCP_PEA_1_T13 and 15 HSACMHCP_PEA_1_T26. Table 43 below describes the starting and ending position of this segment on each transcript. Table 43 - Segment location on transcripts * soenme WO 2005/069724 PCT/IB2005/001306 431 HSACMHCPPEA 1_T2 2763 3005 HSACMHCPPEA_1 T3 2763 3005 HSACMHCPPEA _ T4 2763 3005 HSACMHCPPEA IT6 2763 3005 HSACMHCPPEA_ IT7 2763 3005 HSACMHCPPEA 1 T8 2205 2447 HSACMHCP PEA 1_T13 1237 1479 HSACMHCP_PEA IT26 2592 2834 Segment cluster HSACMHCP_PEA 1_ node_65 according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_1_T2, HSACMHCP_PEA_1 T3, HSACMHCPPEA_1_T4, HSACMHCP_PEA_1 _T6, HSACMHCP_PEAI_T7, HSACMHCP_PEA_1 _T8, HSACMHCP PEA 1 T13 and HSACMHCPPEA_1_T26. Table 44 below describes the starting and ending position of this segment on each transcript. 10 Table 44 - Segment location on transcripts HSACMHCP_PEA 1_T2 3006 3182 HSACMHCP_PEAlT3 3006 3182 HSACMHCPPEA_1_T4 3006 3182 HSACMHCPPEA_1 T6 3006 3182 HSACMHCPPEA 1_T7 3006 3182 HSACMHCP_PEA_l_T8 2448 2624 HSACMHCPPEA 13 1480 1656 HSACMHCP PEAlT 126 2835 3011 WO 2005/069724 PCT/IB2005/001306 432 Segment cluster HSACMHCP_PEA_1 node_67 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_I_T2, HSACMHCPPEA 1 T3, HSACMHCPPEA 1 T4, HSACMHCPPEA 1 T6, 5 HSACMHCP_PEA_I_T7, HSACMHCP_PEA_I_T8, HSACMHCP PEA _ITI3 and HSACMHCPPEA_1_T26. Table 45 below describes the starting and ending position of this segment on each transcript. Table 45 - Segment location on transcripts Tianscript name Segmiint Sement starting position ending posiiIon HSACMHCP PEA 1 T2 3183 3328 HSACMHCP PEA I_ T3 3183 3328 HSACMHCP PEA 1 T4 3183 3328 HSACMHCP PEA 1 T6 3183 3328 HSACMHCP PEA 1 T7 3183 3328 HSACMHCP PEA 1 T8 2625 2770 HSACMHCP PEA 1 T13 1657 1802 HSACMHCP PEA 1 T26 3012 3157 10 Segment cluster HSACMHCP_PEA 1 node_71 according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3 HSACMHCP_PEAlT4, HSACMHCPPEA 1 T6, 15 HSACMHCPPEA_ 1_T7, HSACMHCP_PEA_1_T8, HSACMHCPPEA 1 T13 and HSACMHCP_PEA_1 T26. Table 46 below describes the starting and ending position of this segment on each transcript. Table 46 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 433 Transcript name Segment Segment startmg position ending position HSACMHCP PEA _1 T2 3420 3689 HSACMHCP PEA 1 T3 3420 3689 HSACMHCP PEA 1 T4 3420 3689 HSACMHCP PEA _lT6 3420 3689 HSACMHCP PEA 1 T7 3420 3689 HSACMHCP PEA 1 T8 2862 3131 HSACMHCP PEA 1 T13 1894 2163 HSACMHCP PEA 1 T26 3249 3518 Segment cluster HSACMHCPPEA 1 node_81 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA_1_T3. Table 47 below describes the starting and ending position of this segment on each transcript. Table 47 - Segment location on transcripts HSACMHCP PEA 1 T3 4056 4392 10 Segment cluster HSACMHCP_PEA_1 node_87 according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEAlT2, HSACMHCP_PEA 1_T3, HSACMHCP_PEAlT4, HSACMHCP_PEAlT6, HSACMHCPPEAIT7, HSACMHCPPEA 1 T8, HSACMHCPPEA_I1T13, 15 HSACMHCPPEA_1_T14 and HSACMHCPPEA 1_T26. Table 48 below describes the starting and ending position of this segment on each transcript. Table 48 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 434 Transcript name Segment Segment starting position ending position HSACMHCP PEA 1 T2 4253 4436 HSACMHCP PEA 1 T3 4590 4773 HSACMHCPPEA l T4 4253 4436 HSACMHCP PEA 1 T6 4253 4436 HSACMHCP PEA_1 T7 4253 4436 HSACMHCP PEA 1 T8 3695 3878 HSACMHCPPEA 1 T13 2727 2910 HSACMHCP PEA 1 T14 833 1016 HSACMHCP PEA 1 T26 4082 4265 Segment cluster HSACMHCP_PEA_1_ node_89 according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_1 T2, HSACMHCPPEA_ 1 T3 HSACMHCP_PEA 1_T4, HSACMHCP_PEA_1_T6, HSACMHCPPEA 1 T7 HSACMHCPPEA 1 T8, HSACMHCP_PEAI_T13, HSACMHCP PEAIT14 and HSACMHCPPEAlT26. Table 49 below describes the starting and ending position of this segment on each transcript. 10 Table 49 - Segment location on transcripts HSACMHCP PEA 1 T4 4437 4602 HSACMHCPPEA-lT3 4774 4939 HSACMHCPPEA-lT4 4437 4602 HSACMHCP PEA _l T6 4437 4602 HSACMHCP PEA 1 T7 4437 4602 HSACMHCP PEA 1 T8 3879 4044 WO 2005/069724 PCT/IB2005/001306 435 HSACMHCP PEA 1 T13 2911 3076 HSACMI-ICP PEA 1 TI4 1017 1182 HSACMHCP PEA 1 T26 4266 4431 Segment cluster HSACMHCP_PEA 1 node_96 according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA_l1T2, HSACMHCP PEA 1 T3 HSACMHCP PEAI _T4, HSACMHCPPEA 1 T6, HSACMHCPPEA 1 T7, HSACMHCP_PEA_I_T8, HSACMHCP_PEAIT13, HSACMHCPPEA 1_T14 and HSACMHCPPEA _T26. Table 50 below describes the starting and ending position of this segment on each transcript. 10 Table 50 - Segment location on transcripts HSACMHCP PEA 1 T2 4743 4877 HSACMHCP PEA 1 T3 5080 5214 HSACMHCPPEA_1_T4 4847 4981 HSACMHCP PEA 1 T6 4743 4877 HSACMHCP PEA lT7 4743 4877 HSACMHCP PEA 1 T8 4185 4319 HSACMHCP PEA 1 T13 3217 3351 HSACMHCP PEA _1 T14 1323 1457 HSACMHCP PEA 1 T26 4572 4706 Segment cluster HSACMHCP_PEA 1 node_97 according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This 15 segment can be found in the following transcript(s): HSACMHCP_PEA_1 T2, HSACMHCPPEA 1 T3, HSACMHCPPEA 1_T4, HSACMHCPPEA_1 T6, WO 2005/069724 PCT/IB2005/001306 436 HSACMHCP_PEA_ 1_T7 HSACMHCPPEA 1 T8 HSACMHICP_PEA_I_ TI3, HSACMHCPPEA IT14 and HSACMHCP PEA lT26. Table 51 below describes the starting and ending position of this segment on each transcript. Table 51 - Segment location on transcripts Transcript name Segnment Segiment startmg positIn ending position HSACMHCP PEA _1 T2 4878 5006 HSACMHCP PEA 1 T3 5215 5343 HSACMHCPPEA 1_T4 4982 5110 HSACMHCP PEA 1 T6 4878 5006 HSACMHCP PEA 1 T7 4878 5006 HSACMHCP PEA 1 T8 4320 4448 HSACMHCP PEA 1_TI3 3352 3480 HSACMHCP PEA 1 T14 1458 1586 HSACMHCPPEAlT26 4707 4835 5 Segment cluster HSACMHCPPEA 1 node_100 according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, 10 HSACMHCPPEA_1 T3, HSACMHCPPEA 1_T4, HSACMHCP PEA 1 T6, HSACMHCP_PEA_1_T7, HSACMHCP_PEA_1 T8, HSACMHCP_PEA_1_T13, HSACMHCPPEA_1_T14 and HSACMHCPPEA_1 T26. Table 52 below describes the starting and ending position of this segment on each transcript. Table 52 - Segment location on transcripts HSACMHCP PEA 1 T2 5037 5240 HSACMHCP PEA 1 T3 5374 5577 WO 2005/069724 PCT/IB2005/001306 437 HSACMHCP PEA I T4 5141 5344 HSACMHCP PEA IT6 5037 5240 HSACMHCP PEA 1 T7 5037 5240 HSACMHCP PEA 1 T8 4479 4682 HSACMHCP PEA 1 T13 3511 3714 HSACMHCP PEA 1 T14 1617 1820 HSACMHCP PEA 1 T26 4866 5069 Segment cluster HSACMHCP_PEA_1 _node_105 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_1_T7. Table 53 below describes the starting and ending position of this segment on each transcript. Table 53 - Segment location on transcripts HSACMHCPPEA 1_T7 5367 5564 10 Segment cluster HSACMHCP_PEA 1 node_106 according to the present invention is supported by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA 1 lT2, HSACMHCPPEA_l1T3, HSACMHCPPEA_ 1T4, HSACMHCP PEA 1_T6, HSACMHCPPEA_1_T7, HSACMHCPPEA_1 T8, HSACMHCPPEA__T13, 15 HSACMHCP PEA 1_T14 and HSACMHCPPEA 1 T26. Table 54 below describes the starting and ending position of this segment on each transcript. Table 54 - Segment location on transcripts *arn~ Men WO 2005/069724 PCT/IB2005/001306 438 HSACMHCP PEA IT2 5367 5642 HSACMHCP PEA _1 T3 5704 5979 HSACMHCP PEA 1 T4 5471 5746 HSACMHCP PEA 1 T6 5367 5642 HSACMHCP PEA 1 T7 5565 5840 HSACMHCP PEA 1_T8 4809 5084 HSACMHCP PEA 1 T13 3841 4116 HSACMHCP PEA 1 T14 1947 2222 HSACMHCP PEA 1 T26 5196 5471 Segment cluster HSACMHCPPEA 1 node_107 according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA_1 T6, HSACMHCP PEA 1 T7 and HSACMHCPPEA 1 T26. Table 55 below describes the starting and ending position of this segment on each transcript. Table 55 - Segment location on transcripts HSACMHCP PEA 1 T2 5643 5866 HSACMHCPPEA_1_T6 5643 5866 HSACMHCP PEA 1 T7 5841 6064 HSACMHCP PEA 1 T26 5472 5695 10 Segment cluster HSACMHCP_PEA 1_node 108 according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP PEA_1 T2, HSACMHCPPEA_1_T7 and HSACMHCPPEA_1 T26. Table 56 below describes the 15 starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 439 Table 56 - Segment location on transcripts Transcript name Segment Segment starting position ending position HSACMHCP PEA 1 T2 5867 6763 HSACMHCP PEA 1 T7 6065 6961 HSACMHCP PEA 1 T26 5696 6592 Segment cluster HSACMHCP_PEA 1_node_111 according to the present invention is 5 supported by 20 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA 1 T2, HSACMHCP_PEA_I_T3, HSACMHCP_PEAIT4, HSACMHCP_PEA_1_T6, HSACMHCP PEA 1_T7, HSACMHCPPEAIT8, HSACMHCPPEA_1_T13, HSACMHCPPEA_1_TI4 and HSACMHCPPEA_1_T26. Table 57 below describes the 10 starting and ending position of this segment on each transcript. Table 57- Segment location on transcripts HSACMHCP PEA 1 T2 6860 6994 HSACMHCP PEA 1 T3 6076 6210 HSACMHCP PEA 1 T4 5843 5977 HSACMHCP PEA 1 T6 5963 6097 HSACMHCP PEA 1 T7 7058 7192 HSACMHCP PEA 1 T8 5181 5315 HSACMHCP PEA 1 T13 4213 4347 HSACMHCPPEA_1 T14 2319 2453 HSACMHCP PEA 1 T26 6689 6823 Segment cluster HSACMHCP_PEA 1_node_113 according to the present invention is WO 2005/069724 PCT/IB2005/001306 440 supported by 20 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA _I_T2, HSACMHCPPEA_ 1 T3 HSACMHCPPEA 1 T4 HSACMHCP PEA_I_T6, HSACMHCP PEA_ 1 T7 HSACMHCP_PEA_1_T8, HSACMHCP PEA__1 TI3, 5 HSACMHCP PEAIT14 and HSACMHCPPEAIT26. Table 58 below describes the starting and ending position of this segment on each transcript. Table 58 - Segment location on transcripts Transcript name Segiit Segment starting position ending position HSACMHCP PEA 1_T2 6995 8921 HSACMHCP PEA 1 T3 6211 6290 HSACMHCP PEA 1 T4 5978 6057 HSACMHCP PEA 1 T6 6098 6177 HSACMHCP PEA 1 T7 7193 9119 HSACMHCPPEA 1 T8 5316 5395 HSACMHCP PEA 1 T13 4348 4427 HSACMHCP PEA 1 T14 2454 2533 HSACMHCPPEA 1 T26 6824 6903 10 According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description. Segment cluster HSACMHCP_PEA_1_node_0 according to the present invention can be 15 found in the following transcript(s): HSACMHCP_PEA 1_T8. Table 59 below describes the starting and ending position of this segment on each transcript. Table 59 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 441 Transcript name Segment Segment starting position ending position HSACMHCPPEA 1_T8 1 21 Segment cluster HSACMHCP_PEA_1 node_3 according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA1__T14. Table 60 below describes the starting and ending position of this segment on each transcript. Table 60 - Segment location on transcripts Transcript n1une Segment Segment starting poIton endIg position HSACMHCPPEA lT14 329 374 10 Segment cluster HSACMHCP_PEA_1 node_4 according to the present invention can be found in the following transcript(s): HSACMHCP_PEA 1 T14. Table 61 below describes the starting and ending position of this segment on each transcript. Table 61 - Segment location on transcripts HSACMHCPPEA-lTI4 375 389 15 Segment cluster HSACMHCP_PEA_1_node_16 according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3, HSACMHCP_PEAIT4, HSACMHCPPEA 1 T6, 20 HSACMHCP_PEAIT7, HSACMHCP PEA_1_T17 and HSACMHCPPEA_1_T26. Table WO 2005/069724 PCT/IB2005/001306 442 62 below describes the starting and ending position of this segment on each transcript. Table 62 - Segment location on transcripts Transcript name Segment Segment start ng position endig position HSACMHCP PEA 1 T2 1 31 HSACMHCP PEA 1 T3 1 31 HSACMHCP PEA 1 T4 1 31 HSACMHCP PEA_1 T6 1 31 HSACMHCPPEA 1_T7 1 31 HSACMHCPPEA 1 T17 1 31 HSACMHCP PEA 1 T26 1 31 5 Segment cluster HSACMHCP_PEA 1 node_18 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3 HSACMHCP_PEA_1_T4, HSACMHCP_PEA 1 T6, HSACMHCPPEA 1 T7, HSACMHCPPEA 1 T17 and HSACMHCP PEA 1 T26. Table 10 63 below describes the starting and ending position of this segment on each transcript. Table 63 - Segment location on transcripts HSACMHCP PEA 1 T2 32 64 HSACMHCPPEA_1 T3 32 64 HSACMHCP PEA 1 T4 32 64 HSACMHCP PEA 1 IT6 32 64 HSACMHCP PEA 1_T7 32 64 HSACMHCP PEA 1 T17 32 64 HSACMHCP PEA 1 T26 32 64 WO 2005/069724 PCT/IB2005/001306 443 Segment cluster HSACMHCP_PEA_1 node_23 according to the present invention can be found in the following transcript(s): HSACMHCP_PEA l_T2, HSACMHCP_PEA 1 T3, 5 HSACMHCPPEA 1 T4, HSACMHCP PEA 1 T6, HSACMHCP_PEA_1 T7, HSACMHCPPEA 1 T17 and HSACMHCP PEA 1 T26. Table 64 below describes the starting and ending position of this segment on each transcript. Table 64 - Segment location on transcripts Tranrpt lutme Segment Sgment starting position ending position HSACMHCP PEA 1 T2 401 422 HSACMHCP PEA 1 T3 401 422 HSACMHCP PEA 1 T4 401 422 HSACMHCP PEA 1 T6 401 422 HSACMHCP PEA_1 T7 401 422 HSACMHCP PEA 1 T17 401 422 HSACMHCP PEA 1 T26 401 422 10 Segment cluster HSACMHCP_PEA_1_node_27 according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEAlT2, HSACMHCPPEA 1 T3, HSACMHCPPEA 1T4, HSACMHCPPEA_1_T6, 15 HSACMHCP_PEA 1 _T7, HSACMHCP_PEA 1 _T8, HSACMHCP_PEA_1_T17 and HSACMHCPPEA_1_T26. Table 65 below describes the starting and ending position of this segment on each transcript. Table 65 - Segment location on transcripts * ae $ elet WO 2005/069724 PCT/IB2005/001306 444 I-ISACMHCP PEA l T2 580 607 l-HSACMHCP PEA IT3 580 607 HSACMHCP PEA_ 1T4 580 607 HSACMHCP PEA _ T6 580 607 HSACMHCP PEA 1 T7 580 607 HSACMHCP PEA 1 T8 22 49 HSACMHCP PEA 1 T17 580 607 HSACMHCP PEA 1 T26 580 607 Segment cluster HSACMHCP_PEAInode_29 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA 1 T2, HSACMHCP_PEA_1_T3, HSACMHCP_PEA_ 1T4, HSACMHCP_PEA__T6, HSACMHCPPEA 1 T7 HSACMHCPPEA 1 T8, HSACMHCPPEA 1 T17 and HSACMHCPPEAlT26. Table 66 below describes the starting and ending position of this segment on each transcript. 10 Table 66 - Segment location on transcripts HSACMHCP PEA 1 T2 608 719 HSACMHCPPEA 1_T3 608 719 HSACMHCP PEA 1 T4 608 719 HSACMHCP PEA 1_T6 608 719 HSACMHCP PEA 1 T7 608 719 HSACMHCP PEA_1_T8 50 161 HSACMHCPPEA_1_T17 608 719 HSACMHCPPEA 1 T26 608 719 WO 2005/069724 PCT/IB2005/001306 445 Segment cluster HSACMHCP PEA I node 31 according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP PEA_1_T2, HSACMHCPPEAI T3, HSACMHCP PEA 1 T4, HSACMHCP PFA 1 T6, 5 HSACMHCP_PEA_ 1_T7, HSACMHCP PEA_I_T8, HSACMHCP_PEAITI7 and HSACMHCP_PEA_1 T26. Table 67 below describes the starting and ending position of this segment on each transcript. Table 67 - Segment location on transcripts Transcript name tarting position eding position HSACMHCP PEA 1 T2 720 812 HSACMHCP PEA 1 IT3 720 812 HSACMHCP PEA 1 T4 720 812 HSACMHCP PEA 1 T6 720 812 HSACMHCP PEA 1 T7 720 812 HSACMHCP PEA 1 T8 162 254 HSACMHCP PEA 1 T17 720 812 HSACMHCP PEA 1 T26 720 812 10 Segment cluster HSACMHCPPEA_1 node_33 according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3 HSACMHCPPEA 1 T4, HSACMHCPPEA 1 T6, 15 HSACMHCP_PEA_I_.T7, HSACMHCP_PEA_I_T8, HSACMHCP_PEA 1 T17 and HSACMHCP_PEA_1 T26. Table 68 below describes the starting and ending position of this segment on each transcript. Table 68 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 446 Transcript name Segment Segment starting position ending position HSACMHCP PEA 1 T2 813 876 HSACMHCP PEA lT3 813 876 HSACMHICP PEA 1 T4 813 876 HSACMHCP PEA 1 T6 813 876 HSACMHCPPEA__T7 813 876 HSACMHCP PEA 1 T8 255 318 HSACMHCP PEA 1 T17 813 876 HSACMHCP PEA 1 T26 813 876 Segment cluster HSACMHCP_PEA 1 node_35 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA 1 T2, HSACMHCPPEA_ 1 T3 HSACMHCPPEA 1 T4, HSACMHCPPEA 1 T6, HSACMHCPPEA_1_T7, HSACMHCP_PEA_I_T8, HSACMHCPPEA_1_T17 and HSACMHCP_PEAlT26. Table 69 below describes the starting and ending position of this segment on each transcript. 10 Table 69 - Segment location on transcripts HSACMHCP PEA_1 T2 877 975 HSACMHCP PEA 1 T3 877 975 HSACMHCP PEA 1 T4 877 975 HSACMHCP PEA 1 T6 877 975 HSACMHCP PEA_1 T7 877 975 HSACMHCP PEA 1_T8 319 417 HSACMHCP PEA 1 T17 877 975 WO 2005/069724 PCT/IB2005/001306 447 HSACMHCPPEA_1_T26 877 975 Segment cluster HSACMHCP_PEA_1 node_37 according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_I_T2, HSACMHCP PEA 1lT3, HSACMHCP PEA 1T4, HSACMHCP PEA 1 T6, HSACMHCP_PEA_1_T7, HSACMHCP_PEAI_T8, HSACMHCP_PEA_1 T17 and HSACMHCP_PEA_1_T26. Table 70 below describes the starting and ending position of this segment on each transcript. 10 Table 70 - Segment location on transcripts TraserIpt-name Segment Segment ~s~tnposItIOn~ CHnding, _ __tI) HSACMHCP PEA 1 T2 976 1079 HSACMHCP PEA 1 T3 976 1079 HSACMHCP PEA 1 T4 976 1079 HSACMHCP PEA 1 T6 976 1079 HSACMHCP PEA 1 T7 976 1079 HSACMHCP PEA 1 T8 418 521 HSACMHCP PEA 1 T17 976 1079 HSACMHCP PEA 1 T26 976 1079 Segment cluster HSACMHCP_PEA_1_node_39 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This 15 segment can be found in the following transcript(s): HSACMHCP_PEA_1 _T2, HSACMHCP_PEA_1_T3, HSACMHCP_PEA 1_T4, HSACMHCP_PEA_1_T6, HSACMHCP PEA 1_T7, HSACMHCP PEA_1_T8, HSACMHCPPEA_1 T17 and HSACMHCPPEA 1_T26. Table 71 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 448 Table 71 - Segment location on transcripts Transcript nane Segment Segment starting position ending position HSACMHCP PEA I T2 1080 1196 HSACMHCP PEA I T3 1080 1196 HSACMHCP PEA 1 T4 1080 1196 HSACMHCP PEA 1 T6 1080 1196 HSACMHCP PEA 1 T7 1080 1196 HSACMHCP PEA 1 T8 522 638 HSACMHCP PEA 1 T17 1080 1196 HSACMHCP PEA 1 T26 1080 1196 Segment cluster HSACMHCP_PEA_1_node 40 according to the present invention can be 5 found in the following transcript(s): HSACMHCP_PEA 1 T2, HSACMHCP_PEA_1 T3, HSACMHCPPEA_1 T4, HSACMHCPPEA_1 _T6, HSACMHCPPEA_1_ T7, HSACMHCPPEA_ 1T8, HSACMHCP PEA 1_T17 and HSACMHCP PEA_1_T26. Table 72 below describes the starting and ending position of this segment on each transcript. Table 72 - Segment location on transcripts HSACMHCP PEA 1 T2 1197 1218 HSACMHCP PEA 1 T3 1197 1218 HSACMHCP PEA 1 T4 1197 1218 HSACMHCP PEA 1 T6 1197 1218 HSACMHCP PEA 1 T7 1197 1218 HSACMHCP PEA 1 T8 639 660 HSACMHCP PEA 1 T17 1197 1218 HSACMHCP PEA 1 T26 1197 1218 10 WO 2005/069724 PCT/IB2005/001306 449 Segment cluster HSACMHCP PEA 1 node_51 according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_ lT2, 5 HSACMHCPPEA 1 T3 HSACMHCP_PEA_ 1_T4, HSACMHCPPEA 1 T6, HSACMHCP_PEA_ 1_T7, HSACMHCPPEA _T8, HSACMHCPPEA 1 T13 and HSACMHCP PEAlT26. Table 73 below describes the starting and ending position of this segment on each transcript. Table 73 - Segment location on transcripts Transcriptname SegmentSme starting position ending position HSACMHCP PEA l T2 1969 2039 HSACMHCP PEA 1 T3 1969 2039 HSACMHCP PEA 1 T4 1969 2039 HSACMHCP PEA 1 T6 1969 2039 HSACMHCP PEA 1 T7 1969 2039 HSACMHCP PEA 1 T8 1411 1481 HSACMHCP PEA 1 T13 443 513 HSACMHCP PEA 1 T26 1798 1868 10 Segment cluster HSACMHCP_PEA_1 node_53 according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA I_T2, 15 HSACMHCP_PEA 1_T3, HSACMHCPPEA 1 T4, HSACMHCP_PEAI_T6, HSACMHCPPEA_ 1 T7 HSACMHCP_PEA__T8, HSACMHCPPEA 1 T13 and HSACMHCP PEA_1_T26. Table 74 below describes the starting and ending position of this segment on each transcript. Table 74 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 450 Transcript name Segment Segm ent starting position ending osiion HSACMHCPPEA _ T2 2040 2127 HSACMHCP PEA lT3 2040 2127 HSACMHCPPEAI T4 2040 2127 HSACMHCP PEA 1 T6 2040 2127 HSACMHCP PEA 1 T7 2040 2127 HISACMHCP PEA 1 T8 1482 1569 HSACMHCP PEA 1 T13 514 601 HSACMHCPPEA 1 T26 1869 1956 Segment cluster HSACMHCP_PEA_1_Inode_55 according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_1_T2, HSACMHCPPEA 1 T3 HSACMHCP PEA 1 T4, HSACMHCP_PEAlT6, HSACMHCP_PEA_1 T7, HSACMHCP_PEA 1 T8, HSACMHCP_PEA_1_T13 and HSACMHCP_PEAlT26. Table 75 below describes the starting and ending position of this segment on each transcript. 10 Table 75 - Segment location on transcripts HSACMHCP PEA 1 T2 2128 2245 HSACMHCP PEA 1 T3 2128 2245 HSACMHCPPEA 1 T4 2128 2245 HSACMHCP PEA 1 T6 2128 2245 HSACMHCP PEA 1 T7 2128 2245 HSACMHCP PEA 1 T8 1570 1687 HSACMHCP PEA 1 T13 602 719 WO 2005/069724 PCT/IB2005/001306 451 HSACMHCPPEA 1_T26 1957 2074 Segment cluster HSACMHCP_PEA_ 1_node_69 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_I_T2, HSACMHCPPEA 1_T3, HSACMHCPPEA lT4, HSACMHCP PEA_1_T6, HSACMHCPPEA 1_T7, HSACMHCPPEA_I_T8, HSACMHCPPEA 1_T13 and HSACMHCP_PEA_1 T26. Table 76 below describes the starting and ending position of this segment on each transcript. 10 Table 76 - Segment location on transcripts TranscrIpt name Semn Tbegment "tarHtinP poPitioE End n T42 p39 stI HSACMHCP PEA 1 T2 3329 3419 HSACMHCP PEA 1 T3 3329 3419 HSACMHCP PEA 1 T4 3329 3419 HSACMHCP PEA 1 T6 3329 3419 HSACMHCP PEA 1 T7 3329 3419 HSACMHCP PEA 1 T8 2771 2861 HSACMHCP PEA 1 T13 1803 1893 HSACMHCP PEA 1 T26 3158 3248 Segment cluster HSACMHCP_PEA _I_ node_72 according to the present invention can be found in the following transcript(s): HSACMHCP_PEA_I_T2, HSACMHCP_PEA 1_T3, 15 HSACMHCPPEA_l1T4, HSACMHCPPEA 1_T6, HSACMHCPPEA_1_T7, HSACMHCPPEA_1 T8, HSACMHCPPEA_1_T13 and HSACMHCP PEAIT26. Table 77 below describes the starting and ending position of this segment on each transcript. Table 77 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 452 Transcript name Segment Segment ;7 startmig position ending position HSACMHCP PEA_ IT2 3690 3701 HSACMHCP PEA I T3 3690 3701 HSACMHCP PEA _1 T4 3690 3701 HSACMHCP PEA 1 T6 3690 3701 HSACMHCP PEA_1 T7 3690 3701 HSACMHCP PEA 1 T8 3132 3143 HSACMHCP PEA 1 T13 2164 2175 HSACMHCPPEA _ T26 3519 3530 Segment cluster HSACMHCPPEA 1 node_73 according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA 1_T2, HSACMHCPPEA_I_T3, HSACMHCPPEA 1T4, HSACMHCPPEA 1_T6, HSACMHCPPEA_I_T7, HSACMHCPPEA 1 T8, HSACMHCPPEA_1_T13 and HSACMHCP_PEA_1 T26. Table 78 below describes the starting and ending position of this segment on each transcript. 10 Table 78 - Segment location on transcripts HSACMHCP PEA 1 T2 3702 3731 HSACMHCP PEA 1 T3 3702 3731 HSACMHCP PEAl 1T4 3702 3731 HSACMHCP PEA 1 T6 3702 3731 HSACMHCPPEA 1 T7 3702 3731 HSACMHCP PEA 1 T8 3144 3173 HSACMHCP PEA 1 T13 2176 2205 WO 2005/069724 PCT/IB2005/001306 453 IHSACMHICPPEA __T26 3531 3560 Segment cluster HSACMHCP_PEA 1 node_74 according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HISACMHCP_PEA_1 T2, H-ISACMHCPPEA 1 T3 HSACMHCP_PEA 1lT4, HSACMHCPPEA_I_T6, HSACMHCPPEA_1_T7, HSACMHCP_PEAI_T8, HSACMHCPPEA 1 TI3 and HSACMHCP_PEA_1 T26. Table 79 below describes the starting and ending position of this segment on each transcript. 10 Table 79 - Segment location on transcripts Transcript name Segment~ ~ Segnient~~ starting position ending position HSACMHCP PEA 1 T2 3732 3809 HSACMHCP PEA 1 T3 3732 3809 HSACMHCP PEA 1 T4 3732 3809 HSACMHCP PEA_ 1T6 3732 3809 HSACMHCP PEA 1 T7 3732 3809 HSACMHCP PEA 1 T8 3174 3251 HSACMHCP PEA 1 T13 2206 2283 HSACMHCP PEA 1 T26 3561 3638 Segment cluster HSACMHCP_PEA _1node_77 according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This 15 segment can be found in the following transcript(s): HSACMHCP_PEA__1 T2, HSACMHCPPEA_1 T3, HSACMHCPPEA 1 T4, HSACMHCPPEA 1_T6, HSACMHCP_PEA_1_T7 HSACMHCPPEA_ 1 T8, HSACMHCP_PEA 1 T13, HSACMHCPPEA_1_T14 and HSACMHCPPEA lT26. Table 80 below describes the starting and ending position of this segment on each transcript.

WO 2005/069724 PCT/IB2005/001306 454 Table 80 - Segment location on transcripts Transcript name Segment , . Segment -starting pos ion endmng position. HSACMHCP PEAT 12 3810 3911 HSACMHCP PEA 1 T3 3810 3911 HSACMHCP PEA 1 T4 3810 3911 HSACMHCP PEA 1 T6 3810 3911 HSACMHCP PEA 1 T7 3810 3911 HSACMHCP PEA 1 T8 3252 3353 HSACMHCP PEA_1 T13 2284 2385 HSACMHCP PEA 1 T14 390 491 HSACMHCP PEA 1 T26 3639 3740 Segment cluster HSACMHCP_PEA_1_node_78 according to the present invention can be 5 found in the following transcript(s): HSACMHCPPEAlT2, HSACMHCP_PEA 1_T3, HSACMHCP PEA_1_ T4, HSACMHCPPEA 1 T6, HSACMHCPPEA_1 T7, HSACMHCP_PEA 1 _T8, HSACMHCP_PEA 1_T13, HSACMHCPPEA_1_T14 and HSACMHCP_PEA_1_T26. Table 81 below describes the starting and ending position of this segment on each transcript. 10 Table 81 - Segment location on transcripts HSACMHCPPEA_1_T2 3912 3936 HSACMHCP PEA 1 T3 3912 3936 HSACMHCP PEA 1 T4 3912 3936 HSACMHCP PEA 1 T6 3912 3936 HSACMHCP PEA 1 T7 3912 3936 HSACMHCP PEA 1 T8 3354 3378 WO 2005/069724 PCT/IB2005/001306 455 HSACMHCP PEA I TI3 2386 2410 HSACMHCP PEA_1 TI4 492 516 HSACMHCP PEA 1 T26 3741 3765 Segment cluster HSACMHCP_PEA 1 Inode_80 according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEAIT2, HSACMHCPPEA_1 T3, HSACMHCPPEA __T4, HSACMHCP_PEA 1 T6, HSACMHCP_PEA 1T7, HSACMHCP_PEA_ 1T8, HSACMHCP_PEA _I_TI3, HSACMHCPPEA_1_T14 and HSACMHCPPEA_1_T26. Table 82 below describes the starting and ending position of this segment on each transcript. 10 Table 82 - Segment location on transcripts HSACMHCPPEA 1 T2 3937 4055 HSACMHCPPEA 1_T3 3937 4055 HSACMHCPPEA-l_ T4 3937 4055 HSACMHCP PEA 1 T4 3937 4055 HSACMHCP PEA 1 T6 3937 4055 HSACMHCPPEA 1_T7 3937 4055 HSACMHCP PEA 1 T8 3379 3497 HSACMHCP PEA 1_T13 2411 2529 HSACMHCP PEA 1 T14 517 635 HSACMHCP PEA 1 T26 3766 3884 Segment cluster HSACMHCP_PEA 1_node_82 according to the present invention can be found in the following transcript(s): HSACMHCPPEA_1 T2, HSACMHCP_PEA 1_T3, 15 HSACMHCP_PEA_1 T4, HSACMHCP_PEA 1 T6, HSACMHCPPEA_1_T7, HSACMHCP_PEA_IT8, HSACMHCPPEA 1 T13, HSACMHCPPEA 1 T14 and WO 2005/069724 PCT/IB2005/001306 456 HSACMHICP_PEAlT26. Table 83 below describes the starting and ending position of this segment on each transcript. Table 83 - Segment location on transcripts Transcript name Segment Segment starting position ending position HSACMHCP PEA 1 T2 4056 4079 HSACMHCP PEA 1_T3 4393 4416 HSACMHCP PEA 1 T4 4056 4079 HSACMHCP PEA 1 T6 4056 4079 HSACMHCP PEA 1 T7 4056 4079 HSACMHCP PEA 1 T8 3498 3521 HSACMHCP PEA 1 TI3 2530 2553 HSACMHCP PEA 1 T14 636 659 HSACMHCP PEA 1 T26 3885 3908 5 Segment cluster HSACMHCPPEA 1 node_83 according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA 1_T2, HSACMHCP PEA_ 1T3, HSACMHCP PEA 1_T4, HSACMHCP PEA 1 T6, 10 HSACMHCP_PEA_1_T7, HSACMHCPPEA_1_T8, HSACMHCP_PEA_1 T13, HSACMHCPPEA_1_T14 and HSACMHCPPEA_1 T26. Table 84 below describes the starting and ending position of this segment on each transcript. Table 84 - Segment location on transcripts a4°° i a HSACMHCPPEA_1_T2 4080 4145 HSACMHCPPEA_1_T3 4417 4482 HSACMHCPPEAlT4 4080 4145 WO 2005/069724 PCT/IB2005/001306 457 HSACMHCPPEA _T6 4080 4145 HSACMHCP PEA 1_T7 4080 4145 HSACMHCPPEA 1 T8 3522 3587 HSACMHCP PEA 1 T13 2554 2619 HSACMHCP PEA I T14 660 725 HSACMHCP PEA 1 T26 3909 3974 Segment cluster HSACMHCPPEA_1_node_84 according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCPPEA_1_ T2, HSACMHCP_PEA_1_T3, HSACMHCP_PEA 1_T4, HSACMHCP_PEA_1_T6, HSACMHCPPEA_1_T7, HSACMHCP PEA_1lT , HSACMHCPPEA_1_T13, HSACMHCPPEA_1 T14 and HSACMHCPPEAlT26. Table 85 below describes the starting and ending position of this segment on each transcript. 10 Table 85 - Segment location on transcripts HSACMHCPPEA 1 T2 4146 4217 HSACMHCP PEA 1 T3 4483 4554 HSACMHCP PEA_1 T4 4146 4217 HSACMHCP PEA 1 T6 4146 4217 HSACMHCPPEA 1 T7 4146 4217 HSACMHCP PEA 1 T8 3588 3659 HSACMHCP PEA1 1 T13 2620 2691 HSACMHCP PEA 1_T14 726 797 HSACMHCP PEA 1 T26 3975 4046 Segment cluster HSACMHCP_PEA 1 node_85 according to the present invention is WO 2005/069724 PCT/IB2005/001306 458 supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA _I_T2, HSACMHCP PEA _I T3 HSACMHCPPEAIT4, HSACMHCPPEA _I_ T6, HSACMHCP PEA__1 T7, HSACMHCP_PEA_1_T8, HSACMHCP_PEA_I_T13, 5 HSACMHCP PEA 1 T14 and HSACMHCPPEAlT26. Table 86 below describes the starting and ending position of this segment on each transcript. Table 86 - Segment location on transcripts Transcipt name Seget eget statii position ending position HSACMHCP PEA 1 T2 4218 4252 HSACMHCP PEA 1 T3 4555 4589 HSACMHCP PEA I T4 4218 4252 HSACMHCP PEA 1 T6 4218 4252 HSACMHCP PEA 1 T7 4218 4252 HSACMHCP PEA 1 T8 3660 3694 HSACMHCP PEA 1 TI3 2692 2726 HSACMHCP PEA 1 T14 798 832 HSACMHCP PEA 1 T26 4047 4081 10 Segment cluster HSACMHCPPEA_1 node_90 according to. the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA 1 T4. Table 87 below describes the starting and ending position of this segment on each transcript. Table 87- Segment location on transcripts HSACMHCP PEA_1_T4 4603 4706 15 WO 2005/069724 PCT/IB2005/001306 459 Segment cluster HSACMHCP_PEA lnode_91 according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_ 1_T2, 5 HSACMHCP_PEA_IT3, HSACMHCPPEA _I_T4, HSACMHCPPEA I T6, HSACMHCPPEAI _T7, HSACMHCP_PEA_1_T8, HSACMHCP PEA_ 1_T13, HSACMHCP_PEAIT14 and HSACMHCPPEA_1_T26. Table 88 below describes the starting and ending position of this segment on each transcript. Table 88 - Segment location on transcripts Transcript name beinenit ~ 'Segment> -_ start i p sitiIon ending position HSACMHCPPEA 1 T2 4603 4679 HSACMHCP PEA l T3 4940 5016 HSACMHCPPEA_ lT4 4707 4783 HSACMHCP PEA 1 T6 4603 4679 HSACMHCPPEA 1_T7 4603 4679 HSACMHCP PEA 1_T8 4045 4121 HSACMHCP PEA 1 TI3 3077 3153 HSACMHCPPEA 1 TI4 1183 1259 HSACMHCP PEA 1 T26 4432 4508 10 Segment cluster HSACMHCP PEA 1 Inode_92 according to the present invention can be found in the following transcript(s): HSACMHCP_PEA_1 T2, HSACMHCP_PEA _1_T3 HSACMHCP_PEA_I_T4, HSACMHCPPEAI_T6, HSACMHCP PEA_1 _T7, 15 HSACMHCP_PEA 1_T8, HSACMHCP_PEA 1 T13, HSACMHCP PEA_1_T14 and HSACMHCP_PEA_1_T26. Table 89 below describes the starting and ending position of this segment on each transcript. Table 89 - Segment location on transcripts WO 2005/069724 PCT/IB2005/001306 460 Transcript name Segment Segmient starting position endin i position HSACMHCP PEA I T2 4680 4700 HSACMHCP PEA IT3 5017 5037 HSACMHCP PEA 1 T4 4784 4804 HSACMHCP PEA 1 T6 4680 4700 HSACMHCP PEA _ T7 4680 4700 HSACMHCP PEA 1 T8 4122 4142 HSACMHCP PEA 1 T13 3154 3174 HSACMHCP PEA 1 T14 1260 1280 HSACMHCP PEAI T26 4509 4529 Segment cluster HSACMHCP_PEA 1 node_93 according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP PEAlT2, HSACMHCPPEA 1 T3 HSACMHCP_PEAlT4, HSACMHCP_PEA_1_T6, HSACMHCPPEA 1 T7 HSACMHCP_PEAIT8, HSACMHCP_PEA_1_T13, HSACMHCPPEA_1_T14 and HSACMHCP PEA lT26. Table 90 below describes the starting and ending position of this segment on each transcript. 10 Table 90 - Segment location on transcripts HSACMHCPPEA_1_T2 4701 4727 HSACMHCPPEA lT3 5038 5064 HSACMHCP PEA 1_T4 4805 4831 HSACMHCP PEA 1 T6 4701 4727 HSACMHCP PEA_1 T7 4701 4727 HSACMHCP PEA 1 T8 4143 4169 WO 2005/069724 PCT/IB2005/001306 461 H-ISACMHCP PEA 1 T13 3175 3201 HSACMHCP PEA1__T14 1281 1307 HSACMHCP PEA 1 T26 4530 4556 Segment cluster HSACMHCP_PEA 1 node_95 according to the present invention can be found in the following transcript(s): HSACMHCPPEA 1_T2, HSACMHCPPEA_1 T3, 5 HSACMHCPPEA_ 1 T4 HSACMHCP_PEA 1_T6, HSACMHCPPEA 1 T7, HSACMHCPPEA_1_T8, HSACMHCP PEA l T13, HSACMHCP PEA 1 TI4 and HSACMHCP PEA_1_T26. Table 91 below describes the starting and ending position of this segment on each transcript. Table 91 - Segment location on transcripts HSACMHCP PEA 1 T2 4728 4742 HSACMHCP PEA 1_T3 5065 5079 HSACMHCP PEA IT4 4832 4846 HSACMHCP PEA 1 T6 4728 4742 HSACMHCP PEA 1 T7 4728 4742 HSACMHCP PEA 1 T8 4170 4184 HSACMHCP PEA 1 T13 3202 3216 HSACMHCP PEA 1 T14 1308 1322 HSACMHCP PEA 1 T26 4557 4571 10 Segment cluster HSACMHCP_PEA_1_node_98 according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCP_PEA_1 T2, 15 HSACMHCPPEA_ 1 T3 HSACMHCPPEA 1 T4, HSACMHCP_PEA_1_T6, HSACMHCP_PEA 1_T7, HSACMHCPPEA 1 T8, HSACMHCP_PEA 1_T13, WO 2005/069724 PCT/IB2005/001306 462 HSACMHCP PEA I TI4 and HSACMHCP PEA _ T26. Table 92 below describes the starting and ending position of this segment on each transcript. Table 92 - Segment location on transcripts Transcript name SegmenIt -Segment Stig position ending position HSACMI-ICP PEA 1 T2 5007 5036 HSACMHCP PEA 1 T3 5344 5373 HSACMHCP PEA 1 T4 5111 5140 HSACMHCP PEA 1 T6 5007 5036 HSACMHCP PEA 1 T7 5007 5036 HSACMHCPPEA 1_T8 4449 4478 HSACMHCP PEA 1 T13 3481 3510 HSACMHCP PEA 1 T14 1587 1616 HSACMHCP PEA 1 T26 4836 4865 5 Segment cluster HSACMHCP_PEA_1 node_103 according to the present invention is supported by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSACMHCPPEA 1_T2, HSACMHCPPEA_1 T3, HSACMHCPPEA 1_T4, HSACMHCP_PEA__T6, 10 HSACMHCPPEA_ 1 T7 HSACMHCPPEA 1 T8, HSACMHCP_PEA_1 T13, HSACMHCP PEA_1 T14 and HSACMHCPPEA_1 T26. Table 93 below describes the starting and ending position of this segment on each transcript. Table 93 - Segment location on transcripts HSACMHCP PEA 1 T2 5241 5297 HSACMHCP PEA 1 T3 5578 5634 HSACMHCP PEA 1 T4 5345 5401 WO 2005/069724 PCT/IB2005/001306 463 HSACMI-ICP PEA 1 T6 5241 5297 HSACMHCP PEA lT7 5241 5297 HSACMHCP PEA 1 T8 4683 4739 HSACMHCP PEA 1 T13 3715 3771 HSACMHCP PEA 1 T14 1821 1877 HSACMH-CP PEA 1 T26 5070 5126 Segment cluster HSACMHCP_PEA 1 node_104 according to the present invention is supported by 18 libraries. The number of libraries was determined as previously described. This 5 segment can be found in the following transcript(s): HSACMHCP_PEA_1_T2, HSACMHCPPEA 1 T3, HSACMHCPPEAIT4, HSACMHCPPEA 1 _T6, HSACMHCPPEA 1 T7, HSACMHCPPEA 1 T8, HSACMHCPPEA 1_T13, HSACMHCPPEA_1_TI4 and HSACMHCPPEA_1 T26. Table 94 below describes the starting and ending position of this segment on each transcript. 10 Table 94 - Segment location on transcripts HSACMHCPPEA 1 T2 5298 5366 HSACMHCPPEA lT3 5635 5703 HSACMHCP PEA 1 T4 5402 5470 HSACMHCP PEA 1_T6 5298 5366 HSACMHCP PEA 1 T7 5298 5366 HSACMHCP PEA 1 T8 4740 4808 HSACMHCP PEA1 1T3 3772 3840 HSACMHCP PEA 1 TI4 1878 1946 HSACMHCPPEA 1 T26 5127 5195 Segment cluster HSACMHCP_PEA 1 node_109 according to the present invention is WO 2005/069724 PCT/IB2005/001306 464 supported by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): lISACMHCPPEA_1_T2, HSACMHCP_PEA_I_T3, HSACMHCPPEA 1 T4, HSACMHCP PEA_1_T6, HSACMHCP PEA 1 T7 HSACMHCPPEAIT8, HSACMHCP_PEA_1_T13, 5 HSACMHCPPEA 1_T14 and HSACMHCP PEA_1 T26. Table 95 below describes the starting and ending position of this segment on each transcript. Table 95 - Segment location on transcripts Transcript name Segiment Segment starting position ending position HSACMHCP PEA 1 T2 6764 6859 HSACMHCP PEA 1 T3 5980 6075 HSACMHCP PEA 1 T4 5747 5842 HSACMHCP PEA 1 T6 5867 5962 HSACMHCP PEA 1 T7 6962 7057 HSACMHCP PEA 1 T8 5085 5180 HSACMHCP PEA 1 T13 4117 4212 HSACMHCP PEA 1 T14 2223 2318 HSACMHCP PEA 1 T26 6593 6688 10 Variant protein alignment to the previously known protein: Sequence name: MYH6 HUMAN V1 Sequence documentation: 15 Alignment of: HSACMHCP PEA 1 P2 x MYH6_HUMAN VI Alignment segment i/i: 20 Quality: 17978.00 Escore: 0 Matching length: 1855 Total length: 1855 WO 2005/069724 PCT/IB2005/001306 465 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 5 Alignment: 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 1 1 1 l I i l l l l Il l l l l l l l l l l l l l l l 11 1l l I 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 10 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 I l l l l Il l ll II ll l l l l ii li l l l l I ll11 1 l II i l l l l l l 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 15 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 I l l Il1 Ill l l l l l l l1 i l li l l l l i l l l l l l l l l l l l 1 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 2 0 I i l l l i l l i l l l l l l l l !Il l l i l l I l i l 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 I il l I l l i l i l l l i l l l i i l l i ll llT II 25 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 l l l l l l I i l l l I l l l l l l l l l l l l I l l l l l l i 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 30 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 I l l1I I l l l l l l I l l l i i ll iii l llI I I I11 l l l l l I 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 35 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 1 1l l l lI l l l lI 1 ll i l l I l i l l l iI l l l l l I llL L lI II 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 WO 2005/069724 PCT/IB2005/001306 466 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 II II I 1111 II I IFII FIll 111111 Fli l 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 5 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 Ii l l I l l l l l l l I 1 1 l i ll l l l l l l l Il l 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 1 0 I l l Il Il l l l I I I 1 1 1 1 l l l i l l I 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 IIl l l I l I I I l 1 l l l l l I l l I l l I I I l 15 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 IFl111lll Ill F lllll 1l l llll FFlll 1ll Flll FllllllFF li 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 20 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 I I I I 11111F 1111111111 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 25 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 3 0 I l l Il l l I I I I IF lI I I I l l l l Il I IF 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 I I I l l l il l I l I l l l I l l I lIl l I I I I I I I l 35 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 I I l l I FlF l I I I l l I I I I [l l l Il l l l ilI I I ll WO 2005/069724 PCT/IB2005/001306 467 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 I il l l l l i l l i l fl i l l i l l l l l I l lI l l I l i l l i l l l | 5 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 I l l1l l l I Ili l l1 l ll lllllil11ll 111lI Ill III 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 10 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 I l i l I I l l l l l l l l l l l l l l l l l l l i i l l I l l i l l 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 15 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 I lfll l l l llil il l l l i l I I l l l l I l l I I I 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 2 0 I l llIll l l l i l l lll I I l I l l I I I I 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 I l l l I l I l l l i l l I i l l l I l l l I l l l i l l l l i l l 25 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 I l l l l l l l I l l I I I l i l l l l l l l l l l I l l l l l l l l l 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 30 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 I I IIll I II l l l I lI II I l l Il l l lI l l l l l l l 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 35 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350iI 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 WO 2005/069724 PCT/IB2005/001306 468 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 11111111II111I 111I111111111 III 1111 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 5 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 I 11111111 F 111111 I11 II1111111I11111 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 10 III I 1l l I l l l l l lil I I ll l 1 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 1501 KRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAE 1550 15 1501 KRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAE 1550 1551 ASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQ 1600 1551 ASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQ 1600 20 1601 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1650 1601 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1650 25 1651 LLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERS 1700 I l l I I l l l I l l l l l l l l l II I I l l l I I 1651 LLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERS 1700 1701 RKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 1750 3 0 II I IIII l II I I I 1701 RKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 1750 1751 RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLD 1800 lii 11111 I1111 I1111111111 I111111II1 I 35 1751 RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLD 1800 1801 EAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIK 1850 I l l l I l I I I I l l I l l I I I l i l l I l I l I I I Il l WO 2005/069724 PCT/IB2005/001306 469 1801 EAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIK 1850 1851 ELTYQ 1855 5 1851 ELTYQ 1855 Sequence name: MYH6 HUMAN V2 Sequence documentation: 10 Alignment of: HSACMHCP PEA 1 P3 x MYH6 HUMAN V2 Alignment segment 1/1: 15 Quality: 12901.00 Escore: 0 Matching length: 1328 Total length: 1328 Matching Percent Similarity: 99.92 Matching Percent Identity: 99.85 Total Percent Similarity: 99.92 Total Percent Identity: 99.85 Gaps: 0 20 Alignment: 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 IlllllIlllIllilllllillillllllllllllllllilliii 25 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 II l l l l l l l l l i l 1 1 l l l l l l l l l li l l l l I l I l ll l l l i l l l l l 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 30 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 Il li l l l l l l lI l l l l l l lI l l l l i l l l l l l llI l l l l l l l l l l l l l 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 35 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 lI I l l l l l l i l il l l l i l l l l l l l l i l l l l l l II I l l l l l l l l I 0 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 WO 2005/069724 PCT/IB2005/001306 470 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 I l l l I l i l l i l l l l I L l l l l I I l l l l l l lll l I I I l l 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 5 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 SIl l i l lll lI i l ll illl l i l l l i l l l l i l il l i l l I 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 10 1l l l ll l l l F l 1 l l 1 ill11 F11 1 l l1 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 111111111F 111111F 111111111F 111111F I 15 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 I l l l l I l l l l I l l l l l i l I l I I I l l l I I l 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 20 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 1111F FF11111111 FF111 1111111F 11111F 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 25 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 I l l l l l I l l l l l lIl I i I I l i l l i l l l i l I l 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 3 0 I F II1 l lI1l l li l I l l l l l l l l l I l l i1 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 I l l l l lII I I I I I I l I I I I l l I I~ l l l lI II I I I l i 35 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 III1 l ll l l l l lll lF1 llIII l ll l l l l lll lI1 WO 2005/069724 PCT/IB2005/001306 471 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 1111111I 111111111111111111 111111111111 5 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 111lllllllilllll1lll1ll1l1lllllll111111lll1llilllli 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 10 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 I l l l l l l l l l lIl l1 l I l i I llI l l l l l l ll1I l lI l l lIII 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 15 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 I l 1 I l ll1 l l l Ill1 l ll llI l l l iIl l llI l l il l ll1l l l i 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 2 0 I I l l I I I l l l l l l l l l I l l l l i l I l I l 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 Il l l l l l l l l l l l l l i l l l l l l1 l l l l l l l lll ll llIl l l l l l l l i 25 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 I l l l l l l lI l l l l ll I II l l I l l l l Il I l I l l II 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 30 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 I l I l l l l l l l l l I l l l l I I I l l l l l l l I l l l l l l 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 35 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150II 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 WO 2005/069724 PCT/IB2005/001306 472 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 l l ll l l I l l lI l l l l lI l i ll l I l l li l I l l l ll I l ll l ll l i ll 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 5 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 I l i l l l l i l l l l l l l l l l l l l l l l l l i l l l l l lI l l l I l ll l l 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 1 0 I ll l l ll l l l l l il lI l lll l i l l l l ll l l l l i l ii l l 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKVR 1328 illlllIlllllllllllllllll~l : 15 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAK 1328 Sequence name: MYH6 HUMAN V2 Sequence documentation: 20 Alignment of: HSACMHCP PEA 1 P4 x MYH6_HUMANV2 Alignment segment 1/1: 25 Quality: 14661.00 Escore: 0 Matching length: 1508 Total length: 1508 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 30 Alignment: 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 I I l l l l l l Il l l l l l l I l l lll l l l i l l l l l l l li l l l I I I l l i 35 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 Il l ll I I I I l l l l l l l l l i l i l l l l I I I Il l l l i l l l l l l l l l l ll WO 2005/069724 PCT/IB2005/001306 473 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 1111 [111111 111 II111 lii 11111111 11111 1111 5 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 I l l l l l l l l l l Il l l I l l l l l l l l l l l l l l l l l l I I l I I I 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 10 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 l l l l1 1l I l Ill1i lllIllIlll1lI ll1lil 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 15 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 I l l 1 1 11 1 1 1 l i l l l Il l l l l l l l l l l l II l l I I I I 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 20I Il lill il I I I l I l l I l l l lI 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 Ill l l l I I I l I II l i l l l l I l I l l l l I l I l l 25 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 I l l 1 1 l l l i l l l l l l l 1l 1 I I 11 l l I l 1l Il l l l l I l l I I I I 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 30 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 IIll l l l l l l I II l l I l l l l l l l l I l I l l l l I 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 35 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 501 EYKKEGIEWTFIDFGMDLQACIDLIEKIIMGIMSILEEECMFPKATDMTFK 550IIII 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 WO 2005/069724 PCT/IB2005/001306 474 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 I1111111111II1 II 111111111 111 111111I1 F 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 5 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 I I II l l l l i l l i l l l l i l l i l l l l l l l l l I l l 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 10 Il F l li i l I l l lll 111111 111111111 i 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 I I I Il 1111 F 11111111 15 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 I I Il l lII~ l l l l l l l Ii l l l l l l I l l l l l 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 20 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 I I II l l l l l i l l i l l l l l l I l l l i l l l i l 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 25 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 I l fl i I I I l l l l l i l l l l l l l l l i l l l l l l l l 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 3 0I I I II I II Il l IlI 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 I ll1lll Il ! 11 III lll Il llllFF I llli l FI F1ll l ll 35 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 I l l I I I I Il l l l l l l l l Il il l l I l Il l l IlFl I I l l IIFI l WO 2005/069724 PCT/IB2005/001306 475 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 illl Fil l llll lllli lll l 1111111ll ll l l lll ll lll I l 5 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 I l l l I l l l l l l l l l I l l l l l l 1 1 1 1 l l l l I l i lI l lI l l l l l 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 10 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 I l l l l lI l lI l l l l llIl l l l I I Il l I l l l l l Il I l l l l l l l l l 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 15 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 II I l l l l l l l I I I I l l l l I l l l I i l l l l i 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 2 0 I l l l l l l l I l l l l lI l I l l l l l I l l l l l 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 25 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 I l l l l I l l l I I l I l l Il l Il l l l l l l l l I l 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 30 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 II l l l I I I l l I l l l I I I l l l l l l l l l l l l l i 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 35 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500I 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 WO 2005/069724 PCT/IB2005/001306 476 1501 KRENKNLQ 1508 Illlll 1501 KRENKNLQ 1508 5 Sequence name: MYH6_HUMAN Vl Sequence documentation: Alignment of: HSACMHCP PEA 1 P6 x MYH6 HUMAN Vl 10 Alignment segment 1/1: Quality: 17088.00 Escore: 0 Matching length: 1763 Total length: 1763 15 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 Alignment: 20 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 llllllllllllllllllllllltllllllilllllllllllllllllll 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 25 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 I1I lllllllIIlllllllllIIIllllllllIllllllllll 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 3 0 I l l l l l l l l l l Il l l l l llil l ll l l l l l l l l l l l l l Il l l l 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 IlIlllIIlIlllllllIIIIIlIIIllllIlllIIIIIlIllllIII 35 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 IlllllllllllllllIIIllllIIllllllllllllllllllli WO 2005/069724 PCT/IB2005/001306 477 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 l i l l l il l l1 1 1 1 il l l 1l l l i l i l l FI l ll l l I I l l 111 5 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 10 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 I l l f I l l l i l l l I il l l f i ll l I Il l l l l l I 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 15 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 I I l l l l l I l i l I l I I I l l l l l l i l l l 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 2 0 ll l il i I i lII l I I 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 25 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 IIl l I i I I I i l l l il li l l l l Il 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 30 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 I l l l l I I I li l I l l I I I l l lI l l l i l l l I I l 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 35 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNLVMHQLRCNGV 700l 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 WO 2005/069724 PCT/IB2005/001306 478 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 l l l l ll i I l l~ l l Il l l l i l i l I l i l l l [ I I 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 5 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 I l l l i l l l lll I l l l l l I l I l l l l l l l l l l l l l l l I I 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 10 1 1 1 1l I l ll i l I li I l llil ll i l I II I 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 I l l l I l l l I I I I I l l l l I l l l l l l l l i l i I l l i 15 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 I l l l lI i l l l l l I i l l I I i I l l I l i l 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 20 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 25 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 3 0 I l lI I IIil l I ll 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 I l l l l l1 l l II I l l l I l II Il l I l l l l I l l I I I I I l i 35 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 l l l l l lI I l l I I I I I I I l l l Il i l l l l l l l l I ill WO 2005/069724 PCT/IB2005/001306 479 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 i l l l l l l li l l l l l l i l l il l Il i t l l l l l I l I i I l l l l 5 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 l l l i l l l lll li liil l il l I l l l i l l I l l l l i l 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 10 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 I l l l l l l l l l I l l i l I l l I l l l l l I I I l l I 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 15 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 l l l l l l l i l I l l l l llli l l l l l l l lfII I i l 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 2 0 l ll il I i lI l l i i l l l l i i l l l l 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 I l l l l l l l l I l l l I l l I l l l l l l l l l l I l l l l l l l 25 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 1501 KRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAE 1550 I l l I l l i l I l l I l l l l I i l l l l l l l l l l l i 1501 KRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAE 1550 30 1551 ASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQ 1600 I I l l i I I l I I I lI l I I i I I l l l l l l I l i I l l l l l 1551 ASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQ 1600 35 1601 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1650 1601 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1650ili 1601 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1650 WO 2005/069724 PCT/IB2005/001306 480 1651 LLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERS 1700 Illlllllillllllllll[1111llllllillilillll1lllll 1651 LLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERS 1700 5 1701 RKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 1750 lllliliJlllliilllllllllllilllilllillillllll~ 1701 RKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 1750 1751 RNAEEKAKKAITD 1763 10 1 1 1 1 1 1 1 1 1 1 11) 1751 RNAEEKAKKAITD 1763 Sequence name: MYH6_HUMANV3 15 Sequence documentation: Alignment of: HSACMHCP PEA 1 P12 x MYH6 HUMAN V3 Alignment segment 1/1: 20 Quality: 13633.00 Escore: 0 Matching length: 1413 Total length: 1413 Matching Percent Similarity: 100.00 Matching Percent Identity: 99.93 Total Percent Similarity: 100.00 Total Percent Identity: 99.93 25 Gaps: 0 Alignment: 22 QPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEA 71 3 0 : l l l l l l l l I I I Il l l l l l l l l l l l l llll l l l l llI I I I I l l l 527 KPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEA 576 72 HFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYA 121 IIllilllllllllllllillilllllilIllllllllllllllllllll 35 577 HFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYA 626 122 TADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCII 171 Il l l l l l l l l l l l l l l l l l I I l l I I l l l l l l l l i l l l l l l I l l WO 2005/069724 PCT/IB2005/001306 481 627 TADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCII 676 172 PNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRI 221 1 l l l l l l l l i l l l l l l l l l l l l I l l l I 1 1 i l l l I t i ll li 5 677 PNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRI 726 222 LNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLE 271 il lil l l i l ll l ll II l l l il ll l li ii I l l i lll 727 LNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLE 776 10 272 EMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGV 321 I i lll l l l l i l l l l l l l i i l l l [ I l l l i l l l i l l li i l l i 777 EMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGV 826 15 322 KNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELE 371 Ili ill i llll11 lll illlIIill i illl ll i lllllillll111 ll 827 KNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELE 876 372 EKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNE 421 2 0 I I l l l l l l i l l l l l l i i l l I I I I 877 EKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNE 926 422 RLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENK 471 II li lll1 ll lllll ill l I il i ll l illi i l I ll I I 25 927 RLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENK 976 472 VKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDKVNSLSKSK 521 Ilii l i l l li l l l ii l i l l i i l l l l l l l l l l l l I l lI l l li 977 VKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDKVNSLSKSK 1026 30 522 VKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKL 571 Il l l l l li l l l Il lll li i i l I II li l l I lill I l l l l l l Il 1027 VKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKL 1076 35 572 QLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEA 621 I1 0ll I 1 I Il l l l l I l l I l I I ll l l l i l l III Il l l l ii 1077 QLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEA 1126 WO 2005/069724 PCT/IB2005/001306 482 622 ERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKM 671 I 1111111 I il III111F111F [111ll1111 1127 ERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKM 1176 5 672 RRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF 721 I II I l l l I l l I l l lI l l lI I I I Il i l lI l ll l l 1 1177 RRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEF 1226 722 KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFT 771 10 i l i l l i i l1II l ll I l l l 1 1 I I i l I 1227 KLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFT 1276 772 TQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGK 821 i llI I l l l [ll l l il l l l l l l I l l l l l l l l l l I 15 1277 TQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGK 1326 822 AKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTK 871 I l l l l l I l I FI Il l l l l l I I l l l l 1 1 1I Il I l l 1327 AKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTK 1376 20 872 YETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNE 921 Il11 IIll lF IFlll1 11 l l111 lllI l FF1 11111 1 1 1377 YETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNE 1426 25 922 IEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEA 971 11 illlll1 Fll IIIllllllIl l il 1lllI I II ll i 1427 IEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEA 1476 972 RSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVH 1021 3 0I I Ii l ll l I Il l l 1477 RSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVH 1526 1022 ELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIER 1071 I 1l lII I l I I I I I l l I l l ll I I I 1 l l l 1 i l l lI l l I l l I 35 1527 ELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIER 1576 1072 KLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNE 1121 I ll Fi 11l Il ll 1lIl lll 1 I l l I II II I ll ll WO 2005/069724 PCT/IB2005/001306 483 1577 KLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNE 1626 1122 MEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIV 1171 I i l l l l l l l I l l I I l l l l l l l I l l I I I l l l l I l l l l l 5 1627 MEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIV 1676 1172 ERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLI 1221 I II IllFII lI 1111 IF 11111111 I11111 1677 ERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLI 1726 10 1222 NQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQD 1271 I l l l l l l l l l l I l l l l l l l l l l l l l l l l i l l l l l l I l l l 1727 NQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQD 1776 15 1272 TSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEG 1321 Il Il I li l 111 lll 1l I illllll1 1777 TSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEG 1826 1322 ELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLLRLQDLVDKLQLK 1371 2 0 l l l l l l F I l l I l l 1 l l l I l i l l l l l il l l ll i l 1827 ELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLLRLQDLVDKLQLK 1876 1372 VKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKS 1421 F IIl ll l I I i ll l l llI l l l l ll ll l l I l l l l ll1 l i l l l l 25 1877 VKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKS 1926 1422 RDIGAKQKMHDEE 1434 I ll I l l l I 1927 RDIGAKQKMHDEE 1939 30 Sequence name: MYH6_HUMAN V2 Sequence documentation: 35 Alignment of: HSACMHCP PEA 1 Pl6 x MYH6 HUMAN V2 Alignment segment 1/1: WO 2005/069724 PCT/IB2005/001306 484 Quality: 5155.00 Escore: 0 Matching length: 527 Total length: 527 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 5 Gaps: 0 Alignment: 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 10 I 1 l l l l il l lI I I 1 1 1 l li l l I ll l l l l l 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 I I I l l l l l l l l l l l l l l l li l l l l l l l ll l I l I l l l l 15 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 I I l l il l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l llll1 1 1 I I I 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 20 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 I l l ~ l l l l I l i I I l l l l l l l l l l I l l l l l I I If 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 25 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 l i l l l l l 1I I I III l l Il l l l l l l l l l l l l l l l l l l l l I l l l1 I 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 3 0 I I l l l I il l l l l1I I l l l l l l l I I I l I I 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 I l l i l I l l l I I I l l l l lI I II 1 I I l l l l i l lll i l l l lI I II 35 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 I l l l l l l l l l 1 l l l l l l l l l l l l llll ll 1I i l lI l l l I l l l WO 2005/069724 PCT/IB2005/001306 485 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 I I~ ll l i11111111111111 l lll l ll ll ll111l lilli 5 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 I I I I l l I ll i l lI l l l l l ll l lI l l l l l l l l l l l l 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 10 501 EYKKEGIEWTFIDFGMDLQACIDLIEK 527 I li l l l I l l l l l I l l I l l l l l l l ll i 501 EYKKEGIEWTFIDFGMDLQACIDLIEK 527 15 Sequence name: MYH6_HUMAN_V1 Sequence documentation: Alignment of: HSACMHCP PEA 1 P25 x MYH6 HUMAN Vl 20 Alignment segment 1/1: Quality: 17293.00 Escore: 0 Matching length: 1798 Total length: 1855 25 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 96.93 Total Percent Identity: 96.93 Gaps: 1 Alignment: 30 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 IllllllllIlllllilllllllIlllllllllllllillllllillll 1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAK 50 35 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 li l l l1 l l l l II I I I I I I I I IVEll I l l l I l ll ill l l l l l l l l lI l l 1 51 ILSREGGKVIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPA 100 WO 2005/069724 PCT/IB2005/001306 486 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 l 1 ll li i i llllllllIL l 111 I I 11 1 I 11111 III II 101 VLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEA 150 5 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 111 1 I II I I 1 FFI1111 II I1 151 PPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAA 200 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 1 0 l l l II I l i l l I l I I l l l l l l l I I l 201 IGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIR 250 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 11111F 1111 F 1I11I I1 FF11111111111I1111 15 251 IHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLD 300 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 Ill l l l l l l l l l l I l l l F l I I l l l l I II l Il l I l lIF I II 301 MLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGV 350 20 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 351 YKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGL 400 25 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 I I l l l I l I l l l I l l l l l lI lI l l l l l l l l l l l l l II I 401 CHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLET 450 451 KQPRQYFIGVLDIAGFEIFD .............................. 470 3 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 451 KQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQE 500 471 ...........................PMGIMSILEEECMFPKATDMTFK 493 I I I I I l l I I I I II I I I I I I I I 35 501 EYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFK 550 494 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 543 I l I l lI II I I I I I I I I l l l l l l l I l l II I I I I I I I l I I I l lI I I WO 2005/069724 PCT/IB2005/001306 487 551 AKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKD 600 544 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 593 I I II I I I l l l l l ll l l I I Il l l I l l l l l l l l l Il l l l l Il l 5 601 PLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVS 650 594 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 643 I II III IIIII [11111 11111 II 651 ALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGV 700 10 644 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 693 II II l l l l l l l l l l l l l l l l l l l l lI l l l l I l 701 LEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS 750 15 694 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 743 I I II l l l Ii l l l l Il lIl Il l l l l l l l l I l I l l I l i 751 LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMR 800 744 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 793 2 0 1 1 1 1 1 1 1 1 1 1 1 1 1I l l l lI l l 801 IEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKE 850 794 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 843 l l l I l l l I l l I l l l l l l l I I I l l l l I l l I lI l l l I 25 851 MATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNL 900 844 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 893 I l l I l I l l l I l l l l l l l l l I I I I l l l I I I I I I l 901 NDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECS 950 30 894 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 943 II IIll l l lI I I I IIlIll l l l lIli l l l l I l l l I 951 ELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKA 1000 35 944 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 993 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050I I 1001 LQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDL 1050 WO 2005/069724 PCT/IB2005/001306 488 994 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1043 11111111111111I1I111111 1 l 11 1111 l III 1051 ERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQ 1100 5 1044 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1093 I l l l l l l l l l l l I l l l i l I l l l 1 1 ll l l l l l l l l I F I I 1101 ALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE 1150 1094 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1143 10 11111111111111111 F 11111 1 111ll l I i I Fill 1151 RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHAD 1200 1144 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1193 15 1201 SVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKV 1250 1194 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1243 Ill1 ll1 lFI lllll F l lI l llll l 11 [11111FF ll 1 II l I 1251 SRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALI 1300 20 1244 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1293 I l Il l l l l I FI I l l l I l l I l l i l lI li l I l l l l l I 1301 SQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYE 1350 25 1294 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1343 I I l l I l l l I l l I I I I l l l l l l I l l lI I I l l i 1351 EETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQ 1400 1344 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1393 3 0 i l l l l l Il l l I i l l l l l lI I l I I I I 1401 DAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRN 1450 1394 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1443 I I i l l l l l l i l l li l l I l I l l l l l l l I l l l l l l l I l i 35 1451 FDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETF 1500 1444 KRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAE 1493 I II I l l l II l l l I I Il II l l l l l l l l l l l l I I I II WO 2005/069724 PCT/IB2005/001306 489 1501 KRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAE 1550 1494 ASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQ 1543 1 1 l l l I Il l I I l l l l1F I l l l l l lll I l ll l l l l l l l i 5 1551 ASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQ 1600 1544 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1593 I l l l iI I l l I II l l l l l l l l l I i i l l l i l l 1601 TSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQS 1650 10 1594 LLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERS 1643 I l l l l l l l I I I I l l i l l l l l I l l l l l i l l l l l 1 1 1 I l i I l 1651 LLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERS 1700 15 1644 RKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 1693 l l l l l I l l l l lI I I l l l ll i ll l Il i l l l l l I 1701 RKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQEC 1750 1694 RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLD 1743 2 0 I l l l I I I I l I l l l li1l l l l l l l l l l l l l l l i 1751 RNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLD 1800 1744 EAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIK 1793 l l l l i l I I l l l l l l I l l l l l I I I [ l l l l I l ll I I 25 1801 EAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIK 1850 1794 ELTYQ 1798 IllII 1851 ELTYQ 1855 30 Sequence name: MYH6 HUMAN V3 Sequence documentation: 35 Alignment of: HSACMHCP PEA 1 P28 x MYH6 HUMAN V3 Alignment segment 1/1: WO 2005/069724 PCT/IB2005/001306 490 Quality: 17163.00 Escore: 0 Matching length: 1775 Total length: 1775 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 5 Gaps: 0 Alignment: 1 MLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANK 50 10 I l Il ili Il [ Illl llI Lll l 111111111 l1I I 165 MLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANK 214 51 GTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADI 100 I l l l l l l l l l l l il l I ll lI I l I I l l l Il l l lI l l l l l I 15 215 GTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADI 264 101 ETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNPYDYAFV 150 I l l il I I l ll l l l l I l l I l l 265 ETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNPYDYAFV 314 20 151 SQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMK 200 I l l l i l lll l l I i l l ~ l l I I I l l l i l l l l l I 315 SQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMK 364 25 201 FKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTK 250 I l l l I l l I l l l l l I I l l l l l l l I l I l I I I I l 365 FKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTK 414 251 GQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIA 300 3 0 I l l l l Illl l l l I II I Il l l I l l l l l l 415 GQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPR QYFIGVLDIA 464 301 GFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDF 350 I I I ~ l I I I I I l l I l l l I I l l l l I l l l l l l l l l l l l 35 465 GFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDF 514 351 GMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNF 400 I l l l I l l l I I Il Il l l l l l I I l l I I I I I I I l l I WO 2005/069724 PCT/IB2005/001306 491 515 GMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNF 564 401 QKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSS 450 5 565 QKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSS 614 451 LKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNL 500 I l I l l I l i l l l l l l l l l l l l l lli ll l ll l l ll[ I [ 615 LKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNL 664 10 501 RTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNR 550 Illl1 l l ll il l l l li illlll I IIlI lll Il I I IIl 665 RTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNR 714 15 551 ILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTK 600 I I11I1111111111 II 11111I Ii I I 715 ILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTK 764 601 VFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALL 650 20 I ll li l I Il l I ll l111 I 111111111I I 765 VFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALL 814 651 VIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKET 700 I l i i l l l l l l l l l I l l l l l l I l l l l l l l I l l I I 25 815 VIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKET 864 701 LEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNK 750 l l l I l l l l I I l i I l l l i I I l l l l I I 865 LEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNK 914 30 751 IQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLA 800 I l l l II l l l I I I I l l l I l I I I l l il l l IIII IIl l l l l l l I 915 IQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLA 964 35 801 KVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQV 850 9 6 l l i l l l l l i l l l l l l l l I I l l l l l ll l l ll I I I I II 965 KVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQV 1014 WO 2005/069724 PCT/IB2005/001306 492 851 EEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLT 900 I l l I l i l I I l l i l l l l l l l l l lll ll l l i l l i 1015 EEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLT 1064 5 901 QESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQ 950 l i l l l l f l I I I IE I I l l I 1065 QESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQ 1114 951 ARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIE 1000 ]1 II l 11111 11111 111111111 1 11111lii I 1115 ARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIE 1164 1001 MNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQR 1050 I l l l l i l l lli ll l l l l l l l l l i l i l l i l l l 15 1165 MNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQR 1214 1051 VKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVK 1100 1215 VKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVK 1264 20 1101 LEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQM 1150 I l l l l Il l l l l l l I l l l l l l i l l l I I l l l I l l l Il l l l 1265 LEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQM 1314 25 1151 EDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLS 1200 ll l l I I l l Il l l lI l l l I l l l i l l l l lI l l l i l 1315 EDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLS 1364 1201 KANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCS 1250 3 0 I llI lll l l l l l lll Il i l l I I l il l l 1365 KANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCS 1414 1251 SLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEE 1300 I l l I ll l l l lll l I I l l ll II I l l l l I l I l l 35 1415 SLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEE 1464 1301 SQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDL 1350 I l l l i l I l l lI I I l ll i ll I l l l l l i l l l l il l I II WO 2005/069724 PCT/IB2005/001306 493 1465 SQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDL 1514 1351 TEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQ 1400 I l l il l l i l lll l I I l l l llI l l i l l 1 1 i l l I l | 5 1515 TEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQ 1564 1401 LEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVL 1450 I l i l l I l l l l i illI li l l l l l i lll l l l l l l l l i l 1565 LEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVL 1614 10 1451 RVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVR 1500 I l l IllF F F l l Ilil l l l l l l l l l l l l l lFl l ilFF F F 1 1 l 1615 RVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVR 1664 15 1501 ANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSER 1550 I I l l l lIl l l l l l l l l l l l l ll I l l l l iF 1 l l l l l l l 1665 ANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSER 1714 1551 VQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDA 1600 20 I l Fl IIIl I F I l l II lll F Illllll ll 1715 VQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDA 1764 1601 AMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQL 1650 i l l l l l E l i l l l l l l l l l l I l l l I l I l l l l i l l l l 25 1765 AMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQL 1814 1651 QKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLL 1700 I l l l l l i l l l II I I I l l l l I I I l l l l l l il l l lI l l 1815 QKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLL 1864 30 1701 RLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADI 1750 I 1 1L l l I I Il lI l l lF 1 l l l I III l l l l l l l l l l lI l lF F 1865 RLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADI 1914 35 1751 AESQVNKLRAKSRDIGAKQKMHDEE 1775 1915 AESQVNKLRAKSRDIGAKQKMHDEE 1939IIII III 1915 AESQVNKLRAKSRDIGAKQKMHDEE 1939 WO 2005/069724 PCT/IB2005/001306 494 Sequence name: MYH6 HUMAN V3 Sequence documentation: 5 Alignment of: HSACMHCP PEA 1 P29 x MYH6 HUMAN V3 Alignment segment 1/1: Quality: 7441.00 Escore: 0 10 Matching length: 775 Total length: 775 Matching Percent Similarity: 100.00 Matching Percent Identity: 100.00 Total Percent Similarity: 100.00 Total Percent Identity: 100.00 Gaps: 0 15 Alignment: 1 MNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQR 50 l i 1 ll l l l l lll l l l l l l l l1i ll l li ii [ il l l l l il l i l 1165 MNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQR 1214 20 51 VKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVK 100 I l l l l l l i l l l i l l l l l l l l l l i l lll i l l lI l l l l l l 1215 VKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVK 1264 25 101 LEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQM 150 I il l l l l I l l l l li l I l f l l l l I l l l l I I I l I lI l l 1265 LEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQM 1314 151 EDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLS 200 3 0 l I I i l l l l l l l l l l l l l IlI lI l l l l l l l l I 1315 EDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLS 1364 201 KANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCS 250 I l l l l I l l l l l l l l I l li l l l i l l l l l I l l I I i l ll l 1 35 1365 KANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCS 1414 251 SLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEE 300 l Il l l l l I I I I I Il l l l l l l I I Il I l l l l l l i I l I l lI WO 2005/069724 PCT/IB2005/001306 495 1415 SLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEE 1464 301 SQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDL 350 I l Il l l l lll i l l i l l l l l l li l l l 11 1 1 1 l1 ll l i l i I l l l 5 1465 SQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDL 1514 351 TEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQ 400 l I l l l l i l l l l l l l l l l l l l l l l I l l l l I I I ll I l i l l l l i 1515 TEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQ 1564 10 401 LEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVL 450 I F1F 11 1FiF1111111111lllIlllI111lll11 1565 LEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVL 1614 15 451 RVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVR 500 I l l Il l I I I l l i l l l I I l l i l l l l I i l I l l l I l l 1615 RVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVR 1664 501 ANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSER 550 2 0I 1ll l lF 1l1l l l l l ll l i I ll Ill 1665 ANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSER 1714 551 VQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDA 600 I l l l l i I l l l l l l l l l I l l l l l l l l l l l l l l I I I 25 1715 VQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDA 1764 601 AMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQL 650 II Ill l l I l i l l l I I I I I l l lI I I i l l ll I l l i 1765 AMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQL 1814 30 651 QKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLL 700 I II ~ l ll l I I I Il l l l i l lllI ll l l ll I l l l I 1815 QKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLL 1864 35 701 RLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADI 750 1865 RLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADI 1914 1865 RLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADI 1914 WO 2005/069724 PCT/IB2005/001306 496 751 AESQVNKLRAKSRDIGAKQKMHDEE 775 1915 AESQVNKLRAKSRDIGAKQKMHDEE 1939 5 It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in 10 the context of a single embodiment, may also be provided separately or in any suitable subcombination. Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, 15 modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in 20 this application shall not be construed as an admission that such reference is available as prior art to the present invention.

WO 2005/069724 PCT/IB2005/001306 497 <160> NUMBER OF SEQ ID NOS: 350 <210> SEQ ID NO 1 <211> Length: 2,110 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 1 >S67314 PEA 1 T4 TCTGCAGGAGGGAGCTGGGAACGACCTGAGCTAAAGCTCGGAGCTGTGCGAAGAAACCGGAAAAGCCCAGAGCACT TGCAGGGGCGGGTGGGGAGCTAGATGGTGGGGTGGGGTGGGGACGGAGGAGGGCCAGCAGGAGACATTCCGCAGGGA GGGGCAAGCACGTGTGAGGCGGGCGGGGCGCGAAGGGTCAGGCTTTTGCTCAAAACAGGCAGAGGACAAGGTCAGCT CAGCCGCAGACCGAGCCGCTGGTGACTGTCTCCGCCACCAGGCAGTGAGAGTGAAGGGAGAGCGCGAGCTCTGAAGC CCGCTAGACTAAGCTTGGAATCTGAGCTCCATTCACCCCCTCCTATTTCTTGAGACCTTGTCAGTTCCCCTGTGAGC CTCGGACTCCTCACTTGTAAAACGAGGACAGATGCCCGTGCCAGAAGTCAACCAGAGCTTTCCCCGGCGTGGGCACC AGCCCAAGGGCGTTTTGCTTTTCTAGTCTCATCTCTGCTCTGACGCTAAGCTCAAAGAGGGACTGGGGGACGGGAAG ATATCCACCATGGCATGCGCCCTAGCTCTCGGGCTGGTGTTGGCTGCTTCCTTCTCAGATTCCAGAGTGCCTAGAGG CCAGGAAAGGGAGAAGGTCCTACCAGCCTGGGGTAGGGACTCGGGGCCAGGCACTGGCGCTGACGCAGGCTAGCAG GGCGCCACTGGCTGGTCCCCACCCACCTCGGTGGGTTGGGGGATGGGCGCACCAGCCCCTCCTGGGTGAGCCCTAGC CTGGGGCTTCCTATTTCGGGAGCCGGGGGCGTGGGCCACGTCTCCTCATGTGATGCGAGGGCTATTTAAAGCGGCAG CCCGGGCAGGGAGCCGCCGTCGGAGCCCTTGCACGCCTGCTCTCTTGTAGCTTCTCTCAGCCTAGCCCAGCATCACT ATGGTGGACGCTTTCCTGGGCACCTGGAAGCTAGTGGACAGCAAGAATTTCGATGACTACATGAAGTCACTCGGTGT GGGTTTTGCTACCAGGCAGGTGGCCAGCATGACCAAGCCTACCACAATCATCGAAAAGAATGGGGACATTCTCACCC TAAAAACACACAGCACCTTCAAGAACACAGAGATCAGCTTTAAGTTGGGGGTGGAGTTCGATGAGACAACAGCAGAT GACAGGAAGGTCAAGTCCATTGTGACACTGGATGGAGGGAAACTTGTTCACCTGCAGAAATGGGACGGGCAAGAGAC CACACTTGTGCGGGAGCTAATTGATGGAAAACTCATCCTGGTAAGATGGGCAACTTTGGAGCTATATCTGATTGGTT ATTACTACTGCTCTTTCAGCCAAGCCTGTTCTAAAAAGCCAAGTCCTCCCCTGAGAGCTGTAGAAGCTGGGACAAGA GAGTGGTTGTGGGTCAGGGTGGTATCAGGTGGGAATTTTCTGTGTAGTGGCTTTGGACTCACACAGGCCGGAACTCA AATCTTACCTTATAGGCTACATGACTGTGGGCAAATCACCTTTTCCAAGTGCAACTGTAAAACGGGTATTAATAATA CCAACCTTGTAGGGCTGCTGGGAAGCCTGTAAGAGACAGTGTATGCACAGCACAAAGCATCACTGATTGAGGAACAC AGCAGGTGCTCCATGTCCTTTGTTTGCTCTTCCTGTGTTTCTACCTTGCCTCACCTCAGGAAGAAGTAGAAAACAGG GCCAAATCTGATCCCAGGCCCTCTAGGAGGGGCTCCCATTGCCTATCTCAGCATTCCCTTTCCTCTCCTCCCTAGGA CTGCATTGTCACTTGCAGGGACAGGCTCGTGACTGGTGGGGACACTGAATGACAGTACAGTCCTTTCTTCCCCATTC TAGTCCTACCCCATTTCATGCTTTCTATGTCTGGCCTACTGAAACTACTTGACTACTGCTTGGGTAGGAAGTACCA CAGCCAGGCTGGCAGATCTGTTCAAGCTTGGGGACTTCACTTGGAGAATCTAGCCTTGACTGAATTCCCCCCAGACC CAGGGAGAGCAGCCAACTGTGGATTCTGCCTAACCACAGGGCCTCAGGTTTTCACCTAGGCATCTTCACTGCACACC

TTCTTGGGTCAGCATAACCTGTTAACTGCAT

WO 2005/069724 PCT/IB2005/001306 498 <210> SEQ ID NO 2 <211> Length: 1,733 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 2 >S67314 PEA 1 T5 TCTGCAGGAGGGGAGCTGGGAACGACCTGAGCTAAAGCTCGGAGCTGTGCGAAGAAACCGGAAAAGCCCAGAGCACT TGCAGGGGCGGGTGGGGAGCTAGATGGTGGGGTGGGGTGGGGACGGAGGAGGGCCAGCAGGAGACATTCCGCAGGGA GGGGCAAGCACGTGTGAGGCGGGCGGGGCGCGAAGGGTCAGGCTTTTGCTCAAAACAGGCAGAGGACAAGGTCAGCT CAGCCGCAGACCGAGCCGCTGGTGACTGTCTCCGCCACCAGGCAGTGAGAGTGAAGGGAGAGCGCGAGCTCTGAAGC CCGCTAGACTAAGCTTGCAATCTGAGCTCCATTCACCCCCTCCTATTTCTTGAGACCTTGTCAGTTCCCCTGTGAGC CTCGGACTCCTCACTTGTAAAACGAGGACAGATGCCCGTGCCAGAAGTCAACCAGAGCTTTCCCCGGCGTGGGCACC AGCCCAAGGGCGTTTTGCTTTTCTAGTCTCATCTCTGCTCTGACGCTAAGCTCAAAGAGGGACTGGGGGACGGGAAG ATATCCACCATGGCATGCGCCCTAGCTCTCGGGCTGGTGTTGGCTGCTTCCTTCTCAGATTCCAGAGTGCCTAGAGG CCAGGAAAGGGAGAAGGTCCTACCAGCCTGGGGTAGGGACTCGGGGGCCAGGCACTGGCGCTGACGCAGGCTAGCAG GGCGCCACTGGCTGGTCCCCACCCACCTCGGTGGGTTGGGGGATGGGCGCACCAGCCCCTCCTGGGTGAGCCCTAGC CTGGGGCTTCCTATTTCGGGAGCCGGGGGCGTGGGCCACGTCTCCTCATGTGATGCGAGGGCTATTTAAAGCGGCAG CCCGGGCAGGGAGCCGCCGTCGGAGCCCTTGCACGCCTGCTCTCTTGTAGCTTCTCTCAGCCTAGCCCAGCATCACT ATGGTGGACGCTTTCCTGGGCACCTGGAAGCTAGTGGACAGCAAGAATTTCGATGACTACATGAAGTCACTCGGTGT GGGTTTTGCTACCAGGCAGGTGGCCAGCATGACCAAGCCTACCACAATCATCGAAAAGAATGGGGACATTCTCACCC TAAAAACACACAGCACCTTCAAGAACACAGAGATCAGCTTTAAGTTGGGGGTGGAGTTCGATGAGACAACAGCAGAT GACAGGAAGGTCAAGTCCATTGTGACACTGGATGGAGGGAAACTTGTTCACCTGCAGAAATGGGACGGGCAAGAGAC CACACTTGTGCGGGAGCTAATTGATGGAAAACTCATCCTGGATGTTCTGACAGCCTGGCCAAGCATCTACAGGAGAC AAGTCAAAGTTTTAAGAGAAGATGAAATAACAATTCTTCCTTGGCATCTCCAATGGAGTAGAGAGAAGGCAACAAAG CTTCTCAGACCCACATTACCGAGCTATAACAACCATGGCTGGGAGGAGCTGAGAGTTGGCAAATCAATAGTTTAGCT ATGTTGCTGAACCTTCCTGGATGGCAAGACCATGGAAGTCCATCACAAGATATTATGGGGTCAGGAGCCTCACTGGG TTCTGCCCCTTATATAGGTGAATATCCTGGGAAAGTAAAAATGAAAATACAGAGTCTGGCACCAGTTCCCTGCAAGC CTGGTCCAGCCTGGATAAAGAAGTGAGGAGAGTAATAATACTGCCTTACACCTAAACAGTGCTTTAGTTTATCAAGC TTTTTGCATCCTTATCTTACAATAATAGTCTGTAGAGTC <210> SEQ ID NO 3 <211> Length: 1,822 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 3 WO 2005/069724 PCT/IB2005/001306 499 >S67314 PEA 1 T6 TCTGCAGGAGGGGAGCTGGGAACGACCTGAGCTAAAGCTCGGAGCTGTGCGAAGAAACCGGAAAAGCCCAGAGCACT TGCAGGGGCGGGTGGGGAGCTAGATGGTGGGGTGGGGTGGGGACGGAGGAGGGCCAGCAGGAGACATTCCGCAGGGA GGGGCAAGCACGTGTGAGGCGGGCGGGGCGCGAAGGGTCAGGCTTTTGCTCAAAACAGGCAGAGGACAAGGTCAGCT CAGCCGCAGACCGAGCCGCTGGTGACTGTCTCCGCCACCAGGCAGTGAGAGTGAAGGGAGAGCGCGAGCTCTGAAGC CCGCTAGACTAAGCTTGCAATCTGAGCTCCATTCACCCCCTCCTATTTCTTGAGACCTTGTCAGTTCCCCTGTGAGC CTCGGACTCCTCACTTGTAAAACGAGGACAGATGCCCGTGCCAGAAGTCAACCAGAGCTTTCCCCGGCGTGGGCACC AGCCCAAGGGCGTTTTGCTTTTCTAGTCTCATCTCTGCTCTGACGCTAAGCTCAAAGAGGGACTGGGGGACGGGAAG ATATCCACCATGGCATGCGCCCTAGCTCTCGGGCTGGTGTTGGCTGCTTCCTTCTCAGATTCCAGAGTGCCTAGAGG CCAGGAAAGGGAGAAGGTCCTACCAGCCTGGGGTAGGGACTCGGGGGCCAGGCACTGGCGCTGACGCAGGCTAGCAG GGCGCCACTGGCTGGTCCCCACCCACCTCGGTGGGTTGGGGGATGGGCGCACCAGCCCCTCCTGGGTGAGCCCTAGC CTGGGGCTTCCTATTTCGGGAGCCGGGGGCGTGGGCCACGTCTCCTCATGTGATGCGAGGGCTATTTAAAGCGGCAG CCCGGGCAGGGAGCCGCCGTCGGAGCCCTTGCACGCCTGCTCTCTTGTAGCTTCTCTCAGCCTAGCCCAGCATCACT ATGGTGGACGCTTTCCTGGGCACCTGGAAGCTAGTGGACAGCAAGAATTTCGATGACTACATGAAGTCACTCGGTGT GGGTTTTGCTACCAGGCAGGTGGCCAGCATGACCAAGCCTACCACAATCATCGAAAAGAATGGGGACATTCTCACCC TAAAAACACACAGCACCTTCAAGAACACAGAGATCAGCTTTAAGTTGGGGGTGGAGTTCGATGAGACAACAGCAGAT GACAGGAAGGTCAAGTCCATTGTGACACTGGATGGAGGGAAACTTGTTCACCTGCAGAAATGGGACGGGCAAGAGAC CACACTTGTGCGGGAGCTAATTGATGGAAAACTCATCCTGATGGAAAAACTGCAACTCAGAAATGTAAAGTGAGTCG ACCAAGGCTAAAGCGGCAAAACCACTATACTTTATAACACAGAGTTTGGCACTATTTCCACTTTGTTCTCTCTCAAA GATGAAGGCTCAGGAGGAGGGAAGATAAAAACAAATCACTGGAGAGTCCTGGCATGCTGGAACATGGACTCTAGCTA GCAAGAAGGGCTCAAGGAGGTGGCCTTCTCCTAGACCTCAACTTTGATGCAAAAGCTGTTTTGCAGCCTGAACAAAG ACAATCCAATCCTCCAGCAAATGGCGTCATTTTCCCTACGTGTCTAGCCTTGAGCTACAGAACAAAAGAACAATCAC ATCCGAAGTTGTAGTTCGCCTGGTTGCGGTGGCTCACGCCTGTGATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGA TCACCTGAGGTCAGGAGGTCGAGACTAGCCTGACCAACATGAAGAAACCCCATCTCTACTAAAAATACAAAATTAGC TGGGCGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCA <210> SEQ ID NO 4 <211> Length: 3,531 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 4 >S67314 PEA 1 T7 TCTGCAGGAGGGGAGCTGGGAACGACCTGAGCTAAAGCTCGGAGCTGTGCGAAGAAACCGGAAAAGCCCAGAGCACT TGCAGGGGCGGGTGGGGAGCTAGATGGTGGGGTGGGGTGGGGACGGAGGAGGGCCAGCAGGAGACATTCCGCAGGGA GGGGCAAGCACGTGTGAGGCGGGCGGGGCGCGAAGGGTCAGGCTTTTGCTCAAAACAGGCAGAGGACAAGGTCAGCT CAGCCGCAGACCGAGCCGCTGGTGACTGTCTCCGCCACCAGGCAGTGAGAGTGAAGGGAGAGCGCGAGCTCTGAAGC

CCGCTAGACTAAGCTTGCAATCTGAGCTCCATTCACCCCCTCCTATTTCTTGAGACCTTGTCAGTTCCCCTGTGAGC

WO 2005/069724 PCT/IB2005/001306 500 CTCGGACTCCTCACTTGTAAAACGAGGACAGATGCCCGTGCCAGAAGTCAACCAGAGCTTTCCCCGGCGTGGGCACC AGCCCAAGGGCGTTTTGCTTTTCTAGTCTCATCTCTGCTCTGACGCTAAGCTCAAAGAGGGACTGGGGGACGGGAAG ATATCCACCATGGCATGCGCCCTAGCTCTCGGGCTGGTGTTGGCTGCTTCCTTCTCAGATTCCAGAGTGCCTAGAGG CCAGGAAAGGGAGAAGGTCCTACCAGCCTGGGGTAGGGACTCGGGGGCCAGGCACTGGCGCTGACGCAGGCTAGCAG GGCGCCACTGGCTGGTCCCCACCCACCTCGGTGGGTTGGGGGATGGGCGCACCAGCCCCTCCTGGGTGAGCCCTAGC CTGGGGCTTCCTATTTCGGGAGCCGGGGGCGTGGGCCACGTCTCCTCATGTGATGCGAGGGCTATTTAAAGCGGCAG CCCGGGCAGGGAGCCGCCGTCGGAGCCCTTGCACGCCTGCTCTCTTGTAGCTTCTCTCAGCCTAGCCCAGCATCACT ATGGTGGACGCTTTCCTGGGCACCTGGAAGCTAGTGGACAGCAAGAATTTCGATGACTACATGAAGTCACTCGCTCA TATACTCATAACCTTCCCCCTACCCTCAGGTGTGGGTTTTGCTACCAGGCAGGTGGCCAGCATGACCAAGCCTACCA CAATCATCGAAAAGAATGGGGACATTCTCACCCTAAAAACACACAGCACCTTCAAGAACACAGAGATCAGCTTTAAG TTGGGGGTGGAGTTCGATGAGACAACAGCAGATGACAGGAAGGTCAAGTCCATTGTGACACTGGATGGAGGGAAACT TGTTCACCTGCAGAAATGGGACGGGCAAGAGACCACACTTGTGCGGGAGCTAATTGATGGAAAACTCATCCTGACAC TCACCCACGGCACTGCAGTTTGCACTCGCACTTATGAGAAAGAGGCATGACCTGACTGCACTGTTGCTGACTACTAC TCTGCCAATCGGCTACCCCTCGACTCAGCACCACATTGCCTCATTTCTTCCTCTGCATTTTGTACAAATCCACGAAT TCTTCTGGGTCAGGTGCCACTGACCGGGATCCAGTTCCAGTTCCCATGGTGTATGTGGTTTTTTTTTTTTTTTTTT AACTGCACTCATAGGGTGCTCTGAGGTCAATAAAGCAGAGCCAAGGCCACCCAGTTGCCTTTTTGCCTTTGGTAACA TAACTCTGGGAGTCTTGGTTTATCCTGTGTGTCAGAGAGTGGGCAGAAATAACGGCCTGAAGGTTACTGAGGAAGAA GCACTGGATGGGAGACTGAAATGGACAGTCTCGGAGCCTGTTAATCAGCTGATCACCTTACACATTTAATAATAAAA GAGCTGTACCTACACGTTGCCTTTACACTGCCCCCCCTCCATGGTCAAATGACCTAGTTCAGTCAGTGATGGGGCTT CCCCAGGTTTGGCTATTGAACTGTCACTTCAGGCCCATCCTACACTGAAAGCTCTTGGGTCTGGCTGTTCTCTGTGA AATGCTGTAGTCTCTCCCTTTCCAGAATTCAGGTTCAGGGCACAGAACCCAGGCTTGTACCATGGTGGTGGGAGAAA ATGACCACTGGCCAAGAGGACTGCTGACCTGTGCACCAGGCTAGTACTTATGACTACAAATTCTTACTGCTTCTCTA ATCAACTCTGAGGGAAGAGGGCATCTGATCATTACAAAAGGGAGGGCTTATAAGTGATCTCCCAAGAAGGCAGTGAT CTGCTAGTGCCTTTGGCTCTGTACCTCTGCTGGGCATCTCTCCAAGGTCTAAGGTAACATATTAAATGTTTTTGTCA GCTAATGCAGGCTCAGTGACTTTAAGTCTGTAAGTTACCCAGGAAGAAGGATTATAGGAAAAATAACTCAGTAAGTT TAAAACCAAACACATTTCCATTTAGTGACAGGAATTTAAGCAAGGACCTGAAGTAGAATCAACTGATTCACACAGTA GTAAATACAAAGTAGAACAATGATCTTGGCTTCGCTGTCTGGTTCAGTGGTCTGCTGGAATGCAATACACAAGTTAA GTCACACTGCAGACTGTTTTCTAGCTGTGGCCGCTGGATGCCACTTCTAGCATAGTAGAACTATGTTAGGAGGAATG GGAAAAGTGAGCACCACTTCTCACCATGTTCCCCCCTCCTGCTGCCAGTCTCTGCTCCCATGTTGGATGCAGCAGAG ATCACCCACCAGTTGGCCCAGGACAGACCAATAGGAAGGGTCCAATCACTCTAACTACAGCCGAACTCACCTCCACA ACAGTCTCTGTGGCTCTAGCCTGGACTCCTTTACAGGAATCCAGCTCTGGCAGTGGCAGCTGGAGAGGGTAATAGGG CCTCCTGCTGAATGAAGGAAGTTGGGTGAATGAATGGGTGAGCTGCAGGGTTCACTTGCAAAGGGACCAGGAGTGAT AAGGAAACAACAACTCATTCAGGCAGCTGCTTTTGACCTCTAACTCCCAAACCTGCCTGTTGCATGAGGGGAAGCCA TCTCCCATGGGAGCGAAGTTAATGGGGTGGGAGGCTATATTCTCACTATTGAGTCTTTCCAGGAGTCTCAAGGCACA AGGCTCCTGGTTTCTTACTCTCAACCACCCCCTACACTCTTTATACTCTCACTCCTTGTGCTTCTTCTTGTGCTTCT TCTTCTTTTTCTTCTTCTTTGCTGCCTTGCTGTCTTTTGATGTGTGCCTTGCCCTCTTGCCTGTATCACTCTCAGAG TCTGAGCTGTCAGAGTCAGATGACTTCCTATCTCTATGTTTCTTTTTCTTCTTCTCCTGAAAAGAAAATTTTAAAAA

TCAACACTGTATGTGTATATTTGCTTTTAACAATCATAGCACATAATTGGCCAGGTGCAGTGGCTCACACCTGTAAT

WO 2005/069724 PCT/IB2005/001306 501 CCTAGTACTTTGGGAAGCCGAGGTGGGAGGAATGCTTGAGGCCAGGAGTTCAAGATCAACCTGGCTAACATAGCAAG ATCTCATCTCTAAAAAGAGAAAAAAAGAAAAATTATAGCACACAATCAATAGGGGACCACTTAATTTTCTTTTAGAC AGTCTCGCTCTGTTGCCCAGGCTAGAGTGCAGTGCAGTGGCACGATCACAGCTCACTGCAACCTCA <210> SEQ ID NO 5 <211> Length: 2,778 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 5 >N56180 Tl ATGCGTGCGTGCGTGCGTGCGTGTGTGTGTGTGTGTGCCTCTGCTCTTTGTCCTGAGCCCACGATTCCAGAGCTGGC TGGACCCAAGGAGGTGAAGAGTCACTTTTCAGCCCCAGGAAGGGCAAAGAAGAGAGAAAATCAGCCTGTCTGCTCTC TCCTTGGCTCAACAAGGCCTCTAACAGTCTTCTGTCCTCTATTCTGCACACGGCATATTTGGGAACGAGAAACAAAA GTTTTCCCAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCTGTCCTCTTGCAGGGCAGAAGAGGGGC TTAATTTCCCCACATATGATGGGAAGGACCGAGTGGTAAGTCTTTCCGAGAAGAACTTCAAGCAGGTTTTAAAGAAA TATGACTTGCTTTGCCTCTACTACCATGAGCCGGTGTCTTCAGATAAGGTCACGCAAAAACAGTTCCAACTGAAAGA AATCGTGCTTGAGCTTGTGGCCCAGGTCCTTGAACATAAAGCTATAGGCTTTGTGATGGTGGATGCCAAGAAAGAAG CCAAGCTTGCCAAGAAACTGGGTTTTGATGAAGAAGGAAGCCTGTATATTCTTAAGGGTGATCGCACAATAGAGTTT GATGGCGAGTTTGCAGCTGATGTCTTGGTGGAGTTCCTCTTGGATCTAATTGAAGACCCAGTGGAGATCATCAGCAG CAAACTGGAAGTCCAAGCCTTCGAACGCATTGAAGACTACATCAAACTCATTGGCTTTTTCAAGAGTGAGGACTCAG AATACTACAAGGCTTTTGAAGAAGCAGCTGAACACTTCCAGCCTTACATCAAATTCTTTGCCACCTTTGACAAAGGG GTGCTGTGGCTCACACCTGTAATCCCAACACTTTGGGAGGCTGACGGGGGTGGATTGCATGAGCCTTGGAGTTGGAG ACCAGCCTGGGCAACATGGTTGCAAAGAAATTATCTTTGAAGATGAATGAGGTTGACTTCTATGAGCCATTTATGGA TGAGCCCATTGCCATCCCCAACAAACCTTACACAGAAGAGGAGCTGGTGGAGTTTGTGAAGGAACACCAAAGACCCA CTCTACGTCGCCTGCGCCCAGAAGAAATGTTTGAAACATGGGAAGATGATTTGAATGGGATCCACATTGTGGCCTTT GCAGAGAAGAGTGATCCAGATGGCTACGAATTCCTGGAGATCCTGAAACAGGTTGCCCGGGACAATACTGACAACCC CGATCTGAGCATCCTGTGGATCGACCCGGACGACTTTCCTCTGCTCGTTGCCTACTGGGAGAAGACTTTCAAGATTG ACCTATTCAGGCCACAGATTGGGGTGGTGAATGTCACAGATGCTGACAGTGTCTGGATGGAGATTCCAGATGATGAC GATCTTCCAACTGCTGAGGAGCTGGAGGACTGGATTGAGGATGTGCTTTCTGGAAAGATAAACACTGAAGATGATGA TGAAGATGATGATGATGATGATAATTCTGATGAAGAGGATAATGATGACAGTGATGACGATGATGATGAATAGCCCA ACTCCAAACAATTCTGATGAAAACAAAATCACAGCACCCCACCTACATACAGACAGCACAAGGTGGCAGCAAGCAATT CTGCCCCACACCCAGCCAGCTCCTTTCCCTTTTCCATCATCTCTTTTCCCACTCCCTTTGCGTCAGGAGCAGCATCA TTCAGCAAATGCCTTTTCAAATGCAGCAATCCCACTTAGCAGGGACAGGAGAAAAATTATTCCCATGTTGACTGTCT TGACTGTCACGGAACAGATCTTGTTCTTTGCTGGACCATCAAGGGTCATGGCAGTGCCTGAACATGGCAGTCTAGGG TGAACAATCCCCTAACACAAGTTTACTTGTCTTTGATTATGACAGTAACAAAATTGACAGCTTTCTAACTCACAGGC ATAGAGTGACCTTTTAATCAGAGCCCAGGGAAGACACATGATTAATGATTTAGCTCCCTCCATACCTCGAACATCAG

TTGGGATCCCTCCTCCAGCCAAGATGATCCTTCTTAGAGAAGGCTCAGCCTTGGAAGCAAACTTATAAATCATATTC

WO 2005/069724 PCT/IB2005/001306 502 TCATGGCTTTGTTAAACTTATTTCAAGTGATGGTCATTCATATCACTATGAACTTGGATATTCAAGCCTTTGGATGG CTATGGAGAGGCCTTGAAATGTGTACAGGTGTCACCATCATTTCTAGTATATTAGGAAACTGGGATGGGAGGTTGAT TTGCTCTCTAAACTTCCCTCTAGTTGGCAAGTCTCACATATTCATCAGCAGGAGTGGAGGGTGGGGGAAAACTAGAA AGATGAAAACTTTTACATTTTTCTGATGGGTTCATGTCTCTGATTGGGTCAGCTGGCTTCCTAGCCTAAGCTGGGAT CTGAATACCCCTTCTCTGTAGCTGCTAGTGAGCCTTCCCATTTAGATTAAAGATTGCTTTATCCAGCAGTCAATTAA CTCTCCAGTTATCAGTACTCCCACAATTGGCCAGGGCAACAATAATTGGAGTTCATACTGATGCCCTGAGGCACTGA AAAAAAAAAAAATCCCAAAGTGCCTTCTGAGCTGTCTAAAAGTTACATTGTGCTTGGTAGATTTAGTGTTAAGTGTG CAGTATAATTTTCTAATTTATTTTCTCAATCTTTTAGCACATGTGTAAGACACTGTGCAAATTTTTTGAAAATAGAG CAATACTTTTTGTGGAATACTAGCTAACTAATTCTGTCATTAAACTCATATTTTGAAAATATTCAGACAATGTTGAA AATCCT <210> SEQ ID NO 6 <211> Length: 2,824 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 6 >N56180 T3 ATGCGTGCGTGCGTGCGTGCGTGTGTGTGTGTGTGTGCCTCTGCTCTTTGTCCTGAGCCCACGATTCCAGAGCTGGC TGGACCCAAGGAGGTGAAGAGTCACTTTTCAGCCCCAGGAAGGGCAAAGAAGAGAGAAAATCAGCCTGTCTGCTCTC TCCTTGGCTCAACAAGGCCTCTAACAGTCTTCTGTCCTCTATTCTGCACACGGCATATTTGGGAACGAGAAACAAAA GTTTTCCCAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCTGTCCTCTTGCAGGGCAGAAGAGGGGC TTAATTTCCCCACATATGATGGGAAGGACCGAGTGGTAAGTCTTTCCGAGAAGAACTTCAAGCAGGTTTTAAAGAAA TATGACTTGCTTTGCCTCTACTACCATGAGCCGGTGTCTTCAGATAAGGTCACGCAAAAACAGTTCCAACTGAAAGA AATCGTGCTTGAGCACTGGCAAATATCCCAGTGGTGGTTGCATTTCCAAACCCCAAGAGAGGAAGGCAAAATGAAGT TGCTGGAGTTGAGTGAATCTGCAGATGGAGCTGCGTGGAAACGCTGGGGAGGGAATAGCAACACACACAGGATTCAG CTTGTGGCCCAGGTCCTTGAACATAAAGCTATAGGCTTTGTGATGGTGGATGCCAAGAAAGAAGCCAAGCTTGCCAA GAAACTGGGTTTTGATGAAGAAGGAAGCCTGTATATTCTTAAGGGTGATCGCACAATAGAGTTTGATGGCGAGTTTG CAGCTGATGTCTTGGTGGAGTTCCTCTTGGATCTAATTGAAGACCCAGTGGAGATCATCAGCAGCAAACTGGAAGTC CAAGCCTTCGAACGCATTGAAGACTACATCAAACTCATTGGCTTTTTCAAGAGTGAGGACTCAGAATACTACAAGGC TTTTGAAGAAGCAGCTGAACACTTCCAGCCTTACATCAAATTCTTTGCCACCTTTGACAAAGGGGTTGCAAAGAAAT TATCTTTGAAGATGAATGAGGTTGACTTCTATGAGCCATTTATGGATGAGCCCATTGCCATCCCCAACAAACCTTAC ACAGAAGAGGAGCTGGTGGAGTTTGTGAAGGAACACCAAAGACCCACTCTACGTCGCCTGCGCCCAGAAGAAATGTT TGAAACATGGGAAGATGATTTGAATGGGATCCACATTGTGGCCTTTGCAGAGAAGAGTGATCCAGATGGCTACGAAT TCCTGGAGATCCTGAAACAGGTTGCCCGGGACAATACTGACAACCCCGATCTGAGCATCCTGTGGATCGACCCGGAC GACTTTCCTCTGCTCGTTGCCTACTGGGAGAAGACTTTCAAGATTGACCTATTCAGGCCACAGATTGGGGTGGTGAA TGTCACAGATGCTGACAGTGTCTGGATGGAGATTCCAGATGATGACGATCTTCCAACTGCTGAGGAGCTGGAGGACT

GGATTGAGGATGTGCTTTCTGGAAAGATAAACACTGAAGATGATGATGAAGATGATGATGATGATGATAATTCTGAT

WO 2005/069724 PCT/IB2005/001306 503 GAAGAGGATAATGATGACAGTGATGACGATGATGATGAATAGCCCAACTCCAAACAATTCTGATGAAAACAAAATCA CAGCACCCACTACCATACAGACAGCACAAGGTGGCAGCAAGCAATTCTGCCCCACACCCAGCCAGCTCCTTTCCCTT TTCCATCATCTCTTTTCCCACTCCCTTTGCGTCAGGAGCAGCATCATTCAGCAAATGCCTTTTCAAATGCAGCAATC CCACTTAGCAGGGACAGGAGAAAAATTATTCCCATGTTGACTGTCTTGACTGTCACGGAACAGATCTTGTTCTTTGC TGGACCATCAAGGGTCATGGCAGTGCCTGAACATGGCAGTCTAGGGTGAACAATCCCCTAACACAAGTTTACTTGTC TTTGATTATGACAGTAACAAAATTGACAGCTTTCTAACTCACAGGCATAGAGTGACCTTTTAATCAGAGCCCAGGGA AGACACATGATTAATGATTTAGCTCCCTCCATACCTCGAACATCAGTTGGGATCCCTCCTCCAGCCAAGATGATCCT TCTTAGAGAAGGCTCAGCCTTGGAAGCAAACTTATAAATCATATTCTCATGGCTTTGTTAAACTTATTTCAAGTGAT GGTCATTCATATCACTATGAACTTGGATATTCAAGCCTTTGGATGGCTATGGAGAGGCCTTGAAATGTGTACAGGTG TCACCATCATTTCTAGTATATTAGGAAACTGGGATGGGAGGTTGATTTGCTCTCTAAACTTCCCTCTAGTTGGCAAG TCTCACATATTCATCAGCAGGAGTGGAGGGTGGGGGAAAACTAGAAAGATGAAAACTTTTACATTTTTCTGATGGGT TCATGTCTCTGATTGGGTCAGCTGGCTTCCTAGCCTAAGCTGGGATCTGAATACCCCTTCTCTGTAGCTGCTAGTGA GCCTTCCCATTTAGATTAAAGATTGCTTTATCCAGCAGTCAATTAACTCTCCAGTTATCAGTACTCCCACAATTGGC CAGGGCAACAATAATTGGAGTTCATACTGATGCCCTGAGGCACTGAAAAAAAAAAAAATCCCAAAGTGCCTTCTGAG CTGTCTAAAAGTTACATTGTGCTTGGTAGATTTAGTGTTAAGTGTGCAGTATAATTTTCTAATTTATTTTCTCAATC TTTTAGCACATGTGTAAGACACTGTGCAAATTTTTTGAAAATAGAGCAATACTTTTTGTGGAATACTAGCTAACTAA TTCTGTCATTAAACTCATATTTTGAAAATATTCAGACAATGTTGAAAATCCT <210> SEQ ID NO 7 <211> Length: 2,497 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 7 >N56180 T4 ATGCGTGCGTGCGTGCGTGCGTGTGTGTGTGTGTGTGCCTCTGCTCTTTGTCCTGAGCCCACGATTCCAGAGCTGGC TGGACCCAAGGAGGTGAAGAGTCACTTTTCAGCCCCAGGAAGGGCAAAGAAGAGAGAAAATCAGCCTGTCTGCTCTC TCCTTGGCTCAACAAGGCCTCTAACAGTCTTCTGTCCTCTATTCTGCACACGGCATATTTGGGAACGAGAAACAAAA GTTTTCCCAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCTGTCCTCTTGCAGGGCAGAAGAGGGGC TTAATTTCCCCACATATGATGGGAAGGACCGAGTGGTAAGTCTTTCCGAGAAGAACTTCAAGCAGGTTTTAAAGAAA TATGACTTGCTTTGCCTCTACTACCATGAGCCGGTGTCTTCAGATAAGGTCACGCAAAAACAGTTCCAACTGAAAGA AATCGTGCTTGAGCTTGTGGCCCAGGTCCTTGAACATAAAGCTATAGGCTTTGTGATGGTGGATGCCAAGAAAGAAG CCAAGCTTGCCAAGAAACTGGGTTTTGATGAAGAAGGAAGCCTGTATATTCTTAAGGGTGATCGCACAATAGAGTTT GATGGCGAGTTTGCAGCTGATGTCTTGGTGGAGTTCCTCTTGGATGTTGCAAAGAAATTATCTTTGAAGATGAATGA GGTTGACTTCTATGAGCCATTTATGGATGAGCCCATTGCCATCCCCAACAAACCTTACACAGAAGAGGAGCTGGTGG AGTTTGTGAAGGAACACCAAAGACCCACTCTACGTCGCCTCGCCCCAGAAGAAATGTTTGAAACATGGGAAGATGAT TTGAATGGGATCCACATTGTGGCCTTTGCAGAGAAGAGTGATCCAGATGGCTACGAATTCCTGGAGATCCTGAAACA

GGTTGCCCGGGACAATACTGACAACCCCGATCTGAGCATCCTGTGGATCGACCCGGACGACTTTCCTCTGCTCGTTG

WO 2005/069724 PCT/IB2005/001306 504 CCTACTGGGAGAAGACTTTCAAGATTGACCTATTCAGGCCACAGATTGGGGTGGTGAATGTCACAGATGCTGACAGT GTCTGGATGGAGATTCCAGATGATGACGATCTTCCAACTGCTGAGGAGCTGGAGGACTGGATTGAGGATGTGCTTTC TGGAAAGATAAACACTGAAGATGATGATGAAGATGATGATGATGATGATAATTCTGATGAAGAGGATAATGATGACA GTGATGACGATGATGATGAATAGCCCAACTCCAAACAATTCTGATGAAAACAAAATCACAGCACCCACTACCATACA GACAGCACAAGGTGGCAGCAAGCAATTCTGCCCCACACCCAGCCAGCTCCTTTCCCTTTTCCATCATCTCTTTTCCC ACTCCCTTTGCGTCAGGAGCAGCATCATTCAGCAAATGCCTTTTCAAATGCAGCAATCCCACTTAGCAGGGACAGGA GAAAAATTATTCCCATGTTGACTGTCTTGACTGTCACGGAACAGATCTTGTTCTTTGCTGGACCATCAAGGGTCATG GCAGTGCCTGAACATGGCAGTCTAGGGTGAACAATCCCCTAACACAAGTTTACTTGTCTTTGATTATGACAGTAACA AAATTGACAGCTTTCTAACTCACAGGCATAGAGTGACCTTTTAATCAGAGCCCAGGGAAGACACATGATTAATGATT TAGCTCCCTCCATACCTCGAACATCAGTTGGGATCCCTCCTCCAGCCAAGATGATCCTTCTTAGAGAAGGCTCAGCC TTGGAAGCAAACTTATAAATCATATTCTCATGGCTTTGTTAAACTTATTTCAAGTGATGGTCATTCATATCACTATG AACTTGGATATTCAAGCCTTTGGATGGCTATGGAGAGGCCTTGAAATGTGTACAGGTGTCACCATCATTTCTAGTAT ATTAGGAAACTGGGATGGGAGGTTGATTTGCTCTCTAAACTTCCCTCTAGTTGGCAAGTCTCACATATTCATCAGCA GGAGTGGAGGGTGGGGGAAAACTAGAAAGATGAAAACTTTTACATTTTTCTGATGGGTTCATGTCTCTGATTGGGTC AGCTGGCTTCCTAGCCTAAGCTGGGATCTGAATACCCCTTCTCTGTAGCTGCTAGTGAGCCTTCCCATTTAGATTAA AGATTGCTTTATCCAGCAGTCAATTAACTCTCCAGTTATCAGTACTCCCACAATTGGCCAGGGCAACAATAATTGGA GTTCATACTGATGCCCTGAGGCACTGAAAAAAAAAAAAATCCCAAAGTGCCTTCTGAGCTGTCTAAAAGTTACATTG TGCTTGGTAGATTTAGTGTTAAGTGTGCAGTATAATTTTCTAATTTATTTTCTCAATCTTTTAGCACATGTGTAAGA CACTGTGCAAATTTTTTGAAAATAGAGCAATACTTTTTGTGGAATACTAGCTAACTAATTCTGTCATTAAACTCATA TTTTGAAAATATTCAGACAATGTTGAAAATCCT <210> SEQ ID NO 8 <211> Length: 2,209 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 8 >N56180 T5 TAATGAGACAGAGGCTGAGCAGAGCTATGTAAGGGCAGAAGAGGGGCTTAATTTCCCCACATATGATGGGAAGGACC GAGTGGTAAGTCTTTCCGAGAAGAACTTCAAGCAGGTTTTAAAGAAATATGACTTGCTTTGCCTCTACTACCATGAG CCGGTGTCTTCAGATAAGGTCACGCAAAAACAGTTCCAACTGAAAGAAATCGTGCTTGAGCTTGTGGCCCAGGTCCT TGAACATAAAGCTATAGGCTTTGTGATGGTGGATGCCAAGAAAGAAGCCAAGCTTGCCAAGAAACTGGACTACAAGG CTTTTGAAGAAGCAGCTGAACACTTCCAGCCTTACATCAAATTCTTTGCCACCTTTGACAAAGGGGTTGCAAAGAAA TTATCTTTGAAGATGAATGAGGTTGACTTCTATGAGCCATTTATGGATGAGCCCATTGCCATCCCCAACAAACCTTA CACAGAAGAGGAGCTGGTGGAGTTTGTGAAGGAACACCAAAGACCCACTCTACGTCGCCTGCGCCCAGAAGAAATGT TTGAAACATGGGAAGATGATTTGAATGGGATCCACATTGTGGCCTTTGCAGAGAAGAGTGATCCAGATGGCTACGAA TTCCTGGAGATCCTGAAACAGGTTGCCCGGGACAATACTGACAACCCCGATCTGAGCATCCTGTGGATCGACCCGGA

CGACTTTCCTCTGCTCGTTGCCTACTGGGAGAAGACTTTCAAGATTGACCTATTCAGGCCACAGATTGGGGTGGTGA

WO 2005/069724 PCT/IB2005/001306 505 ATGTCACAGATGCTGACAGTGTCTGGATGGAGATTCCAGATGATGACGATCTTCCAACTGCTGAGGAGCTGGAGGAC TGGATTGAGGATGTGCTTTCTGGAAAGATAAACACTGAAGATGATGATGAAGATGATGATGATGATGATAATTCTGA TGAAGAGGATAATGATGACAGTGATGACGATGATGATGAATAGCCCAACTCCAAACAATTCTGATGAAAACAAAATC ACAGCACCCACTACCATACAGACAGCACAAGGTGGCAGCAAGCAATTCTGCCCCACACCCAGCCAGCTCCTTTCCCT TTTCCATCATCTCTTTTCCCACTCCCTTTGCGTCAGGAGCAGCATCATTCAGCAAATGCCTTTTCAAATGCAGCAAT CCCACTTAGCAGGGACAGGAGAAAAATTATTCCCATGTTGACTGTCTTGACTGTCACGGAACAGATCTTGTTCTTTG CTGGACCATCAAGGGTCATGGCAGTGCCTGAACATGGCAGTCTAGGGTGAACAATCCCCTAACACAAGTTTACTTGT CTTTGATTATGACAGTAACAAAATTGACAGCTTTCTAACTCACAGGCATAGAGTGACCTTTTAATCAGAGCCCAGGG AAGACACATGATTAATGATTTAGCTCCCTCCATACCTCGAACATCAGTTGGGATCCCTCCTCCAGCCAAGATGATCC TTCTTAGAGAAGGCTCAGCCTTGGAAGCAAACTTATAAATCATATTCTCATGGCTTTGTTAAACTTATTTCAAGTGA TGGTCATTCATATCACTATGAACTTGGATATTCAAGCCTTTGGATGGCTATGGAGAGGCCTTGAAATGTGTACAGGT GTCACCATCATTTCTAGTATATTAGGAAACTGGGATGGGAGGTTGATTTGCTCTCTAAACTTCCCTCTAGTTGGCAA GTCTCACATATTCATCAGCAGGAGTGGAGGGTGGGGGAAAACTAGAAAGATGAAAACTTTTACATTTTTCTGATGGG TTCATGTCTCTGATTGGGTCAGCTGGCTTCCTAGCCTAAGCTGGGATCTGAATACCCCTTCTCTGTAGCTGCTAGTG AGCCTTCCCATTTAGATTAAAGATTGCTTTATCCAGCAGTCAATTAACTCTCCAGTTATCAGTACTCCCACAATTGG CCAGGGCAACAATAATTGGAGTTCATACTGATGCCCTGAGGCACTGAAAAAAAAAAAAATCCCAAAGTGCCTTCTGA GCTGTCTAAAAGTTACATTGTGCTTGGTAGATTTAGTGTTAAGTGTGCAGTATAATTTTCTAATTTATTTTCTCAAT CTTTAGCACATGTGTAAGACACTGTGCAAATTTTTTGAAAATAGAGCAATACTTTTTGTGGAATACTAGCTAACTA ATTCTGTCATTAAACTCATATTTTGAAAATATTCAGACAATGTTGAAAATCCT <210> SEQ ID NO 9 <211> Length: 2,209 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 9 >N56180 T6 TGCAGGCAAACAGCAACCATTCTGCCTTGACAACACACTGAACATGTGGCTGCTTTAATCCAGAGAGAAAATGTCTT CCTGGCTATCGGCTGGCTCTCCGAGCTCTTTATCTGTTGTTGCAAAGAAATTATCTTTGAAGATGAATGAGGTTGAC TTCTATGAGCCATTTATGGATGAGCCCATTGCCATCCCCAACAAACCTTACACAGAAGAGGAGCTGGTGGAGTTTGT GAAGGAACACCAAAGACCCACTCTACGTCGCCTGCGCCCAGAAGAAATGTTTGAAACATGGGAAGATGATTTGAATG GGATCCACATTGTGGCCTTTGCAGAGAAGAGTGATCCAGATGGCTACGAATTCCTGGAGATCCTGAAACAGGTTGCC CGGGACAATACTGACAACCCCGATCTGAGCATCCTGTGGATCGACCCGGACGACTTTCCTCTGCTCGTTGCCTACTG GGAGAAGACTTTCAAGATTGACCTATTCAGGCCACAGATTGGGGTGGTGAATGTCACAGATGCTGACAGTGTCTGGA TGGAGATTCCAGATGATGACGATCTTCCAACTGCTGAGGAGCTGGAGGACTGGATTGAGGATGTGCTTTCTGGAAAG ATAAACACTGAAGATGATGATGAAGATGATGATGATGATGATAATTCTGATGAAGAGGATAATGATGACAGTGATGA CGATGATGATGAATAGCCCAACTCCAAACAATTCTGATGAAAACAAAATCACAGCACCCACTACCATACAGACAGCA

CAAGGTGGCAGCAAGCAATTCTGCCCCACACCCAGCCAGCTCCTTTCCCTTTTCCATCATCTCTTTCCCACTCCCT

WO 2005/069724 PCT/IB2005/001306 506 TTGCGTCAGGAGCAGCATCATTCAGCAAATGCCTTTTCAAATGCAGCAATCCCACTTAGCAGGGACAGGAGAAAAAT TATTCCCATGTTGACTGTCTTGACTGTCACGGAACAGATCTTGTTCTTTGCTGGACCATCAAGGGTCATGGCAGTGC CTGAACATGGCAGTCTAGGGTGAACAATCCCCTAACACAAGTTTACTTGTCTTTGATTATGACAGTAACAAAATTGA CAGCTTTCTAACTCACAGGCATAGAGTGACCTTTTAATCAGAGCCCAGGGAAGACACATGATTAATGATTTAGCTCC CTCCATACCTCGAACATCAGTTGGGATCCCTCCTCCAGCCAAGATGATCCTTCTTAGAGAAGGCTCAGCCTTGGAAG CAAACTTATAAATCATATTCTCATGGCTTTGTTAAACTTATTTCAAGTGATGGTCATTCATATCACTATGAACTTGG ATATTCAAGCCTTTGGATGGCTATGGAGAGGCCTTGAAATGTGTACAGGTGTCACCATCATTTCTAGTATATTAGGA AACTGGGATGGGAGGTTGATTTGCTCTCTAAACTTCCCTCTAGTTGGCAAGTCTCACATATTCATCAGCAGGAGTGG AGGGTGGGGGAAAACTAGAAAGATGAAAACTTTTACATTTTTCTGATGGGTTCATGTCTCTGATTGGGTCAGCTGGC TTCCTAGCCTAAGCTGGGATCTGAATACCCCTTCTCTGTAGCTGCTAGTGAGCCTTCCCATTTAGATTAAAGATTGC TTTATCCAGCAGTCAATTAACTCTCCAGTTATCAGTACTCCCACAATTGGCCAGGGCAACAATAATTGGAGTTCATA CTGATGCCCTGAGGCACTGAAAAAAAAAAAAATCCCAAAGTGCCTTCTGAGCTGTCTAAAAGTTACATTGTGCTTGG TAGATTTAGTGTTAAGTGTGCAGTATAATTTTCTAATTTATTTTCTCAATCTTTTAGCACATGTGTAAGACACTGTG CAAATTTTTTGAAAATAGAGCAATACTTTTTGTGGAATACTAGCTAACTAATTCTGTCATTAAACTCATATTTTGAA AATATTCAGACAATGTTGAAAATCCT <210> SEQ ID NO 10 <211> Length: 1,740 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 10 >N56180 T7 TCTATAGAATAATCCTATAATTGAGGGTGAGCACCAAATGTCCTAAGAAGTCCTCGTGGAAAAATCACACTCTGCTC TCCACATTAGAAGCTGTGTATGTGCAGGGGTTACTCAACTCTCTTGAATCCTGTTTCAGATGGCTACGAATTCCTGG AGATCCTGAAACAGGTTGCCCGGGACAATACTGACAACCCCGATCTGAGCATCCTGTGGATCGACCCGGACGACTTT CCTCTGCTCGTTGCCTACTGGGAGAAGACTTTCAAGATTGACCTATTCAGGCCACAGATTGGGGTGGTGAATGTCAC AGATGCTGACAGTGTCTGGATGGAGATTCCAGATGATGACGATCTTCCAACTGCTGAGGAGCTGGAGGACTGGATTG AGGATGTGCTTTCTGGAAAGATAAACACTGAAGATGATGATGAAGATGATGATGATGATGATAATTCTGATGAAGAG GATAATGATGACAGTGATGACGATGATGATGAATAGCCCAACTCCAAACAATTCTGATGAAAACAAAATCACAGCAC CCACTACCATACAGACAGCACAAGGTGGCAGCAAGCAATTCTGCCCCACACCCAGCCAGCTCCTTTCCCTTTTCCAT CATCTCTTTTCCCACTCCCTTTGCGTCAGGAGCAGCATCATTCAGCAAATGCCTTTTCAAATGCAGCAATCCCACTT AGCAGGGACAGGAGAAAAATTATTCCCATGTTGACTGTCTTGACTGTCACGGAACAGATCTTGTTCTTTGCTGGACC ATCAAGGGTCATGGCAGTGCCTGAACATGGCAGTCTAGGGTGAACAATCCCCTAACACAAGTTTACTTGTCTTTGAT TATGACAGTAACAAAATTGACAGCTTTCTAACTCACAGGCATAGAGTGACCTTTTAATCAGAGCCCAGGGAAGACAC ATGATTAATGATTTAGCTCCCTCCATACCTCGAACATCAGTTGGGATCCCTCCTCCAGCCAAGATGATCCTTCTTAG AGAAGGCTCAGCCTTGGAAGCAAACTTATAAATCATATTCTCATGGCTTTGTTAAACTTATTTCAAGTGATGGTCAT

TCATATCACTATGAACTTGGATATTCAAGCCTTTGGATGGCTATGGAGAGGCCTTGAAATGTGTACAGGTGTCACCA

WO 2005/069724 PCT/IB2005/001306 507 TCATTTCTAGTATATTAGGAAACTGGGATGGGAGGTTGATTTGCTCTCTAAACTTCCCTCTAGTTGGCAAGTCTCAC ATATTCATCAGCAGGAGTGGAGGGTGGGGGAAAACTAGAAAGATGAAAACTTTTACATTTTTCTGATGGGTTCATGT CTCTGATTGGGTCAGCTGGCTTCCTAGCCTAAGCTGGGATCTGAATACCCCTTCTCTGTAGCTGCTAGTGAGCCTTC CCATTTAGATTAAAGATTGCTTTATCCAGCAGTCAATTAACTCTCCAGTTATCAGTACTCCCACAATTGGCCAGGGC AACAATAATTGGAGTTCATACTGATGCCCTGAGGCACTGAAAAAAAAAAAAATCCCAAAGTGCCTTCTGAGCTGTCT AAAAGTTACATTGTGCTTGGTAGATTTAGTGTTAAGTGTGCAGTATAATTTTCTAATTTATTTTCTCAATCTTTTAG CACATGTGTAAGACACTGTGCAAATTTTTTGAAAATAGAGCAATACTTTTTGTGGAATACTAGCTAACTAATTCTGT CATTAAACTCATATTTTGAAAATATTCAGACAATGTTGAAAATCCT <210> SEQ ID NO 11 <211> Length: 1,259 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 11 >N56180 T8 ATGCGTGCGTGCGTGCGTGCGTGTGTGTGTGTGTGTGCCTCTGCTCTTTGTCCTGAGCCCACGATTCCAGAGCTGGC TGGACCCAAGGAGGTGAAGAGTCACTTTTCAGCCCCAGGAAGGGCAAAGAAGAGAGAAAATCAGCCTGTCTGCTCTC TCCTTGGCTCAACAAGGCCTCTAACAGTCTTCTGTCCTCTATTCTGCACACGGCATATTTGGGAACGAGAAACAAAA GTTTTCCCAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCTGTCCTCTTGCAGGGCAGAAGAGGGGC TTAATTTCCCCACATATGATGGGAAGGACCGAGTGGTAAGTCTTTCCGAGAAGAACTTCAAGCAGGTTTTAAAGAAA TATGACTTGCTTTGCCTCTACTACCATGAGCCGGTGTCTTCAGATAAGGTCACGCAAAAACAGTTCCAACTGAAAGA AATCGTGCTTGAGCTTGTGGCCCAGGTCCTTGAACATAAAGCTATAGGCTTTGTGATGGTGGATGCCAAGAAAGAAG CCAAGCTTGCCAAGAAACTGGGTTTTGATGAAGAAGGAAGCCTGTATATTCTTAAGGGTGATCGCACAATAGAGTTT GATGGCGAGTTTGCAGCTGATGTCTTGGTGGAGTTCCTCTTGGATCTAATTGAAGACCCAGTGGAGATCATCAGCAG CAAACTGGAAGTCCAAGCCTTCGAACGCATTGAAGACTACATCAAACTCATTGGCTTTTTCAAGAGTGAGGACTCAG AATACTACAAGGCTTTTGAAGAAGCAGCTGAACACTTCCAGCCTTACATCAAATTCTTTGCCACCTTTGACAAAGGG GTTGCAAAGAAATTATCTTTGAAGATGAATGAGGTTGACTTCTATGAGCCATTTATGGATGAGCCCATTGCCATCCC CAACAAACCTTACACAGAAGAGGAGCTGGTGGAGTTTGTGAAGGAACACCAAAGATCAAGGAATTGGACTCAATAGT TAAGTAACTTAGCCAAGGATGAACACTCTATGCATAGAACTTCTGGGAGAGAAATGCTTGATACCACTTAGTGTAGC TCCAGCATGGATCAGCAAACTTTTTCTGTAAAGAACAAAATGGTAAATATTTCAGGTTCTGTGGGCCAGATGGCGTC TGTAGCAACTACTTGACTGCGGCTGTGGCATGAAAGCAGCCATGGATCATGTATAAACAAATGGGTGTGGCTGTGTA CCAGTAAAAGTTTATCCGGAAAAAAAG <210> SEQ ID NO 12 <211> Length: 2,412 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 508 <400> sequence: 12 >T10377 TO GGGGGGGCCTTCGCGGTGCAGCTGAGGCTGCAAGTAGCCGGCGCCGTCCCGCGTCGCCCCCGCGCAGGGCGGGCCCC GCACGCTTATCCTGCCCGGGAGGAACGCCGGCGTCCAGCCCGCTACCGACCGCCGCTGCGGGATGCTGCGCTCCACG TCCACGGTCACCCTGCTCTCGGGCGGCGCCGCCAGGACGCCCGGGGCGCCCAGCAGGAGGGCAAATGTTTGCAGACT ACGGCTGACCGTACCTCCTGAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAGAAAAGAGCAGCTTCTTG ACCTGAGCAATGGAGAACCTACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAGATCAAAAT CAGCAGAAAGAAATGGTGGTGTATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAAGATGTGAG AGCCACTTTGGAAAAGGTGAGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACAGCTCACCC AGGAACTATCAGTTTCCCATGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCCTGGATCGT TTTAATGCCATGAACTCAGCCTTGGCATCAGATTCCATTGGCCTGCAGAAAACCCTCGTGGATGTGACTTTGGAAAA CAGCAACATTAAGGATCAAATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGGAAAAGCAGA GGCAGTTGGAGGTAGCGCAAGTTGAAAACCAGCTGCTAAAAATGAAGGTGGAATCGTCCCAAGAAGCCAATGCTGAG GTGATGCGAGAGATGACCAAGAAGCTGTACAGCCAGTATGAGGAGAAGCTGCAGGAAGAACAGAGGAAGCACAGTGC TGAGAAGGAGGCTCTTTTGGAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGATGCAAGCAG CAGAGATCAGCCTAGAGGAGAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAAAGGAACGT CATCAACTGCAACTTCAACTCCTAGAACATGAAACAGAAATGTCTGGGGAGTTAACTGATTCTGACAAGGAAAGGTA TCAGCAGTTGGAGGAGGCATCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTGCCAGCAGA AGAAAGTCAAGCAGATGGTCGAGGAGATTGAATCATTAAAGAAAAAGTTGCAACAGAAACAGCTCTTAATACTGCAG CTTTTAGAAAAGATATCTTTCTTAGAAGGAGAGAATAATGAACTACAAAGCAGGTTGGACTATTTAACAGAAACCCA GGCCAAGACCGAAGTGGAAACCAGAGAGATAGGAGTGGGCTGTGATCTTCTACCCAGCCAAACAGGCAGGACTCGTG AAATTGTGATGCCTTCTAGGAACTACACCCCATACACAAGAGTCCTGGAGTTAACCATGAAGAAAACTCTGACTTAG GCACTCAGAGGCATACACTTTTTACAGATGGACAAAAGCTCTGGAACCCTGTGGCTTCAAATCCTTTGGGAAGGGTG ACTGTTGTTTCCCCTACACACAGTGTAAGCCGGAATGGGAATCGCTGAGGCTCTGATCCACTTCTAAGACAGGAAGG AAAGTGAAGGCAGAGTGAGCAGGTAAGAGAGGGATATACAAGGTCACATTTCAGACACCCACTCGGCATACCCTGCC GTACTGCATCATCATTTGTTTTCTTTGTAGACACTGAAATCCTATCAGGAGGATTCCTTCACAATGTATTTTATTTG CTAGACTTTGGTTGGGAGGGAAAAGGACATTAATTTGAAGTTTCATGTTATTCATGCCAGGATTGTTTGATAGAGCA TGAAGGTTTTGTTTACCCATAAAAGTATTAGAGGCAGCGTTTCTCTGATACAGAGAGGCCTGTCCACAAGAAGCATG GGCACCCAGCCAAACTTGAACCTGGAAGGGAGGGTTCCCGGCCTGCAGGTGCTCTTTCCTCTTGGTCCCAAGCATCT GTGCAGGGTCGTGGGAGCCACACTGAGAGACTTGTGTGGGCCAGACAAGCTTCATTCTGATGCGCTAGTCCCTTGGT TTAATTTGTGCCTTATGCTTTCATTGGACCAGCTGAAATCACTGTATTTATTCAACTTGTGATTTTTTTTTCTTTCT CACTTTAACTTAAAGAGAATTTTATATGTCTTGGAAATTTAATAATTTAGTGTTCTCAGTATCAATTGGTGTTTTTG TTAAACGAATGAATCATCTGTTCATGCATGCTCTACTTTGATATTATAACCTATGTCACATGTGTTTAATAAATACC ATATATTTTGTTCTACTAAAAAAAT <210> SEQ ID NO 13 <211> Length: 2,393 WO 2005/069724 PCT/IB2005/001306 509 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 13 >T10377 Tl TAGCAGTGGTGTTCAGGGTAGGATGCAGTTCTTCGCATTGTGCATAACACAAGCCCTGAACCAGCTGCTTTGGGAAC CCCTGGGAATAAAGTGCCCTACCTGCCTTTCAGGCACTGCCAAGCCTGGGGCATCTCTGGAGATTGTGTATCCGAGT TTCAGGAGACCATGGAGATCAGCCTCGTAAAATGCTCGGAGGCAAATGTTTGCAGACTACGGCTGACCGTACCTCCT GAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAGAAAAGAGCAGCTTCTTGACCTGAGCAATGGAGAACC TACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAGATCAAAATCAGCAGAAAGAAATGGTGG TGTATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAAGATGTGAGAGCCACTTTGGAAAAGGTG AGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACAGCTCACCCAGGAACTATCAGTTTCCCA TGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCCTGGATCGTTTTAATGCCATGAACTCAG CCTTGGCATCAGATTCCATTGGCCTGCAGAAAACCCTCGTGGATGTGACTTTGGAAAACAGCAACATTAAGGATCAA ATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGGAAAAGCAGAGGCAGTTGGAGGTAGCGCA AGTTGAAAACCAGCTGCTAAAAATGAAGGTGGAATCGTCCCAAGAAGCCAATGCTGAGGTGATGCGAGAGATGACCA AGAAGCTGTACAGCCAGTATGAGGAGAAGCTGCAGGAAGAACAGAGGAAGCACAGTGCTGAGAAGGAGGCTCTTTTG GAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGATGCAAGCAGCAGAGATCAGCCTAGAGGA GAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAAAGGAACGTCATCAACTGCAACTTCAAC TCCTAGAACATGAAACAGAAATGTCTGGGGAGTTAACTGATTCTGACAAGGAAAGGTATCAGCAGTTGGAGGAGGCA TCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTGCCAGCAGAAGAAAGTCAAGCAGATGGT CGAGGAGATTGAATCATTAAAGAAAAAGTTGCAACAGAAACAGCTCTTAATACTGCAGCTTTTAGAAAAGATATCTT TCTTAGAAGGAGAGAATAATGAACTACAAAGCAGGTTGGACTATTTAACAGAAACCCAGGCCAAGACCGAAGTGGAA ACCAGAGAGATAGGAGTGGGCTGTGATCTTCTACCCAGCCAAACAGGCAGGACTCGTGAAATTGTGATGCCTTCTAG GAACTACACCCCATACACAAGAGTCCTGGAGTTAACCATGAAGAAAACTCTGACTTAGGCACTCAGAGGCATACACT TTTTACAGATGGACAAAAGCTCTGGAACCCTGTGGCTTCAAATCCTTTGGGAAGGGTGACTGTTGTTTCCCCTACAC ACAGTGTAAGCCGGAATGGGAATCGCTGAGGCTCTGATCCACTTCTAAGACAGGAAGGAAAGTGAAGGCAGAGTGAG CAGGTAAGAGAGGGATATACAAGGTCACATTTCAGACACCCACTCGGCATACCCTGCCGTACTGCATCATCATTTGT TTTCTTTGTAGACACTGAAATCCTATCAGGAGGATTCCTTCACAATGTATTTTATTTGCTAGACTTTGGTTGGGAGG GAAAAGGACATTAATTTGAAGTTTCATGTTATTCATGCCAGGATTGTTTGATAGAGCATGAAGGTTTTGTTTACCCA TAAAAGTATTAGAGGCAGCGTTTCTCTGATACAGAGAGGCCTGTCCACAAGAAGCATGGGCACCCAGCCAAACTTGA ACCTGGAAGGGAGGGTTCCCGGCCTGCAGGTGCTCTTTCCTCTTGGTCCCAAGCATCTGTGCAGGGTCGTGGGAGCC ACACTGAGAGACTTGTGTGGGCCAGACAAGCTTCATTCTGATGCGCTAGTCCCTTGGTTTAATTTGTGCCTTATGCT TTCATTGGACCAGCTGAAATCACTGTATTTATTCAACTTGTGATTTTTTTTTCTTTCTCACTTTAACTTAAAGAGAA TTTTATATGTCTTGGAAATTTAATAATTTAGTGTTCTCAGTATCAATTGGTGTTTTTGTTAAACGAATGAATCATCT GTTCATGCATGCTCTACTTTGATATTATAACCTATGTCACATGTGTTTAATAAATACCATATATTTTGTTCTACTAA

AAAAAT

WO 2005/069724 PCT/IB2005/001306 510 <210> SEQ ID NO 14 <211> Length: 2,497 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 14 >T10377 T2 GGGGGGGCCTTCGCGGTGCAGCTGAGGCTGCAAGTAGCCGGCGCCGTCCCGCGTCGCCCCCGCGCAGGGCGGGCCCC GCACGCTTATCCTGCCCGGGAGGAACGCCGGCGTCCAGCCCGCTACCGACCGCCGCTGCGGGATGCTGCGCTCCACG TCCACGGTCACCCTGCTCTCGGGCGGCGCCGCCAGGACGCCCGGGGCGCCCAGCAGGAGGGCACTGCCAAGCCTGGG GCATCTCTGGAGATTGTGTATCCGAGTTTCAGGAGACCATGGAGATCAGCCTCGTAAAATGCTCGGAGGCAAATGTT TGCAGACTACGGCTGACCGTACCTCCTGAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAGAAAAGAGCA GCTTCTTGACCTGAGCAATGGAGAACCTACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAG ATCAAAATCAGCAGAAAGAAATGGTGGTGTATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAA GATGTGAGAGCCACTTTGGAAAAGGTGAGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACA GCTCACCCAGGAACTATCAGTTTCCCATGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCC TGGATCGTTTTAATGCCATGAACTCAGCCTTGGCATCAGATTCCATTGGCCTGCAGAAAACCCTCGTGGATGTGACT TTGGAAAACAGCAACATTAAGGATCAAATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGGA AAAGCAGAGGCAGTTGGAGGTAGCGCAAGTTGAAAACCAGCTGCTAAAAATGAAGGTGGAATCGTCCCAAGAAGCCA ATGCTGAGGTGATGCGAGAGATGACCAAGAAGCTGTACAGCCAGTATGAGGAGAAGCTGCAGGAAGAACAGAGGAAG CACAGTGCTGAGAAGGAGGCTCTTTTGGAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGAT GCAAGCAGCAGAGATCAGCCTAGAGGAGAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAA AGGAACGTCATCAACTGCAACTTCAACTCCTAGAACATGAAACAGAAATGTCTGGGGAGTTAACTGATTCTGACAAG GAAAGGTATCAGCAGTTGGAGGAGGCATCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTG CCAGCAGAAGAAAGTCAAGCAGATGGTCGAGGAGATTGAATCATTAAAGAAAAAGTTGCAACAGAAACAGCTTTAA TACTGCAGCTTTTAGAAAAGATATCTTTCTTAGAAGGAGAGAATAATGAACTACAAAGCAGGTTGGACTATTTAACA GAAACCCAGGCCAAGACCGAAGTGGAAACCAGAGAGATAGGAGTGGGCTGTGATCTTCTACCCAGCCAAACAGGCAG GACTCGTGAAATTGTGATGCCTTCTAGGAACTACACCCCATACACAAGAGTCCTGGAGTTAACCATGAAGAAAACTC TGACTTAGGCACTCAGAGGCATACACTTTTTACAGATGGACAAAAGCTCTGGAACCCTGTGGCTTCAAATCCTTTGG GAAGGGTGACTGTTGTTTCCCCTACACACAGTGTAAGCCGGAATGGGAATCGCTGAGGCTCTGATCCACTTCTAAGA CAGGAAGGAAAGTGAAGGCAGAGTGAGCAGGTAAGAGAGGGATATACAAGGTCACATTTCAGACACCCACTCGGCAT ACCCTGCCGTACTGCATCATCATTTGTTTTCTTTGTAGACACTGAAATCCTATCAGGAGGATTCCTTCACAATGTAT TTTATTTGCTAGACTTTGGTTGGGAGGGAAAAGGACATTAATTTGAAGTTTCATGTTATTCATGCCAGGATTGTTTG ATAGAGCATGAAGGTTTTGTTTACCCATAAAAGTATTAGAGGCAGCGTTTCTCTGATACAGAGAGGCCTGTCCACAA GAAGCATGGGCACCCAGCCAAACTTGAACCTGGAAGGGAGGGTTCCCGGCCTGCAGGTGCTCTTTCCTCTTGGTCCC AAGCATCTGTGCAGGGTCGTGGGAGCCACACTGAGAGACTTGTGTGGGCCAGACAAGCTTCATTCTGATGCGCTAGT CCCTTGGTTTAATTTGTGCCTTATGCTTTCATTGGACCAGCTGAAATCACTGTATTTATTCAACTTGTGATTTTTTT

TTCTTTCTCACTTTAACTTAAAGAGAATTTTATATGTCTTGGAAATTTAATAATTTAGTGTTCTCAGTATCAATTGG

WO 2005/069724 PCT/IB2005/001306 511 TGTTTTTGTTAAACGAATGAATCATCTGTTCATGCATGCTCTACTTTGATATTATAACCTATGTCACATGTGTTTAA TAAATACCATATATTTTGTTCTACTAAAAAAAT <210> SEQ ID NO 15 <211> Length: 2,328 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 15 >T10377 T5 GGGGGGGCCTTCGCGGTGCAGCTGAGGCTGCAAGTAGCCGGCGCCGTCCCGCGTCGCCCCCGCGCAGGGCGGGCCCC GCACGCTTATCCTGCCCGGGAGGAACGCCGGCGTCCAGCCCGCTACCGACCGCCGCTGCGGGATGCTGCGCTCCACG TCCACGGTCACCCTGCTCTCGGGCGGCGCCGCCAGGACGCCGGGGCGCCCAGCAGGAGGGCAAATGTTTGCAGACT ACGGCTGACCGTACCTCCTGAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAGAAAAGAGCAGCTTCTTG ACCTGAGCAATGGAGAACCTACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAGATCAAAAT CAGCAGAAAGAAATGGTGGTGTATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAAGATGTGAG AGCCACTTTGGAAAAGGTGAGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACAGCTCACCC AGGAACTATCAGTTTCCCATGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCCTGGATCGT TTTAATGCCATGAACTCAGCCTTGGCATCAGATTCCATTGGCCTGCAGAAAACCCTCGTGGATGTGACTTTGGAAAA CAGCAACATTAAGGATCAAATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGGAAAAGCAGA GGCAGTTGGAGGTAGCGCAAGTTGAAAACCAGCTGCTAAAAATGAAGGTGGAATCGTCCCAAGAAGCCAATGCTGAG GTGATGCGAGAGATGACCAAGAAGCTGTACAGCCAGTATGAGGAGAAGCTGCAGGAAGAACAGAGGAAGCACAGTGC TGAGAAGGAGGCTCTTTGGAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGATGCAAGCAG CAGAGATCAGCCTAGAGGAGAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAAAGGAACGT CATCAACTGCAACTTCAACTCCTAGAACATGAAACAGAAATGTCTGGGGAGTTAACTGATTCTGACAAGGAAAGGTA TCAGCAGTTGGAGGAGGCATCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTGCCAGCAGA AGAAAGTCAAGCAGATGGTCGAGGAGAATAATGAACTACAAAGCAGGTTGGACTATTTAACAGAAACCCAGGCCAAG ACCGAAGTGGAAACCAGAGAGATAGGAGTGGGCTGTGATCTTCTACCCAGCCAAACAGGCAGGACTCGTGAAATTGT GATGCCTTCTAGGAACTACACCCCATACACAAGAGTCCTGGAGTTAACCATGAAGAAAACTCTGACTTAGGCACTCA GAGGCATACACTTTTTACAGATGGACAAAAGCTCTGGAACCCTGTGGCTTCAAATCCTTTGGGAAGGGTGACTGTTG TTTCCCCTACACACAGTGTAAGCCGGAATGGGAATCGCTGAGGCTCTGATCCACTTCTAAGACAGGAAGGAAAGTGA AGGCAGAGTGAGCAGGTAAGAGAGGGATATACAAGGTCACATTTCAGACACCCACTCGGCATACCCTGCCGTACTGC ATCATCATTTGTTTTCTTTGTAGACACTGAAATCCTATCAGGAGGATTCCTTCACAATGTATTTTATTTGCTAGACT TTGGTTGGGAGGGAAAAGGACATTAATTTGAAGTTTCATGTTATTCATGCCAGGATTGTTTGATAGAGCATGAAGGT TTTGTTTACCCATAAAAGTATTAGAGGCAGCGTTTCTCTGATACAGAGAGGCCTGTCCACAAGAAGCATGGGCACCC AGCCAAACTTGAACCTGGAAGGGAGGGTTCCCGGCCTGCAGGTGCTCTTTCCTCTTGGTCCCAAGCATCTGTGCAGG GTCGTGGGAGCCACACTGAGAGACTTGTGTGGGCCAGACAAGCTTCATTCTGATGCGCTAGTCCCTTGGTTTAATTT

GTGCCTTATGCTTTCATTGGACCAGCTGAAATCACTGTATTTATTCAACTTGTGATTTTTTTTTCTTTCTCACTTTA

WO 2005/069724 PCT/IB2005/001306 512 ACTTAAAGAGAATTTTATATGTCTTGGAAATTTAATAATTTAGTGTTCTCAGTATCAATTGGTGTTTTTGTTAAACG AATGAATCATCTGTTCATGCATGCTCTACTTTGATATTATAACCTATGTCACATGTGTTTAATAAATACCATATATT TTGTTCTACTAAAAAAAT <210> SEQ ID NO 16 <211> Length: 2,311 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 16 >T10377 T6 GGGGGGGCCTTCGCGGTGCAGCTGAGGCTGCAAGTAGCCGGCGCCGTCCCGCGTCGCCCCCGCGCAGGGCGGGCCCC GCACGCTTATCCTGCCCGGGAGGAACGCCGGCGTCCAGCCCGCTACCGACCGCCGCTGCGGGATGCTGCGCTCCACG TCCACGGTCACCCTGCTCTCGGGCGGCGCCGCCAGGACGCCCGGGGCGCCCAGCAGGAGGGCAAATGTTTGCAGACT ACGGCTGACCGTACCTCCTGAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAGAAAAGAGCAGCTTCTTG ACCTGAGCAATGGAGAACCTACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAGATCAAAAT CAGCAGAAAGAAATGGTGGTGTATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAAGATGTGAG AGCCACTTTGGAAAAGGTGAGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACAGCTCACCC AGGAACTATCAGTTTCCCATGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCCTGGATCGT TTTAATGCCATGAACTCAGCCTTGGCATCAGATTCCATTGGCCTGCAGAAAACCCTCGTGGATGTGACTTTGGAAAA CAGCAACATTAAGGATCAAATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGGAAAAGCAGA GGCAGTTGGAGGTAGCGCAAGTTGAAAACCAGCTGCTAAAAATGAAGGTGGAATCGTCCCAAGAAGCCAATGCTGAG GTGATGCGAGAGATGACCAAGAAGCTGTACAGCCAGTATGAGGAGAAGCTGCAGGAAGAACAGAGGAAGCACAGTGC TGAGAAGGAGGCTCTTTTGGAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGATGCAAGCAG CAGAGATCAGCCTAGAGGAGAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAAAGGAACGT CATCAACTGCAACTTCAACTCCTAGAACATGAAACAGAAATGTCTGGGAGTTAACTGATTCTGACAAGGAAAGGTA TCAGCAGTTGGAGGAGGCATCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTGCCAGCAGA AGAAAGTCAAGCAGATGGTCGAGGAGATTGAATCATTAAAGAAAAAGTTGCAACAGAAACAGCTCTTAATACTGCAG CTTTTAGAAAAGATATCTTTCTTAGAAGGAGAGCCAAACAGGCAGGACTCGTGAAATTGTGATGCCTTCTAGGAACT ACACCCCATACACAAGAGTCCTGGAGTTAACCATGAAGAAAACTCTGACTTAGGCACTCAGAGGCATACACTTTTTA CAGATGGACAAAAGCTCTGGAACCCTGTGGCTTCAAATCCTTTGGGAAGGGTGACTGTTGTTTCCCCTACACACAGT GTAAGCCGGAATGGGAATCGCTGAGGCTCTGATCCACTTCTAAGACAGGAAGGAAAGTGAAGGCAGAGTGAGCAGGT AAGAGAGGGATATACAAGGTCACATTTCAGACACCCACTCGGCATACCCTGCCGTACTGCATCATCATTTGTTTTCT TTGTAGACACTGAAATCCTATCAGGAGGATTCCTTCACAATGTATTTTATTTGCTAGACTTTGGTTGGGAGGGAAAA GGACATTAATTTGAAGTTTCATGTTATTCATGCCAGGATTGTTTGATAGAGCATGAAGGTTTTGTTTACCCATAAAA GTATTAGAGGCAGCGTTTCTCTGATACAGAGAGGCCTGTCCACAAGAAGCATGGGCACCCAGCCAAACTTGAACCTG GAAGGGAGGGTTCCCGGCCTGCAGGTGCTCTTTCCTCTTGGTCCCAAGCATCTGTGCAGGGTCGTGGGAGCCACACT

GAGAGACTTGTGTGGGCCAGACAAGCTTCATTCTGATGCGCTAGTCCCTTGGTTTAATTTGTGCCTTATGCTTTCAT

WO 2005/069724 PCT/IB2005/001306 513 TGGACCAGCTGAAATCACTGTATTTATTCAACTTGTGATTTTTTTTTCTTTCTCACTTTAACTTAAAGAGAATTTTA TATGTCTTGGAAATTTAATAATTTAGTGTTCTCAGTATCAATTGGTGTTTTTGTTAAACGAATGAATCATCTGTTCA TGCATGCTCTACTTTGATATTATAACCTATGTCACATGTGTTTAATAAATACCATATATTTTGTTCTACTAAAAAAA T <210> SEQ ID NO 17 <211> Length: 1418 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 17 >T10377 T7 GGGGGGGCCTTCGCGGTGCAGCTGAGGCTGCAAGTAGCCGGCGCCGTCCCGCGTCGCCCCCGCGCAGGGCGGGCCCC GCACGCTTATCCTGCCCGGGAGGAACGCCGGCGTCCAGCCCGCTACCGACCGCCGCTGCGGGATGCTGCGCTCCACG TCCACGGTCACCCTGCTCTCGGGCGGCGCCGCCAGGACGCCCGGGGCGCCCAGCAGGAGGGCAAATGTTTGCAGACT ACGGCTGACCGTACCTCCTGAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAGAAAAGAGCAGCTTCTTG ACCTGAGCAATGGAGAACCTACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAGATCAAAAT CAGCAGAAAGAAATGGTGGTGTATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAAGATGTGAG AGCCACTTTGGAAAAGGTGAGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACAGCTCACCC AGGAACTATCAGTTTCCCATGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCCTGGATCGT TTTAATGCCATGAACTCAGCCTTGGCATCAGATTCCATTGGCCTGCAGAAAACCCTCGTGGATGTGACTTTGGAAAA CAGCAACATTAAGGATCAAATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGGAAAAGCAGA GGCAGTTGGAGGTAGCGCAAGTTGAAAACCAGCTGCTAAAAATGAAGGTGGAATCGTCCCAAGAAGCCAATGCTGAG GTGATGCGAGAGATGACCAAGAAGCTGTACAGCCAGTATGAGGAGAAGCTGCAGGAAGAACAGAGGAAGCACAGTGC TGAGAAGGAGGCTCTTTTGGAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGATGCAAGCAG CAGAGATCAGCCTAGAGGAGAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAAAGGAACGT CATCAACTGCAACTTCAACTCCTAGAACATGAAACAGAAATGTCTGGGGAGTTAACTGATTCTGACAAGGAAAGGTA TCAGCAGTTGGAGGAGGCATCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTGCCAGCAGA AGAAAGTCAAGCAGATGGTCGAGGAGATCATGTCGCACGAGCTCTTCTCCAGATTTAGTCTCCGGCTCTTTGGAAGA TGATAAGTTGGTAGCCTGCTCTGGGTTGGAAGCGATTCCTTTATTGTTCGTGATTAGAAGAACACTTGTACACTCTC TGCTGGGAAGAGGTGGTATTTATCTATGATGA <210> SEQ ID NO 18 <211> Length: 1,027 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 18 WO 2005/069724 PCT/IB2005/001306 514 >Z24874 PEA 2 TI0 GTTGGCCCTGACCTCGTTGGAAAACGAAGCTCCCCGCAGGGTCCCGGCCTCTAGGGCTGCTGTGCGGGCGGGGGTGG CCTGGAGCTATTTCCATTCGGCGGCGGGAACAGGTGCCGGCGCCTCCGCCCCATCCCCAGGGGCCGCCTCCCCCGGG GCGGCCTCCAGGCTGCCGAGACCTATAAAGGCGCCAGGTTTTCTCAATGAAGCCGGGACGCACTCCGGAGCGCACTG CGTGGTCGCACCCTACCCGGGCTGCCTTGGAAGTCGTCCCCGCCGCCCCTCCGCACCGGCATGAAGCTCATCGTGGG CATCGGAGGCATGACCAACGGCGGCAAGACCACGCTGACCAACAGCCTGCTCAGAGCCCTGCCCAACTGCTGCGTGA TCCATCAGGATGACTTCTTCAAGCCCCAAGACCAAATAGCAGTTGGGGAAGACGGCTTCAAACAGTGGGACGTGCTG GAGTCTCTGGACATGGAGGCCATGCTGGACACCGTGCAGGCCTGGCTGAGCAGCCCGCAGAAGTTTGCCCGTGCCCA CGGGGTCAGCGTCCAGCCAGAGGCCTCGGACACCCACATCCTCCTCCTGGAAGGCTTCCTGCTCTACAGCTACAAGC CCCTGGTGGACTTGTACAGCCGCCGGTACTTCCTGACCGTCCCGTATGAAGAGTGCAAGTGGAGGAGAAGTCTACCT GGACGGCATGAAGTCCCGAGAGGAGCTCTTCCGTGAAGTCCTGGAAGACATTCAGAACTCGCTGCTGAACCGCTCCC AGGAATCAGCCCCCTCCCCGGCTCGCCCAGCCAGGACACAGGGACCCGGACGCGGATGCGGCCACAGAACGGCCAGG CCTGCAGCGTCCCAGCAGGACAGCATGTGAGCGTTTCCCTATGGGGGTGTCTGTACGTAGGAGAGTGGAGGCCCCAC TCCCAGTTGGGCGTCCCGGAGCTCAGGGACTGAGCCCCAAGACGCCTCTGTAACCTCGCTGCAGCTTCAGTAGTAAA CTGGGTCCTGTTTTTTTAACTGTTGG <210> SEQ ID NO 19 <211> Length: 955 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 19 >Z24874 PEA 2 TIl GTTGGCCCTGACCTCGTTGGAAAACGAAGCTCCCCGCAGGGTCCCGGCCTCTAGGGCTGCTGTGCGGGCGGGGGTGG CCTGGAGCTATTTCCATTCGGCGGCGGGAACAGGTGCCGGCGCCTCCGCCCCATCCCCAGGGGCCGCCTCCCCCGGG GCGGCCTCCAGGCTGCCGAGACCTATAAAGGCGCCAGGTTTTCTCAATGAAGCCGGGACGCACTCCGGAGCGCACTG CGTGGTCGCACCCTACCCGGGCTGCCTTGGAAGTCGTCCCCGCCGCCCCTCCGCACCGGCATGAAGCTCATCGTGGG CATCGGAGGCATGACCAACGGCGGCAAGACCACGCTGACCAACAGCCTGCTCAGAGCCCTGCCCAACTGCTGCGTGA TCCATCAGGATGACTTCTTCAAGCCCCAAGACCAAATAGCAGTTGGGGAAGACGGCTTCAAACAGTGGGACGTGCTG GAGTCTCTGGACATGGAGGCCATGCTGGACACCGTGCAGGCCTGGCTGAGCAGCCCGCAGAAGTTTGCCCGTGCCCA CGGGGTCAGCGTCCAGCCAGAGGCCTCGGACACCCACATCCTCCTCCTGGAAGGCTTCCTGCTCTACAGCTACAATC TACCTGGACGGCATGAAGTCCCGAGAGGAGCTCTTCCGTGAAGTCCTGGAAGACATTCAGAACTCGCTGCTGAACCG CTCCCAGGAATCAGCCCCCTCCCCGGCTCGCCCAGCCAGGACACAGGGACCCGGACGCGGATGCGGCCACAGAACGG CCAGGCCTGCAGCGTCCCAGCAGGACAGCATGTGAGCGTTTCCCTATGGGGGTGTCTGTACGTAGGAGAGTGGAGGC CCCACTCCCAGTTGGGCGTCCCGGAGCTCAGGGACTGAGCCCCAAGACGCCTCTGTAACCTCGCTGCAGCTTCAGTA GTAAACTGGGTCCTGTTTTTTTAACTGTTGG <210> SEQ ID NO 20 WO 2005/069724 PCT/IB2005/001306 515 <211> Length: 986 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 20 >HUMCDDANF T3 GGTTGGATTCCTGGGAGCTTCATCACATTTGGTTCTCAGCTGACTTTATATACTAAAAAATAACTTCCTTTCGCCTG ACCATGGAGAGGGACTGCCAGGGGTGAAGGCAGCCCTGTCTGAGGCCAGAGGTCTGCCCACGTGGCGGATGAGGCAG GTGTGAGGCCAGCTTGAGCATCTGGATCCATTTGTCTCGGGCTGCTGGCTGCCTGCCATTTCCTCCTCTCCACCCTT ATTTGGAGGCCCTGACAGCTGAGCCACAAACAAACCAGGGGAGCTGGGCACCAGCCAAGCGTCACCCTCTGTTTCCC CGCACGGGTACCAGCGTCGAGGAGAAAGAATCCTGAGGCACGGCGAATTTGCTGGACCATTTGGAAGAAAAGATGCC TTTAGAAGATGAGGTCGTGCCCCCACAAGTGCTCAGTGAGCCGAATGAAGAAGCGGGGGCTGCTCTCAGCCCCCTCC CTGAGGTGCCTCCCTGGACCGGGGAAGTCAGCCCAGCCCAGAGAGATGGAGGTGCCCTCGGGCGGGGCCCCTGGGAC TCCTCTGATCGATCTGCCCTCCTAAAAAGCAAGCTGAGGGCGCTGCTCACTGCCCCTCGGAGCCTGCGGAGATCCAG CTGCTTCGGGGGCAGGATGGACAGGATTGGAGCCCAGAGCGGACTGGGCTGTAACAGCTTCCGGTACTGAAGATAAC AGCCAGGGAGGACAAGCAGGGCTGGGCCTAGGGACAGACTGCAAGAGGCTCCTGTCCCCTGGGGTCTCTGCTGCATT TGTGTCATCTTGTTGCCATGGAGTTGTGATCATCCCATCTAAGCTGCAGCTTCCTGTCAACACTTCTCACATCTTAT GCTAACTGTAGATAAAGTGGTTTGATGGTGACTTCCTCGCCTCTCCCACCCCATGCATTAAATTTTAAGGTAGAACC TCACCTGTTACTGAAAGTGGTTTGAAAGTGAATAAACTTCAGCACCATGGACAGAAGACAAA <210> SEQ ID NO 21 <211> Length: 760 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 21 >HUMCDDANF T4 CtGGGAGACAGGGACAGACGTAGGCCAAGAGAGGGGAACCAGAGAGGAACCAGAGGGGAGAGACAGAGCAGCAAGCA GTGGATTGCTCCTTGACGACGCCAGCATGAGCTCCTTCTCCACCACCACCAATTTGCTGGACCATTTGGAAGAAAAG ATGCCTTTAGAAGATGAGGTCGTGCCCCCACAAGTGCTCAGTGAGCCGAATGAAGAAGCGGGGGCTGCTCTCAGCCC CCTCCCTGAGGTGCCTCCCTGGACCGGGGAAGTCAGCCCAGCCCAGAGAGATGGAGGTGCCCTCGGGCGGGGCCCCT GGGACTCCTCTGATCGATCTGCCCTCCTAAAAAGCAAGCTGAGGGCGCTGCTCACTGCCCCTCGGAGCCTGCGGAGA TCCAGCTGCTTCGGGGGCAGGATGGACAGGATTGGAGCCCAGAGCGGACTGGGCTGTAACAGCTTCCGGTACTGAAG ATAACAGCCAGGGAGGACAAGCAGGGCTGGGCCTAGGGACAGACTGCAAGAGGCTCCTGTCCCCTGGGGTCTCTGCT GCATTTGTGTCATCTTGTTGCCATGGAGTTGTGATCATCCCATCTAAGCTGCAGCTTCCTGTCAACACTTCTCACAT CTTATGCTAACTGTAGATAAAGTGGTTTGATGGTGACTTCCTCGCCTCTCCCACCCCATGCATTAAATTTTAAGGTA

GAACCTCACCTGTTACTGAAAGTGGTTTGAAAGTGAATAAACTTCAGCACCATGGACAGAAGACAAA

WO 2005/069724 PCT/IB2005/001306 516 <210> SEQ ID NO 22 <211> Length: 892 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 22 >HUMTROPIA PEA 2 TI0 TCTCAGTGTCCTCGGGGAGTCTCAAGCAGCCCGGAGGAGACTGACGGTCCCTGGGACCCTGAAGGTCACCCGGGCGG CCCCCTCACTGACCCTCCAAACGCCCCTGTCCTCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGG ATGGGAGCAGCGATGCGGTGAGAGCAGCGGGCTAAGGCGTGGCTGGGACCCCCAGGGCCAGGGCTAGGGAACCTCGC CCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAACTACCGCGCTTATGCCACGGAGCCGCACGCCAAGAAAAAATC TAAGATCTCCGCCTCGAGAAAATTGCAGCTGAAGACTCTGCTGCTGCAGATTGCAAAGCAAGAGCTGGAGCGAGAGG CGGAGGAGCGGCGCGGAGAGAAGGGGCGCGCTCTGAGCACCCGCTGCCAGCCGCTGGAGTTGGCCGGGCTGGGCTTC GCGGAGCTGCAGGACTTGTGCCGACAGCTCCACGCCCGTGTGGACAAGGTGGATGAAGAGAGATACGACATAGAGGC AAAAGTCACCAAGAACATCACGGAGATTGCAGATCTGACTCAGAAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGC CCACCCTGCGGAGAGTGAGGATCTCTGCAGATGCCATGATGCAGGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCCTG GACCTGCGGGCCCACCTCAAGCAGGTGAAGAAGGAGGACACCGAGAAGGAAAACCGGGAGGTGGGAGACTGGCGCAA GAACATCGATGCACTGAGTGGAATGGAGGGCCGCAAGAAAAAGTTTGAGAGCTGAGCCTTCCTGCCTACTGCCCCTG CCCTGAGGAGGGCCCTGAGGAATAAAGCTTCTCTCTGAGCTGAAA <210> SEQ ID NO 23 <211> Length: 763 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 23 >HUMTROPIA PEA 2 T15 TCTCAGTGTCCTCGGGGAGTCTCAAGCAGCCCGGAGGAGACTGACGGTCCCTGGGACCCTGAAGGTCACCCGGGCGG CCCCCTCACTGACCCTCCAAACGCCCCTGTCCTCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGG ATGGGAGCAGCGATGCGAAAAAATCTAAGATCTCCGCCTCGAGAAAATTGCAGCTGAAGACTCTGCTGCTGCAGATT GCAAAGCAAGAGCTGGAGCGAGAGGCGGAGGAGCGGCGCGGAGAGAAGGGGCGCGCTCTGAGCACCCGCTGCCAGCC GCTGGAGTTGGCCGGGCTGGGCTTCGCGGAGCTGCAGGACTTGTGCCGACAGCTCCACGCCCGTGTGGACAAGGTGG ATGAAGAGAGATACGACATAGAGGCAAAAGTCACCAAGAACATCACGGAGATTGCAGATCTGACTCAGAAGATCTTT GACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGATCTCTGCAGATGCCATGATGCAGGCGCTGCT GGGGGCCCGGGCTAAGGAGTCCCTGGACCTGCGGGCCCACCTCAAGCAGGTGAAGAAGGAGGACACCGAGAAGGAAA ACCGGGAGGTGGGAGACTGGCGCAAGAACATCGATGCACTGAGTGGAATGGAGGGCCGCAAGAAAAAGTTTGAGAGC

TGAGCCTTCCTGCCTACTGCCCCTGCCCTGAGGAGGGCCCTGAGGAATAAAGCTTCTCTCTGAGCTGAAA

WO 2005/069724 PCT/IB2005/001306 517 <210> SEQ ID NO 24 <211> Length: 1,381 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 24 >HUMTROPIA PEA 2 T3 TCTCAGTGTCCTCGGGGAGTCTCAAGCAGCCCGGAGGAGACTGACGGTCCCTGGGACCCTGAAGGTCACCCGGGCGG CCCCCTCACTGACCCTCCAAACGCCCCTGTCCTCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGG ATGGGAGCAGCGATGCGGCTAGGGAACCTCGCCCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAACTACCGCGCT TATGCCACGGAGCCGCACGCCAAGAAAAAATCTAAGATCTCCGCCTCGAGAAAATTGCAGCTGAAGACTCTGCTGCT GCAGATTGCAAAGCAAGAGCTGGAGCGAGAGGCGGAGGAGCGGCGCGGAGAGAAGGGGCGCGCTCTGAGCACCCGCT GCCAGCCGCTGGAGTTGGCCGGGCTGGGCTTCGCGGAGCTGCAGGACTTGTGCCGACAGCTCCACGCCCGTGTGGAC AAGGTGGATGAAGAGAGATACGACATAGAGGCAAAAGTCACCAAGAACATCACGGAGGTGGGACGCATGGGCAGCTC GGGTACCTTCGGGGTAGGGTGAGATGGCTGGGACTTGGTCTCTGCCTGACCCCTTGCAGCTGCTTTTGGCTGCACAT CCCAGGAGACCCAGGACAACTGTGAGCCTGGCAGGGCTGGGGCAGAAGGATGAGTACAATATAGTCAAGGAAAGCTG TTCTAGGCAGAGGGAACAGCACATGCAAGGCCATGGGTTGGGAAACAGAAAATAAGTTAGTGAACATGCTCAGGGCA TCACATGTTGGTAAATTAGCTCAGGCACTGGCCAGGGAATTGTGATTTGCATGTAGCTGGACCAGGTTATGCCAGTG GTTTTGAGAGGTGAGGCTGGAGCATATGAGGAGGGGGATTCAGTTCCAGGATTAGAAGCCTAGACTGGGAGCCTAAG CCGGGAAGAGACTGGTAAGGCCTCGGTACTGGAAGACGAGATAAGGAGAATAAAAAAGGAGTGTAGGATGGAGGAGT TGGGTGTGCGGGAAATGGAAGGAGAAGTACCCACCCCCTCGTGTGCCCCCAGATTGCAGATCTGACTCAGAAGATCT TTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGATCTCTGCAGATGCCATGATGCAGGCGCTG CTGGGGGCCCGGGCTAAGGAGTCCCTGGACCTGCGGGCCCACCTCAAGCAGGTGAAGAAGGAGGACACCGAGAAGGA AAACCGGGAGGTGGGAGACTGGCGCAAGAACATCGATGCACTGAGTGGAATGGAGGGCCGCAAGAAAAAGTTTGAGA GCTGAGCCTTCCTGCCTACTGCCCCTGCCCTGAGGAGGGCCCTGAGGAATAAAGCTTCTCTCTGAGCTGAAA <210> SEQ ID NO 25 <211> Length: 1,252 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 25 >HUMTROPIA PEA 2 T7 TCTCAGTGTCCTCGGGGAGTCTCAAGCAGCCCGGAGGAGACTGACGGTCCCTGGGACCCTGAAGGTCACCCGGGCGG CCCCCTCACTGACCCTCCAAACGCCCCTGTCCTCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGG ATGGGAGCAGCGATGCGGCTAGGGAACCTCGCCCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAACTACCGCGCT TATGCCACGGAGCCGCACGCCAAGGTGGGACGGGGCTTCCTGGGGGCAGAGTACAGGCGCCGGAGGGATCCAAGACC

CTGGGAGTGGGGGGAGGAGCCAGGGCTGCGAAGGGGGCGGGGACTACGCGGAGGGGCTTCAGGGGCGGAGTTTTGCA

WO 2005/069724 PCT/IB2005/001306 518 GAGGGTCATGCTCGGATTGGTGACAGCAGCCTGCGGGCGGAACTCCGTTGCCCTCGGACTTGCTTAGGGATAGATGG GAAGTGCCTATCCAAAGGAAGAGACCCAGATTGGTGGATGGGAATGAGGGGCGTGGCCTCCCGTAGACTCAGGGCTC AAGTTGGACGTGGGCCCAAATCTGGACCGGCTGGGTTTGCTGGGGGTGTCTTGAGGTCCCCTCCACCGTCGTCTCCG AATCCCCCTCCATGATCCTTCCTTGCTCCATCTCACCCTGGCAGAAAAAATCTAAGATCTCCGCCTCGAGAAAATTG CAGCTGAAGACTCTGCTGCTGCAGATTGCAAAGCAAGAGCTGGAGCGAGAGGCGGAGGAGCGGCGCGGAGAGAAGGG GCGCGCTCTGAGCACCCGCTGCCAGCCGCTGGAGTTGGCCGGGCTGGGCTTCGCGGAGCTGCAGGACTTGTGCCGAC AGCTCCACGCCCGTGTGGACAAGGTGGATGAAGAGAGATACGACATAGAGGCAAAAGTCACCAAGAACATCACGGAG ATTGCAGATCTGACTCAGAAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGATCTC TGCAGATGCCATGATGCAGGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCCTGGACCTGCGGGCCCACCTCAAGCAGG TGAAGAAGGAGGACACCGAGAAGGAAAACCGGGAGGTGGGAGACTGGCGCAAGAACATCGATGCACTGAGTGGAATG GAGGGCCGCAAGAAAAAGTTTGAGAGCTGAGCCTTCCTGCCTACTGCCCCTGCCCTGAGGAGGGCCCTGAGGAATAA AGCTTCTCTCTGAGCTGAAA <210> SEQ ID NO 26 <211> Length: 2,820 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 26 >HUMSMCK T5 TTCCATGCTCTTTAAAAGCCTTATAATTTTCTGGATCTGGGAGCTGGGCTATTTCAGGGTCAATGGATTTATTTCAG TTGGTGCCTGAACTGACTTGAAACAAGTGTGTGTGGAAAAGAGCTATTTTGAGAAGGAATAAACCGAGACTGCCCTG ATGATAGAATATGCAAGCTGGTGGGTCTTGACTCCTTAAAGGATTATGAAATTAATTTGATTGGTCCCAATCTTTAT ATAACCACCCCAATCAGGAAACTTCCCATCCCGCCAAAAGGCCCCCTCACGTGCTCTCCCTGTCAGTACCCCATGCA AAGGTAAAATAGATGATATTTTTAAACATGGGTCGTGTTTAAAAGAAATGGAAACTCCTTCAGAGAATGAAGGAGAA CCACACTGGGTAGAAGGTTATTCCTGGGGCTCCACCCCTTGCTCCATCAAGTCCTCTGAGCATGAGCTGGGCTCTGA GAAGGAAGAGACAGGAACCAATTGGTCATGTCCACGTGGCCTCAGAAGCTGAGTACGTGACGGTCACCAGATGCCTA GGCAGGCTCCCTTGAAATGGCAGGGCTGCTGTCCAAAATCCTGCTGGGTCATTGCTATTTACAGGCAGCCTTCCCGG CGTGCGGTGGATATCCCAAGCGGGGCTATTTTTAAGCAGGGCTATGGCCTGCCGTGGGTTAAGCTGGTGTGGACAGA AAGCGAGATGATCTAGCCATCTACTGCAGGGGGCCTGATCTTGAACAGAAACCTGACTGTAATTGTCCCTGGATCCA GGTCCCAGACAAAGACGCTGGAAGGAGGTCCCTCCAGCCCCTGGCTCAGGGCCCGGTCAGCTGCTGGAGCCAGGCAG CTTGAGACATCCTCCTCTCCGACCTTGGCTTGAGGGGTTCATCCTCCAGAGCTCACCAGGGCCCCAAGGCTGGTACA CCTGAGAGAAGAGAGAAACAAATCCCCCAACAGATGTGCAATTTCACCTGCTGGCCCTTCCATTCTGAGATCCAGAG CCCTGGCAAAGGAGCCTCCAGGACCAGGCCTGGGAAGCAAGACTGGCTCCGCCTTTTACGTTTCAGAGAAAGGGCAG GTGCTATAAAGGGCCCAGCGCCCACGGGCCTGCCTTCAAGGGTACAGCTGTGGGGGCCGGTGCGCCCGGAGGTCTAC GCTGGGATTGGTGAGGTCCTCTGGCCCCGCCCCGCCAGGGAGGATTTCCAGGCCGGCCCGACCAGCTCGCCCTGCAT ACACTTCTTGGCTGTGTGCGCTCAGCAGGACGTGGGAGGCTCCGGCTTCAAGACACTCATCCAAGAGGAAGGATGGC

CAGTATCTTTTCTAAGTTGCTAACTGGCCGCAATGCTTCTCTGCTGTTTGCTACCATGGGCACCAGTGTCCTGACCA

WO 2005/069724 PCT/IB2005/001306 519 CCGGGTACCTGCTGAACCGGCAGAAAGTGTGTGCCGAGGTCCGGGAGCAGCCTAGGCTATTTCCTCCAAGCGCAGAC TACCCAGACCTGCGCAAGCACAACAACTGCATGGCCGAGTGCCTCACCCCCGCCATTTATGCCAAGCTTCGCAACAA GGTGACACCCAACGGCTACACGCTGGACCAGTGCATCCAGACTGGAGTGGACAACCCTGGCCACCCCTTCATAAAGA CTGTGGGCATGGTGGCTGGTGACGAGGAGTCCTATGAGGTGTTTGCTGACCTTTTTGACCCCGTCATCAAACTAAGA CACAACGGCTATGACCCCAGGGTGATGAAGCACACAACGGATCTGGATGCATCAAAGATCACCCAAGGGCAGTTCGA CGAGCATTACGTGCTGTCTTCTCGGGTGCGCACTGGCCGCAGCATCCGTGGGCTGAGCCTGCCTCCAGCCTGCACCC GGGCCGAGCGAAGGGAGGTAGAGAACGTGGCCATCACTGCCCTGGAGGGCCTCAAGGGGGACCTGGCTGGCCGCTAC TACAAGCTGTCCGAGATGACGGAGCAGGACCAGCAGCGGCTCATCGATGACCACTTTCTGTTTGATAAGCCAGTGTC CCCTTTATTAACATGTGCTGGGATGGCCCGTGACTGGCCAGATGCCAGGGGAATCTGGCATAATTATGATAAGACAT TTCTCATCTGGATAAATGAGGAGGATCACACCAGGGTAATCTCAATGGAAAAAGGAGGCAATATGAAACGAGTATTT GAGCGATTCTGTCGTGGACTAAAAGAAGTAGAACGGTTAATCCAAGAACGAGGCTGGGAGTTCATGTGGAATGAGCG CCTAGGATACATTTTGACCTGTCCTTCGAACCTTGGAACAGGACTACGAGCTGGTGTCCACGTTAGGATCCCAAAGC TCAGCAAGGACCCACGCTTTTCTAAGATCCTGGAAAACCTAAGACTCCAGAAGCGTGGCACAGGTGGTGTGGACACT GCCGCGGTCGCAGATGTGTACGACATTTCCAACATAGATAGAATTGGTCGATCAGAGGTAACGTCTCTCTCACTTTC CTAACATGAACTAACAAAATCAGCCTAAGAGAGAATAGAGAAAAGCAAACAGCCTAGCCGTTTTCACAAAATTCGAG ACCTCCTCTTCGCCCATTGAGTCCTGAGTTATGTTAGCTTTTCATTCTGTAACATTATTCTTCCATGGGAAATAACT GCATAAAGGGAAACATAATGTGAGCTGAGAATTTATAGGCAAGTATAGGAATTCACAGTGGGACTGTTGTCACCGAC CTGCCATGAGAGCTATTCCAACAATCCTCAGCGAGCAGGAGCTCTGTTATGCTAAAGGACTGCAGTTTTTTTATTAC TGTAAAGTCAGAACATCTATGCTATCCCTCTGAGGGTGGCAAAATAGT <210> SEQ ID NO 27 <211> Length: 2,448 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 27 >HUMSMCK T6 TTCCATGCTCTTTAAAAGCCTTATAATTTTCTGGATCTGGGAGCTGGGCTATTTCAGGGTCAATGGATTTATTTCAG TTGGTGCCTGAACTGACTTGAAACAAGTGTGTGTGGAAAAGAGCTATTTTGAGAAGGAATAAACCGAGACTGCCCTG ATGATAGAATATGCAAGCTGGTGGGTCTTGACTCCTTAAAGGATTATGAAATTAATTTGATTGGTCCCAATCTTTAT ATAACCACCCCAATCAGGAAACTTCCCATCCCGCCAAAAGGCCCCCTCACGTGCTCTCCCTGTCAGTACCCCATGCA AAGGTAAAATAGATGATATTTTTAAACATGGGTCGTGTTTAAAAGAAATGGAAACTCCTTCAGAGAATGAAGGAGAA CCACACTGGGTAGAAGGTTATTCCTGGGGCTCCACCCCTTGCTCCATCAAGTCCTCTGAGCATGAGCTGGGCTCTGA GAAGGAAGAGACAGGAACCAATTGGTCATGTCCACGTGGCCTCAGAAGCTGAGTACGTGACGGTCACCAGATGCCTA GGCAGGCTCCCTTGAAATGGCAGGGCTGCTGTCCAAAATCCTGCTGGGTCATTGCTATTTACAGGCAGCCTTCCCGG CGTGCGGTGGATATCCCAAGCGGGGCTATTTTTAAGCAGGGCTATGGCCTGCCGTGGGTTAAGCTGGTGTGGACAGA AAGCGAGATGATCTAGCCATCTACTGCAGGGGGCCTGATCTTGAACAGAAACCTGACTGTAATTGTCCCTGGATCCA

GGTCCCAGACAAAGACGCTGGAAGGAGGTCCCTCCAGCCCCTGGCTCAGGGCCCGGTCAGCTGCTGGAGCCAGGCAG

WO 2005/069724 PCT/IB2005/001306 520 CTTGAGACATCCTCCTCTCCGACCTTGGCTTGAGGGGTTCATCCTCCAGAGCTCACCAGGGCCCCAAGGCTGGTACA CCTGAGAGAAGAGAGAAACAAATCCCCCAACAGATGTGCAATTTCACCTGCTGGCCCTTCCATTCTGAGATCCAGAG CCCTGGCAAAGGAGCCTCCAGGACCAGGCCTGGGAAGCAAGACTGGCTCCGCCTTTTACGTTTCAGAGAAAGGGCAG GTGCTATAAAGGGCCCAGCGCCCACGGGCCTGCCTTCAAGGGTACAGCTGTGGGGGCCGGTGCGCCCGGAGGTCTAC GCTGGGATTGGTGAGGTCCTCTGGCCCCGCCCCGCCAGGGAGGATTTCCAGGCCGGCCCGACCAGCTCGCCCTGCAT ACACTTCTTGGCTGTGTGCGCTCAGCAGGACGTGGGAGGCTCCGGCTTCAAGACACTCATCCAAGAGGAAGGATGGC CAGTATCTTTTCTAAGTTGCTAACTGGCCGCAATGCTTCTCTGCTGTTTGCTACCATGGGCACCAGTGTCCTGACCA CCGGGTACCTGCTGAACCGGCAGAAAGTGTGTGCCGAGGTCCGGGAGCAGCCTAGGCTATTTCCTCCAAGCGCAGAC TACCCAGACCTGCGCAAGCACAACAACTGCATGGCCGAGTGCCTCACCCCCGCCATTTATGCCAAGCTTCGCAACAA GGTGACACCCAACGGCTACACGCTGGACCAGTGCATCCAGACTGGAGTGGACAACCCTGGCCACCCCTTCATAAAGA CTGTGGGCATGGTGGCTGGTGACGAGGAGTCCTATGAGGTGTTTGCTGACCTTTTTGACCCCGTCATCAAACTAAGA CACAACGGCTATGACCCCAGGGTGATGAAGCACACAACGGATCTGGATGCATCAAAGATCACCCAAGGGCAGTTCGA CGAGCATTACGTGCTGTCTTCTCGGGTGCGCACTGGCCGCAGCATCCGTGGGCTGAGCCTGCCTCCAGCCTGCACCC GGGCCGAGCGAAGGGAGGTAGAGAACGTGGCCATCACTGCCCTGGAGGGCCTCAAGGGGGACCTGGCTGGCCGCTAC TACAAGCTGTCCGAGATGACGGAGCAGGACCAGCAGCGGCTCATCGATGACCACTTTCTGTTTGATAAGCCAGTGTC CCCTTTATTAACATGTGCTGGGATGGCCCGTGACTGGCCAGATGCCAGGGGAATCTGGCATAATTATGATAAGACAT TTCTCATCTGGATAAATGAGGAGGATCACACCAGGGTAATCTCAATGGAAAAAGGAGGCAATATGAAACGAGTATTT GAGCGATTCTGTCGTGGACTAAAAGAAGTAGAACGGTTAATCCAAGAACGAGGCTGGGAGTTCATGTGGAATGAGCG CCTAGGATACATTTTGACCTGTCCTTCGAACCTTGGAACAGGACTACGAGCTGGTGTCCACGTTAGGATCCCAAAGC TCAGCAAGGTACTGTTATGTGCCCAGTGGCCCTGATGGGCCAGGATCAGCTCAGATGCGACTGCTTTGTGGAGGAAG AAAACATCACTGCCCATTCCTTAACCCTTACTTTCTCTATCTACAATATAAAAATAAGAAA <210> SEQ ID NO 28 <211> Length: 2,632 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 28 >HUMSMCK T7 TTCCATGCTCTTTAAAAGCCTTATAATTTTCTGGATCTGGGAGCTGGGCTATTTCAGGGTCAATGGATTTATTTCAG TTGGTGCCTGAACTGACTTGAAACAAGTGTGTGTGGAAAAGAGCTATTTTGAGAAGGAATAAACCGAGACTGCCCTG ATGATAGAATATGCAAGCTGGTGGGTCTTGACTCCTTAAAGGATTATGAAATTAATTTGATTGGTCCCAATCTTTAT ATAACCACCCCAATCAGGAAACTTCCCATCCCGCCAAAAGGCCCCCTCACGTGCTCTCCCTGTCAGTACCCCATGCA AAGGTAAAATAGATGATATTTTTAAACATGGGTCGTGTTTAAAAGAAATGGAAACTCCTTCAGAGAATGAAGGAGAA CCACACTGGGTAGAAGGTTATTCCTGGGGCTCCACCCCTTGCTCCATCAAGTCCTCTGAGCATGAGCTGGGCTCTGA GAAGGAAGAGACAGGAACCAATTGGTCATGTCCACGTGGCCTCAGAAGCTGAGTACGTGACGGTCACCAGATGCCTA GGCAGGCTCCCTTGAAATGGCAGGGCTGCTGTCCAAAATCCTGCTGGGTCATTGCTATTTACAGGCAGCCTTCCCGG

CGTGCGGTGGATATCCCAAGCGGGGCTATTTTTAAGCAGGGCTATGGCCTGCCGTGGGTTAAGCTGGTGTGGACAGA

WO 2005/069724 PCT/IB2005/001306 521 AAGCGAGATGATCTAGCCATCTACTGCAGGGGGCCTGATCTTGAACAGAAACCTGACTGTAATTGTCCCTGGATCCA GGTCCCAGACAAAGACGCTGGAAGGAGGTCCCTCCAGCCCCTGGCTCAGGGCCCGGTCAGCTGCTGGAGCCAGGCAG CTTGAGACATCCTCCTCTCCGACCTTGGCTTGAGGGGTTCATCCTCCAGAGCTCACCAGGGCCCCAAGGCTGGTACA CCTGAGAGAAGAGAGAAACAAATCCCCCAACAGATGTGCAATTTCACCTGCTGGCCCTTCCATTCTGAGATCCAGAG CCCTGGCAAAGGAGCCTCCAGGACCAGGCCTGGGAAGCAAGACTGGCTCCGCCTTTTACGTTTCAGAGAAAGGGCAG GTGCTATAAAGGGCCCAGCGCCCACGGGCCTGCCTTCAAGGGTACAGCTGTGGGGGCCGGTGCGCCCGGAGGTCTAC GCTGGGATTGGTGAGGTCCTCTGGCCCCGCCCCGCCAGGGAGGATTTCCAGGCCGGCCCGACCAGCTCGCCCTGCAT ACACTTCTTGGCTGTGTGCGCTCAGCAGGACGTGGGAGGCTCCGGCTTCAAGACACTCATCCAAGAGGAAGGATGGC CAGTATCTTTTCTAAGTTGCTAACTGGCCGCAATGCTTCTCTGCTGTTTGCTACCATGGGCACCAGTGTCCTGACCA CCGGGTACCTGCTGAACCGGCAGAAAGTGTGTGCCGAGGTCCGGGAGCAGCCTAGGCTATTTCCTCCAAGCGCAGAC TACCCAGACCTGCGCAAGCACAACAACTGCATGGCCGAGTGCCTCACCCCCGCCATTTATGCCAAGCTTCGCAACAA GGTGACACCCAACGGCTACACGCTGGACCAGTGCATCCAGACTGGAGTGGACAACCCTGGCCACCCCTTCATAAAGA CTGTGGGCATGGTGGCTGGTGACGAGGAGTCCTATGAGGTGTTTGCTGACCTTTTTGACCCCGTCATCAAACTAAGA CACAACGGCTATGACCCCAGGGTGATGAAGCACACAACGGATCTGGATGCATCAAAGATCACCCAAGGGCAGTTCGA CGAGCATTACGTGCTGTCTTCTCGGGTGCGCACTGGCCGCAGCATCCGTGGGCTGAGCCTGCCTCCAGCCTGCACCC GGGCCGAGCGAAGGGAGGTAGAGAACGTGGCCATCACTGCCCTGGAGGGCCTCAAGGGGGACCTGGCTGGCCGCTAC TACAAGCTGTCCGAGATGACGGAGCAGGACCAGCAGCGGCTCATCGATGCATAATTATGATAAGACATTTCTCATCT GGATAAATGAGGAGGATCACACCAGGGTAATCTCAATGGAAAAAGGAGGCAATATGAAACGAGTATTTGAGCGATTC TGTCGTGGACTAAAAGAAGTAGAACGGTTAATCCAAGAACGAGGCTGGGAGTTCATGTGGAATGAGCGCCTAGGATA CATTTTGACCTGTCCTTCGAACCTTGGAACAGGACTACGAGCTGGTGTCCACGTTAGGATCCCAAAGCTCAGCAAGG ACCCACGCTTTTCTAAGATCCTGGAAAACCTAAGACTCCAGAAGCGTGGCACAGGTGGTGTGGACACTGCCGCGGTC GCAGATGTGTACGACATTTCCAACATAGATAGAATTGGTCGATCAGAGGTTGAGCTTGTTCAGATAGTCATCGATGG AGTCAATTACCTGGTGGATTGTGAAAAGAAGTTGGAGAGAGGCCAAGATATTAAGGTGCCACCCCCTCTGCCTCAGT TTGGCAAAAAGTAAACTTTCCCTTTCCCAATTTATAAATAATCTGTCTGCTGGTACGACAGACATAAATCTCTACTC TGAGAGTTTTTATACACTTGGAAAAATATAAAATTGTAGATCCTGCCTATCTTTACAATAAAACTCTCCTTAATATA AAAAACTTTGCTTT <210> SEQ ID NO 29 <211> Length: 2,382 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 29 >HUMSMCK T9 TTCCATGCTCTTTAAAAGCCTTATAATTTTCTGGATCTGGGAGCTGGGCTATTTCAGGGTCAATGGATTTATTTCAG TTGGTGCCTGAACTGACTTGAAACAAGTGTGTGTGGAAAAGAGCTATTTTGAGAAGGAATAAACCGAGACTGCCCTG ATGATAGAATATGCAAGCTGGTGGGTCTTGACTCCTTAAAGGATTATGAAATTAATTTGATTGGTCCCAATCTTTAT

ATAACCACCCCAATCAGGAAACTTCCCATCCCGCCAAAAGGCCCCCTCACGTGCTCTCCCTGTCAGTACCCCATGCA

WO 2005/069724 PCT/IB2005/001306 522 AAGGTAAAATAGATGATATTTTTAAACATGGGTCGTGTTTAAAAGAAATGGAAACTCCTTCAGAGAATGAAGGAGAA CCACACTGGGTAGAAGGTTATTCCTGGGGCTCCACCCCTTGCTCCATCAAGTCCTCTGAGCATGAGCTGGGCTCTGA GAAGGAAGAGACAGGAACCAATTGGTCATGTCCACGTGGCCTCAGAAGCTGAGTACGTGACGGTCACCAGATGCCTA GGCAGGCTCCCTTGAAATGGCAGGGCTGCTGTCCAAAATCCTGCTGGGTCATTGCTATTTACAGGCAGCCTTCCCGG CGTGCGGTGGATATCCCAAGCGGGGCTATTTTTAAGCAGGGCTATGGCCTGCCGTGGGTTAAGCTGGTGTGGACAGA AAGCGAGATGATCTAGCCATCTACTGCAGGGGGCCTGATCTTGAACAGAAACCTGACTGTAATTGTCCCTGGATCCA GGTCCCAGACAAAGACGCTGGAAGGAGGTCCCTCCAGCCCCTGGCTCAGGGCCCGGTCAGCTGCTGGAGCCAGGCAG CTTGAGACATCCTCCTCTCCGACCTTGGCTTGAGGGGTTCATCCTCCAGAGCTCACCAGGGCCCCAAGGCTGGTACA CCTGAGAGAAGAGAGAAACAAATCCCCCAACAGATGTGCAATTTCACCTGCTGGCCCTTCCATTCTGAGATCCAGAG CCCTGGCAAAGGAGCCTCCAGGACCAGGCCTGGGAAGCAAGACTGGCTCCGCCTTTTACGTTTCAGAGAAAGGGCAG GTGCTATAAAGGGCCCAGCGCCCACGGGCCTGCCTTCAAGGGTACAGCTGTGGGGGCCGGTGCGCCCGGAGGTCTAC GCTGGGATTGGTGAGGTCCTCTGGCCCCGCCCCGCCAGGGAGGATTTCCAGGCCGGCCCGACCAGCTCGCCCTGCAT ACACTTCTTGGCTGTGTGCGCTCAGCAGGACGTGGGAGGCTCCGGCTTCAAGACACTCATCCAAGAGGAAGGATGGC CAGTATCTTTTCTAAGTTGCTAACTGGCCGCAATGCTTCTCTGCTGTTTGCTACCATGGGCACCAGTGTCCTGACCA CCGGGTACCTGCTGAACCGGCAGAAAGTGTGTGCCGAGGTCCGGGAGCAGCCTAGGCTATTTCCTCCAAGCGCAGAC TACCCAGACCTGCGCAAGCACAACAACTGCATGGCCGAGTGCCTCACCCCCGCCATTTATGCCAAGCTTCGCAACAA GGTGACACCCAACGGCTACACGCTGGACCAGTGCATCCAGACTGGAGTGGACAACCCTGGCCACCCCTTCATAAAGA CTGTGGGCATGGTGGCTGGTGACGAGGAGTCCTATGAGGTGTTTGCTGACCTTTTTGACCCCGTCATCAAACTAAGA CACAACGGCTATGACCCCAGGGTGATGAAGCACACAACGGATCTGGATGCATCAAAGATCACCCAAGGGCAGTTCGA CGAGCATTACGTGCTGTCTTCTCGGGTGCGCACTGGCCGCAGCATCCGTGGGCTGAGCCTGCCTCCAGCCTGCACCC GGGCCGAGCGAAGGGAGGTAGAGAACGTGGCCATCACTGCCCTGGAGGGCCTCAAGGGGGACCTGGCTGGCCGCTAC TACAAGCTGTCCGAGATGACGGAGCAGGACCAGCAGCGGCTCATCGATGACCACTTTCTGTTTGATAAGCCAGTGTC CCCTTTATTAACATGTGCTGGGATGGCCCGTGACTGGCCAGATGCCAGGGGAATCTGGCATAATTATGATAAGACAT TTCTCATCTGGATAAATGAGGAGGATCACACCAGGGTAATCTCAATGGAAAAAGGAGGCAATATGAAACGAGTATTT GAGCGATTCTGTCGTGGACTAAAAGAAGTAAGATGTTATCTGAGATTTCTGGATATTTATTAAAATAAAATTACCGT ATTGTTTGTTCTTGAAAGAAGACACTATGGTAACTTCCAAGATGGAGCTAATTTTTTTCTAGAAATCAAAGCAACTG CCGCCTCCCAGGTTCAAGTGATTATCCCGCCTCAGCCTCTAGAGTAGCTGGGATTACAGGTGCCACCACCAC <210> SEQ ID NO 30 <211> Length: 2,296 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 30 >HUMSMCK TIl TTCCATGCTCTTTAAAAGCCTTATAATTTTCTGGATCTGGGAGCTGGGCTATTTCAGGGTCAATGGATTTATTTCAG

TTGGTGCCTGAACTGACTTGAAACAAGTGTGTGTGGAAAAGAGCTATTTTGAGAAGGAATAAACCGAGACTGCCCTG

WO 2005/069724 PCT/IB2005/001306 523 ATGATAGAATATGCAAGCTGGTGGGTCTTGACTCCTTAAAGGATTATGAAATTAATTTGATTGGTCCCAATCTTTAT ATAACCACCCCAATCAGGAAACTTCCCATCCCGCCAAAAGGCCCCCTCACGTGCTCTCCCTGTCAGTACCCCATGCA AAGGTAAAATAGATGATATTTTTAAACATGGGTCGTGTTTAAAAGAAATGGAAACTCCTTCAGAGAATGAAGGAGAA CCACACTGGGTAGAAGGTTATTCCTGGGGCTCCACCCCTTGCTCCATCAAGTCCTCTGAGCATGAGCTGGGCTCTGA GAAGGAAGAGACAGGAACCAATTGGTCATGTCCACGTGGCCTCAGAAGCTGAGTACGTGACGGTCACCAGATGCCTA GGCAGGCTCCCTTGAAATGGCAGGGCTGCTGTCCAAAATCCTGCTGGGTCATTGCTATTTACAGGCAGCCTTCCCGG CGTGCGGTGGATATCCCAAGCGGGGCTATTTTTAAGCAGGGCTATGGCCTGCCGTGGGTTAAGCTGGTGTGGACAGA AAGCGAGATGATCTAGCCATCTACTGCAGGGGGCCTGATCTTGAACAGAAACCTGACTGTAATTGTCCCTGGATCCA GGTCCCAGACAAAGACGCTGGAAGGAGGTCCCTCCAGCCCCTGGCTCAGGGCCCGGTCAGCTGCTGGAGCCAGGCAG CTTGAGACATCCTCCTCTCCGACCTTGGCTTGAGGGGTTCATCCTCCAGAGCTCACCAGGGCCCCAAGGCTGGTACA CCTGAGAGAAGAGAGAAACAAATCCCCCAACAGATGTGCAATTTCACCTGCTGGCCCTTCCATTCTGAGATCCAGAG CCCTGGCAAAGGAGCCTCCAGGACCAGGCCTGGGAAGCAAGACTGGCTCCGCCTTTTACGTTTCAGAGAAAGGGCAG GTGCTATAAAGGGCCCAGCGCCCACGGGCCTGCCTTCAAGGGTACAGCTGTGGGGGCCGGTGCGCCCGGAGGTCTAC GCTGGGATTGGTGAGGTCCTCTGGCCCCGCCCCGCCAGGGAGGATTTCCAGGCCGGCCCGACCAGCTCGCCCTGCAT ACACTTCTTGGCTGTGTGCGCTCAGCAGGACGTGGGAGGCTCCGGCTTCAAGACACTCATCCAAGAGGAAGGATGGC CAGTATCTTTTCTAAGTTGCTAACTGGCCGCAATGCTTCTCTGCTGTTTGCTACCATGGGCACCAGTGTCCTGACCA CCGGGTACCTGCTGAACCGGCAGAAAGTGTGTGCCGAGGTCCGGGAGCAGCCTAGGCTATTTCCTCCAAGCGCAGAC TACCCAGACCTGCGCAAGCACAACAACTGCATGGCCGAGTGCCTCACCCCCGCCATTTATGCCAAGCTTCGCAACAA GGTGACACCCAACGGCTACACGCTGGACCAGTGCATCCAGACTGGAGTGGACAACCCTGGCCACCCCTTCATAAAGA CTGTGGGCATGGTGGCTGGTGACGAGGAGTCCTATGAGGTGTTTGCTGACCTTTTTGACCCCGTCATCAAACTAAGA CACAACGGCTATGACCCCAGGGTGATGAAGCACACAACGGATCTGGATGCATCAAAGATCACCCAAGGGCAGTTCGA CGAGCATTACGTGCTGTCTTCTCGGGTGCGCACTGGCCGCAGCATCCGTGGGCTGAGCCTGCCTCCAGCCTGCACCC GGGCCGAGCGAAGGGAGGTAGAGAACGTGGCCATCACTGCCCTGGAGGGCCTCAAGGGGGACCTGGCTGGCCGCTAC TACAAGCTGTCCGAGATGACGGAGCAGGACCAGCAGCGGCTCATCGATGCATAATTATGATAAGACATTTCTCATCT GGATAAATGAGGAGGATCACACCAGGGTAATCTCAATGGAAAAAGGAGGCAATATGAAACGAGTATTTGAGCGATTC TGTCGTGGACTAAAAGAAGTAAGATGTTATCTGAGATTTCTGGATATTTATTAAAATAAAATTACCGTATTGTTTGT TCTTGAAAGAAGACACTATGGTAACTTCCAAGATGGAGCTAATTTTTTTCTAGAAATCAAAGCAACTGCCGCCTCCC AGGTTCAAGTGATTATCCCGCCTCAGCCTCTAGAGTAGCTGGGATTACAGGTGCCACCACCAC <210> SEQ ID NO 31 <211> Length: 3,189 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 31 >H88495 PEA 3 T3 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG

ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC

WO 2005/069724 PCT/IB2005/001306 524 TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCATCATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT CCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGGTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCC TGTGTGGCTACTGCTCCTTCTGCAATCGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATGGGTGAG CACTGCGACCAGTGCCAGGTGAGACCTCACCTCACACTCAAGGCTCCACTGGGCCTCAGGATGCACCGGGACCCTCT GAGGACCCCCAGCCCTAAATCCTGGCCTCTGACCCAACCCCTTACCCCTGATGCAACCTTGACTCCACAAGCGATCC TGACTCCAACCTTAACCTAGACCTAGCCTCTGGTCCGGGTCTGGTCCCGGCCCCATCCTAACTCCGCCCCCGGCCAC GCCCCACGCTCACTCTCTCTCCCCGTCCCCGCCTCCAGCACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAA

ACGGTCTGCGCTCCAGGAAGCTACGTTGACTATTTCTCCTCGTCCCTTTATCAGGCCCTGGCAGACATGCTGGAAAC

WO 2005/069724 PCT/IB2005/001306 525 GCCGGAACCCTGACCCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCCTGCCTTCCAACCCCTTTCCACGAGCTA TATTTATTTCTCCGAATAAACGTGCTCCCCGA <210> SEQ ID NO 32 <211> Length: 3,298 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 32 >H88495 PEA 3 T4 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCATCATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT CCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA

AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA

WO 2005/069724 PCT/IB2005/001306 526 AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGGTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCCC TGTGTGGCTACTGCTCCTTCTGCAATCGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATGGGTGAG CACTGCGACCAGTGCCAGGTGAGACCTCACCTCACACTCAAGGCTCCACTGGGCCTCAGGATGCACCGGGACCCTCT GAGGACCCCCAGCCCTAAATCCTGGCCTCTGACCCAACCCCTTACCCCTGATGCAACCTTGACTCCACAAGCGATCC TGACTCCAACCTTAACCTAGACCTAGCCTCTGGTCCGGGTCTGGTCCCGGCCCCATCCTAACTCCGCCCCCGGCCAC GCCCCACGCTCACTCTCTCTCCCCGTCCCCGCCTCCAGCACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAA ACGGTCTGCGCTCCAGGAAGCTACGTTGACTATTTCTCCTCGTCCCTTTATCAGGCCCTGGCAGACATGCTGGAAAC GCCGGAACCCTGACCCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCCTGCCTTCCAACCCCTTTCCACGAGCTA TATTTATTTCTCCGAATAAACGTGCTCCCCGAAACCTCATTGTCAGACGTGGGGTCTGGGAATCTCAGGGCATCGGG GAATGCGGGTAGGGTCTAGAGACCTGGACCTAGACTTGAGGGATGAGGGGCCTGGACTCCTGGC <210> SEQ ID NO 33 <211> Length: 3,257 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 33 >H88495 PEA 3 T5 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG

ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA

WO 2005/069724 PCT/IB2005/001306 527 GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCATCATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT CCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGGTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCCC TGTGTGGCTACTGCTCCTTCTGCAATCGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATGGGTGAG CACTGCGACCAGTGCCAGCACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAAACGGTCTGCGCTCCAGGTGA GCATGGGCGGGGCCCTGGAAAAACCTGAGGAAGGTGCCGGGCCCAGCGTGGTGAATCCTGGTGGGGGCGGAGCCTGG CCCGGTAGGCTGGTGGGGCGGGGCTAAGAGGGGAGGCGTGGCCAAGGCTCTGAGCACGTGGGCCGGGGCCTGGCTCG AGGAACACCAGGTGGAGTTGCTGGAGCCAAGGGACAGAAATGAGTGGAGGGTTGAGATGCGGGCTTAGAGCCTAATG GGCGAGGCCAACTCAAGTAGGAATCGAAGGGGCGGGGCTACTGGAGAACGGAATCACCCAGAACGAAAAAGGGGTCC GGTAGAAGGGATTCAGTTGACTATTTCTCCTCGTCCCTTTATCAGGCCCTGGCAGACATGCTGGAAACGCCGGAACC CTGACCCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCCTGCCTTCCAACCCCTTTCCACGAGCTATATTTATTT CTCCGAATAAACGTGCTCCCCGA <210> SEQ ID NO 34 <211> Length: 3,366 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 34 >H88495 PEA 3 T6

GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG

WO 2005/069724 PCT/IB2005/001306 528 ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCATCATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGGATATGATGATGATGATGATGGATATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT CCACCATGGCCTTGTAGATGAGGAAGAGAAGAGAAAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGGTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCCC TGTGTGGCTACTGCTCCTTCTGCAATCGATGCACTGAATGTGAAGGCTGTCACTGTGATGAGGAGAACATGGGTGAG CACTGCGACCAGTGCCAGCACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAAACGGTCTGCGCTCCAGGTGA GCATGGGCGGGGCCCTGGAAAAACCTGAGGAAGGTGCCGGGCCCAGCGTGGTGAATCCTGGTGGGGGCGGAGCCTGG CCCGGTAGGCTGGTGGGGCGGGGCTAAGAGGGGAGGCGTGGCCAAGGCTCTGAGCACGTGGGCCGGGGCCTGGCTCG

AGGAACACCAGGTGGAGTTGCTGGAGCCAAGGGACAGAAATGAGTGGAGGGTTGAGATGCGGGCTTAGAGCCTAATG

WO 2005/069724 PCT/IB2005/001306 529 GGCGAGGCCAACTCAAGTAGGAATCGAAGGGGCGGGGCTACTGGAGAACGGAATCACCCAGAACGAAAAAGGGGTCC GGTAGAAGGGATTCAGTTGACTATTTCTCCTCGTCCCTTTATCAGGCCCTGGCAGACATGCTGGAAACGCCGGAACC CTGACCCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCCTGCCTTCCAACCCCTTTCCACGAGCTATATTTATTT CTCCGAATAAACGTGCTCCCCGAAACCTCATTGTCAGACGTGGGGTCTGGGAATCTCAGGGCATCGGGGAATGCGGG TAGGGTCTAGAGACCTGGACCTAGACTTGAGGGATGAGGGGCCTGGACTCCTGGC <210> SEQ ID NO 35 <211> Length: 3,508 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 35 >H88495 PEA 3 T7 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATTCGAGTTCCAGGG ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCATCATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT

CCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC

WO 2005/069724 PCT/IB2005/001306 530 AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGGTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCCC TGTGTGGCTACTGCTCCTTCTGCAATCGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATGGGTGAG CACTGCGACCAGTGCCAGGTGAGACCTCACCTCACACTCAAGGCTCCACTGGGCCTCAGGATGCACCGGGACCCTCT GAGGACCCCCAGCCCTAAATCCTGGCCTCTGACCCAACCCCTTACCCCTGATGCAACCTTGACTCCACAAGCGATCC TGACTCCAACCTTAACCTAGACCTAGCCTCTGGTCCGGGTCTGGTCCCGGCCCCATCCTAACTCCGCCCCCGGCCAC GCCCCACGCTCACTCTCTCTCCCCGTCCCCGCCTCCAGCACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAA ACGGTCTGCGCTCCAGGTGAGCATGGGCGGGGCCCTGGAAAAACCTGAGGAAGGTGCCGGGCCCAGCGTGGTGAATC CTGGTGGGGGCGGAGCCTGGCCCGGTAGGCTGGTGGGGCGGGGCTAAGAGGGGAGGCGTGGCCAAGGCTCTGAGCAC GTGGGCCGGGGCCTGGCTCGAGGAACACCAGGTGGAGTTGCTGGAGCCAAGGGACAGAAATGAGTGGAGGGTTGAGA TGCGGGCTTAGAGCCTAATGGGCGAGGCCAACTCAAGTAGGAATCGAAGGGGCGGGGCTACTGGAGAACGGAATCAC CCAGAACGAAAAAGGGGTCCGGTAGAAGGGATTCAGTTGACTATTTCTCCTCGTCCCTTTATCAGGCCCTGGCAGAC ATGCTGGAAACGCCGGAACCCTGACCCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCCTGCCTTCCAACCCCTT TCCACGAGCTATATTTATTTCTCCGAATAAACGTGCTCCCCGA <210> SEQ ID NO 36 <211> Length: 2,955 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 36 >H88495 PEA 3 T8 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA

CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG

WO 2005/069724 PCT/IB2005/001306 531 TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCAT( :ATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT CCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGGTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCCC TGTGTGGCTACTGCTCCTTCTGCAATCGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATGGGTGAG CACTGCGACCAGTGCCAGGGCCCTGGCAGACATGCTGGAAACGCCGGAACCCTGACCCAGTCGCTCGACTGCGACGC AGGTGTACCTCCCCCTGCCTTCCAACCCCTTTCCACGAGCTATATTTATTTCTCCGAATAAACGTGCTCCCCGAAAC CTCATTGTCAGACGTGGGGTCTGGGAATCTCAGGGCATCGGGGAATGCGGGTAGGGTCTAGAGACCTGGACCTAGAC TTGAGGGATGAGGGGCCTGGACTCCTGGC <210> SEQ ID NO 37 <211> Length: 2,867 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 37 >H88495 PEA 3 T9 WO 2005/069724 PCT/IB2005/001306 532 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGAGGAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCCAACGTTTG TCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATGGGCCACCATAGGCCATGGCTGCACG CTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTG GGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGGAGGCATCAGCAGAGCTTCGCCACCACCT CCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAGAATGGGCATCATTTCTGGAGCCACCCAG ACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACTCCCAGGCCACAGGTCCCAAGACCACAAA GTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTGGGCAGGCCCGTGGGCACAGAGGCCACGG GAGTGAAGACACGGAAGACTCAGCTGAGCACAGGCACCACCTCCCCAGCCACAGGAGCCACAGCCATCAAGACGAGG ATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGACACCGAGGCCATGATGGGGAAGAT GATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACTGAGTATGGACACCAGGCCCACAG GCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCATCATGGCCCCAGCCACAGGCACC AAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGTCTCCATTGAATAT AGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTCTCAGATGGACACCATCATCGCGA CCCCAGCCACAGGCACCGAAGCCATGAAGAAGATGACAATGATGATGATGATGTCTCCACTGAGTATGGACACCAGG CCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCACCATCATGTCCCTGACCAC AGGCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCACTGAACGTTGGCACCAGGGTCCCCAACATGT CCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAGTCCAGTTCGGCCACTATGTTGCAAGCCACC AACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTATAAAACAGAAGTCCCTCACCATCACCACCAC AGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCACCAGGCCCCCAGCCACAGGCAAAGCCACCA AGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGAGCCATCACCCCCCAGGACACACAGTGGTCA AGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAGAAGGAAGAGGACCCCGGCTCCCATGAGGAA GACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAGCCGGGACCAGGAAGATGAGGAGGATGAGGA GGAAGGTCATGGCCTCAGCCTGAACCAGGAGGAGGAAGAAGAGGAAGACAAGGAGGAGGAGGAGGAGGAAGAAGACG AGGGAAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGAGGAGGAGGAG GAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAACCCACTGGACAGGAGAGAGGAGGCTGGAGGTGC CTCCAGCGAGGAGGAAAGCGGTGAGGACACAGCGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATG GGTGAGCACTGCGACCAGTGCCAGCACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAAACGGTCTGCGCTCC AGGAAGCTACGTTGACTATTTCTCCTCGTCCCTTTATCAGGCCCTGGCAGACATGCTGGAAACGCCGGAACCCTGAC CCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCTGCCTTCCAACCCCTTTCCACGAGCTATATTTATTTCTCCG

AATAAACGTGCTCCCCGA

WO 2005/069724 PCT/IB2005/001306 533 <210> SEQ ID NO 38 <211> Length: 2,064 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 38 >Z36249 PEA 3 T2 ACATATTCAGCAGGGTTAGCTTGTCCTCCCCTCCCTCTTCAGCTTCCCAGACACTGAGTCTGGAATGAAAATTCACC TGCCTCTGAGTTGGCTCCTAATGGGGGTGGGAGTGTTACTTCGGTTCCCAGGTTGGAAGATTATCTCACCCGGCCCC AGCTATATAAGCTGACCGGTGTGGAGGGGCCCAGCAGGGCCAACTCCAGGGATTCCTTCCACGACAGAAAAACATAC AAGACTCCTTCAGCCAACATGATGGTACTGAAAGTAGAGGAACTGGTCACTGGAAAGAAGAATGGCAATGGGGAGGC AGGGGAATTCCTTCCTGAGGATTTCAGAGATGGAGAGTATGAAGCTGCTGTTACTTTAGAGAAGCAGGAGGATCTGA AGACACTTCTAGCCCACCCTGTGACCCTGGGGGAGCAACAGTGGAAAAGCGAGAAACAACGAGAGGCAGAGCTCAAA AAGAAAAAACTAGAACAAAGATCAAAGCTTGAAAATTTAGAAGACCTTGAAATAATCATTCAACTGAAGAAAAGGAA AAAATACAGGAAAACTAAAGTTCCAGTTGTAAAGGAACCAGAACCTGAAATCATTTATAAACGGACAGCTCTTCATA GAGCATGCTTGGAAGGACATTTGGCAATTGTGGAGAAGTTAATGGAAGCTGGAGCCCAGATCGAATTCCGTGATATG CTTGAATCCACAGCCATCCACTGGGCAAGCCGTGGAGGAAACCTGGATGTTTTAAAATTGTTGCTGAATAAAGGAGC AAAAATTAGCGCCCGAGATAAGTTGCTCAGCACAGCGCTGCATGTGGCGGTGAGGACTGGCCACTATGAGTGCGCGG AGCATCTTATCGCCTGTGAGGCAGACCTCAACGCCAAAGACAGAGAAGGAGATACCCCGTTGCATGATGCGGTGAGA CTGAACCGCTATAAGATGATCCGACTCCTGATTATGTATGGCGCGGATCTCAACATCAAGAACTGTGCTGGGAAGAC GCCGATGGATCTGGTGCTACACTGGCAGAATGGAACCAAAGCAATATTCGACAGCCTCAGAGAGAACTCCTACAAGA CCTCTCGCATAGCTACATTCTGAGGCAAACGACAGACTCTTAATCAGTAAATGTTCACTGGCATTTTGAAGGCATGG CCCAAGAGAAGAGACACTAGCCATAAAATCTAGTTTCTATTTATCAACGTGTTGTGAAGATGTACCTAATGAAGTTT TGAGAAAGCACAGGGTTATAGGTGTTTAAATTTCCTTTAGTGAAACTTTATTTATTTTTATGTATTCCTGTTTATT TATTTACTGCCACGCTACTGATATTCAGACCTTCATGATCATCCATCTGGTGAGCAGAGCTTCATTTGTATATAACA CTTTCAGAGCCTTCCCACCCATAGGTAGTTCTTAAACCAGGTGAAAGAGCAAAGTTCAAGTGCCTACTTATGTGTCA TTCGCTCATGTAAGAGTTTTTAAGAGAGGGCTGATTATCACAGCCCTCTTTTCTCCTGAATTTTTAATGCAGAAGTT TGAATGAAGCAAGGGAAGGCATGTAGGGACAGGAAAGGAAACAATGGAAGGAAAGTGATTCTGTGAAAAGGACAGTG AAGCCAGCTATTTTACCCCCAGGCTGGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACCGAGTACACAGAGTACC CAAGTGAAGAGAACGTCATGAGTGTAAGTGCAAATCAGTGGAAGGAGCGGCAAACTGGGACATGCAGAATTGAATTT GCTCAAAAAAGATGAAAGGAAATGCAAACTGTAAATGTATAAATGTATATTGTATTGTATGTACATTTTATATTCAT AATAAAGGCAATCAAACTCTAAACCTCTAAGTCCTTCTATAAGTGTGGTGGAAATGTCCTATGTGAAAAAAAAAGCT ATATAGGAGGGTTTTTTTTTTCCATTGTTTTCCAAGTTTTGCAGATTAGAAATGTCCCGTACAACAGCACTCCCAGT ATTTAATATGTATACAGATCACCTGGGGATCTGGTTAAAATGCAGATTTCTGATTCAGCTGG <210> SEQ ID NO 39 <211> Length: 1,472 WO 2005/069724 PCT/IB2005/001306 534 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 39 >Z36249 PEA 3 T3 ACATATTCAGCAGGGTTAGCTTGTCCTCCCCTCCCTCTTCAGCTTCCCAGACACTGAGTCTGGAATGAAAATTCACC TGCCTCTGAGTTGGCTCCTAATGGGGGTGGGAGTGTTACTTCGGTTCCCAGGTTGGAAGATTATCTCACCCGGCCCC AGCTATATAAGCTGACCGGTGTGGAGGGGCCCAGCAGGGCCAACTCCAGGGATTCCTTCCACGACAGAAAAACATAC AAGACTCCTTCAGCCAACATGATGGTACTGAAAGTAGAGGAACTGGTCACTGGAAAGAAGAATGGCAATGGGGAGGC AGGGGAATTCCTTCCTGAGGATTTCAGAGATGGAGAGTATGAAGCTGCTGTTACTTTAGAGAAGCAGGAGGATCTGA AGACACTTCTAGCCCACCCTGTGACCCTGGGGGAGCAACAGTGGAAAAGCGAGAAACAACGAGAGGCAGAGCTCAAA AAGAAAAAACTAGAACAAAGATCAAAGCTTGAAAATTTAGAAGACCTTGAAATAATCATTCAACTGAAGAAAAGGAA AAAATACAGGAAAACTAAAGTTCCAGTTGTAAAGGAACCAGAACCTGAAATCATTACGGAACCTGTGGATGTGCCTA CGTTTCTGAAGGCTGCTCTGGAGAATAAACTGCCAGTAGTAGAAAAATTCTTGTCAGACAAGAACAATCCAGATGTT TGTGATGAGTATAAACGGACAGCTCTTCATAGAGCATGCTTGGAAGGACATTTGGCAATTGTGGAGAAGTTAATGGA AGCTGGAGCCCAGATCGAATTCCGTGATATGGTAAATATATTTCTTTGCTTGGGAATGAGCCAAAAGAAGTAGACTA TATGAAGCTCCGGAAAACCTCCAATGCAAAACCGAGCTGATTGGATTGAAAATTGATCTGAGAGAACTAGGCAAAAG CTCATTTCTCCAAATAAAGGAAAGTTGGGAGATGAGAGTAGGTCATGTGAAAATATTTTCCATACATACTGAAAATA GAGGAATATTTCAGGGAAAAGAAGGAAGTGAAAGCTGTTAAACTGAATTCAATATCCTCATCAGCGAGTTAGTCATT CATTTTCGACACTTGCCTTTCAACAGCCTTGTCCCTCCATTGTTCACAGGGCAGCCTGCTTATGGTTGGCTGCCAGC AACATATACGAATTCTCTAGCTGCACACTTTATATGATAGATGCCAATTGCTACCAATGAGATTTGGGGCTAGACTG CATATGAAATGAATTGCATCTATGGAAAGTAGCTGCTATTCAGACCTCAATAATTCAATCACTGTGATTTCTACGAA GACCAGTATGCAGCATAATTTATGAACTGAAGATTGAGCTGGGAAAATTCTTTATGTATTTAAATGCAGCTCATTTT GACTTTATAGCAAAGCGGCAACGGGATATCAAAGAAATCCAAGGGACTTGGCCAAAATTGAATCCAAAACATAAACA CATTGAAAA <210> SEQ ID NO 40 <211> Length: 1,387 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 40 >Z36249 PEA 3 T5 ACATATTCAGCAGGGTTAGCTTGTCCTCCCCTCCCTCTTCAGCTTCCCAGACACTGAGTCTGGAATGAAAATTCACC TGCCTCTGAGTTGGCTCCTAATGGGGGTGGGAGTGTTACTTCGGTTCCCAGGTTGGAAGATTATCTCACCCGGCCCC AGCTATATAAGCTGACCGGTGTGGAGGGGCCCAGCAGGGCCAACTCCAGGGATTCCTTCCACGACAGAAAAACATAC AAGACTCCTTCAGCCAACATGATGGTACTGAAAGTAGAGGAACTGGTCACTGGAAAGAAGAATGGCAATGGGGAGGC

AGGGGAATTCCTTCCTGAGGATTTCAGAGATGGAGAGTATGAAGCTGCTGTTACTTTAGAGAAGCAGGAGGATCTGA

WO 2005/069724 PCT/IB2005/001306 535 AGACACTTCTAGCCCACCCTGTGACCCTGGGGGAGCAACAGTGGAAAAGCGAGAAACAACGAGAGGCAGAGCTCAAA AAGAAAAAACTAGAACAAAGATCAAAGCTTGAAAATTTAGAAGACCTTGAAATAATCATTCAACTGAAGAAAAGGAA AAAATACAGGAAAACTAAAGTTCCAGTTGTAAAGGAACCAGAACCTGAAATCATTACGGAACCTGTGGATGTGCCTA CGTTTCTGAAGGCTGCTCTGGAGAATAAACTGCCAGTAGTAGAAAAATTCTTGTCAGACAAGAACAATCCAGATGTT TGTGATGAGGTAAGACTCATGCAAAGCACTGCAAAATCCAGCTCATTAATTTTATGTTTCTTATGCTTTACTCCAGT CTTGCTAATATAGTGCCAAAGTCCTTCCACCTGAAACAGTTTCCCCAGCTGTTGCTGTGTATGCCAGGAGCCTAATA GGAGAGTTCAGTGGTCCAAAAAATAAATAGATATTAGATCAGTGATACGGATTGCATTGTTTTTTGCACTCATATAC ATCTGGCTGATTTTTCAGTTTTTCTTTAACTTCTTAGATTCTTGGGATAAGACTTTTAATGTGGGCCAAAAAGTCAC CTTTAGAGATATATTATTAGCATCATCTTTGATTAAAACCAAGCACGTCAACACTAGATAAGAAATCTGGAGATTGG AGTTCAGGGGCCAGTTGTACCACTACTTGGCTATTTGGTTTTGAGCAGCTAATTTGCATCCTCTGGGCTGTGGTTTC CTTATCTGTAAACATGGGGCATTGGAGTGAAATAACGCCTAAAGTTGTTCCAGCTCTAATAGTTCATTAGCCCATTC AAATAAAGCCAATTTATCAGAAATCACTAATCTTTTTGTATTCTTTCCCCCATGAAGTGAAATTGGGGACCGCTTCT GAAGTTGAACTAAAAACATGTCTCCCATTCTCCTAAAAATGAATGGAAACTTTTTGATAGTCTAGCAACAGTCCCAG A <210> SEQ ID NO 41 <211> Length: 1,877 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 41 >Z36249 PEA 3 T9 ACATATTCAGCAGGGTTAGCTTGTCCTCCCCTCCCTCTTCAGCTTCCCAGACACTGAGTCTGGAATGAAAATTCACC TGCCTCTGAGTTGGCTCCTAATGGGGGTGGGAGTGTTACTTCGGTTCCCAGGTTGGAAGATTATCTCACCCGGCCCC AGCTATATAAGCTGACCGGTGTGGAGGGGCCCAGCAGGGCCAACTCCAGGGATTCCTTCCACGACAGAAAAACATAC AAGACTCCTTCAGCCAACATGATGGTACTGAAAGTAGAGGAACTGGTCACTGGAAAGAAGAATGGCAATGGGGAGGC AGGGGAATTCCTTCCTGAGGATTTCAGAGATGGAGAGTATGAAGCTGCTGTTACTTTAGAGAAGCAGGAGGATCTGA AGACACTTCTAGCCCACCCTGTGACCCTGGGGGAGCAACAGTGGAAAAGCGAGAAACAACGAGAGGCAGAGCTCAAA AAGAAAAAACTAGAACAAAGATCAAAGCTTGAAAATTTAGAAGACCTTGAAATAATCATTCAACTGAAGAAAAGGAA AAAATACAGGAAAACTAAAGTTCCAGTTGTAAAGGAACCAGAACCTGAAATCATTACGGAACCTGTGGATGTGCCTA CGTTTCTGAAGGCTGCTCTGGAGAATAAACTGCCAGTAGTAGAAAAATTCTTGTCAGACAAGAACAATCCAGATGTT TGTGATGAGCTTGAATCCACAGCCATCCACTGGGCAAGCCGTGGAGGAAACCTGGATGTTTTAAAATTGTTGCTGAA TAAAGGAGCAAAAATTAGCGCCCGAGATAAGTTGCTCAGCACAGCGCTGCATGTGGCGGTGAGGACTGGCCACTATG AGTGCGCGGAGCATCTTATCGCCTGTGAGGCAGACCTCAACGCCAAAGACAGAGAAGGAGATACCCCGTTGCATGAT GCGGTGAGACTGAACCGCTATAAGATGATCCGACTCCTGATTATGTATGGCGCGGATCTCAACATCAAGAACTGTGC TGGGAAGACGCCGATGGATCTGGTGCTACACTGGCAGAATGGAACCAAAGCAATATTCGACAGCCTCAGAGAGAACT CCTACAAGACCTCTCGCATAGCTACATTCTGAGGCAAACGACAGACTCTTAATCAGTAAATGTTCACTGGCATTTTG

AAGGCATGGCCCAAGAGAAGAGACACTAGCCATAAAATCTAGTTTCTATTTATCAACGTGTTGTGAAGATGTACCTA

WO 2005/069724 PCT/IB2005/001306 536 ATGAAGTTTTGAGAAAGCACAGGGTTATAGGTGTTTAAATTTCCTTTAGTGAAACTCTTATTTATTTTTATGTATTC CTGTTTATTTATTTACTGCCACGCTACTGATATTCAGACCTTCATGATCATCCATCTGGTGAGCAGAGCTTCATTTG TATATAACACTTTCAGAGCCTTCCCACCCATAGGTAGTTCTTAAACCAGGTGAAAGAGCAAAGTTCAAGTGCCTACT TATGTGTCATTCGCTCATGTAAGAGTTTTTAAGAGAGGGCTGATTATCACAGCCCTCTTTTCTCCTGAATTTTTAAT GCAGAAGTTTGAATGAAGCAAGGGAAGGCATGTAGGGACAGGAAAGGAAACAATGGAAGGAAAGTGATTCTGTGAAA AGGACAGTGAAGCCAGCTATTTTACCCCCAGGCTGGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACCGAGTACA CAGAGTACCCAAGTGAAGAGAACGTCATGAGTGTAAGTGCAAATCAGTGGAAGGAGCGGCAAACTGGGACATGCAGA ATTGAATTTGCTCAAAAAAGATGAAAGGAAATGCAAACTGTAAATGTATAAATGTATATTGTATTGTATGTACATTT TATATTCATAATAAAGGCAATCAAACTCT <210> SEQ ID NO 42 <211> Length: 868 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 42 >Z25377 PEA 1 T1 AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG GTGGGGACTGGGCACATCATCAATACGATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTT TAATGGGATTGTGGAAGAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCA CACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTATTTAC CGTGGTTTCTGGGCAGTCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGTGCAGC CCCCTTCGCCAGCCATTTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAGATGGAATTTCTTCTCTCTGTT ACTCAAGCCTCTCAAAGTCCTTATTGTCCCAGCCTCTGCGTGAAACGTCTTCAGCCATCAATGACATCTCACTCCTT CAAGCCCTTATGCCACTGCTGGGATGGACCAGTCACTGGACCTGCATTACAGTGGGCTTATATTGACCTTTACCTCT ACACTTGTATATAACTCGTTTTCCCATTTAGTTGCAAGACACTTGGAAGCACAGACCAAGGCTTACATTTGTGTTTT AATGTTTTTCTTGTAAATGCTTTATGCCTAAATGTTTCTGTACTACTCTTCTTTCCAAATCCTTATTGTTTAAAAGT TTCTCTCCTACTATACCATGCCTTATAAATATTGATTGAATGAATGGATGAAATGCATACCTGCTTATATTTCTAAT TAAAGGCAATTTGGGATTATA <210> SEQ ID NO 43 <211> Length: 3,969 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 43 >Z25377 PEA 1 T5

AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG

WO 2005/069724 PCT/IB2005/001306 537 GTGGGGACTGGGCACATCATCAATACGATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTT TAATGGGATTGTGGAAGAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCA CACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTAGCATC CTATTTTCATTGGTGGTGATGCTGTATGTCATCTGGGTCCAGGCAGTGGCTGACATGGAAAGCTACCGAAACATGAA AATGAAGGACTGCCTGGATTTCACCCCTTCTGTTCTGTATGGCTGGTCATTTTTCCTGGCCCCAGCTGGGATATTTT TTTCTTTGCTAGCTGGATTACTATTTCTGGTTGTTGGACGGCATATTCAGATACATCACTAAATCAACTGTTGCCAC AAGTATTTTCTTGAGAGATTTTAAAACAAGGAATACTTTTTTTCCATTTTGTTTCATTGATCCCAGCATAAAGTTAG TAGATATAACTTTTTAGTTGCTATTCAAATTAATCATTTTACTAAAATTTTCTTCAGTAAGAAGGTCCTAGAATCTC TCCAGACACCAGCAAGCCTCTATCTTGTCTAAGTGCTGTCAAGGACCTAGTTCTTTAGGGAATAGGTAAACAGGTCT CCCTTTCATTGAACATGTTAGAGTTCATGCAGGTCGCAAAGGCCTGATAATAGCTTAATACCATGACATGGGGAAAA TCTCGATAGATTTGGCTTAAAGTCTCCTTGGCATTCACTTCTGCTAATTAAAAAAAATCCTTGAAGAATAATTAAGA ATGGGCAAGGTTGTCAGAGAATTTATTTTGTTTCTTGCCCACACAGATAATATCCACATACACATTCACTGGCTCTT GTGAGCAAATGAATTTAAAAATAGACAGCAGTTGTTCTAATTAGTGGGAGCCATGTACTCACCAGTTAAAATGGGCC ACAACAAACAAGACTGAGAGCATGTACTTATCTTGCTTTTTCACCAACAGTGGTTTGGTTACCTAGTTTTATTCACT TAATTGTGCATGCTTACATAAACTTTAAACTACATTTAAAACTAGCAAATCTGCATACCAAATTATGTATAACGTAG ATTGAATTTTTATGAACTTAAAGTGAGTTAATTGTATAATGTAATATTGTTTAAAATATGTAAAAACCAAGCATTTC CGCTTGGTCCATAATTCTATTTGATATTTTAAAATTCTCATTTAAAAATTATATTGCTATCATTCAGCATGTGAAAA TTTATTGATAAAATGTGATTTTAATATTTTTTAGATATAAACTTTCAACGTACTTCCATATGAGGATTATAATAGCC CTGCTTTATTAAAGACCATAAAATATTAACTTTCCCCAAGATGTTATGGGTTCCAGTTCTTCTGATCATTTGATTCC TTTAATTACTGTCCCTCAATTTCTTCATCTTTACAATAGATATATTAACATTTACAGATCGACTATTTCCTTTAACC TCCTAGAAGAAAGTTTTTGTGGGGAAAGATGATTCTGTATTATTCAGTAGCATAGACATTTTGCATATCAAAGATGT TCATTTGGCACTAATGTTGATTGAAATCAAATCCATCTGAGATGCCTAGCTCGTATTTGCATTCTGGAAGCCTCCAT CGCAGGGGAGCTCGGCAGGGTATGTGAGCTTTGTTGGAGGTGCGGTGTTTCATTCTGCAGCTGTTGTGAGGACAGAG AGGCATGGCCCACAGGCAAAAAAAGTCACCACCCAGAAGATGCTCTGGGATAGAGGAACTGCTCCTTTTCATCAGCT CTTCCAATGCCGTGGGAGAGGTGATCCCAGTCTTCTCTGTACATCTTGTGCTTTTCCATTAAGACTTGTTCCAGTGG GAAGGAGCTTTGGAAAAATTGCAAAGGTCTGAATCTTCAGGGCATTTTCATGACAGGACTTGCCAATAATAATAATA ATAATAATAATAATAATAATAATAATAAAGCTCCAGAGGCCTAACTGGTTTCTCAAGTCATTTCAGTGATATCATTG AAACGTTTTTGTGGTACTTCCCTTTGTCTTTCACTGTTTCATTTTTATATTGCTTCATTTACTTCTTTGCTTTTGGC TTTGTTATTAGAAAAAATAATTATGAGGTCTGTTGTGCATGTTGACTGTGATATTAAGTTATGGCATGCCATTAAGT TTTCCAGACGATGTTGGATGTATCTGATTAGTTCATGTCATCTGTAAATACAATTCTTTTTTGTAGTACTTTGGAAT GGAGCCTTTTTCTGGTGTACTGTATGCCATTTAAGTTTCACATACAAGCTGCTTTCGGCAAAGGCTTGAATATTTAT AAATTTCAGATGGTTATCCTCACTTTATAGTACACTTAAGTGGCTACCATATATTTTTTATATGACAATTGGCTGAA TAGCTGATGTGTATGACACTTTTACACAGATTTGCACTTTGGAACTATTTTATAGTTGTAATGCATCAATCAAATAC ATTTCAAGCACATTTCTTGATCAATTTACCAGCAACCCTCTGAAGGAATGAAGGAGAGTTGTGATTGCTATGTCAAT GAGTGAAATATACTTAAAAATGGCAGAGTTATATAGTACATTATTGTAGCAACCTTATATCTGATTTGAGATACTGT GTTGCCAAATGTCCATGTTATGTTTATTTCTCTATTGGTTGTATTTATTAATTTTTAGAAGCCTTTAAACTGTGTTA GAATCTTTTTGAAAAATGTTGATTTTGCATCATAAAGTTTCAATTTATCAAGGATATCTTTTCAGTTACACTTTTAG

AAAGAGTGAATAAAAAGGGCAGTGAGTTATGCTCTTGGACTTGGTGAAAGCTATCATCTCTCCATATTGTATTTGTT

WO 2005/069724 PCT/IB2005/001306 538 CAGCTGGTTTAATTCACTCAGGTGGATGATTGCACATACATTGGAATTGGCTGGAGAGACTACACAGAGAAGTTTAA TGATCGTGTACAATTTGAGGGTTGATGGTAGGGCTTTCTAAAAAAAGTAATATCAAGTGTGTTGTTAGTATTCATTT AGTCATTTTTATTACTAATCTATAAATATATTTATTAAATTTGAAGATTAAATGGAATTATAAAGGAATATATTGGA GGAAGTGTCAGTGTTGGTAATTATTCATCTATTTATCTGTCTATCATCAATATATATGGGTGCATGTCTGTGTATAT TTGTGTGTATGTAAGTGTGCATGTGTATTATATGTTTGGGTAGAAAGAGATACATTGAATGGTATAAATCAATATAT TTGAGCTAAGCAAGTTAAAAAAAAATCAGTTATCTTTGGGAACAGCAATCTATTATTGTTGTTTCCCTGAGTGCCAC TTTAACTGTTTCACTCAATGGATGGTGGTTTATTCAGTTCAACACGTAATTTGATTTCTATTTTCTTAAAAGTAACC ATGTTGGACTTACAAAGAGACTTAGAATGTCAGAGGTGTTAGGCAGATATTGGATACCAGTAAAATTGGCTGGATAT GTCTGAAGGTCGGTGGAATTGTGAGAAAGACCAATGGTGATGGGGTTACATTGAAGAAAATATAAGATGAGCTAAAT CAAAACCAGATTTGATTTTTTTGGGACTCCACCAGAAGTGGAAACTCATAAACAAGAGATGAAACAGAAAACTACAT TTTTATTGATTGTATGAAGGAGTTAAATATATGGAGACATTTCCTCAGTGATGATCAAGGGTAGGTGGGGAAATTCC AATAAGAATGTAGGATGACAATACCTTAGATATGTTGAAAACCAAGGAGGATGGGGATATAGTATCTTTCGTATTAT AATAAGCATAAAGTTAGCAAAGGGACATTTAATTTGGTTAGC <210> SEQ ID NO 44 <211> Length: 978 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 44 >Z25377 PEA 1 T7 AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG GTGGGGACTGGGCACATCATCAATACGATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTT TAATGGGATTGTGGAAGAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCA CACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTATTTAC CGTGGTTTCTGGGCAGTCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGTGCAGC CCCCTTCGCCAGCCATTTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAGGAATCTAGAAGATGGGGGGAT GGAAGTGAAGTGGAATGTAAAAACGTCTGCCAGTGCCCCATGGTCTCCAACCCACTTTCAGATGCACCGTCTCATTT CAACAGATATAGATGGAATTTCTTCTCTCTGTTACTCAAGCCTCTCAAAGTCCTTATTGTCCCAGCCTCTGCGTGAA ACGTCTTCAGCCATCAATGACATCTCACTCCTTCAAGCCCTTATGCCACTGCTGGGATGGACCAGTCACTGGACCTG CATTACAGTGGGCTTATATTGACCTTTACCTCTACACTTGTATATAACTCGTTTTCCCATTTAGTTGCAAGACACTT GGAAGCACAGACCAAGGCTTACATTTGTGTTTTAATGTTTTTCTTGTAAATGCTTTATGCCTAAATGTTTCTGTACT ACTCTTCTTTCCAAATCCTTATTGTTTAAAAGTTTCTCTCCTACTATACCATGCCTTATAAATATTGATTGAATGAA TGGATGAAATGCATACCTGCTTATATTTCTAATTAAAGGCAATTTGGGATTATA <210> SEQ ID NO 45 <211> Length: 708 <212> Type: DNA WO 2005/069724 PCT/IB2005/001306 539 <213> ORGANISM: Homo sapiens <400> sequence: 45 >Z25377 PEA 1 T8 AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG GTGGGGACTGGGCACATCATCAATACGATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTT TAATGGGATTGTGGAAGAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCA CACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTAGTCTT CTTTGATTCCTCATGGCAAACCAAATCCAGCAGCACATCAAAAAGCTTATCCACCATGATCAAGTGGGCTTCATCCC TGGGATGCAAGGCTGGTTCAATATATGCAAATCAATAAATGTAATCCAGCATATAAACAGAACCAAAGACAAAAACC ACATGATTATCTCAATAGATGCAGAAAAGGCCTTTGACAAAATTCAACAACACTTCATGCTAAAAACTCTCAATAAA TTAGGTATTGACGGGATGTATCTCAAAATAATAAGAGCTATCTATGACAAACCCACAGCCAATATCATACTGAATGG GCAAAAACTGGAAGCATTCCCTTTGAAAACTGGCAAAAGACAGGGATGCCCTCTCTCACCACTCCTATTCAACATAG TGTTGGAAGTTCTGG <210> SEQ ID NO 46 <211> Length: 783 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 46 >Z25377 PEA 1 T9 AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG GTGGGGACTGGGCACATCATCAATACGATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTT TAATGGGATTGTGGAAGAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCA CACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTATTTAC CGTGGTTTCTGGGCAGTCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGTGCAGC CCCCTTCGCCAGCCATTTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAGTTTCTGTGGGTCAAGAGTGTG GAAGTGGCTAAGCAGAATGAGTCCAGCTCAGAATCCCATGAGTCTGCTAATCAAGCTATTTTCTGGGGTTGCAATCA TCTGAAGGCCCAGCTGGGGCTAAAGAACGCACTTTGCAGCTCGCTTTTTGCCTGGCTCAGAAGATCCATTTCCAGAC TCACTTACACTGGCAGGCCTCAGTTCCTTGCCATGTGAATCACTGGGATGGGCTGCCTGGACCTCCTCAGGATACAG CAATTGCTAATAAAAGAGGTTTAAGGGGAACCAGAGAACTAGACGATAAAAGAAGTTGGCTAACATGAAAGCCCCAC CTCCAACATTGGG <210> SEQ ID NO 47 <211> Length: 730 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 540 <400> sequence: 47 >Z25377 PEA 1_TI0 AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG GTGGGGACTGGGCACATCATCAATACGATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTT TAATGGGATTGTGGAAGAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCA CACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTAATGGA ATTTCTTCTCTCTGTTACTCAAGCCTCTCAAAGTCCTTATTGTCCCAGCCTCTGCGTGAAACGTCTTCAGCCATCAA TGACATCTCACTCCTTCAAGCCCTTATGCCACTGCTGGGATGGACCAGTCACTGGACCTGCATTACAGTGGGCTTAT ATTGACCTTTACCTCTACACTTGTATATAACTCGTTTTCCCATTTAGTTGCAAGACACTTGGAAGCACAGACCAAGG CTTACATTTGTGTTTTAATGTTTTTCTTGTAAATGCTTTATGCCTAAATGTTTCTGTACTACTCTTCTTTCCAAATC CTTATTGTTTAAAAGTTTCTCTCCTACTATACCATGCCTTATAAATATTGATTGAATGAATGGATGAAATGCATACC TGCTTATATTTCTAATTAAAGGCAATTTGGGATTATA <210> SEQ ID NO 48 <211> Length: 1,193 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 48 >Z25377 PEA 1 TIl GAATCTGCCGGTGGGGCGTGAGCGAGAAGCCACCAAAACATGAGCTAGGACAGCCTTCTCAAGAAGATTCTGCCAAC TCAAAAATATTATTCTTTTTTTTTTTTTTTTGCTGTTGTTTCTGAGAAACTAGGTGTCTTACCATTTTAAAATTTCA TATTTTATTTAAAAGGAAACCAGTGAATTGAAAATGAGACTAAATATCGCTATCTTCTTTGGAGCTCTCTTTGGTGC TTTGGGGGTGTTACTCTTTTTGGTGGCTTTTGGATCGGATTATTGGCTTCTTGCAACTGAAGTGGGGAGATGTTCAG GTGAAAAGAATATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTTTAATGGGATTGTGGAA GAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCACACATGCTTACCTGTC TCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTATTTACCGTGGTTTCTGGGCAG TCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGTGCAGCCCCCTTCGCCAGCCAT TTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAGGAATCTAGAAGATGGGGGGATGGAAGTGAAGTGGAAT GTAAAAACGTCTGCCAGTGCCCCATGGTCTCCAACCCACTTTCAGATGCACCGTCTCATTTCAACAGATATAGATGG AATTTCTTCTCTCTGTTACTCAAGCCTCTCAAAGTCCTTATTGTCCCAGCCTCTGCGTGAAACGTCTTCAGCCATCA ATGACATCTCACTCCTTCAAGCCCTTATGCCACTGCTGGGATGGACCAGTCACTGGACCTGCATTACAGTGGGCTTA TATTGACCTTTACCTCTACACTTGTATATAACTCGTTTTCCCATTTAGTTGCAAGACACTTGGAAGCACAGACCAAG GCTTACATTTGTGTTTTAATGTTTTTCTTGTAAATGCTTTATGCCTAAATGTTTCTGTACTACTCTTCTTTCCAAAT CCTTATTGTTTAAAAGTTTCTCTCCTACTATACCATGCCTTATAAATATTGATTGAATGAATGGATGAAATGCATAC

CTGCTTATATTTCTAATTAAAGGCAATTTGGGATTATA

WO 2005/069724 PCT/IB2005/001306 541 <210> SEQ ID NO 49 <211> Length: 998 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 49 >Z25377 PEA 1 T12 GAATCTGCCGGTGGGGCGTGAGCGAGAAGCCACCAAAACATGAGCTAGGACAGCCTTCTCAAGAAGATTCTGCCAAC TCAAAAATATTATTCTTTTTTTTTTTTTTTTGCTGTTGTTTCTGAGAAACTAGGTGTCTTACCATTTTAAAATTTCA TATTTTATTTAAAAGGAAACCAGTGAATTGAAAATGAGACTAAATATCGCTATCTTCTTTGGAGCTCTCTTTGGTGC TTTGGGGGTGTTACTCTTTTTGGTGGCTTTTGGATCGGATTATTGGCTTCTTGCAACTGAAGTGGGGAGATGTTCAG GTGAAAAGAATATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTTTAATGGGATTGTGGAA GAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCACACATGCTTACCTGTC TCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTATTTACCGTGGTTTCTGGGCAG TCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGTGCAGCCCCCTTCGCCAGCCAT TTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAGTTTCTGTGGGTCAAGAGTGTGGAAGTGGCTAAGCAGA ATGAGTCCAGCTCAGAATCCCATGAGTCTGCTAATCAAGCTATTTTCTGGGGTTGCAATCATCTGAAGGCCCAGCTG GGGCTAAAGAACGCACTTTGCAGCTCGCTTTTTGCCTGGCTCAGAAGATCCATTTCCAGACTCACTTACACTGGCAG GCCTCAGTTCCTTGCCATGTGAATCACTGGGATGGGCTGCCTGGACCTCCTCAGGATACAGCAATTGCTAATAAAAG AGGTTTAAGGGGAACCAGAGAACTAGACGATAAAAGAAGTTGGCTAACATGAAAGCCCCACCTCCAACATTGGG <210> SEQ ID NO 50 <211> Length: 1,083 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 50 >Z25377 PEA 1 T13 GAATCTGCCGGTGGGGCGTGAGCGAGAAGCCACCAAAACATGAGCTAGGACAGCCTTCTCAAGAAGATTCTGCCAAC TCAAAAATATTATTCTTTTTTTTTTTTTTTTGCTGTTGTTTCTGAGAAACTAGGTGTCTTACCATTTTAAAATTTCA TATTTTATTTAAAAGGAAACCAGTGAATTGAAAATGAGACTAAATATCGCTATCTTCTTTGGAGCTCTCTTTGGTGC TTTGGGGGTGTTACTCTTTTTGGTGGCTTTTGGATCGGATTATTGGCTTCTTGCAACTGAAGTGGGGAGATGTTCAG GTGAAAAGAATATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTTTAATGGGATTGTGGAA GAGAATGACTCCAATATTTGGAAGTTCTGGTACACCAATCAGCCACCGTCCAAGAACTGCACACATGCTTACCTGTC TCCGTACCCCTTCATGAGAGGCGAGCACAACTCGACCTCCTATGACTCTGCAGTTATTTACCGTGGTTTCTGGGCAG TCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGTGCAGCCCCCTTCGCCAGCCAT TTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAGATGGAATTTCTTCTCTCTGTTACTCAAGCCTCTCAAA

GTCCTTATTGTCCCAGCCTCTGCGTGAAACGTCTTCAGCCATCAATGACATCTCACTCCTTCAAGCCCTTATGCCAC

WO 2005/069724 PCT/IB2005/001306 542 TGCTGGGATGGACCAGTCACTGGACCTGCATTACAGTGGGCTTATATTGACCTTTACCTCTACACTTGTATATAACT CGTTTTCCCATTTAGTTGCAAGACACTTGGAAGCACAGACCAAGGCTTACATTTGTGTTTTAATGTTTTTCTTGTAA ATGCTTTATGCCTAAATGTTTCTGTACTACTCTTCTTTCCAAATCCTTATTGTTTAAAAGTTTCTCTCCTACTATAC CATGCCTTATAAATATTGATTGAATGAATGGATGAAATGCATACCTGCTTATATTTCTAATTAAAGGCAATTTGGGA TTATA <210> SEQ ID NO 51 <211> Length: 8,921 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 51 >HSACMHCP PEA 1 T2 GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTT CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCA GTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACT TTGGCATGGACCTGCAGGCCTGCATTGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGC ATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCA GAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACA

TCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAG

WO 2005/069724 PCT/IB2005/001306 543 CTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAA GGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCC ATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCAC CAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGA CTTCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAG AGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGG CTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGG CCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGG CCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACG GAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAA GGAGCTGGAGGAGAAGATGGTTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACA ACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATG AATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTC AGAGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACA AGGTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTA CAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGT CAAGCTGGAGCAGCAGGTGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAG CAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCCATATGGACCTGGAAAATGATAAACTGCAGCTG GAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCT TCAACTACAGAAGAAACTGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCG CCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCC GGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGA GGAGGCCACGCTGCAGCACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCG AGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGAC GTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGC CAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGA CCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCT TATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACT GCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGC GCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAG GAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAA GTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCA ATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAG GAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGC CTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGAGGAAATCTCGGACCTTA CTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTG GAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGA

GTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACC

WO 2005/069724 PCT/IB2005/001306 544 ACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAG AAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAA GCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACC TGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTG GAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTC CCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTCGGAAGTGGAGGAGG CAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTG AAGAAGGAGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCA CCGGCTGGACGAGGCCGAGCAGATCGCCCTCAAGGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCGGGTGCGGG AGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGC ATCAAGGAGCTCACCTACCAGGTGCGGCGGACGCCAGACACCGGGAGTAGATGTGGAAGTTTCTTCTCTGGCCCCAC TGCCCCGCCCTCACAGGGCTCCTCTCACCTCCTCCTTGAGATGCTGTTGGTAGATTTAACGTTCTTCTCACGCTCTG CAGTCAGTTTGACTTGAGTCTATGAGTTTTTCCAGCAAATGAAGAATCTACTTCTACTTCCTGAAAACTCTTCTAAC TAGTCTTTCCCCAGGTTTCTTTCTTTCTTTTTTTTTTTTTTTAATAACTCTAAGTGCTACCATGAAGACTTCAGAAC AGTTCAAAGAATCCTTCCACCTTCGACTGTGGGGATAAGAGTCAGGGGAGGGGAAAAGACCCGGAAATCTTCCATAG AACTTCTGGCACACAAAGAGAAGGCCACAGAGAAAGAGGACCCTAGAATGCTCTAAAACCTCCACTTGCATAGCTGA GAGCTGTGCCCTTGGCCCGTTATTTTCAGTGTACCTGGGAAGAAAAGGCCAAGGAGACGAGGGTGTCAGTCCATTTG ATAGATGGATACCAGAGGCACAAGAAAGAGGTTACAGATACAGAACCACAGAGTGATTTGTGGACAGAAGTAGAAAT GGCATCCTGGCACATACAATGATAAAGAGATAGGAATGATCGAGTGACGTTGGAGCCAGTGATCCCGATGCCTGAAT TCTGGCCCAGTACAATATATTAGAATGTAGAATAATCTGGATTATGATAATACCCCCTTCTTTCTGCATTCTTTTTC TGGTCAAGAACTACTGGCCAAGAGAACCTATGTAAGTCCAGGTTGGAGCTTTATCCACCATACTGGAGCTGGAACAG ACCTGGTGCTTTTATATTACCACATTAGGGAATTCCATTAGGTTCTGAGCCCCTCCCCCTACTTCTAGCTTTATGAC TTCAGCCTTCATTGCTCTGTGGATCCCTGACTGACAACCTTGCATTGCCCCTTTGACCTACGATAGAGTCAGAGAAT CTTCCCCACCACCTCTTTGACCTGGATCATTGCAGGGAGGGGCAGCAAAGGCAAGGGGAGAAGAGTAAAATGATGGA GGAGGGAAAGGTGATTGCATTTGCTCCCCCTCCAAACCAGCTTCTCCCACCCTCCCACCCCCAGACAGAGGAAGACA AAAAGAACCTGCTGCGGCTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAG GAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCG GGCGGACATCGCTGAGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCACG ATGAGGAGTGACACTGCCTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCAAACTCTGCCTGAGCC CATCTGTCCTTCCTGCCAGCTGTCCATCCTGGATCAGGGCAGTAGGGGGCCTGAGAGGAGGGAGGCCCCCAGCCCCT GTATCAGAGCTGCCAGAGCCAAGGCATCCCATATCCACAAGGAAGGAGACCGAGGTGCAGAGGAGTGAGGTGTTCTG CCTGACGTGGACAGCTGTGAGTCCCAGTTCTGCTCAGTCAACCACACAAGGGTGGAGAGGGAGAAATTTCAAAAGTG AAGAAAACAATGGCATCAAAATGGTGAGCCAGTCCAAGATGCTACGAGATAGAATTTTGGTGCCGAAGTTGAAGCCA CTCTCCACCTACCCCACCCCTGAGGCTGCAATGATTAAAGGTGTCCTAGGACACCCATTCTTTCTGAAATGAATTTT CCACCAATGCCAGAAAAGGCTCAGAGCTGGCTGAGAATTAAGGTATGGGAAAGGAGATGGGAGAGATTCCATTCTAG TCAGCCCCTAGGAAGTAACTCCCAGGGAGCCCCCTCCCTGTCTTCCCCAGGGGTCTCCCCCTGCCTCCTATGATTCA GCACCTCACCGTGAGGGCATCTTGAGACTCTGGGGCCAATCAACACTGAGCCCAAACCAATATGCCATGAGGACCAA

GCCTGGGCATTGCTCATTTCATGTTGGTTCTCACACAGACACAGATGGCACAGGTGCCTGTACAGGGAAACACTGTG

WO 2005/069724 PCT/IB2005/001306 545 GTCACATTTCTGCTCTCTCTAAGCTCCTACTGGGGACAGTCTGGCCTGGATCACACAGCTGCTTGTGGGACAGGCCC GGTCCTGACCCCGTTCTGCACAAAGCAAATCCCCACTCCCCACTGGGCTTTGCAGCCAGGCTCTGCTGACCGCCTCC TTAACCGTTCACCTGGCACCCCATCTCCCTGACTCCCCAAGTGGAGCCTCTTCTATCCCTCCTCTGAGACCATGAGA ATGGACTGTGCATAAAGCCCTGAGAAATGTGAGCAGTGACCAGAGAAACACAAAATCCTGTTGGTTCTAGCCCAGGA GAGGCTGCCAGTTCTGATGGTGAGCCAGGACACAAGGATAGGAGAACAGGAAGCAGGAGGCAGGAAAAAGACCAAGA GAGAGGAGTGGCTGCCACCAAGGAAGCAGAGCGCTCTGACCAGAGTTCAAGATCCAGGGTTCGGGCAGGACTTGGGA GCTGGGGCCTGCAGCTGGAAGGAGCGCTCCAGAAGAAGGATTGTATCTCAGGGCGGGAACACACACACATCAGCGAC AGGAGATAGCACGTCAGCTGGGATGGAGCTGCTGAGCCAGGCCATGCTGGGCTCCTCGGGCTGGGCAGGAACGTCTG GCTGCACATCTGTCTGTCTCGGCCCAGCAGGGCTGACTCCCGGGCTGTGGCAGTGTCTGCTCCAAACTCCCCTGGGC CTTCCCATAGCATTCACTGTGGGGAGCTCTTGACCAGCTTGTCTCTTTCCCAGCCTGTGAGTGCTAAAGGGCAGGCC CCCCGTCACCTCTGAGGCCCTGGCACCCAGCACAGTGTGCATGGGAGATGCTCAGGAAATGTGTGCTGAGGAGCTGG CAAGCTGGGAGGGTGGACCCGCAGTGGAGGGAAGAGTTGGCCATTCTTTTCTGAGCTACAAGGAGGCTCAGTACAGT ATCCAGAACACTCGCTTAGGTGTCAGAAGAGCTGCGTTCTGGCCCTAGCTCTGTCACAAATGAGTTCACCTCCCCTG GCTGGGCCTGTTTTCTCTTATGTGAAATGAGGGCATTGGACCAGCTGATAATCAACGGCTTCCCCAGCATTCGCATT TTGGGAAATCTTCTCCCTCCTCTGATACCTCAGGCTGCCCTCTCCCTGCCTCCTGTTCCTGTCATAG <210> SEQ ID NO 52 <211> Length: 6,290 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 52 >HSACMHCP PEA 1 T3 GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTT CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA

TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT

WO 2005/069724 PCT/IB2005/001306 546 ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCA GTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACT TTGGCATGGACCTGCAGGCCTGCATTGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGC ATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCA GAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACA TCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAG CTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAA GGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCC ATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCAC CAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGA CTTCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAG AGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGG CTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGG CCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGG CCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACG GAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAA GGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACA ACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATG AATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTC AGAGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACA AGGTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTA CAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGT CAAGCTGGAGCAGCAGGTGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAG CAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTG GAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCT TCAACTACAGAAGAAACTGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCG CCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCC GGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGA GGAGGCCACGCTGCAGCACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCG AGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGAC GTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGC CAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGA CCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCT

TATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGTGAGGCCCAGTGGGGAGGGTGGGCA

WO 2005/069724 PCT/IB2005/001306 547 GGCTTGATGGCAGCCCTGGGGCAATTCATCTCAGTGCCAGAAATGGAGCCTGGAGCTGGAAAGAGTCCTCTGCAAGG GAAAGACCCTCCAGTCTAGGTTCTGCCCTGCAGCTAAGCGTCATTTAATGCCTCTTTTCTTATTCGTAAGGGGATGG GGTGAGCAGACTGGGAAACTCCTCAAACAGTGAGGTGCCACATCAGCCCACATGGTGAATAAGGCTGGGCTTGGTTG AAGTACTACATAAGAAGAGAATCTAGAGAATGGGGCACAGGGAGTCCCTCCCACCTCCTGGTGCCCCCCCCCCTCCC CAGGCGAAGAACGCCCTGGCCCATGCACTGCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGA GGAGACAGAGGCCAAGGCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGT ATGAGACGGACGCCATTCAGCGGACTGAGGAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCC GAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGA GGACTTGATGGTGGACGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGA TCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTC AGCACAGAGCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAA GAACCTTCAGGAGGAAATCTCGGACCTTACTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGG TCCGCAAACAGCTGGAGGTGGAGAAGCTGGAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAG GAGGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGA CGAGGAGATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACAC GCAGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCAC GCCAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCT GGACGATGCGGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGG CTGAGCTGGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAG ACCAGCGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCT GACCCAGCTCCAGTCGGAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCA CGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAAC ATGGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGATCGCCCTCAAGGGAGGCAAGAAGCA GCTGCAGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGG TGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACAGAGGAAGACAAAAAGAACCTGCTG CGGCTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCA AGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTG AGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCACGATGAGGAGTGACAC TGCCTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCAAACTC <210> SEQ ID NO 53 <211> Length: 6,057 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 53 >HSACMHCP PEA 1 T4

GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG

WO 2005/069724 PCT/IB2005/001306 548 ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTT CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCA GTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACT TTGGCATGGACCTGCAGGCCTGCATTGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGC ATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCA GAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACA TCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAG CTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAA GGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCC ATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCAC CAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGA CTTCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAG AGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGG CTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGG CCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGG CCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACG GAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAA GGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACA ACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATG AATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTC

AAGGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACA

WO 2005/069724 PCT/IB2005/001306 549 AGGTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTA CAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGT CAAGCTGGAGCAGCAGGTGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAG CAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTG GAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCT TCAACTACAGAAGAAACTGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCG CCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCC GGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGA GGAGGCCACGCTGCAGCACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCG AGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGAC GTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGC CAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGA CCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCT TATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACT GCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGC GCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAG GAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAA GTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCA ATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAG GAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGC CTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGGTGTGCTGGGGGTCCAAG AGGCCAGAGATGAGTTGGTGGGAGGGAGGGCCATGCAGGGGCAGGGGGAACATAGGCTTTGAGCTTTCTGGCCCTCT GGTCCCCAGAGGAAATCTCGGACCTTACTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTC CGCAAACAGCTGGAGGTGGAGAAGCTGGAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGA GGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACG AGGAGATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACACGC AGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCACGC CAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCTGG ACGATGCGGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCT GAGCTGGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAGAC CAGCGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGA CCCAGCTCCAGTCGGAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACG GATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACAT GGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGATCGCCCTCAAGGGAGGCAAGAAGCAGC TGCAGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTG AAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACAGAGGAAGACAAAAAGAACCTGCTGCG GCTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAG

CCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTGAG

WO 2005/069724 PCT/IB2005/001306 550 TCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCACGATGAGGAGTGACACTG CCTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCAAACTC <210> SEQ ID NO 54 <211> Length: 6,177 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 54 >HSACMHCP PEA 1 T6 GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTT CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCA GTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACT TTGGCATGGACCTGCAGGCCTGCATTGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGC ATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCA GAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACA TCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAG CTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAA GGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCC

ATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCAC

WO 2005/069724 PCT/IB2005/001306 551 CAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGA CTTCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAG AGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGG CTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGG CCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGG CCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACG GAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAA GGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACA ACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATG AATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTC AGAGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACA AGGTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTA CAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGT CAAGCTGGAGCAGCAGGTGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAG CAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTG GAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCT TCAACTACAGAAGAAACTGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCG CCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCC GGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGA GGAGGCCACGCTGCAGCACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCG AGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGAC GTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGC CAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGA CCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCT TATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACT GCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGC GCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAG GAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAA GTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCA ATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAG GAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGC CTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGAGGAAATCTCGGACCTTA CTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTG GAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGA GTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACC ACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAG AAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAA

GCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACC

WO 2005/069724 PCT/IB2005/001306 552 TGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTG GAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTC CCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTCGGAAGTGGAGGAGG CAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTG AAGAAGGAGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCA CCGGCTGGACGAGGCCGAGCAGATCGCCCTCAAGGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCGGGTGCGGG AGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGC ATCAAGGAGCTCACCTACCAGGTGCGGCGGACGCCAGACACCGGGAGTAGATGTGGAAGTTTCTTCTCTGGCCCCAC TGCCCCGCCCTCACAGGGCTCCTCTCACCTCCTCCTTGAGATGCTGTTGGTAGATTTAACGTTCTTCTCACGCTCTG CAGTCAGTTTGACTTGAGTCTATGAGTTTTTCCAGCAAATGAAGAATCTACTTCTACTTCCTGAAAACTCTTCTAAC TAGTCTTTCCCCAGACAGAGGAAGACAAAAAGAACCTGCTGCGGCTACAGGACCTGGTGGACAAGCTGCAACTGAAG GTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCA GCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTGAGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTG ACATTGGTGCCAAGCAAAAAATGCACGATGAGGAGTGACACTGCCTCGGGAACCTCACTCTTGCCAACCTGTAATAA ATATGAGTGCCAAACTC <210> SEQ ID NO 55 <211> Length: 9,119 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 55 >HSACMHCP PEA 1 T7 GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTT CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA

TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT

WO 2005/069724 PCT/IB2005/001306 553 ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCA GTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACT TTGGCATGGACCTGCAGGCCTGCATTGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGC ATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCA GAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACA TCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAG CTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAA GGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCC ATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCAC CAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGA CTTCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAG AGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGG CTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGG CCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGG CCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACG GAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAA GGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACA ACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATG AATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTC AGAGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACA AGGTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTA CAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGT CAAGCTGGAGCAGCAGGTGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAG CAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTG GAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCT TCAACTACAGAAGAAACTGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCG CCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCC GGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGA GGAGGCCACGCTGCAGCACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCG AGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAGCAGCGAGTTCAAGCTGGAGCTGGATGAC GTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGC CAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGA CCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCT

TATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACT

WO 2005/069724 PCT/IB2005/001306 554 GCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGC GCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAG GAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAA GTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCA ATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAG GAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGC CTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGAGGAAATCTCGGACCTTA CTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTG GAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGA GTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACC ACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAG AAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAA GCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACC TGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTG GAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTC CCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTCGGAAGTGGAGGAGG CAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGTAAGTGACCGCCCACCTTCCGCC TCCCCTAAAGACAGAAACAAGGCCTTGGGTCCAGGCCAGGCCACTGTGCTGTAACACCAAGCCAACTCTGCAGTTCT GTGGATTTGAGGGCCTGATGGGAGAAAGGAGATCCTTGGGGGGCAAAAGGCCCCGGCCCCTGGCCCATGTTCCTTGC CACCTCTCTCCTGCACACAGGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACCTGGAG CGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGATCGCCCTCAA GGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGC GCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGGTGCGGCGGACG CCAGACACCGGGAGTAGATGTGGAAGTTTCTTCTCTGGCCCCACTGCCCCGCCCTCACAGGGCTCCTCTCACCTCCT CCTTGAGATGCTGTTGGTAGATTTAACGTTCTTCTCACGCTCTGCAGTCAGTTTGACTTGAGTCTATGAGTTTTTCC AGCAAATGAAGAATCTACTTCTACTTCCTGAAAACTCTTCTAACTAGTCTTTCCCCAGGTTTCTTTCTTTCTTTTTT TTTTTTTTTAATAACTCTAAGTGCTACCATGAAGACTTCAGAACAGTTCAAAGAATCCTTCCACCTTCGACTGTGGG GATAAGAGTCAGGGGAGGGGAAAAGACCCGGAAATCTTCCATAGAACTTCTGGCACACAAAGAGAAGGCCACAGAGA AAGAGGACCCTAGAATGCTCTAAAACCTCCACTTGCATAGCTGAGAGCTGTGCCCTTGGCCCGTTATTTTCAGTGTA CCTGGGAAGAAAAGGCCAAGGAGACGAGGGTGTCAGTCCATTTGATAGATGGATACCAGAGGCACAAGAAAGAGGTT ACAGATACAGAACCACAGAGTGATTTGTGGACAGAAGTAGAAATGGCATCCTGGCACATACAATGATAAAGAGATAG GAATGATCGAGTGACGTTGGAGCCAGTGATCCCGATGCCTGAATTCTGGCCCAGTACAATATATTAGAATGTAGAAT AATCTGGATTATGATAATACCCCCTTCTTTCTGCATTCTTTTTCTGGTCAAGAACTACTGGCCAAGAGAACCTATGT AAGTCCAGGTTGGAGCTTTATCCACCATACTGGAGCTGGAACAGACCTGGTGCTTTTATATTACCACATTAGGGAAT TCCATTAGGTTCTGAGCCCCTCCCCCTACTTCTAGCTTTATGACTTCAGCCTTCATTGCTCTGTGGATCCCTGACTG ACAACCTTGCATTGCCCCTTTGACCTACGATAGAGTCAGAGAATCTTCCCCACCACCTCTTTGACCTGGATCATTGC AGGGAGGGGCAGCAAAGGCAAGGGGAGAAGAGTAAAATGATGGAGGAGGGAAAGGTGATTGCATTTGCTCCCCCTCC

AAACCAGCTTCTCCCACCCTCCCACCCCCAGACAGAGGAAGACAAAAAGAACCTGCTGCGGCTACAGGACCTGGTGG

WO 2005/069724 PCT/IB2005/001306 555 ACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCC AAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTGAGTCCCAGGTCAACAAGCT TCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCACGATGAGGAGTGACACTGCCTCGGGAACCTCACTC TTGCCAACCTGTAATAAATATGAGTGCCAAACTCTGCCTGAGCCCATCTGTCCTTCCTGCCAGCTGTCCATCCTGGA TCAGGGCAGTAGGGGGCCTGAGAGGAGGGAGGCCCCCAGCCCCTGTATCAGAGCTGCCAGAGCCAAGGCATCCCATA TCCACAAGGAAGGAGACCGAGGTGCAGAGGAGTGAGGTGTTCTGCCTGACGTGGACAGCTGTGAGTCCCAGTTCTGC TCAGTCAACCACACAAGGGTGGAGAGGGAGAAATTTCAAAAGTGAAGAAAACAATGGCATCAAAATGGTGAGCCAGT CCAAGATGCTACGAGATAGAATTTTGGTGCCGAAGTTGAAGCCACTCTCCACCTACCCCACCCCTGAGGCTGCAATG ATTAAAGGTGTCCTAGGACACCCATTCTTTCTGAAATGAATTTTCCACCAATGCCAGAAAAGGCTCAGAGCTGGCTG AGAATTAAGGTATGGGAAAGGAGATGGGAGAGATTCCATTCTAGTCAGCCCCTAGGAAGTAACTCCCAGGGAGCCCC CTCCCTGTCTTCCCCAGGGGTCTCCCCCTGCCTCCTATGATTCAGCACCTCACCGTGAGGGCATCTTGAGACTCTGG GGCCAATCAACACTGAGCCCAAACCAATATGCCATGAGGACCAAGCCTGGGCATTGCTCATTTCATGTTGGTTCTCA CACAGACACAGATGGCACAGGTGCCTGTACAGGGAAACACTGTGGTCACATTTCTGCTCTCTCTAAGCTCCTACTGG GGACAGTCTGGCCTGGATCACACAGCTGCTTGTGGGACAGGCCCGGTCCTGACCCCGTTCTGCACAAAGCAAATCCC CACTCCCCACTGGGCTTTGCAGCCAGGCTCTGCTGACCGCCTCCTTAACCGTTCACCTGGCACCCCATCTCCCTGAC TCCCCAAGTGGAGCCTCTTCTATCCCTCCTCTGAGACCATGAGAATGGACTGTGCATAAAGCCCTGAGAAATGTGAG CAGTGACCAGAGAAACACAAAATCCTGTTGGTTCTAGCCCAGGAGAGGCTGCCAGTTCTGATGGTGAGCCAGGACAC AAGGATAGGAGAACAGGAAGCAGGAGGCAGGAAAAAGACCAAGAGAGAGGAGTGGCTGCCACCAAGGAAGCAGAGCG CTCTGACCAGAGTTCAAGATCCAGGGTTCGGGCAGGACTTGGGAGCTGGGGCCTGCAGCTGGAAGGAGCGCTCCAGA AGAAGGATTGTATCTCAGGGCGGGAACACACACACATCAGCGACAGGAGATAGCACGTCAGCTGGGATGGAGCTGCT GAGCCAGGCCATGCTGGGCTCCTCGGGCTGGGCAGGAACGTCTGGCTGCACATCTGTCTGTCTCGGCCCAGCAGGGC TGACTCCCGGGCTGTGGCAGTGTCTGCTCCAAACTCCCCTGGGCCTTCCCATAGCATTCACTGTGGGGAGCTCTTGA CCAGCTTGTCTCTTTCCCAGCCTGTGAGTGCTAAAGGGCAGGCCCCCCGTCACCTCTGAGGCCCTGGCACCCAGCAC AGTGTGCATGGGAGATGCTCAGGAAATGTGTGCTGAGGAGCTGGCAAGCTGGGAGGGTGGACCCGCAGTGGAGGGAA GAGTTGGCCATTCTTTTCTGAGCTACAAGGAGGCTCAGTACAGTATCCAGAACACTCGCTTAGGTGTCAGAAGAGCT GCGTTCTGGCCCTAGCTCTGTCACAAATGAGTTCACCTCCCCTGGCTGGGCCTGTTTTCTCTTATGTGAAATGAGGG CATTGGACCAGCTGATAATCAACGGCTCTCCCAGCATTCGCATTTTGGGAAATCTCTCCCTCCTCTGATACCTCAGG CTGCCCCTCCCCTGCCTCCTGTTCCTGTCATAG <210> SEQ ID NO 56 <211> Length: 5,395 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 56 >HSACMHCP PEA 1 T8 CCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATCCGGGGCGGGGAAGACTGTG

AACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCAAGAAGGACAATGCCAATGC

WO 2005/069724 PCT/IB2005/001306 556 GAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTCGGCAATGCCAAGACTGTCC GGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGGAAAGCTGGCTTCTGCAGAC ATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAAACTACCACATCTTCTACCA GATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCCTACGACTACGCCTTCGTGT CTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGATAGTGCCTTTGACGTGCTG GGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACTACGGGAACATGAAGTTCAA GCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCGGCCTACCTCATGGGGCTGA ACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTATGTCACCAAGGGGCAGAGC GTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGTTCAACTGGATGGTGACGCG CATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGACATCGCTGGCTTCGAGATCT TCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCAGTTCTTCAACCACCACATG TTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACTTTGGCATGGACCTGCAGGC CTGCATTGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGCATGTTCCCCAAGGCCACTG ACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCAGAAGCCACGCAACATCAAG GGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACATCCTGGGCTGGCTGGAAAA AAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAGCTCATGGCCACTCTCTTCT CCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAAGGGCTCATCCTTCCAGACG GTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCCATCCTCACTTTGTGCGTTG CATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCACCAGCTGCGCTGCAATGGCG TGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGACTTCCGGCAGAGGTATCGC ATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAGAGAAGCTGCTCAGCTTCTCT GGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGGCTGCTTGGGCTGCTGGAGG AGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGGCCAGCTCATGCGCATTGAG TTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGGCCTTCATGGGGGTCAAGAA TTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACGGAGAAGGAGATGGCCACCA TGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAAGGAGCTGGAGGAGAAGATG GTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACAACCTCAATGATGCTGAGGA GCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATGAATGAGAGGCTGGAGGATG AGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTCAGAGCTCAAGAAGGACATT GATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACAAGGTGAAGAACCTAACAGA GGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTACAAGAGGCCCATCAGCAGG CCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGTCAAGCTGGAGCAGCAGGTG GATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAGCAAAGCGGAAACTGGAGGG CGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTGGAAGAAAAGCTTAAGAAGA AGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCTTCAACTACAGAAGAAACTG AAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGGCTAAGGTGGAGAA GCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCCGGCGGGGCCACGTCCGTGC

AGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGCAC

WO 2005/069724 PCT/IB2005/001306 557 GAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCGAGCAGATCGACAACCTGCA GCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGACGTCACCTCCAACATGGAGC AGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGCCAATGAGTACCGCGTGAAG CTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGACCGAGAATGGAGAGTTGGC CCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCTTATACCCAGCAAATGGAGG ACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACTGCAGTCGGCCCGGCATGAC TGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAA CTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAGGAGCTCGAAGAGGCCAAAA AGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTCACTGGAGAAG ACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCT GGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCAGTCTGAGCTGG AGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAG CACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGAGGAAATCTCGGACCTTACTGAGCAGCTAGGAGAAGG AGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTGGAGCTGCAGTCAGCCCTGG AGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGGCA GAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGACTC GCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGACC TCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAG AGCTTGCTGAAGGACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCCAT CGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCC GGAAGCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCATC AACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTCGGAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAA CGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCA GCGCCCACCTGGAGCGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAG CAGATCGCCCTCAAGGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGA GGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACC AGACAGAGGAAGACAAAAAGAACCTGCTGCGGCTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTAC AAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGA TGAGGCAGAGGAGCGGGCGGACATCGCTGAGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCA AGCAAAAAATGCACGATGAGGAGTGACACTGCCTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCA AACTC <210> SEQ ID NO 57 <211> Length: 4,427 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 57 WO 2005/069724 PCT/IB2005/001306 558 >HSACMHCP PEA 1 T13 GTACCAGCACAGCGCCCCTTCAGCAGGCCAGCGCTACTGGCTCCAGATTCCTTTTCCTGTCAGGGTATGGGACTGTG GAAGCCTGGGAGTGTGCTCAGTGATTCTCTCTTTGCCTCTTCACCCTGCCCTCAGCCCATGGGCATCATGTCCATCC TGGAGGAGGAGTGCATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAG TCCAACAATTTCCAGAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCAC TGTGGACTACAACATCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGA AGTCCTCCCTCAAGCTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAA GGAGGCAAGAAAAAGGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAA CCTGAGGACCACCCATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACC CCCTGGTCATGCACCAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGC ATCCTCTACGGGGACTTCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAG CAGGAAGGGGACAGAGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGT TCTTCAAGGCAGGGCTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAG GCCCAAGCCCGGGGCCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCA GTGGAACATTCGGGCCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGA AGAGCGCAGAGACGGAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCC GAGGCTCGCCGCAAGGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCA GGCGGAACAAGACAACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCA AAGTAAAGGAGATGAATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTG GAAGACGAGTGCTCAGAGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCA TGCAACAGAGAACAAGGTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGG AGAAGAAAGCTCTACAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTG TCCAAGTCTAAGGTCAAGCTGGAGCAGCAGGTGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCAT GGACCTGGAGCGAGCAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATG ATAAACTGCAGCTGGAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAG CAGGCGCTGGCCCTTCAACTACAGAAGAAACTGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGA GGCCGAGCGCACCGCCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGC GGCTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATG CGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGT GGCCGAGCTGGGCGAGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGC TGGAGCTGGATGACGTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACG CTGGAGGACCAGGCCAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCG AGCCAAGCTGCAGACCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCC GGGGGAAGCTCTCTTATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCC CTGGCCCATGCACTGCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAA GGCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCA TTCAGCGGACTGAGGAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAG

GCTGTTAATGCCAAGTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGA

WO 2005/069724 PCT/IB2005/001306 559 CGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGA AGCAGAAGTATGAGGAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTC AAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGAGGA AATCTCGGACCTTACTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGG AGGTGGAGAAGCTGGAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTC CGGGCCCAGCTAGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACA GGCCAAGCGCAACCACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGG TCCTGAGGGTGAAGAAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCC GCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCTGGACGATGCGGTCCG TGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGC TGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTG CAGCTGCTGCATTCCCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTC GGAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGA TGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGAGCAGACCATT AAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGATCGCCCTCAAGGGAGGCAAGAAGCAGCTGCAGAAGCTGGA AGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGA AGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACAGAGGAAGACAAAAAGAACCTGCTGCGGCTACAGGACCTG GTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCT GTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTGAGTCCCAGGTCAACA AGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCACGATGAGGAGTGACACTGCCTCGGGAACCTC ACTCTTGCCAACCTGTAATAAATATGAGTGCCAAACTC <210> SEQ ID NO 58 <211> Length: 2,533 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 58 >HSACMHCP PEA 1 T14 GCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGCTAAGGTGGAGAAGCTGCGCTCAGAC CTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGAA CAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCACTGCCG CGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCGAGCAGATCGACAACCTGCAGCGGGTGAAGCAG AAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGACGTCACCTCCAACATGGAGCAGATCATCAAGGC CAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGCCAATGAGTACCGCGTGAAGCTAGAAGAGGCCC AACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGACCGAGAATGGAGAGTTGGCCCGGCAGCTAGAG GAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCTTATACCCAGCAAATGGAGGACCTCAAAAGGCA

GCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACTGCAGTCGGCCCGGCATGACTGCGACCTGCTGC

WO 2005/069724 PCT/IB2005/001306 560 GGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAACTCGGAGGTGGCC CAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAGGAGCTCGAAGAGGCCAAAAAGAAGCTGGCCCA GCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTCACTGGAGAAGACCAAGCACCGGC TACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAG AGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCAGTCTGAGCTGGAGTCCTCACAGAA GGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCT TCAAGCGGGAGAACAAGAACCTTCAGGAGGAAATCTCGGACCTTACTGAGCAGCTAGGAGAAGGAGGAAAGAATGTG CATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTGGAGCTGCAGTCAGCCCTGGAGGAGGCAGAGGC CTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGA AGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGACTCGCTGCAGACCTCC CTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGACCTCAATGAGATGGA GATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGG ACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGC AACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAAGCTGGCGGA GCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCATCAACCAGAAGAAGA AGATGGAGTCGGATCTGACCCAGCTCCAGTCGGAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAACGCCGAGGAGAAG GCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACCTGGA GCGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGATCGCCCTCA AGGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAG CGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACAGAGGAAGA CAAAAAGAACCTGCTGCGGCTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCG AGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAG CGGGCGGACATCGCTGAGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCA CGATGAGGAGTGACACTGCCTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCAAACTC <210> SEQ ID NO 59 <211> Length: 2,477 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 59 >HSACMHCP PEA 1 T17 GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTT

CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA

WO 2005/069724 PCT/IB2005/001306 561 AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCA GTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACT TTGGCATGGACCTGCAGGCCTGCATTGACCTCATCGAGAAGGTGCCTCCTTGGCCTCACCACCTATGCCCCCTCCTC TGCCATCCAGACAAAGTGGTGGCTGAGTCCCTTCTACACCCAAGAAACTAGAGTCCCAAGAATCCCAGGCCTTTCTC CAGGCCCAGCTTCTCCCCACTGTGAAGTCATGGGCATGAACAGGATGATCCCCCCACTCTTCCTTTCCCAGGACCTT GCACTTTATGCCCCTTTGTGGTGGTCCCCTCAGTGTCTTAAGAGTGAGATGTAGTGAAGGAGAGGCCCCTGGCCCCT CTGACCGCCCATGAGAAGCGTCATTCATGGAAAGATCCTAGGCTGAAATTAGAGATGTTTGGCCTCCCACCACCTTC CTGTTGGTTGAGAAATAAGCCAGTCTCCAGCCCTCTTGCTTATGGGCATTCCTCAGAAGAGACAAGGCCGCAGGCGG GAGGCCCCATAGGCCGGGGCTGACTTGCTCTCAGTGAACCTCTGCTCTTTGTCAGCATAGGCCAGAGCCCGGATTGT CTGACCCACACCCAGCCCAGCCACGGCCTTCATGAAATGGGAGCTTCCCCACATGCTTTGGGTCATTATCCAGATTC TTAACCAGAGTTCTCATGTTTCAGAGCCCTCAGAATGCCATAAAACTGTGTGTGGAAAAAAGCATGTGTACATTCAT ACATACATGTGTTGTGCTTGTGCATGTGTGTGTGTGTACGTGTGTGTGTGTACATGCGTTTTTCTGGAGAGACAGTCT TTAGCTTCAACAAATTCTTAAAAGGATTCCTGCCCCAAGAAAAATCAAGAACCACCAGGTTTTTGGAAGTGCAGAGT GTGGTAAAGAACC <210> SEQ ID NO 60 <211> Length: 6,903 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 60 >HSACMHCP PEA 1 T26 GAGGACAGATAGAGAGACTCCTGCGGCCCAGATTCTTCAGGATTCTCCGTGAAGGGATAACCAGGGGAAGCACCAAG ATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAGAGGC

CCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAAGATTT

WO 2005/069724 PCT/IB2005/001306 562 TGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTGTTG CAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTT CAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA AGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGCCTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATC TTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGATCGGGAGAACCAGTCCATCCTCATCACGGGAGAATC CGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCA AGAAGGACAATGCCAATGCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTC GGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGCTTTGGGAAATTCATTAGGATCCACTTTGGGGCCACTGG AAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAA ACTACCACATCTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCC TACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGATGACTCCGAGGAGCTCATGGCCACCGA TAGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACT ACGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCG GCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAACGAGTA TGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGT TCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGAC ATCGCTGGCTTCGAGATCTTCGACCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGCATGTTCCCCAAGGCCAC TGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCCAACAATTTCCAGAAGCCACGCAACATCA AGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACATCCTGGGCTGGCTGGAA AAAAACAAGGATCCTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAGCTCATGGCCACTCTCTT CTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAAGGGCTCATCCTTCCAGA CGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCCATCCTCACTTTGTGCGT TGCATCATCCCCAATGAGCGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCACCAGCTGCGCTGCAATGG CGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTTCCCCAACCGCATCCTCTACGGGGACTTCCGGCAGAGGTATC GCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAGAGAAGCTGCTCAGCTCT CTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCAGGGCTGCTTGGGCTGCTGGA GGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGGCCAGCTCATGCGCATTG AGTTCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGGCCTTCATGGGGGTCAAG AATTGGCCCTGGATGAAGCTCTACTTCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACGGAGAAGGAGATGGCCAC CATGAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAAGGAGCTGGAGGAGAAGA TGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACAACCTCAATGATGCTGAG GAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGTAAAGGAGATGAATGAGAGGCTGGAGGA TGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAGACGAGTGCTCAGAGCTCAAGAAGGACA TTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCAACAGAGAACAAGGTGAAGAACCTAACA GAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTACAAGAGGCCCATCAGCA GGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGTCAAGCTGGAGCAGCAGG TGGATGATCTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAGCAAAGCGGAAACTGGAG

GGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTGGAAGAAAAGCTTAAGAA

WO 2005/069724 PCT/IB2005/001306 563 GAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCTTCAACTACAGAAGAAAC TGAAGGAAAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGGCTAAGGTGGAG AAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCCGGCGGGGCCACGTCCGT GCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGC ACGAGGCCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCGAGCAGATCGACAACCTG CAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGACGTCACCTCCAACATGGA GCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGCCAATGAGTACCGCGTGA AGCTAGAAGAGGCCCAACGCTCCCTCAATGATTTCACCACCCAGCGAGCCAAGCTGCAGACCGAGAATGGAGAGTTG GCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCTTATACCCAGCAAATGGA GGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACTGCAGTCGGCCCGGCATG ACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGCGCGTCCTGTCCAAGGCC AACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAGGAGCTCGAAGAGGCCAA AAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTCACTGGAGA AGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCAATGCTGCTGCTGCAGCC CTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCAGTCTGAGCT GGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGG AGCACCTAGAGACCTTCAAGCGGGAGAACAAGAACCTTCAGGAGGAAATCTCGGACCTTACTGAGCAGCTAGGAGAA GGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTGGAGCTGCAGTCAGCCCT GGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGG CAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGAC TCGCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGA CCTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCC AGAGCTTGCTGAAGGACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCC ATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTC CCGGAAGCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCA TCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTCGGAAGTGGAGGAGGCAGTGCAGGAGTGCAGA AACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACAC CAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCG AGCAGATCGCCCTCAAGGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTG GAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTA CCAGGTGCGGCGGACGCCAGACACCGGGAGTAGATGTGGAAGTTTCTTCTCTGGCCCCACTGCCCCGCCCTCACAGG GCTCCTCTCACCTCCTCCTTGAGATGCTGTTGGTAGATTTAACGTTCTTCTCACGCTCTGCAGTCAGTTTGACTTGA GTCTATGAGTTTTTCCAGCAAATGAAGAATCTACTTCTACTTCCTGAAAACTCTTCTAACTAGTCTTTCCCCAGGTT TCTTTCTTTCTTTTTTTTTTTTTTTAATAACTCTAAGTGCTACCATGAAGACTTCAGAACAGTTCAAAGAATCCTTC CACCTTCGACTGTGGGGATAAGAGTCAGGGGAGGGGAAAAGACCCGGAAATCTTCCATAGAACTTCTGGCACACAAA GAGAAGGCCACAGAGAAAGAGGACCCTAGAATGCTCTAAAACCTCCACTTGCATAGCTGAGAGCTGTGCCCTTGGCC CGTTATTTTCAGTGTACCTGGGAAGAAAAGGCCAAGGAGACGAGGGTGTCAGTCCATTTGATAGATGGATACCAGAG

GCACAAGAAAGAGGTTACAGATACAGAACCACAGAGTGATTTGTGGACAGAAGTAGAAATGGCATCCTGGCACATAC

WO 2005/069724 PCT/IB2005/001306 564 AATGATAAAGAGATAGGAATGATCGAGTGACGTTGGAGCCAGTGATCCCGATGCCTGAATTCTGGCCCAGTACAATA TATTAGAATGTAGAATAATCTGGATTATGATAATACCCCCTTCTTTCTGCATTCTTTTTCTGGTCAAGAACTACTGG CCAAGAGAACCTATGTAAGTCCAGGTTGGAGCTTTATCCACCATACTGGAGCTGGAACAGACCTGGTGCTTTTATAT TACCACATTAGGGAATTCCATTAGGTTCTGAGCCCCTCCCCCTACTTCTAGCTTTATGACTTCAGCCTTCATTGCTC TGTGGATCCCTGACTGACAACCTTGCATTGCCCCTTTGACCTACGATAGAGTCAGAGAATCTTCCCCACCACCTCTT TGACCTGGATCATTGCAGGGAGGGGCAGCAAAGGCAAGGGGAGAAGAGTAAAATGATGGAGGAGGGAAAGGTGATTG CATTTGCTCCCCCTCCAAACCAGCTTCTCCCACCCTCCCACCCCCAGACAGAGGAAGACAAAAAGAACCTGCTGCGG CTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGC CAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTGAGT CCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAATGCACGATGAGGAGTGACACTGC CTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCAAACTC <210> SEQ ID NO 61 <211> Length: 22 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 61 >S67314 segllF TCCCCTGAGAGCTGTAGAAGCT <210> SEQ ID NO 62 <211> Length: 19 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 62>S67314 segllR CGGCCTGTGTGAGTCCAAA<210> SEQ ID NO 63 <211> Length: 101 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 63>S67314 segll TCCCCTGAGAGCTGTAGAAGCTGGGACAAGAGAGTGGTTGTGGGTCAGGGTGGTATCAGGTGGGAATTTTCTGTGTA GTGGCTTTGGACTCACACAGGCCG<210> SEQ ID NO 64 <211> Length: 20 <212> Type: DNA WO 2005/069724 PCT/IB2005/001306 565 <213> ORGANISM: Homo sapiens <400> sequence: 64>S67314 seglSF Forward primer TTCCTTGGCATCTCCAATGG <210> SEQ ID NO 65 <211> Length: 997 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 65 >S67314 PEA 1 node 0 TCTGCAGGAGGGGAGCTGGGAACGACCTGAGCTAAAGCTCGGAGCTGTGCGAAGAAACCGGAAAAGCCCAGAGCACT TGCAGGGGCGGGTGGGGAGCTAGATGGTGGGGTGGGGTGGGGACGGAGGAGGGCCAGCAGGAGACATTCCGCAGGGA GGGGCAAGCACGTGTGAGGCGGGCGGGGCGCGAAGGGTCAGGCTTTTGCTCAAAACAGGCAGAGGACAAGGTCAGCT CAGCCGCAGACCGAGCCGCTGGTGACTGTCTCCGCCACCAGGCAGTGAGAGTGAAGGGAGAGCGCGAGCTCTGAAGC CCGCTAGACTAAGCTTGCAATCTGAGCTCCATTCACCCCCTCCTATTTCTTGAGACCTTGTCAGTTCCCCTGTGAGC CTCGGACTCCTCACTTGTAAAACGAGGACAGATGCCCGTGCCAGAAGTCAACCAGAGCTTTCCCCGGCGTGGGCACC AGCCCAAGGGCGTTTTGCTTTTCTAGTCTCATCTCTGCTCTGACGCTAAGCTCAAAGAGGGACTGGGGGACGGGAAG ATATCCACCATGGCATGCGCCCTAGCTCTCGGGCTGGTGTTGGCTGCTTCCTTCTCAGATTCCAGAGTGCCTAGAGG CCAGGAAAGGGAGAAGGTCCTACCAGCCTGGGGTAGGGACTCGGGGGCCAGGCACTGGCGCTGACGCAGGCTAGCAG GGCGCCACTGGCTGGTCCCCACCCACCTCGGTGGGTTGGGGGATGGGCGCACCAGCCCCTCCTGGGTGAGCCCTAGC CTGGGGCTTCCTATTTCGGGAGCCGGGGGCGTGGGCCACGTCTCCTCATGTGATGCGAGGGCTATTTAAAGCGGCAG CCCGGGCAGGGAGCCGCCGTCGGAGCCCTTGCACGCCTGCTCTCTTGTAGCTTCTCTCAGCCTAGCCCAGCATCACT ATGGTGGACGCTTTCCTGGGCACCTGGAAGCTAGTGGACAGCAAGAATTTCGATGACTACATGAAGTCACTCG <210> SEQ ID NO 66 <211> Length: 838 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 66 >S67314 PEA 1 node 11 GTAAGATGGGCAACTTTGGAGCTATATCTGATTGGTTATTACTACTGCTCTTTCAGCCAAGCCTGTTCTAAAAAGCC AAGTCCTCCCCTGAGAGCTGTAGAAGCTGGGACAAGAGAGTGGTTGTGGGTCAGGGTGGTATCAGGTGGGAATTTTC

TGTGTAGTGGCTTTGGACTCACACAGGCCGGAACTCAAATCTTACCTTATAGGCTACATGACTGTGGGCAAATCACC

WO 2005/069724 PCT/IB2005/001306 566 TTTTCCAAGTGCAACTGTAAAACGGGTATTAATAATACCAACCTTGTAGGGCTGCTGGGAAGCCTGTAAGAGACAGT GTATGCACAGCACAAAGCATCACTGATTGAGGAACACAGCAGGTGCTCCATGTCCTTTGTTTGCTCTTCCTGTGTTT CTACCTTGCCTCACCTCAGGAAGAAGTAGAAAACAGGGCCAAATCTGATCCCAGGCCCTCTAGGAGGGGCTCCCATT GCCTATCTCAGCATTCCCTTTCCTCTCCTCCCTAGGACTGCATTGTCACTTGCAGGGACAGGCTCGTGACTGGTGGG GACACTGAATGACAGTACAGTCCTTTCTTCCCCATTCTAGTCCTACCCCATTTTCATGCTTTCTATGTCTGGCCTAC TGAAACTACTTGACTACTGCTTGGGTAGGAAGTACCACAGCCAGGCTGGCAGATCTGTTCAAGCTTGGGGACTTCAC TTGGAGAATCTAGCCTTGACTGAATTCCCCCCAGACCCAGGGAGAGCAGCCAACTGTGGATTCTGCCTAACCACAGG GCCTCAGGTTTTCACCTAGGCATCTTCACTGCACACCTTCTTGGGTCAGCATAACCTGTTAACTGCAT <210> SEQ ID NO 67 <211> Length: 2,226 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 67 >S67314 PEA 1 node 13 ACACTCACCCACGGCACTGCAGTTTGCACTCGCACTTATGAGAAAGAGGCATGACCTGACTGCACTGTTGCTGACTA CTACTCTGCCAATCGGCTACCCCTCGACTCAGCACCACATTGCCTCATTTCTTCCTCTGCATTTTGTACAAATCCAC GAATTCTTCTGGGGTCAGGTGCCACTGACCGGGATCCAGTTCCAGTTCCCATGGTGTATGTGGTTTTTTTTTTTTTT TTTTAACTGCACTCATAGGGTGCTCTGAGGTCAATAAAGCAGAGCCAAGGCCACCCAGTTGCCTTTTTGCCTTTGGT AACATAACTCTGGGAGTCTTGGTTTATCCTGTGTGTCAGAGAGTGGGCAGAAATAACGGCCTGAAGGTTACTGAGGA AGAAGCACTGGATGGGAGACTGAAATGGACAGTCTCGGAGCCTGTTAATCAGCTGATCACCTTACACATTTAATAAT AAAAGAGCTGTACCTACACGTTGCCTTTACACTGCCCCCCCTCCATGGTCAAATGACCTAGTTCAGTCAGTGATGGG GCTTCCCCAGGTTTGGCTATTGAACTGTCACTTCAGGCCCATCCTACACTGAAAGCTCTTGGGTCTGGCTGTTCTCT GTGAAATGCTGTAGTCTCTCCCTTTCCAGAATTCAGGTTCAGGGCACAGAACCCAGGCTTGTACCATGGTGGTGGGA GAAAATGACCACTGGCCAAGAGGACTGCTGACCTGTGCACCAGGCTAGTACTTATGACTACAAATTCTTACTGCTTC TCTAATCAACTCTGAGGGAAGAGGGCATCTGATCATTACAAAAGGGAGGGCTTATAAGTGATCTCCCAAGAAGGCAG TGATCTGCTAGTGCCTTTGGCTCTGTACCTCTGCTGGGCATCTCTCCAAGGTCTAAGGTAACATATTAAATGTTTTT GTCAGCTAATGCAGGCTCAGTGACTTTAAGTCTGTAAGTTACCCAGGAAGAAGGATTATAGGAAAAATAACTCAGTA AGTTTAAAACCAAACACATTTCCATTTAGTGACAGGAATTTAAGCAAGGACCTGAAGTAGAATCAACTGATTCACAC AGTAGTAAATACAAAGTAGAACAATGATCTTGGCTTCGCTGTCTGGTTCAGTGGTCTGCTGGAATGCAATACACAAG TTAAGTCACACTGCAGACTGTTTTCTAGCTGTGGCCGCTGGATGCCACTTCTAGCATAGTAGAACTATGTTAGGAGG AATGGGAAAAGTGAGCACCACTTCTCACCATGTTCCCCCCTCCTGCTGCCAGTCTCTGCTCCCATGTTGGATGCAGC AGAGATCACCCACCAGTTGGCCCAGGACAGACCAATAGGAAGGGTCCAATCACTCTAACTACAGCCGAACTCACCTC CACAACAGTCTCTGTGGCTCTAGCCTGGACTCCTTTACAGGAATCCAGCTCTGGCAGTGGCAGCTGGAGAGGGTAAT AGGGCCTCCTGCTGAATGAAGGAAGTTGGGTGAATGAATGGGTGAGCTGCAGGGTTCACTTGCAAAGGGACCAGGAG TGATAAGGAAACAACAACTCATTCAGGCAGCTGCTTTTGACCTCTAACTCCCAAACCTGCCTGTTGCATGAGGGGAA

GCCATCTCCCATGGGAGCGAAGTTAATGGGGTGGGAGGCTATATTCTCACTATTGAGTCTTTCCAGGAGTCTCAAGG

WO 2005/069724 PCT/IB2005/001306 567 CACAAGGCTCCTGGTTTCTTACTCTCAACCACCCCCTACACTCTTTATACTCTCACTCCTTGTGCTTCTTCTTGTGC TTCTTCTTCTTTTTCTTCTTCTTTGCTGCCTTGCTGTCTTTTGATGTGTGCCTTGCCCTCTTGCCTGTATCACTCTC AGAGTCTGAGCTGTCAGAGTCAGATGACTTCCTATCTCTATGTTTCTTTTTCTTCTTCTCCTGAAAAGAAAATTTTA AAAATCAACACTGTATGTGTATATTTGCTTTTAACAATCATAGCACATAATTGGCCAGGTGCAGTGGCTCACACCTG TAATCCTAGTACTTTGGGAAGCCGAGGTGGGAGGAATGCTTGAGGCCAGGAGTTCAAGATCAACCTGGCTAACATAG CAAGATCTCATCTCTAAAAAGAGAAAAAAAGAAAAATTATAGCACACAATCAATAGGGGACCACTTAATTTTCTTTT AGACAGTCTCGCTCTGTTGCCCAGGCTAGAGTGCAGTGCAGTGGCACGATCACAGCTCACTGCAACCTCA <210> SEQ ID NO 68 <211> Length: 461 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 68 >S67314 PEA 1 node 15 GATGTTCTGACAGCCTGGCCAAGCATCTACAGGAGACAAGTCAAAGTTTTAAGAGAAGATGAAATAACAATTCTTCC TTGGCATCTCCAATGGAGTAGAGAGAAGGCAACAAAGCTTCTCAGACCCACATTACCGAGCTATAACAACCATGGCT GGGAGGAGCTGAGAGTTGGCAAATCAATAGTTTAGCTATGTTGCTGAACCTTCCTGGATGGCAAGACCATGGAAGTC CATCACAAGATATTATGGGGTCAGGAGCCTCACTGGGTTCTGCCCCTTATATAGGTGAATATCCTGGGAAAGTAAAA ATGAAAATACAGAGTCTGGCACCAGTTCCCTGCAAGCCTGGTCCAGCCTGGATAAAGAAGTGAGGAGAGTAATAATA CTGCCTTACACCTAAACAGTGCTTTAGTTTATCAAGCTTTTTGCATCCTTATCTTACAATAATAGTCTGTAGAGTC <210> SEQ ID NO 69 <211> Length: 550 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 69 >S67314 PEA 1 node 17 ATGGAAAAACTGCAACTCAGAAATGTAAAGTGAGTCGACCAAGGCTAAAGCGGCAAAACCACTATACTTTATAACAC AGAGTTTGGCACTATTTCCACTTTGTTCTCTCTCAAAGATGAAGGCTCAGGAGGAGGGAAGATAAAAACAAATCACT GGAGAGTCCTGGCATGCTGGAACATGGACTCTAGCTAGCAAGAAGGGCTCAAGGAGGTGGCCTTCTCCTAGACCTCA ACTTTGATGCAAAAGCTGTTTTGCAGCCTGAACAAAGACAATCCAATCCTCCAGCAAATGGCGTCATTTTCCCTACG TGTCTAGCCTTGAGCTACAGAACAAAAGAACAATCACATCCGAAGTTGTAGTTCGCCTGGTTGCGGTGGCTCACGCC TGTGATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGATCACCTGAGGTCAGGAGGTCGAGACTAGCCTGACCAACAT GAAGAAACCCCATCTCTACTAAAAATACAAAATTAGCTGGGCGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGG

AGGCTGAGGCA

WO 2005/069724 PCT/IB2005/001306 568 <210> SEQ ID NO 70 <211> Length: 173 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 70 >S67314 PEA 1 node 4 GTGTGGGTTTTGCTACCAGGCAGGTGGCCAGCATGACCAAGCCTACCACAATCATCGAAAAGAATGGGGACATTCTC ACCCTAAAAACACACAGCACCTTCAAGAACACAGAGATCAGCTTTAAGTTGGGGGTGGAGTTCGATGAGACAACAGC AGATGACAGGAAGGTCAAG <210> SEQ ID NO 71 <211> Length: 102 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 71 >S67314 PEA 1 node 10 TCCATTGTGACACTGGATGGAGGGAAACTTGTTCACCTGCAGAAATGGGACGGGCAAGAGACCACACTTGTGCGGGA GCTAATTGATGGAAAACTCATCCTG <210> SEQ ID NO 72 <211> Length: 33 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 72 >S67314 PEA 1 node 3 CTCATATACTCATAACCTTCCCCCTACCCTCAG <210> SEQ ID NO 73 <211> Length: 237 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 73 >N56180 node 2

ATGCGTGCGTGCGTGCGTGCGTGTGTGTGTGTGTGTGCCTCTGCTCTTTGTCCTGAGCCCACGATTCCAGAGCTGGC

WO 2005/069724 PCT/IB2005/001306 569 TGGACCCAAGGAGGTGAAGAGTCACTTTTCAGCCCCAGGAAGGGCAAAGAAGAGAGAAAATCAGCCTGTCTGCTCTC TCCTTGGCTCAACAAGGCCTCTAACAGTCTTCTGTCCTCTATTCTGCACACGGCATATTTGGGAACGAGAAACAAAA GTTTTC <210> SEQ ID NO 74 <211> Length: 131 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 74 >N56180 node 20 GTTGCAAAGAAATTATCTTTGAAGATGAATGAGGTTGACTTCTATGAGCCATTTATGGATGAGCCCATTGCCATCCC CAACAAACCTTACACAGAAGAGGAGCTGGTGGAGTTTGTGAAGGAACACCAAAG <210> SEQ ID NO 75 <211> Length: 281 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 75 >N56180 node 22 ATCAAGGAATTGGACTCAATAGTTAAGTAACTTAGCCAAGGATGAACACTCTATGCATAGAACTTCTGGGAGAGAAA TGCTTGATACCACTTAGTGTAGCTCCAGCATGGATCAGCAAACTTTTTCTGTAAAGAACAAAATGGTAAATATTTCA GGTTCTGTGGGCCAGATGGCGTCTGTAGCAACTACTTGACTGCGGCTGTGGCATGAAAGCAGCCATGGATCATGTAT AAACAAATGGGTGTGGCTGTGTACCAGTAAAAGTTTATCCGGAAAAAAAG <210> SEQ ID NO 76 <211> Length: 136 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 76 >N56180 node 28 TCTATAGAATAATCCTATAATTGAGGGTGAGCACCAAATGTCCTAAGAAGTCCTCGTGGAAAAATCACACTCTGCTC TCCACATTAGAAGCTGTGTATGTGCAGGGGTTACTCAACTCTCTTGAATCCTGTTTCAG <210> SEQ ID NO 77 <211> Length: 248 <212> Type: DNA WO 2005/069724 PCT/IB2005/001306 570 <213> ORGANISM: Homo sapiens <400> sequence: 77 >N56180 node 34 CTGCTGAGGAGCTGGAGGACTGGATTGAGGATGTGCTTTCTGGAAAGATAAACACTGAAGATGATGATGAAGATGAT GATGATGATGATAATTCTGATGAAGAGGATAATGATGACAGTGATGACGATGATGATGAATAGCCCAACTCCAAACA ATTCTGATGAAAACAAAATCACAGCACCCACTACCATACAGACAGCACAAGGTGGCAGCAAGCAATTCTGCCCCACA CCCAGCCAGCTCCTTTC <210> SEQ ID NO 78 <211> Length: 1,124 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 78 >N56180 node 36 CATCTCTTTTCCCACTCCCTTTGCGTCAGGAGCAGCATCATTCAGCAAATGCCTTTTCAAATGCAGCAATCCCACTT AGCAGGGACAGGAGAAAAATTATTCCCATGTTGACTGTCTTGACTGTCACGGAACAGATCTTGTTCTTTGCTGGACC ATCAAGGGTCATGGCAGTGCCTGAACATGGCAGTCTAGGGTGAACAATCCCCTAACACAAGTTTACTTGTCTTTGAT TATGACAGTAACAAAATTGACAGCTTTCTAACTCACAGGCATAGAGTGACCTTTTAATCAGAGCCCAGGGAAGACAC ATGATTAATGATTTAGCTCCCTCCATACCTCGAACATCAGTTGGGATCCCTCCTCCAGCCAAGATGATCCTTCTTAG AGAAGGCTCAGCCTTGGAAGCAAACTTATAAATCATATTCTCATGGCTTTGTTAAACTTATTTCAAGTGATGGTCAT TCATATCACTATGAACTTGGATATTCAAGCCTTTGGATGGCTATGGAGAGGCCTTGAAATGTGTACAGGTGTCACCA TCATTTCTAGTATATTAGGAAACTGGGATGGGAGGTTGATTTGCTTCCTAAACTTCCCTCTAGTTGGCAAGTCTCAC ATATTCATCAGCAGGAGTGGAGGGTGGGGGAAAACTAGAAAGATGAAAACTTTTACATTTTTCTGATGGGTTCATGT CTCTGATTGGGTCAGCTGGCTTCCTAGCCTAAGCTGGGATCTGAATACCCCTTCTCTGTAGCTGCTAGTGAGCCTTC CCATTTAGATTAAAGATTGCTTTATCCAGCAGTCAATTAACTCTCCAGTTATCAGTACTCCCACAATTGGCCAGGGC AACAATAATTGGAGTTCATACTGATGCCCTGAGGCACTGAAAAAAAAAAAAATCCCAAAGTGCCTTCTGAGCTGTCT AAAAGTTACATTGTGCTTGGTAGATTTAGTGTTAAGTGTGCAGTATAATTTTCTAATTTATTTTCTCAATCTTTTAG CACATGTGTAAGACACTGTGCAAATTTTTTGAAAATAGAGCAATACTTTTTGTGGAATACTAGCTAACTAATTCTGT CATTAAACTCATATTTTGAAAATATTCAGACAATGTTGAAAATCCT <210> SEQ ID NO 79 <211> Length: 181 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 79 >N56180 node 4

GGCAGAAGAGGGGCTTAATTTCCCCACATATGATGGGAAGGACCGAGTGGTAAGTCTTTCCGAGAAGAACTTCAAGC

WO 2005/069724 PCT/IB2005/001306 571 AGGTTTTAAAGAAATATGACTTGCTTTGCCTCTACTACCATGAGCCGGTGTCTTCAGATAAGGTCACGCAAAAACAG TTCCAACTGAAAGAAATCGTGCTTGAG <210> SEQ ID NO 80 <211> Length: 141 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 80 >N56180 node 6 CACTGGCAAATATCCCAGTGGTGGTTGCATTTCCAAACCCCAAGAGAGGAAGGCAAAATGAAGTTGCTGGAGTTGAG TGAATCTGCAGATGGAGCTGCGTGGAAACGCTGGGGAGGGAATAGCAACACACACAGGATTCAG <210> SEQ ID NO 81 <211> Length: 33 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 81 >N56180 node 0 TAATGAGACAGAGGCTGAGCAGAGCTATGTAAG <210> SEQ ID NO 82 <211> Length: 100 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 82 >N56180 node 10 GTTTTGATGAAGAAGGAAGCCTGTATATTCTTAAGGGTGATCGCACAATAGAGTTTGATGGCGAGTTTGCAGCTGAT GTCTTGGTGGAGTTCCTCTTGGAT <210> SEQ ID NO 83 <211> Length: 112 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 83 WO 2005/069724 PCT/IB2005/001306 572 >N56180 node 12 CTAATTGAAGACCCAGTGGAGATCATCAGCAGCAAACTGGAAGTCCAAGCCTTCGAACGCATTGAAGACTACATCAA ACTCATTGGCTTTTTCAAGAGTGAGGACTCAGAAT <210> SEQ ID NO 84 <211> Length: 74 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 84 >N56180 node 14 ACTACAAGGCTTTTGAAGAAGCAGCTGAACACTTCCAGCCTTACATCAAATTCTTTGCCACCTTTGACAAAGGG <210> SEQ ID NO 85 <211> Length: 95 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 85 >N56180 node 16 GTGCTGTGGCTCACACCTGTAATCCCAACACTTTGGGAGGCTGACGGGGGTGGATTGCATGAGCCTTGGAGTTGGAG ACCAGCCTGGGCAACATG <210> SEQ ID NO 86 <211> Length: 115 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 86 >N56180 node 18 TGCAGGCAAACAGCAACCATTCTGCCTTGACAACACACTGAACATGTGGCTGCTTTAATCCAGAGAGAAAATGTCTT CCTGGCTATCGGCTGGCTCTCCGAGCTCTTTATCTGTT <210> SEQ ID NO 87 <211> Length: 46 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 573 <400> sequence: 87 >N56180 node 24 ACCCACTCTACGTCGCCTGCGCCCAGAAGAAATGTTTGAAACATGG <210> SEQ ID NO 88 <211> Length: 55 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 88 >N56180 node 26 GAAGATGATTTGAATGGGATCCACATTGTGGCCTTTGCAGAGAAGAGTGATCCAG <210> SEQ ID NO 89 <211> Length: 101 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 89 >N56180 node 29 ATGGCTACGAATTCCTGGAGATCCTGAAACAGGTTGCCCGGGACAATACTGACAACCCCGATCTGAGCATCCTGTGG ATCGACCCGGACGACTTTCCTCTG <210> SEQ ID NO 90 <211> Length: 57 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 90 >N56180 node 3 CCAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCTGTCCTCTTGCAG <210> SEQ ID NO 91 <211> Length: 75 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 91 WO 2005/069724 PCT/IB2005/001306 574 >N56180 node 31 CTCGTTGCCTACTGGGAGAAGACTTTCAAGATTGACCTATTCAGGCCACAGATTGGGGTGGTGAATGTCACAGAT <210> SEQ ID NO 92 <211> Length: 46 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 92 >N56180 node 33 GCTGACAGTGTCTGGATGGAGATTCCAGATGATGACGATCTTCCAA <210> SEQ ID NO 93 <211> Length: 10 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 93 >N56180 node 35 CCTTTTCCAT <210> SEQ ID NO 94 <211> Length: 84 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 94 >N56180 node 8 CTTGTGGCCCAGGTCCTTGAACATAAAGCTATAGGCTTTGTGATGGTGGATGCCAAGAAAGAAGCCAAGCTTGCCAA GAAACTGG <210> SEQ ID NO 95 <211> Length: 214 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 95 >T10377 node 0 WO 2005/069724 PCT/IB2005/001306 575 GGGGGGGCCTTCGCGGTGCAGCTGAGGCTGCAAGTAGCCGGCGCCGTCCCGCGTCGCCCCCGCGCAGGGCGGGCCCC GCACGCTTATCCTGCCCGGGAGGAACGCCGGCGTCCAGCCCGCTACCGACCGCCGCTGCGGGATGCTGCGCTCCACG TCCACGGTCACCCTGCTCTCGGGCGGCGCCGCCAGGACGCCCGGGGCGCCCAGCAGGAGG <210> SEQ ID NO 96 <211> Length: 133 <212> Type: DNA <213 > ORGANISM: Homo sapiens <400> sequence: 96 >T10377 node 17 TTTGGAAAACAGCAACATTAAGGATCAAATCAGAAATCTGCAGCAGACGTATGAAGCATCCATGGACAAGCTGAGGG AAAAGCAGAGGCAGTTGGAGGTAGCGCAAGTTGAAAACCAGCTGCTAAAAATGAAG <210> SEQ ID NO 97 <211> Length: 126 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 97 >T10377 node 19 GTGGAATCGTCCCAAGAAGCCAATGCTGAGGTGATGCGAGAGATGACCAAGAAGCTGTACAGCCAGTATGAGGAGAA GCTGCAGGAAGAACAGAGGAAGCACAGTGCTGAGAAGGAGGCTCTTTTG <210> SEQ ID NO 98 <211> Length: 129 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 98 >T10377 node 21 GAAGAAACCAATAGTTTTCTGAAAGCGATTGAAGAAGCCAATAAAAAGATGCAAGCAGCAGAGATCAGCCTAGAGGA GAAAGACCAGAGGATCGGGGAGCTGGACAGGCTGATTGAGCGCATGGAAAAG <210> SEQ ID NO 99 <211> Length: 160 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 576 <400> sequence: 99 >T10377 node 27 ATCATGTCGCACGAGCTCTTCTCCAGATTTAGTCTCCGGCTCTTTGGAAGATGATAAGTTGGTAGCCTGCTCTGGGT TGGAAGCGATTCCTTTATTGTTCGTGATTAGAAGAACACTTGTACACTCTCTGCTGGGAAGAGGTGGTATTTATCTA TGATGA <210> SEQ ID NO 100 <211> Length: 969 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 100 >T10377 node 33 CCAAACAGGCAGGACTCGTGAAATTGTGATGCCTTCTAGGAACTACACCCCATACACAAGAGTCCTGGAGTTAACCA TGAAGAAAACTCTGACTTAGGCACTCAGAGGCATACACTTTTTACAGATGGACAAAAGCTCTGGAACCCTGTGGCTT CAAATCCTTTGGGAAGGGTGACTGTTGTTTCCCCTACACACAGTGTAAGCCGGAATGGGAATCGCTGAGGCTCTGAT CCACTTCTAAGACAGGAAGGAAAGTGAAGGCAGAGTGAGCAGGTAAGAGAGGGATATACAAGGTCACATTTCAGACA CCCACTCGGCATACCCTGCCGTACTGCATCATCATTTGTTTTCTTTGTAGACACTGAAATCCTATCAGGAGGATTCC TTCACAATGTATTTTATTTGCTAGACTTTGGTTGGGAGGGAAAAGGACATTAATTTGAAGTTTCATGTTATTCATGC CAGGATTGTTTGATAGAGCATGAAGGTTTTGTTTACCCATAAAAGTATTAGAGGCAGCGTTTCTCTGATACAGAGAG GCCTGTCCACAAGAAGCATGGGCACCCAGCCAAACTTGAACCTGGAAGGGAGGGTTCCCGGCCTGCAGGTGCTCTTT CCTCTTGGTCCCAAGCATCTGTGCAGGGTCGTGGGAGCCACACTGAGAGACTTGTGTGGGCCAGACAAGCTTCATTC TGATGCGCTAGTCCCTTGGTTTAATTTGTGCCTTATGCTTTCATTGGACCAGCTGAAATCACTGTATTTATTCAACT TGTGATTTTTTTTTCTTTCTCACTTTAACTTAAAGAGAATTTTATATGTCTTGGAAATTTAATAATTTAGTGTTCTC AGTATCAATTGGTGTTTTTGTTAAACGAATGAATCATCTGTTCATGCATGCTCTACTTTGATATTATAACCTATGTC ACATGTGTTTAATAAATACCATATATTTTGTTCTACTAAAAAAAT <210> SEQ ID NO 101 <211> Length: 93 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 101 >T10377 node 12 GTGAAGAGCCACTTTGGAAAAGGTGAGAAAGCGAATGTATGGAGACTATGATGAGATGAGACAGAAGATTCGACAGCT

CACCCAGGAACTATCA

WO 2005/069724 PCT/IB2005/001306 577 <210> SEQ ID NO 102 <211> Length: 114 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 102 >T10377 node 14 GTTTCCCATGCTCAGCAGGAGTATCTGGAGAATCACATCCAAACCCAGTCGTCTGCCCTGGATCGTTTTAATGCCAT GAACTCAGCCTTGGCATCAGATTCCATTGGCCTGCAG <210> SEQ ID NO 103 <211> Length: 20 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 103 >T10377 node 16 AAAACCCTCGTGGATGTGAC <210> SEQ ID NO 104 <211> Length: 110 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 104 >T10377 node 2 TAGCAGTGGTGTTCAGGGTAGGATGCAGTTCTTCGCATTGTGCATAACACAAGCCCTGAACCAGCTGCTTTGGGAAC CCCTGGGAATAAAGTGCCCTACCTGCCTTTCAG <210> SEQ ID NO 105 <211> Length: 80 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 105 >T10377 node 23 GAACGTCATCAACTGCAACTTCAACTCCTAGAACATGAAACAGAAATGTCTGGGGAGTTAACTGATTCTGACAAGGA

AAG

WO 2005/069724 PCT/IB2005/001306 578 <210> SEQ ID NO 106 <211> Length: 105 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 106 >T10377 node 25 GTATCAGCAGTTGGAGGAGGCATCAGCCAGCCTCCGTGAGCGGATCAGACACCTAGATGACATGGTGCATTGCCAGC AGAAGAAAGTCAAGCAGATGGTCGAGGAG <210> SEQ ID NO 107 <211> Length: 84 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 107 >T10377 node 29 ATTGAATCATTAAAGAAAAAGTTGCAACAGAAACAGCTCTTAATACTGCAGCTTTTAGAAAAGATATCTTTCTTAGA AGGAGAG <210> SEQ ID NO 108 <211> Length: 85 <212> Type: DNA <213> ORGANISM: Homo sapiens 400> sequence: 108 >T10377 node 3 GCACTGCCAAGCCTGGGGCATCTCTGGAGATTGTGTATCCGAGTTTCAGGAGACCATGGAGATCAGCCTCGTAAAAT GCTCGGAG <210> SEQ ID NO 109 <211> Length: 101 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 109 >T10377 node 31 WO 2005/069724 PCT/IB2005/001306 579 AATAATGAACTACAAAGCAGGTTGGACTATTTAACAGAAACCCAGGCCAAGACCGAAGTGGAAACCAGAGAGATAGG AGTGGGCTGTGATCTTCTACCCAG <210> SEQ ID NO 110 <211> Length: 87 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 110 >T10377 node 5 GCAAATGTTTGCAGACTACGGCTGACCGTACCTCCTGAGAGTCCAGTTCCTGAGCAATGTGAAAAGAAGATTGAGAG AAAAGAGCAG <210> SEQ ID NO 111 <211> Length: 106 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 111 >TI10377 node 8 CTTCTTGACCTGAGCAATGGAGAACCTACCAGGAAACTTCCTCAGGGTGTTGTTTATGGTGTGGTGCGAAGATCAGA TCAAAATCAGCAGAAAGAAATGGTGGTGT <210> SEQ ID NO 112 <211> Length: 50 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 112 >T10377 node 9 ATGGGTGGTCCACCAGTCAGCTGAAAGAAGAGATGAACTACATCAAAGAT <210> SEQ ID NO 113 <211> Length: 341 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 113 WO 2005/069724 PCT/IB2005/001306 580 >Z24874 PEA 2 node 21 TCTACCTGGACGGCATGAAGTCCCGAGAGGAGCTCTTCCGTGAAGTCCTGGAAGACATTCAGAACTCGCTGCTGAAC CGCTCCCAGGAATCAGCCCCCTCCCCGGCTCGCCCAGCCAGGACACAGGGACCCGGACGCGGATGCGGCCACAGAAC GGCCAGGCCTGCAGCGTCCCAGCAGGACAGCATGTGAGCGTTTCCCTATGGGGGTGTCTGTACGTAGGAGAGTGGAG GCCCCACTCCCAGTTGGGCGTCCCGGAGCTCAGGGACTGAGCCCCAAGACGCCTCTGTAACCTCGCTGCAGCTTCAG TAGTAAACTGGGTCCTGTTTTTTTAACTGTTGG <210> SEQ ID NO 114 <211> Length: 180 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 114 >Z24874 PEA 2 node 4 GGGCCGCCTCCCCCGGGGCGGCCTCCAGGCTGCCGAGACCTATAAAGGCGCCAGGTTTTCTCAATGAAGCCGGGACG CACTCCGGAGCGCACTGCGTGGTCGCACCCTACCCGGGCTGCCTTGGAAGTCGTCCCCGCCGCCCCTCCGCACCGGC ATGAAGCTCATCGTGGGCATCGGAGG <210> SEQ ID NO 115 <211> Length: 77 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 115 >Z24874 PEA 2 node 0 GTTGGCCCTGACCTCGTTGGAAAACGAAGCTCCCCGCAGGGTCCCGGCCTCTAGGGCTGCTGTGCGGGCGGGGGTGG <210> SEQ ID NO 116 <211> Length: 49 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 116 >Z24874 PEA 2 node 10 CCCCAAGACCAAATAGCAGTTGGGGAAGACGGCTTCAAACAGTGGGACG <210> SEQ ID NO 117 <211> Length: 57 WO 2005/069724 PCT/IB2005/001306 581 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 117 >Z24874 PEA 2 node 12 TGCTGGAGTCTCTGGACATGGAGGCCATGCTGGACACCGTGCAGGCCTGGCTGAGCAGCCCGCAGAA <210> SEQ ID NO 118 <211> Length: 37 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 118 >Z24874 PEA 2 node 13 GTTTGCCCGTGCCCACGGGGTCAGCGTCCAGCCAGAG <210> SEQ ID NO 119 <211> Length: 53 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 119 >Z24874 PEA 2 node 14 GCCTCGGACACCCACATCCTCCTCCTGGAAGGCTTCCTGCTCTACAGCTACAA <210> SEQ ID NO 120 <211> Length: 72 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 120 >Z24874 PEA 2 node 16 GCCCCTGGTGGACTTGTACAGCCGCCGGTACTTCCTGACCGTCCCGTATGAAGAGTGCAAGTGGAGGAGAAG <210> SEQ ID NO 121 <211> Length: 60 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 582 <400> sequence: 121 >Z24874 PEA 2 node 3 CCTGGAGCTATTTCCATTCGGCGGCGGGAACAGGTGCCGGCGCCTCCGCCCCATCCCCAG <210> SEQ ID NO 122 <211> Length: 91 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 122 >Z24874 PEA 2 node 6 CATGACCAACGGCGGCAAGACCACGCTGACCAACAGCCTGCTCAGAGCCCTGCCCAACTGCTGCGTGATCCATCAGG ATGACTTCTTCAAG <210> SEQ ID NO 123 <211> Length: 353 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 123 >HUMCDDANF node 0 GGTTGGATTCCTGGGAGCTTCATCACATTTGGTTCTCAGCTGACTTTATATACTAAAAAATAACTTCCTTTCGCCTG ACCATGGAGAGGGACTGCCAGGGGTGAAGGCAGCCCTGTCTGAGGCCAGAGGTCTGCCCACGTGGCGGATGAGGCAG GTGTGAGGCCAGCTTGAGCATCTGGATCCATTTGTCTCGGGCTGCTGGCTGCCTGCCATTTCCTCCTCTCCACCCTT ATTTGGAGGCCCTGACAGCTGAGCCACAAACAAACCAGGGGAGCTGGGCACCAGCCAAGCGTCACCCTCTGTTTCCC CGCACGGGTACCAGCGTCGAGGAGAAAGAATCCTGAGGCACGGCG <210> SEQ ID NO 124 <211> Length: 128 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 124 >HUMCDDANF node 10 GCTGCAGCTTCCTGTCAACACTTCTCACATCTTATGCTAACTGTAGATAAAGTGGTTTGATGGTGACTTCCTCGCCT

CTCCCACCCCATGCATTAAATTTTAAGGTAGAACCTCACCTGTTACTGAAA

WO 2005/069724 PCT/IB2005/001306 583 <210> SEQ ID NO 125 <211> Length: 127 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 125 >HUMCDDANF node 2 CtGGGAGACAGGGACAGACGTAGGCCAAGAGAGGGGAACCAGAGAGGAACCAGAGGGGAGAGACAGAGCAGCAAGCA GTGGATTGCTCCTTGACGACGCCAGCATGAGCTCCTTCTCCACCACCACC <210> SEQ ID NO 126 <211> Length: 327 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 126 >HUMCDDANF node 5 AATTTGCTGGACCATTTGGAAGAAAAGATGCCTTTAGAAGATGAGGTCGTGCCCCCACAAGTGCTCAGTGAGCCGAA TGAAGAAGCGGGGGCTGCTCTCAGCCCCCTCCCTGAGGTGCCTCCCTGGACCGGGGAAGTCAGCCCAGCCCAGAGAG ATGGAGGTGCCCTCGGGCGGGGCCCCTGGGACTCCTCTGATCGATCTGCCCTCCTAAAAAGCAAGCTGAGGGCGCTG CTCACTGCCCCTCGGAGCCTGCGGAGATCCAGCTGCTTCGGGGGCAGGATGGACAGGATTGGAGCCCAGAGCGGACT GGGCTGTAACAGCTTCCGG <210> SEQ ID NO 127 <211> Length: 132 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 127 >HUMCDDANF node 8 TACTGAAGATAACAGCCAGGGAGGACAAGCAGGGCTGGGCCTAGGGACAGACTGCAAGAGGCTCCTGTCCCCTGGGG TCTCTGCTGCATTTGTGTCATCTTGTTGCCATGGAGTTGTGATCATCCCATCTAA <210> SEQ ID NO 128 <211> Length: 11 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 584 <400> sequence: 128 >HUMCDDANF node 11 GTGGTTTGAAA <210> SEQ ID NO 129 <211> Length: 35 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 129 >HUMCDDANF node 12 GTGAATAAACTTCAGCACCATGGACAGAAGACAAA <210> SEQ ID NO 130 <211> Length: 158 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 130 >HUMTROPIA PEA 2 node 0 TCTCAGTGTCCTCGGGGAGTCTCAAGCAGCCCGGAGGAGACTGACGGTCCCTGGGACCCTGAAGGTCACCCGGGCGG CCCCCTCACTGACCCTCCAAACGCCCCTGTCCTCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGG ATGG <210> SEQ ID NO 131 <211> Length: 405 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 131 >HUMTROPIA PEA 2 node 10 GTGGGACGGGGCTTCCTGGGGGCAGAGTACAGGCGCCGGAGGGATCCAAGACCCTGGGAGTGGGGGGAGGAGCCAGG GCTGCGAAGGGGGCGGGGACTACGCGGAGGGGCTTCAGGGGCGGAGTTTTGCAGAGGGTCATGCTCGGATTGGTGAC AGCAGCCTGCGGGCGGAACTCCGTTGCCCTCGGACTTGCTTAGGGATAGATGGGAAGTGCCTATCCAAAGGAAGAGA CCCAGATTGGTGGATGGGAATGAGGGGCGTGGCCTCCCGTAGACTCAGGGCTCAAGTTGGACGTGGGCCCAAATCTG GACCGGCTGGGTTTGCTGGGGGTGTCTTGAGGTCCCCTCCACCGTCGTCTCCGAATCCCCCTCCATGATCCTTCCTT

GCTCCATCTCACCCTGGCAG

WO 2005/069724 PCT/IB2005/001306 585 <210> SEQ ID NO 132 <211> Length: 534 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 132 >HUMTROPIA PEA 2 node 22 GTGGGACGCATGGGCAGCTCGGGTACCTTCGGGGTAGGGTGAGATGGCTGGGACTTGGTCTCTGCCTGACCCCTTGC AGCTGCTTTTGGCTGCACATCCCAGGAGACCCAGGACAACTGTGAGCCTGGCAGGGCTGGGGCAGAAGGATGAGTAC AATATAGTCAAGGAAAGCTGTTCTAGGCAGAGGGAACAGCACATGCAAGGCCATGGGTTGGGAAACAGAAAATAAGT TAGTGAACATGCTCAGGGCATCACATGTTGGTAAATTAGCTCAGGCACTGGCCAGGGAATTGTGATTTGCATGTAGC TGGACCAGGTTATGCCAGTGGTTTTGAGAGGTGAGGCTGGAGCATATGAGGAGGGGGATTCAGTTCCAGGATTAGAA GCCTAGACTGGGAGCCTAAGCCGGGAAGAGACTGGTAAGGCCTCGGTACTGGAAGACGAGATAAGGAGAATAAAAAA GGAGTGTAGGATGGAGGAGTTGGGTGTGCGGGAAATGGAAGGAGAAGTACCCACCCCCTCGTGTGCCCCCAG <210> SEQ ID NO 133 <211> Length: 144 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 133 >HUMTROPIA PEA 2 node 23 ATTGCAGATCTGACTCAGAAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGATCTC TGCAGATGCCATGATGCAGGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCCTGGACCTGCGGGCCCAC <210> SEQ ID NO 134 <211> Length: 42 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 134 >HUMTROPIA PEA 2 node 11 AAAAAATCTAAGATCTCCGCCTCGAGAAAATTGCAGCTGAAG <210> SEQ ID NO 135 <211> Length: 36 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 586 <400> sequence: 135 >HUMTROPIA PEA 2 node 14 ACTCTGCTGCTGCAGATTGCAAAGCAAGAGCTGGAG <210> SEQ ID NO 136 <211> Length: 44 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 136 >HUMTROPIA PEA 2 node 15 CGAGAGGCGGAGGAGCGGCGCGGAGAGAAGGGCGCGCGCTCTGAG <210> SEQ ID NO 137 <211> Length: 52 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 137 >HUMTROPIA PEA 2 node 16 CACCCGCTGCCAGCCGCTGGAGTTGGCCGGGCTGGGCTTCGCGGAGCTGCAG <210> SEQ ID NO 138 <211> Length: 36 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 138 >HUMTROPIA PEA 2 node 20 GACTTGTGCCGACAGCTCCACGCCCGTGTGGACAAG <210> SEQ ID NO 139 <211> Length: 54 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 139 WO 2005/069724 PCT/IB2005/001306 587 >HUMTROPIA PEA 2 node 21 GTGGATGAAGAGAGATACGACATAGAGGCAAAAGTCACCAAGAACATCACGGAG <210> SEQ ID NO 140 <211> Length: 18 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 140 >HUMTROPIA PEA 2 node 24 CTCAAGCAGGTGAAGAAG <210> SEQ ID NO 141 <211> Length: 15 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 141 >HUMTROPIA PEA 2 node 25 GAGGACACCGAGAAG <210> SEQ ID NO 142 <211> Length: 20 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 142 >HUMTROPIA PEA 2 node 29 GAAAACCGGGAGGTGGGAGA <210> SEQ ID NO 143 <211> Length: 13 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 143 >HUMTROPIA PEA 2 node 30

CTGGCGCAAGAAC

WO 2005/069724 PCT/IB2005/001306 588 <210> SEQ ID NO 144 <211> Length: 24 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 144 >HUMTROPIA PEA 2 node 31 ATCGATGCACTGAGTGGAATGGAG <210> SEQ ID NO 145 <211> Length: 94 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 145 >HUMTROPIA PEA 2 node 32 GGCCGCAAGAAAAAGTTTGAGAGCTGAGCCTTCCTGCCTACTGCCCCTGCCCTGAGGAGGGCCCTGAGGAATAAAGC TTCTCTCTGAGCTGAAA <210> SEQ ID NO 146 <211> Length: 13 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 146 >HUMTROPIA PEA 2 node 4 GAGCAGCGATGCG <210> SEQ ID NO 147 <211> Length: 45 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 147 >HUMTROPIA PEA 2 node 5 GTGAGAGCAGCGGGCTAAGGCGTGGCTGGGACCCCCAGGGCCAGG <210> SEQ ID NO 148 WO 2005/069724 PCT/IB2005/001306 589 <211> Length: 50 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 148 >HUMTROPIA PEA 2 node 8 GCTAGGGAACCTCGCCCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAA <210> SEQ ID NO 149 <211> Length: 34 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 149 >HUMTROPIA PEA 2 node 9 CTACCGCGCTTATGCCACGGAGCCGCACGCCAAG <210> SEQ ID NO 150 <211> Length: 1,284 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 150 >HUMSMCK node 0 TTCCATGCTCTTTAAAAGCCTTATAATTTTCTGGATCTGGGAGCTGGGCTATTTCAGGGTCAATGGATTTATTTCAG TTGGTGCCTGAACTGACTTGAAACAAGTGTGTGTGGAAAAGAGCTATTTTGAGAAGGAATAAACCGAGACTGCCCTG ATGATAGAATATGCAAGCTGGTGGGTCTTGACTCCTTAAAGGATTATGAAATTAATTTGATTGGTCCCAATCTTTAT ATAACCACCCCAATCAGGAAACTTCCCATCCCGCCAAAAGGCCCCCTCACGTGCTCTCCCTGTCAGTACCCCATGCA AAGGTAAAATAGATGATATTTTTAAACATGGGTCGTGTTTAAAAGAAATGGAAACTCCTTCAGAGAATGAAGGAGAA CCACACTGGGTAGAAGGTTATTCCTGGGGCTCCACCCCTTGCTCCATCAAGTCCTCTGAGCATGAGCTGGGCTCTGA GAAGGAAGAGACAGGAACCAATTGGTCATGTCCACGTGGCCTCAGAAGCTGAGTACGTGACGGTCACCAGATGCCTA GGCAGGCTCCCTTGAAATGGCAGGGCTGCTGTCCAAAATCCTGCTGGGTCATTGCTATTTACAGGCAGCCTTCCCGG CGTGCGGTGGATATCCCAAGCGGGGCTATTTTTAAGCAGGGCTATGGCCTGCCGTGGGTTAAGCTGGTGTGGACAGA AAGCGAGATGATCTAGCCATCTACTGCAGGGGGCCTGATCTTGAACAGAAACCTGACTGTAATTGTCCCTGGATCCA GGTCCCAGACAAAGACGCTGGAAGGAGGTCCCTCCAGCCCCTGGCTCAGGGCCCGGTCAGCTGCTGGAGCCAGGCAG CTTGAGACATCCTCCTCTCCGACCTTGGCTTGAGGGGTTCATCCTCCAGAGCTCACCAGGGCCCCAAGGCTGGTACA CCTGAGAGAAGAGAGAAACAAATCCCCCAACAGATGTGCAATTTCACCTGCTGGCCCTTCCATTCTGAGATCCAGAG

CCCTGGCAAAGGAGCCTCCAGGACCAGGCCTGGGAAGCAAGACTGGCTCCGCCTTTTACGTTTCAGAGAAAGGGCAG

WO 2005/069724 PCT/IB2005/001306 590 GTGCTATAAAGGGCCCAGCGCCCACGGGCCTGCCTTCAAGGGTACAGCTGTGGGGGCCGGTGCGCCCGGAGGTCTAC GCTGGGATTGGTGAGGTCCTCTGGCCCCGCCCCGCCAGGGAGGATTTCCAGGCCGGCCCGACCAGCTCGCCCTGCAT ACACTTCTTGGCTGTGTGCGCTCAGCAGGACGTGGGAGGCTCCGGCTTCAAG <210> SEQ ID NO 151 <211> Length: 172 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 151 >HUMSMCK node 7 ACACTCATCCAAGAGGAAGGATGGCCAGTATCTTTTCTAAGTTGCTAACTGGCCGCAATGCTTCTCTGCTGTTTGCT ACCATGGGCACCAGTGTCCTGACCACCGGGTACCTGCTGAACCGGCAGAAAGTGTGTGCCGAGGTCCGGGAGCAGCC TAGGCTATTTCCTCCAAG <210> SEQ ID NO 152 <211> Length: 180 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 152 >HUMSMCK node 12 CGCAAGCACAACAACTGCATGGCCGAGTGCCTCACCCCCGCCATTTATGCCAAGCTTCGCAACAAGGTGACACCCAA CGGCTACACGCTGGACCAGTGCATCCAGACTGGAGTGGACAACCCTGGCCACCCCTTCATAAAGACTGTGGGCATGG TGGCTGGTGACGAGGAGTCCTATGAG <210> SEQ ID NO 153 <211> Length: 222 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 153 >HUMSMCK node 17 ATCACCCAAGGGCAGTTCGACGAGCATTACGTGCTGTCTTCTCGGGTGCGCACTGGCCGCAGCATCCGTGGGCTGAG CCTGCCTCCAGCCTGCACCCGGGCCGAGCGAAGGGAGGTAGAGAACGTGGCCATCACTGCCCTGGAGGGCCTCAAGG GGGACCTGGCTGGCCGCTACTACAAGCTGTCCGAGATGACGGAGCAGGACCAGCAGCGGCTCATCGAT <210> SEQ ID NO 154 WO 2005/069724 PCT/IB2005/001306 591 <211> Length: 124 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 154 >HUMSMCK node 22 GCATAATTATGATAAGACATTTCTCATCTGGATAAATGAGGAGGATCACACCAGGGTAATCTCAATGGAAAAAGGAG GCAATATGAAACGAGTATTTGAGCGATTCTGTCGTGGACTAAAAGAA <210> SEQ ID NO 155 <211> Length: 199 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 155 >HUMSMCK node 23 GTAAGATGTTATCTGAGATTTCTGGATATTTATTAAAATAAAATTACCGTATTGTTTGTTCTTGAAAGAAGACACTA TGGTAACTTCCAAGATGGAGCTAATTTTTTTCTAGAAATCAAAGCAACTGCCGCCTCCCAGGTTCAAGTGATTATCC CGCCTCAGCCTCTAGAGTAGCTGGGATTACAGGTGCCACCACCAC <210> SEQ ID NO 156 <211> Length: 135 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 156 >HUMSMCK node 25 GTAGAACGGTTAATCCAAGAACGAGGCTGGGAGTTCATGTGGAATGAGCGCCTAGGATACATTTTGACCTGTCCTTC GAACCTTGGAACAGGACTACGAGCTGGTGTCCACGTTAGGATCCCAAAGCTCAGCAAG <210> SEQ ID NO 157 <211> Length: 130 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 157 >HUMSMCK node 26 GTACTGTTATGTGCCCAGTGGCCCTGATGGGCCAGGATCAGCTCAGATGCGACTGCTTTGTGGAGGAAGAAAACATC

ACTGCCCATTCCTTAACCCTTACTTTCTCTATCTACAATATAAAAATAAGAAA

WO 2005/069724 PCT/IB2005/001306 592 <210> SEQ ID NO 158 <211> Length: 126 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 158 >HUMSMCK node 28 GACCCACGCTTTTCTAAGATCCTGGAAAACCTAAGACTCCAGAAGCGTGGCACAGGTGGTGTGGACACTGCCGCGGT CGCAGATGTGTACGACATTTCCAACATAGATAGAATTGGTCGATCAGAG <210> SEQ ID NO 159 <211> Length: 376 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 159 >HUMSMCK node 29 GTAACGTCTCTCTCACTTTCCTAACATGAACTAACAAAATCAGCCTAAGAGAGAATAGAGAAAAGCAAACAGCCTAG CCGTTTTCACAAAATTCGAGACCTCCTCTTCGCCCATTGAGTCCTGAGTTATGTTAGCTTTTCATTCTGTAACATTA TTCTTCCATGGGAAATAACTGCATAAAGGGAAACATAATGTGAGCTGAGAATTTATAGGCAAGTATAGGAATTCACA GTGGGACTGTTGTCACCGACCTGCCATGAGAGCTATTCCAACAATCCTCAGCGAGCAGGAGCTCTGTTATGCTAAAG GACTGCAGTTTTTTTATTACTGTAAAGTCAGAACATCTATGCTATCCCTCTGAGGGTGGCAAAATAGT <210> SEQ ID NO 160 <211> Length: 274 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 160 >HUMSMCK node 32 GTTGAGCTTGTTCAGATAGTCATCGATGGAGTCAATTACCTGGTGGATTGTGAAAAGAAGTTGGAGAGAGGCCAAGA TATTAAGGTGCCACCCCCTCTGCCTCAGTTTGGCAAAAAGTAAACTTTCCCTTTCCCAATTTATAAATAATCTGTCT GCTGGTACGACAGACATAAATCTCTACTCTGAGAGTTTTTATACACTTGGAAAAATATAAAATTGTAGATCCTGCCT ATCTTTACAATAAAACTCTCCTTAATATAAAAAACTTTGCTTT <210> SEQ ID NO 161 <211> Length: 19 WO 2005/069724 PCT/IB2005/001306 593 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 161 >HUMSMCK node 11 CGCAGACTACCCAGACCTG <210> SEQ ID NO 162 <211> Length: 96 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 162 >HUMSMCK node 14 GTGTTTGCTGACCTTTTTGACCCCGTCATCAAACTAAGACACAACGGCTATGACCCCAGGGTGATGAAGCACACAAC GGATCTGGATGCATCAAAG <210> SEQ ID NO 163 <211> Length: 86 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 163 >HUMSMCK node 19 GACCACTTTCTGTTTGATAAGCCAGTGTCCCCTTTATTAACATGTGCTGGGATGGCCCGTGACTGGCCAGATGCCAG GGGAATCTG <210> SEQ ID NO 164 <211> Length: 665 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 164 >H88495 PEA 3 node 0 GAGTCCCCCTACCCCTCCCAGCTGTATTTATAGCCCTGGCCTAGCCCAGTCCCTGCCCCCAGATCTGAGTTCCAGGG ACAGGAGGTCATGGGCACGTGTGTTGGGGGCCATGTTCCTTTCCCCCCATTCTAGGGCCTCAATACTGACATCACTC TCTCACCAGCACGTATCATTCCAGCTGGAAACACCCCGCAATCGAACCCCCAGTCCTTCCGTCCCAGGAGTCTCTCC

CCTCTGATAAGTCTCTTCTGCCTCCCCCAGGTGCCCCAGGCTCCCCCAAAAACCTGCTAAAAGTCTAGCCTTTGTCT

WO 2005/069724 PCT/IB2005/001306 594 TTGCAGCTGCCAAACGTGAGCTTGTTGGTAGTTCAAAGTCAAGTCCCTTGGCCACCGTCTCCTGGCCAGGGAGAGAC CCCTCACTGGTCCCCTCCCCAGCTGGGAGGAGGAGGAGCAGGAGGCAGGCAGGCGGGGACTGACCCAGAATAACTCA GGGCTGAGAGTAAATTTAGCTGGAGAGAGGGGAGGGGAAGGACCCTATTGGCTGGGGAATGGGGAGGGAGGGCCCCA GAGGGGGGTCAGGGGGCTCCGGAGACAGCCTCAGAGGGGTGTCCAGAGCCAGGCAGCAAGGACCAGAGGAAGGTGGA CAGAGACCGAAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAAC <210> SEQ ID NO 165 <211> Length: 513 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 165 >H88495 PEA 3 node 1 CCCAAAGGGACAAAGACCCCAACGTTTGTCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCC ATGGGCCACCATAGGCCATGGCTGCACGCTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTCCTCCCCCCGGCCAT GACCCAGCAGCTCAGAGGGGATGGGCTGGGCTTCAGAAACCGGAACAACAACACTGGAGTCGCCGGGCTCTCCGAGG AGGCATCAGCAGAGCTTCGCCACCACCTCCACAGCCCTAGAGACCATCCAGATGAGAACAAGGATGTTTCCACAGAG AATGGGCATCATTTCTGGAGCCACCCAGACCGTGAAAAGGAGGATGAAGATGTCGCCAAGGAATATGGGCACCTACT CCCAGGCCACAGGTCCCAAGACCACAAAGTCGGAGATGAGGGTGTCTCAGGTGAGGAGGTCTTTGCAGAGCATGGTG GGCAGGCCCGTGGGCACAGAGGCCACGGGAGTGAAGACACGGAAGACTCAG <210> SEQ ID NO 166 <211> Length: 437 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 166 >H88495 PEA 3 node 4 GAGCCACAGCCATCAAGACGAGGATGAGGATGAAGTTGTGTCCAGTGAGCATCACCATCATATCCTCAGGCATGGAC ACCGAGGCCATGATGGGGAAGATGATGAAGGAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAAGAGGAGGCCTCCACT GAGTATGGACACCAGGCCCACAGGCACCGAGGCCATGGGAGTGAAGAGGATGAGGATGTCTCAGATGGACACCATCA TCATGGCCCCAGCCACAGGCACCAAGGCCATGAAGAAGATGACGATGATGATGATGATGATGATGATGATGATGATG ATGATGATGTCTCCATTGAATATAGACACCAGGCTCACAGGCACCAAGGCCACGGGATTGAAGAGGATGAAGATGTC TCAGATGGACACCATCATCGCGACCCCAGCCACAGGCACCGAAGCCATGAAG <210> SEQ ID NO 167 <211> Length: 517 <212> Type: DNA WO 2005/069724 PCT/IB2005/001306 595 <213> ORGANISM: Homo sapiens <400> sequence: 167 >H88495 PEA 3 node 9 TGAACGTTGGCACCAGGGTCCCCAACATGTCCACCATGGCCTTGTAGATGAGGAAGAGGAAGAAGAGGAGATCACAG TCCAGTTCGGCCACTATGTTGCAAGCCACCAACCTCGAGGCCACAAGAGTGATGAAGAGGACTTCCAAGATGAGTAT AAAACAGAAGTCCCTCACCATCACCACCACAGAGTCCCCAGGGAGGAAGATGAGGAGGTCTCTGCTGAGCTTGGCCA CCAGGCCCCCAGCCACAGGCAAAGCCACCAAGATGAAGAAACTGGCCATGGTCAAAGAGGGTCCATCAAAGAGATGA GCCATCACCCCCCAGGACACACAGTGGTCAAGGATAGAAGCCATTTGAGGAAGGATGATTCTGAGGAGGAAAAGGAG AAGGAAGAGGACCCCGGCTCCCATGAGGAAGACGATGAAAGTTCAGAGCAGGGAGAGAAAGGCACCCATCATGGCAG CCGGGACCAGGAAGATGAGGAGGATGAGGAGGAAGGTCATGGCCTCAGCCTGAAC <210> SEQ ID NO 168 <211> Length: 132 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 168 >H88495 PEA 3 node 13 GAAGAAGACGAGGAGAGGAGGGAAGAGAGGGCTGAGGTTGGGGCCCCACTGAGCCCAGACCACAGCGAGGAGGAAGA GGAGGAGGAGGAGGGGCTGGAGGAAGATGAGCCCCGCTTCACCATCATCCCCAAC <210> SEQ ID NO 169 <211> Length: 251 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 169 >H88495 PEA 3 node 19 GTGAGACCTCACCTCACACTCAAGGCTCCACTGGGCCTCAGGATGCACCGGGACCCTCTGAGGACCCCCAGCCCTAA ATCCTGGCCTCTGACCCAACCCCTTACCCCTGATGCAACCTTGACTCCACAAGCGATCCTGACTCCAACCTTAACCT AGACCTAGCCTCTGGTCCGGGTCTGGTCCCGGCCCCATCCTAACTCCGCCCCCGGCCACGCCCCACGCTCACTCTCT CTCCCCGTCCCCGCCTCCAG <210> SEQ ID NO 170 <211> Length: 327 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 596 <400> sequence: 170 >H88495 PEA 3 node 21 GTGAGCATGGGCGGGGCCCTGGAAAAACCTGAGGAAGGTGCCGGGCCCAGCGTGGTGAATCCTGGTGGGGGCGGAGC CTGGCCCGGTAGGCTGGTGGGGCGGGGCTAAGAGGGGAGGCGTGGCCAAGGCTCTGAGCACGTGGGCCGGGGCCTGG CTCGAGGAACACCAGGTGGAGTTGCTGGAGCCAAGGGACAGAAATGAGTGGAGGGTTGAGATGCGGGCTTAGAGCCT AATGGGCGAGGCCAACTCAAGTAGGAATCGAAGGGGCGGGGCTACTGGAGAACGGAATCACCCAGAACGAAAAAGGG GTCCGGTAGAAGGGATTCA <210> SEQ ID NO 171 <211> Length: 242 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 171 >H88495 PEA 3 node 26 GGCCCTGGCAGACATGCTGGAAACGCCGGAACCCTGACCCAGTCGCTCGACTGCGACGCAGGTGTACCTCCCCCTGC CTTCCAACCCCTTTCCACGAGCTATATTTATTTCTCCGAATAAACGTGCTCCCCGAAACCTCATTGTCAGACGTGGG GTCTGGGAATCTCAGGGCATCGGGGAATGCGGGTAGGGTCTAGAGACCTGGACCTAGACTTGAGGGATGAGGGGCCT GGACTCCTGGC <210> SEQ ID NO 172 <211> Length: 31 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 172 >H88495 PEA 3 node 2 CTGAGCACAGGCACCACCTCCCCAGCCACAG <210> SEQ ID NO 173 <211> Length: 30 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 173 >H88495 PEA 3 node 5

AAGATGACAATGATGATGATGATGTCTCCA

WO 2005/069724 PCT/IB2005/001306 597 <210> SEQ ID NO 174 <211> Length: 107 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 174 >H88495 PEA 3 node 6 CTGAGTATGGACACCAGGCCCACAGGCACCAAGACCACAGAAAGGAAGAGGTTGAGGCTGTCTCAGGTGAACACCAC CATCATGTCC <210> SEQ ID NO 175 <211> Length: 10 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 175 >H88495 PEA 3 node 7 CTGACCACAG <210> SEQ ID NO 176 <211> Length: 45 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 176 >H88495 PEA 3 node 8 GCACCAAGGCCACAGAGACGAGGAAGAAGATGAGGATGTGTCCAC <210> SEQ ID NO 177 <211> Length: 18 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 177 >H88495 PEA 3 node 10

CAGGAGGAGGAAGAAGAG

WO 2005/069724 PCT/IB2005/001306 598 <210> SEQ ID NO 178 <211> Length: 9 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 178 >H88495 PEA 3 node 11 GAAGACAAG <210> SEQ ID NO 179 <211> Length: 15 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 179 >H88495 PEA 3 node 12 GAGGAGGAGGAGGAG <210> SEQ ID NO 180 <211> Length: 64 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 180 >H88495 PEA 3 node 14 CCACTGGACAGGAGAGAGGAGGCTGGAGGTGCCTCCAGCGAGGAGGAAAGCGGTGAGGACACAG <210> SEQ ID NO 181 <211> Length: 71 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 181 >H88495 PEA 3 node 16 GTCCACAGGATGCTCAGGAGTATGGGAACTACCAGCCAGGGTCCCTGTGTGGCTACTGCTCCTTCTGCAAT <210> SEQ ID NO 182 WO 2005/069724 PCT/IB2005/001306 599 <211> Length: 69 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 182 >H88495 PEA 3 node 18 CGATGCACTGAATGTGAGAGCTGTCACTGTGATGAGGAGAACATGGGTGAGCACTGCGACCAGTGCCAG <210> SEQ ID NO 183 <211> Length: 55 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 183 >H88495 PEA 3 node 20 CACTGTCAGTTCTGCTATCTCTGCCCGCTGGTCTGCGAAACGGTCTGCGCTCCAG <210> SEQ ID NO 184 <211> Length: 8 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 184 >H88495 PEA 3 node 23 GAAGCTAC <210> SEQ ID NO 185 <211> Length: 29 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 185 >H88495 PEA 3 node 24 GTTGACTATTTCTCCTCGTCCCTTTATCA <210> SEQ ID NO 186 <211> Length: 276 <212> Type: DNA WO 2005/069724 PCT/IB2005/001306 600 <213> ORGANISM: Homo sapiens <400> sequence: 186 >Z36249 PEA 3 node 0 ACATATTCAGCAGGGTTAGCTTGTCCTCCCCTCCCTCTTCAGCTTCCCAGACACTGAGTCTGGAATGAAAATTCACC TGCCTCTGAGTTGGCTCCTAATGGGGGTGGGAGTGTTACTTCGGTTCCCAGGTTGGAAGATTATCTCACCCGGCCCC AGCTATATAAGCTGACCGGTGTGGAGGGGCCCAGCAGGGCCAACTCCAGGGATTCCTTCCACGACAGAAAAACATAC AAGACTCCTTCAGCCAACATGATGGTACTGAAAGTAGAGGAACTG <210> SEQ ID NO 187 <211> Length: 180 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 187 >Z36249 PEA 3 node 3 GTCACTGGAAAGAAGAATGGCAATGGGGAGGCAGGGGAATTCCTTCCTGAGGATTTCAGAGATGGAGAGTATGAAGC TGCTGTTACTTTAGAGAAGCAGGAGGATCTGAAGACACTTCTAGCCCACCCTGTGACCCTGGGGGAGCAACAGTGGA AAAGCGAGAAACAACGAGAGGCAGAG <210> SEQ ID NO 188 <211> Length: 138 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 188 >Z36249 PEA 3 node 5 CTCAAAAAGAAAAAACTAGAACAAAGATCAAAGCTTGAAAATTTAGAAGACCTTGAAATAATCATTCAACTGAAGAA AAGGAAAAAATACAGGAAAACTAAAGTTCCAGTTGTAAAGGAACCAGAACCTGAAATCATT <210> , SEQ ID NO 189 <211> Length: 685 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 189 >Z36249 PEA 3 node 11

GTAAGACTCATGCAAAGCACTGCAAAATCCAGCTCATTAATTTTATGTTTCTTATGCTTTACTCCAGTCTTGCTAAT

WO 2005/069724 PCT/IB2005/001306 601 ATAGTGCCAAAGTCCTTCCACCTGAAACAGTTTCCCCAGCTGTTGCTGTGTATGCCAGGAGCCTAATAGGAGAGTTC AGTGGTCCAAAAAATAAATAGATATTAGATCAGTGATACGGATTGCATTGTTTTTTGCACTCATATACATCTGGCTG ATTTTTCAGTTTTTCTTTAACTTCTTAGATTCTTGGGATAAGACTTTTAATGTGGGCCAAAAAGTCACCTTTAGAGA TATATTATTAGCATCATCTTTGATTAAAACCAAGCACGTCAACACTAGATAAGAAATCTGGAGATTGGAGTTCAGGG GCCAGTTGTACCACTACTTGGCTATTTGGTTTTGAGCAGCTAATTTGCATCCTCTGGGCTGTGGTTTCCTTATCTGT AAACATGGGGCATTGGAGTGAAATAACGCCTAAAGTTGTTCCAGCTCTAATAGTTCATTAGCCCATTCAAATAAAGC CAATTTATCAGAAATCACTAATCTTTTTGTATTCTTTCCCCCATGAAGTGAAATTGGGGACCGCTTCTGAAGTTGAA CTAAAAACATGTCTCCCATTCTCCTAAAAATGAATGGAAACTTTTTGATAGTCTAGCAACAGTCCCAGA <210> SEQ ID NO 190 <211> Length: 671 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 190 >Z36249 PEA 3 node 14 GTAAATATATTTCTTTGCTTGGGAATGAGCCAAAAGAAGTAGACTATATGAAGCTCCGGAAAACCTCCAATGCAAAA CCGAGCTGATTGGATTGAAAATTGATCTGAGAGAACTAGGCAAAAGCTCATTTCTCCAAATAAAGGAAAGTTGGGAG ATGAGAGTAGGTCATGTGAAAATATTTTCCATACATACTGAAAATAGAGGAATATTTCAGGGAAAAGAAGGAAGTGA AAGCTGTTAAACTGAATTCAATATCCTCATCAGCGAGTTAGTCATTCATTTTCGACACTTGCCTTTCAACAGCCTTG TCCCTCCATTGTTCACAGGGCAGCCTGCTTATGGTTGGCTGCCAGCAACATATACGAATTCTCTAGCTGCACACTTT ATATGATAGATGCCAATTGCTACCAATGAGATTTGGGGCTAGACTGCATATGAAATGAATTGCATCTATGGAAAGTA GCTGCTATTCAGACCTCAATAATTCAATCACTGTGATTTCTACGAAGACCAGTATGCAGCATAATTTATGAACTGAA GATTGAGCTGGGAAAATTCTTTATGTATTTAAATGCAGCTCATTTTGACTTTATAGCAAAGCGGCAACGGGATATCA AAGAAATCCAAGGGACTTGGCCAAAATTGAATCCAAAACATAAACACATTGAAAA <210> SEQ ID NO 191 <211> Length: 1,074 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 191 >Z36249 PEA 3 node 24 GCTGGGAAGACGCCGATGGATCTGGTGCTACACTGGCAGAATGGAACCAAAGCAATATTCGACAGCCTCAGAGAGAA CTCCTACAAGACCTCTCGCATAGCTACATTCTGAGGCAAACGACAGACTCTTAATCAGTAAATGTTCACTGGCATTT TGAAGGCATGGCCCAAGAGAAGAGACACTAGCCATAAAATCTAGTTTCTATTTATCAACGTGTTGTGAAGATGTACC TAATGAAGTTTTGAGAAAGCACAGGGTTATAGGTGTTTAAATTTCCTTTAGTGAAACTCTTATTTATTTTTATGTAT TCCTGTTTATTTATTTACTGCCACGCTACTGATATTCAGACCTTCATGATCATCCATCTGGTGAGCAGAGCTTCATT

TGTATATAACACTTTCAGAGCCTTCCCACCCATAGGTAGTTCTTAAACCAGGTGAAAGAGCAAAGTTCAAGTGCCTA

WO 2005/069724 PCT/IB2005/001306 602 CTTATGTGTCATTCGCTCATGTAAGAGTTTTTAAGAGAGGGCTGATTATCACAGCCCTCTTTTCTCCTGAATTTTTA ATGCAGAAGTTTGAATGAAGCAAGGGAAGGCATGTAGGGACAGGAAAGGAAACAATGGAAGGAAAGTGATTCTGTGA AAAGGACAGTGAAGCCAGCTATTTTACCCCCAGGCTGGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACCGAGTA CACAGAGTACCCAAGTGAAGAGAACGTCATGAGTGTAAGTGCAAATCAGTGGAAGGAGCGGCAAACTGGGACATGCA GAATTGAATTTGCTCAAAAAAGATGAAAGGAAATGCAAACTGTAAATGTATAAATGTATATTGTATTGTATGTACAT TTTATATTCATAATAAAGGCAATCAAACTCTAAACCTCTAAGTCCTTCTATAAGTGTGGTGGAAATGTCCTATGTGA AAAAAAAAGCTATATAGGAGGGTTTTTTTTTTCCATTGTTTTCCAAGTTTTGCAGATTAGAAATGTCCCGTACAACA GCACTCCCAGTATTTAATATGTATACAGATCACCTGGGGATCTGGTTAAAATGCAGATTTCTGATTCAGCTGG <210> SEQ ID NO 192 <211> Length: 108 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 192 >Z36249 PEA 3 node 10 ACGGAACCTGTGGATGTGCCTACGTTTCTGAAGGCTGCTCTGGAGAATAAACTGCCAGTAGTAGAAAAATTCTTGTC AGACAAGAACAATCCAGATGTTTGTGATGAG <210> SEQ ID NO 193 <211> Length: 99 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 193 >Z36249 PEA 3 node 13 TATAAACGGACAGCTCTTCATAGAGCATGCTTGGAAGGACATTTGGCAATTGTGGAGAAGTTAATGGAAGCTGGAGC CCAGATCGAATTCCGTGATATG <210> SEQ ID NO 194 <211> Length: 99 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 194 >Z36249 PEA 3 node 17 CTTGAATCCACAGCCATCCACTGGGCAAGCCGTGGAGGAAACCTGGATGTTTTAAAATTGTTGCTGAATAAAGGAGC

AAAAATTAGCGCCCGAGATAAG

WO 2005/069724 PCT/IB2005/001306 603 <210> SEQ ID NO 195 <211> Length: 99 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 195 >Z36249 PEA 3 node 19 TTGCTCAGCACAGCGCTGCATGTGGCGGTGAGGACTGGCCACTATGAGTGCGCGGAGCATCTTATCGCCTGTGAGGC AGACCTCAACGCCAAAGACAGA <210> SEQ ID NO 196 <211> Length: 99 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 196 >Z36249 PEA 3 node 21 GAAGGAGATACCCCGTTGCATGATGCGGTGAGACTGAACCGCTATAAGATGATCCGACTCCTGATTATGTATGGCGC GGATCTCAACATCAAGAACTGT <210> SEQ ID NO 197 <211> Length: 319 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 197 >Z25377 PEA 1 node 5 GAATCTGCCGGTGGGGCGTGAGCGAGAAGCCACCAAAACATGAGCTAGGACAGCCTTCTCAAGAAGATTCTGCCAAC TCAAAAATATTATTCTTTTTTTTTTTTTTTTGCTGTTGTTTCTGAGAAACTAGGTGTCTTACCATTTTAAAATTTCA TATTTTATTTAAAAGGAAACCAGTGAATTGAAAATGAGACTAAATATCGCTATCTTCTTTGGAGCTCTCTTTGGTGC TTTGGGGGTGTTACTCTTTTTGGTGGCTTTTGGATCGGATTATTGGCTTCTTGCAACTGAAGTGGGGAGATGTTCAG GTGAAAAGAAT <210> SEQ ID NO 198 <211> Length: 405 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 604 <400> sequence: 198 >Z25377 PEA 1 node 12 GTCTTCTTTGATTCCTCATGGCAAACCAAATCCAGCAGCACATCAAAAAGCTTATCCACCATGATCAAGTGGGCTTC ATCCCTGGGATGCAAGGCTGGTTCAATATATGCAAATCAATAAATGTAATCCAGCATATAAACAGAACCAAAGACAA AAACCACATGATTATCTCAATAGATGCAGAAAAGGCCTTTGACAAAATTCAACAACACTTCATGCTAAAAACTCTCA ATAAATTAGGTATTGACGGGATGTATCTCAAAATAATAAGAGCTATCTATGACAAACCCACAGCCAATATCATACTG AATGGGCAAAAACTGGAAGCATTCCCTTTGAAAACTGGCAAAAGACAGGGATGCCCTCTCTCACCACTCCTATTCAA CATAGTGTTGGAAGTTCTGG <210> SEQ ID NO 199 <211> Length: 138 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 199 >Z25377 PEA 1 node 15 TTTACCGTGGTTTCTGGGCAGTCCTGATGCTCCTGGGGGTAGTTGCTGTAGTCATCGCAAGCTTTTTGATCATCTGT GCAGCCCCCTTCGCCAGCCATTTTCTCTACAAAGCTGGGGGAGGCTCATATATTGCTGCAG <210> SEQ ID NO 200 <211> Length: 188 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 200 >Z25377 PEA 1 node 17 GCATCCTATTTTCATTGGTGGTGATGCTGTATGTCATCTGGGTCCAGGCAGTGGCTGACATGGAAAGCTACCGAAAC ATGAAAATGAAGGACTGCCTGGATTTCACCCCTTCTGTTCTGTATGGCTGGTCATTTTTCCTGGCCCCAGCTGGGAT ATTTTTTTCTTTGCTAGCTGGATTACTATTTCTG <210> SEQ ID NO 201 <211> Length: 3,478 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 201 >Z25377 PEA 1 node 18 WO 2005/069724 PCT/IB2005/001306 605 GTTGTTGGACGGCATATTCAGATACATCACTAAATCAACTGTTGCCACAAGTATTTTCTTGAGAGATTTTAAAACAA GGAATACTTTTTTTCCATTTTGTTTCATTGATCCCAGCATAAAGTTAGTAGATATAACTTTTTAGTTGCTATTCAAA TTAATCATTTTACTAAAATTTTCTTCAGTAAGAAGGTCCTAGAATCTCTCCAGACACCAGCAAGCCTCTATCTTGTC TAAGTGCTGTCAAGGACCTAGTTCTTTAGGGAATAGGTAAACAGGTCTCCCTTTCATTGAACATGTTAGAGTTCATG CAGGTCGCAAAGGCCTGATAATAGCTTAATACCATGACATGGGGAAAATCTCGATAGATTTGGCTTAAAGTCTCCTT GGCATTCACTTCTGCTAATTAAAAAAAATCCTTGAAGAATAATTAAGAATGGGCAAGGTTGTCAGAGAATTTATTTT GTTTCTTGCCCACACAGATAATATCCACATACACATTCACTGGCTCTTGTGAGCAAATGAATTTAAAAATAGACAGC AGTTGTTCTAATTAGTGGGAGCCATGTACTCACCAGTTAAAATGGGCCACAACAAACAAGACTGAGAGCATGTACTT ATCTTGCTTTTTCACCAACAGTGGTTTGGTTACCTAGTTTTATTCACTTAATTGTGCATGCTTACATAAACTTTAAA CTACATTTAAAACTAGCAAATCTGCATACCAAATTATGTATAACGTAGATTGAATTTTTATGAACTTAAAGTGAGTT AATTGTATAATGTAATATTGTTTAAAATATGTAAAAACCAAGCATTTCCGCTTGGTCCATAATTCTATTTGATATTT TAAAATTCTCATTTAAAAATTATATTGCTATCATTCAGCATGTGAAAATTTATTGATAAAATGTGATTTTAATATTT TTTAGATATAAACTTTCAACGTACTTCCATATGAGGATTATAATAGCCCTGCTTTATTAAAGACCATAAAATATTAA CTTTCCCCAAGATGTTATGGGTTCCAGTTCTTCTGATCATTTGATTCCTTTAATTACTGTCCCTCAATTTCTTCATC TTTACAATAGATATATTAACATTTACAGATCGACTATTTCCTTTAACCTCCTAGAAGAAAGTTTTTGTGGGGAAAGA TGATTCTGTATTATTCAGTAGCATAGACATTTTGCATATCAAAGATGTTCATTTGGCACTAATGTTGATTGAAATCA AATCCATCTGAGATGCCTAGCTCGTATTTGCATTCTGGAAGCCTCCATCGCAGGGGAGCTCGGCAGGGTATGTGAGC TTTGTTGGAGGTGCGGTGTTTCATTCTGCAGCTGTTGTGAGGACAGAGAGGCATGGCCCACAGGCAAAAAAAGTCAC CACCCAGAAGATGCTCTGGGATAGAGGAACTGCTCCTTTTCATCAGCTCTTCCAATGCCGTGGGAGAGGTGATCCCA GTCTTCTCTGTACATCTTGTGCTTTTCCATTAAGACTTGTTCCAGTGGGAAGGAGCTTTGGAAAAATTGCAAAGGTC TGAATCTTCAGGGCATTTTCATGACAGGACTTGCCAATAATAATAATAATAATAATAATAATAATAATAATAATAAA GCTCCAGAGGCCTAACTGGTTTCTCAAGTCATTTCAGTGATATCATTGAAACGTTTTTGTGGTACTTCCCTTTGTCT TTCACTGTTTCATTTTTATATTGCTTCATTTACTTCTTTGCTTTTGGCTTTGTTATTAGAAAAAATAATTATGAGGT CTGTTGTGCATGTTGACTGTGATATTAAGTTATGGCATGCCATTAAGTTTTCCAGACGATGTTGGATGTATCTGATT AGTTCATGTCATCTGTAAATACAATTCTTTTTTGTAGTACTTTGGAATGGAGCCTTTTTCTGGTGTACTGTATGCCA TTTAAGTTTCACATACAAGCTGCTTTCGGCAAAGGCTTGAATATTTATAAATTTCAGATGGTTATCCTCACTTTATA GTACACTTAAGTGGCTACCATATATTTTTTATATGACAATTGGCTGAATAGCTGATGTGTATGACACTTTTACACAG ATTTGCACTTTGGAACTATTTTATAGTTGTAATGCATCAATCAAATACATTTCAAGCACATTTCTTGATCAATTTAC CAGCAACCCTCTGAAGGAATGAAGGAGAGTTGTGATTGCTATGTCAATGAGTGAAATATACTTAAAAATGGCAGAGT TATATAGTACATTATTGTAGCAACCTTATATCTGATTTGAGATACTGTGTTGCCAAATGTCCATGTTATGTTTATTT CTCTATTGGTTGTATTTATTAATTTTTAGAAGCCTTTAAACTGTGTTAGAATCTTTTTGAAAAATGTTGATTTTGCA TCATAAAGTTTCAATTTATCAAGGATATCTTTTCAGTTACACTTTTAGAAAGAGTGAATAAAAAGGGCAGTGAGTTA TGCTCTTGGACTTGGTGAAAGCTATCATCTCTCCATATTGTATTTGTTCAGCTGGTTTAATTCACTCAGGTGGATGA TTGCACATACATTGGAATTGGCTGGAGAGACTACACAGAGAAGTTTAATGATCGTGTACAATTTGAGGGTTGATGGT AGGGCTTTCTAAAAAAAGTAATATCAAGTGTGTTGTTAGTATTCATTTAGTCATTTTTATTACTAATCTATAAATAT ATTTATTAAATTTGAAGATTAAATGGAATTATAAAGGAATATATTGGAGGAAGTGTCAGTGTTGGTAATTATTCATC TATTTATCTGTCTATCATCAATATATATGGGTGCATGTCTGTGTATATTTGTGTGTATGTAAGTGTGCATGTGTATT

ATATGTTTGGGTAGAAAGAGATACATTGAATGGTATAAATCAATATATTTGAGCTAAGCAAGTTAAAAAAAAATCAG

WO 2005/069724 PCT/IB2005/001306 606 TTATCTTTGGGAACAGCAATCTATTATTGTTGTTTCCCTGAGTGCCACTTTAACTGTTTCACTCAATGGATGGTGGT TTATTCAGTTCAACACGTAATTTGATTTCTATTTTCTTAAAAGTAACCATGTTGGACTTACAAAGAGACTTAGAATG TCAGAGGTGTTAGGCAGATATTGGATACCAGTAAAATTGGCTGGATATGTCTGAAGGTCGGTGGAATTGTGAGAAAG ACCAATGGTGATGGGGTTACATTGAAGAAAATATAAGATGAGCTAAATCAAAACCAGATTTGATTTTTTTGGGACTC CACCAGAAGTGGAAACTCATAAACAAGAGATGAAACAGAAAACTACATTTTTATTGATTGTATGAAGGAGTTAAATA TATGGAGACATTTCCTCAGTGATGATCAAGGGTAGGTGGGGAAATTCCAATAAGAATGTAGGATGACAATACCTTAG ATATGTTGAAAACCAAGGAGGATGGGGATATAGTATCTTTCGTATTATAATAAGCATAAAGTTAGCAAAGGGACATT TAATTTGGTTAGC <210> SEQ ID NO 202 <211> Length: 427 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 202 >Z25377 PEA 1 node 22 ATGGAATTTCTTCTCTCTGTTACTCAAGCCTCTCAAAGTCCTTATTGTCCCAGCCTCTGCGTGAAACGTCTTCAGCC ATCAATGACATCTCACTCCTTCAAGCCCTTATGCCACTGCTGGGATGGACCAGTCACTGGACCTGCATTACAGTGGG CTTATATTGACCTTTACCTCTACACTTGTATATAACTCGTTTTCCCATTTAGTTGCAAGACACTTGGAAGCACAGAC CAAGGCTTACATTTGTGTTTTAATGTTTTTCTTGTAAATGCTTTATGCCTAAATGTTTCTGTACTACTCTTCTTTCC AAATCCTTATTGTTTAAAAGTTTCTCTCCTACTATACCATGCCTTATAAATATTGATTGAATGAATGGATGAAATGC ATACCTGCTTATATTTCTAATTAAAGGCAATTTGGGATTATA <210> SEQ ID NO 203 <211> Length: 342 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 203 >Z25377 PEA 1 node 24 TTTCTGTGGGTCAAGAGTGTGGAAGTGGCTAAGCAGAATGAGTCCAGCTCAGAATCCCATGAGTCTGCTAATCAAGC TATTTTCTGGGGTTGCAATCATCTGAAGGCCCAGCTGGGGCTAAAGAACGCACTTTGCAGCTCGCTTTTTGCCTGGC TCAGAAGATCCATTTCCAGACTCACTTACACTGGCAGGCCTCAGTTCCTTGCCATGTGAATCACTGGGATGGGCTGC CTGGACCTCCTCAGGATACAGCAATTGCTAATAAAAGAGGTTTAAGGGGAACCAGAGAACTAGACGATAAAAGAAGT TGGCTAACATGAAAGCCCCACCTCCAACATTGGG <210> SEQ ID NO 204 <211> Length: 104 WO 2005/069724 PCT/IB2005/001306 607 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 204 >Z25377 PEA 1 node 0 AGAGAGGGGGCGGGTGCTACCTGGCAGCTCCGCGGGTGCGTGGCCGGTGCTGGCTGGGAGTTCTGGTCTCAGGCAAG GTGGGGACTGGGCACATCATCAATACG <210> SEQ ID NO 205 <211> Length: 95 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 205 >Z25377 PEA 1 node 7 ATAGAGAACGTCACTTTTCACCATGAAGGGTTCTTCTGGAGGTGTTGGTTTAATGGGATTGTGGAAGAGAATGACTC CAATATTTGGAAGTTCTG <210> SEQ ID NO 206 <211> Length: 5 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 206 >Z25377 PEA 1 node 8 GTACA <210> SEQ ID NO 207 <211> Length: 99 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 207 >Z25377 PEA 1 node 10 CCAATCAGCCACCGTCCAAGAACTGCACACATGCTTACCTGTCTCCGTACCCCTTCATGAGAGGCGAGCACAACTCG ACCTCCTATGACTCTGCAGTTA <210> SEQ ID NO 208 WO 2005/069724 PCT/IB2005/001306 608 <211> Length: 110 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 208 >Z25377 PEA 1 node 20 GAATCTAGAAGATGGGGGGATGGAAGTGAAGTGGAATGTAAAAACGTCTGCCAGTGCCCCATGGTCTCCAACCCACT TTCAGATGCACCGTCTCATTTCAACAGATATAG <210> SEQ ID NO 209 <211> Length: 328 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 209 >HSACMHCP PEA 1 node 2 GCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGCTAAGGTGGAGAAGCTGCGCTCAGAC CTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGAA CAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCACTGCCG CGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCGAGCAGATCGACAACCTGCAGCGGGTGAAGCAG AAGCTGGAGAAGGAGAAGAG <210> SEQ ID NO 210 <211> Length: 214 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 210 >HSACMHCP PEA 1 node 20 GGGAAGCACCAAGATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGG AGCGTCTAGAGGCCCAGACCCGGCCCTTTGACATTCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTC AAAGCCAAGATTTTGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAG <210> SEQ ID NO 211 <211> Length: 122 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 609 <400> sequence: 211 >HSACMHCP PEA 1 node 22 ACGGTGACTGTGAAGGAGGACCAGGTGTTGCAGCAGAACCCACCCAAGTTCGACAAGATTGAGGACATGGCCATGCT GACCTTCCTGCACGAGCCCGCGGTGCTTTTCAACCTCAAGGAGCG <210> SEQ ID NO 212 <211> Length: 157 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 212 >HSACMHCP PEA 1 node 25 ACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACAAGTGGCTGCCGGTGTACAATGCCGAAGTGGTGGCCGC CTACAGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATCTTCTCCATCTCCGACAACGCCTATCAGTACATGCTGA CAG <210> SEQ ID NO 213 <211> Length: 269 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 213 >HSACMHCP PEA 1 node 43 ATGCTGACAAGTCGGCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAA GTGGGCAACGAGTATGTCACCAAGGGGCAGAGCGTGCAGCAGGTGTACTACTCCATCGGGGCTCTGGCCAAGGCAGT GTATGAGAAGATGTTCAACTGGATGGTGACGCGCATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCA TAGGAGTCCTGGACATCGCTGGCTTCGAGATCTTCGAC <210> SEQ ID NO 214 <211> Length: 171 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 214 >HSACMHCP PEA 1 node 45 TTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCAGTTCTTCAACCACCACATGTTCGT GCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACTTTGGCATGGACCTGCAGGCCTGCA

TTGACCTCATCGAGAAG

WO 2005/069724 PCT/IB2005/001306 610 <210> SEQ ID NO 215 <211> Length: 819 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 215 >HSACMHCP PEA 1 node 46 GTGCCTCCTTGGCCTCACCACCTATGCCCCCTCCTCTGCCATCCAGACAAAGTGGTGGCTGAGTCCCTTCTACACCC AAGAAACTAGAGTCCCAAGAATCCCAGGCCTTTCTCCAGGCCCAGCTTCTCCCCACTGTGAAGTCATGGGCATGAAC AGGATGATCCCCCCACTCTTCCTTTCCCAGGACCTTGCACTTTATGCCCCTTTGTGGTGGTCCCCTCAGTGTCTTAA GAGTGAGATGTAGTGAAGGAGAGGCCCCTGGCCCCTCTGACCGCCCATGAGAAGCGTCATTCATGGAAAGATCCTAG GCTGAAATTAGAGATGTTTGGCCTCCCACCACCTTCCTGTTGGTTGAGAAATAAGCCAGTCTCCAGCCCTCTTGCTT ATGGGCATTCCTCAGAAGAGACAAGGCCGCAGGCGGGAGGCCCCATAGGCCGGGGCTGACTTGCTCTCAGTGAACCT CTGCTCTTTGTCAGCATAGGCCAGAGCCCGGATTGTCTGACCCACACCCAGCCCAGCCACGGCCTTCATGAAATGGG AGCTTCCCCACATGCTTTGGGTCATTATCCAGATTCTTAACCAGAGTTCTCATGTTTCAGAGCCCTCAGAATGCCAT AAAACTGTGTGTGGAAAAAAGCATGTGTACATTCATACATACATGTGTGTGCTTGTGCATGTGTGTGTGTGTACGTG TGTGTGTGTACATGCGTTTTTCTGGAGAGACAGTCTTTAGCTTCAACAAATTCTTAAAAGGATTCCTGCCCCAAGAA AAATCAAGAACCACCAGGTTTTTGGAAGTGCAGAGTGTGGTAAAGAACC <210> SEQ ID NO 216 <211> Length: 132 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 216 >HSACMHCP PEA 1 node 48 GTACCAGCACAGCGCCCCTTCAGCAGGCCAGCGCTACTGGCTCCAGATTCCTTTTCCTGTCAGGGTATGGGACTGTG GAAGCCTGGGAGTGTGCTCAGTGATTCTCTCTTTGCCTCTTCACCCTGCCCTCAG <210> SEQ ID NO 217 <211> Length: 310 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 217 >HSACMHCP PEA 1 node 49

CCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGCATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCT

WO 2005/069724 PCT/IB2005/001306 611 GTACGACAACCACCTGGGCAAGTCCAACAATTTCCAGAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCT CCCTGATCCACTACGCCGGCACTGTGGACTACAACATCCTGGGCTGGCTGGAAAAAAACAAGGATCCTCTCAACGAG ACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAGCTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATAC TG <210> SEQ ID NO 218 <211> Length: 124 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 218 >HSACMHCP PEA 1 node 57 GTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTTCATTGATAGCAGGAAGGGGACAGAGAAGCTGCTCA GCTCTCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAG <210> SEQ ID NO 219 <211> Length: 137 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 219 >HSACMHCP PEA 1 node 59 GTGTTCTTCAAGGCAGGGCTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCAT GCAGGCCCAAGCCCGGGGCCAGCTCATGCGCATTGAGTTCAAGAAGATAGTGGAACGCAG <210> SEQ ID NO 220 <211> Length: 256 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 220 >HSACMHCP PEA 1 node 61 GGATGCCCTGCTGGTAATCCAGTGGAACATTCGGGCCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACT TCAAGATCAAGCCGCTGCTGAAGAGCGCAGAGACGGAGAAGGAGATGGCCACCATGAAGGAAGAGTTCGGGCGCATC AAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAAGGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAA TGACCTGCAGCTCCAAGTGCAGGCG <210> SEQ ID NO 221 WO 2005/069724 PCT/IB2005/001306 612 <211> Length: 243 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 221 >HSACMHCP PEA 1 node 63 GAACAAGACAACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATTCAGCTGGAGGCCAAAGT AAAGGAGATGAATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGCTGGAAG ACGAGTGCTCAGAGCTCAAGAAGGACATTGATGACCTGGAGCTGACACTGGCCAAGGTGGAGAAGGAGAAGCATGCA ACAGAGAACAAG <210> SEQ ID NO 222 <211> Length: 177 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 222 >HSACMHCP PEA 1 node 65 GTGAAGAACCTAACAGAGGAGATGGCTGGGCTGGATGAAATCATCGCTAAGCTGACCAAGGAGAAGAAAGCTCTACA AGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGTCA AGCTGGAGCAGCAGGTGGATGAT <210> SEQ ID NO 223 <211> Length: 146 <212> Type: DNA <213> ORGANISM: Homo sapiens >HSACMHCP PEA 1 node 67 CTGGAGGGATCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAGCAAAGCGGAAACTGGAGGGCGACCT GAAGCTGACCCAGGAGAGCATCATGGACCTGGAAAATGATAAACTGCAGCTGGAAGAAAAGCTTAAGAA <210> SEQ ID NO 224 <211> Length: 270 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 224 >HSACMHCP PEA 1 node 71

GCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGGCTAAGGTGGAGAAGCTGCGCTCAGA

WO 2005/069724 PCT/IB2005/001306 613 CCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGA ACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCACTGCC GCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAG <210> SEQ ID NO 225 <211> Length: 337 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 225 >HSACMHCP PEA 1 node 81 GTGAGGCCCAGTGGGGAGGGTGGGCAGGCTTGATGGCAGCCCTGGGGCAATTCATCTCAGTGCCAGAAATGGAGCCT GGAGCTGGAAAGAGTCCTCTGCAAGGGAAAGACCCTCCAGTCTAGGTTCTGCCCTGCAGCTAAGCGTCATTTAATGC CTCTTTTCTTATTCGTAAGGGGATGGGGTGAGCAGACTGGGAAACTCCTCAAACAGTGAGGTGCCACATCAGCCCAC ATGGTGAATAAGGCTGGGCTTGGTTGAAGTACTACATAAGAAGAGAATCTAGAGAATGGGGCACAGGGAGTCCCTCC CACCTCCTGGTGCCCCCCCCCCTCCCCAG <210> SEQ ID NO 226 <211> Length: 184 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 226 >HSACMHCP PEA 1 node 87 AAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTCACTGGAGA AGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGACGTAGAGCGCTCCAATGCTTGCGCTGCAGCC CTGGACAAGAAGCAGAGAAACTTTGACAAG <210> SEQ ID NO 227 <211> Length: 189 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 227 >HSACMHCP PEA 1 node 89 ATCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCT CAGCACAGAGCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACA

AGAACCTTCAGG

WO 2005/069724 PCT/IB2005/001306 614 <210> SEQ ID NO 228 <211> Length: 135 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 228 >HSACMHCP PEA 1 node 96 GAGGAGGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAA GGACGAGGAGATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGACTCGCTGCAG <210> SEQ ID NO 229 <211> Length: 129 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 229 >HSACMHCP PEA 1 node 97 ACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGACCTCAATGA GATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAAG <210> SEQ ID NO 230 <211> Length: 204 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 230 >HSACMHCP PEA 1 node 100 GACACCCAGATCCAGCTGGACGATGCGGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCG CAACAACCTGCTGCAGGCTGAGCTGGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAAGCTGGCGG AGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCATTCCCAG <210> SEQ ID NO 231 <211> Length: 198 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 231 WO 2005/069724 PCT/IB2005/001306 615 >HSACMHCP PEA 1 node 105 GTAAGTGACCGCCCACCTTCCGCCTCCCCTAAAGACAGAAACAAGGCCTTGGGTCCAGGCCAGGCCACTGTGCTGTA ACACCAAGCCAACTCTGCAGTTCTGTGGATTTGAGGGCCTGATGGGAGAAAGGAGATCCTTGGGGGGCAAAAGGCCC CGGCCCCTGGCCCATGTTCCTTGCCACCTCTCTCCTGCACACAG <210> SEQ ID NO 232 <211> Length: 276 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 232 >HSACMHCP PEA 1 node 106 GCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGA GCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGATCGCCCTCAAGGGAGGCAAGAAGCAGCTGC AGAAGCTGGAAGCGCGGGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAG GGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAG <210> SEQ ID NO 233 <211> Length: 224 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 233 >HSACMHCP PEA 1 node 107 GTGCGGCGGACGCCAGACACCGGGAGTAGATGTGGAAGTTTCTTCTCTGGCCCCACTGCCCCGCCCTCACAGGGCTC CTCTCACCTCCTCCTTGAGATGCTGTTGGTAGATTTAACGTTCTTCTCACGCTCTGCAGTCAGTTTGACTTGAGTCT ATGAGTTTTTCCAGCAAATGAAGAATCTACTTCTACTTCCTGAAAACTCTTCTAACTAGTCTTTCCCCAG <210> SEQ ID NO 234 <211> Length: 897 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 234 >HSACMHCP PEA 1 node 108 GTTTCTTTCTTTCTTTTTTTTTTTTTTTAATAACTCTAAGTGCTACCATGAAGACTTCAGAACAGTTCAAAGAATCC TTCCACCTTCGACTGTGGGGATAAGAGTCAGGGGAGGGGAAAAGACCCGGAAATCTTCCATAGAACTTCTGGCACAC

AAAGAGAAGGCCACAGAGAAAGAGGACCCTAGAATGCTCTAAAACCTCCACTTGCATAGCTGAGAGCTGTGCCCTTG

WO 2005/069724 PCT/IB2005/001306 616 GCCCGTTATTTTCAGTGTACCTGGGAAGAAAAGGCCAAGGAGACGAGGGTGTCAGTCCATTTGATAGATGGATACCA GAGGCACAAGAAAGAGGTTACAGATACAGAACCACAGAGTGATTTGTGGACAGAAGTAGAAATGGCATCCTGGCACA TACAATGATAAAGAGATAGGAATGATCGAGTGACGTTGGAGCCAGTGATCCCGATGCCTGAATTCTGGCCCAGTACA ATATATTAGAATGTAGAATAATCTGGATTATGATAATACCCCCTTCTTTCTGCATTCTTTTTCTGGTCAAGAACTAC TGGCCAAGAGAACCTATGTAAGTCCAGGTTGGAGCTTTATCCACCATACTGGAGCTGGAACAGACCTGGTGCTTTTA TATTACCACATTAGGGAATTCCATTAGGTTCTGAGCCCCTCCCCCTACTTCTAGCTTTATGACTTCAGCCTTCATTG CTCTGTGGATCCCTGACTGACAACCTTGCATTGCCCCTTTGACCTACGATAGAGTCAGAGAATCTTCCCCACCACCT CTTTGACCTGGATCATTGCAGGGAGGGGCAGCAAAGGCAAGGGGAGAAGAGTAAAATGATGGAGGAGGGAAAGGTGA TTGCATTTGCTCCCCCTCCAAACCAGCTTCTCCCACCCTCCCACCCCCAG <210> SEQ ID NO 235 <211> Length: 135 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 235 >HSACMHCP PEA 1 node 111 GAGGAGCAAGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGA CATCGCTGAGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAG <210> SEQ ID NO 236 <211> Length: 1,927 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 236 >HSACMHCP PEA 1 node 113 CAAAAAATGCACGATGAGGAGTGACACTGCCTCGGGAACCTCACTCTTGCCAACCTGTAATAAATATGAGTGCCAAA CTCTGCCTGAGCCCATCTGTCCTTCCTGCCAGCTGTCCATCCTGGATCAGGGCAGTAGGGGGCCTGAGAGGAGGGAG GCCCCCAGCCCCTGTATCAGAGCTGCCAGAGCCAAGGCATCCCATATCCACAAGGAAGGAGACCGAGGTGCAGAGGA GTGAGGTGTTCTGCCTGACGTGGACAGCTGTGAGTCCCAGTTCTGCTCAGTCAACCACACAAGGGTGGAGAGGGAGA AATTTCAAAAGTGAAGAAAACAATGGCATCAAAATGGTGAGCCAGTCCAAGATGCTACGAGATAGAATTTTGGTGCC GAAGTTGAAGCCACTCTCCACCTACCCCACCCCTGAGGCTGCAATGATTAAAGGTGTCCTAGGACACCCATTCTTTC TGAAATGAATTTTCCACCAATGCCAGAAAAGGCTCAGAGCTGGCTGAGAATTAAGGTATGGGAAAGGAGATGGGAGA GATTCCATTCTAGTCAGCCCCTAGGAAGTAACTCCCAGGGAGCCCCCTCCCTGTCTTCCCCAGGGGTCTCCCCCTGC CTCCTATGATTCAGCACCTCACCGTGAGGGCATCTTGAGACTCTGGGGCCAATCAACACTGAGCCCAAACCAATATG CCATGAGGACCAAGCCTGGGCATTGCTCATTTCATGTTGGTTCTCACACAGACACAGATGGCACAGGTGCCTGTACA

GGGAAACACTGTGGTCACATTTCTGCTCTCTCTAAGCTCCTACTGGGGACAGTCTGGCCTGGATCACACAGCTGCTT

WO 2005/069724 PCT/IB2005/001306 617 GTGGGACAGGCCCGGTCCTGACCCCGTTCTGCACAAAGCAAATCCCCACTCCCCACTGGGCTTTGCAGCCAGGCTCT GCTGACCGCCTCCTTAACCGTTCACCTGGCACCCCATCTCCCTGACTCCCCAAGTGGAGCCTCTTCTATCCCTCCTC TGAGACCATGAGAATGGACTGTGCATAAAGCCCTGAGAAATGTGAGCAGTGACCAGAGAAACACAAAATCCTGTTGG TTCTAGCCCAGGAGAGGCTGCCAGTTCTGATGGTGAGCCAGGACACAAGGATAGGAGAACAGGAAGCAGGAGGCAGG AAAAAGACCAAGAGAGAGGAGTGGCTGCCACCAAGGAAGCAGAGCGCTCTGACCAGAGTTCAAGATCCAGGGTTCGG GCAGGACTTGGGAGCTGGGGCCTGCAGCTGGAAGGAGCGCTCCAGAAGAAGGATTGTATCTCAGGGCGGGAACACAC ACACATCAGCGACAGGAGATAGCACGTCAGCTGGGATGGAGCTGCTGAGCCAGGCCATGCTGGGCTCCTCGGGCTGG GCAGGAACGTCTGGCTGCACATCTGTCTGTCTCGGCCCAGCAGGGCTGACTCCCGGGCTGTGGCAGTGTCTGCTCCA AACTCCCCTGGGCCTTCCCATAGCATTCACTGTGGGGAGCTCTTGACCAGCTTGTCTCTTTCCCAGCCTGTGAGTGC TAAAGGGCAGGCCCCCCGTCACCTCTGAGGCCCTGGCACCCAGCACAGTGTGCATGGGAGATGCTCAGGAAATGTGT GCTGAGGAGCTGGCAAGCTGGGAGGGTGGACCCGCAGTGGAGGGAAGAGTTGGCCATTCTTTTCTGAGCTACAAGGA GGCTCAGTACAGTATCCAGAACACTCGCTTAGGTGTCAGAAGAGCTGCGTTCTGGCCCTAGCTTGTCACAAATGAG TTCACCTCCCCTGGCTGGGCCTGTTTTCTCTTATGTGAAATGAGGGCATTGGACCAGCTGATAATCAACGGCTCTCC CAGCATTCGCATTTTGGGAAATCTCTCCCTCCTCTGATACCTCAGGCTGCCCTCTCCCTGCCTCCTGTTCCTGTCAT AG <210> SEQ ID NO 237 <211> Length: 21 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 237 >HSACMHCP PEA 1 node 0 CCTATCAGTACATGCTGACAG <210> SEQ ID NO 238 <211> Length: 46 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 238 >HSACMHCP PEA 1 node 3 CGAGTTCAAGCTGGAGCTGGATGACGTCACCTCCAACATGGAGCAG <210> SEQ ID NO 239 <211> Length: 15 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 618 <400> sequence: 239 >HSACMHCP PEA 1 node 4 ATCATCAAGGCCAAG <210> SEQ ID NO 240 <211> Length: 31 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 240 >HSACMHCP PEA 1 node 16 GAGGACAGATAGAGAGACTCCTGCGGCCCAG <210> SEQ ID NO 241 <211> Length: 33 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 241 >HSACMHCP PEA 1 node 18 ATTCTTCAGGATTCTCCGTGAAGGGATAACCAG <210> SEQ ID NO 242 <211> Length: 22 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 242 >HSACMHCP PEA 1 node 23 CTACGCGGCCTGGATGATATAT <210> SEQ ID NO 243 <211> Length: 28 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 243 >HSACMHCP PEA 1 node 27 WO 2005/069724 PCT/IB2005/001306 619 ATCGGGAGAACCAGTCCATCCTCATCAC <210> SEQ ID NO 244 <211> Length: 112 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 244 >HSACMHCP PEA 1 node 29 GGGAGAATCCGGGGCGGGGAAGACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTG ACCGTGGCAAGAAGGACAATGCCAATGCGAACAAG <210> SEQ ID NO 245 <211> Length: 93 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 245 >HSACMHCP PEA 1 node 31 GGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCCTTCGGCAATGCCAAGACTGTCCGGAAtGA CAACTCCTCCCGCTTT <210> SEQ ID NO 246 <211> Length: 64 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 246 >HSACMHCP PEA 1 node 33 GGGAAATTCATTAGGATCCACTTTGGGGCCACTGGAAAGCTGGCTTCTGCAGACATAGAGACCT <210> SEQ ID NO 247 <211> Length: 99 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 247 >HSACMHCP PEA 1 node 35

ACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAAACTACCACATCTTCTACCAGATTCTGTCC

WO 2005/069724 PCT/IB2005/001306 620 AACAAGAAGCCGGAGTTGCTGG <210> SEQ ID NO 248 <211> Length: 104 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 248 >HSACMHCP PEA 1 node 37 ACATGCTGCTGGTCACCAACAATCCCTACGACTACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGAT GACTCCGAGGAGCTCATGGCCACCGAT <210> SEQ ID NO 249 <211> Length: 117 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 249 >HSACMHCP PEA 1 node 39 AGTGCCTTTGACGTGCTGGGCTTCACTTCAGAGGAGAAAGCTGGCGTCTACAAGCTGACGGGAGCCATCATGCACTA CGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAG <210> SEQ ID NO 250 <211> Length: 22 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 250 >HSACMHCP PEA 1 node 40 GCGGAGCCAGACGGCACCGAAG <210> SEQ ID NO 251 <211> Length: 71 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 251 >HSACMHCP PEA 1 node 51 WO 2005/069724 PCT/IB2005/001306 621 GGGACAGTGGTAAAAGCAAAGGAGGCAAGAAAAAGGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGG <210> SEQ ID NO 252 <211> Length: 88 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 252 >HSACMHCP PEA 1 node 53 GAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCCATCCTCACTTTGTGCGTTGCATCATCCCCAATGAGCG GAAGGCTCCAG <210> SEQ ID NO 253 <211> Length: 118 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 253 >HSACMHCP PEA 1 node 55 GGGTGATGGACAACCCCCTGGTCATGCACCAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAG GGCTTCCCCAACCGCATCCTCTACGGGGACTTCCGGCAGAG <210> SEQ ID NO 254 <211> Length: 91 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 254 >HSACMHCP PEA 1 node 69 GAAGGAGTTTGACATTAATCAGCAGAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCTTCAACTACAGAAGAAAC TGAAGGAAAACCAG <210> SEQ ID NO 255 <211> Length: 12 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 255 >HSACMHCP PEA 1 node 72 WO 2005/069724 PCT/IB2005/001306 622 CTGGGCGAGCAG <210> SEQ ID NO 256 <211> Length: 30 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 256 >HSACMHCP PEA 1 node 73 ATCGACAACCTGCAGCGGGTGAAGCAGAAG <210> SEQ ID NO 257 <211> Length: 78 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 257 >HSACMHCP PEA 1 node 74 CTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGACGTCACCTCCAACATGGAGCAGATCATCAAGGCCAA G <210> SEQ ID NO 258 <211> Length: 102 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 258 >HSACMHCP PEA 1 node 77 GCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGCCAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAACG CTCCCTCAATGATTTCACCACCCAG <210> SEQ ID NO 259 <211> Length: 25 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 259 >HSACMHCP PEA 1 node 78 WO 2005/069724 PCT/IB2005/001306 623 CGAGCCAAGCTGCAGACCGAGAATG <210> SEQ ID NO 260 <211> Length: 119 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 260 >HSACMHCP PEA 1 node 80 GAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCCGGGGGAAGCTCTCTTATACCCAG CAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAG <210> SEQ ID NO 261 <211> Length: 24 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 261 >HSACMHCP PEA 1 node 82 GCGAAGAACGCCCTGGCCCATGCA <210> SEQ ID NO 262 <211> Length: 66 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 262 >HSACMHCP PEA 1 node 83 CTGCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAG <210> SEQ ID NO 263 <211> Length: 72 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 263 >HSACMHCP PEA 1 node 84

GCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGAC

WO 2005/069724 PCT/IB2005/001306 624 <210> SEQ ID NO 264 <211> Length: 35 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 264 >HSACMHCP PEA 1 node 85 GCCATTCAGCGGACTGAGGAGCTCGAAGAGGCCAA <210> SEQ ID NO 265 <211> Length: 104 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 265 >HSACMHCP PEA 1 node 90 GTGTGCTGGGGGTCCAAGAGGCCAGAGATGAGTTGGTGGGAGGGAGGGCCATGCAGGGGCAGGGGGAACATAGGCTT TGAGCTTTCTGGCCCTCTGGTCCCCAG <210> SEQ ID NO 266 <211> Length: 77 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 266 >HSACMHCP PEA 1 node 91 AGGAAATCTCGGACCTTACTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAG <210> SEQ ID NO 267 <211> Length: 21 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 267 >HSACMHCP PEA 1 node 92

CTGGAGGTGGAGAAGCTGGAG

WO 2005/069724 PCT/IB2005/001306 625 <210> SEQ ID NO 268 <211> Length: 27 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 268 >HSACMHCP PEA 1 node 93 CTGCAGTCAGCCCTGGAGGAGGCAGAG <210> SEQ ID NO 269 <211> Length: 15 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 269 >HSACMHCP PEA 1 node 95 GCCTCCCTGGAGCAC <210> SEQ ID NO 270 <211> Length: 30 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 270 >HSACMHCP PEA 1 node 98 CAAGTCAAGAGCCTCCAGAGCTTGCTGAAG <210> SEQ ID NO 271 <211> Length: 57 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 271 >HSACMHCP PEA 1 node 103 AACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAG <210> SEQ ID NO 272 <211> Length: 69 WO 2005/069724 PCT/IB2005/001306 626 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 272 >HSACMHCP PEA 1 node 104 TCGGAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGAT <210> SEQ ID NO 273 <211> Length: 96 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 273 >HSACMHCP PEA 1 node 109 ACAGAGGAAGACAAAAAGAACCTGCTGCGGCTACAGGACCTGGTGGACAAGCTGCAACTGAAGGTCAAGGCCTACAA GCGCCAGGCCGAGGAGGCG <210> SEQ ID NO 274 <211> Length: 20 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 274>S67314 segl5R Reverse primer GCCAACTCTCAGCTCCTCCC <210> SEQ ID NO 275 <211> Length: 101 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 275>S67314 segl5 Amplicon TTCCTTGGCATCTCCAATGGAGTAGAGAGAAGGCAACAAAGCTTCTCAGACCCACATTACCGAGCTATAACAACCAT GGCTGGGAGGAGCTGAGAGTTGGC<210> SEQ ID NO 276 <211> Length: 21 <212> Type: DNA <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 627 <400> sequence: 276>Forward primer S67314seg4F CCAAGCCTACCACAATCATCG <210> SEQ ID NO 277 <211> Length: 21 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 277>Reverse primer S67314seg4R CTCCACCCCCAACTTAAAGCT <210> SEQ ID NO 278 <211> Length: 101 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 278>Amplicon S67314seg4: CCAAGCCTACCACAATCATCGAAAAGAATGGGGACATTCTCACCCTAAAAACACACAGCACCTTCAAGAACACAGAG ATCAGCTTTAAGTTGGGGGTGGAG<210> SEQ ID NO 279 <211> Length: 22 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 279>N56180 seg6F ATATCCCAGTGGTGGTTGCATT <210> SEQ ID NO 280 <211> Length: 17 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 280>N56180 seg6R CCCTCCCAGCGTTTCC <210> SEQ ID NO 281 <211> Length: 215 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 281 WO 2005/069724 PCT/IB2005/001306 628 >S67314 PEA 1 P4 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTAD DRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILVRWATLELYLIGYYYCSFSQACSKKPSPPLRAVEAGTR EWLWVRVVSGGNFLCSGFGLTQAGTQILPYRLHDCGQITFSKCNCKTGINNTNLVGLLGSL <210> SEQ ID NO 282 <211> Length: 178 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 282 >S67314 PEA 1 P5 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTAD DRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILDVLTAWPSIYRRQVKVLREDEITILPWHLQWSREKATK LLRPTLPSYNNHGWEELRVGKSIV <210> SEQ ID NO 283 <211> Length: 126 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 283 >S67314 PEA 1 P6 MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTAD DRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILMEKLQLRNVK <210> SEQ ID NO 284 <211> Length: 144 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 284 >S67314 PEA 1 P7 MVDAFLGTWKLVDSKNFDDYMKSLAHILITFPLPSGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFK LGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA <210> SEQ ID NO 285 <211> Length: 240 WO 2005/069724 PCT/IB2005/001306 629 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 285 >N56180 P2 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVL ELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLE VQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVLWLTPVIPTLWEADGGGLHEPWSWRPAW ATWLQRNYL <210> SEQ ID NO 286 <211> Length: 446 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 286 >N56180 P4 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVL EHWQISQWWLHFQTPREEGKMKLLELSESADGAAWKRWGGNSNTHRIQLVAQVLEHKAIGFVMVDAKKEAKLAKKLG FDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEE AAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETW EDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTD ADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE <210> SEQ ID NO 287 <211> Length: 337 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 287 >N56180 P5 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVL ELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDVAKKLSLKMNEVDF YEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVAR DNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKI NTEDDDEDDDDDDNSDEEDNDDSDDDDDE <210> SEQ ID NO 288 WO 2005/069724 PCT/IB2005/001306 630 <211> Length: 321 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 288 >N56180 P6 NETEAEQSYVRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVL EHKAIGFVMVDAKKEAKLAKKLDYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPIAIPNKPY TEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPD DFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSD EEDNDDSDDDDDE <210> SEQ ID NO 289 <211> Length: 212 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 289 >N56180 P7 MSSWLSAGSPSSLSVVAKKLSLKMNEVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDD LNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADS VWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE <210> SEQ ID NO 290 <211> Length: 133 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 290 >N56180 P8 MCRGYSTLLNPVSDGYEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVW MEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDDDDDDNSDEEDNDDSDDDDDE <210> SEQ ID NO 291 <211> Length: 252 <212> Type: PRT <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 631 <400> sequence: 291 >N56180 P9 MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVL ELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLE VQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPIAIPNKP YTEEELVEFVKEHQRSRNWTQ <210> SEQ ID NO 292 <211> Length: 451 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 292 >T10377 P2 MEISLVKCSEANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGW STSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQSSALDRFNAMNSALAS DSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMREMTKKLY SQYEEKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIGELDRLIERMEKERHQLQLQLLEH ETEMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEG ENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNYTPYTRVLELTMKKTLT <210> SEQ ID NO 293 <211> Length: 438 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 293 >T10377 P5 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGVVR RSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQS SALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQ EANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIGELDRLIER MEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEENNELQSRLDYLT ETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNYTPYTRVLELTMKKTLT <210> SEQ ID NO 294 <211> Length: 407 <212> Type: PRT WO 2005/069724 PCT/IB2005/001306 632 <213> ORGANISM: Homo sapiens <400> sequence: 294 >T10377 P6 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGVVR RSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQS SALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQ EANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIGELDRLIER MEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQ LLILQLLEKISFLEGEPNRQDS <210> SEQ ID NO 295 <211> Length: 390 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 295 >T10377 P7 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGVVR RSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQS SALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQ EANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIGELDRLIER MEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIMSHELFSRFSL RLFGR <210> SEQ ID NO 296 <211> Length: 466 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 296 >T10377 P8 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSNGEPTRKLPQGVVYGVVR RSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYGDYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQS SALDRFNAMNSALASDSIGLQKTLVDVTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQ EANAEVMREMTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFLKAIEEANKKMQAAEISLEEKDQRIGELDRLIER MEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLRERIRHLDDMVHCQQKKVKQMVEEIESLKKKLQQKQ

LLILQLLEKISFLEGENNELQSRLDYLTETQAKTEVETREIGVGCDLLPSQTGRTREIVMPSRNYTPYTRVLELTMK

WO 2005/069724 PCT/IB2005/001306 633 KTLT <210> SEQ ID NO 297 <211> Length: 145 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 297 >Z24874 PEA 2 P5 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLESLDMEAMLDTVQAWLSSPQ KFARAHGVSVQPEASDTHILLLEGFLLYSYKPLVDLYSRRYFLTVPYEECKWRRSLPGRHEVPRGALP <210> SEQ ID NO 298 <211> Length: 121 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 298 >Z24874 PEA 2 P6 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLESLDMEAMLDTVQAWLSSPQ KFARAHGVSVQPEASDTHILLLEGFLLYSYNLPGRHEVPRGALP <210> SEQ ID NO 299 <211> Length: 101 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 299 >HUMCDDANF P2 MPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKLRALLTAPRSLRR SSCFGGRMDRIGAQSGLGCNSFRY <210> SEQ ID NO 300 <211> Length: 118 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 300 WO 2005/069724 PCT/IB2005/001306 634 >HUMCDDANF P3 MSSFSTTTNLLDHLEEKMPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRGPWDSSDRSAL LKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY <210> SEQ ID NO 301 <211> Length: 137 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 301 >HUMTROPIA PEA 2 PS MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALS TRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEVGRMGSSGTFGVG <210> SEQ ID NO 302 <211> Length: 182 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 302 >HUMTROPIA PEA 2 P12 MADGSSDAKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLHARVD KVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVRISADAMMQALLGARAKESLDLRAHLKQVKKEDTE KENREVGDWRKNIDALSGMEGRKKKFES <210> SEQ ID NO 303 <211> Length: 85 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 303 >HUMTROPIA PEA 2 Pl7 MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKVGRGFLGAEYRRRRDPRPWEWGEEPGLRRGRGLRGGASGAE FCRGSCSDW <210> SEQ ID NO 304 <211> Length: 13 <212> Type: PRT WO 2005/069724 PCT/IB2005/001306 635 <213> ORGANISM: Homo sapiens <400> sequence: 304 >HUMTROPIA PEA 2 P18 MADGSSDAVRAAG <210> SEQ ID NO 305 <211> Length: 387 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 305 >HUMSMCK P4 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPAIYAKLR NKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQ FDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKP VSPLLTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQERGWEFMWN ERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLRLQKRGTGGVDTAAVADVYDISNIDRIGRSEVTSLS LS <210> SEQ ID NO 306 <211> Length: 346 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 306 >HUMSMCK P5 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPAIYAKLR NKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQ FDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKP VSPLLTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQERGWEFMWN ERLGYILTCPSNLGTGLRAGVHVRIPKLSKVLLCAQWP <210> SEQ ID NO 307 <211> Length: 224 <212> Type: PRT <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 636 <400> sequence: 307 >HUMSMCK P6 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPAIYAKLR NKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQ FDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDA <210> SEQ ID NO 308 <211> Length: 304 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 308 >HUMSMCK P8 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPAIYAKLR NKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQ FDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKP VSPLLTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVRCYLRFLDIY <210> SEQ ID NO 309 <211> Length: 708 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 309 >H88495 PEA 3 P15 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTE NGHHFWSHPDREKEDEDVAKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPS HRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGH HHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDD DVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMS HHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEED KEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQ EYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQVRPHLTLKAPLGLRMHRDPLRTPSPKSWPLTQPLTP DATLTPQAILTPTLT <210> SEQ ID NO 310 <211> Length: 685 WO 2005/069724 PCT/IB2005/001306 637 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 310 >H88495 PEA 3 Pl6 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTE NGHHFWSHPDREKEDEDVAKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPS HRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGH HHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDD DVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMS HHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEED KEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQ EYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQFCYLCPLVCETVCAPGEHGRGPGKT <210> SEQ ID NO 311 <211> Length: 696 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 311 >H88495 PEA 3 Pl7 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTE NGHHFWSHPDREKEDEDVAKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPS HRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGH HHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDD DVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMS HHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEED KEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQ EYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQGPGRHAGNAGTLTQSLDCDAGVPPPAFQPLSTSYIY FSE <210> SEQ ID NO 312 <211> Length: 613 <212> Type: PRT <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 638 <400> sequence: 312 >H88495 PEA 3 P18 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNNTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTE NGHHFWSHPDREKEDEDVAKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPS HRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGH HHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDD DVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMS HHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEED KEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTAMH <210> SEQ ID NO 313 <211> Length: 283 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 313 >Z36249 PEA 3 P2 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGEQQWKSEKQREAELKKKKLEQ RSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIIYKRTALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAI HWASRGGNLDVLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDREGDTPLHDAVRLNRYKM IRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTKAIFDSLRENSYKTSRIATF <210> SEQ ID NO 314 <211> Length: 197 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 314 >Z36249 PEA 3 P3 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGEQQWKSEKQREAELKKKKLEQ RSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDEYKR TALHRACLEGHLAIVEKLMEAGAQIEFRDMVNIFLCLGMSQKK <210> SEQ ID NO 315 <211> Length: 177 <212> Type: PRT WO 2005/069724 PCT/IB2005/001306 639 <213> ORGANISM: Homo sapiens <400> sequence: 315 >Z36249 PEA 3 P4 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGEQQWKSEKQREAELKKKKLEQ RSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDEVRL MQSTAKSSSLILCFLCFTPVLLI <210> SEQ ID NO 316 <211> Length: 286 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 316 >Z36249 PEA 3 P5 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGEQQWKSEKQREAELKKKKLEQ RSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDELES TAIHWASRGGNLDVLKLLLNKGAKISARDKLLSTALHVAVRTGHYECAEHLIACEADLNAKDREGDTPLHDAVRLNR YKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTKAIFDSLRENSYKTSRIATF <210> SEQ ID NO 317 <211> Length: 158 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 317 >Z25377 PEA 1 Pl2 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRCWFNGIVEENDSNIWKFWY TNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYI AAGI <210> SEQ ID NO 318 <211> Length: 166 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 318 >Z25377 PEA 1 Pl3 WO 2005/069724 PCT/IB2005/001306 640 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRCWFNGIVEENDSNIWKFWY TNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYI AAVSVGQECGSG <210> SEQ ID NO 319 <211> Length: 210 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 319 >Z25377 PEA 1 P14 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRCWFNGIVEENDSNIWKFWY TNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYI AADGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY <210> SEQ ID NO 320 <211> Length: 114 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 320 >Z25377 PEA 1 P15 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAADGISSLCYSSLSKSLLS QPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY <210> SEQ ID NO 321 <211> Length: 87 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 321 >Z25377 PEA 1 Pl7 MRGEHNSTSYDSAVSILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAGLLFL VVGRHIQIHH <210> SEQ ID NO 322 <211> Length: 62 <212> Type: PRT WO 2005/069724 PCT/IB2005/001306 641 <213> ORGANISM: Homo sapiens <400> sequence: 322 >Z25377 PEA 1 P18 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGI <210> SEQ ID NO 323 <211> Length: 45 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 323 >Z25377 PEA 1 P19 MKGSSGGVGLMGLWKRMTPIFGSSGTPISHRPRTAHMLTCLRTPS <210> SEQ ID NO 324 <211> Length: 70 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 324 >Z25377 PEA 1 P20 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAVSVGQECGSG <210> SEQ ID NO 325 <211> Length: 68 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 325 >Z25377 PEA 1 P21 MRGEHNSTSYDSAVNGISSLCYSSLSKSLLSQPLRETSSAINDISLLQALMPLLGWTSHWTCITVGLY <210> SEQ ID NO 326 <211> Length: 1,904 <212> Type: PRT <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 642 <400> sequence: 326 >HSACMHCP PEA 1 P2 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTE ELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYE ESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKL ELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVK KKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVV EQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEEL KKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERR IKELTYQVRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT <210> SEQ ID NO 327 <211> Length: 1,336 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 327 >HSACMHCP PEA 1 P3 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI

FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF

WO 2005/069724 PCT/IB2005/001306 643 GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKVRPSGEGGQA <210> SEQ ID NO 328 <211> Length: 1,534 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 328 >HSACMHCP PEA 1 P4 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL

EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA

WO 2005/069724 PCT/IB2005/001306 644 GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTE ELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYE ESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQGVLGVQEARDELVGGRAMQGQGEHRL <210> SEQ ID NO 329 <211> Length: 1,788 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 329 >HSACMHCP PEA 1 P6 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTE ELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYE ESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKL ELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVK KKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVV EQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDVSDRPPSA

SPKDRNKALGPGQATVL

WO 2005/069724 PCT/IB2005/001306 645 <210> SEQ ID NO 330 <211> Length: 1,434 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 330 >HSACMHCP PEA 1 P12 MGLWKPGSVLSDSLFASSPCPQPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIH YAGTVDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNK LMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQ FIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDAL LVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQ LQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVE KEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEK KVRMDLERAKRKLEGDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELE EELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKH ADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDF TTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEE TEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIED LMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKN LQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDE EMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLD DAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLT QLQSEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQL QKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQA NTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGAKQKMHDEE <210> SEQ ID NO 331 <211> Length: 555 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 331 >HSACMHCP PEA 1 Pl6 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF

GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP

WO 2005/069724 PCT/IB2005/001306 646 YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKVPPWPHHLCPLL CHPDKVVAESLLHPRN <210> SEQ ID NO 332 <211> Length: 1,847 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 332 >HSACMHCP PEA 1 P25 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLE KNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVR CIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVK NWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAE ERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLT EEMAGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLE GDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVE KLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNL QRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGEL ARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKA NSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAA LDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGE GGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVD SLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIA IVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECR NAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGEL EAEQKRNAESVKGMRKSERRIKELTYQVRRTPDTGSRCGSFFSGPTAPPSQGSSHLLLEMLLVDLTFFSRSAVSLT <210> SEQ ID NO 333 WO 2005/069724 PCT/IB2005/001306 647 <211> Length: 1,775 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 333 >HSACMHCP PEA 1 P28 MLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDN SSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFY QILSNKKPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKF KQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVT RINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQ ACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLE KNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVR CIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSS LDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVK NWPWMKLYFKIKPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAE ERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLT EEMAGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLE GDLKLTQESIMDLENDKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVE KLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNL QRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGEL ARQLEEKEALISQLTRGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKA NSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAA LDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGE GGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVD SLQTSLDAETRSRNEVLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIA IVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECR NAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGEL EAEQKRNAESVKGMRKSERRIKELTYQTEEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHEL DEAEERADIAESQVNKLRAKSRDIGAKQKMHDEE <210> SEQ ID NO 334 <211> Length: 775 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 334 >HSACMHCP PEA 1 P29 WO 2005/069724 PCT/IB2005/001306 648 MNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQII KAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLK RQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKL AQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESS QKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEA EASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKKKMEGDLNE MEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKL AEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAH LERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERRIKELTYQTE EDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGAKQK MHDEE <210> SEQ ID NO 335 <211> Length: 108 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 335>N56180 seg6 ATATCCCAGTGGTGGTTGCATTTCCAAACCCCAAGAGAGGAAGGCAAAATGAAGTTGCTGGAGTTGAGTGAATCTGC AGATGGAGCTGCGTGGAAACGCTGGGGAGGG<210> SEQ ID NO 336 <211> Length: 26 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 336>N56180 seg F TTGATACCACTTAGTGTAGCTCCAGC <210> SEQ ID NO 337 <211> Length: 23 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 337>N56180 seg R TCAAGTAGTTGCTACAGACGCCA <210> SEQ ID NO 338 <211> Length: 1,939 <212> Type: PRT <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 649 <400> sequence: 338 >MYH6 HUMAN V1 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTE ELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYE ESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKL ELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVK KKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVV EQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEEL KKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERR IKELTYQTEEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAK SRDIGAKQKMHDEE <210> SEQ ID NO 339 <211> Length: 1,939 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 339 >MYH6 HUMAN V2 WO 2005/069724 PCT/IB2005/001306 650 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTE ELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYE ESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKL ELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVK KKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVV EQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMEADLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEEL KKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERR IKELTYQTEEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAK SRDIGAKQKMHDEE <210> SEQ ID NO 340 <211> Length: 1,939 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 340 >MYH6 HUMAN V3 MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVK EDQVLQQNPPKFDKIQDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSE

APPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANP

WO 2005/069724 PCT/IB2005/001306 651 ALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLL VTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTE DADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYF IGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSI LEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQ KSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDN PLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKV FFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLL KSAETEKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEA KVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTK EKKALQEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLEN DKLQLEEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISE RLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFK LELDDVTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLT RGKLSYTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDA IQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEW KQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQL EVEKLELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNE VLRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEE LRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQLQSEVEEAVQECRNAEEKAKKAITDAAM MAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMR KSERRIKELTYQTEEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVN KLRAKSRDIGAKQKMHDEE <210> SEQ ID NO 341 <211> Length: 229 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 341 >BAC85244 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRCWFNGIVEENDSNIWKFWY TNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYI AAGILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH <210> SEQ ID NO 342 <211> Length: 133 <212> Type: PRT WO 2005/069724 PCT/IB2005/001306 652 <213> ORGANISM: Homo sapiens <400> sequence: 342 >Q96NR4 MRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGILFSLVVMLYVIWVQA VADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH <210> SEQ ID NO 343 <211> Length: 110 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 343 >Q8WW45 MLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYIAAGILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVL YGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH <210> SEQ ID NO 344 <211> Length: 319 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 344 >Q96LE7 MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGEQQWKSEKQREAELKKKKLEQ RSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDEYKR TALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLDVLKLLLNKGAKISARDKLLSTALHVAVRTGH YECAEHLIACEADLNAKDREGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTKAIFDSLRE NSYKTSRIATF <210> SEQ ID NO 345 <211> Length: 319 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 345 >Q15327

MMVLKVEELVTGKKNGNGEAGEFLPEDFRDGEYEAAVTLEKQEDLKTLLAHPVTLGEQQWKSEKQREAELPKKKLEQ

WO 2005/069724 PCT/IB2005/001306 653 RSKLENLEDLEIIIQLKKRKKYRKTKVPVVKEPEPEIITEPVDVPTFLKAALENKLPVVEKFLSDKNNPDVCDEYKR TALHRACLEGHLAIVEKLMEAGAQIEFRDMLESTAIHWASRGGNLDVLKLLLNKGAKISARDKLLSTALHVAVRTGH YECAEHLIACEADLNAKDREGDTPLHDAVRLNRYKMIRLLIMYGADLNIKNCAGKTPMDLVLHWQNGTKAIFDSLRE NSYKTSRIATF <210> SEQ ID NO 346 <211> Length: 699 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 346 >SRCH HUMAN V1 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTE NGHHFWSHPDREKEDEDVAKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPS HRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGH HHHGPSHRHQGHEEDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDD DVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMS HHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEED KEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQ EYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQFCYLCPLVCETVCAPGSYVDYFSSSLYQALADM LETPEP <210> SEQ ID NO 347 <211> Length: 419 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 347 >KCRS HUMAN V1 MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPA IYAKLRNKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDAS KITQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDH FLFDKPVSPLLTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQERG WEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLRLQKRGTGGVDTAAVADVYDISNIDRIGRS EVELVQIVIDGVNYLVDCEKKLERGQDIKVPPPLPQFGKK <210> SEQ ID NO 348 WO 2005/069724 PCT/IB2005/001306 654 <211> Length: 132 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 348 >Fatty acid-binding protein, heart VDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFD ETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA <210> SEQ ID NO 349 <211> Length: 399 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 349 >Calsequestrin, cardiac muscle isoform precursor MKRTHLFIVGIYFLSSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQ LKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEI ISSKLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPI AIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDGYEFLEILKQVARDNTDNPDLS ILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEIPDDDDLPTAEELEDWIEDVLSGKINTEDDDEDD DDDDNSDEEDNDDSDDDDDE <210> SEQ ID NO 350 <211> Length: 151 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 350 >Atrial natriuretic factor precursor MSSFSTTTVSFLLLLAFQLLGQTRANPMYNAVSNADLMDFKNLLDHLEEKMPLEDEVVPPQVLSEPNEEAG AALSPLPEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNS FRY <210> SEQ ID NO 351 <211> Length: 209 <212> Type: PRT <213> ORGANISM: Homo sapiens WO 2005/069724 PCT/IB2005/001306 655 <400> sequence: 351 >Troponin I, cardiac muscle, known protein ADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKG RALSTRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVRIS ADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGMEGRKKKFES <210> SEQ ID NO 352 <211> Length: 175 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 352 >Troponin I, cardiac muscle, variant from SNP MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQELEREAEERRGE KGRALSTRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVR ISADAMMQALLGARAKESWTCGPTSSR <210> SEQ ID NO 353 <211> Length: 846 <212> Type: DNA <213> ORGANISM: Homo sapiens <400> sequence: 353 > HUMTROPIA TO SNP646 #LN 846 TCTCAGTGTCCTCGGGGAGTCTCAAGCAGCCCGGAGGAGACTGACGGTCCCTGGGACCCT GAAGGTCACCCGGGCGGCCCCCTCACTGACCCTCCAAACGCCCCTGTCCTCGCCCTGCCT CCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGGATGGGAGCAGCGATGCGGCTAGGGAA CCTCGCCCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAACTACCGCGCTTATGCCACG GAGCCGCACGCCAAGAAAAAATCTAAGATCTCCGCCTCGAGAAAATTGCAGCTGAAGACT CTGCTGCTGCAGATTGCAAAGCAAGAGCTGGAGCGAGAGGCGGAGGAGCGGCGCGGAGAG AAGGGGCGCGCTCTGAGCACCCGCTGCCAGCCGCTGGAGTTGGCCGGGCTGGGCTTCGCG GAGCTGCAGGACTTGTGCCGACAGCTCCACGCCCGTGTGGACAAGGTGGATGAAGAGAGA TACGACATAGAGGCAAAAGTCACCAAGAACATCACGGAGATTGCAGATCTGACTCAGAAG ATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGATCTCTGCA GATGCCATGATGCAGGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCTGGACCTGCGGGCCC ACCTCAAGCAGGTGAAGAAGGAGGACACCGAGAAGGAAAACCGGGAGGTGGGAGACTGGC

GCAAGAACATCGATGCACTGAGTGGAATGGAGGGCCGCAAGAAAAAGTTTGAGAGCTGAG

WO 2005/069724 PCT/IB2005/001306 656 CCTTCCTGCCTACTGCCCCTGCCCTGAGGAGGGCCCTGAGGAATAAAGCTTCTCTCTGAG CTGAAA <210> SEQ ID NO 354 <211> Length: 85 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 354 >CDS-1 frame 1 from 148 to 406 length 259 (bp) = 86 (aa)(similar to Troponin I N-ter) MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKVGRGFLGAEYRRRRDPRPWEWGE EPGLRRGRGLRGGASGAEFCRGSCSDW <210> SEQ ID NO 355 <211> Length: 185 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 355 >CDS-2 frame 1 from 628 to 1183 length 556 (bp) = 185 (aa) (similar to Troponin I C-ter) MILPCSISPWQKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALSTRCQPLE LAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPT LRRVRISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGME GRKKKFES <210> SEQ ID NO 356 <211> Length: 158 <212> Type: PRT <213> ORGANISM: Homo sapiens <400> sequence: 356 >CDS-3 frame 2 from 155 to 629 length 475 (bp) = 158 (aa)(Not similar to Troponin I)

MGAAMRLGNLALHQPQSDAAPPTTALMPRSRTPRWDGASWGQSTGAGGIQDPGSGGRSQ

WO 2005/069724 PCT/IB2005/001306 657 GCEGGGDYAEGLQGRSFAEGHARIGDSSLRAELRCPRTCLGIDGKCLSKGRDPDWWMGM RGVASRRLRAQVGRGPKSGPAGFAGGVLRSPPPSSPNPPP <210> SEQ ID NO 357 <211> Length: 20 <212> Type: DNA <213> ORGANISM: artificial sequence <400> sequence: 357 >Tropfor CCCTCACTGACCCTCCAAAC <210> SEQ ID NO 358 <211> Length: 20 <212> Type: DNA <213> ORGANISM: artificial sequence <400> sequence: 358 >TropRev CTTCCCATCTATCCCTAAGC <210> SEQ ID NO 359 <211> Length: 27 <212> Type: DNA <213> ORGANISM: artificial sequence <400> sequence: 359 > Trop Nhelfor ACAGCTAGCATGGCGGATGGGAGCAGC <210> SEQ ID NO 360 <211> Length: 27 <212> Type: DNA <213> ORGANISM: artificial sequence WO 2005/069724 PCT/IB2005/001306 658 <400> sequence: 360 > TropHindIIIrev CCTAAGCTTCACCAATCCGAGCATGAC <210> SEQ ID NO 361 <211> Length: 113 <212> Type: DNA <213> ORGANISM: artificial sequence <400> sequence: 361 >N56180 seg TTGATACCACTTAGTGTAGCTCCAGCATGGATCAGCAAACTTTTTCTGTAAAGAACAAAATGGTAAATATTTCAGGT TCTGTGGGCCAGATGGCGTCTGTAGCAACTACTTGA SEQ ID NO 362 >Q96NF5 MLRSTSTVTLLSGGAARTPGAPSRRANVCRLRLTVPPESPVPEQCEKKIERKEQLLDLSN GEPTRKLPQGVVYGVVRRSDQNQQKEMVVYGWSTSQLKEEMNYIKDVRATLEKVRKRMYG DYDEMRQKIRQLTQELSVSHAQQEYLENHIQTQSSALDRFNAMNSALASDSIGLQKTLVD VTLENSNIKDQIRNLQQTYEASMDKLREKQRQLEVAQVENQLLKMKVESSQEANAEVMRE MTKKLYSQYEEKLQEEQRKHSAEKEALLEETNSFLKVIEEANKKMQAAEISLEEKDQRIG ELDRLIERMEKERHQLQLQLLEHETEMSGELTDSDKERYQQLEEASASLRERIRHLDDMV HCQQKKVKQMVEEIESLKKKLQQKQLLILQLLEKISFLEGENNELQSRLDYLTETQAKTE VETREIGVGCDLLPSQTGRTREIVMPSRNYTPYTRVLELTMKKTLT SEQ ID NO 363 >T10377 junc25-31F AGCAGATGGTCGAGGAGAATAATG SEQ ID NO 364 >T10377 junc25-31R ATCTCTCTGGTTTCCACTTCGG SEQ ID NO 365 >T10377 junc25-31 AGCAGATGGTCGAGGAGAATAATGAACTACAAAGCAGGTTGGACTATTTAACAGAAACCCAGGCCAAGACCGAAGTG

GAAACCAGAGAGAT

WO 2005/069724 PCT/IB2005/001306 659 SEQ ID NO 366 >T10377 junc29-33F CTTTCTTAGAAGGAGAGCCAAACAG SEQ ID NO 367 >T10377 junc29-33R CCTAAGTCAGAGTTTTCTTCATGGTTAAC SEQ ID NO 368 >T10377 junc29-33 CTTTCTTAGAAGGAGAGCCAAACAGGCAGGACTCGTGAAATTGTGATGCCTTCTAGGAACTACACCCCATACACAAG AGTCCTGGAGTTAACCATGAAGAAAACTCTGACTTAGG SEQ ID NO 369 >T10377 seg2-3F CTTCGCATTGTGCATAACACAA SEQ ID NO 370 >T10377 seg2-3R GAAACTCGGATACACAATCTCCAGA SEQ ID NO 371 >T10377 seg2-3 CTTCGCATTGTGCATAACACAAGCCCTGAACCAGCTGCTTTGGGAACCCCTGGGAATAAAGTGCCCTACCTGCCTTT CAGGCACTGCCAAGCCTGGGGCATCTCTGGAGATTGTGTATCCGAGTTTC SEQ ID NO 372 >Q9NPI5 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLESL DMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLEGFLLYSYKPLVDLYSRRYFL TVPYEECKWRRSTRNYTVPDPPGLFDGHVWPMYQKYRQEMEANGVEVVYLDGMKSREELF REVLEDIQNSLLNRSQESAPSPARPARTQGPGRGCGHRTARPAASQQDSM SEQ ID NO 373 >Q9NZK3 MKLIVGIGGMTNGGKTTLTNSLLRALPNCCVIHQDDFFKPQDQIAVGEDGFKQWDVLESL DMEAMLDTVQAWLSSPQKFARAHGVSVQPEASDTHILLLEGFLLYSYKPQKYRQEMEANG

VEVVYLDGMKSREELFREVLEDIQNSLLNRSQESAPSPARPARTQGPGRGCGHRTARPAA

WO 2005/069724 PCT/IB2005/001306 660 SQQDSM SEQ ID NO 374 >Forward primer HUMCDDANFjunc2-5F2 CTTCTCCACACACCACCAATTTG SEQ ID NO 375 >Reverse primer HUMCDDANFjunc2-5R2 GAGAGCAGCCCCCGCT SEQ ID NO 376 >Amplicon HUMCDDANFjunc2-5F2R2 CTTCTCCACCACCACCAATTTGCTGGACCATTTGGAAGAAAAGATGCCTTTAGAAGATGAGGTCGTGCCCCCACAAG TGCTCAGTGAGCCGAATGAAGAAGCGGGGGCTGCTCTC SEQ ID NO 377 >HUMTROPIA segl Forward primer TTGCAGAGGGTCATGCTCG SEQ ID NO 378 >HUMTROPIA segl Reverse primer TCCTTTGGATAGGCACTTCCC SEQ ID NO 379 >HUMTROPIA segl Amplicon TTGCAGAGGGTCATGCTCGGATTGGTGACAGCAGCCTGCGGGCGGAACTCCGTTGCCCTCGGACTTGCTTAGGGATA GATGGGAAGTGCCTATCCAAAGGA SEQ ID NO 380 >HUMTROPIA seg22 Forward primer GTGGGACGCATGGGCA SEQ ID NO 381 >HUMTROPIA seg22 Reverse primer TTGTCCTGGGTCTCCTGGG SEQ ID NO 382 >HUMTROPIA seg22 Amplicon WO 2005/069724 PCT/IB2005/001306 661 GTGGGACGCATGGGCAGCTCGGGTACCTTCGGGGTAGGGTGAGATGGCTGGGACTTGGTCTCTGCCTGACCCCTTGC AGCTGCTTTTGGCTGCACATCCCAGGAGACCCAGGACAA SEQ ID NO 383 >Forward primer HUMTROPIA seg23-24-25F AAGATCTTTGACCTTCGAGGCA SEQ ID NO 384 >Reverse primer HUMTROPIA seg23-24-25R CTGCTTGAGGTGGGCCC SEQ ID NO 385 >Amplicon HUMTROPIA seg23-24-25 AAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGGATCTCTGCAGATGCCATGATGCA GGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCCTGGACCTGCGGGCCCACCTCAAGCAG SEQ ID NO 386 > DNA sequence of HisTroponin T7 pRSETA GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTA ACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGGCGGATGGGA GCAGCGATGCGGCTAGGGAACCTCGCCCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAACTACCGCGCTTATGCC ACGGAGCCGCACGCCAAGGTGGGACGGGGCTTCCTGGGGGCAGAGTACAGGCGCCGGAGGGATCCAAGACCCTGGGA GTGGGGGGAGGAGCCAGGGCTGCGAAGGGGGCGGGGACTACGCGGAGGGGCTTCAGGGGCGGAGTTTTGCAGAGGGT CATGCTCGGATTGGTGAAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTG AGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCC GGATCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGAC GCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGG GGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT AGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTT CCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATT GGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCA CTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATG TATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTT CCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAA AAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGA

CGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAA

WO 2005/069724 PCT/IB2005/001306 662 AGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAAC TTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCT TGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAA CAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCG GATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGA GCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGG GGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTG TCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGAT CCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGA TCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAA CCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAG AGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAAC GACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACA GGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTAT AGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAA AAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTAT CCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGC AGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTA ATGCAG SEQ ID NO 387 >HIS-TAG TROPONIN I VARIANT MRGSHHHHHHGMASMADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKVGRGFLGAEYRRRRDPRPWEWGEEPGL RRGRGLRGGASGAEFCRGSCSDW SEQ ID NO 388 >Creatine kinase, sarcomeric mitochondrial precursor MASIFSKLLTGRNASLLFATMGTSVLTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPAIYSKLR NKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQ FDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKP VSPLLTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQERGWEFMWN ERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLRLQKRGTGGVDTAAVADVYDISNIDRIGRSEVELVQ IVIDGVNYLVDCEKKLERGQDIKVPPPLPQFGKK SEQ ID NO 389 >Sarcoplasmic reticulum histidine-rich calcium-binding protein precursor WO 2005/069724 PCT/IB2005/001306 663 MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTE NGHHFWSHPDREKEDEDVSKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPS HRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGH HHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDD DVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITV QFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMS HHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEED KEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQ EYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQFCYLCPLVCETVCAPGSYVDYFSSSLYQALADM LETPEP SEQ ID NO 390 >Hypothetical protein FLJ26352 MRLNIAIFFGALFGALGVLLFLVAFGSDYWLLATEVGRCSGEKNIENVTFHHEGFFWRCWFNGIVEENDSNIWKFWY TNQPPSKNCTHAYLSPYPFMRGEHNSTSYDSAVIYRGFWAVLMLLGVVAVVIASFLIICAAPFASHFLYKAGGGSYI AAGILFSLVVMLYVIWVQAVADMESYRNMKMKDCLDFTPSVLYGWSFFLAPAGIFFSLLAGLLFLVVGRHIQIHH SEQ ID NO 391 >Myosin heavy chain, cardiac muscle alpha isoform MTDAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGKVIAETENGKTVTVKEDQVL QQNPPKFDKIQDMAMLTFLHEPAVLFNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHI FSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAF GNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNP YDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKS AYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLD IAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEEC MFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLK LMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMH QLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAG LLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAET EKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLNDAEERCDQLIKNKIQLEAKVKEM NERLEDEEEMNAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKAL QEAHQQALDDLQVEEDKVNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL EEKLKKKEFDINQQNSKIEDEQALALQLQKKLKENQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEA GGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDD VTSNMEQIIKAKANLEKVSRTLEDQANEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLS YTQQMEDLKRQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTE

ELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYE

WO 2005/069724 PCT/IB2005/001306 664 ESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKL ELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVK KKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVV EQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMEADLTQLQSEVEEAVQECRNAEEKAKKAITDAAMMAEEL KKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELEGELEAEQKRNAESVKGMRKSERR IKELTYQTEEDKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAK SRDIGAKQKMHDEE SEQ ID NO 392 >S67314 0 0 741 CACAGAGCCAGGATGTTCTTCTGACCTCAGTATCTACTCCAGCTCCAGCT SEQ ID NO 393 >S67314 0 0 744

TGGCATGCTGGAACATGGACTCTAGCTAGCAAGAAGGGCTCAAGGAGGTG

Claims

1. An isolated polynucleotide comprising a transcript selected from the group consisting of SEQ ID NOs: 22-25, 353 or 386, or a polynucleotide at least about 95% homologous thereto.

2. An isolated polynucleotide comprising a segment selected from the group consisting of SEQ ID NOs: 130-149, or a polynucleotide at least about 95% homologous thereto.

3. An isolated polypeptide comprising a protein variant selected from the group consisting of SEQ ID NOs: 301-304, 325, 354-356 or 387, or a polypeptide at least about 95% homologous thereto.

4. An isolated chimeric polypeptide encoding for SEQ ID NO. 301, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 124 of TRIC_HUMAN, which also corresponds to amino acids 1 - 124 of SEQ ID NO. 301, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 125- 137 of SEQ ID NO. 301, wherein said first and second amino acid sequences are contiguous and in a sequential order.

5. An isolated polypeptide encoding for a tail of SEQ ID NO. 301, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VGRMGSSGTFGVG in SEQ ID NO. 301.

6. An isolated chimeric polypeptide encoding for SEQ ID NO. 302, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 8 of TRIC_HUMAN, which also corresponds to amino acids 1 - 8 of SEQ ID NO. 302, and a second WO 2005/069724 PCT/IB2005/001306 666 amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 36 - 209 of TRIC_HUMAN, which also corresponding to amino acids 9 - 182 of SEQ ID NO. 302, wherein said first and second amino acid sequences are contiguous and in a sequential order.

7. An isolated chimeric polypeptide encoding for an edge portion of SEQ ID NO. 302, comprising a polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AK, having a structure as follows: a sequence starting from any of amino acid numbers 8-x to 8; and ending at any of amino acid numbers 9+ ((n-2) - x), in which x varies from 0 to n-2.

8. An isolated chimeric polypeptide encoding for SEQ ID NO. 303, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 36 of TRIC_HUMAN, which also corresponds t) amino acids 1 - 36 of SEQ ID NO. 303, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 37- 86 of SEQ ID NO. 303, wherein said first and second amino acid sequences are contiguous and in a sequential order.

9. An isolated polypeptide encoding for a tail of SEQ ID NO. 303, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VGRGFLGAEYRRRRDPRPWEWGEEPGLRRGRGLRGGASGAEFCRGSCSDW in SEQ ID NO. 303.

10. An isolated chimeric polypeptide encoding for SEQ ID NO. 304, comprising a first amino acid sequence being at least 90 % homologous to amino acids 1 - 8 of TRIC_HUMAN, which also corresponds to amino acids 1 - 8 of SEQ ID NO. 304, and a second WO 2005/069724 PCT/IB2005/001306 667 amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide sequence corresponding to amino acids 9- 13 of SEQ ID NO. 304, wherein said first and second amino acid sequences are contiguous and in a sequential order.

I 1. An isolated polypeptide encoding for a tail of SEQ ID NO. 304, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRAAG in SEQ ID NO. 304.

12. An isolated oligonucleotide, comprising an amplicon selected from the group consisting of SEQ ID NOs: 379, 382 or 385.

13. A primer pair, comprising a pair of isolated oligonucleotides capable of amplifying said amplicon of claim 12.

14. The primer pair of claim 13, comprising a pair of isolated oligonucleotides selected from the group consisting of: SEQ NOs 377 and 378; 380 and 381; or 383 and 384.

15. An antibody capable of specifically binding to an epitope of an amino acid sequence of any of claims 3-11.

16. The antibody of claim 15, wherein said amino acid sequence comprises one of: a tail of SEQ ID NO. 301, comprising a polypeptide being at least 70 homologous to the sequence VGRMGSSGTFGVG in SEQ ID NO. 301; a tail of SEQ ID NO. 303, comprising a polypeptide being at least 70% homologous to the sequence VGRGFLGAEYRRRRDPRPWEWGEEPGLRRGRGLRGGASGAEFCRGSCSDW in SEQ ID NO. 303; a tail of SEQ ID NO. 304, comprising a polypeptide being at least 70% homologous to the sequence VRAAG in SEQ ID NO. 304; or WO 2005/069724 PCT/IB2005/001306 668 an edge portion of SEQ ID NO. 302, comprising a polypeptide having a length "n", wherein "n" is at least about 10 amino acids in length, wherein at least two amino acids comprise AK, having a structure as follows: a sequence starting from any of amino acid numbers 8-x to 8; and ending at any of amino acid numbers 9+ ((n-2) - x), in which x varies from 0 to n-2.

17. The antibody of claims 15, wherein said antibody is capable of differentiating between a splice variant having said epitope and a corresponding known protein TRIC HUMAN.

18. A kit for detecting heart disorders, comprising a kit detecting overexpression of a splice variant according to any of claims 1-11.

19. The kit of claim 18, wherein said kit comprises a NAT-based technology.

20. The kit of claim 19, wherein said kit further comprises at least one primer pair capable of selectively amplifying the nucleic acid sequence.

21. The kit of claim 18, wherein said kit further comprises at least one oligonucleotide capable of selectively hybridizing to the nucleic acid sequence.

22. A kit for detecting heart disorders, comprising a kit an antibody according of claim 15.

23. The kit of claim 22, wherein said kit further comprises at least one reagent for performing an ELISA or a Western blot.

24. A method for detecting heart disorders, comprising detecting overexpression of a splice variant according to any of claims 1-11.

25. The method of claim 24, wherein said detecting overexpression is performed WO 2005/069724 PCT/IB2005/001306 669 with a NAT-based technology.

26. The method of claim 24, wherein said detecting overexpression is performed with an immunoassay.

27. The method of claim 26, wherein said immunoassay comprises an antibody.

28. A biomarker capable of detecting heart disorders, comprising the nucleic acid sequences or a fragment thereof, or amino acid sequences or a fragment thereof of any of claims 1-12.

29. A method for screening for heart disorders, comprising detecting heart disorder cells using the biomarkers or antibodies of any of claims 1-12.

30. A method for diagnosing heart disorders, comprising detecting heart disorder cells using the biomarkers or antibodies of any of claims 1-12.

31. A method for monitoring disease progression, or treatment efficacy, or relapse of heart disorders, or any combination thereof, comprising detecting heart disorder cells using the biomarkers or antibodies or a method or assay according to any of claims 1-12.

32. A method of selecting a therapy for heart disorders, comprising detecting heart disorder cells with any of the above biomarkers or antibodies or a method or assay according to any of claims 1-12 and selecting a therapy according to said detection.

33. A method according to claim 28, wherein a heart disorder and/or cardiac disease and/or cardiac pathology comprises at least one of: Myocardial infarct, ungina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, the detection of reinfarction, the detection of success of thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, or assessing the size of infarct in Myocardial infarct. WO 2005/069724 PCT/IB2005/001306 670

34. A method according to claim 29, wherein a heart disorder and/or cardiac disease and/or cardiac pathology comprises at least one of: Myocardial infarct, ungina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, the detection of reinfarction, the detection of success of thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, or assessing the size of infarct in Myocardial infarct.

35. A method according to claim 30, wherein a heart disorder and/or cardiac disease and/or cardiac pathology comprises at least one of: Myocardial infarct, ungina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, the detection of reinfarction, the detection of success of thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, or assessing the size of infarct in Myocardial infarct.

36. A method according to claim 31, wherein a heart disorder and/or cardiac disease and/or cardiac pathology comprises at least one of: Myocardial infarct, ungina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, the detection of reinfarction, the detection of success of thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, or assessing the size of infarct in Myocardial infarct.

37. A method according to claim 32, wherein a heart disorder and/or cardiac disease and/or cardiac pathology comprises at least one of: Myocardial infarct, ungina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, the detection of reinfarction, the detection of success of thrombolytic therapy after Myocardial infarct, Myocardial infarct after surgery, or assessing the size of infarct in Myocardial infarct.